Event Information:
-
Team 5: Atherothrombotic Disease in Heart and Brain
Group leaders: Gabriel STEG & Grégory DUCROCQ
The Atherothrombotic disease in heart and brain team (Team 5, P.G. Steg) focuses on clinical epidemiology of CAD (P. Gabriel Steg) and stroke (P. Amarenco), via the design, conduct and analysis of large-scale observational registries and of randomized clinical trials. The team received French government funding for an integrated research program on innovations in atherothrombosis science (RHU IVASC) which involves ongoing epidemiologic studies and interventional studies to establish the relationship(s) between chronic periodontitis, sleep disordered breathing, and atherothrombosis. The TIA.org registry established the benefit of rapid management of transient ischaemic attacks through specialized centers worldwide, initially and at 5-year follow-up.
Recent trials have studied the impact of lipid lowering interventions after acute coronary syndromes (using alirocumab, a PCSK9 inhibitor, in the ODYSSEY OUTCOMES trial) or after ischaemic stroke in patients with atherothrombosis (comparing two target LDL cholesterol levels, in the TST trial which established the clinical benefit of targeting LDL to <70 mg/dL rather than 100 mg/dL). A large-scale trial, THEMIS (the largest randomized trial in diabetes) established the value of dual antiplatelet therapy with ticagrelor and aspirin in patients with stable CAD and diabetes, particularly if they have a prior history of percutaneous coronary intervention.
The research program will be developed on 3 different and synergistic aspects:
1/ Registry-based randomized clinical trials and novel trial designs
2/ Deep learning and cardiology
3/ Evaluation of novel risk factors for atherothrombosis.
Publications
2460799 5BTMJQCK 2024 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-cd453e90df126352ab7c7e4b5a4242dd%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22MTPCCPGK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Weintraub%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EWeintraub%20WS%2C%20Bhatt%20DL%2C%20Zhang%20Z%2C%20Dolman%20S%2C%20Boden%20WE%2C%20Bress%20AP%2C%20Bellows%20BK%2C%20Derington%20CG%2C%20Philip%20S%2C%20Steg%20G%2C%20Miller%20M%2C%20Brinton%20EA%2C%20Jacobson%20TA%2C%20Tardif%20J%2C%20Ballantyne%20CM%2C%20Kolm%20P.%202024.%20Cost%26%23x2010%3BEffectiveness%20of%20Icosapent%20Ethyl%20in%20REDUCE%26%23x2010%3BIT%20USA%3A%20Results%20From%20Patients%20Randomized%20in%20the%20United%20States.%20JAHA%2013%3Ae032413.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cost%5Cu2010Effectiveness%20of%20Icosapent%20Ethyl%20in%20REDUCE%5Cu2010IT%20USA%3A%20Results%20From%20Patients%20Randomized%20in%20the%20United%20States%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20S.%22%2C%22lastName%22%3A%22Weintraub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zugui%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarahfaye%22%2C%22lastName%22%3A%22Dolman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20E.%22%2C%22lastName%22%3A%22Boden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20P.%22%2C%22lastName%22%3A%22Bress%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brandon%20K.%22%2C%22lastName%22%3A%22Bellows%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20G.%22%2C%22lastName%22%3A%22Derington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sephy%22%2C%22lastName%22%3A%22Philip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliot%20A.%22%2C%22lastName%22%3A%22Brinton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%20A.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Kolm%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%203146%20REDUCE%5Cu2010IT%20USA%20%28Reduction%20of%20Cardiovascular%20Events%20With%20Icosapent%20Ethyl%20Intervention%20Trial%20USA%29%20participants%2C%20icosapent%20ethyl%20%28IPE%29%20reduced%20first%20and%20total%20cardiovascular%20events%20by%2031%25%20and%2036%25%2C%20respectively%2C%20over%204.9%5Cu2009years%20of%20follow%5Cu2010up.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20used%20participant%5Cu2010level%20data%20from%20REDUCE%5Cu2010IT%20USA%2C%202021%20US%20costs%2C%20and%20IPE%20costs%20ranging%20from%20%244.59%20to%20%2411.48%20per%20day%2C%20allowing%20us%20to%20examine%20a%20range%20of%20possible%20medication%20costs.%20The%20in%5Cu2010trial%20analysis%20was%20participant%5Cu2010level%2C%20whereas%20the%20lifetime%20analysis%20used%20a%20Markov%20model.%20Both%20analyses%20considered%20value%20from%20a%20US%20health%20sector%20perspective.%20The%20incremental%20cost%5Cu2010effectiveness%20ratio%20%28incremental%20costs%20divided%20by%20incremental%20quality%5Cu2010adjusted%20life%5Cu2010years%29%20of%20IPE%20compared%20with%20standard%20care%20%28SC%29%20was%20the%20primary%20outcome%20measure.%20There%20was%20incremental%20gain%20in%20quality%5Cu2010adjusted%20life%5Cu2010years%20with%20IPE%20compared%20with%20SC%20using%20in%5Cu2010trial%20%283.28%20versus%203.13%29%20and%20lifetime%20%2810.36%20versus%209.83%29%20horizons.%20Using%20an%20IPE%20cost%20of%20%244.59%20per%20day%2C%20health%20care%20costs%20were%20lower%20with%20IPE%20compared%20with%20SC%20for%20both%20in%5Cu2010trial%20%28%2429%5Cu2009420%20versus%20%2430%20947%29%20and%20lifetime%20%28%24216%5Cu2009243%20versus%20%24219%20212%29%20analyses.%20IPE%20versus%20SC%20was%20a%20dominant%20strategy%20in%20trial%20and%20over%20the%20lifetime%2C%20with%2099.7%25%20lifetime%20probability%20of%20an%20incremental%20cost%5Cu2010effectiveness%20ratio%20%3C%2450%5Cu2009000%20per%20quality%5Cu2010adjusted%20life%5Cu2010year%20gained.%20At%20a%20medication%20cost%20of%20%2411.48%20per%20day%2C%20the%20cost%20per%20quality%5Cu2010adjusted%20life%5Cu2010year%20gained%20was%20%2436%5Cu2009208%20in%20trial%20and%20%249582%20over%20the%20lifetime.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20analysis%2C%20at%20%244.59%20per%20day%2C%20IPE%20offers%20better%20outcomes%20than%20SC%20at%20lower%20costs%20in%20trial%20and%20over%20a%20lifetime%20and%20is%20cost%5Cu2010effective%20at%20%2411.48%20per%20day%20for%20conventional%20willingness%5Cu2010to%5Cu2010pay%20thresholds.%20Treatment%20with%20IPE%20should%20be%20strongly%20considered%20in%20US%20patients%20like%20those%20enrolled%20in%20REDUCE%5Cu2010IT%20USA.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01492361.%22%2C%22date%22%3A%222024-01-02%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.123.032413%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.123.032413%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A32Z%22%7D%7D%2C%7B%22key%22%3A%222Y4YF4VK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wiernik%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EWiernik%20E%2C%20Renuy%20A%2C%20Kab%20S%2C%20Steg%20PG%2C%20Goldberg%20M%2C%20Zins%20M%2C%20Caligiuri%20G%2C%20Bouchard%20P%2C%20Carra%20MC.%202024.%20Prevalence%20of%20self%26%23x2010%3Breported%20severe%20periodontitis%3A%20Data%20from%20the%20population%26%23x2010%3Bbased%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3ECONSTANCES%3C%5C%2Fspan%3E%20cohort.%20J%20Clinic%20Periodontology%20jcpe.13969.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20self%5Cu2010reported%20severe%20periodontitis%3A%20Data%20from%20the%20population%5Cu2010based%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3ECONSTANCES%3C%5C%2Fspan%3E%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Wiernik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Renuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofiane%22%2C%22lastName%22%3A%22Kab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Goldberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Zins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppina%22%2C%22lastName%22%3A%22Caligiuri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Bouchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Clotilde%22%2C%22lastName%22%3A%22Carra%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aim%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20assess%20the%20prevalence%20of%20severe%20periodontitis%20based%20on%20the%20population%5Cu2010based%20CONSTANCES%20cohort%20using%20a%20validated%20self%5Cu2010reported%20questionnaire.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Materials%20and%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Individuals%20were%20selected%20from%20the%20adult%20population%20in%20France%20using%20a%20random%20sampling%20scheme.%20Analyses%20were%20restricted%20to%20those%20invited%20in%202013%5Cu20132014%20who%20completed%20the%20periodontal%20health%20questionnaire%20at%20the%202017%20follow%5Cu2010up.%20The%20risk%20of%20severe%20periodontitis%20was%20assessed%20using%20the%20periodontal%20screening%20score%20%28PESS%29%20and%20weighting%20coefficients%20were%20applied%20to%20provide%20representative%20results%20in%20the%20general%20French%20population.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20study%20included%2019%2C859%20participants%20%289204%20men%2C%20mean%20age%3A%2052.8%5Cu2009%5Cu00b1%5Cu200912.6%5Cu2009years%29.%20Based%20on%20a%20PESS%5Cu2009%5Cu2265%5Cu20095%2C%207106%20participants%20were%20at%20risk%20of%20severe%20periodontitis%2C%20corresponding%20to%20a%20weighted%20prevalence%20of%2031.6%25%20%2895%25%20confidence%20interval%3A%2030.6%25%5Cu201332.7%25%29.%20This%20prevalence%20was%20higher%20among%20participants%20aged%2055%20and%20over%2C%20those%20with%20lower%20socio%5Cu2010economic%20status%20as%20well%20as%20current%20smokers%2C%20e%5Cu2010cigarette%20users%20and%20heavy%20drinkers.%20Among%20individuals%20at%20risk%20of%20severe%20periodontitis%2C%20only%2018.8%25%20%2817.3%25%5Cu201320.4%25%29%20thought%20they%20had%20gum%20disease%2C%20although%2050.5%25%20%2848.6%25%5Cu201352.5%25%29%20reported%20that%20their%20last%20dental%20visit%20was%20less%20than%206%5Cu2009months.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20present%20survey%20indicates%20that%20%281%29%20self%5Cu2010reported%20severe%20periodontitis%20is%20highly%20prevalent%20with%20marked%20disparities%20between%20groups%20in%20the%20general%20French%20adult%20population%2C%20and%20%282%29%20periodontitis%20could%20frequently%20be%20under%5Cu2010diagnosed%20given%20the%20low%20awareness.%22%2C%22date%22%3A%222024-03-02%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fjcpe.13969%22%2C%22ISSN%22%3A%220303-6979%2C%201600-051X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fjcpe.13969%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22T8G3K6CS%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gautier%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGautier%20A%2C%20Picard%20F%2C%20Ducrocq%20G%2C%20Elbez%20Y%2C%20Fox%20KM%2C%20Ferrari%20R%2C%20Ford%20I%2C%20Tardif%20J-C%2C%20Tendera%20M%2C%20Steg%20PG%2C%20CLARIFY%20investigators%2C%20Guerrero%20AA%2C%20Basara%20M%2C%20Belcastro%20F%2C%20Bertarini%20JA%2C%20Cazenave%20C%2C%20Dreycopp%20H%2C%20Egido%20J%2C%20Estrella%20J%2C%20Garofalo%20D%2C%20Giordano%20J%2C%20Lagioia%20H%2C%20Lago%20N%2C%20Greca%20RL%2C%20Lema%20L%2C%20Cabanillas%20NL%2C%20Luquez%20H%2C%20Miller%20C%2C%20Prada%20E%2C%20Rodenas%20P%2C%20Schena%20RG%2C%20Suarez%20G%2C%20Tomatti%20A%2C%20Colquhoun%20DM%2C%20Conradie%20A%2C%20Cox%20S%2C%20Cross%20D%2C%20Fathi%20R%2C%20Fitzgerald%20B%2C%20Hamilton-Craig%20I%2C%20Holt%20G%2C%20Jayasinghe%20SR%2C%20Mai%20N%2C%20Moolman%20J%2C%20Motyer%20RA%2C%20Phillips%20K%2C%20Rafter%20A%2C%20Rahman%20A%2C%20Rainbird%20A%2C%20Scalia%20G%2C%20Taylor%20A%2C%20West%20P%2C%20Alford%20K%2C%20Amor%20R%2C%20Astridge%20P%2C%20Bastian%20B%2C%20Bates%20F%2C%20Doohan%20MM%2C%20Du%20Plooy%20J%2C%20Ford%20JC%2C%20Kanagaratnam%20L%2C%20Khoury%20V%2C%20Parkin%20R%2C%20Rogers%20J%2C%20Sceats%20G%2C%20Waldman%20A%2C%20Wang%20D%2C%20Wright%20S%2C%20Ardill%20J%2C%20Aylward%20P%2C%20Beltrame%20JF%2C%20Bradley%20J%2C%20Heddle%20W%2C%20Joseph%20M%2C%20Rajendran%20S%2C%20Varughese%20S%2C%20Brice%20E%2C%20Hockings%20B%2C%20Janssen%20J%2C%20Kozlowski%20A%2C%20O%26%23x2019%3BShea%20J%2C%20Tan%20J%2C%20Playford%20DA%2C%20Woollard%20K%2C%20Ajani%20A%2C%20Barron%20G%2C%20Better%20N%2C%20Carruthers%20T%2C%20Chan%20B%2C%20Chan%20R%2C%20Cotroneo%20J%2C%20Counsell%20JT%2C%20Eccleston%20DS%2C%20Forge%20BHR%2C%20Hamer%20A%2C%20Horrigan%20M%2C%20Jelinek%20VMJ%2C%20Lew%20R%2C%20O%26%23x2019%3BDonnell%20D%2C%20Panetta%20F%2C%20Sebastian%20M%2C%20Shetty%20P%2C%20Soward%20A%2C%20Srivastava%20P%2C%20Strathmore%20NF%2C%20Sylivris%20S%2C%20Szto%20G%2C%20Veth%20V%2C%20Yip%20T%2C%20Badr-Eslam%20R%2C%20Kleemann%20L%2C%20Steurer%20G%2C%20M%26%23xF6%3Brz-Proszowski%20B%2C%20Auhser%20F%2C%20Teleky%20U%2C%20Sepp%20G%2C%20Beinhauer%20A%2C%20Ker%26%23xF6%3B%20D%2C%20Lavicka%20C%2C%20Perger%20T%2C%20Hadjiivanov%20V%2C%20Feldner-Busztin%20M%2C%20Mika%20R%2C%20Filip%20W%2C%20Mahr%20A%2C%20Toplak%20J%2C%20Millauer%20MG%2C%20Haralambus%20P%2C%20Walcher%20K%2C%20Karner%20KH%2C%20Ziak%20E%2C%20Painsipp%20P%2C%20Frank%20U%2C%20Suntinger%20A%2C%20Gritsch%20W%2C%20Bode%20G%2C%20Herrmann%20R%2C%20Raffelsberger%20R%2C%20Topf%20H%2C%20Moser%20E%2C%20F%26%23xF6%3Bchterle%20J%2C%20Honsig%20T%2C%20Mayr%20K%2C%20Mayr%20H%2C%20Kaserbacher%20R%2C%20Dzien%20A%2C%20Galehr%20E%2C%20Felbermayer%20M%2C%20Schwarz%20R%2C%20Amini%20R%2C%20Appeltants%20H%2C%20Ballet%20A%2C%20De%20Niel%20C%2C%20Berkenboom%20G%2C%20Bernard%20X%2C%20Bouvy%20T%2C%20Claeys%20M%2C%20Dascotte%20Y%2C%20Davin%20L%2C%20De%20Backer%20T%2C%20De%20Meester%20A%2C%20De%20Ridder%20S%2C%20Dendale%20P%2C%20Denef%20K%2C%20Emonts%20M%2C%20Geraedts%20JTM%2C%20Goethals%20M%2C%20Gr%26%23xE9%3Bgoire%20J-M%2C%20Herbots%20T%2C%20Hoffer%20E%2C%20Hutse%20WHJ%2C%20Lafontaine%20P%2C%20Lefebvre%20P%2C%20Lesseliers%20H%2C%20Odent%20G%2C%20Pasquet%20A%2C%20Peperstraete%20B%2C%20Purnode%20P%2C%20Rogowsky%20A%2C%20Rosseel%20M%2C%20Salembier%20J-P%2C%20Surmont%20P%2C%20Vandeplas%20AMF%2C%20Van%20De%20Walle%20S%2C%20Van%20Den%20Branden%20F%2C%20Vandergoten%20P%2C%20Vanhauwaert%20BG%2C%20Vanneste%20L%2C%20Vercammen%20J%2C%20Verleyen%20D%2C%20Vermander%20D%2C%20Weytjens%20C%2C%20De%20Lorenzo%20AR%2C%20Issa%20AFC%2C%20Mioto%20BM%2C%20Vianna%20CDB%2C%20Okawabata%20C%2C%20Rossi%20EG%2C%20Fernandes%20F%2C%20Pitella%20F%2C%20Cesena%20FHY%2C%20Ferreira%20JFM%2C%20Junior%20JF%2C%20Tonet%20L%2C%20Cesar%20LM%2C%20Gowdak%20LH%2C%20Matos%20MA%2C%20Moretti%20M%2C%20Amato%20RV%2C%20Munhoz%20RT%2C%20Coimbra%20SR%2C%20De%20Lorenzo%20AR%2C%20Issa%20AFC%2C%20Mioto%20BM%2C%20Vianna%20CDB%2C%20Okawabata%20C%2C%20Rossi%20EG%2C%20Fernandes%20F%2C%20Pitella%20F%2C%20Cesena%20FHY%2C%20Ferreira%20JFM%2C%20Junior%20JF%2C%20Tonet%20L%2C%20Cesar%20LM%2C%20Gowdak%20LH%2C%20Matos%20MA%2C%20Moretti%20M%2C%20Amato%20RV%2C%20Munhoz%20RT%2C%20Coimbra%20SR%2C%20Luqman%20HN%2C%20Yakovova%20S%2C%20Mantcheva%20M%2C%20Mincheva%20V%2C%20Baurenski%20L%2C%20Karastanev%20K%2C%20Yordanova%20V%2C%20Peneva%20Y%2C%20Wong%20P%2C%20Fagan%20M%2C%20Sabe-Affaki%20G%2C%20Villasenor%20FM%2C%20Son%20WK%2C%20Manyari%20DE%2C%20Giacomantonio%20N%2C%20Lubelsky%20BJ%2C%20Ezekiel%20D%2C%20Leong%20JCS%2C%20Grover%20A%2C%20Vavougios%20J%2C%20Pesant%20Y%2C%20Kushner%20AM%2C%20Yeung%20MMW%2C%20Vertes%20GE%2C%20Nasser-Sharif%20FJ%2C%20Spensieri%20D%2C%20Roy%20A%2C%20Nguyen%20TT%2C%20Leclair%20M%2C%20Morra%20P%2C%20Biglow%20CE%2C%20Baril%20JF%2C%20Lai%20K%2C%20Wong%20DS%2C%20Martinho%20V%2C%20Antoniadis%20GA%2C%20Searles%20GR%2C%20Rouse%20D%2C%20Brisson%20G%2C%20Wong%20SK%2C%20Collette%20RS%2C%20Ho%20MSC%2C%20Constance%20C%2C%20Gendreau%20R%2C%20Kellam%20GW%2C%20Lara%20TAC%2C%20Boyrazian%20HA%2C%20Shamsuzzaman%20M%2C%20Spink%20DR%2C%20T%20Wong%20AP%2C%20Janes%20J%2C%20Czarnecka%20M%2C%20Saulnier%20D%2C%20Levesque%20G%2C%20Clavette%20PF%2C%20Kokis%20A%2C%20Orenstein-Lyall%20TL%2C%20Pandey%20AS%2C%20Robb%20J%2C%20Verret%20G%2C%20Czarnecki%20W%2C%20Perreault%20F%2C%20Chouinard%20G%2C%20Lafrance%20G%2C%20Fullerton%20GM%2C%20LeBouthillier%20P%2C%20Tran%20QH%2C%20Marrero%20IR%2C%20Ramadan%20FB%2C%20Talbot%20P%2C%20Fazil%20MA%2C%20Cha%20JY-M%2C%20Garg%20S%2C%20Chehayeb%20R%2C%20Roy%20B%2C%20Chan%20YK%2C%20Harlos%20HE%2C%20Matheson%20HB%2C%20Patel%20R%2C%20Vaz%20GF%2C%20Bhatt%20JS%2C%20Liu%20E%2C%20Ashton%20TH%2C%20Sullivan%20H%2C%20Quinn%20LP%2C%20Yared%20K%2C%20Gupta%20AK%2C%20Sullivan%20B%2C%20Campbell%20J%2C%20Pallie%20S%2C%20Kim%20HH%2C%20Savard%20D%2C%20Cherry%20JM%2C%20Gold%20J%2C%20Brouillette%20G%2C%20Belanger%20A%2C%20Berlingieri%20J%2C%20Nisker%20W%2C%20Boutros%20G%2C%20Bakbak%20AI%2C%20Lasalle%20L%2C%20Chen%20LL%2C%20Chen%20MH%2C%20Chen%20MY%2C%20Chen%20XP%2C%20Chen%20YD%2C%20Cong%20HL%2C%20Ding%20SF%2C%20Dong%20JT%2C%20Dong%20SH%2C%20Du%20ZM%2C%20Feng%20LL%2C%20Gao%20W%2C%20Ge%20H%2C%20Ge%20SJ%2C%20Guo%20T%2C%20Guo%20Y%2C%20Huang%20Z%2C%20Huo%20Y%2C%20Jin%20HG%2C%20Ke%20YN%2C%20Li%20HW%2C%20Li%20HM%2C%20Li%20ZC%2C%20Li%20YJ%2C%20Liu%20JL%2C%20Liu%20QL%2C%20Liu%20SW%2C%20Lv%20SZ%2C%20Miao%20W%2C%20Pan%20GZ%2C%20Pu%20XD%2C%20Qian%20ZM%2C%20Su%20X%2C%20Tao%20JH%2C%20Wang%20HP%2C%20Wang%20JA%2C%20Wang%20NF%2C%20Wang%20T%2C%20Wang%20W%2C%20Wang%20Y%2C%20Wei%20M%2C%20Wu%20SY%2C%20Wu%20YJ%2C%20Xiong%20LG%2C%20Xu%20D%2C%20Yan%20J%2C%20Yang%20K%2C%20Yang%20M%2C%20Yang%20TL%2C%20Yang%20XL%2C%20Yu%20JM%2C%20Zeng%20HS%2C%20Zhang%20H%2C%20Zhang%20HQ%2C%20Zhang%20L%2C%20Zhou%20SX%2C%20Zhou%20YL%2C%20Bozkova%20J%2C%20Carda%20J%2C%20Dedkova%20S%2C%20Dufka%20A%2C%20Fridrich%20J%2C%20Hodac%20T%2C%20Jirmar%20R%2C%20Kadleckova%20A%2C%20Karlicek%20M%2C%20Krupicka%20J%2C%20Kuchar%20J%2C%20Lavicka%20V%2C%20Leso%20J%2C%20Lorenc%20Z%2C%20Micko%20M%2C%20Navratil%20P%2C%20Petrova%20I%2C%20Povolna%20P%2C%20Raisova%20L%2C%20Raska%20P%2C%20Ravlyk%20V%2C%20Schlesingerova%20S%2C%20Smrckova%20E%2C%20Sternthal%20P%2C%20Stursova%20H%2C%20Vymetal%20P%2C%20Wiggers%20P%2C%20Markenvard%20J%2C%20Andersen%20LK%2C%20Frost%20L%2C%20Refsgaard%20J%2C%20Strange%20S%2C%20Egstrup%20K%2C%20Sykulski%20R%2C%20Hildebrant%20P%2C%20Haghfelt%20T%2C%20Ege%20M%2C%20Saaby%20L%2C%20Cattan%20S%2C%20Adam-Blanpain%20M%2C%20Adda%20M%2C%20Aimouch%20N%2C%20Ardouin%20L%2C%20Assouline%20S%2C%20Aumjaud%20A%2C%20Barjhoux%20C%2C%20Baroudi%20R%2C%20Beaurain%20C%2C%20Bennouna%20MA%2C%20Bernard%20A%2C%20Bernardeau%20C%2C%20Blanc%20E%2C%20Blum-Decary%20I%2C%20Bodur%20G%2C%20Boesch%20C%2C%20Bonal%20J%2C%20Bonhomme%20R%2C%20Bonnet%20JL%2C%20Bories%20J%2C%20Bourachot%20ML%2C%20Brumelot%20F%2C%20Petaut%20MB%2C%20Brunschwig%20C%2C%20Buffet%20P%2C%20Calmettes%20P%2C%20Centa%20I%2C%20Chartier%20B%2C%20Chemin%20P%2C%20Chometon%20F%2C%20Cohen%20J%2C%20Colin%20R%2C%20Cottin%20Y%2C%20Crespo%20F%2C%20Dabboura%20A%2C%20David%20F%2C%20Dehayes%20P%2C%20Dematteo%20P%2C%20Dibon%20O%2C%20Dodemant%20P%2C%20Dormagen%20V%2C%20Dreyfus%20X%2C%20Dubois%20JM%2C%20Duclos%20F%2C%20Ducoudre%20M%2C%20Duprez%20O%2C%20Durand%20P%2C%20Durand%20E%2C%20Egloff%20P%2C%20Escande%20M%2C%20Berdou%20MCE%2C%20Ashari%20GE%2C%20Feldmann%20I%2C%20Ferrieres%20J%2C%20Foltzer%20E%2C%20Fontanet%20B%2C%20Garandeau%20M%2C%20Garban%20T%2C%20Geffroy%20S%2C%20Gillet%20T%2C%20Godart%20S%2C%20Gosse%20P%2C%20Gratia%20P%2C%20Greiner%20O%2C%20Gueusquin%20A%2C%20Guiu%20E%2C%20Guy%20JM%2C%20Haddad%20S%2C%20Hennebelle%20V%2C%20Honorat%20S%2C%20Hourany%20A%2C%20Hua%20G%2C%20Jacquier%20P%2C%20Jean%20S%2C%20Jeremiasz%20R%2C%20Kohler%20P%2C%20Lacroix%20A%2C%20Leandri%20M%2C%20Lemiere%20Y%2C%20Liautard%20M%2C%20Loheac%20P%2C%20Louchart%20JC%2C%20Magnus%20P%2C%20Maheu%20B%2C%20Malaterre%20HR%2C%20Manchet%20G%2C%20Mantoux%20J%2C%20Manzi%20D%2C%20Marachli%20M%2C%20Maroun%20M%2C%20Meneveau%20N%2C%20Messas%20E%2C%20Mougeolle%20JL%2C%20Mouhat%20T%2C%20Muller%20J%2C%20Naisseh%20M%2C%20Nocon%20P%2C%20Onger%20D%2C%20Ouguoujil%20A%2C%20Ovize%20M%2C%20Page%20E%2C%20Pareathumby%20K%2C%20Pleskof%20A%2C%20Poinson%20P%2C%20Pons%20G%2C%20Pouderou%20P%2C%20Poujois%20JN%2C%20Probst%20V%2C%20Prunier%20F%2C%20Prunier%20L%2C%20Puel%20V%2C%20Rechtman%20D%2C%20Rennert%20R%2C%20Rijavec%20B%2C%20Riou%20Y%2C%20Robert%20J%2C%20Roche%20C%2C%20Roul%20G%2C%20Salaun%20B%2C%20Saleh%20B%2C%20Sandalian%20A%2C%20Sander%20M%2C%20Schenowitz%20A%2C%20Silvestre%20A%2C%20Soleille%20H%2C%20Tabet%20S%2C%20Tardy%20M%2C%20Thomas-Richard%20F%2C%20Truong%20B%2C%20Varaldi%20J%2C%20Vial%20H%2C%20Walch%20JM%2C%20Wazana%20M%2C%20Zeitouni%20R%2C%20Audibert%20H%2C%20Alizon%20F%2C%20Amlaiky%20A%2C%20Asplanato%20M%2C%20Baranes%20C%2C%20Bariaud%20M%2C%20Bernasconi%20F%2C%20Bousquet%20P%2C%20Ceraulo%20C%2C%20De%20Geeter%20G%2C%20Donetti%20J%2C%20Doucet%20B%2C%20Doucet%20J%2C%20Dutoya%20T%2C%20Ennouchi%20D%2C%20Fallacher%20MH%2C%20Fouquet%20G%2C%20Fourchard%20V%2C%20Gdalia%20J%2C%20Grollier%20G%2C%20Guerard%20S%2C%20Jeannerat%20PA%2C%20Jobic%20Y%2C%20Joulie%20V%2C%20Jourdain%20P%2C%20Jouve%20V%2C%20Ketelers%20R%2C%20Khaznadar%20G%2C%20Kohan%20P%2C%20Koujan%20B%2C%20Lammens%20B%2C%20Landragin%20I%2C%20Moal%20EL%2C%20M%26%23x2019%3BBey%20D%2C%20Maes%20F%2C%20Morlet%20SM%2C%20Massabie%20R%2C%20Meddah%20D%2C%20Meriaux%20FX%2C%20Mestre-Fernandes%20C%2C%20Meyssonnier%20P%2C%20Migliore%20M%2C%20Milewski%20J%2C%20Millet%20JF%2C%20Mingam%20S%2C%20Nazeyrollas%20P%2C%20Paganelli%20F%2C%20Pellerin%20F%2C%20Petitjean%20F%2C%20Pinzani%20A%2C%20Pladys%20A%2C%20Primot%20P%2C%20Pucheu%20A%2C%20Rahali%20A%2C%20Ravoala%20P%2C%20Rousson%20D%2C%20Samama%20P%2C%20Sardon%20M%2C%20Silvestri%20R%2C%20Soskin%20P%2C%20Tabone%20X%2C%20Tricot%20C%2C%20Vaquette%20B%2C%20Vogel%20M%2C%20Weingrod%20M%2C%20Aboyans%20V%2C%20Amoretti%20R%2C%20Aubry%20J%2C%20Berthezene%20P%2C%20Binet%20D%2C%20Bonnaud%20X%2C%20Bonnet%20P%2C%20Bonny%20A%2C%20Bouchaya%20T%2C%20Boureux%20C%2C%20Bourgeois%20JM%2C%20Brottier%20L%2C%20Cavert%20B%2C%20Cleron%20S%2C%20Dechoux%20E%2C%20Delhomme%20C%2C%20Detienne%20JP%2C%20Dubs%20JP%2C%20Faudon%20B%2C%20Fellous%20F%2C%20Fressonnet%20R%2C%20Garaud%20Y%2C%20Garcia%20D%2C%20Geneves%20M%2C%20Gleizes%20JL%2C%20Guyetand%20C%2C%20Hermellin%20B%2C%20Iovescu%20D%2C%20Kanner%20JP%2C%20Khanoyan%20P%2C%20Leherissier%20A%2C%20Maximovitch%20A%2C%20Merian%20B%2C%20Messali%20P%2C%20Moreau%20Y%2C%20Moyal%20J%2C%20Payot%20L%2C%20Peuch%20LP%2C%20Prevot%20JL%2C%20Raymond%20P%2C%20Relange%20D%2C%20Reymond%20S%2C%20Robert%20JF%2C%20Rosenstein%20H%2C%20Schneider%20J%2C%20Schultz%20R%2C%20Tanielian%20P%2C%20Thoin%20F%2C%20Thomas%20L%2C%20Touzet%20P%2C%20Steg%20G%2C%20Sauvinet%20GAO%2C%20Domengetroy%20FB%2C%20Chamou%20K%2C%20Etcheverry%20B%2C%20Farges%20JL%2C%20Fraboulet%20JY%2C%20Goralski%20M%2C%20Janody%20D%2C%20Mamez%20B%2C%20Manlay%20W%2C%20Paillard%20F%2C%20Pelier%20F%2C%20Petit%20A%2C%20Skonieczny%20M%2C%20Augarde%20R%2C%20Fournier%20JB%2C%20Liandrat%20S%2C%20Lim%20P%2C%20Noury%20AI%2C%20Paris%20D%2C%20Saade%20M%2C%20Stordeur%20JM%2C%20Danchin%20N%2C%20Pornin%20M%2C%20Fauchier%20L%2C%20Galinier%20M%2C%20Balice-Pasquinelli%20MA%2C%20Sosner%20P%2C%20Yvorra%20S%2C%20Delcoulx%20E%2C%20Mouquet%20F%2C%20Poulard%20JE%2C%20Sudre%20A%2C%20Heno%20P%2C%20Biausque%20F%2C%20Guenoun%20M%2C%20Attia%20G%2C%20Pouwels%20S%2C%20Carpentier%20L%2C%20Verbrugge%20E%2C%20Ziccarelli%20C%2C%20Elkohen%20M%2C%20Tricoire%20J%2C%20Lang%20P%2C%20Huttin%20O%2C%20Altevogt%20B-M%2C%20Altmann%20U%2C%20Baar%20M%2C%20Berrisch-Rahmel%20S%2C%20Birkenhagen%20A%2C%20Bl%26%23xE4%3Bse%20I%2C%20Blindt%20R%2C%20Bosch%20R%2C%20Brattstr%26%23xF6%3Bm%20A%2C%20Breuer%20H-H%2C%20Castrucci%20M%2C%20Cicek-Hartvig%20S%2C%20Cierpka%20R%2C%20Claus%20M%2C%20Deissner%20M%2C%20Drexler%20M%2C%20Eggeling%20T%2C%20Eisele%20G%2C%20Enayat%20D%2C%20Frickel%20S%2C%20Gessner%20S%2C%20Giokoglu%20K%2C%20Gmehling%20J%2C%20Goss%20F%2C%20Grooterhorst%20P%2C%20Gysan%20DB%2C%20Haberl%20R%2C%20Haerer%20W%2C%20Jun%20NH%2C%20Heinemann-Meerz%20S%2C%20Henschel%20F%2C%20Hinrichsen%20M%2C%20Hofer%20W%2C%20Hofmeister%20A%2C%20Hoh%20G%2C%20Horstkotte%20E%2C%20J%26%23xE4%3Bger%20F%2C%20Jeserich%20M%2C%20Keil%20U%2C%20Killat%20H%2C%20Kimmel%20S%2C%20Kindel%20M%2C%20Kindler%20P%2C%20Kleta%20S%2C%20K%26%23xF6%3Bnemann%20J%2C%20K%26%23xF6%3Bnig%20K%2C%20Krause-Allmendinger%20H%2C%20Kronberg%20K%2C%20Kruck%20I%2C%20M%26%23xE4%3Bnnl%20V%2C%20Meinel%20A%2C%20Mentz%20G%2C%20Meyer-Michael%20E%2C%20Mibach%20F%2C%20M%26%23xF6%3Bller%20S%2C%20Muth%20S%2C%20Nelb%26%23xF6%3Bck-Huber%20E%2C%20Ohlmeyer%20D%2C%20%26%23xD6%3Bzkan-Rashed%20Z%2C%20Paulus%20C-P%2C%20Perings%20S%2C%20Placke%20J%2C%20Raters%20C%2C%20Reifart%20N%2C%20Rink%20A%2C%20Rybak%20K%2C%20Salecker%20I%2C%20Schermaul%20K-H%2C%20Schlesinger-Irsch%20U%2C%20Schmidt%20E%2C%20Schmitz%20K-H%2C%20Sch%26%23xF6%3Bn%20N%2C%20Schr%26%23xF6%3Bder%20T%2C%20Sievers%20B%2C%20Simon%20M%2C%20Spengler%20U%2C%20Speth-Nitschke%20M%2C%20Stumpp%20A%2C%20Szabo%20S%2C%20Taggeselle%20J%2C%20Tamm%20A%2C%20Thelemann%20A%2C%20Thelemann%20C%2C%20Th%26%23xFC%3Bmmel%20H%2C%20Unger%20G%2C%20Utech%20A%2C%20Volmar%20J%2C%20Wauer%20B%2C%20Wehr%20G%2C%20Weinrich%20L%2C%20Weinrich%20R%2C%20Windstetter%20U%2C%20Wirtz%20JH%2C%20Wittlich%20N%2C%20Ziehn%20P%2C%20Z%26%23xFC%3Bndorf%20P%2C%20Wahshi%20YA%2C%20Singh%20PP%2C%20Narayan%20A%2C%20Tamimi%20FA%2C%20Yazeedi%20JA%2C%20Ayche%20M%2C%20Lawati%20AA%2C%20Dhanki%20MA%2C%20Salustri%20A%2C%20Salah%20T%2C%20Tamimi%20MY%2C%20Agrawal%20A%2C%20Wassef%20A%2C%20Baslaib%20F%2C%20Radaideh%20GA%2C%20Yusufali%20A%2C%20Bazargani%20N%2C%20Akbar%20M%2C%20Wahab%20HA%2C%20Malak%20SA%2C%20Ghaly%20I%2C%20Hafez%20H%2C%20Kandari%20FA%2C%20Haiba%20M%2C%20Alanbaei%20M%2C%20Gomaa%20MM%2C%20Khalifa%20A%2C%20Avgerinos%20C%2C%20Gouli%20O%2C%20Stergiou%20D%2C%20Alexopoulos%20I%2C%20Pappas%20C%2C%20Petropoulos%20I%2C%20Chatzioakim%20G%2C%20Pontikakis%20N%2C%20Priftis%20C%2C%20Mpompoth%20P%2C%20Bourazanis%20I%2C%20Papathanasioy%20A%2C%20Avlonitis%20S%2C%20Zakopoulos%20C%2C%20Koutsimpanis%20G%2C%20Tsamopoulos%20I%2C%20Christoforidis%20C%2C%20Zachos%20V%2C%20Kalaras%20P%2C%20Karachaliou%20M%2C%20Liatas%20C%2C%20Pournaras%20G%2C%20Theodorakis%20G%2C%20Orestis%20I%2C%20Panisois%20K%2C%20Chalkiadakis%20E%2C%20Arfaras%20V%2C%20Kolios%20G%2C%20Boutsikos%20P%2C%20Kotsalos%20A%2C%20Mitropoulos%20D%2C%20Samothrakitis%20A%2C%20Svolis%20K%2C%20Anastasiou%20E%2C%20Gkinis%20T%2C%20Dalampyras%20P%2C%20Kalampalikis%20A%2C%20Leontaridis%20I%2C%20Gabriilidis%20S%2C%20Konstantinidis%20I%2C%20Plastiras%20V%2C%20Tarenidis%20P%2C%20Marozs%26%23xE1%3Bn%20I%2C%20%26%23xC9%3Bdes%20I%2C%20Czuriga%20I%2C%20Czir%26%23xE1%3Bki%20A%2C%20T%26%23xF3%3Bth%20K%2C%20Dong%26%23xF3%3B%20%26%23xC1%3B%2C%20T%26%23xFA%3Bri%20P%2C%20Forster%20T%2C%20Borbola%20J%2C%20Bachmann%20B%2C%20Masszi%20G%2C%20Orb%26%23xE1%3Bn%20M%2C%20Gerges%20G%2C%20Balogh%20G%2C%20Bajcsi%20%26%23xC9%3B%2C%20Tak%26%23xE1%3Bcs%20I%2C%20Nagy%20L%2C%20Kisj%26%23xF3%3Bs%20B%2C%20J%26%23xE1%3Bnosi%20A%2C%20Nagy%20A%2C%20Nagy%20K%2C%20B%26%23xFC%3Bttl%20A%2C%20Lippai%20J%2C%20Sziegl%20Z%2C%20Malk%26%23xF3%3Bcs%20Z%2C%20F%26%23xF6%3Bldi%20A%2C%20Fikker%20K%2C%20Szab%26%23xF3%3B%20E%2C%20Forrai%20R%2C%20Seb%26%23xF5%3Bk%20Z%2C%20Merkely%20B%2C%20Gupta%20R%2C%20Natarajan%20S%2C%20Dalal%20J%2C%20Saran%20RK%2C%20Mehta%20A%2C%20Samal%20MP%2C%20Khan%20IA%2C%20Ghose%20T%2C%20Sawhney%20JPS%2C%20Roy%20T%2C%20Chandra%20S%2C%20Modi%20S%2C%20Singh%20MM%2C%20Vijayaraghavan%20G%2C%20Murthy%20LS%2C%20Ramesh%20SS%2C%20Dayasagar%20RV%2C%20Chenniappan%20MS%2C%20Vadavi%20A%2C%20Kunhali%20K%2C%20Reddy%20KS%2C%20Vallal%20ST%2C%20Khera%20P%2C%20Prasad%20B%2C%20Shukla%20D%2C%20Trivedi%20AK%2C%20Ahuja%20R%2C%20Rawal%20J%2C%20Karnik%20R%2C%20Hiremath%20MS%2C%20Kumbla%20DK%2C%20Shetty%20SR%2C%20Chonkar%20NS%2C%20MJuneja%20L%2C%20Goyal%20BK%2C%20Sheahan%20R%2C%20Daly%20C%2C%20Vaughan%20C%2C%20Fleming%20S%2C%20Shiels%20P%2C%20Keelan%20P%2C%20Kiernan%20T%2C%20Day%20B%2C%20Kelly%20K%2C%20MacNamara%20F%2C%20Maguire%20B%2C%20Clifford%20A%2C%20O%26%23x2019%3BGara%20A%2C%20Guardigli%20G%2C%20Pes%20G%2C%20Caridi%20G%2C%20Frattola%20A%2C%20Doronzo%20B%2C%20Riccioni%20G%2C%20Lacch%26%23xE8%3B%20A%2C%20Massari%20F%2C%20Orazi%20S%2C%20Carretta%20D%2C%20Provvidenza%20M%2C%20Pedretti%20R%2C%20Nicolino%20A%2C%20Felis%20S%2C%20Pernice%20V%2C%20Gaglione%20A%2C%20Gori%20P%2C%20Martina%20P%2C%20d%26%23x2019%3BAlessandro%20V%2C%20Giacomazzi%20F%2C%20Terrosu%20P%2C%20Cernetti%20C%2C%20Antonicelli%20R%2C%20Ansalone%20G%2C%20Balbi%20M%2C%20Tamburino%20C%2C%20Moretti%20L%2C%20Tantillo%20S%2C%20Patriarchi%20F%2C%20Proietti%20F%2C%20Sinicropi%20G%2C%20Maragoni%20G%2C%20Mallamaci%20V%2C%20d%26%23x2019%3BEste%20D%2C%20Azzolini%20P%2C%20Brscic%20E%2C%20Bongo%20S%2C%20Gigantino%20A%2C%20Perna%20G%2C%20Mayer%20MS%2C%20Rosa%20CL%2C%20Muscio%20G%2C%20Scollo%20V%2C%20Magliari%20F%2C%20Pio%20CP%2C%20Castellari%20M%2C%20Pasquale%20PD%2C%20Scalzo%20D%2C%20Saporito%20F%2C%20Capuano%20N%2C%20Alitto%20F%2C%20Marchionni%20N%2C%20Turiel%20M%2C%20Bianco%20A%2C%20Greco%20C%2C%20Marullo%20L%2C%20Testa%20R%2C%20Vicentini%20A%2C%20Novo%20S%2C%20Varra%20FL%2C%20Tavazzi%20L%2C%20Conte%20MR%2C%20Lazerevic%20Z%2C%20Colivicchi%20F%2C%20Macchi%20C%2C%20Mule%20JD%2C%20Sibilio%20G%2C%20Achilli%20A%2C%20Proto%20C%2C%20Kang%20SM%2C%20Koo%20BK%2C%20Hong%20SK%2C%20Kim%20W%2C%20Lee%20SH%2C%20Yoo%20BS%2C%20Seo%20HS%2C%20Gwon%20HC%2C%20Kang%20DH%2C%20Kwon%20HM%2C%20Chae%20IH%2C%20Oh%20SJ%2C%20Shin%20JH%2C%20Goh%20CW%2C%20Byun%20YS%2C%20Zo%20JH%2C%20Hong%20TJ%2C%20Kim%20DS%2C%20Cha%20TJ%2C%20Ryu%20JK%2C%20Kim%20YJ%2C%20Hwang%20JY%2C%20Hur%20SH%2C%20Jeong%20MH%2C%20Oh%20SK%2C%20Jin%20DK%2C%20Jung%20KT%2C%20Rhew%20JY%2C%20Lee%20S%2C%20Jeon%20DW%2C%20Yoon%20SJ%2C%20Kim%20SH%2C%20Mintale%20I%2C%20Latkovskis%20G%2C%20Hansone%20S%2C%20Rozkova%20N%2C%20Baika%20A%2C%20Jasinkevica%20I%2C%20Abele%20S%2C%20Laizane%20I%2C%20Pontaga%20N%2C%20Ecina%20V%2C%20Mihailova%20I%2C%20Kondratovica%20A%2C%20Laucevi%26%23x10D%3Bius%20A%2C%20Jurgaitien%26%23x117%3B%20R%2C%20%26%23x160%3Blapikas%20R%2C%20Barauskien%26%23x117%3B%20G%2C%20Jankauskien%26%23x117%3B%20E%2C%20Revien%26%23x117%3B%20S%2C%20Zaronskien%26%23x117%3B%20D%2C%20%26%23x160%3Blapikien%26%23x117%3B%20OB%2C%20Kupstyt%26%23x117%3B%20N%2C%20Rink%26%23x16B%3Bnien%26%23x117%3B%20E%2C%20Stepon%26%23x117%3Bnien%26%23x117%3B%20R%2C%20Kojelien%26%23x117%3B%20J%2C%20Badarien%26%23x117%3B%20J%2C%20D%26%23x17E%3Benkevi%26%23x10D%3Bi%26%23x16B%3Bt%26%23x117%3B%20V%2C%20Sadauskien%26%23x117%3B%20E%2C%20Butkuvien%26%23x117%3B%20I%2C%20Stankevi%26%23x10D%3Bius%20R%2C%20Paliulionien%26%23x117%3B%20R%2C%20Snikyt%26%23x117%3B%20R%2C%20Ma%26%23x17E%3Butavi%26%23x10D%3Bius%20R%2C%20Jamaluddin%20AN%2C%20Rahim%20AAA%2C%20Yusof%20AKM%2C%20Chee%20KH%2C%20Sadiq%20MA%2C%20Ramanaidu%20S%2C%20Sim%20KH%2C%20Ong%20TK%2C%20Fong%20AYY%2C%20Chang%20BC%2C%20Chua%20SK%2C%20Cham%20YL%2C%20Amin%20NHM%2C%20Tan%20SK%2C%20Khiew%20NZ%2C%20Said%20A%2C%20Abdullah%20CK%2C%20Cheah%20YW%2C%20Sinnadurai%20J%2C%20Lau%20KKH%2C%20Choor%20CK%2C%20Sia%20KK%2C%20Ang%20CC%2C%20Singh%20JSA%2C%20Wahab%20MZA%2C%20Wong%20CK%2C%20Ghapar%20AK%2C%20Muthu%20A%2C%20Mahendran%20KA%2C%20Jaafar%20AH%2C%20Ng%20KH%2C%20Ruhani%20AI%2C%20Tahir%20HAR%2C%20Manap%20HA%2C%20Ch%26%23x2019%3Bng%20BSK%2C%20Ch%26%23x2019%3Bng%20ET%2C%20Abdullah%20AS%2C%20Ismail%20O%2C%20Sahar%20AS%2C%20Kareem%20BBA%2C%20Kader%20MASA%2C%20Ma%20SK%2C%20Chan%20KK%2C%20Goh%20TH%2C%20Singh%20A%2C%20Liew%20HB%2C%20Chu%20CM%2C%20Bhaskaran%20RKM%2C%20Shah%20RP%2C%20Joseph%20KL%2C%20Hasni%20HN%2C%20Ng%20WK%2C%20Choo%20GH%2C%20Saaidin%20N%2C%20Yeo%20CK%2C%20Lai%20VM%2C%20Lai%20YC%2C%20Tay%20MH%2C%20Lim%20BA%2C%20Luqman%20HN%2C%20Esperon%20GL%2C%20Alvarez%20JDJZSYA%2C%20Manzur%20FA%2C%20S%26%23xE1%3Bnchez%20CJ%2C%20Rojas%20JC%2C%20Calvillo%20JC%2C%20Aranguren%20FP%2C%20S%26%23xE1%3Bnchez%20CM%2C%20Sangabriel%20A%26%23xC1%3B%2C%20Vieyra%20G%2C%20Romero%20SG%2C%20Barrag%26%23xE1%3Bn%20AP%2C%20Escalante%20FR%2C%20Paez%20JC%2C%20Valadez%20EF%2C%20Gaxiola%20E%2C%20Manautou%20LE%2C%20Otero%20OH%2C%20Bustillos%20MB%2C%20Pons%20JLL%2C%20%26%23xC1%3Blvarez%20EG%2C%20Santana%20JRR%2C%20Redding%20JM%2C%20Mendoza%20AA%2C%20Briones%20IR%2C%20Arellano%20JDJR%2C%20Le%26%23xF3%3Bn%20JLA%2C%20Gamba%20MA%2C%20Alexanderson%20E%2C%20Esparza%20MER%2C%20Sifuentes%20LAE%2C%20Brise%26%23xF1%3Bo%20JL%2C%20Rodriguez%20ES%2C%20Delgado%20MLF%2C%20Navarrete%20SS%2C%20Juarezy%20UC%2C%20Pinales%20AL%2C%20Castro%20A%2C%20Carpio%20RC%2C%20Rodr%26%23xED%3Bguez%20E%2C%20Rojas%20G%2C%20Solache%20G%2C%20Ju%26%23xE1%3Brez%20RD%2C%20Bale%26%23xF3%3Bn%20R%2C%20Solorio%20CF%2C%20Reyes%20HAR%2C%20Mart%26%23xED%3Bnez%20ML%2C%20Maldonado%20MAR%2C%20De%20La%20Pe%26%23xF1%3Ba%20JE%2C%20Orozco%20JHJ%2C%20Cisneros%20FAR%2C%20Gil%20J%26%23xC1%3B%2C%20L%26%23xF3%3Bpez%20GB%2C%20Ibarra%20MODLR%2C%20I%20Tulevski%20I%2C%20Somsen%20GA%2C%20Miedema%20K%2C%20Chlewicka%20I%2C%20Brodzicki%20P%2C%20Stasiuk%20T%2C%20Sza%26%23x142%3Bkowski%20P%2C%20Kulig%20W%2C%20Maliszewski%20M%2C%20Kr%26%23xF3%3Blicka%20K%2C%20Zdrojewska%20J%2C%20Nikodemska%20I%2C%20Szpak%20A%2C%20Wr%26%23x119%3Bbiak-Trznadel%20M%2C%20Prokop%20A%2C%20Szulc%20M%2C%20Olszewski%20A%2C%20K%26%23x119%3Bpa%20W%2C%20Banach%20J%2C%20W%26%23x119%3Bglarz%20M%2C%20Ga%26%23x142%3Buszka-Bili%26%23x144%3Bska%20A%2C%20Kr%26%23xF3%3Blak%20A%2C%20Cisowska-Drozd%20E%2C%20Orzechowski%20K%2C%20Je%26%23x17C%3Bewska%20M%2C%20Adamaszek%20K%2C%20Glanowska%20G%2C%20Pitsch%20T%2C%20Matuszewska%20G%2C%20Nowowiejska-Wiewi%26%23xF3%3Bra%20A%2C%20Dere%26%23x144%3B%20M%2C%20Walawski%20G%2C%20So%26%23x142%3Btysiak%20M%2C%20Wysocki%20R%2C%20Jarosi%26%23x144%3Bski%20G%2C%20Drzewiecka%20A%2C%20%26%23x141%3Bugowski%20T%2C%20Jankowska%20A%2C%20B%26%23x142%3Baszczak%20P%2C%20Drozd%20J%2C%20%26%23x141%3Botocka%20E%2C%20Duchowska%20R%2C%20Sobczyk%20D%2C%20Jarmu%26%23x17C%3Bek%20P%2C%20Sidor%20M%2C%20Adamczyk-Kot%20D%2C%20Sudnik%20J%2C%20Cygler%20J%2C%20Skoczylas%20I%2C%20Poprawa%20B%2C%20Kisiel%20L%2C%20Kossowska%20U%2C%20Sikorska-Buczkowska%20B%2C%20Modzelewska%20K%2C%20Demianiuk%20B%2C%20Streb%20W%2C%20Mularek-Kubzdela%20T%2C%20Bogda%26%23x144%3Bski%20P%2C%20Ka%26%23x17A%3Bmierczak%20E%2C%20Zimol%26%23x105%3Bg%20R%2C%20Lorenc%20J%2C%20Furtak%20R%2C%20Regulska%20A%2C%20Winter%20M%2C%20Fic%20M%2C%20Turek%20P%2C%20Nowicka%20E%2C%20Bryl%20W%2C%20Lenartowska%20L%2C%20Jerzykowska%20O%2C%20Ma%26%23x107%3Bk%26%23xF3%3Bw%20M%2C%20Gadzi%26%23x144%3Bski%20W%2C%20Kacorzyk%20R%2C%20Zalewska%20D%2C%20Sad%26%23x142%3Bowski%20R%2C%20S%26%23x142%3Baboszewska%20J%2C%20Grucha%26%23x142%3Ba%20M%2C%20Frankiewicz%20A%2C%20Walczewska%20J%2C%20Adamkiewicz-Piejko%20A%2C%20Chyrek%20R%2C%20Jankowska%20L%2C%20Correia%20A%2C%20Gir%26%23xE3%3Bo%20A%2C%20Herdade%20%26%23xC1%3B%2C%20Sequeira%20A%2C%20Taveira%20ATE%2C%20Gonzaga%20A%2C%20Ribeiro%20A%2C%20Albuquerque%20A%2C%20Fernandes%20A%2C%20Estriga%20A%2C%20De%20Almeida%20AR%2C%20Louren%26%23xE7%3Bo%20A%2C%20Pereira%20A%2C%20Faria%20A%2C%20De%20Moura%20BC%2C%20Camossa%20C%2C%20Alves%20C%2C%20Aguiar%20C%2C%20Rodrigues%20C%2C%20Wellenkamp%20E%2C%20De%20Sousa%20FF%2C%20Pinto%20FM%2C%20Matias%20F%2C%20Alves%20GS%2C%20Bragan%26%23xE7%3Ba%20G%2C%20Proen%26%23xE7%3Ba%20G%2C%20P%26%23xEA%3Bgo%20GM%2C%20Vinhas%20H%2C%20Arroja%20I%2C%20Morais%20J%2C%20S%26%23xE1%3B%20JSE%2C%20Vasconcelos%20J%2C%20Matos%20J%2C%20Freitas%20J%2C%20Ferreira%20J%2C%20Costa%20J%2C%20Alcaravela%20J%2C%20Mimoso%20J%2C%20Antunes%20J%2C%20Dos%20Santos%20JF%2C%20Dos%20Santos%20JN%2C%20Fernandes%20J%2C%20De%20Aguiar%20JC%2C%20Moreira%20J%2C%20Carvalho%20J%2C%20De%20Carvalho%20JF%2C%20Cala%26%23xE7%3Ba%20J%2C%20Sim%26%23xF5%3Bes%20L%2C%20Antunes%20LL%2C%20Soares%20L%2C%20Semedo%20L%2C%20Macedo%20L%2C%20Sargento%20L%2C%20Basto%20L%2C%20Rebelo%20L%2C%20Oliveira%20L%2C%20Carvalho%20MC%2C%20Costa%20MA%2C%20Gamboa%20MC%2C%20Vasconcelos%20MFFE%2C%20Cust%26%23xF3%3Bdio%20MH%2C%20Mendon%26%23xE7%3Ba%20MI%2C%20Vaz%20MJP%2C%20De%20Macedo%20ME%2C%20Lazaro%20M%2C%20Oliveira%20MM%2C%20Pelicano%20N%2C%20Lousada%20N%2C%20Rodrigues%20O%2C%20Dias%20PM%2C%20Fonseca%20PF%2C%20Ferreira%20P%2C%20Abreu%20PFE%2C%20Monteiro%20P%2C%20Gomes%20RS%2C%20Carvalho%20R%2C%20Santos%20R%2C%20Soares%20RR%2C%20Baptista%20S%2C%20Monteiro%20SR%2C%20Gil%20V%2C%20Sanfins%20V%2C%20Martins%20V%2C%20Anghel%20M%2C%20Georgescu%20CA%2C%20Babes%20K%2C%20Banu%20M%2C%20Beyer%20R%2C%20Bratu%20I%2C%20Bumbu%20A%2C%20Capalneanu%20R%2C%20Chioncel%20OD%2C%20Chiscaneanu%20T%2C%20Christodorescu%20R%2C%20Nica%20NC%2C%20Cinteza%20M%2C%20Coman%20S%2C%20Constantinescu%20M%2C%20Craiu%20E%2C%20Dan%20GA%2C%20Dan%20DC%2C%20Dan%20A%2C%20David%20CM%2C%20Dorobantu%20M%2C%20Farcas%20D%2C%20Firastrau%20V%2C%20Florescu%20C%2C%20Ghicu%20A%2C%20Giuca%20A%2C%20Grigoriu%20R%2C%20Ionescu%20DD%2C%20Iosipescu%20LC%2C%20Ivan%20MV%2C%20Lighezan%20D%2C%20Magheru%20S%2C%20Magherusan%20M%2C%20Marinescu%20SM%2C%20Motoc%20AC%2C%20Musetescu%20R%2C%20Rau%20M%2C%20Rus%20LRH%2C%20Sirbu%20O%2C%20Sorodoc%20L%2C%20Spinu%20CM%2C%20Stanciulescu%20G%2C%20Statescu%20C%2C%20Toringhibel%20M%2C%20Trambitas%20R%2C%20Trocan%20N%2C%20Tudose%20A%2C%20Vinereanu%20D%2C%20Zagreanu%20M%2C%20Motomancea%20R%2C%20Militaru%20C%2C%20Dymova%20D%2C%20Semenova%20N%2C%20Zherebtsova%20A%2C%20Fedoskin%20V%2C%20Gurianova%20N%2C%20Bolotova%20N%2C%20Knyazeva%20V%2C%20Spitsina%20T%2C%20Sytilina%20N%2C%20Atamanchuk%20N%2C%20Giorgadze%20M%2C%20Zarechnova%20S%2C%20Kutuzova%20S%2C%20Sharapova%20Y%2C%20Stelmakh%20I%2C%20Sinyukova%20O%2C%20Rostik%20S%2C%20Evtukhova%20L%2C%20Sukhanova%20L%2C%20Makhieva%20T%2C%20Tereshko%20S%2C%20Kolesnikov%20V%2C%20Kochurov%20E%2C%20Marchenko%20B%2C%20Nurgalieva%20S%2C%20Galeeva%20Z%2C%20Andreicheva%20E%2C%20Zakirova%20V%2C%20Baleeva%20L%2C%20Minsafina%20A%2C%20Borodina%20N%2C%20Arkhipova%20Y%2C%20Krechunova%20T%2C%20Scherbak%20M%2C%20Merkhi%20A%2C%20Aksyutina%20N%2C%20Ratovskaya%20O%2C%20Suglobova%20E%2C%20Kozhelenko%20Y%2C%20Potapova%20E%2C%20Poluyanova%20G%2C%20Naberezhnova%20N%2C%20Daniels%20E%2C%20Atueva%20K%2C%20Tsaryabina%20L%2C%20Kurekhyan%20A%2C%20Khishova%20N%2C%20Dubinina%20E%2C%20Demina%20O%2C%20Mochkina%20P%2C%20Bukanina%20E%2C%20Tolpygina%20S%2C%20Polyanskaya%20Y%2C%20Malysheva%20A%2C%20Kheliya%20T%2C%20Serazhim%20A%2C%20Voronina%20V%2C%20Lukina%20Y%2C%20Dubinskaya%20R%2C%20Dmitrieva%20N%2C%20Kuzyakina%20M%2C%20Khartova%20N%2C%20Bokuchava%20N%2C%20Smirnova%20E%2C%20Esenokova%20A%2C%20Pavlova%20Y%2C%20Smirnova%20O%2C%20Astrakhantseva%20P%2C%20Bykovskaya%20S%2C%20Charikova%20O%2C%20Berdnik%20K%2C%20Karaseva%20T%2C%20Zhabina%20L%2C%20Oleinikova%20N%2C%20Dzhkha%20O%2C%20Grigoryan%20S%2C%20Yakovenko%20E%2C%20Ivaschenko%20T%2C%20Kiseleva%20I%2C%20Shokina%20T%2C%20Novikova%20M%2C%20Khodanov%20A%2C%20Popova%20L%2C%20Latyntseva%20L%2C%20Kilaberiya%20O%2C%20Makarenkova%20K%2C%20Nosova%20N%2C%20Gerasimova%20T%2C%20Boikova%20L%2C%20Sharapova%20N%2C%20Kulikova%20Y%2C%20Pasechnaya%20N%2C%20Bulakhova%20E%2C%20Kurochkina%20S%2C%20Bratishko%20I%2C%20Likhobabina%20O%2C%20Panova%20E%2C%20Voronina%20N%2C%20Bizyaeva%20N%2C%20Gusev%20O%2C%20Nevolina%20N%2C%20Arsentieva%20T%2C%20Budanova%20I%2C%20Melnikova%20EL%2C%20Khripun%20A%2C%20Polyaeva%20L%2C%20Osadchuk%20E%2C%20Krasnoslobodskaya%20O%2C%20Yakimova%20N%2C%20Lugin%20A%2C%20Sosnova%20Y%2C%20Il%26%23x2019%3Bina%20E%2C%20Kositsina%20G%2C%20Shanina%20I%2C%20Kostomarova%20S%2C%20Malgina%20M%2C%20Omelchenko%20M%2C%20Gorlova%20I%2C%20Eidelman%20S%2C%20Salakhova%20A%2C%20Bondarenko%20B%2C%20Sopia%20R%2C%20Baboshina%20N%2C%20Eliseeva%20N%2C%20Tumarov%20F%2C%20Petrochenko%20N%2C%20Khudina%20I%2C%20Arabadzhi%20N%2C%20Samakhovets%20V%2C%20Tkhorzhevskaya%20L%2C%20Sinotova%20T%2C%20Zherlitsyna%20E%2C%20Minkin%20S%2C%20Petrova%20N%2C%20Tikhonov%20Y%2C%20Shmakova%20N%2C%20Abduvalieva%20V%2C%20Kuzmicheva%20M%2C%20Nikolaeva%20L%2C%20Varezhnikova%20O%2C%20Dmitrieva%20T%2C%20Mikhailova%20E%2C%20Yanina%20Y%2C%20Kapustina%20L%2C%20Vazhdaeva%20Z%2C%20Golovina%20G%2C%20Fedorova%20N%2C%20Nikolaeva%20I%2C%20Fillipova%20O%2C%20Gareeva%20L%2C%20Tuktarova%20F%2C%20Khmelevskikh%20N%2C%20Karnot%20V%2C%20Golub%20M%2C%20Surovtseva%20I%2C%20Kulygina%20V%2C%20Shelomova%20N%2C%20Kruglova%20I%2C%20Pokrovskaya%20I%2C%20Rodina%20O%2C%20Polkina%20L%2C%20Biryukova%20N%2C%20Filippova%20E%2C%20Kotova%20E%2C%20Ignatieva%20T%2C%20Alekseeva%20T%2C%20Gruznykh%20L%2C%20Mozerova%20E%2C%20Moksyuta%20E%2C%20Kosachek%20E%2C%20Srtumilenko%20N%2C%20Baranova%20O%2C%20Voronova%20T%2C%20Bayakhchan%20L%2C%20Grudtsina%20I%2C%20Gorshkova%20L%2C%20Shamsutdinova%20O%2C%20Getman%20M%2C%20Gorodilova%20I%2C%20Karnaukhova%20N%2C%20Rotenberger%20V%2C%20Isaeva%20L%2C%20Lebischak%20G%2C%20Ryzhkova%20V%2C%20Usoltseva%20E%2C%20Mescharekova%20D%2C%20Tavlueva%20E%2C%20Mineeva%20E%2C%20Stikhurova%20M%2C%20Kosareva%20L%2C%20Grechishkina%20O%2C%20Nikishina%20S%2C%20Ilyukhina%20A%2C%20Gureeva%20O%2C%20Soin%20I%2C%20Erofeev%20S%2C%20Lebedev%20S%2C%20Kudryavtsev%20L%2C%20Gamzatov%20E%2C%20Maximchuk%20N%2C%20Grekhova%20L%2C%20Kolevatova%20L%2C%20Kazakovtseva%20M%2C%20Kolesova%20O%2C%20Zharikova%20L%2C%20Kukaleva%20V%2C%20Starostina%20N%2C%20Grushetskaya%20I%2C%20Kazachkova%20V%2C%20Pashentseva%20I%2C%20Shimonenko%20S%2C%20Sirazov%20I%2C%20Chernozemova%20A%2C%20Golubeva%20O%2C%20Mingalaeva%20S%2C%20Zatsarina%20E%2C%20Kozlov%20D%2C%20Davydova%20N%2C%20Larina%20O%2C%20Alhabib%20KF%2C%20Hersi%20A%2C%20Al-Backer%20H%2C%20AlFaleh%20H%2C%20Mobeirek%20A%2C%20Arafah%20M%2C%20Al-Shamiri%20M%2C%20El-Shaer%20F%2C%20Zaibag%20MA%2C%20Bdeir%20M%2C%20Suliman%20I%2C%20Mukhtar%20A%2C%20Omar%20H%2C%20Jamiel%20A%2C%20Elkrail%20A%2C%20Alanazy%20M%2C%20Habab%20M%2C%20Ashmak%20K%2C%20Nourallah%20R%2C%20Mak%20KH%2C%20Singh%20B%2C%20Chee%20TS%2C%20Koo%20CC%2C%20Low%20LP%2C%20Nair%20VP%2C%20Ng%20KS%2C%20Quek%20SSS%2C%20Tan%20EHM%2C%20Ng%20ALR%2C%20Chuang%20HH%2C%20Kamensky%20G%2C%20Kaliska%20G%2C%20Murin%20J%2C%20Hatalova%20K%2C%20Gaspar%20L%2C%20Simkova%20I%2C%20Dubrava%20J%2C%20Pjontek%20J%2C%20Pella%20D%2C%20Banikova%20A%2C%20Szentivanyi%20M%2C%20Kovar%20F%2C%20Benacka%20J%2C%20Gonos%20I%2C%20Fazekas%20F%2C%20Kycina%20P%2C%20Poles%20J%2C%20Fras%20Z%2C%20Pernat%20A%2C%20Veternik%20A%2C%20%26%23x10C%3Berni%26%23x10D%3B-%26%23x160%3Buligoj%20N%2C%20Kerbev%20M%2C%20Krajnc%20I%2C%20Zago%26%23x17E%3Ben%20P%2C%20Alam%20A%2C%20Brown%20B%2C%20Luke%20B%2C%20Variava%20E%2C%20Nethononda%20R%2C%20Joubert%20S%2C%20Matthews%20P%2C%20Nkombua%20L%2C%20Antia%20V%2C%20Naidoo%20DP%2C%20Bhayat%20J%2C%20George%20SK%2C%20Ranjith%20N%2C%20Vawda%20GHM%2C%20Govender%20S%2C%20Soosiwala%20I%2C%20Shein%20K%2C%20Panajatovic%20M%2C%20Flores%20J%2C%20Khan%20MSH%2C%20Blignaut%20S%2C%20Coetzee%20K%2C%20Burgess%20L%2C%20Freeman%20V%2C%20Theron%20HD%2C%20Vives%20MAA%2C%20Oliva%20FJA%2C%20Carrascosa%20PA%2C%20Mart%26%23xED%3Bnez%20VA%2C%20Colomer%20JMA%2C%20Ezquerra%20EA%2C%20Fern%26%23xE1%3Bndez%20CAA%2C%20Recalde%20NA%2C%20Au%26%23xF1%3Bon%20AA%2C%20Garc%26%23xED%3Ba%20PA%2C%20Fern%26%23xE1%3Bndez%20CA%2C%20Galito%20CA%2C%20Viguiristi%20RA%2C%20Feal%20MA%2C%20Capell%20AA%2C%20Pardo%20JA%2C%20Garc%26%23xED%3Ba%20GA%2C%20Esteban%20VA%2C%20Alonso%20MB%2C%20P%26%23xE9%3Brez%20PB%2C%20Mayor%20JLB%2C%20Alvarez%20VB%2C%20Celorio%20AB%2C%20Mart%26%23xED%3Bn%20BB%2C%20Valero%20DB%2C%20Casti%26%23xF1%3Beiras%20JB%2C%20Ojeda%20FB%2C%20Penas%20CB%2C%20Redondo%20HB%2C%20Cortada%20JB%2C%20Sol%26%23xE9%3B%20RC%2C%20Iglesias%20FC%2C%20Miguel%20SC%2C%20Cardoso%20RC%2C%20Pi%26%23xE9%3B%20MC%2C%20Gim%26%23xE9%3Bnez%20PC%2C%20Lue%26%23xF1%3Ba%20EC%2C%20Moreno%20JAC%2C%20Orive%20MC%2C%20Gonz%26%23xE1%3Blez%20AC%2C%20Alcubilla%20JMC%2C%20Pay%26%23xE1%3B%20VC%2C%20Gil%20MAC%2C%20Mart%26%23xED%3Bn%20JLC%2C%20Clemente%20AC%2C%20S%26%23xE1%3Bnchez%20RC%2C%20Luengo%20DC%2C%20Soler%20SD%2C%20Novales%20JDA%2C%20Aritmendiz%20RDC%2C%20Baguda%20JDJ%2C%20L%26%23xF3%3Bpez%20MDLR%2C%20Prieto%20JLD%2C%20D%26%23xED%3Baz%20JLD%2C%20Cervantes%20CE%2C%20Sasieta%20JE%2C%20Rubio%20LF%2C%20Salvador%20CF%2C%20Zaragoza%20PF%2C%20Alvarez%20RF%2C%20De%20La%20Cigo%26%23xF1%3Ba%20FF%2C%20L%26%23xE1%3Bzaro%20LAF%2C%20L%26%23xE9%3Boz%20LCF%2C%20Mouzo%20RF%2C%20G%26%23xF3%3Bmez%20MF-V%2C%20Rodr%26%23xED%3Bguez%20BF%2C%20Aranda%20CF%2C%20Corzo%20JF%2C%20Alonso%20JF%2C%20Beneitez%20JF%2C%20Basilio%20EG%2C%20Garc%26%23xED%3Ba%20CG%2C%20Mart%26%23xED%3Bnez%20MJG%2C%20Gonz%26%23xE1%3Blez%20MJG%2C%20Ortego%20SG%2C%20Pindado%20CG%2C%20Saavedra%20VG%2C%20Marim%26%23xF3%3Bn%20JG-M%2C%20Rubia%20RG%2C%20Lorente%20DG%2C%20Pav%26%23xF3%3Bn%20HG%2C%20G%26%23xF3%3Bmez%20RG%2C%20Barrado%20JJG%2C%20Doblas%20JJG%2C%20Martinez%20MJG%2C%20Juanatey%20CG%2C%20Toda%20VG%2C%20Ortega%20MG%2C%20Higuero%20EG%2C%20Afonso%20JH%2C%20Fern%26%23xE1%3Bndez%20DH%2C%20Espinach%20EH%2C%20Gastearena%20AI%2C%20Latasa%20MI%2C%20Gonz%26%23xE1%3Blez%20RI%2C%20Herter%20MJ%2C%20Carballo%20ML%2C%20Gal%26%23xE1%3Bn%20JAL%2C%20Gonz%26%23xE1%3Blez%20BL%2C%20Aranda%20MAL%2C%20Barreiro%20LL%2C%20G%26%23xF3%3Bmez%20DL%2C%20Granados%20AL%2C%20Mouri%26%23xF1%3Bo%20VL%2C%20L%26%23xF3%3Bpez-Send%26%23xF3%3Bn%20JL%2C%20M%26%23xE9%3Bndez%20ML%2C%20Latorre%20LM%2C%20Araez%20EM%2C%20Ortu%26%23xF1%3Bo%20FM%2C%20Santana%20AM%2C%20Florez%20JM%2C%20Gonz%26%23xE1%3Blez%20JM%2C%20Rivero%20JFM%2C%20Mart%26%23xED%3Bn%20DM%2C%20Mignaqui%20GFM%2C%20Pita%20AM%2C%20Laborda%20EM%2C%20Escriv%26%23xE1%3B%20GM%2C%20Saavedra%20VM%2C%20Gaspar%20MAM%2C%20Robles%20JM%2C%20Gonz%26%23xE1%3Blez%20JM%2C%20Arribas%20JM%2C%20Casquete%20MTM%2C%20L%26%23xF3%3Bpez%20CM%2C%20Eizagaechevarr%26%23xED%3Ba%20NM%2C%20Garc%26%23xED%3Ba%20FN%2C%20Manch%26%23xF3%3Bn%20JN%2C%20Navas%20CN%2C%20Garc%26%23xED%3Ba%20EN%2C%20Gamero%20JAN%2C%20Espa%26%23xF1%3Ba%20AO%2C%20L%26%23xF3%3Bpez%20JAODM%2C%20Soler%20EO%2C%20Chulian%20EO%2C%20Torres%20LP%2C%20S%26%23xE1%3Bnchez%20AJP%2C%20Bermejo%20MAP%2C%20Del%20Moral%20VP%2C%20P%26%23xE9%3Brez%20GP%2C%20Egido%20J%26%23xC1%3BP%2C%20De%20Isla%20LP%2C%20Ibiricu%20SP%2C%20Mart%26%23xED%3Bnez%20MAP%2C%20Paredes%20MP%2C%20Domingo%20EP%2C%20Cubero%20AMP%2C%20Sopena%20JP%2C%20Rodr%26%23xED%3Bguez%20CP%2C%20Lozano%20MJP%2C%20Ram%26%23xED%3Brez%20CP%2C%20Ramos%20YP%2C%20Moriche%20EP%2C%20Ariznabarreta%20FR%2C%20Guti%26%23xE9%3Brrez%20MR%2C%20Catal%26%23xE1%3Bn%20JMR%2C%20Almod%26%23xF3%3Bvar%20AR%2C%20Collado%20JR%2C%20Fern%26%23xE1%3Bndez%20AR%2C%20Fern%26%23xE1%3Bndez%20JAR%2C%20Hern%26%23xE1%3Bndez%20JAR%2C%20Tejero%20IR%2C%20Castillejo%20IR%2C%20Alvira%20DR%2C%20Hinojosa%20JAR%2C%20Menor%20CR%2C%20Sevillano%20PR%2C%20Calle%20ECR%2C%20Soriano%20JR%2C%20P%26%23xE9%3Brez%20PR%2C%20Gorostiza%20TS%2C%20Hidalgo%20IS%2C%20Roll%26%23xE1%3Bn%20MS%2C%20Rodr%26%23xED%3Bguez%20SS%2C%20Olmeda%20ES%2C%20Iglesias%20JLS%2C%20Rodr%26%23xED%3Bguez%20MLS%2C%20Laborda%20IS%2C%20Garc%26%23xED%3Ba%20SS%2C%20Toral%20BS%2C%20Melchor%20LS%2C%20Mart%26%23xED%3Bn-Ambrioso%20ES%2C%20Casado%20RS%2C%20Navarro%20CS%2C%20Ruiz%20MIS%2C%20Calle%20PT%2C%20Fern%26%23xE1%3Bndez%20ET%2C%20D%26%23xED%3Baz%20PLT%2C%20Gil%20AT%2C%20Berraquero%20FT%2C%20Mart%26%23xED%3Bnez%20MAU%2C%20S%26%23xE1%3Bnchez%20JU%2C%20Herreros%20CV%2C%20Garc%26%23xED%3Ba%20AV%2C%20Barbado%20JLV%2C%20Espejo-Saavedra%20EV%2C%20Vera%20TV%2C%20Guti%26%23xE9%3Brrez%20MV%2C%20Mariscal%20CV%2C%20Boniato%20GV%2C%20Amen%20LW%2C%20Bowden%20GY%2C%20Wonenburger%20JCY%2C%20G%26%23xF3%3Bmez%20JLZ%2C%20Navarro%20JZ%2C%20Monnier%20P%2C%20Jaussi%20A%2C%20Forclaz%20A%2C%20Grob%26%23xE9%3Bty%20M%2C%20Schlueter%20L%2C%20Vuille%20C%2C%20Nacht%20CA%2C%20Ev%26%23xE9%3Bquoz%20D%2C%20Ciaroni%20S%2C%20Domin%26%23xE9%3B%20F%2C%20B%26%23xE9%3Brub%26%23xE9%3B%20J%2C%20Rickli%20H%2C%20Hellermann%20J%2C%20Koller%20R%2C%20Bourgeois%20G%2C%20Engel%20R%2C%20Niederberger%20C%2C%20Stadler%20P%2C%20Gn%26%23xE4%3Bdinger%20M%2C%20Schmied%20C%2C%20Wettstein%20T%2C%20Hilti%20P%2C%20Ch%26%23xE9%3Btelat%20CA%2C%20Sepulcri%20F%2C%20Brunner%20H%2C%20Schindler%20J%2C%20Kraus%20M%2C%20Vivekaphirat%20V%2C%20Panpunnung%20S%2C%20Kuanprasert%20S%2C%20Wongcharoen%20W%2C%20Phrommintikul%20A%2C%20Harinasuta%20J%2C%20Si%20O%2C%20Chaithiraphan%20V%2C%20Boonyasirinant%20T%2C%20Boonyapisit%20W%2C%20Kittipovanonth%20M%2C%20Buakhamsri%20A%2C%20Piyayotai%20D%2C%20Hutayanon%20P%2C%20Junejo%20S%2C%20Aiyegbayo%20O%2C%20Ancliff%20H%2C%20Bradshaw%20C%2C%20Cervenak%20R%2C%20Choi%20H%2C%20George%20E%2C%20Gilmour%20I%2C%20Gough%20D%2C%20Idrissi-Sbai%20A%2C%20Ingham%20J%2C%20Al-Khalidi%20B%2C%20Liston%20A%2C%20Mackrell%20J%2C%20Pattison%20I%2C%20Ramachandran%20R%2C%20Ray%20N%2C%20Reddy%20G%2C%20Sen%20I%2C%20Shetty%20K%2C%20Singh%20L%2C%20Stanley%20M%2C%20Wallace%20A%2C%20Weatherhead%20M%2C%20Gilbert%20T%2C%20McCansh%20G%2C%20Higgins%20S%2C%20Killeen%20C%2C%20Cromarty%20I%2C%20Franklin%20P%2C%20Pinch%20E%2C%20Dhesi%20A%2C%20Dernedde%20C%2C%20Lawrence%20M%2C%20Simper%20H%2C%20Noble%20M%2C%20Dalton%20G%2C%20Stevens%20L%2C%20Berry%20P%2C%20Hand%20C%2C%20Oliver%20R%2C%20Jones%20H%2C%20Sampson%20P%2C%20Taylor%20N%2C%20Grogono%20R%2C%20Dalrymple%20J%2C%20Martin%20A%2C%20Thurston%20S%2C%20Elsby%20K%2C%20Vallis%20M%2C%20Morrison%20G%2C%20Lang%20C%2C%20Watson%20A%2C%20Thomson%20A%2C%20Dougall%20H%2C%20Hay%20BL%2C%20Compson%20L%2C%20McCracken%20A%2C%20Calder%20J%2C%20Weber%20F%2C%20Richmond%20D%2C%20Brownlie%20R%2C%20Brown%20G%2C%20MacCowan%20H%2C%20Heap%20A%2C%20Perry%20M%2C%20Holden%20LA%2C%20Scott%20G%2C%20Haldane%20N%2C%20Hood%20S%2C%20Cullen%20I%2C%20Bell%20J%2C%20McNaught%20P%2C%20Sharif%20M%2C%20Dunn%20J%2C%20Hay%20D%2C%20Ross%20S%2C%20Shaw%20R%2C%20Hay%20L%2C%20Langridge%20S%2C%20Burns%20R%2C%20Crawford%20L%2C%20Kennedy%20A%2C%20Logan%20D%2C%20McAlavey%20P%2C%20Brown%20M%2C%20Costello%20P%2C%20McLaren%20G%2C%20Potter%20A%2C%20McPherson%20J%2C%20Drijfhout%20M%2C%20Finlayson%20J%2C%20Troup%20D%2C%20Woodall%20A%2C%20Pearce%20J%2C%20Williams%20S%2C%20Parkar%20W%2C%20Yusuf%20A%2C%20Benett%20I%2C%20Bishop%20P%2C%20Thomas%20H%2C%20Caldwell%20I%2C%20Ormiston%20P%2C%20Kwok%20S%2C%20Wright%20S%2C%20Kanumilli%20N%2C%20Saul%20P%2C%20Milligan%20H%2C%20Wilkinson%20I%2C%20Vance%20A%2C%20Paul%20N%2C%20Paul%20C%2C%20Shaikh%20I%2C%20Ellis%20R%2C%20Vites%20N%2C%20Steeds%20R%2C%20Goodwin%20D%2C%20Aftab%20A%2C%20Banham%20S%2C%20Chauhan%20N%2C%20Grocutt%20MS%2C%20Gupte%20A%2C%20Jordan%20R%2C%20Jheeta%20BS%2C%20Ladha%20K%2C%20Nazir%20M%2C%20Pal%20R%2C%20Patel%20RP%2C%20McManus%20R%2C%20Singal%20A%2C%20Saunders%20P%2C%20Syed%20AB%2C%20Bahal%20A%2C%20Dau%20H%2C%20Walker%20DM%2C%20McNeilly%20R%2C%20Bolidai%20A%2C%20MacCarthy%20N%2C%20Lawton%20D%2C%20Vardhani%20M%2C%20Sengupta%20G%2C%20Kinloch%20D%2C%20Howie%20F%2C%20Serrano-Garcia%20A%2C%20Paget%20SE%2C%20Till%20R%2C%20Seal%20P%2C%20Morrell%20J%2C%20Maxwell%20T%2C%20Singh%20G%2C%20Warden%20D%2C%20Elias%20R%2C%20Dixon%20C%2C%20Pandey%20RK%2C%20Challenor%20V%2C%20Davies%20S%2C%20Gibbs%20M%2C%20Gillet%20A%2C%20Goldie%20C%2C%20Jarvis%20I%2C%20Johnson%20P%2C%20Malden%20M%2C%20Moore%20J%2C%20Morton%20C%2C%20Nehrig%20K%2C%20Sheringham%20P%2C%20Wilson%20G%2C%20Halcox%20J%2C%20O%26%23x2019%3BConnor%20I%2C%20Ling%20K%2C%20Edwards%20D%2C%20Charles%20H%2C%20Weatherup%20A%2C%20Davies%20E%2C%20Watkins%20N%2C%20Morgan%20D%2C%20Davies%20R%2C%20Lindsay%20A%2C%20Beacock%20D%2C%20Balai%20R%2C%20Kirmond%20P%2C%20Brindle%20P%2C%20Bundy%20C%2C%20Cahill%20T%2C%20Dayani%20A%2C%20Eavis%20P%2C%20Mohr%20S%2C%20Hayne%20S%2C%20Krasucki%20C%2C%20Micheals%20M%2C%20Orpen%20I%2C%20Parker%20I%2C%20Sewell%20R%2C%20Sharp%20D%2C%20Smith%20A%2C%20Stevens%20A%2C%20Upton%20J%2C%20Victory%20J%2C%20Wernham%20C%2C%20Davis%20R%2C%20Mays%20C%2C%20Andrews%20M%2C%20Takhar%20J%2C%20Travill%20C%2C%20Choudhury%20P%2C%20Matta%20W%2C%20Ihonor%20A%2C%20O%26%23x2019%3BDong%20C%2C%20Rahman%20S%2C%20Singer%20P%2C%20Gillam%20S%2C%20Bath%20PS%2C%20Razzaq%20N%2C%20O%26%23x2019%3BToole%20O%2C%20Rowe%20P%2C%20Williams%20H%2C%20Kalra%20P%2C%20Allcock%20A%2C%20Tucker%20A%2C%20Sprott%20V%2C%20Kyd%20K%2C%20Cunliffe%20G%2C%20Arden%20C%2C%20Bateman%20A%2C%20Kassianos%20G%2C%20Sinclair%20D%2C%20Turner%20C%2C%20Jagathesan%20R%2C%20Sattar%20F%2C%20Ashford%20A%2C%20Chukwu%20A%2C%20Taylor%20H%2C%20Pradhan%20R%2C%20Rundell%20T%2C%20Howlett%20R%2C%20Bietzk%20R%2C%20Patel%20R%2C%20Myint%20M%2C%20Partington%20M%2C%20O%26%23x2019%3BReilly%20F%2C%20Baverstock%20M%2C%20Dixon%20S%2C%20Tennekoon%20M%2C%20Brand%20N%2C%20Haimes%20P%2C%20Keller%20P%2C%20Whetstone%20S%2C%20Davis%20R%2C%20Mays%20C%2C%20Andrews%20M%2C%20Takhar%20J%2C%20Parker%20L%2C%20Anscombe%20M%2C%20Beale%20G%2C%20Murphy%20L%2C%20Smith%20A%2C%20Brown%20S%2C%20Lindford%20J%2C%20Serrano%20A%2C%20Preston%20S%2C%20Sethi%20R%2C%20Hutchinson%20S%2C%20Kovyrshyna%20O%2C%20Rogozhyna%20V%2C%20Kiver%20T%2C%20Vasylenko%20V%2C%20Kucheryava%20L%2C%20Salimova%20S%2C%20Alekseenko%20V%2C%20Gukov%20O%2C%20Myhailiv%20I%2C%20Kardashevskaya%20L%2C%20Prikolota%20O%2C%20Bashkirtcev%20O%2C%20Andreev%20E%2C%20Tkachenko%20L%2C%20Mospan%20M%2C%20Batushkin%20V%2C%20Reshotko%20D%2C%20Safonova%20L%2C%20Ogorodnichuk%20A%2C%20Pustovit%20S%2C%20Romanov%20S%2C%20Burlakova%20L%2C%20Voloshko%20Y%2C%20Lafarenko%20V%2C%20Vlasuk%20Z%2C%20Leshchuk%20O%2C%20Chushak%20S%2C%20Koval%20V%2C%20Stasuk%20O%2C%20Pogrebna%20O%2C%20Kornienko%20S%2C%20Tikhonova%20S%2C%20Fesenko%20T%2C%20Kuzmina%20T%2C%20Ushakov%20O%2C%20Vechtomova%20N%2C%20Potapska%20L%2C%20Illushechkin%20I%2C%20Kryvenkova%20E%2C%20Lysunets%20O%2C%20Tsygankov%20O%2C%20Bardachenko%20L%2C%20Voloshyna%20L%2C%20Ginzburg%20V%2C%20Franskyavichene%20L%2C%20Korotich%20T%2C%20Vyshnevaya%20N%2C%20Bilous%20N%2C%20Kulinich%20S%2C%20Kulik%20V%2C%20Sadykova%20I%2C%20Zalyzniak%20O%2C%20Berezhna%20T%2C%20Molotyagina%20S%2C%20Nguyen%20LV%2C%20Pham%20MH%2C%20Pham%20HT%2C%20Khong%20NH%2C%20Do%20KB%2C%20Le%20TB%2C%20Do%20PA%2C%20Do%20TC%2C%20Nguyen%20NQ%2C%20Do%20QH%2C%20Vu%20KC%2C%20Pham%20NH%2C%20Pham%20THT%2C%20Ta%20MC%2C%20Phan%20DP%2C%20Nguyen%20TTH%2C%20Pham%20TTN%2C%20To%20TL%2C%20Le%20VT%2C%20Dang%20L%2C%20Bui%20L%2C%20Pham%20TTH%2C%20Phan%20HH%2C%20Bui%20TTH%2C%20Tuong%20TVA%2C%20Nguyen%20TP%2C%20Nguyen%20TH%2C%20Nguyen%20BK%2C%20Vu%20DB%2C%20Pham%20NS%2C%20Do%20TQ%2C%20Pham%20TS%2C%20Dang%20VD%2C%20Le%20DT%2C%20Do%20VC%2C%20Nguyen%20TKL%2C%20Luong%20HD%2C%20Luu%20TQ%2C%20Pham%20NV%2C%20Huynh%20TK%2C%20Tu%20NTH%2C%20Ngo%20KA%2C%20Nguyen%20TTC%2C%20Ong%20TTL%2C%20Doan%20VB%2C%20Kim%20TB%2C%20Vo%20TN%2C%20Tran%20TTT%2C%20Nguyen%20TA%2C%20Tran%20VD%2C%20Nguyen%20AK%2C%20Tran%20AC%2C%20Ngo%20MH%2C%20Vu%20NH%2C%20Ly%20IT%2C%20Tran%20NPH%2C%20Tran%20LUP%2C%20Nguyen%20TN%2C%20Tran%20TH%2C%20Truong%20PH%2C%20Mai%20TL%2C%20Hoang%20VS%2C%20Bui%20CMA%2C%20Dang%20VP%2C%20Truong%20QB%2C%20Vo%20MP%2C%20Nguyen%20VT%2C%20Chau%20NH%2C%20Ta%20TTH%2C%20Dinh%20HN%2C%20Tran%20H%2C%20Nguyen%20HKN%2C%20Chung%20A%2C%20Chung%20E%2C%20Martina-Hooi%20B%2C%20Angela%20R%2C%20Ramoutar%20P%2C%20Fillet%20R%2C%20Tilluckdharry%20R%2C%20Dookie%20T%2C%20Foster%20E%2C%20Hart%20C%2C%20Omardeen%20F%2C%20Ramphall%20S%2C%20Lalla%20C%2C%20Henry%20R%2C%20Cheng%20J%2C%20Elliott%20V%2C%20Falconer%20H%2C%20Hurlock-Clarke%20L%2C%20Ishmael%20R%2C%20Lalljie%20G%2C%20Lee%20K%2C%20Liqui-Lung%20A%2C%20Massay%20R%2C%20Mohammed%20H%2C%20Brown%20C%2C%20Daniel%20R%2C%20Didier%20M.%202024.%20New-onset%20atrial%20fibrillation%20and%20chronic%20coronary%20syndrome%20in%20the%20CLARIFY%20registry.%20European%20Heart%20Journal%2045%3A366%26%23x2013%3B375.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22New-onset%20atrial%20fibrillation%20and%20chronic%20coronary%20syndrome%20in%20the%20CLARIFY%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Gautier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CLARIFY%20investigators%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Ahuad%22%2C%22lastName%22%3A%22Guerrero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Basara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Belcastro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%22%2C%22lastName%22%3A%22Bertarini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Cazenave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Dreycopp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Egido%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Estrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Garofalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Giordano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Lagioia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Lago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20La%22%2C%22lastName%22%3A%22Greca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Lema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Lopez%22%2C%22lastName%22%3A%22Cabanillas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Luquez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Prada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Rodenas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20G%22%2C%22lastName%22%3A%22Schena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Suarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Tomatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20M%22%2C%22lastName%22%3A%22Colquhoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Conradie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Cross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Fathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Fitzgerald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Hamilton-Craig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Holt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20R%22%2C%22lastName%22%3A%22Jayasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Mai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Moolman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20A%22%2C%22lastName%22%3A%22Motyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Rafter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Rahman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Rainbird%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Scalia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22West%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Alford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Amor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Astridge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Bastian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Bates%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20M%22%2C%22lastName%22%3A%22Doohan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Du%20Plooy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20C%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kanagaratnam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Khoury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Parkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Sceats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Waldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Wright%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Ardill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Aylward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Beltrame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bradley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Heddle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Joseph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Rajendran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Varughese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Brice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Hockings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Janssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kozlowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22O%27Shea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20A%22%2C%22lastName%22%3A%22Playford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Woollard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ajani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Barron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Better%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Carruthers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Cotroneo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20T%22%2C%22lastName%22%3A%22Counsell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20S%22%2C%22lastName%22%3A%22Eccleston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20H%20R%22%2C%22lastName%22%3A%22Forge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Hamer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Horrigan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20M%20J%22%2C%22lastName%22%3A%22Jelinek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Lew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22O%27Donnell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Panetta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Sebastian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Shetty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Soward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Srivastava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20F%22%2C%22lastName%22%3A%22Strathmore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Sylivris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Szto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Veth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Yip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Badr-Eslam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kleemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Steurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22M%5Cu00f6rz-Proszowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Auhser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Teleky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Sepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Beinhauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Ker%5Cu00f6%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Lavicka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Perger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Hadjiivanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Feldner-Busztin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Mika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Filip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Mahr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Toplak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20G%22%2C%22lastName%22%3A%22Millauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Haralambus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Walcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20H%22%2C%22lastName%22%3A%22Karner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Ziak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Painsipp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Frank%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Suntinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Gritsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Bode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Raffelsberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Topf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Moser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22F%5Cu00f6chterle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Honsig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Mayr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Mayr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Kaserbacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Dzien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Galehr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Felbermayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Schwarz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Amini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Appeltants%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ballet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22De%20Niel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Berkenboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Bouvy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Claeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Dascotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Davin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22De%20Backer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22De%20Meester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22De%20Ridder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Dendale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Denef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Emonts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20T%20M%22%2C%22lastName%22%3A%22Geraedts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Goethals%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J-M%22%2C%22lastName%22%3A%22Gr%5Cu00e9goire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Herbots%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Hoffer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%20H%20J%22%2C%22lastName%22%3A%22Hutse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Lafontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Lesseliers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Odent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Peperstraete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Purnode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Rogowsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Rosseel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J-P%22%2C%22lastName%22%3A%22Salembier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Surmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20M%20F%22%2C%22lastName%22%3A%22Vandeplas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Van%20De%20Walle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Van%20Den%20Branden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Vandergoten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20G%22%2C%22lastName%22%3A%22Vanhauwaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Vanneste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Vercammen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Verleyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Vermander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Weytjens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Rocha%22%2C%22lastName%22%3A%22De%20Lorenzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Felice%20Castro%22%2C%22lastName%22%3A%22Issa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Mahler%22%2C%22lastName%22%3A%22Mioto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20De%20Brito%22%2C%22lastName%22%3A%22Vianna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Okawabata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Giusti%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Pitella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Henpin%20Yue%22%2C%22lastName%22%3A%22Cesena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%20Monteiro%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Junior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Tonet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Machado%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20H%22%2C%22lastName%22%3A%22Gowdak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%22%2C%22lastName%22%3A%22Matos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Moretti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Vicente%22%2C%22lastName%22%3A%22Amato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Tadeu%22%2C%22lastName%22%3A%22Munhoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20R%22%2C%22lastName%22%3A%22Coimbra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Rocha%22%2C%22lastName%22%3A%22De%20Lorenzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Felice%20Castro%22%2C%22lastName%22%3A%22Issa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Mahler%22%2C%22lastName%22%3A%22Mioto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20De%20Brito%22%2C%22lastName%22%3A%22Vianna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Okawabata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Giusti%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Pitella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Henpin%20Yue%22%2C%22lastName%22%3A%22Cesena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%20Monteiro%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Junior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Tonet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Machado%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20H%22%2C%22lastName%22%3A%22Gowdak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%22%2C%22lastName%22%3A%22Matos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Moretti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Vicente%22%2C%22lastName%22%3A%22Amato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Tadeu%22%2C%22lastName%22%3A%22Munhoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20R%22%2C%22lastName%22%3A%22Coimbra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20N%22%2C%22lastName%22%3A%22Luqman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Yakovova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Mantcheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Mincheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Baurenski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Karastanev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Yordanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Peneva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Fagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Sabe-Affaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20M%22%2C%22lastName%22%3A%22Villasenor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%20K%22%2C%22lastName%22%3A%22Son%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20E%22%2C%22lastName%22%3A%22Manyari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Giacomantonio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20J%22%2C%22lastName%22%3A%22Lubelsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Ezekiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20C%20S%22%2C%22lastName%22%3A%22Leong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Grover%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Vavougios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Pesant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20M%22%2C%22lastName%22%3A%22Kushner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20M%20W%22%2C%22lastName%22%3A%22Yeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20E%22%2C%22lastName%22%3A%22Vertes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20J%22%2C%22lastName%22%3A%22Nasser-Sharif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Spensieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Roy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Leclair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Morra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Everton%22%2C%22lastName%22%3A%22Biglow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Baril%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Lai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20S%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Martinho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20A%22%2C%22lastName%22%3A%22Antoniadis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20R%22%2C%22lastName%22%3A%22Searles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Rouse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Brisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20King%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20S%22%2C%22lastName%22%3A%22Collette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20S%20C%22%2C%22lastName%22%3A%22Ho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Constance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Gendreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20W%22%2C%22lastName%22%3A%22Kellam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20A%20Cieza%22%2C%22lastName%22%3A%22Lara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20A%22%2C%22lastName%22%3A%22Boyrazian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Shamsuzzaman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20R%22%2C%22lastName%22%3A%22Spink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20P%22%2C%22lastName%22%3A%22T%20Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Janes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Czarnecka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Saulnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Levesque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20F%22%2C%22lastName%22%3A%22Clavette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kokis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20L%22%2C%22lastName%22%3A%22Orenstein-Lyall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Shekhar%22%2C%22lastName%22%3A%22Pandey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Czarnecki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Perreault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Chouinard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Lafrance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20M%22%2C%22lastName%22%3A%22Fullerton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22LeBouthillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q%20H%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20Rodriguez%22%2C%22lastName%22%3A%22Marrero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20B%22%2C%22lastName%22%3A%22Ramadan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Talbot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%22%2C%22lastName%22%3A%22Fazil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Yi-Ming%22%2C%22lastName%22%3A%22Cha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Chehayeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Roy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20K%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20E%22%2C%22lastName%22%3A%22Harlos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20B%22%2C%22lastName%22%3A%22Matheson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20F%22%2C%22lastName%22%3A%22Vaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20S%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20H%22%2C%22lastName%22%3A%22Ashton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Sullivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20P%22%2C%22lastName%22%3A%22Quinn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Yared%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20K%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Sullivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Pallie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20H%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Savard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Cherry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Gold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Brouillette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Belanger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Berlingieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Nisker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Boutros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20I%22%2C%22lastName%22%3A%22Bakbak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Lasalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20L%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Y%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%20P%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20D%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20L%22%2C%22lastName%22%3A%22Cong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20F%22%2C%22lastName%22%3A%22Ding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20T%22%2C%22lastName%22%3A%22Dong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20H%22%2C%22lastName%22%3A%22Dong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%20M%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20L%22%2C%22lastName%22%3A%22Feng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Ge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20J%22%2C%22lastName%22%3A%22Ge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Huo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20G%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20N%22%2C%22lastName%22%3A%22Ke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20W%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20M%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%20C%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20J%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q%20L%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20W%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Z%22%2C%22lastName%22%3A%22Lv%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Miao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Z%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%20D%22%2C%22lastName%22%3A%22Pu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%20M%22%2C%22lastName%22%3A%22Qian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%22%2C%22lastName%22%3A%22Su%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20H%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20P%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20F%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Y%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20J%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20G%22%2C%22lastName%22%3A%22Xiong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20L%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%20L%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20S%22%2C%22lastName%22%3A%22Zeng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20Q%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20X%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20L%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bozkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Carda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Dedkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Dufka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Fridrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Hodac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Jirmar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kadleckova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Karlicek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Krupicka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Kuchar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Lavicka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Leso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Lorenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Micko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Navratil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Petrova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Povolna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Raisova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Raska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Ravlyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Schlesingerova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Smrckova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Sternthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Stursova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Vymetal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Wiggers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Markenvard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20K%22%2C%22lastName%22%3A%22Andersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Frost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Refsgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Strange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Egstrup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sykulski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Hildebrant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Haghfelt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Ege%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Saaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Cattan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Adam-Blanpain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Adda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Aimouch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Ardouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Assouline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aumjaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Barjhoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Baroudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Beaurain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%22%2C%22lastName%22%3A%22Bennouna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Bernardeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Blanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Blum-Decary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Bodur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Boesch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bonal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Bonhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20L%22%2C%22lastName%22%3A%22Bourachot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Brumelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Brunehaut%22%2C%22lastName%22%3A%22Petaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Brunschwig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Buffet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Calmettes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Centa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Chartier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Chemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Chometon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Crespo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Dabboura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Dehayes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Dematteo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Dibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Dodemant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Dormagen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%22%2C%22lastName%22%3A%22Dreyfus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Duclos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Ducoudre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Duprez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Durand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Durand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Egloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Escande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20C%20Escourrou%22%2C%22lastName%22%3A%22Berdou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Esna%22%2C%22lastName%22%3A%22Ashari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Feldmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Ferrieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Foltzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Fontanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Garandeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Garban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Geffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Gillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Godart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Gosse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Gratia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Greiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gueusquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Guiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Guy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Hennebelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Honorat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Hourany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Hua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Jacquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Jean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Jeremiasz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kohler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Lacroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Leandri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Lemiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Liautard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Loheac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20C%22%2C%22lastName%22%3A%22Louchart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Magnus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Maheu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20R%22%2C%22lastName%22%3A%22Malaterre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Manchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Mantoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Manzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Marachli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Maroun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Meneveau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Messas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Mougeolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Mouhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Muller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Naisseh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Nocon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Onger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ouguoujil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Ovize%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Pareathumby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pleskof%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Poinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Pons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Pouderou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20N%22%2C%22lastName%22%3A%22Poujois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Probst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Prunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Prunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Puel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Rechtman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Rennert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Rijavec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Roche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Roul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Salaun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Saleh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Sandalian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Sander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Schenowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Silvestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Soleille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Tabet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Tardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Thomas-Richard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Truong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Varaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Walch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Wazana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Zeitouni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Audibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Alizon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Amlaiky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Asplanato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Baranes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Bariaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Bernasconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Bousquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Ceraulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22De%20Geeter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Donetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Doucet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Doucet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Dutoya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Ennouchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Fallacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Fouquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Fourchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Gdalia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Grollier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Guerard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20A%22%2C%22lastName%22%3A%22Jeannerat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Jobic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Joulie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Jourdain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Jouve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Ketelers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Khaznadar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kohan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Koujan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Lammens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Landragin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Le%22%2C%22lastName%22%3A%22Moal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22M%27Bey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Maes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Maheas%22%2C%22lastName%22%3A%22Morlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Massabie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Meddah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20X%22%2C%22lastName%22%3A%22Meriaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Mestre-Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Meyssonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Migliore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Milewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Mingam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Nazeyrollas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Paganelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Pellerin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Petitjean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pinzani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pladys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Primot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pucheu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Rahali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Ravoala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Rousson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Samama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Sardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Silvestri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Soskin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%22%2C%22lastName%22%3A%22Tabone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Tricot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Vaquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Weingrod%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Aboyans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Amoretti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Berthezene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Binet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X%22%2C%22lastName%22%3A%22Bonnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bonny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Bouchaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Boureux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Bourgeois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Brottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Cavert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Cleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Dechoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Delhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%22%2C%22lastName%22%3A%22Detienne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%22%2C%22lastName%22%3A%22Dubs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Faudon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Fellous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Fressonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Garaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Geneves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Gleizes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Guyetand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Hermellin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Iovescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%22%2C%22lastName%22%3A%22Kanner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Khanoyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Leherissier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Maximovitch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Merian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Messali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Payot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Petoin%22%2C%22lastName%22%3A%22Peuch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Prevot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Raymond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Relange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Reymond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Rosenstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Schneider%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Schultz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Tanielian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Thoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Touzet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Amiel%20Oster%22%2C%22lastName%22%3A%22Sauvinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Baylac%22%2C%22lastName%22%3A%22Domengetroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Chamou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Etcheverry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Farges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Y%22%2C%22lastName%22%3A%22Fraboulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Goralski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Janody%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Mamez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Manlay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Paillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Pelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Petit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Skonieczny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Augarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20B%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Liandrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20I%22%2C%22lastName%22%3A%22Noury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Paris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Saade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Stordeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Pornin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Fauchier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Galinier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%22%2C%22lastName%22%3A%22Balice-Pasquinelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Sosner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Yvorra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Delcoulx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mouquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20E%22%2C%22lastName%22%3A%22Poulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Sudre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Heno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Biausque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Guenoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Attia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Pouwels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Verbrugge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Ziccarelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Elkohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Tricoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Huttin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B-M%22%2C%22lastName%22%3A%22Altevogt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Altmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Baar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Berrisch-Rahmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Birkenhagen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Bl%5Cu00e4se%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Blindt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Brattstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H-H%22%2C%22lastName%22%3A%22Breuer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Castrucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Cicek-Hartvig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Cierpka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Claus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Deissner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Drexler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Eggeling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Eisele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Enayat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Frickel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Gessner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Giokoglu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Gmehling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Goss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Grooterhorst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20B%22%2C%22lastName%22%3A%22Gysan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Haberl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Haerer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Hassler%22%2C%22lastName%22%3A%22Jun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Heinemann-Meerz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Henschel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Hinrichsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Hofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Hofmeister%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Hoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Horstkotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22J%5Cu00e4ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Jeserich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Keil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Killat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kimmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kindel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kindler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kleta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22K%5Cu00f6nemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22K%5Cu00f6nig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Krause-Allmendinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Kronberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Kruck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22M%5Cu00e4nnl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Meinel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Mentz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Meyer-Michael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mibach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22M%5Cu00f6ller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Muth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Nelb%5Cu00f6ck-Huber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Ohlmeyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22%5Cu00d6zkan-Rashed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C-%20P%22%2C%22lastName%22%3A%22Paulus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Perings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Placke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Raters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Reifart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Rink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Rybak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Salecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K-H%22%2C%22lastName%22%3A%22Schermaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Schlesinger-Irsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Schmidt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K-H%22%2C%22lastName%22%3A%22Schmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Schr%5Cu00f6der%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Spengler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Speth-Nitschke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Stumpp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Szabo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Taggeselle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Tamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Thelemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Thelemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Th%5Cu00fcmmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Unger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Utech%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Volmar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Wauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Wehr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Weinrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Weinrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Windstetter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20H%22%2C%22lastName%22%3A%22Wirtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Wittlich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Ziehn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Z%5Cu00fcndorf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20Al%22%2C%22lastName%22%3A%22Wahshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20P%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Narayan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Al%22%2C%22lastName%22%3A%22Tamimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Al%22%2C%22lastName%22%3A%22Yazeedi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Ayche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Al%22%2C%22lastName%22%3A%22Lawati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Al%22%2C%22lastName%22%3A%22Dhanki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Salustri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Salah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Y%22%2C%22lastName%22%3A%22Tamimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Agrawal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Wassef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Baslaib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Al%22%2C%22lastName%22%3A%22Radaideh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Yusufali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Bazargani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Akbar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20Abdel%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Abdel%22%2C%22lastName%22%3A%22Malak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Ghaly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Hafez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Al%22%2C%22lastName%22%3A%22Kandari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Haiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Alanbaei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20M%22%2C%22lastName%22%3A%22Gomaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Avgerinos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Gouli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Stergiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Alexopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Pappas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Petropoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Chatzioakim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Pontikakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Priftis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Mpompoth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Bourazanis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Papathanasioy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Avlonitis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Zakopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Koutsimpanis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Tsamopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Christoforidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Zachos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kalaras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Karachaliou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Liatas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Pournaras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Theodorakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Orestis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Panisois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Chalkiadakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Arfaras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kolios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Boutsikos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kotsalos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Mitropoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Samothrakitis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Svolis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Anastasiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Gkinis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Dalampyras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kalampalikis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Leontaridis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Gabriilidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Konstantinidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Plastiras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Tarenidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Marozs%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22%5Cu00c9des%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Czuriga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Czir%5Cu00e1ki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22T%5Cu00f3th%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1%22%2C%22lastName%22%3A%22Dong%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22T%5Cu00fari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Forster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Borbola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Bachmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Masszi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Orb%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Gerges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Balogh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Bajcsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Tak%5Cu00e1cs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Nagy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Kisj%5Cu00f3s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22J%5Cu00e1nosi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Nagy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Nagy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22B%5Cu00fcttl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Lippai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zs%22%2C%22lastName%22%3A%22Sziegl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zs%22%2C%22lastName%22%3A%22Malk%5Cu00f3cs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22F%5Cu00f6ldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Fikker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Szab%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Forrai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Seb%5Cu00f5k%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Merkely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Natarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Dalal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20K%22%2C%22lastName%22%3A%22Saran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20P%22%2C%22lastName%22%3A%22Samal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20A%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Ghose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%20S%22%2C%22lastName%22%3A%22Sawhney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Roy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Chandra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Modi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20M%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Vijayaraghavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Sreenivasa%22%2C%22lastName%22%3A%22Murthy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20S%22%2C%22lastName%22%3A%22Ramesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rao%20V%22%2C%22lastName%22%3A%22Dayasagar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20S%22%2C%22lastName%22%3A%22Chenniappan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Vadavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Kunhali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20Srinivasa%22%2C%22lastName%22%3A%22Reddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%20Thillai%22%2C%22lastName%22%3A%22Vallal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Khera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Prasad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Shukla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20K%22%2C%22lastName%22%3A%22Trivedi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Ahuja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Rawal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Karnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20S%22%2C%22lastName%22%3A%22Hiremath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20K%22%2C%22lastName%22%3A%22Kumbla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20R%22%2C%22lastName%22%3A%22Shetty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20S%22%2C%22lastName%22%3A%22Chonkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Late%22%2C%22lastName%22%3A%22MJuneja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20K%22%2C%22lastName%22%3A%22Goyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sheahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Daly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Vaughan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Fleming%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Shiels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Keelan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Kiernan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Day%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22MacNamara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Maguire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Clifford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22O%27Gara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Guardigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Pes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Caridi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Frattola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Doronzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Riccioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Lacch%5Cu00e8%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Massari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Orazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Carretta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Provvidenza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Pedretti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Nicolino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Felis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Pernice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gaglione%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Gori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Martina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22d%5Cu2019Alessandro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Giacomazzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Terrosu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Cernetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Antonicelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Ansalone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Balbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Tamburino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Moretti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Tantillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Patriarchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Proietti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Sinicropi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Maragoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Mallamaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22d%27Este%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Azzolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Brscic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Bongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gigantino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Perna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20S%22%2C%22lastName%22%3A%22Mayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20La%22%2C%22lastName%22%3A%22Rosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Muscio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Scollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Magliari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Petrillo%22%2C%22lastName%22%3A%22Pio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Castellari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Di%22%2C%22lastName%22%3A%22Pasquale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dr%22%2C%22lastName%22%3A%22Scalzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Saporito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Capuano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Alitto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Marchionni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Turiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bianco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Greco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Marullo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Testa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Vicentini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Novo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20La%22%2C%22lastName%22%3A%22Varra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Tavazzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20R%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Lazerevic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Colivicchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Macchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Dalle%22%2C%22lastName%22%3A%22Mule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Sibilio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Achilli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Proto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20M%22%2C%22lastName%22%3A%22Kang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20K%22%2C%22lastName%22%3A%22Koo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20K%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20H%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20S%22%2C%22lastName%22%3A%22Yoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20S%22%2C%22lastName%22%3A%22Seo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20C%22%2C%22lastName%22%3A%22Gwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20H%22%2C%22lastName%22%3A%22Kang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20M%22%2C%22lastName%22%3A%22Kwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20H%22%2C%22lastName%22%3A%22Chae%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20J%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20H%22%2C%22lastName%22%3A%22Shin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20W%22%2C%22lastName%22%3A%22Goh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20S%22%2C%22lastName%22%3A%22Byun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20H%22%2C%22lastName%22%3A%22Zo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20J%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20S%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20J%22%2C%22lastName%22%3A%22Cha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20K%22%2C%22lastName%22%3A%22Ryu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20J%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Y%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20H%22%2C%22lastName%22%3A%22Hur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Jeong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20K%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20K%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20T%22%2C%22lastName%22%3A%22Jung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Y%22%2C%22lastName%22%3A%22Rhew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20W%22%2C%22lastName%22%3A%22Jeon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20J%22%2C%22lastName%22%3A%22Yoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20H%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Mintale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Latkovskis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Hansone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Rozkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Baika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Jasinkevica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Abele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Laizane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Pontaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Ecina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Mihailova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kondratovica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Laucevi%5Cu010dius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Jurgaitien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22%5Cu0160lapikas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Barauskien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Jankauskien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Revien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Zaronskien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%20B%22%2C%22lastName%22%3A%22%5Cu0160lapikien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Kupstyt%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Rink%5Cu016bnien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Stepon%5Cu0117nien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Kojelien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Badarien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22D%5Cu017eenkevi%5Cu010di%5Cu016bt%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Sadauskien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Butkuvien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Stankevi%5Cu010dius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Paliulionien%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Snikyt%5Cu0117%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Ma%5Cu017eutavi%5Cu010dius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20N%22%2C%22lastName%22%3A%22Jamaluddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20A%20Abdul%22%2C%22lastName%22%3A%22Rahim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20K%20Mohamed%22%2C%22lastName%22%3A%22Yusof%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20H%22%2C%22lastName%22%3A%22Chee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%22%2C%22lastName%22%3A%22Sadiq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Ramanaidu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20H%22%2C%22lastName%22%3A%22Sim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20K%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Y%20Y%22%2C%22lastName%22%3A%22Fong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20C%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20K%22%2C%22lastName%22%3A%22Chua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20L%22%2C%22lastName%22%3A%22Cham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20H%20Mohd%22%2C%22lastName%22%3A%22Amin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20K%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Z%22%2C%22lastName%22%3A%22Khiew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Said%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20K%22%2C%22lastName%22%3A%22Abdullah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20W%22%2C%22lastName%22%3A%22Cheah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Sinnadurai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20K%20H%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20K%22%2C%22lastName%22%3A%22Choor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20K%22%2C%22lastName%22%3A%22Sia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20C%22%2C%22lastName%22%3A%22Ang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20S%20Awtar%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Z%20Abdul%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20K%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20K%22%2C%22lastName%22%3A%22Ghapar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Muthu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20A%22%2C%22lastName%22%3A%22Mahendran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20H%22%2C%22lastName%22%3A%22Jaafar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20H%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20I%22%2C%22lastName%22%3A%22Ruhani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20A%20R%22%2C%22lastName%22%3A%22Tahir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20Abdul%22%2C%22lastName%22%3A%22Manap%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20S%20K%22%2C%22lastName%22%3A%22Ch%27ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20T%22%2C%22lastName%22%3A%22Ch%27ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20S%22%2C%22lastName%22%3A%22Abdullah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20S%22%2C%22lastName%22%3A%22Sahar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20B%20Abdul%22%2C%22lastName%22%3A%22Kareem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20Sheikh%20Abdul%22%2C%22lastName%22%3A%22Kader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20K%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20K%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20H%22%2C%22lastName%22%3A%22Goh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20B%22%2C%22lastName%22%3A%22Liew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20M%22%2C%22lastName%22%3A%22Chu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20K%20M%22%2C%22lastName%22%3A%22Bhaskaran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20P%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20L%22%2C%22lastName%22%3A%22Joseph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20Noor%22%2C%22lastName%22%3A%22Hasni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%20K%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20H%22%2C%22lastName%22%3A%22Choo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Saaidin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20K%22%2C%22lastName%22%3A%22Yeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20M%22%2C%22lastName%22%3A%22Lai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20C%22%2C%22lastName%22%3A%22Lai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Tay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20A%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20N%22%2C%22lastName%22%3A%22Luqman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillermo%20Llamas%22%2C%22lastName%22%3A%22Esperon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20De%20Je%5Cu00fas%20Zu%5Cu00f1iga%20Sedano%20Y%20America%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Azar%22%2C%22lastName%22%3A%22Manzur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Jerjes%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Cerda%22%2C%22lastName%22%3A%22Rojas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Carrillo%22%2C%22lastName%22%3A%22Calvillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Petersen%22%2C%22lastName%22%3A%22Aranguren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Mart%5Cu00ednez%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20%5Cu00c1lvarez%22%2C%22lastName%22%3A%22Sangabriel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Vieyra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Gonz%5Cu00e1lez%22%2C%22lastName%22%3A%22Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Puente%22%2C%22lastName%22%3A%22Barrag%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Redding%22%2C%22lastName%22%3A%22Escalante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Ch%5Cu00e1vez%22%2C%22lastName%22%3A%22Paez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Fernandez%22%2C%22lastName%22%3A%22Valadez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Gaxiola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20E%22%2C%22lastName%22%3A%22Manautou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%20Henne%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Barrera%22%2C%22lastName%22%3A%22Bustillos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Leyva%22%2C%22lastName%22%3A%22Pons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20G%5Cu00f3mez%22%2C%22lastName%22%3A%22%5Cu00c1lvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20R%20Romo%22%2C%22lastName%22%3A%22Santana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Mart%5Cu00ednez%22%2C%22lastName%22%3A%22Redding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Arias%22%2C%22lastName%22%3A%22Mendoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Briones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20De%20Jes%5Cu00fas%20Rivera%22%2C%22lastName%22%3A%22Arellano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Arenas%22%2C%22lastName%22%3A%22Le%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Alcocer%22%2C%22lastName%22%3A%22Gamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Alexanderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20E%20Ru%5Cu00edz%22%2C%22lastName%22%3A%22Esparza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20A%20Elizondo%22%2C%22lastName%22%3A%22Sifuentes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22Brise%5Cu00f1o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Sandoval%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20L%20Fuantos%22%2C%22lastName%22%3A%22Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Sandoval%22%2C%22lastName%22%3A%22Navarrete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%20Casas%22%2C%22lastName%22%3A%22Juarezy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Loera%22%2C%22lastName%22%3A%22Pinales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Cue%22%2C%22lastName%22%3A%22Carpio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Rojas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Solache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20D%5Cu00edaz%22%2C%22lastName%22%3A%22Ju%5Cu00e1rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Bale%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Ferreyra%22%2C%22lastName%22%3A%22Solorio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20A%20Ram%5Cu00edrez%22%2C%22lastName%22%3A%22Reyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20Romero%22%2C%22lastName%22%3A%22Maldonado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Escobedo%22%2C%22lastName%22%3A%22De%20La%20Pe%5Cu00f1a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Hilario%20Jim%5Cu00e9nez%22%2C%22lastName%22%3A%22Orozco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20A%20Reyes%22%2C%22lastName%22%3A%22Cisneros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20%5Cu00c1lvarez%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Bautista%22%2C%22lastName%22%3A%22L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Od%5Cu00edn%20De%20Los%20R%5Cu00edos%22%2C%22lastName%22%3A%22Ibarra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22I%20Tulevski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20A%22%2C%22lastName%22%3A%22Somsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Miedema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Chlewicka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Brodzicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Stasiuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Sza%5Cu0142kowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Kulig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Maliszewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Kr%5Cu00f3licka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Zdrojewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Nikodemska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Szpak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Wr%5Cu0119biak-Trznadel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Prokop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Szulc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Olszewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22K%5Cu0119pa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Banach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22W%5Cu0119glarz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ga%5Cu0142uszka-Bili%5Cu0144ska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kr%5Cu00f3lak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Cisowska-Drozd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Orzechowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Je%5Cu017cewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Adamaszek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Glanowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Pitsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Matuszewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Nowowiejska-Wiewi%5Cu00f3ra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Dere%5Cu0144%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Walawski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22So%5Cu0142tysiak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Wysocki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Jarosi%5Cu0144ski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Drzewiecka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22%5Cu0141ugowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Jankowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22B%5Cu0142aszczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Drozd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22%5Cu0141otocka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Duchowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Sobczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Jarmu%5Cu017cek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Sidor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Adamczyk-Kot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Sudnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Cygler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Skoczylas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Poprawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kisiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U%22%2C%22lastName%22%3A%22Kossowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Sikorska-Buczkowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Modzelewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Demianiuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Streb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Mularek-Kubzdela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Bogda%5Cu0144ski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Ka%5Cu017amierczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Zimol%5Cu0105g%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Lorenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Furtak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Regulska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Fic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Turek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Nowicka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Bryl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Lenartowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Jerzykowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Ma%5Cu0107k%5Cu00f3w%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Gadzi%5Cu0144ski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Kacorzyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Zalewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sad%5Cu0142owski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22S%5Cu0142aboszewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Grucha%5Cu0142a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Frankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Walczewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Adamkiewicz-Piejko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Chyrek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Jankowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Correia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gir%5Cu00e3o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1%22%2C%22lastName%22%3A%22Herdade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Sequeira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Tavares%20E%22%2C%22lastName%22%3A%22Taveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gonzaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Albuquerque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Estriga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Rocha%22%2C%22lastName%22%3A%22De%20Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Louren%5Cu00e7o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Faria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Carvalho%22%2C%22lastName%22%3A%22De%20Moura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Camossa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Aguiar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Wellenkamp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Fernandes%22%2C%22lastName%22%3A%22De%20Sousa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Moreira%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Matias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Silva%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Bragan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Proen%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Mariano%22%2C%22lastName%22%3A%22P%5Cu00eago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Vinhas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Arroja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Morais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Silva%20E%22%2C%22lastName%22%3A%22S%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Vasconcelos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Matos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Freitas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Alcaravela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Mimoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Antunes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Ferreira%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Nobre%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Chambel%22%2C%22lastName%22%3A%22De%20Aguiar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Forte%22%2C%22lastName%22%3A%22De%20Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Cala%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Sim%5Cu00f5es%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Lopes%22%2C%22lastName%22%3A%22Antunes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Soares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Semedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Macedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Sargento%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Basto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Rebelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Catarino%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Alves%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20C%22%2C%22lastName%22%3A%22Gamboa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20F%20Ferr%5Cu00e3o%20E%22%2C%22lastName%22%3A%22Vasconcelos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Cust%5Cu00f3dio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20I%22%2C%22lastName%22%3A%22Mendon%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20J%20Pinto%22%2C%22lastName%22%3A%22Vaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Espiga%22%2C%22lastName%22%3A%22De%20Macedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Lazaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Martins%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Pelicano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Lousada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Matos%22%2C%22lastName%22%3A%22Dias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20F%22%2C%22lastName%22%3A%22Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Farto%20E%22%2C%22lastName%22%3A%22Abreu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Monteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Seabra%22%2C%22lastName%22%3A%22Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Rosado%22%2C%22lastName%22%3A%22Soares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Baptista%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Reis%22%2C%22lastName%22%3A%22Monteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Sanfins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Martins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Anghel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Arsenescu%22%2C%22lastName%22%3A%22Georgescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Babes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Banu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Beyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Bratu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bumbu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Capalneanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%20D%22%2C%22lastName%22%3A%22Chioncel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Chiscaneanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Christodorescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Cindea%22%2C%22lastName%22%3A%22Nica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Cinteza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Coman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Constantinescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Craiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20A%22%2C%22lastName%22%3A%22Dan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20C%22%2C%22lastName%22%3A%22Dan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Dan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20M%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Dorobantu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Farcas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Firastrau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Florescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ghicu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Giuca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Grigoriu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20D%22%2C%22lastName%22%3A%22Ionescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20C%22%2C%22lastName%22%3A%22Iosipescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20V%22%2C%22lastName%22%3A%22Ivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Lighezan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Magheru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Magherusan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20M%22%2C%22lastName%22%3A%22Marinescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20C%22%2C%22lastName%22%3A%22Motoc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Musetescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Rau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Rotaru%20H%22%2C%22lastName%22%3A%22Rus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Sirbu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Sorodoc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20M%22%2C%22lastName%22%3A%22Spinu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Stanciulescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Statescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Toringhibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Trambitas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Trocan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Tudose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Vinereanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Zagreanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Motomancea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Militaru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Dymova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Semenova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Zherebtsova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Fedoskin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Gurianova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Bolotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Knyazeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Spitsina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Sytilina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Atamanchuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Giorgadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Zarechnova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kutuzova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Sharapova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Stelmakh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Sinyukova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Rostik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Evtukhova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Sukhanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Makhieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Tereshko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Kolesnikov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Kochurov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Marchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Nurgalieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Galeeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Andreicheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Zakirova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Baleeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Minsafina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Borodina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Arkhipova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Krechunova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Scherbak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Merkhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Aksyutina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Ratovskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Suglobova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Kozhelenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Potapova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Poluyanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Naberezhnova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Daniels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Atueva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Tsaryabina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kurekhyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Khishova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Dubinina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Demina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Mochkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Bukanina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Tolpygina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Polyanskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Malysheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Kheliya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Serazhim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Voronina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Lukina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Dubinskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Dmitrieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kuzyakina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Khartova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Bokuchava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Smirnova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Esenokova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Pavlova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Smirnova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Astrakhantseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Bykovskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Charikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Berdnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Karaseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Zhabina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Oleinikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Dzhkha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Grigoryan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Yakovenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Ivaschenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Kiseleva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Shokina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Novikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Khodanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Popova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Latyntseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Kilaberiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Makarenkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Nosova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Gerasimova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Boikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Sharapova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Kulikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Pasechnaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Bulakhova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kurochkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Bratishko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Likhobabina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Panova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Voronina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Bizyaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Gusev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Nevolina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Arsentieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Budanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20London%22%2C%22lastName%22%3A%22Melnikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Khripun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Polyaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Osadchuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Krasnoslobodskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Yakimova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Lugin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Sosnova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Il%27ina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kositsina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Shanina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kostomarova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Malgina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Omelchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Gorlova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Eidelman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Salakhova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Bondarenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sopia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Baboshina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Eliseeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Tumarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Petrochenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Khudina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Arabadzhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Samakhovets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Tkhorzhevskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Sinotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Zherlitsyna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Minkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Petrova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Tikhonov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Shmakova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Abduvalieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kuzmicheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Nikolaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Varezhnikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Dmitrieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Mikhailova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Yanina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kapustina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Vazhdaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Golovina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Fedorova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Nikolaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Fillipova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Gareeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Tuktarova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Khmelevskikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Karnot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Golub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Surovtseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Kulygina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Shelomova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Kruglova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Pokrovskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Rodina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Polkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Biryukova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Filippova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Kotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Ignatieva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Alekseeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Gruznykh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Mozerova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Moksyuta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Kosachek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Srtumilenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Baranova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Voronova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Bayakhchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Grudtsina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Gorshkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Shamsutdinova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Getman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Gorodilova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Karnaukhova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Rotenberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Isaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Lebischak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Ryzhkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Usoltseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Mescharekova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Tavlueva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Mineeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Stikhurova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kosareva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Grechishkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Nikishina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ilyukhina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Gureeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Soin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Erofeev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Lebedev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kudryavtsev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Gamzatov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Maximchuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Grekhova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kolevatova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kazakovtseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Kolesova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Zharikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Kukaleva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Starostina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Grushetskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Kazachkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Pashentseva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Shimonenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Sirazov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Chernozemova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Golubeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Mingalaeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Zatsarina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Kozlov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Davydova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Larina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20F%22%2C%22lastName%22%3A%22Alhabib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Hersi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Al-Backer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22AlFaleh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Mobeirek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Arafah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Al-Shamiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22El-Shaer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Al%22%2C%22lastName%22%3A%22Zaibag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Bdeir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Suliman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Mukhtar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Jamiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Elkrail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Alanazy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Habab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Ashmak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Nourallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20H%22%2C%22lastName%22%3A%22Mak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20S%22%2C%22lastName%22%3A%22Chee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20C%22%2C%22lastName%22%3A%22Koo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20P%22%2C%22lastName%22%3A%22Low%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20P%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20S%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20S%20S%22%2C%22lastName%22%3A%22Quek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20H%20M%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20L%20R%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20H%22%2C%22lastName%22%3A%22Chuang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kamensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kaliska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Murin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Hatalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Simkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Dubrava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Pjontek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Pella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Banikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Szentivanyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Kovar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Benacka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Gonos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Fazekas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kycina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Poles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Fras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Pernat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Veternik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22%5Cu010cerni%5Cu010d-%5Cu0160uligoj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kerbev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Krajnc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Zago%5Cu017een%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Alam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Luke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Variava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Nethononda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Matthews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Nkombua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Antia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20P%22%2C%22lastName%22%3A%22Naidoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bhayat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20K%22%2C%22lastName%22%3A%22George%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Ranjith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20H%20M%22%2C%22lastName%22%3A%22Vawda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Govender%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Soosiwala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Shein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Panajatovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20S%20H%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Blignaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Coetzee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Burgess%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20D%22%2C%22lastName%22%3A%22Theron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20Arnau%22%2C%22lastName%22%3A%22Vives%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20J%20Abard%5Cu00eda%22%2C%22lastName%22%3A%22Oliva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Aguar%22%2C%22lastName%22%3A%22Carrascosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Albero%22%2C%22lastName%22%3A%22Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%20Alegret%22%2C%22lastName%22%3A%22Colomer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Alegr%5Cu00eda%22%2C%22lastName%22%3A%22Ezquerra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20A%20Almeida%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Alvarenga%22%2C%22lastName%22%3A%22Recalde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Alvarez%22%2C%22lastName%22%3A%22Au%5Cu00f1on%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Alvarez%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Amo%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Amoros%22%2C%22lastName%22%3A%22Galito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Anc%5Cu00edn%22%2C%22lastName%22%3A%22Viguiristi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Aparici%22%2C%22lastName%22%3A%22Feal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Ardiaca%22%2C%22lastName%22%3A%22Capell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Arnedillo%22%2C%22lastName%22%3A%22Pardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Arquero%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Arrarte%22%2C%22lastName%22%3A%22Esteban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Baquero%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Barahona%22%2C%22lastName%22%3A%22P%5Cu00e9rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Bardaj%5Cu00ed%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Barriales%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Batalla%22%2C%22lastName%22%3A%22Celorio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Berzal%22%2C%22lastName%22%3A%22Mart%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20Bierge%22%2C%22lastName%22%3A%22Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Blanco%22%2C%22lastName%22%3A%22Casti%5Cu00f1eiras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Bosa%22%2C%22lastName%22%3A%22Ojeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Botana%22%2C%22lastName%22%3A%22Penas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20Brufau%22%2C%22lastName%22%3A%22Redondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Bruguera%22%2C%22lastName%22%3A%22Cortada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Cabrera%22%2C%22lastName%22%3A%22Sol%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Calvo%22%2C%22lastName%22%3A%22Iglesias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Cantabrana%22%2C%22lastName%22%3A%22Miguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Carrillo%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Casanovas%22%2C%22lastName%22%3A%22Pi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Casas%22%2C%22lastName%22%3A%22Gim%5Cu00e9nez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Castillo%22%2C%22lastName%22%3A%22Lue%5Cu00f1a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20Castillo%22%2C%22lastName%22%3A%22Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Castillo%22%2C%22lastName%22%3A%22Orive%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Chirivella%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%20Chopo%22%2C%22lastName%22%3A%22Alcubilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Climent%22%2C%22lastName%22%3A%22Pay%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20Cobos%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Colomer%22%2C%22lastName%22%3A%22Mart%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Concepci%5Cu00f3n%22%2C%22lastName%22%3A%22Clemente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Cort%5Cu00e9s%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20Cremer%22%2C%22lastName%22%3A%22Luengo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Darnes%22%2C%22lastName%22%3A%22Soler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20De%20Andr%5Cu00e9s%22%2C%22lastName%22%3A%22Novales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20De%20Castro%22%2C%22lastName%22%3A%22Aritmendiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20De%20Juan%22%2C%22lastName%22%3A%22Baguda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20De%20Los%20Reyes%22%2C%22lastName%22%3A%22L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Delgado%22%2C%22lastName%22%3A%22Prieto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20D%5Cu00edaz%22%2C%22lastName%22%3A%22D%5Cu00edaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Escobar%22%2C%22lastName%22%3A%22Cervantes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Ezcurdia%22%2C%22lastName%22%3A%22Sasieta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Facila%22%2C%22lastName%22%3A%22Rubio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Falces%22%2C%22lastName%22%3A%22Salvador%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Federico%22%2C%22lastName%22%3A%22Zaragoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Fern%5Cu00e1ndez%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Fern%5Cu00e1ndez%22%2C%22lastName%22%3A%22De%20La%20Cigo%5Cu00f1a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20A%20Fern%5Cu00e1ndez%22%2C%22lastName%22%3A%22L%5Cu00e1zaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20C%20Fern%5Cu00e1ndez%22%2C%22lastName%22%3A%22L%5Cu00e9oz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Fern%5Cu00e1ndez%22%2C%22lastName%22%3A%22Mouzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Fern%5Cu00e1ndez-Valls%22%2C%22lastName%22%3A%22G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Ferreiro%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Franco%22%2C%22lastName%22%3A%22Aranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Freire%22%2C%22lastName%22%3A%22Corzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Fuertes%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Fuertes%22%2C%22lastName%22%3A%22Beneitez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Galve%22%2C%22lastName%22%3A%22Basilio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20J%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20J%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Ortego%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Pindado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Saavedra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Garc%5Cu00eda-Moll%22%2C%22lastName%22%3A%22Marim%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Gascue%5Cu00f1a%22%2C%22lastName%22%3A%22Rubia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20Gentille%22%2C%22lastName%22%3A%22Lorente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20Gervas%22%2C%22lastName%22%3A%22Pav%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Gilabert%22%2C%22lastName%22%3A%22G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20J%20G%5Cu00f3mez%22%2C%22lastName%22%3A%22Barrado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20J%20G%5Cu00f3mez%22%2C%22lastName%22%3A%22Doblas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20J%20G%5Cu00f3mez%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Gonz%5Cu00e1lez%22%2C%22lastName%22%3A%22Juanatey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Gonz%5Cu00e1lez%22%2C%22lastName%22%3A%22Toda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Gonzalvez%22%2C%22lastName%22%3A%22Ortega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Gordillo%22%2C%22lastName%22%3A%22Higuero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Hern%5Cu00e1ndez%22%2C%22lastName%22%3A%22Afonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20Herrera%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Homs%22%2C%22lastName%22%3A%22Espinach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Idoate%22%2C%22lastName%22%3A%22Gastearena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Irurita%22%2C%22lastName%22%3A%22Latasa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Izquierdo%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Jaquet%22%2C%22lastName%22%3A%22Herter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Lagares%22%2C%22lastName%22%3A%22Carballo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20Lastra%22%2C%22lastName%22%3A%22Gal%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Limeres%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22Aranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22Barreiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22Granados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22Mouri%5Cu00f1o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Luaces%22%2C%22lastName%22%3A%22M%5Cu00e9ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Mainar%22%2C%22lastName%22%3A%22Latorre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Mar%5Cu00edn%22%2C%22lastName%22%3A%22Araez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Mar%5Cu00edn%22%2C%22lastName%22%3A%22Ortu%5Cu00f1o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Mart%5Cu00edn%22%2C%22lastName%22%3A%22Santana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Mart%5Cu00ednez%22%2C%22lastName%22%3A%22Florez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Mart%5Cu00ednez%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%20Mart%5Cu00ednez%22%2C%22lastName%22%3A%22Rivero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20Marzal%22%2C%22lastName%22%3A%22Mart%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20F%20Mazzanti%22%2C%22lastName%22%3A%22Mignaqui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Melero%22%2C%22lastName%22%3A%22Pita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Molina%22%2C%22lastName%22%3A%22Laborda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Mi%5Cu00f1ana%22%2C%22lastName%22%3A%22Escriv%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Montagud%22%2C%22lastName%22%3A%22Saavedra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00aa%20A%20Montero%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Mora%22%2C%22lastName%22%3A%22Robles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Morales%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Moreno%22%2C%22lastName%22%3A%22Arribas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00aa%20T%20Moreno%22%2C%22lastName%22%3A%22Casquete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Moya%22%2C%22lastName%22%3A%22L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Murga%22%2C%22lastName%22%3A%22Eizagaechevarr%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Narro%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Navarro%22%2C%22lastName%22%3A%22Manch%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Navas%22%2C%22lastName%22%3A%22Navas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Novo%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20N%5Cu00fa%5Cu00f1ez%22%2C%22lastName%22%3A%22Gamero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Ord%5Cu00f3%5Cu00f1ez%22%2C%22lastName%22%3A%22Espa%5Cu00f1a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20Ortiz%20De%20Murua%22%2C%22lastName%22%3A%22L%5Cu00f3pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Orts%22%2C%22lastName%22%3A%22Soler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Otero%22%2C%22lastName%22%3A%22Chulian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Pastor%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20J%20Paule%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20Paz%22%2C%22lastName%22%3A%22Bermejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20Pedrosa%22%2C%22lastName%22%3A%22Del%20Moral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Pe%5Cu00f1a%22%2C%22lastName%22%3A%22P%5Cu00e9rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20%5Cu00c1%20Perea%22%2C%22lastName%22%3A%22Egido%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20P%5Cu00e9rez%22%2C%22lastName%22%3A%22De%20Isla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20P%5Cu00e9rez%22%2C%22lastName%22%3A%22Ibiricu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00aa%20A%20P%5Cu00e9rez%22%2C%22lastName%22%3A%22Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20P%5Cu00e9rez%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Peris%22%2C%22lastName%22%3A%22Domingo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20M%20Peset%22%2C%22lastName%22%3A%22Cubero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Pinar%22%2C%22lastName%22%3A%22Sopena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Pindado%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00aa%20J%20Pinilla%22%2C%22lastName%22%3A%22Lozano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Pi%5Cu00f1ero%22%2C%22lastName%22%3A%22Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20Porras%22%2C%22lastName%22%3A%22Ramos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Prieto%22%2C%22lastName%22%3A%22Moriche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Ramos%22%2C%22lastName%22%3A%22Ariznabarreta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Rayo%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%20Roca%22%2C%22lastName%22%3A%22Catal%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Almod%5Cu00f3var%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Collado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Tejero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20Romeo%22%2C%22lastName%22%3A%22Castillejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20Romero%22%2C%22lastName%22%3A%22Alvira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20A%20Romero%22%2C%22lastName%22%3A%22Hinojosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Romero%22%2C%22lastName%22%3A%22Menor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Rossi%22%2C%22lastName%22%3A%22Sevillano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20C%20Rueda%22%2C%22lastName%22%3A%22Calle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Rueda%22%2C%22lastName%22%3A%22Soriano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Ruiz%22%2C%22lastName%22%3A%22P%5Cu00e9rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20Sagastagoitia%22%2C%22lastName%22%3A%22Gorostiza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20Sainz%22%2C%22lastName%22%3A%22Hidalgo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Sandin%22%2C%22lastName%22%3A%22Roll%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Santaolalla%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Santas%22%2C%22lastName%22%3A%22Olmeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Santos%22%2C%22lastName%22%3A%22Iglesias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20L%20Sanz%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20Segura%22%2C%22lastName%22%3A%22Laborda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Serrano%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Sevilla%22%2C%22lastName%22%3A%22Toral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Silva%22%2C%22lastName%22%3A%22Melchor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Simarro%22%2C%22lastName%22%3A%22Mart%5Cu00edn-Ambrioso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Sola%22%2C%22lastName%22%3A%22Casado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Soriano%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00aa%20I%20Soto%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Talavera%22%2C%22lastName%22%3A%22Calle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Teijeira%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20L%20Torres%22%2C%22lastName%22%3A%22D%5Cu00edaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20Troncoso%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%20Trujillo%22%2C%22lastName%22%3A%22Berraquero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20A%20Ulecia%22%2C%22lastName%22%3A%22Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Umaran%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Vatic%5Cu00f3n%22%2C%22lastName%22%3A%22Herreros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20V%5Cu00e1zquez%22%2C%22lastName%22%3A%22Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Vega%22%2C%22lastName%22%3A%22Barbado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%20Velasco%22%2C%22lastName%22%3A%22Espejo-Saavedra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20Vicente%22%2C%22lastName%22%3A%22Vera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Vida%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20Villar%22%2C%22lastName%22%3A%22Mariscal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Vives%22%2C%22lastName%22%3A%22Boniato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Wu%22%2C%22lastName%22%3A%22Amen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%20Yanes%22%2C%22lastName%22%3A%22Bowden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20C%20Ya%5Cu00f1ez%22%2C%22lastName%22%3A%22Wonenburger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20L%20Zamorano%22%2C%22lastName%22%3A%22G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Zarauza%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Monnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Jaussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Forclaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Grob%5Cu00e9ty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Schlueter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Vuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20A%22%2C%22lastName%22%3A%22Nacht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Ev%5Cu00e9quoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Ciaroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Domin%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22B%5Cu00e9rub%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Rickli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Hellermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Koller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Bourgeois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Engel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Niederberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Stadler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Gn%5Cu00e4dinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Schmied%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Wettstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Hilti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20A%22%2C%22lastName%22%3A%22Ch%5Cu00e9telat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Sepulcri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Brunner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Schindler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kraus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Vivekaphirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Panpunnung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kuanprasert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Wongcharoen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Phrommintikul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Harinasuta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Si%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Chaithiraphan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Boonyasirinant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Boonyapisit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kittipovanonth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Buakhamsri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Piyayotai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Hutayanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Junejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Aiyegbayo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Ancliff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Bradshaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Cervenak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22George%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Gilmour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Gough%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Idrissi-Sbai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Ingham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Al-Khalidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Liston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Mackrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Pattison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Ramachandran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Reddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Sen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Shetty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Stanley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Wallace%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Weatherhead%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Gilbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22McCansh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Higgins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Killeen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Cromarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Franklin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Pinch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Dhesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Dernedde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Lawrence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Simper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Noble%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Dalton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Stevens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Berry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Hand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Oliver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Sampson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Grogono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Dalrymple%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Thurston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Elsby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vallis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Morrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Thomson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Dougall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20La%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Compson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22McCracken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Calder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Richmond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Brownlie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22MacCowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Heap%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Perry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20A%22%2C%22lastName%22%3A%22Holden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Haldane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Hood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Cullen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22McNaught%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Sharif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Dunn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Langridge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Burns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Crawford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Kennedy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Logan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22McAlavey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Costello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22McLaren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Potter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22McPherson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Drijfhout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Finlayson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Troup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Woodall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Pearce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Parkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Yusuf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Benett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Bishop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Caldwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Ormiston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kwok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Wright%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Kanumilli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Saul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Milligan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Vance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Shaikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Ellis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Vites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Steeds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Goodwin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aftab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Banham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Chauhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20S%22%2C%22lastName%22%3A%22Grocutt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Jordan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20S%22%2C%22lastName%22%3A%22Jheeta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Ladha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Nazir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Pal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20P%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22McManus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Singal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Saunders%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20B%22%2C%22lastName%22%3A%22Syed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Dau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20M%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22McNeilly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bolidai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22MacCarthy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Lawton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vardhani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Sengupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Kinloch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Howie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Serrano-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20E%22%2C%22lastName%22%3A%22Paget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Till%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Seal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Morrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Warden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Elias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20K%22%2C%22lastName%22%3A%22Pandey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Challenor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Gibbs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Gillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Goldie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Jarvis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Malden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Morton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Nehrig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Sheringham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Halcox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22O%27Connor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Ling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Charles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Weatherup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Watkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Morgan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Lindsay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Beacock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Balai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kirmond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Brindle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Bundy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Cahill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Dayani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Eavis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Mohr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Hayne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Krasucki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Micheals%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Orpen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sewell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Sharp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Stevens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Upton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Victory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Wernham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Mays%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Andrews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Takhar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Travill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Choudhury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Matta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ihonor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22O%27Dong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Rahman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Singer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Gillam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20S%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Razzaq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22O%27Toole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Rowe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Kalra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Allcock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Tucker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Sprott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Kyd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Cunliffe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Arden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Bateman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kassianos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Sinclair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Jagathesan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Sattar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ashford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Chukwu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Pradhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Rundell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Howlett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Bietzk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Myint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Partington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22O%27Reilly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Baverstock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Tennekoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Brand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Haimes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Whetstone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Mays%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Andrews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Takhar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Anscombe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Beale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Murphy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Lindford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Serrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Preston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sethi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Hutchinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Kovyrshyna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Rogozhyna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Kiver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Vasylenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kucheryava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Salimova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Alekseenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Gukov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Myhailiv%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Kardashevskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Prikolota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Bashkirtcev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Andreev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Tkachenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Mospan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Batushkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Reshotko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Safonova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Ogorodnichuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Pustovit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Romanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Burlakova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Voloshko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Lafarenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%22%2C%22lastName%22%3A%22Vlasuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Leshchuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Chushak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Koval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Stasuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Pogrebna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kornienko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Tikhonova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Fesenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Kuzmina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Ushakov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Vechtomova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Potapska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Illushechkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Kryvenkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Lysunets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Tsygankov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Bardachenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Voloshyna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Ginzburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Franskyavichene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Korotich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Vyshnevaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Bilous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Kulinich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Kulik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Sadykova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O%22%2C%22lastName%22%3A%22Zalyzniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Berezhna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Molotyagina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20V%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20T%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20H%22%2C%22lastName%22%3A%22Khong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20B%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20B%22%2C%22lastName%22%3A%22Le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20A%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20C%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20Q%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q%20H%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20C%22%2C%22lastName%22%3A%22Vu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20H%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20H%20T%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20C%22%2C%22lastName%22%3A%22Ta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20P%22%2C%22lastName%22%3A%22Phan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20H%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20N%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20L%22%2C%22lastName%22%3A%22To%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20T%22%2C%22lastName%22%3A%22Le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Dang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20H%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20H%22%2C%22lastName%22%3A%22Phan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20H%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20V%20A%22%2C%22lastName%22%3A%22Tuong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20P%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20H%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20K%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20B%22%2C%22lastName%22%3A%22Vu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20S%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20Q%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20S%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20D%22%2C%22lastName%22%3A%22Dang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20T%22%2C%22lastName%22%3A%22Le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20C%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20K%20L%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20D%22%2C%22lastName%22%3A%22Luong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20Q%22%2C%22lastName%22%3A%22Luu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20V%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20K%22%2C%22lastName%22%3A%22Huynh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20T%20H%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20A%22%2C%22lastName%22%3A%22Ngo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20C%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20L%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20B%22%2C%22lastName%22%3A%22Doan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20B%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20N%22%2C%22lastName%22%3A%22Vo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20T%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20A%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20D%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20K%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%20C%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20H%22%2C%22lastName%22%3A%22Ngo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20H%22%2C%22lastName%22%3A%22Vu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%20T%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20P%20H%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20U%20P%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20N%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20H%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20H%22%2C%22lastName%22%3A%22Truong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20L%22%2C%22lastName%22%3A%22Mai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20S%22%2C%22lastName%22%3A%22Hoang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%20M%20A%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20P%22%2C%22lastName%22%3A%22Dang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q%20B%22%2C%22lastName%22%3A%22Truong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20P%22%2C%22lastName%22%3A%22Vo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%20T%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%20H%22%2C%22lastName%22%3A%22Chau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%20T%20H%22%2C%22lastName%22%3A%22Ta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20N%22%2C%22lastName%22%3A%22Dinh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%20K%20N%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Martina-Hooi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Angela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Ramoutar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Fillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Tilluckdharry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Dookie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Foster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Hart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Omardeen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Ramphall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Lalla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Elliott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Falconer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Hurlock-Clarke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Ishmael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Lalljie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Liqui-Lung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Massay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%22%2C%22lastName%22%3A%22Mohammed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Daniel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Didier%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%20and%20aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Data%20on%20new-onset%20atrial%20fibrillation%20%28NOAF%29%20in%20patients%20with%20chronic%20coronary%20syndromes%20%28CCS%29%20are%20scarce.%20This%20study%20aims%20to%20describe%20the%20incidence%2C%20predictors%2C%20and%20impact%20on%20cardiovascular%20%28CV%29%20outcomes%20of%20NOAF%20in%20CCS%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Data%20from%20the%20international%20%2845%20countries%29%20CLARIFY%20registry%20%28prospeCtive%20observational%20LongitudinAl%20RegIstry%20oF%20patients%20with%20stable%20coronary%20arterY%20disease%29%20were%20used.%20Among%2029%20001%20CCS%20outpatients%20without%20previously%20reported%20AF%20at%20baseline%2C%20patients%20with%20at%20least%20one%20episode%20of%20AF%5C%2Fflutter%20diagnosed%20during%205-year%20follow-up%20were%20compared%20with%20patients%20in%20sinus%20rhythm%20throughout%20the%20study.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20incidence%20rate%20of%20NOAF%20was%201.12%20%5B95%25%20confidence%20interval%20%28CI%29%201.06%5Cu20131.18%5D%20per%20100%20patient-years%20%28cumulative%20incidence%20at%205%20years%3A%205.0%25%29.%20Independent%20predictors%20of%20NOAF%20were%20increasing%20age%2C%20increasing%20body%20mass%20index%2C%20low%20estimated%20glomerular%20filtration%20rate%2C%20Caucasian%20ethnicity%2C%20alcohol%20intake%2C%20and%20low%20left%20ventricular%20ejection%20fraction%2C%20while%20high%20triglycerides%20were%20associated%20with%20lower%20incidence.%20New-onset%20atrial%20fibrillation%20was%20associated%20with%20a%20substantial%20increase%20in%20the%20risk%20of%20adverse%20outcomes%2C%20with%20adjusted%20hazard%20ratios%20of%202.01%20%2895%25%20CI%201.61%5Cu20132.52%29%20for%20the%20composite%20of%20CV%20death%2C%20non-fatal%20myocardial%20infarction%2C%20or%20non-fatal%20stroke%2C%202.61%20%2895%25%20CI%202.04%5Cu20133.34%29%20for%20CV%20death%2C%201.64%20%2895%25%20CI%201.07%5Cu20132.50%29%20for%20non-fatal%20myocardial%20infarction%2C%202.27%20%2895%25%20CI%201.85%5Cu20132.78%29%20for%20all-cause%20death%2C%208.44%20%2895%25%20CI%207.05%5Cu201310.10%29%20for%20hospitalization%20for%20heart%20failure%2C%20and%204.46%20%2895%25%20CI%202.85%5Cu20136.99%29%20for%20major%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20CCS%20patients%2C%20NOAF%20is%20common%20and%20is%20strongly%20associated%20with%20worse%20outcomes.%20Whether%20more%20intensive%20preventive%20measures%20and%20more%20systematic%20screening%20for%20AF%20would%20improve%20prognosis%20in%20this%20population%20deserves%20further%20investigation.%22%2C%22date%22%3A%222024-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehad556%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F45%5C%2F5%5C%2F366%5C%2F7249155%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22V88PBS93%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sherratt%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESherratt%20SCR%2C%20Mason%20RP%2C%20Libby%20P%2C%20Steg%20PG%2C%20Bhatt%20DL.%202024.%20Do%20patients%20benefit%20from%20omega-3%20fatty%20acids%3F%20Cardiovascular%20Research%20cvad188.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Do%20patients%20benefit%20from%20omega-3%20fatty%20acids%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20C%20R%22%2C%22lastName%22%3A%22Sherratt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Preston%22%2C%22lastName%22%3A%22Mason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Libby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Omega-3%20fatty%20acids%20%28O3FAs%29%20possess%20beneficial%20properties%20for%20cardiovascular%20%28CV%29%20health%20and%20elevated%20O3FA%20levels%20are%20associated%20with%20lower%20incident%20risk%20for%20CV%20disease%20%28CVD.%29%20Yet%2C%20treatment%20of%20at-risk%20patients%20with%20various%20O3FA%20formulations%20has%20produced%20disparate%20results%20in%20large%2C%20well-controlled%20and%20well-conducted%20clinical%20trials.%20Prescription%20formulations%20and%20fish%20oil%20supplements%20containing%20low-dose%20mixtures%20of%20eicosapentaenoic%20acid%20%28EPA%29%20and%20docosahexaenoic%20acid%20%28DHA%29%20have%20routinely%20failed%20to%20prevent%20CV%20events%20in%20primary%20and%20secondary%20prevention%20settings%20when%20added%20to%20contemporary%20care%2C%20as%20shown%20most%20recently%20in%20the%20STRENGTH%20and%20OMEMI%20trials.%20However%2C%20as%20observed%20in%20JELIS%2C%20REDUCE-IT%2C%20and%20RESPECT-EPA%2C%20EPA-only%20formulations%20significantly%20reduce%20CVD%20events%20in%20high-risk%20patients.%20The%20CV%20mechanism%20of%20action%20of%20EPA%2C%20while%20certainly%20multifaceted%2C%20does%20not%20depend%20solely%20on%20reductions%20of%20circulating%20lipids%2C%20including%20triglycerides%20%28TG%29%20and%20LDL%2C%20and%20event%20reduction%20appears%20related%20to%20achieved%20EPA%20levels%20suggesting%20that%20the%20particular%20chemical%20and%20biological%20properties%20of%20EPA%2C%20as%20compared%20to%20DHA%20and%20other%20O3FAs%2C%20may%20contribute%20to%20its%20distinct%20clinical%20efficacy.%20In%20vitro%20and%20in%20vivo%20studies%20have%20shown%20different%20effects%20of%20EPA%20compared%20with%20DHA%20alone%20or%20EPA%5C%2FDHA%20combination%20treatments%2C%20on%20atherosclerotic%20plaque%20morphology%2C%20LDL%20and%20membrane%20oxidation%2C%20cholesterol%20distribution%2C%20membrane%20lipid%20dynamics%2C%20glucose%20homeostasis%2C%20endothelial%20function%2C%20and%20downstream%20lipid%20metabolite%20function.%20These%20findings%20indicate%20that%20prescription-grade%2C%20EPA-only%20formulations%20provide%20greater%20benefit%20than%20other%20O3FAs%20formulations%20tested.%20This%20review%20summarizes%20the%20clinical%20findings%20associated%20with%20various%20O3FA%20formulations%2C%20their%20efficacy%20in%20treating%20CV%20disease%2C%20and%20their%20underlying%20mechanisms%20of%20action.%22%2C%22date%22%3A%222024-01-22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fcvr%5C%2Fcvad188%22%2C%22ISSN%22%3A%220008-6363%2C%201755-3245%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fcardiovascres%5C%2Fadvance-article%5C%2Fdoi%5C%2F10.1093%5C%2Fcvr%5C%2Fcvad188%5C%2F7585216%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A57Z%22%7D%7D%5D%7D1.Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif J, Ballantyne CM, Kolm P. 2024. Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States. JAHA 13:e032413.1.Wiernik E, Renuy A, Kab S, Steg PG, Goldberg M, Zins M, Caligiuri G, Bouchard P, Carra MC. 2024. Prevalence of self‐reported severe periodontitis: Data from the population‐based CONSTANCES cohort. J Clinic Periodontology jcpe.13969.1.Gautier A, Picard F, Ducrocq G, Elbez Y, Fox KM, Ferrari R, Ford I, Tardif J-C, Tendera M, Steg PG, CLARIFY investigators, Guerrero AA, Basara M, Belcastro F, Bertarini JA, Cazenave C, Dreycopp H, Egido J, Estrella J, Garofalo D, Giordano J, Lagioia H, Lago N, Greca RL, Lema L, Cabanillas NL, Luquez H, Miller C, Prada E, Rodenas P, Schena RG, Suarez G, Tomatti A, Colquhoun DM, Conradie A, Cox S, Cross D, Fathi R, Fitzgerald B, Hamilton-Craig I, Holt G, Jayasinghe SR, Mai N, Moolman J, Motyer RA, Phillips K, Rafter A, Rahman A, Rainbird A, Scalia G, Taylor A, West P, Alford K, Amor R, Astridge P, Bastian B, Bates F, Doohan MM, Du Plooy J, Ford JC, Kanagaratnam L, Khoury V, Parkin R, Rogers J, Sceats G, Waldman A, Wang D, Wright S, Ardill J, Aylward P, Beltrame JF, Bradley J, Heddle W, Joseph M, Rajendran S, Varughese S, Brice E, Hockings B, Janssen J, Kozlowski A, O’Shea J, Tan J, Playford DA, Woollard K, Ajani A, Barron G, Better N, Carruthers T, Chan B, Chan R, Cotroneo J, Counsell JT, Eccleston DS, Forge BHR, Hamer A, Horrigan M, Jelinek VMJ, Lew R, O’Donnell D, Panetta F, Sebastian M, Shetty P, Soward A, Srivastava P, Strathmore NF, Sylivris S, Szto G, Veth V, Yip T, Badr-Eslam R, Kleemann L, Steurer G, Mörz-Proszowski B, Auhser F, Teleky U, Sepp G, Beinhauer A, Kerö D, Lavicka C, Perger T, Hadjiivanov V, Feldner-Busztin M, Mika R, Filip W, Mahr A, Toplak J, Millauer MG, Haralambus P, Walcher K, Karner KH, Ziak E, Painsipp P, Frank U, Suntinger A, Gritsch W, Bode G, Herrmann R, Raffelsberger R, Topf H, Moser E, Föchterle J, Honsig T, Mayr K, Mayr H, Kaserbacher R, Dzien A, Galehr E, Felbermayer M, Schwarz R, Amini R, Appeltants H, Ballet A, De Niel C, Berkenboom G, Bernard X, Bouvy T, Claeys M, Dascotte Y, Davin L, De Backer T, De Meester A, De Ridder S, Dendale P, Denef K, Emonts M, Geraedts JTM, Goethals M, Grégoire J-M, Herbots T, Hoffer E, Hutse WHJ, Lafontaine P, Lefebvre P, Lesseliers H, Odent G, Pasquet A, Peperstraete B, Purnode P, Rogowsky A, Rosseel M, Salembier J-P, Surmont P, Vandeplas AMF, Van De Walle S, Van Den Branden F, Vandergoten P, Vanhauwaert BG, Vanneste L, Vercammen J, Verleyen D, Vermander D, Weytjens C, De Lorenzo AR, Issa AFC, Mioto BM, Vianna CDB, Okawabata C, Rossi EG, Fernandes F, Pitella F, Cesena FHY, Ferreira JFM, Junior JF, Tonet L, Cesar LM, Gowdak LH, Matos MA, Moretti M, Amato RV, Munhoz RT, Coimbra SR, De Lorenzo AR, Issa AFC, Mioto BM, Vianna CDB, Okawabata C, Rossi EG, Fernandes F, Pitella F, Cesena FHY, Ferreira JFM, Junior JF, Tonet L, Cesar LM, Gowdak LH, Matos MA, Moretti M, Amato RV, Munhoz RT, Coimbra SR, Luqman HN, Yakovova S, Mantcheva M, Mincheva V, Baurenski L, Karastanev K, Yordanova V, Peneva Y, Wong P, Fagan M, Sabe-Affaki G, Villasenor FM, Son WK, Manyari DE, Giacomantonio N, Lubelsky BJ, Ezekiel D, Leong JCS, Grover A, Vavougios J, Pesant Y, Kushner AM, Yeung MMW, Vertes GE, Nasser-Sharif FJ, Spensieri D, Roy A, Nguyen TT, Leclair M, Morra P, Biglow CE, Baril JF, Lai K, Wong DS, Martinho V, Antoniadis GA, Searles GR, Rouse D, Brisson G, Wong SK, Collette RS, Ho MSC, Constance C, Gendreau R, Kellam GW, Lara TAC, Boyrazian HA, Shamsuzzaman M, Spink DR, T Wong AP, Janes J, Czarnecka M, Saulnier D, Levesque G, Clavette PF, Kokis A, Orenstein-Lyall TL, Pandey AS, Robb J, Verret G, Czarnecki W, Perreault F, Chouinard G, Lafrance G, Fullerton GM, LeBouthillier P, Tran QH, Marrero IR, Ramadan FB, Talbot P, Fazil MA, Cha JY-M, Garg S, Chehayeb R, Roy B, Chan YK, Harlos HE, Matheson HB, Patel R, Vaz GF, Bhatt JS, Liu E, Ashton TH, Sullivan H, Quinn LP, Yared K, Gupta AK, Sullivan B, Campbell J, Pallie S, Kim HH, Savard D, Cherry JM, Gold J, Brouillette G, Belanger A, Berlingieri J, Nisker W, Boutros G, Bakbak AI, Lasalle L, Chen LL, Chen MH, Chen MY, Chen XP, Chen YD, Cong HL, Ding SF, Dong JT, Dong SH, Du ZM, Feng LL, Gao W, Ge H, Ge SJ, Guo T, Guo Y, Huang Z, Huo Y, Jin HG, Ke YN, Li HW, Li HM, Li ZC, Li YJ, Liu JL, Liu QL, Liu SW, Lv SZ, Miao W, Pan GZ, Pu XD, Qian ZM, Su X, Tao JH, Wang HP, Wang JA, Wang NF, Wang T, Wang W, Wang Y, Wei M, Wu SY, Wu YJ, Xiong LG, Xu D, Yan J, Yang K, Yang M, Yang TL, Yang XL, Yu JM, Zeng HS, Zhang H, Zhang HQ, Zhang L, Zhou SX, Zhou YL, Bozkova J, Carda J, Dedkova S, Dufka A, Fridrich J, Hodac T, Jirmar R, Kadleckova A, Karlicek M, Krupicka J, Kuchar J, Lavicka V, Leso J, Lorenc Z, Micko M, Navratil P, Petrova I, Povolna P, Raisova L, Raska P, Ravlyk V, Schlesingerova S, Smrckova E, Sternthal P, Stursova H, Vymetal P, Wiggers P, Markenvard J, Andersen LK, Frost L, Refsgaard J, Strange S, Egstrup K, Sykulski R, Hildebrant P, Haghfelt T, Ege M, Saaby L, Cattan S, Adam-Blanpain M, Adda M, Aimouch N, Ardouin L, Assouline S, Aumjaud A, Barjhoux C, Baroudi R, Beaurain C, Bennouna MA, Bernard A, Bernardeau C, Blanc E, Blum-Decary I, Bodur G, Boesch C, Bonal J, Bonhomme R, Bonnet JL, Bories J, Bourachot ML, Brumelot F, Petaut MB, Brunschwig C, Buffet P, Calmettes P, Centa I, Chartier B, Chemin P, Chometon F, Cohen J, Colin R, Cottin Y, Crespo F, Dabboura A, David F, Dehayes P, Dematteo P, Dibon O, Dodemant P, Dormagen V, Dreyfus X, Dubois JM, Duclos F, Ducoudre M, Duprez O, Durand P, Durand E, Egloff P, Escande M, Berdou MCE, Ashari GE, Feldmann I, Ferrieres J, Foltzer E, Fontanet B, Garandeau M, Garban T, Geffroy S, Gillet T, Godart S, Gosse P, Gratia P, Greiner O, Gueusquin A, Guiu E, Guy JM, Haddad S, Hennebelle V, Honorat S, Hourany A, Hua G, Jacquier P, Jean S, Jeremiasz R, Kohler P, Lacroix A, Leandri M, Lemiere Y, Liautard M, Loheac P, Louchart JC, Magnus P, Maheu B, Malaterre HR, Manchet G, Mantoux J, Manzi D, Marachli M, Maroun M, Meneveau N, Messas E, Mougeolle JL, Mouhat T, Muller J, Naisseh M, Nocon P, Onger D, Ouguoujil A, Ovize M, Page E, Pareathumby K, Pleskof A, Poinson P, Pons G, Pouderou P, Poujois JN, Probst V, Prunier F, Prunier L, Puel V, Rechtman D, Rennert R, Rijavec B, Riou Y, Robert J, Roche C, Roul G, Salaun B, Saleh B, Sandalian A, Sander M, Schenowitz A, Silvestre A, Soleille H, Tabet S, Tardy M, Thomas-Richard F, Truong B, Varaldi J, Vial H, Walch JM, Wazana M, Zeitouni R, Audibert H, Alizon F, Amlaiky A, Asplanato M, Baranes C, Bariaud M, Bernasconi F, Bousquet P, Ceraulo C, De Geeter G, Donetti J, Doucet B, Doucet J, Dutoya T, Ennouchi D, Fallacher MH, Fouquet G, Fourchard V, Gdalia J, Grollier G, Guerard S, Jeannerat PA, Jobic Y, Joulie V, Jourdain P, Jouve V, Ketelers R, Khaznadar G, Kohan P, Koujan B, Lammens B, Landragin I, Moal EL, M’Bey D, Maes F, Morlet SM, Massabie R, Meddah D, Meriaux FX, Mestre-Fernandes C, Meyssonnier P, Migliore M, Milewski J, Millet JF, Mingam S, Nazeyrollas P, Paganelli F, Pellerin F, Petitjean F, Pinzani A, Pladys A, Primot P, Pucheu A, Rahali A, Ravoala P, Rousson D, Samama P, Sardon M, Silvestri R, Soskin P, Tabone X, Tricot C, Vaquette B, Vogel M, Weingrod M, Aboyans V, Amoretti R, Aubry J, Berthezene P, Binet D, Bonnaud X, Bonnet P, Bonny A, Bouchaya T, Boureux C, Bourgeois JM, Brottier L, Cavert B, Cleron S, Dechoux E, Delhomme C, Detienne JP, Dubs JP, Faudon B, Fellous F, Fressonnet R, Garaud Y, Garcia D, Geneves M, Gleizes JL, Guyetand C, Hermellin B, Iovescu D, Kanner JP, Khanoyan P, Leherissier A, Maximovitch A, Merian B, Messali P, Moreau Y, Moyal J, Payot L, Peuch LP, Prevot JL, Raymond P, Relange D, Reymond S, Robert JF, Rosenstein H, Schneider J, Schultz R, Tanielian P, Thoin F, Thomas L, Touzet P, Steg G, Sauvinet GAO, Domengetroy FB, Chamou K, Etcheverry B, Farges JL, Fraboulet JY, Goralski M, Janody D, Mamez B, Manlay W, Paillard F, Pelier F, Petit A, Skonieczny M, Augarde R, Fournier JB, Liandrat S, Lim P, Noury AI, Paris D, Saade M, Stordeur JM, Danchin N, Pornin M, Fauchier L, Galinier M, Balice-Pasquinelli MA, Sosner P, Yvorra S, Delcoulx E, Mouquet F, Poulard JE, Sudre A, Heno P, Biausque F, Guenoun M, Attia G, Pouwels S, Carpentier L, Verbrugge E, Ziccarelli C, Elkohen M, Tricoire J, Lang P, Huttin O, Altevogt B-M, Altmann U, Baar M, Berrisch-Rahmel S, Birkenhagen A, Bläse I, Blindt R, Bosch R, Brattström A, Breuer H-H, Castrucci M, Cicek-Hartvig S, Cierpka R, Claus M, Deissner M, Drexler M, Eggeling T, Eisele G, Enayat D, Frickel S, Gessner S, Giokoglu K, Gmehling J, Goss F, Grooterhorst P, Gysan DB, Haberl R, Haerer W, Jun NH, Heinemann-Meerz S, Henschel F, Hinrichsen M, Hofer W, Hofmeister A, Hoh G, Horstkotte E, Jäger F, Jeserich M, Keil U, Killat H, Kimmel S, Kindel M, Kindler P, Kleta S, Könemann J, König K, Krause-Allmendinger H, Kronberg K, Kruck I, Männl V, Meinel A, Mentz G, Meyer-Michael E, Mibach F, Möller S, Muth S, Nelböck-Huber E, Ohlmeyer D, Özkan-Rashed Z, Paulus C-P, Perings S, Placke J, Raters C, Reifart N, Rink A, Rybak K, Salecker I, Schermaul K-H, Schlesinger-Irsch U, Schmidt E, Schmitz K-H, Schön N, Schröder T, Sievers B, Simon M, Spengler U, Speth-Nitschke M, Stumpp A, Szabo S, Taggeselle J, Tamm A, Thelemann A, Thelemann C, Thümmel H, Unger G, Utech A, Volmar J, Wauer B, Wehr G, Weinrich L, Weinrich R, Windstetter U, Wirtz JH, Wittlich N, Ziehn P, Zündorf P, Wahshi YA, Singh PP, Narayan A, Tamimi FA, Yazeedi JA, Ayche M, Lawati AA, Dhanki MA, Salustri A, Salah T, Tamimi MY, Agrawal A, Wassef A, Baslaib F, Radaideh GA, Yusufali A, Bazargani N, Akbar M, Wahab HA, Malak SA, Ghaly I, Hafez H, Kandari FA, Haiba M, Alanbaei M, Gomaa MM, Khalifa A, Avgerinos C, Gouli O, Stergiou D, Alexopoulos I, Pappas C, Petropoulos I, Chatzioakim G, Pontikakis N, Priftis C, Mpompoth P, Bourazanis I, Papathanasioy A, Avlonitis S, Zakopoulos C, Koutsimpanis G, Tsamopoulos I, Christoforidis C, Zachos V, Kalaras P, Karachaliou M, Liatas C, Pournaras G, Theodorakis G, Orestis I, Panisois K, Chalkiadakis E, Arfaras V, Kolios G, Boutsikos P, Kotsalos A, Mitropoulos D, Samothrakitis A, Svolis K, Anastasiou E, Gkinis T, Dalampyras P, Kalampalikis A, Leontaridis I, Gabriilidis S, Konstantinidis I, Plastiras V, Tarenidis P, Marozsán I, Édes I, Czuriga I, Cziráki A, Tóth K, Dongó Á, Túri P, Forster T, Borbola J, Bachmann B, Masszi G, Orbán M, Gerges G, Balogh G, Bajcsi É, Takács I, Nagy L, Kisjós B, Jánosi A, Nagy A, Nagy K, Büttl A, Lippai J, Sziegl Z, Malkócs Z, Földi A, Fikker K, Szabó E, Forrai R, Sebõk Z, Merkely B, Gupta R, Natarajan S, Dalal J, Saran RK, Mehta A, Samal MP, Khan IA, Ghose T, Sawhney JPS, Roy T, Chandra S, Modi S, Singh MM, Vijayaraghavan G, Murthy LS, Ramesh SS, Dayasagar RV, Chenniappan MS, Vadavi A, Kunhali K, Reddy KS, Vallal ST, Khera P, Prasad B, Shukla D, Trivedi AK, Ahuja R, Rawal J, Karnik R, Hiremath MS, Kumbla DK, Shetty SR, Chonkar NS, MJuneja L, Goyal BK, Sheahan R, Daly C, Vaughan C, Fleming S, Shiels P, Keelan P, Kiernan T, Day B, Kelly K, MacNamara F, Maguire B, Clifford A, O’Gara A, Guardigli G, Pes G, Caridi G, Frattola A, Doronzo B, Riccioni G, Lacchè A, Massari F, Orazi S, Carretta D, Provvidenza M, Pedretti R, Nicolino A, Felis S, Pernice V, Gaglione A, Gori P, Martina P, d’Alessandro V, Giacomazzi F, Terrosu P, Cernetti C, Antonicelli R, Ansalone G, Balbi M, Tamburino C, Moretti L, Tantillo S, Patriarchi F, Proietti F, Sinicropi G, Maragoni G, Mallamaci V, d’Este D, Azzolini P, Brscic E, Bongo S, Gigantino A, Perna G, Mayer MS, Rosa CL, Muscio G, Scollo V, Magliari F, Pio CP, Castellari M, Pasquale PD, Scalzo D, Saporito F, Capuano N, Alitto F, Marchionni N, Turiel M, Bianco A, Greco C, Marullo L, Testa R, Vicentini A, Novo S, Varra FL, Tavazzi L, Conte MR, Lazerevic Z, Colivicchi F, Macchi C, Mule JD, Sibilio G, Achilli A, Proto C, Kang SM, Koo BK, Hong SK, Kim W, Lee SH, Yoo BS, Seo HS, Gwon HC, Kang DH, Kwon HM, Chae IH, Oh SJ, Shin JH, Goh CW, Byun YS, Zo JH, Hong TJ, Kim DS, Cha TJ, Ryu JK, Kim YJ, Hwang JY, Hur SH, Jeong MH, Oh SK, Jin DK, Jung KT, Rhew JY, Lee S, Jeon DW, Yoon SJ, Kim SH, Mintale I, Latkovskis G, Hansone S, Rozkova N, Baika A, Jasinkevica I, Abele S, Laizane I, Pontaga N, Ecina V, Mihailova I, Kondratovica A, Laucevičius A, Jurgaitienė R, Šlapikas R, Barauskienė G, Jankauskienė E, Revienė S, Zaronskienė D, Šlapikienė OB, Kupstytė N, Rinkūnienė E, Steponėnienė R, Kojelienė J, Badarienė J, Dženkevičiūtė V, Sadauskienė E, Butkuvienė I, Stankevičius R, Paliulionienė R, Snikytė R, Mažutavičius R, Jamaluddin AN, Rahim AAA, Yusof AKM, Chee KH, Sadiq MA, Ramanaidu S, Sim KH, Ong TK, Fong AYY, Chang BC, Chua SK, Cham YL, Amin NHM, Tan SK, Khiew NZ, Said A, Abdullah CK, Cheah YW, Sinnadurai J, Lau KKH, Choor CK, Sia KK, Ang CC, Singh JSA, Wahab MZA, Wong CK, Ghapar AK, Muthu A, Mahendran KA, Jaafar AH, Ng KH, Ruhani AI, Tahir HAR, Manap HA, Ch’ng BSK, Ch’ng ET, Abdullah AS, Ismail O, Sahar AS, Kareem BBA, Kader MASA, Ma SK, Chan KK, Goh TH, Singh A, Liew HB, Chu CM, Bhaskaran RKM, Shah RP, Joseph KL, Hasni HN, Ng WK, Choo GH, Saaidin N, Yeo CK, Lai VM, Lai YC, Tay MH, Lim BA, Luqman HN, Esperon GL, Alvarez JDJZSYA, Manzur FA, Sánchez CJ, Rojas JC, Calvillo JC, Aranguren FP, Sánchez CM, Sangabriel AÁ, Vieyra G, Romero SG, Barragán AP, Escalante FR, Paez JC, Valadez EF, Gaxiola E, Manautou LE, Otero OH, Bustillos MB, Pons JLL, Álvarez EG, Santana JRR, Redding JM, Mendoza AA, Briones IR, Arellano JDJR, León JLA, Gamba MA, Alexanderson E, Esparza MER, Sifuentes LAE, Briseño JL, Rodriguez ES, Delgado MLF, Navarrete SS, Juarezy UC, Pinales AL, Castro A, Carpio RC, Rodríguez E, Rojas G, Solache G, Juárez RD, Baleón R, Solorio CF, Reyes HAR, Martínez ML, Maldonado MAR, De La Peña JE, Orozco JHJ, Cisneros FAR, Gil JÁ, López GB, Ibarra MODLR, I Tulevski I, Somsen GA, Miedema K, Chlewicka I, Brodzicki P, Stasiuk T, Szałkowski P, Kulig W, Maliszewski M, Królicka K, Zdrojewska J, Nikodemska I, Szpak A, Wrębiak-Trznadel M, Prokop A, Szulc M, Olszewski A, Kępa W, Banach J, Węglarz M, Gałuszka-Bilińska A, Królak A, Cisowska-Drozd E, Orzechowski K, Jeżewska M, Adamaszek K, Glanowska G, Pitsch T, Matuszewska G, Nowowiejska-Wiewióra A, Dereń M, Walawski G, Sołtysiak M, Wysocki R, Jarosiński G, Drzewiecka A, Ługowski T, Jankowska A, Błaszczak P, Drozd J, Łotocka E, Duchowska R, Sobczyk D, Jarmużek P, Sidor M, Adamczyk-Kot D, Sudnik J, Cygler J, Skoczylas I, Poprawa B, Kisiel L, Kossowska U, Sikorska-Buczkowska B, Modzelewska K, Demianiuk B, Streb W, Mularek-Kubzdela T, Bogdański P, Kaźmierczak E, Zimoląg R, Lorenc J, Furtak R, Regulska A, Winter M, Fic M, Turek P, Nowicka E, Bryl W, Lenartowska L, Jerzykowska O, Maćków M, Gadziński W, Kacorzyk R, Zalewska D, Sadłowski R, Słaboszewska J, Gruchała M, Frankiewicz A, Walczewska J, Adamkiewicz-Piejko A, Chyrek R, Jankowska L, Correia A, Girão A, Herdade Á, Sequeira A, Taveira ATE, Gonzaga A, Ribeiro A, Albuquerque A, Fernandes A, Estriga A, De Almeida AR, Lourenço A, Pereira A, Faria A, De Moura BC, Camossa C, Alves C, Aguiar C, Rodrigues C, Wellenkamp E, De Sousa FF, Pinto FM, Matias F, Alves GS, Bragança G, Proença G, Pêgo GM, Vinhas H, Arroja I, Morais J, Sá JSE, Vasconcelos J, Matos J, Freitas J, Ferreira J, Costa J, Alcaravela J, Mimoso J, Antunes J, Dos Santos JF, Dos Santos JN, Fernandes J, De Aguiar JC, Moreira J, Carvalho J, De Carvalho JF, Calaça J, Simões L, Antunes LL, Soares L, Semedo L, Macedo L, Sargento L, Basto L, Rebelo L, Oliveira L, Carvalho MC, Costa MA, Gamboa MC, Vasconcelos MFFE, Custódio MH, Mendonça MI, Vaz MJP, De Macedo ME, Lazaro M, Oliveira MM, Pelicano N, Lousada N, Rodrigues O, Dias PM, Fonseca PF, Ferreira P, Abreu PFE, Monteiro P, Gomes RS, Carvalho R, Santos R, Soares RR, Baptista S, Monteiro SR, Gil V, Sanfins V, Martins V, Anghel M, Georgescu CA, Babes K, Banu M, Beyer R, Bratu I, Bumbu A, Capalneanu R, Chioncel OD, Chiscaneanu T, Christodorescu R, Nica NC, Cinteza M, Coman S, Constantinescu M, Craiu E, Dan GA, Dan DC, Dan A, David CM, Dorobantu M, Farcas D, Firastrau V, Florescu C, Ghicu A, Giuca A, Grigoriu R, Ionescu DD, Iosipescu LC, Ivan MV, Lighezan D, Magheru S, Magherusan M, Marinescu SM, Motoc AC, Musetescu R, Rau M, Rus LRH, Sirbu O, Sorodoc L, Spinu CM, Stanciulescu G, Statescu C, Toringhibel M, Trambitas R, Trocan N, Tudose A, Vinereanu D, Zagreanu M, Motomancea R, Militaru C, Dymova D, Semenova N, Zherebtsova A, Fedoskin V, Gurianova N, Bolotova N, Knyazeva V, Spitsina T, Sytilina N, Atamanchuk N, Giorgadze M, Zarechnova S, Kutuzova S, Sharapova Y, Stelmakh I, Sinyukova O, Rostik S, Evtukhova L, Sukhanova L, Makhieva T, Tereshko S, Kolesnikov V, Kochurov E, Marchenko B, Nurgalieva S, Galeeva Z, Andreicheva E, Zakirova V, Baleeva L, Minsafina A, Borodina N, Arkhipova Y, Krechunova T, Scherbak M, Merkhi A, Aksyutina N, Ratovskaya O, Suglobova E, Kozhelenko Y, Potapova E, Poluyanova G, Naberezhnova N, Daniels E, Atueva K, Tsaryabina L, Kurekhyan A, Khishova N, Dubinina E, Demina O, Mochkina P, Bukanina E, Tolpygina S, Polyanskaya Y, Malysheva A, Kheliya T, Serazhim A, Voronina V, Lukina Y, Dubinskaya R, Dmitrieva N, Kuzyakina M, Khartova N, Bokuchava N, Smirnova E, Esenokova A, Pavlova Y, Smirnova O, Astrakhantseva P, Bykovskaya S, Charikova O, Berdnik K, Karaseva T, Zhabina L, Oleinikova N, Dzhkha O, Grigoryan S, Yakovenko E, Ivaschenko T, Kiseleva I, Shokina T, Novikova M, Khodanov A, Popova L, Latyntseva L, Kilaberiya O, Makarenkova K, Nosova N, Gerasimova T, Boikova L, Sharapova N, Kulikova Y, Pasechnaya N, Bulakhova E, Kurochkina S, Bratishko I, Likhobabina O, Panova E, Voronina N, Bizyaeva N, Gusev O, Nevolina N, Arsentieva T, Budanova I, Melnikova EL, Khripun A, Polyaeva L, Osadchuk E, Krasnoslobodskaya O, Yakimova N, Lugin A, Sosnova Y, Il’ina E, Kositsina G, Shanina I, Kostomarova S, Malgina M, Omelchenko M, Gorlova I, Eidelman S, Salakhova A, Bondarenko B, Sopia R, Baboshina N, Eliseeva N, Tumarov F, Petrochenko N, Khudina I, Arabadzhi N, Samakhovets V, Tkhorzhevskaya L, Sinotova T, Zherlitsyna E, Minkin S, Petrova N, Tikhonov Y, Shmakova N, Abduvalieva V, Kuzmicheva M, Nikolaeva L, Varezhnikova O, Dmitrieva T, Mikhailova E, Yanina Y, Kapustina L, Vazhdaeva Z, Golovina G, Fedorova N, Nikolaeva I, Fillipova O, Gareeva L, Tuktarova F, Khmelevskikh N, Karnot V, Golub M, Surovtseva I, Kulygina V, Shelomova N, Kruglova I, Pokrovskaya I, Rodina O, Polkina L, Biryukova N, Filippova E, Kotova E, Ignatieva T, Alekseeva T, Gruznykh L, Mozerova E, Moksyuta E, Kosachek E, Srtumilenko N, Baranova O, Voronova T, Bayakhchan L, Grudtsina I, Gorshkova L, Shamsutdinova O, Getman M, Gorodilova I, Karnaukhova N, Rotenberger V, Isaeva L, Lebischak G, Ryzhkova V, Usoltseva E, Mescharekova D, Tavlueva E, Mineeva E, Stikhurova M, Kosareva L, Grechishkina O, Nikishina S, Ilyukhina A, Gureeva O, Soin I, Erofeev S, Lebedev S, Kudryavtsev L, Gamzatov E, Maximchuk N, Grekhova L, Kolevatova L, Kazakovtseva M, Kolesova O, Zharikova L, Kukaleva V, Starostina N, Grushetskaya I, Kazachkova V, Pashentseva I, Shimonenko S, Sirazov I, Chernozemova A, Golubeva O, Mingalaeva S, Zatsarina E, Kozlov D, Davydova N, Larina O, Alhabib KF, Hersi A, Al-Backer H, AlFaleh H, Mobeirek A, Arafah M, Al-Shamiri M, El-Shaer F, Zaibag MA, Bdeir M, Suliman I, Mukhtar A, Omar H, Jamiel A, Elkrail A, Alanazy M, Habab M, Ashmak K, Nourallah R, Mak KH, Singh B, Chee TS, Koo CC, Low LP, Nair VP, Ng KS, Quek SSS, Tan EHM, Ng ALR, Chuang HH, Kamensky G, Kaliska G, Murin J, Hatalova K, Gaspar L, Simkova I, Dubrava J, Pjontek J, Pella D, Banikova A, Szentivanyi M, Kovar F, Benacka J, Gonos I, Fazekas F, Kycina P, Poles J, Fras Z, Pernat A, Veternik A, Černič-Šuligoj N, Kerbev M, Krajnc I, Zagožen P, Alam A, Brown B, Luke B, Variava E, Nethononda R, Joubert S, Matthews P, Nkombua L, Antia V, Naidoo DP, Bhayat J, George SK, Ranjith N, Vawda GHM, Govender S, Soosiwala I, Shein K, Panajatovic M, Flores J, Khan MSH, Blignaut S, Coetzee K, Burgess L, Freeman V, Theron HD, Vives MAA, Oliva FJA, Carrascosa PA, Martínez VA, Colomer JMA, Ezquerra EA, Fernández CAA, Recalde NA, Auñon AA, García PA, Fernández CA, Galito CA, Viguiristi RA, Feal MA, Capell AA, Pardo JA, García GA, Esteban VA, Alonso MB, Pérez PB, Mayor JLB, Alvarez VB, Celorio AB, Martín BB, Valero DB, Castiñeiras JB, Ojeda FB, Penas CB, Redondo HB, Cortada JB, Solé RC, Iglesias FC, Miguel SC, Cardoso RC, Pié MC, Giménez PC, Lueña EC, Moreno JAC, Orive MC, González AC, Alcubilla JMC, Payá VC, Gil MAC, Martín JLC, Clemente AC, Sánchez RC, Luengo DC, Soler SD, Novales JDA, Aritmendiz RDC, Baguda JDJ, López MDLR, Prieto JLD, Díaz JLD, Cervantes CE, Sasieta JE, Rubio LF, Salvador CF, Zaragoza PF, Alvarez RF, De La Cigoña FF, Lázaro LAF, Léoz LCF, Mouzo RF, Gómez MF-V, Rodríguez BF, Aranda CF, Corzo JF, Alonso JF, Beneitez JF, Basilio EG, García CG, Martínez MJG, González MJG, Ortego SG, Pindado CG, Saavedra VG, Marimón JG-M, Rubia RG, Lorente DG, Pavón HG, Gómez RG, Barrado JJG, Doblas JJG, Martinez MJG, Juanatey CG, Toda VG, Ortega MG, Higuero EG, Afonso JH, Fernández DH, Espinach EH, Gastearena AI, Latasa MI, González RI, Herter MJ, Carballo ML, Galán JAL, González BL, Aranda MAL, Barreiro LL, Gómez DL, Granados AL, Mouriño VL, López-Sendón JL, Méndez ML, Latorre LM, Araez EM, Ortuño FM, Santana AM, Florez JM, González JM, Rivero JFM, Martín DM, Mignaqui GFM, Pita AM, Laborda EM, Escrivá GM, Saavedra VM, Gaspar MAM, Robles JM, González JM, Arribas JM, Casquete MTM, López CM, Eizagaechevarría NM, García FN, Manchón JN, Navas CN, García EN, Gamero JAN, España AO, López JAODM, Soler EO, Chulian EO, Torres LP, Sánchez AJP, Bermejo MAP, Del Moral VP, Pérez GP, Egido JÁP, De Isla LP, Ibiricu SP, Martínez MAP, Paredes MP, Domingo EP, Cubero AMP, Sopena JP, Rodríguez CP, Lozano MJP, Ramírez CP, Ramos YP, Moriche EP, Ariznabarreta FR, Gutiérrez MR, Catalán JMR, Almodóvar AR, Collado JR, Fernández AR, Fernández JAR, Hernández JAR, Tejero IR, Castillejo IR, Alvira DR, Hinojosa JAR, Menor CR, Sevillano PR, Calle ECR, Soriano JR, Pérez PR, Gorostiza TS, Hidalgo IS, Rollán MS, Rodríguez SS, Olmeda ES, Iglesias JLS, Rodríguez MLS, Laborda IS, García SS, Toral BS, Melchor LS, Martín-Ambrioso ES, Casado RS, Navarro CS, Ruiz MIS, Calle PT, Fernández ET, Díaz PLT, Gil AT, Berraquero FT, Martínez MAU, Sánchez JU, Herreros CV, García AV, Barbado JLV, Espejo-Saavedra EV, Vera TV, Gutiérrez MV, Mariscal CV, Boniato GV, Amen LW, Bowden GY, Wonenburger JCY, Gómez JLZ, Navarro JZ, Monnier P, Jaussi A, Forclaz A, Grobéty M, Schlueter L, Vuille C, Nacht CA, Evéquoz D, Ciaroni S, Dominé F, Bérubé J, Rickli H, Hellermann J, Koller R, Bourgeois G, Engel R, Niederberger C, Stadler P, Gnädinger M, Schmied C, Wettstein T, Hilti P, Chételat CA, Sepulcri F, Brunner H, Schindler J, Kraus M, Vivekaphirat V, Panpunnung S, Kuanprasert S, Wongcharoen W, Phrommintikul A, Harinasuta J, Si O, Chaithiraphan V, Boonyasirinant T, Boonyapisit W, Kittipovanonth M, Buakhamsri A, Piyayotai D, Hutayanon P, Junejo S, Aiyegbayo O, Ancliff H, Bradshaw C, Cervenak R, Choi H, George E, Gilmour I, Gough D, Idrissi-Sbai A, Ingham J, Al-Khalidi B, Liston A, Mackrell J, Pattison I, Ramachandran R, Ray N, Reddy G, Sen I, Shetty K, Singh L, Stanley M, Wallace A, Weatherhead M, Gilbert T, McCansh G, Higgins S, Killeen C, Cromarty I, Franklin P, Pinch E, Dhesi A, Dernedde C, Lawrence M, Simper H, Noble M, Dalton G, Stevens L, Berry P, Hand C, Oliver R, Jones H, Sampson P, Taylor N, Grogono R, Dalrymple J, Martin A, Thurston S, Elsby K, Vallis M, Morrison G, Lang C, Watson A, Thomson A, Dougall H, Hay BL, Compson L, McCracken A, Calder J, Weber F, Richmond D, Brownlie R, Brown G, MacCowan H, Heap A, Perry M, Holden LA, Scott G, Haldane N, Hood S, Cullen I, Bell J, McNaught P, Sharif M, Dunn J, Hay D, Ross S, Shaw R, Hay L, Langridge S, Burns R, Crawford L, Kennedy A, Logan D, McAlavey P, Brown M, Costello P, McLaren G, Potter A, McPherson J, Drijfhout M, Finlayson J, Troup D, Woodall A, Pearce J, Williams S, Parkar W, Yusuf A, Benett I, Bishop P, Thomas H, Caldwell I, Ormiston P, Kwok S, Wright S, Kanumilli N, Saul P, Milligan H, Wilkinson I, Vance A, Paul N, Paul C, Shaikh I, Ellis R, Vites N, Steeds R, Goodwin D, Aftab A, Banham S, Chauhan N, Grocutt MS, Gupte A, Jordan R, Jheeta BS, Ladha K, Nazir M, Pal R, Patel RP, McManus R, Singal A, Saunders P, Syed AB, Bahal A, Dau H, Walker DM, McNeilly R, Bolidai A, MacCarthy N, Lawton D, Vardhani M, Sengupta G, Kinloch D, Howie F, Serrano-Garcia A, Paget SE, Till R, Seal P, Morrell J, Maxwell T, Singh G, Warden D, Elias R, Dixon C, Pandey RK, Challenor V, Davies S, Gibbs M, Gillet A, Goldie C, Jarvis I, Johnson P, Malden M, Moore J, Morton C, Nehrig K, Sheringham P, Wilson G, Halcox J, O’Connor I, Ling K, Edwards D, Charles H, Weatherup A, Davies E, Watkins N, Morgan D, Davies R, Lindsay A, Beacock D, Balai R, Kirmond P, Brindle P, Bundy C, Cahill T, Dayani A, Eavis P, Mohr S, Hayne S, Krasucki C, Micheals M, Orpen I, Parker I, Sewell R, Sharp D, Smith A, Stevens A, Upton J, Victory J, Wernham C, Davis R, Mays C, Andrews M, Takhar J, Travill C, Choudhury P, Matta W, Ihonor A, O’Dong C, Rahman S, Singer P, Gillam S, Bath PS, Razzaq N, O’Toole O, Rowe P, Williams H, Kalra P, Allcock A, Tucker A, Sprott V, Kyd K, Cunliffe G, Arden C, Bateman A, Kassianos G, Sinclair D, Turner C, Jagathesan R, Sattar F, Ashford A, Chukwu A, Taylor H, Pradhan R, Rundell T, Howlett R, Bietzk R, Patel R, Myint M, Partington M, O’Reilly F, Baverstock M, Dixon S, Tennekoon M, Brand N, Haimes P, Keller P, Whetstone S, Davis R, Mays C, Andrews M, Takhar J, Parker L, Anscombe M, Beale G, Murphy L, Smith A, Brown S, Lindford J, Serrano A, Preston S, Sethi R, Hutchinson S, Kovyrshyna O, Rogozhyna V, Kiver T, Vasylenko V, Kucheryava L, Salimova S, Alekseenko V, Gukov O, Myhailiv I, Kardashevskaya L, Prikolota O, Bashkirtcev O, Andreev E, Tkachenko L, Mospan M, Batushkin V, Reshotko D, Safonova L, Ogorodnichuk A, Pustovit S, Romanov S, Burlakova L, Voloshko Y, Lafarenko V, Vlasuk Z, Leshchuk O, Chushak S, Koval V, Stasuk O, Pogrebna O, Kornienko S, Tikhonova S, Fesenko T, Kuzmina T, Ushakov O, Vechtomova N, Potapska L, Illushechkin I, Kryvenkova E, Lysunets O, Tsygankov O, Bardachenko L, Voloshyna L, Ginzburg V, Franskyavichene L, Korotich T, Vyshnevaya N, Bilous N, Kulinich S, Kulik V, Sadykova I, Zalyzniak O, Berezhna T, Molotyagina S, Nguyen LV, Pham MH, Pham HT, Khong NH, Do KB, Le TB, Do PA, Do TC, Nguyen NQ, Do QH, Vu KC, Pham NH, Pham THT, Ta MC, Phan DP, Nguyen TTH, Pham TTN, To TL, Le VT, Dang L, Bui L, Pham TTH, Phan HH, Bui TTH, Tuong TVA, Nguyen TP, Nguyen TH, Nguyen BK, Vu DB, Pham NS, Do TQ, Pham TS, Dang VD, Le DT, Do VC, Nguyen TKL, Luong HD, Luu TQ, Pham NV, Huynh TK, Tu NTH, Ngo KA, Nguyen TTC, Ong TTL, Doan VB, Kim TB, Vo TN, Tran TTT, Nguyen TA, Tran VD, Nguyen AK, Tran AC, Ngo MH, Vu NH, Ly IT, Tran NPH, Tran LUP, Nguyen TN, Tran TH, Truong PH, Mai TL, Hoang VS, Bui CMA, Dang VP, Truong QB, Vo MP, Nguyen VT, Chau NH, Ta TTH, Dinh HN, Tran H, Nguyen HKN, Chung A, Chung E, Martina-Hooi B, Angela R, Ramoutar P, Fillet R, Tilluckdharry R, Dookie T, Foster E, Hart C, Omardeen F, Ramphall S, Lalla C, Henry R, Cheng J, Elliott V, Falconer H, Hurlock-Clarke L, Ishmael R, Lalljie G, Lee K, Liqui-Lung A, Massay R, Mohammed H, Brown C, Daniel R, Didier M. 2024. New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry. European Heart Journal 45:366–375.1.Sherratt SCR, Mason RP, Libby P, Steg PG, Bhatt DL. 2024. Do patients benefit from omega-3 fatty acids? Cardiovascular Research cvad188.2460799 5BTMJQCK 2023 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-afdaf148b790aee8e9e7514d5e787a09%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22GB2VW4EK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Clapp%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-26%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EClapp%20L%2C%20Giembycz%20M%2C%20Heinemann%20A%2C%20Jones%20RL%2C%20Narumiya%20S%2C%20Norel%20X%2C%20Sugimoto%20Y%2C%20Woodward%20DF%2C%20Yao%20C.%202023.%20Prostanoid%20receptors%20in%20GtoPdb%20v.2023.1.%20GtoPdb%20CITE%202023.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prostanoid%20receptors%20in%20GtoPdb%20v.2023.1%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Clapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Giembycz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akos%22%2C%22lastName%22%3A%22Heinemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuh%22%2C%22lastName%22%3A%22Narumiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukihiko%22%2C%22lastName%22%3A%22Sugimoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20F.%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcan%22%2C%22lastName%22%3A%22Yao%22%7D%5D%2C%22abstractNote%22%3A%22Prostanoid%20receptors%20%28nomenclature%20as%20agreed%20by%20the%20NC-IUPHAR%20Subcommittee%20on%20Prostanoid%20Receptors%20%5B701%5D%29%20are%20activated%20by%20the%20endogenous%20ligands%20prostaglandins%20PGD2%2C%20PGE1%2C%20PGE2%20%2C%20PGF2%5Cu03b1%2C%20PGH2%2C%20prostacyclin%20%5BPGI2%5D%20and%20thromboxane%20A2.%20Differences%20and%20similarities%20between%20human%20and%20rodent%20prostanoid%20receptor%20orthologues%2C%20and%20their%20specific%20roles%20in%20pathophysiologic%20conditions%20are%20reviewed%20in%20%5B452%5D.%20%20%20%20Measurement%20of%20the%20potency%20of%20PGI2%20and%20thromboxane%20A2%20is%20hampered%20by%20their%20instability%20in%20physiological%20salt%20solution%3B%20they%20are%20often%20replaced%20by%20cicaprost%20and%20U46619%2C%20respectively%2C%20in%20receptor%20characterization%20studies.%22%2C%22date%22%3A%222023-04-26%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2218%5C%2Fgtopdb%5C%2FF58%5C%2F2023.1%22%2C%22ISSN%22%3A%222633-1020%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.ed.ac.uk%5C%2Fgtopdb-cite%5C%2Farticle%5C%2Fview%5C%2F8705%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A30Z%22%7D%7D%2C%7B%22key%22%3A%2269D2YQYY%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mimouni%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMimouni%20M%2C%20Bulsei%20J%2C%20Darlington%20M%2C%20Estellat%20C%2C%20Rouzet%20F%2C%20Hyafil%20F%2C%20Durand-Zaleski%20I%2C%20the%20RUBIS%20Trial%20Group%2C%20Chequer%20R%2C%20Ducrocq%20G%2C%20Alfaiate%20T%2C%20Regaieg%20H%2C%20Abtan%20J%2C%20Leygnac%20S%2C%20Milliner%20M%2C%20Burg%20S%2C%20Azzouna%20RB%2C%20Potier%20L%2C%20Laou%26%23xE9%3Bnan%20C%2C%20Quintin%20C%2C%20Roussel%20R%2C%20Steg%20G%2C%20Le%20Guludec%20D%2C%20Sorbets%20E%2C%20Imbert%20L%2C%20Marie%20P-Y%2C%20Hartemann%20A%2C%20Montalescot%20G.%202023.%20Cost-effectiveness%20of%2082-Rubidium%20PET%20myocardial%20perfusion%20imaging%20for%20the%20diagnosis%20of%20myocardial%20ischemia%20depending%20on%20the%20prevalence%20of%20coronary%20artery%20disease.%20EJNMMI%20Res%2013%3A9.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cost-effectiveness%20of%2082-Rubidium%20PET%20myocardial%20perfusion%20imaging%20for%20the%20diagnosis%20of%20myocardial%20ischemia%20depending%20on%20the%20prevalence%20of%20coronary%20artery%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maroua%22%2C%22lastName%22%3A%22Mimouni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Bulsei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meryl%22%2C%22lastName%22%3A%22Darlington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Estellat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Rouzet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Hyafil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Durand-Zaleski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20RUBIS%20Trial%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Chequer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toni%22%2C%22lastName%22%3A%22Alfaiate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hamza%22%2C%22lastName%22%3A%22Regaieg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9mie%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Leygnac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milan%22%2C%22lastName%22%3A%22Milliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Burg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rana%20Ben%22%2C%22lastName%22%3A%22Azzouna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Potier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Laou%5Cu00e9nan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Quintin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronan%22%2C%22lastName%22%3A%22Roussel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Le%20Guludec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sorbets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Marie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Hartemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%2082-Rubidium-Positron%20emission%20tomography%20myocardial%20perfusion%20imaging%20%28Rb-PET-MPI%29%20offers%20higher%20diagnostic%20performance%20for%20the%20detection%20of%20myocardial%20ischemia%20compared%20to%20Tc-SPECT-MPI.%20The%20aim%20of%20this%20economic%20evaluation%20was%20to%20perform%20a%20cost-effectiveness%20analysis%20of%20Rb-PET-MPI%20versus%20Tc-SPECT-MPI%20in%20patients%20with%20suspected%20myocardial%20ischemia%20according%20to%20pretest%20probabilities%20%28PTP%29%20of%20obstructive%20coronary%20artery%20disease%20based%20on%20the%20results%20of%20the%20RUBIS%20Trial.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Costs%20and%20effectiveness%20were%20calculated%20for%20all%20patients%20over%201%20year%20and%20an%20incremental%20analysis%20of%20differences%20in%20costs%20and%20effectiveness%20in%20terms%20of%20diagnostic%20accuracy%20was%20performed.%20The%20uncertainty%20of%20the%20results%20was%20estimated%20using%20bootstrap.%20The%20analysis%20was%20conducted%20from%20the%20perspective%20of%20the%20French%20health%20care%20system%20with%20a%20time%20horizon%20of%2012%5Cu00a0months.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20average%20cost%20of%20a%20Rb-PET-MPI-based%20strategy%20for%20the%20detection%20of%20myocardial%20ischemia%20was%20%5Cu20ac219%20lower%20than%20a%20SPECT-MPI-based%20strategy%20%28%5Cu20ac1192%20%28%5Cu00b1%5Cu20091834%29%20vs%20%5Cu20ac973%20%28%5Cu00b1%5Cu20091939%29%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3C%5Cu20090.01%29.%20The%20one-year%20incremental%20cost-effectiveness%20ratio%20was%20negative%3A%20%5Cu2212%5Cu00a0%5Cu20ac2730%20%28money%20saved%20per%20additional%20accurate%20diagnosis%29%20in%20patients%20presenting%20PTP%5Cu2009%3E%5Cu200915%25%20for%20the%20Rb-PET-MPI%20vs.%20Tc-SPECT-MPI%20strategy.%20Analysis%20of%20the%20joint%20distribution%20of%20costs%20and%20outcomes%20found%20that%20the%20Rb-PET-MPI%20strategy%20had%20a%2092%25%20probability%20to%20be%20dominant%20%28cost-saving%20and%20outcome-improving%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Rb-PET-MPI%20is%20cost-effective%20compared%20to%20Tc-SPECT-MPI%20for%20the%20detection%20of%20myocardial%20ischemia%20in%20patients%20with%20PTP%5Cu2009%3E%5Cu200915%25%20of%20obstructive%20coronary%20artery%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20RUBIS%20Trial%20registration%3A%20NCT01679886%2C%20Registered%2003%20September%202012%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fclinicaltrials.gov%5C%2Fct2%5C%2Fshow%5C%2FNCT01679886%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%22%2C%22date%22%3A%222023-02-08%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13550-023-00954-x%22%2C%22ISSN%22%3A%222191-219X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fejnmmires.springeropen.com%5C%2Farticles%5C%2F10.1186%5C%2Fs13550-023-00954-x%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22L5BD9Q2H%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Goodman%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGoodman%20SG%2C%20Steg%20PG%2C%20Poulouin%20Y%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Diaz%20R%2C%20Garon%20G%2C%20Harrington%20RA%2C%20Jukema%20JW%2C%20Manvelian%20G%2C%20Stipek%20W%2C%20Szarek%20M%2C%20White%20HD%2C%20Schwartz%20GG%2C%20for%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202023.%20Long%26%23x2010%3BTerm%20Efficacy%2C%20Safety%2C%20and%20Tolerability%20of%20Alirocumab%20in%208242%20Patients%20Eligible%20for%203%20to%205%20Years%20of%20Placebo%26%23x2010%3BControlled%20Observation%20in%20the%20ODYSSEY%20OUTCOMES%20Trial.%20JAHA%2012%3Ae029216.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long%5Cu2010Term%20Efficacy%2C%20Safety%2C%20and%20Tolerability%20of%20Alirocumab%20in%208242%20Patients%20Eligible%20for%203%20to%205%20Years%20of%20Placebo%5Cu2010Controlled%20Observation%20in%20the%20ODYSSEY%20OUTCOMES%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Poulouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevieve%22%2C%22lastName%22%3A%22Garon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garen%22%2C%22lastName%22%3A%22Manvelian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wanda%22%2C%22lastName%22%3A%22Stipek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-09-19%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.029216%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.122.029216%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22BU3NGMCK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marquis%5Cu2010Gravel%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMarquis%26%23x2010%3BGravel%20G%2C%20Boivin%26%23x2010%3BProulx%20L%2C%20Huang%20Z%2C%20Zelenkofske%20SL%2C%20Lincoff%20AM%2C%20Mehran%20R%2C%20Steg%20PG%2C%20Bode%20C%2C%20Alexander%20JH%2C%20Povsic%20TJ.%202023.%20Femoral%20Vascular%20Closure%20Devices%20and%20Bleeding%2C%20Hemostasis%2C%20and%20Ambulation%20Following%20Percutaneous%20Coronary%20Intervention.%20JAHA%2012%3Ae025666.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Femoral%20Vascular%20Closure%20Devices%20and%20Bleeding%2C%20Hemostasis%2C%20and%20Ambulation%20Following%20Percutaneous%20Coronary%20Intervention%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Marquis%5Cu2010Gravel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurie%5Cu2010Anne%22%2C%22lastName%22%3A%22Boivin%5Cu2010Proulx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhen%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20L.%22%2C%22lastName%22%3A%22Zelenkofske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20Michael%22%2C%22lastName%22%3A%22Lincoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Bode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20H.%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20J.%22%2C%22lastName%22%3A%22Povsic%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20effectiveness%20of%20vascular%20closure%20devices%20%28VCDs%29%20to%20reduce%20bleeding%20after%20transfemoral%20percutaneous%20coronary%20intervention%20remains%20unsettled.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Participants%20in%20the%20REGULATE%5Cu2010PCI%20%28Effect%20of%20the%20REG1%20anticoagulation%20system%20versus%20bivalirudin%20on%20outcomes%20after%20percutaneous%20coronary%20intervention%29%20trial%20who%20underwent%20transfemoral%20percutaneous%20coronary%20intervention%20with%20VCD%20implantation%20were%20compared%20with%20those%20who%20underwent%20manual%20compression.%20The%20primary%20effectiveness%20end%20point%20was%20type%202%2C%203%2C%20or%205%20Bleeding%20Academic%20Research%20Consortium%20access%20site%20bleeding%20at%20day%203.%20Univariate%20and%20multivariate%20analyses%20were%20adjusted%20by%20the%20inverse%20probability%20weighting%20method%20using%20propensity%20score.%20Time%20to%20hemostasis%20and%20time%20to%20ambulation%20were%20compared%20between%20groups.%20Of%20the%201580%20patients%20who%20underwent%20transfemoral%20percutaneous%20coronary%20intervention%2C%201004%20%2863.5%25%29%20underwent%20VCD%20implantation%20and%20576%20%2836.5%25%29%20had%20manual%20compression.%20The%20primary%20effectiveness%20end%20point%20occurred%20in%2064%20%286.4%25%29%20participants%20in%20the%20VCD%20group%20and%20in%2038%20%286.6%25%29%20participants%20in%20the%20manual%20compression%20group%20%28inverse%20probability%20weighting%5Cu2013adjusted%20odds%20ratio%2C%201.02%20%5B95%25%20CI%2C%200.77%5Cu20131.36%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.89%29.%20There%20were%20statistically%20significant%202%5Cu2010way%20interactions%20between%20VCD%20use%20and%20female%20sex%2C%20chronic%20kidney%20disease%2C%20and%20use%20of%20high%5Cu2010potency%20P2Y12%20inhibition%20%28ticagrelor%20or%20prasugrel%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.05%20for%20all%29%20with%20less%20bleeding%20with%20VCD%20use%20in%20these%20high%5Cu2010risk%20subgroups.%20Median%20time%20to%20hemostasis%20and%20time%20to%20ambulation%20were%20shorter%20in%20the%20VCD%20versus%20the%20manual%20compression%20group%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.01%20for%20both%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Following%20transfemoral%20percutaneous%20coronary%20intervention%2C%20VCD%20use%20is%20associated%20with%20a%20shorter%20time%20to%20hemostasis%20and%20time%20to%20ambulation%20but%20not%20less%20bleeding.%20Further%20study%20of%20patients%20with%20high%5Cu2010bleeding%20risk%20is%20required%2C%20including%20women%2C%20patients%20with%20chronic%20kidney%20disease%2C%20and%20those%20using%20high%5Cu2010potency%20P2Y12%20inhibitors.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fclinicaltrials.gov%5C%2Fct2%5C%2Fshow%5C%2FNCT01848106%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01848106.%22%2C%22date%22%3A%222023-01-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.025666%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.122.025666%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A29Z%22%7D%7D%2C%7B%22key%22%3A%222PVUTKGN%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Olshansky%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EOlshansky%20B%2C%20Bhatt%20DL%2C%20Miller%20M%2C%20Steg%20PhG%2C%20Brinton%20EA%2C%20Jacobson%20TA%2C%20Ketchum%20SB%2C%20Doyle%20RT%2C%20Juliano%20RA%2C%20Jiao%20L%2C%20Kowey%20PR%2C%20Reiffel%20JA%2C%20Tardif%20J%2C%20Ballantyne%20CM%2C%20Chung%20MK%2C%20the%20REDUCE%26%23x2010%3BIT%20Investigators.%202023.%20Cardiovascular%20Benefits%20of%20Icosapent%20Ethyl%20in%20Patients%20With%20and%20Without%20Atrial%20Fibrillation%20in%20REDUCE%26%23x2010%3BIT.%20JAHA%2012%3Ae026756.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiovascular%20Benefits%20of%20Icosapent%20Ethyl%20in%20Patients%20With%20and%20Without%20Atrial%20Fibrillation%20in%20REDUCE%5Cu2010IT%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Olshansky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliot%20A.%22%2C%22lastName%22%3A%22Brinton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%20A.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20B.%22%2C%22lastName%22%3A%22Ketchum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20T.%22%2C%22lastName%22%3A%22Doyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%20A.%22%2C%22lastName%22%3A%22Juliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lixia%22%2C%22lastName%22%3A%22Jiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20R.%22%2C%22lastName%22%3A%22Kowey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20A.%22%2C%22lastName%22%3A%22Reiffel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mina%20K.%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20REDUCE%5Cu2010IT%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20REDUCE%5Cu2010IT%20%28Reduction%20of%20Cardiovascular%20Events%20With%20Icosapent%20Ethyl%5Cu2013Intervention%20Trial%29%2C%20icosapent%20ethyl%20%28IPE%29%20versus%20placebo%29%20reduced%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20stroke%2C%20coronary%20revascularization%2C%20or%20unstable%20angina%20requiring%20hospitalization%2C%20but%20was%20associated%20with%20increased%20atrial%20fibrillation%5C%2Fatrial%20flutter%20%28AF%29%20hospitalization%20%283.1%25%20IPE%20versus%202.1%25%20placebo%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.004%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20performed%20post%20hoc%20efficacy%20and%20safety%20analyses%20of%20patients%20with%20or%5Cu00a0without%5Cu00a0prior%20AF%20%28before%20randomization%29%20and%5Cu00a0with%5Cu00a0or%20without%5Cu00a0in%5Cu2010study%20time%5Cu2010varying%20AF%20hospitalization%20to%20assess%20relationships%20of%20IPE%20%28versus%20placebo%29%20and%20outcomes.%20In%5Cu2010study%20AF%20hospitalization%20event%20rates%20were%20higher%20in%20patients%20with%20prior%20AF%20%2812.5%25%20versus%206.3%25%2C%20IPE%20versus%20placebo%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.007%29%20versus%20without%20prior%20AF%20%282.2%25%20versus%201.6%25%2C%20IPE%20versus%20placebo%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.09%29.%20Serious%20bleeding%20rates%20trended%20higher%20in%20patients%20with%20%287.3%25%20versus%206.0%25%2C%20IPE%20versus%20placebo%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.59%29%20versus%20without%20prior%20AF%20%282.3%25%20versus%201.7%25%2C%20IPE%20versus%20placebo%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.08%29.%20With%20IPE%2C%20serious%20bleeding%20trended%20higher%20regardless%20of%20prior%20AF%20%28interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20value%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20int%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5D%3D0.61%29%20or%20postrandomization%20AF%20hospitalization%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20int%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.66%29.%20Patients%20with%20prior%20AF%20%28n%3D751%2C%209.2%25%29%20versus%20without%20prior%20AF%20%28n%3D7428%2C%2090.8%25%29%20had%20similar%20relative%20risk%20reductions%20of%20the%20primary%20composite%20and%20key%20secondary%20composite%20end%20points%20with%20IPE%20versus%20placebo%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20int%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.37%20and%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20int%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.55%2C%20respectively%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20REDUCE%5Cu2010IT%2C%20in%5Cu2010study%20AF%20hospitalization%20rates%20were%20higher%20in%20patients%20with%20prior%20AF%20especially%20in%20those%20randomized%20to%20IPE.%20Although%20serious%20bleeding%20trended%20higher%20in%20those%20randomized%20to%20IPE%20versus%20placebo%20over%20the%20course%20of%20the%20study%2C%20serious%20bleeding%20was%20not%20different%20regardless%20of%20prior%20AF%20or%20in%5Cu2010study%20AF%20hospitalization.%20Patients%20with%20prior%20AF%20or%20in%5Cu2010study%20AF%20hospitalization%20had%20consistent%20relative%20risk%20reductions%20across%20primary%2C%20key%20secondary%2C%20and%20stroke%20end%20points%20with%20IPE.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fclinicaltrials.gov%5C%2Fct2%5C%2Fshow%5C%2FNCT01492361%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20Identifier%3A%20NCT01492361%22%2C%22date%22%3A%222023-03-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.121.026756%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.121.026756%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22JZYI85U5%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bikdeli%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBikdeli%20B%2C%20Erlinge%20D%2C%20Valgimigli%20M%2C%20Kastrati%20A%2C%20Han%20Y%2C%20Steg%20PG%2C%20Stables%20RH%2C%20Mehran%20R%2C%20James%20SK%2C%20Frigoli%20E%2C%20Goldstein%20P%2C%20Li%20Y%2C%20Shahzad%20A%2C%20Sch%26%23xFC%3Bpke%20S%2C%20Mehdipoor%20G%2C%20Chen%20S%2C%20Redfors%20B%2C%20Crowley%20A%2C%20Zhou%20Z%2C%20Stone%20GW.%202023.%20Bivalirudin%20Versus%20Heparin%20During%20PCI%20in%20NSTEMI%3A%20Individual%20Patient%20Data%20Meta-Analysis%20of%20Large%20Randomized%20Trials.%20Circulation%20148%3A1207%26%23x2013%3B1219.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bivalirudin%20Versus%20Heparin%20During%20PCI%20in%20NSTEMI%3A%20Individual%20Patient%20Data%20Meta-Analysis%20of%20Large%20Randomized%20Trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Behnood%22%2C%22lastName%22%3A%22Bikdeli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Erlinge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaling%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rod%20H.%22%2C%22lastName%22%3A%22Stables%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20K.%22%2C%22lastName%22%3A%22James%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Frigoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Goldstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeel%22%2C%22lastName%22%3A%22Shahzad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Sch%5Cu00fcpke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghazaleh%22%2C%22lastName%22%3A%22Mehdipoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shmuel%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bj%5Cu00f6rn%22%2C%22lastName%22%3A%22Redfors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aaron%22%2C%22lastName%22%3A%22Crowley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhipeng%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20benefit%3Arisk%20profile%20of%20bivalirudin%20versus%20heparin%20anticoagulation%20in%20patients%20with%20non%5Cu2013ST-segment%5Cu2013elevation%20myocardial%20infarction%20undergoing%20percutaneous%20coronary%20intervention%20%28PCI%29%20is%20uncertain.%20Study-level%20meta-analyses%20lack%20granularity%20to%20provide%20conclusive%20answers.%20We%20sought%20to%20compare%20the%20outcomes%20of%20bivalirudin%20and%20heparin%20in%20patients%20with%20non%5Cu2013ST-segment%5Cu2013elevation%20myocardial%20infarction%20undergoing%20PCI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20performed%20an%20individual%20patient%20data%20meta-analysis%20of%20patients%20with%20non%5Cu2013ST-segment%5Cu2013elevation%20myocardial%20infarction%20in%20all%205%20trials%20that%20randomized%20%5Cu22651000%20patients%20with%20any%20myocardial%20infarction%20undergoing%20PCI%20to%20bivalirudin%20versus%20heparin%20%28MATRIX%20%5BMinimizing%20Adverse%20Hemorrhagic%20Events%20by%20Transradial%20Access%20Site%20and%20Systemic%20Implementation%20of%20Angiox%5D%2C%20VALIDATE-SWEDEHEART%20%5BBivalirudin%20Versus%20Heparin%20in%20ST-Segment%20and%20Non%5Cu2013ST-Segment%20Elevation%20Myocardial%20Infarction%20in%20Patients%20on%20Modern%20Antiplatelet%20Therapy%20in%20the%20Swedish%20Web%20System%20for%20Enhancement%20and%20Development%20of%20Evidence-Based%20Care%20in%20Heart%20Disease%20Evaluated%20According%20to%20Recommended%20Therapies%20Registry%20Trial%5D%2C%20ISAR-REACT%204%20%5BIntracoronary%20Stenting%20and%20Antithrombotic%20Regimen%3A%20Rapid%20Early%20Action%20for%20Coronary%20Treatment%204%5D%2C%20ACUITY%20%5BAcute%20Catheterization%20and%20Urgent%20Intervention%20Triage%20Strategy%5D%2C%20and%20BRIGHT%20%5BBivalirudin%20in%20Acute%20Myocardial%20Infarction%20vs%20Heparin%20and%20GPI%20Plus%20Heparin%20Trial%5D%29.%20The%20primary%20effectiveness%20and%20safety%20end%20points%20were%2030-day%20all-cause%20mortality%20and%20serious%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20total%20of%2012%5Cu2009155%20patients%20were%20randomized%3A%206040%20to%20bivalirudin%20%2852.3%25%20with%20a%20post-PCI%20bivalirudin%20infusion%29%2C%20and%206115%20to%20heparin%20%2853.2%25%20with%20planned%20glycoprotein%20IIb%5C%2FIIIa%20inhibitor%20use%29.%20Thirty-day%20mortality%20was%20not%20significantly%20different%20between%20bivalirudin%20and%20heparin%20%281.2%25%20versus%201.1%25%3B%20adjusted%20odds%20ratio%2C%201.24%20%5B95%25%20CI%2C%200.86%5Cu20131.79%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.25%29.%20Cardiac%20mortality%2C%20reinfarction%2C%20and%20stent%20thrombosis%20rates%20were%20also%20not%20significantly%20different.%20Bivalirudin%20reduced%20serious%20bleeding%20%28both%20access%20site%5Cu2013related%20and%20non%5Cu2014access%20site%5Cu2013related%29%20compared%20with%20heparin%20%283.3%25%20versus%205.5%25%3B%20adjusted%20odds%20ratio%2C%200.59%3B%2095%25%20CI%2C%200.48%5Cu20130.72%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29.%20Outcomes%20were%20consistent%20regardless%20of%20use%20of%20a%20post-PCI%20bivalirudin%20infusion%20or%20routine%20lycoprotein%20IIb%5C%2FIIIa%20inhibitor%20use%20with%20heparin%20and%20during%201-year%20follow-up.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSIONS%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20non%5Cu2013ST-segment%5Cu2013elevation%20myocardial%20infarction%20undergoing%20PCI%2C%20procedural%20anticoagulation%20with%20bivalirudin%20and%20heparin%20did%20not%20result%20in%20significantly%20different%20rates%20of%20mortality%20or%20ischemic%20events%2C%20including%20stent%20thrombosis%20and%20reinfarction.%20Bivalirudin%20reduced%20serious%20bleeding%20compared%20with%20heparin%20arising%20both%20from%20the%20access%20site%20and%20nonaccess%20sites.%22%2C%22date%22%3A%222023-10-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.123.063946%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.123.063946%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A04Z%22%7D%7D%2C%7B%22key%22%3A%2232JEPBD2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hochman%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHochman%20JS%2C%20Anthopolos%20R%2C%20Reynolds%20HR%2C%20Bangalore%20S%2C%20Xu%20Y%2C%20O%26%23x2019%3BBrien%20SM%2C%20Mavromichalis%20S%2C%20Chang%20M%2C%20Contreras%20A%2C%20Rosenberg%20Y%2C%20Kirby%20R%2C%20Bhargava%20B%2C%20Senior%20R%2C%20Banfield%20A%2C%20Goodman%20SG%2C%20Lopes%20RD%2C%20Praco%26%23x144%3B%20R%2C%20L%26%23xF3%3Bpez-Send%26%23xF3%3Bn%20J%2C%20Maggioni%20AP%2C%20Newman%20JD%2C%20Berger%20JS%2C%20Sidhu%20MS%2C%20White%20HD%2C%20Troxel%20AB%2C%20Harrington%20RA%2C%20Boden%20WE%2C%20Stone%20GW%2C%20Mark%20DB%2C%20Spertus%20JA%2C%20Maron%20DJ%2C%20Hochman%20JS%2C%20Maron%20DJ%2C%20Reynolds%20HR%2C%20Bangalore%20S%2C%20Mavromichalis%20S%2C%20Chang%20M%2C%20Contreras%20A%2C%20Esquenazi-Karonika%20S%2C%20Gilsenan%20M%2C%20Gwiszcz%20E%2C%20Mathews%20P%2C%20Mohamed%20S%2C%20Naumova%20A%2C%20Roberts%20A%2C%20VanLoo%20K%2C%20Anthopolos%20R%2C%20Xu%20Y%2C%20Troxel%20AB%2C%20Lu%20Y%2C%20Huang%20Z%2C%20Broderick%20S%2C%20Guzm%26%23xE1%3Bn%20L%2C%20Selvanayagam%20J%2C%20Lopes%20RD%2C%20Goodman%20SG%2C%20Steg%20G%2C%20Juliard%20J-M%2C%20Doerr%20R%2C%20Keltai%20M%2C%20Bhargava%20B%2C%20Thomas%20B%2C%20Sharir%20T%2C%20Nikolsky%20E%2C%20Maggioni%20AP%2C%20Kohsaka%20S%2C%20Escobedo%20J%2C%20White%20HD%2C%20Praco%26%23x144%3B%20R%2C%20Bockeria%20O%2C%20L%26%23xF3%3Bpez-Send%26%23xF3%3Bn%20J%2C%20Held%20C%2C%20Senior%20R%2C%20Banfield%20A%2C%20Shaw%20LJ%2C%20Phillips%20L%2C%20Berman%20D%2C%20Kwong%20RY%2C%20Picard%20MH%2C%20Chaitman%20BR%2C%20Ali%20Z%2C%20Min%20J%2C%20Mancini%20GBJ%2C%20Leipsic%20J%2C%20Guzm%26%23xE1%3Bn%20L%2C%20Hillis%20G%2C%20Thambar%20S%2C%20Joseph%20M%2C%20Selvanayagam%20J%2C%20Beltrame%20J%2C%20Lang%20I%2C%20Schuchlenz%20H%2C%20Huber%20K%2C%20Goetschalckx%20K%2C%20Hueb%20W%2C%20Caramori%20PR%2C%20De%20Quadros%20A%2C%20Smanio%20P%2C%20Mesquita%20C%2C%20Lopes%20RD%2C%20Vitola%20J%2C%20Marin-Neto%20J%2C%20Da%20Silva%20ER%2C%20Tumelero%20R%2C%20Andrade%20M%2C%20Alves%20AR%2C%20Dall%26%23x2019%3BOrto%20F%2C%20Polanczyk%20C%2C%20Figueiredo%20E%2C%20Howarth%20A%2C%20Gosselin%20G%2C%20Cheema%20A%2C%20Bainey%20K%2C%20Phaneuf%20D%2C%20Diaz%20A%2C%20Garg%20P%2C%20Mehta%20S%2C%20Wong%20G%2C%20Lam%20A%2C%20Cha%20J%2C%20Galiwango%20P%2C%20Uxa%20A%2C%20Chow%20B%20%28Ben%29%2C%20Hameed%20A%2C%20Udell%20J%2C%20Cheema%20A%2C%20Hamid%20M%2C%20Hauguel-Moreau%20M%2C%20Furber%20A%2C%20Goube%20P%2C%20Steg%20P-G%2C%20Barone-Rochette%20G%2C%20Thuaire%20C%2C%20Slama%20M%2C%20Doerr%20R%2C%20Nickenig%20G%2C%20Bekeredjian%20R%2C%20Schulze%20PC%2C%20Merkely%20B%2C%20Fontos%20G%2C%20V%26%23xE9%3Brtes%20A%2C%20Varga%20A%2C%20Bhargava%20B%2C%20Kumar%20A%2C%20Nair%20RG%2C%20Grant%20P%2C%20Manjunath%20C%2C%20Moorthy%20N%2C%20Satheesh%20S%2C%20Nath%20RK%2C%20Wander%20G%2C%20Christopher%20J%2C%20Dwivedi%20S%2C%20Oomman%20A%2C%20Mathur%20A%2C%20Gadkari%20M%2C%20Naik%20S%2C%20Punnoose%20E%2C%20Kachru%20R%2C%20Christopher%20J%2C%20Kaul%20U%2C%20Sharir%20T%2C%20Kerner%20A%2C%20Tarantini%20G%2C%20Perna%20GP%2C%20Racca%20E%2C%20Mortara%20A%2C%20Monti%20L%2C%20Briguori%20C%2C%20Leone%20G%2C%20Amati%20R%2C%20Salvatori%20M%2C%20Di%20Chiara%20A%2C%20Calabro%20P%2C%20Galvani%20M%2C%20Provasoli%20S%2C%20Fukuda%20K%2C%20Kohsaka%20S%2C%20Nakano%20S%2C%20Laucevicius%20A%2C%20Kedev%20S%2C%20Khairuddin%20A%2C%20Escobedo%20J%2C%20Riezebos%20R%2C%20Timmer%20J%2C%20Heald%20S%2C%20Stewart%20R%2C%20Ramos%20WM%2C%20Demkow%20M%2C%20Mazurek%20T%2C%20Drozdz%20J%2C%20Szwed%20H%2C%20Witkowski%20A%2C%20Ferreira%20N%2C%20Pinto%20F%2C%20Ramos%20R%2C%20Popescu%20B%2C%20Pop%20C%2C%20Bockeria%20L%2C%20Bockeria%20O%2C%20Demchenko%20E%2C%20Romanov%20A%2C%20Bershtein%20L%2C%20Jizeeri%20A%2C%20Stankovic%20G%2C%20Apostolovic%20S%2C%20Adjic%20NC%2C%20Zdravkovic%20M%2C%20Beleslin%20B%2C%20Dekleva%20M%2C%20Davidovic%20G%2C%20Chua%20T%2C%20Foo%20D%2C%20Poh%20KK%2C%20Ntsekhe%20M%2C%20Sionis%20A%2C%20Marin%20F%2C%20Mir%26%23xF3%3B%20V%2C%20L%26%23xF3%3Bpez-Send%26%23xF3%3Bn%20J%2C%20Blancas%20MG%2C%20Gonz%26%23xE1%3Blez-Juanatey%20J%2C%20Fern%26%23xE1%3Bndez-Avil%26%23xE9%3Bs%20F%2C%20Peteiro%20J%2C%20Luena%20JEC%2C%20Held%20C%2C%20Aspberg%20J%2C%20Rossi%20M%2C%20Kuanprasert%20S%2C%20Yamwong%20S%2C%20Johnston%20N%2C%20Donnelly%20P%2C%20Moriarty%20A%2C%20Senior%20R%2C%20Elghamaz%20A%2C%20Gurunathan%20S%2C%20Karogiannis%20N%2C%20Shah%20BN%2C%20Trimlett%20RHJ%2C%20Rubens%20MB%2C%20Nicol%20ED%2C%20Mittal%20TK%2C%20Hampson%20R%2C%20Gamma%20R%2C%20De%20Belder%20M%2C%20Nageh%20T%2C%20Lindsay%20S%2C%20Mavromatis%20K%2C%20Miller%20T%2C%20Banerjee%20S%2C%20Reynolds%20H%2C%20Nour%20K%2C%20Stone%20P.%202023.%20Survival%20After%20Invasive%20or%20Conservative%20Management%20of%20Stable%20Coronary%20Disease.%20Circulation%20147%3A8%26%23x2013%3B19.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Survival%20After%20Invasive%20or%20Conservative%20Management%20of%20Stable%20Coronary%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20S.%22%2C%22lastName%22%3A%22Hochman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Anthopolos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harmony%20R.%22%2C%22lastName%22%3A%22Reynolds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sripal%22%2C%22lastName%22%3A%22Bangalore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yifan%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%20M.%22%2C%22lastName%22%3A%22O%5Cu2019Brien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavroula%22%2C%22lastName%22%3A%22Mavromichalis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aira%22%2C%22lastName%22%3A%22Contreras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Rosenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%22%2C%22lastName%22%3A%22Kirby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Balram%22%2C%22lastName%22%3A%22Bhargava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxy%22%2C%22lastName%22%3A%22Senior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22Banfield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rados%5Cu0142aw%22%2C%22lastName%22%3A%22Praco%5Cu0144%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aldo%20Pietro%22%2C%22lastName%22%3A%22Maggioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20D.%22%2C%22lastName%22%3A%22Newman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20S.%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mandeep%20S.%22%2C%22lastName%22%3A%22Sidhu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%20B.%22%2C%22lastName%22%3A%22Troxel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20E.%22%2C%22lastName%22%3A%22Boden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20B.%22%2C%22lastName%22%3A%22Mark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20A.%22%2C%22lastName%22%3A%22Spertus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Maron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20S.%22%2C%22lastName%22%3A%22Hochman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Maron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harmony%20R.%22%2C%22lastName%22%3A%22Reynolds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sripal%22%2C%22lastName%22%3A%22Bangalore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavroula%22%2C%22lastName%22%3A%22Mavromichalis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aira%22%2C%22lastName%22%3A%22Contreras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shari%22%2C%22lastName%22%3A%22Esquenazi-Karonika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%22%2C%22lastName%22%3A%22Gilsenan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ewelina%22%2C%22lastName%22%3A%22Gwiszcz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patenne%22%2C%22lastName%22%3A%22Mathews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samaa%22%2C%22lastName%22%3A%22Mohamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Naumova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arline%22%2C%22lastName%22%3A%22Roberts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerrie%22%2C%22lastName%22%3A%22VanLoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Anthopolos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yifan%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%20B.%22%2C%22lastName%22%3A%22Troxel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ying%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhen%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Broderick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Guzm%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Selvanayagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Juliard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rolf%22%2C%22lastName%22%3A%22Doerr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matyas%22%2C%22lastName%22%3A%22Keltai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Balram%22%2C%22lastName%22%3A%22Bhargava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boban%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tali%22%2C%22lastName%22%3A%22Sharir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugenia%22%2C%22lastName%22%3A%22Nikolsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aldo%20P.%22%2C%22lastName%22%3A%22Maggioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shun%22%2C%22lastName%22%3A%22Kohsaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Escobedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rados%5Cu0142aw%22%2C%22lastName%22%3A%22Praco%5Cu0144%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Bockeria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxy%22%2C%22lastName%22%3A%22Senior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22Banfield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslee%20J.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Berman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%20Y.%22%2C%22lastName%22%3A%22Kwong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%20R.%22%2C%22lastName%22%3A%22Chaitman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziad%22%2C%22lastName%22%3A%22Ali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Min%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.B.%20John%22%2C%22lastName%22%3A%22Mancini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathon%22%2C%22lastName%22%3A%22Leipsic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Guzm%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Hillis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suku%22%2C%22lastName%22%3A%22Thambar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Majo%22%2C%22lastName%22%3A%22Joseph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Selvanayagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Beltrame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herwig%22%2C%22lastName%22%3A%22Schuchlenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Huber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaatje%22%2C%22lastName%22%3A%22Goetschalckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Whady%22%2C%22lastName%22%3A%22Hueb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulo%20Ricardo%22%2C%22lastName%22%3A%22Caramori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22De%20Quadros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Smanio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%22%2C%22lastName%22%3A%22Mesquita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00e3o%22%2C%22lastName%22%3A%22Vitola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Marin-Neto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Expedito%20Ribeiro%22%2C%22lastName%22%3A%22Da%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rog%5Cu00e9rio%22%2C%22lastName%22%3A%22Tumelero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianna%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%20Rabelo%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederico%22%2C%22lastName%22%3A%22Dall%5Cu2019Orto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carisi%22%2C%22lastName%22%3A%22Polanczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estev%5Cu00e3o%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Howarth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilbert%22%2C%22lastName%22%3A%22Gosselin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asim%22%2C%22lastName%22%3A%22Cheema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Bainey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Phaneuf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariel%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pallav%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andy%22%2C%22lastName%22%3A%22Lam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Cha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Galiwango%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amar%22%2C%22lastName%22%3A%22Uxa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20%28Ben%29%22%2C%22lastName%22%3A%22Chow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Hameed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22Udell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asim%22%2C%22lastName%22%3A%22Cheema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magdy%22%2C%22lastName%22%3A%22Hamid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Hauguel-Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Furber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Goube%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe-Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Barone-Rochette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Thuaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Slama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rolf%22%2C%22lastName%22%3A%22Doerr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Nickenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffi%22%2C%22lastName%22%3A%22Bekeredjian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Christian%22%2C%22lastName%22%3A%22Schulze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bela%22%2C%22lastName%22%3A%22Merkely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geza%22%2C%22lastName%22%3A%22Fontos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e1s%22%2C%22lastName%22%3A%22V%5Cu00e9rtes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Varga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Balram%22%2C%22lastName%22%3A%22Bhargava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajit%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%20G.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Purvez%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cholenahally%22%2C%22lastName%22%3A%22Manjunath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagaraja%22%2C%22lastName%22%3A%22Moorthy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santhosh%22%2C%22lastName%22%3A%22Satheesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ranjit%20Kumar%22%2C%22lastName%22%3A%22Nath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gurpreet%22%2C%22lastName%22%3A%22Wander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johann%22%2C%22lastName%22%3A%22Christopher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sudhanshu%22%2C%22lastName%22%3A%22Dwivedi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abraham%22%2C%22lastName%22%3A%22Oomman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Atul%22%2C%22lastName%22%3A%22Mathur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milind%22%2C%22lastName%22%3A%22Gadkari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sudhir%22%2C%22lastName%22%3A%22Naik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eapen%22%2C%22lastName%22%3A%22Punnoose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ranjan%22%2C%22lastName%22%3A%22Kachru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johann%22%2C%22lastName%22%3A%22Christopher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Kaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tali%22%2C%22lastName%22%3A%22Sharir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Kerner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Tarantini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gian%20Piero%22%2C%22lastName%22%3A%22Perna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Racca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Mortara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Monti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Briguori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gianpiero%22%2C%22lastName%22%3A%22Leone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Amati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mauro%22%2C%22lastName%22%3A%22Salvatori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Di%20Chiara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Calabro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcello%22%2C%22lastName%22%3A%22Galvani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Provasoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keiichi%22%2C%22lastName%22%3A%22Fukuda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shun%22%2C%22lastName%22%3A%22Kohsaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shintaro%22%2C%22lastName%22%3A%22Nakano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleksandras%22%2C%22lastName%22%3A%22Laucevicius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sasko%22%2C%22lastName%22%3A%22Kedev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Khairuddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Escobedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Riezebos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorik%22%2C%22lastName%22%3A%22Timmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spencer%22%2C%22lastName%22%3A%22Heald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walter%20Mogrovejo%22%2C%22lastName%22%3A%22Ramos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcin%22%2C%22lastName%22%3A%22Demkow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Mazurek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jarozlaw%22%2C%22lastName%22%3A%22Drozdz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanna%22%2C%22lastName%22%3A%22Szwed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Witkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nuno%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruben%22%2C%22lastName%22%3A%22Ramos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bogdan%22%2C%22lastName%22%3A%22Popescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Calin%22%2C%22lastName%22%3A%22Pop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%22%2C%22lastName%22%3A%22Bockeria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Bockeria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Demchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Romanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonid%22%2C%22lastName%22%3A%22Bershtein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Jizeeri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Goran%22%2C%22lastName%22%3A%22Stankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svetlana%22%2C%22lastName%22%3A%22Apostolovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nada%20Cemerlic%22%2C%22lastName%22%3A%22Adjic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marija%22%2C%22lastName%22%3A%22Zdravkovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Branko%22%2C%22lastName%22%3A%22Beleslin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milica%22%2C%22lastName%22%3A%22Dekleva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Goran%22%2C%22lastName%22%3A%22Davidovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terrance%22%2C%22lastName%22%3A%22Chua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Foo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kian%20Keong%22%2C%22lastName%22%3A%22Poh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpiko%22%2C%22lastName%22%3A%22Ntsekhe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Sionis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Marin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vicente%22%2C%22lastName%22%3A%22Mir%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Montserrat%20Gracida%22%2C%22lastName%22%3A%22Blancas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez-Juanatey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez-Avil%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jes%5Cu00fas%22%2C%22lastName%22%3A%22Peteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Enrique%20Castillo%22%2C%22lastName%22%3A%22Luena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Aspberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariagrazia%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srun%22%2C%22lastName%22%3A%22Kuanprasert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sukit%22%2C%22lastName%22%3A%22Yamwong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Donnelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Moriarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxy%22%2C%22lastName%22%3A%22Senior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Elghamaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sothinathan%22%2C%22lastName%22%3A%22Gurunathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolaos%22%2C%22lastName%22%3A%22Karogiannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoy%20N.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20H.J.%22%2C%22lastName%22%3A%22Trimlett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20B.%22%2C%22lastName%22%3A%22Rubens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20D.%22%2C%22lastName%22%3A%22Nicol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tarun%20K.%22%2C%22lastName%22%3A%22Mittal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reinette%22%2C%22lastName%22%3A%22Hampson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reto%22%2C%22lastName%22%3A%22Gamma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22De%20Belder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thuraia%22%2C%22lastName%22%3A%22Nageh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Lindsay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kreton%22%2C%22lastName%22%3A%22Mavromatis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Todd%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subhash%22%2C%22lastName%22%3A%22Banerjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harmony%22%2C%22lastName%22%3A%22Reynolds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khaled%22%2C%22lastName%22%3A%22Nour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Stone%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20ISCHEMIA%20trial%20%28International%20Study%20of%20Comparative%20Health%20Effectiveness%20With%20Medical%20and%20Invasive%20Approaches%29%20compared%20an%20initial%20invasive%20versus%20an%20initial%20conservative%20management%20strategy%20for%20patients%20with%20chronic%20coronary%20disease%20and%20moderate%20or%20severe%20ischemia%2C%20with%20no%20major%20difference%20in%20most%20outcomes%20during%20a%20median%20of%203.2%20years.%20Extended%20follow-up%20for%20mortality%20is%20ongoing.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ISCHEMIA%20participants%20were%20randomized%20to%20an%20initial%20invasive%20strategy%20added%20to%20guideline-directed%20medical%20therapy%20or%20a%20conservative%20strategy.%20Patients%20with%20moderate%20or%20severe%20ischemia%2C%20ejection%20fraction%20%5Cu226535%25%2C%20and%20no%20recent%20acute%20coronary%20syndromes%20were%20included.%20Those%20with%20an%20unacceptable%20level%20of%20angina%20were%20excluded.%20Extended%20follow-up%20for%20vital%20status%20is%20being%20conducted%20by%20sites%20or%20through%20central%20death%20index%20search.%20Data%20obtained%20through%20December%202021%20are%20included%20in%20this%20interim%20report.%20We%20analyzed%20all-cause%2C%20cardiovascular%2C%20and%20noncardiovascular%20mortality%20by%20randomized%20strategy%2C%20using%20nonparametric%20cumulative%20incidence%20estimators%2C%20Cox%20regression%20models%2C%20and%20Bayesian%20methods.%20Undetermined%20deaths%20were%20classified%20as%20cardiovascular%20as%20prespecified%20in%20the%20trial%20protocol.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Baseline%20characteristics%20for%205179%20original%20ISCHEMIA%20trial%20participants%20included%20median%20age%2065%20years%2C%2023%25%20women%2C%2016%25%20Hispanic%2C%204%25%20Black%2C%2042%25%20with%20diabetes%2C%20and%20median%20ejection%20fraction%200.60.%20A%20total%20of%20557%20deaths%20accrued%20during%20a%20median%20follow-up%20of%205.7%20years%2C%20with%20268%20of%20these%20added%20in%20the%20extended%20follow-up%20phase.%20This%20included%20a%20total%20of%20343%20cardiovascular%20deaths%2C%20192%20noncardiovascular%20deaths%2C%20and%2022%20unclassified%20deaths.%20All-cause%20mortality%20was%20not%20different%20between%20randomized%20treatment%20groups%20%287-year%20rate%2C%2012.7%25%20in%20invasive%20strategy%2C%2013.4%25%20in%20conservative%20strategy%3B%20adjusted%20hazard%20ratio%2C%201.00%20%5B95%25%20CI%2C%200.85%5Cu20131.18%5D%29.%20There%20was%20a%20lower%207-year%20rate%20cardiovascular%20mortality%20%286.4%25%20versus%208.6%25%3B%20adjusted%20hazard%20ratio%2C%200.78%20%5B95%25%20CI%2C%200.63%5Cu20130.96%5D%29%20with%20an%20initial%20invasive%20strategy%20but%20a%20higher%207-year%20rate%20of%20noncardiovascular%20mortality%20%285.6%25%20versus%204.4%25%3B%20adjusted%20hazard%20ratio%2C%201.44%20%5B95%25%20CI%2C%201.08%5Cu20131.91%5D%29%20compared%20with%20the%20conservative%20strategy.%20No%20heterogeneity%20of%20treatment%20effect%20was%20evident%20in%20prespecified%20subgroups%2C%20including%20multivessel%20coronary%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20There%20was%20no%20difference%20in%20all-cause%20mortality%20with%20an%20initial%20invasive%20strategy%20compared%20with%20an%20initial%20conservative%20strategy%2C%20but%20there%20was%20lower%20risk%20of%20cardiovascular%20mortality%20and%20higher%20risk%20of%20noncardiovascular%20mortality%20with%20an%20initial%20invasive%20strategy%20during%20a%20median%20follow-up%20of%205.7%20years.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT04894877.%22%2C%22date%22%3A%222023-01-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.122.062714%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.122.062714%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22NMZFXHCM%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Steg%20and%20Kiko%5Cu00efne%22%2C%22parsedDate%22%3A%222023-01-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESteg%20PG%2C%20Kiko%26%23xEF%3Bne%20J.%202023.%20Do%20We%20Need%20Ischemia%20Testing%20to%20Monitor%20Asymptomatic%20Patients%20With%20Chronic%20Coronary%20Syndromes%3F%20Circulation%20147%3A5%26%23x2013%3B7.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Do%20We%20Need%20Ischemia%20Testing%20to%20Monitor%20Asymptomatic%20Patients%20With%20Chronic%20Coronary%20Syndromes%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Kiko%5Cu00efne%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-01-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.122.053565%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.122.053565%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22WQ57WRYW%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puymirat%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-31%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPuymirat%20E%2C%20Cayla%20G%2C%20Simon%20T%2C%20Steg%20PG%2C%20Montalescot%20G%2C%20Durand-Zaleski%20I%2C%20Siaha%20FN%2C%20Gallet%20R%2C%20Khalife%20K%2C%20Morelle%20J-F%2C%20Motreff%20P%2C%20Lemesle%20G%2C%20Dillinger%20J-G%2C%20Lhermusier%20T%2C%20Silvain%20J%2C%20Roule%20V%2C%20Lab%26%23xE8%3Bque%20J-N%2C%20Rang%26%23xE9%3B%20G%2C%20Ducrocq%20G%2C%20Cottin%20Y%2C%20Blanchard%20D%2C%20Nelson%20AC%2C%20Djadi-Prat%20J%2C%20Chatellier%20G%2C%20Danchin%20N%2C%20the%20FLOWER-MI%20study%20investigators.%202023.%20Three-year%20outcomes%20with%20fractional%20flow%20reserve-%20or%20angiography-guided%20multivessel%20percutaneous%20coronary%20intervention%20for%20myocardial%20infarction.%20preprint.%20Cardiovascular%20Medicine.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22report%22%2C%22title%22%3A%22Three-year%20outcomes%20with%20fractional%20flow%20reserve-%20or%20angiography-guided%20multivessel%20percutaneous%20coronary%20intervention%20for%20myocardial%20infarction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cayla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Durand-Zaleski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabiola%20Ngaleu%22%2C%22lastName%22%3A%22Siaha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Gallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khalife%22%2C%22lastName%22%3A%22Khalife%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Morelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Motreff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Guillaume%22%2C%22lastName%22%3A%22Dillinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Lhermusier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanne%22%2C%22lastName%22%3A%22Silvain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Roule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Noel%22%2C%22lastName%22%3A%22Lab%5Cu00e8que%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Rang%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%20Charles%22%2C%22lastName%22%3A%22Nelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Djadi-Prat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Chatellier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20FLOWER-MI%20study%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22ABSTRACT%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20In%20multivessel%20disease%20%28MVD%29%20patients%20with%20successful%20primary%20percutaneous%20coronary%20intervention%20%28PCI%29%20for%20ST-elevation%20myocardial%20infarction%20%28STEMI%29%2C%20the%20Flow%20Evaluation%20to%20Guide%20Revascularization%20in%20Multivessel%20ST-Elevation%20Myocardial%20Infarction%20%28FLOWER-MI%29%20trial%20showed%20that%20a%20fractional%20flow%20reserve%20%28FFR%29-guided%20strategy%20was%20not%20superior%20to%20an%20angiography-guided%20strategy%20for%20treatment%20of%20non-infarct-related%20artery%20lesions%20regarding%20the%20one-year%20risk%20of%20death%20from%20any%20cause%2C%20MI%2C%20or%20unplanned%20hospitalization%20leading%20to%20urgent%20revascularization.%20The%20extension%20phase%20of%20the%20trial%20was%20planned%20using%20the%20same%20primary%20outcome%20to%20determine%20whether%20a%20difference%20in%20outcomes%20would%20be%20observed%20with%20a%20longer%20follow-up.%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20multicenter%20trial%2C%20we%20randomly%20assigned%20patients%20with%20STEMI%20and%20MVD%20with%20successful%20PCI%20of%20the%20infarct-related%20artery%20to%20receive%20complete%20revascularization%20guided%20by%20either%20FFR%20%28n%3D586%29%20or%20angiography%20%28n%3D577%29.%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%203%20years%2C%20a%20primary%20outcome%20event%20occurred%20in%2052%20of%20498%20patients%20in%20the%20FFR-guided%20group%20and%20in%2044%20of%20502%20patients%20in%20the%20angiography-guided%20group%20%28hazard%20ratio%5BHR%5D%2C%201.19%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.79-1.77%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%3D0.4%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29.%20Death%20occurred%20in%2022%20patients%20in%20the%20FFR-guided%20group%20and%20in%2023%20in%20the%20angiography-guided%20group%20%28HR%2C%200.96%3B%2095%25%20CI%200.53-1.71%29%3B%20nonfatal%20MI%20in%2023%20and%2014%29%2C%20respectively%20%28HR%2C%201.63%3B%2095%25%20CI%200.84-3.16%29%3B%20and%20unplanned%20hospitalization%20leading%20to%20urgent%20revascularization%20in%2021%20and%2018%20%28HR%2C%201.15%3B%2095%25%20CI%200.61-2.16%29%2C%20respectively.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Although%20event%20rates%20in%20the%20trial%20were%20lower%20than%20expected%2C%20in%20patients%20with%20STEMI%20undergoing%20complete%20revascularization%2C%20an%20FFR-guided%20strategy%20had%20not%20a%20significant%20benefit%20over%20an%20angiography-guided%20strategy%20with%20respect%20to%20the%20risk%20of%20death%2C%20MI%2C%20or%20urgent%20revascularization%20up%20to%203%20years.%20%28Funded%20by%20the%20French%20Ministry%20of%20Health%20and%20Abbott%3B%20FLOWER-MI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20number%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT02943954%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%29%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20CLINICAL%20PERSPECTIVE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20What%20Is%20New%3F%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20STEMI%20patients%20with%20MVD%2C%20an%20FFR-guided%20strategy%20is%20not%20superior%20to%20an%20angiography-guided%20strategy%20for%20treatment%20of%20non-infarct-related%20artery%20lesions%20regarding%20the%20risk%20of%20death%20from%20any%20cause%2C%20MI%2C%20or%20unplanned%20hospitalization%20leading%20to%20urgent%20revascularization%20at%203%20years.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20What%20Are%20the%20Clinical%20Implications%3F%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20STEMI%20undergoing%20complete%20revascularization%2C%20an%20FFR-guided%20strategy%20had%20no%20significant%20benefit%20over%20an%20angiography-guided%20strategy%20with%20respect%20to%20the%20risk%20of%20death%2C%20MI%2C%20or%20urgent%20revascularization%20up%20to%203%20years.%22%2C%22reportNumber%22%3A%22%22%2C%22reportType%22%3A%22preprint%22%2C%22institution%22%3A%22Cardiovascular%20Medicine%22%2C%22date%22%3A%222023-08-31%22%2C%22language%22%3A%22en%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fmedrxiv.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1101%5C%2F2023.08.30.23294648%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%2295SJNEEH%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vidal-Petiot%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVidal-Petiot%20E%2C%20Elbez%20Y%2C%20Mesnier%20J%2C%20Ducrocq%20G%2C%20Ford%20I%2C%20Tendera%20M%2C%20Ferrari%20R%2C%20Tardif%20J-C%2C%20Fox%20KM%2C%20Steg%20PG.%202023.%20Optimal%20or%20standard%20control%20of%20systolic%20and%20diastolic%20blood%20pressure%20across%20risk%20factor%20categories%20in%20patients%20with%20chronic%20coronary%20syndromes.%20European%20Journal%20of%20Preventive%20Cardiology%2030%3A935%26%23x2013%3B947.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimal%20or%20standard%20control%20of%20systolic%20and%20diastolic%20blood%20pressure%20across%20risk%20factor%20categories%20in%20patients%20with%20chronic%20coronary%20syndromes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Vidal-Petiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jules%22%2C%22lastName%22%3A%22Mesnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Guidelines%20have%20lowered%20blood%20pressure%20%28BP%29%20targets%20to%20%26lt%3B130%5C%2F80%20mmHg.%20We%20examined%20the%20benefit%20of%20intensive%20control%20for%20each%20BP%20component%2C%20vs.%20the%20burden%20of%20other%20modifiable%20risk%20factors%2C%20in%20patients%20with%20chronic%20coronary%20syndromes%20%28CCS%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20CLARIFY%20registry%20%28ISRCTN43070564%29%20enrolled%2032%20703%20patients%20with%20CCS%2C%20from%202009%20to%202010%2C%20with%20a%205-year%20follow-up.%20Patients%20with%20either%20BP%20component%20below%20European%20guideline%20safety%20boundaries%20%28120%5C%2F70%20mmHg%29%20were%20excluded%2C%20leaving%2019%20167%20patients%20%28mean%20age%3A%2063.8%20%5Cu00b1%2010.1%20years%2C%2078%25%20men%29%20in%20the%20present%20analysis.%20A%20multivariable-adjusted%20Cox%20proportional%20hazards%20model%20showed%20a%20gradual%20increase%20in%20cardiovascular%20risk%20%28cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20stroke%29%20when%20the%20number%20of%20uncontrolled%20risk%20factors%20%28active%20smoking%2C%20no%20physical%20activity%2C%20low-density%20lipoprotein%20cholesterol%20%5Cu2265100%20mg%5C%2FdL%2C%20and%20diabetes%20with%20glycated%20haemoglobin%20%5Cu22657%25%29%20increased%20%5Badjusted%20hazard%20ratio%20%28HR%29%3A%201.34%3B%2095%25%20confidence%20interval%20%28CI%29%3A%201.17%5Cu20131.52%2C%201.65%20%281.40%5Cu20131.94%29%2C%20and%202.47%20%281.90%5Cu20133.21%29%20for%201%2C%202%2C%20and%203%20or%204%20uncontrolled%20risk%20factors%2C%20respectively%2C%20vs.%200%5D%2C%20without%20significant%20interaction%20with%20BP.%20Although%20uncontrolled%20systolic%20%28%5Cu2265140%20mmHg%29%20and%20diastolic%20%28%5Cu226590%20mmHg%29%20BP%20were%20both%20associated%20with%20higher%20risk%20than%20standard%20BP%2C%20standard%20BP%20was%20associated%20with%20higher%20risk%20than%20optimal%20control%20for%20only%20the%20diastolic%20component%20%28adjusted%20HR%3A%201.08%3B%2095%25%20CI%3A%200.94%5Cu20131.25%20for%20systolic%20BP%20130%5Cu2013139%20vs.%20120%5Cu2013129%20mmHg%20and%201.43%3B%2095%25%20CI%3A%201.27%5Cu20131.62%20for%20diastolic%20BP%2080%5Cu201389%20vs.%2070%5Cu201379%20mmHg%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Our%20results%20suggest%20that%20the%20optimal%20BP%20target%20in%20CCS%20may%20be%20%5Cu2264139%5C%2F79%20mmHg%20and%20that%20optimizing%20the%20burden%20of%20other%20risk%20factors%20should%20be%20prioritized%20over%20the%20further%20reduction%20of%20systolic%20BP.%22%2C%22date%22%3A%222023-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurjpc%5C%2Fzwad004%22%2C%22ISSN%22%3A%222047-4873%2C%202047-4881%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurjpc%5C%2Farticle%5C%2F30%5C%2F10%5C%2F935%5C%2F6974677%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22PW8BTVQD%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Costa%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECosta%20F%2C%20Montalto%20C%2C%20Branca%20M%2C%20Hong%20S-J%2C%20Watanabe%20H%2C%20Franzone%20A%2C%20Vranckx%20P%2C%20Hahn%20J-Y%2C%20Gwon%20H-C%2C%20Feres%20F%2C%20Jang%20Y%2C%20De%20Luca%20G%2C%20Kedhi%20E%2C%20Cao%20D%2C%20Steg%20PG%2C%20Bhatt%20DL%2C%20Stone%20GW%2C%20Micari%20A%2C%20Windecker%20S%2C%20Kimura%20T%2C%20Hong%20M-K%2C%20Mehran%20R%2C%20Valgimigli%20M.%202023.%20Dual%20antiplatelet%20therapy%20duration%20after%20percutaneous%20coronary%20intervention%20in%20high%20bleeding%20risk%3A%20a%20meta-analysis%20of%20randomized%20trials.%20European%20Heart%20Journal%2044%3A954%26%23x2013%3B968.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dual%20antiplatelet%20therapy%20duration%20after%20percutaneous%20coronary%20intervention%20in%20high%20bleeding%20risk%3A%20a%20meta-analysis%20of%20randomized%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%22%2C%22lastName%22%3A%22Montalto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mattia%22%2C%22lastName%22%3A%22Branca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sung-Jin%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hirotoshi%22%2C%22lastName%22%3A%22Watanabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Franzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joo-Yong%22%2C%22lastName%22%3A%22Hahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyeon-Cheol%22%2C%22lastName%22%3A%22Gwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%22%2C%22lastName%22%3A%22Feres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yangsoo%22%2C%22lastName%22%3A%22Jang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22De%20Luca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elvin%22%2C%22lastName%22%3A%22Kedhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Davide%22%2C%22lastName%22%3A%22Cao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Micari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takeshi%22%2C%22lastName%22%3A%22Kimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myeong-Ki%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20optimal%20duration%20of%20dual%20antiplatelet%20therapy%20%28DAPT%29%20after%20percutaneous%20coronary%20intervention%20%28PCI%29%20in%20patients%20at%20high%20bleeding%20risk%20%28HBR%29%20is%20still%20debated.%20The%20current%20study%2C%20using%20the%20totality%20of%20existing%20evidence%2C%20evaluated%20the%20impact%20of%20an%20abbreviated%20DAPT%20regimen%20in%20HBR%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20systematic%20review%20and%20meta-analysis%20was%20performed%20to%20search%20randomized%20clinical%20trials%20comparing%20abbreviated%20%5Bi.e.%20very-short%20%281%20month%29%20or%20short%20%283%20months%29%5D%20with%20standard%20%28%5Cu22656%20months%29%20DAPT%20in%20HBR%20patients%20without%20indication%20for%20oral%20anticoagulation.%20A%20total%20of%2011%20trials%2C%20including%209006%20HBR%20patients%2C%20were%20included.%20Abbreviated%20DAPT%20reduced%20major%20or%20clinically%20relevant%20non-major%20bleeding%20%5Brisk%20ratio%20%28RR%29%3A%200.76%2C%2095%25%20confidence%20interval%20%28CI%29%3A%200.61%5Cu20130.94%3B%20I2%20%3D%2028%25%5D%2C%20major%20bleeding%20%28RR%3A%200.80%2C%2095%25%20CI%3A%200.64%5Cu20130.99%2C%20I2%20%3D%200%25%29%2C%20and%20cardiovascular%20mortality%20%28RR%3A%200.79%2C%2095%25%20CI%3A%200.65%5Cu20130.95%2C%20I2%20%3D%200%25%29%20compared%20with%20standard%20DAPT.%20No%20difference%20in%20all-cause%20mortality%2C%20major%20adverse%20cardiovascular%20events%2C%20myocardial%20infarction%2C%20or%20stent%20thrombosis%20was%20observed.%20Results%20were%20consistent%2C%20irrespective%20of%20HBR%20definition%20and%20clinical%20presentation.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20HBR%20patients%20undergoing%20PCI%2C%20a%201-%20or%203-month%20abbreviated%20DAPT%20regimen%20was%20associated%20with%20lower%20bleeding%20and%20cardiovascular%20mortality%2C%20without%20increasing%20ischaemic%20events%2C%20compared%20with%20a%20%5Cu22656-month%20DAPT%20regimen.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Study%20registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20PROSPERO%20registration%20number%20CRD42021284004%22%2C%22date%22%3A%222023-03-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehac706%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F44%5C%2F11%5C%2F954%5C%2F6881138%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A31Z%22%7D%7D%2C%7B%22key%22%3A%229Q9SV5UZ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lamy%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELamy%20A%2C%20Eikelboom%20J%2C%20Tong%20W%2C%20Yuan%20F%2C%20Bangdiwala%20SI%2C%20Bosch%20J%2C%20Connolly%20S%2C%20Lonn%20E%2C%20Dagenais%20GR%2C%20Branch%20KRH%2C%20Wang%20W-J%2C%20Bhatt%20DL%2C%20Probstfield%20J%2C%20Ertl%20G%2C%20St%26%23xF6%3Brk%20S%2C%20Steg%20PG%2C%20Aboyans%20V%2C%20Durand-Zaleski%20I%2C%20Ryden%20L%2C%20Yusuf%20S.%202023.%20The%20cost-effectiveness%20of%20rivaroxaban%20with%20or%20without%20aspirin%20in%20the%20COMPASS%20trial.%20European%20Heart%20Journal%20-%20Quality%20of%20Care%20and%20Clinical%20Outcomes%209%3A502%26%23x2013%3B510.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20cost-effectiveness%20of%20rivaroxaban%20with%20or%20without%20aspirin%20in%20the%20COMPASS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Eikelboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wesley%22%2C%22lastName%22%3A%22Tong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fei%22%2C%22lastName%22%3A%22Yuan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shrikant%20I%22%2C%22lastName%22%3A%22Bangdiwala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackie%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Lonn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%20R%22%2C%22lastName%22%3A%22Dagenais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelley%20R%20H%22%2C%22lastName%22%3A%22Branch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei-Jhih%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeff%22%2C%22lastName%22%3A%22Probstfield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Ertl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22St%5Cu00f6rk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Aboyans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Durand-Zaleski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Ryden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Yusuf%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20Cardiovascular%20Outcomes%20for%20People%20Using%20Anticoagulation%20Strategies%20%28COMPASS%29%20trial%20demonstrated%20that%20rivaroxaban%202.5%5Cu00a0mg%20BID%20with%20aspirin%20100%5Cu00a0mg%20was%20more%20effective%20than%20aspirin%20100%5Cu00a0mg%20daily%20alone%20for%20the%20prevention%20of%20cardiovascular%20%28CV%29%20death%2C%20stroke%2C%20or%20myocardial%20infarction%20in%20patients%20with%20stable%20coronary%20artery%20disease%20%28CAD%29%20or%20peripheral%20artery%20disease%20%28PAD%29.%20We%20aimed%20to%20examine%20the%20cost-effectiveness%20of%20rivaroxaban%20using%20patient-level%20data%20from%20the%20COMPASS%20trial.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20performed%20an%20in-trial%20analysis%20and%20extrapolated%20our%20results%20for%2033%20years%20using%20a%20two-state%20Markov%20model%20with%20a%201-year%20cycle%20length.%20Hospitalization%20events%2C%20procedures%2C%20and%20study%20drugs%20were%20documented%20for%20patients.%20We%20applied%20country-specific%20%28Canada%2C%20France%2C%20and%20Germany%29%20direct%20healthcare%20system%20costs%20%28in%20USD%29%20to%20healthcare%20resources%20consumed%20by%20patients.%20Average%20cost%20per%20patient%20during%20the%20trial%20%28mean%20follow-up%20of%2023%20months%29%2C%20quality-adjusted%20life%20years%20%28QALYs%29%2C%20and%20lifetime%20cost-effectiveness%20were%20calculated.%20Costs%20of%20events%20and%20procedures%20were%20reduced%20with%20rivaroxaban%202.5%5Cu00a0mg%20BID%20with%20aspirin.%20The%20addition%20of%20rivaroxaban%202.5%5Cu00a0mg%20BID%20increased%20total%20costs%20for%20the%20combination%20group.%20Over%20a%20lifetime%20horizon%20%28in%20trial%20%2B33%20years%29%2C%20rivaroxaban%20plus%20aspirin%20was%20associated%20with%201.17%20QALYs%20gained%2C%20yielding%20an%20incremental%20cost-effectiveness%20ratio%20%28ICER%29%20of%20%243946%5C%2FQALY%2C%20%249962%5C%2FQALY%2C%20and%20%2410%5Cu00a0264%5C%2FQALY%20in%20Canada%2C%20France%2C%20and%20Germany%2C%20respectively.%20PAD%20and%20polyvascular%20disease%20subgroups%20had%20lower%20ICERs.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Rivaroxaban%202.5%5Cu00a0mg%20twice%20daily%20plus%20aspirin%20compared%20with%20aspirin%20alone%20reduces%20direct%20healthcare%20costs.%20After%20acquisition%20costs%20of%20rivaroxaban%2C%20the%20lifetime%20cost-effectiveness%20of%202.5%5Cu00a0mg%20twice%20daily%20plus%20aspirin%20is%20highly%20cost-effective%20in%20Canada%2C%20France%2C%20and%20Germany.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28COMPASS%20ClinicalTrials.gov%20identifier%3A%20NCT01776424%29%22%2C%22date%22%3A%222023-08-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjqcco%5C%2Fqcac054%22%2C%22ISSN%22%3A%222058-5225%2C%202058-1742%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjqcco%5C%2Farticle%5C%2F9%5C%2F5%5C%2F502%5C%2F6674756%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22RG6KP8WN%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durand-Zaleski%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-28%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDurand-Zaleski%20I%2C%20Ducrocq%20G%2C%20Mimouni%20M%2C%20Frenkiel%20J%2C%20Avendano-Sol%26%23xE1%3B%20C%2C%20Gonzalez-Juanatey%20JR%2C%20Ferrari%20E%2C%20Lemesle%20G%2C%20Puymirat%20E%2C%20Berard%20L%2C%20Cachanado%20M%2C%20Arnaiz%20JA%2C%20Mart%26%23xED%3Bnez-Sell%26%23xE9%3Bs%20M%2C%20Silvain%20J%2C%20Ariza-Sol%26%23xE9%3B%20A%2C%20Calvo%20G%2C%20Danchin%20N%2C%20Paco%20S%2C%20Drouet%20E%2C%20Abergel%20H%2C%20Rousseau%20A%2C%20Simon%20T%2C%20Steg%20PG.%202023.%20Economic%20evaluation%20of%20restrictive%20vs.%20liberal%20transfusion%20strategy%20following%20acute%20myocardial%20infarction%20%28REALITY%29%3A%20trial-based%20cost%26%23x2013%3Beffectiveness%20and%20cost%26%23x2013%3Butility%20analyses.%20European%20Heart%20Journal%20-%20Quality%20of%20Care%20and%20Clinical%20Outcomes%209%3A194%26%23x2013%3B202.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Economic%20evaluation%20of%20restrictive%20vs.%20liberal%20transfusion%20strategy%20following%20acute%20myocardial%20infarction%20%28REALITY%29%3A%20trial-based%20cost%5Cu2013effectiveness%20and%20cost%5Cu2013utility%20analyses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Durand-Zaleski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maroua%22%2C%22lastName%22%3A%22Mimouni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Frenkiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Avendano-Sol%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20R%22%2C%22lastName%22%3A%22Gonzalez-Juanatey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emile%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Cachanado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan%20Albert%22%2C%22lastName%22%3A%22Arnaiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Sell%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanne%22%2C%22lastName%22%3A%22Silvain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Ariza-Sol%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gonzalo%22%2C%22lastName%22%3A%22Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Paco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Drouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Abergel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20estimate%20the%20cost%5Cu2013effectiveness%20and%20cost%5Cu2013utility%20ratios%20of%20a%20restrictive%20vs.%20liberal%20transfusion%20strategy%20in%20acute%20myocardial%20infarction%20%28AMI%29%20patients%20with%20anaemia.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20%28n%5Cu00a0%3D%5Cu00a0666%29%20with%20AMI%20and%20haemoglobin%20between%207%5Cu20138%20and%2010%5Cu00a0g%5C%2FdL%20recruited%20in%2035%20hospitals%20in%20France%20and%20Spain%20were%20randomly%20assigned%20to%20a%20restrictive%20%28n%5Cu00a0%3D%5Cu00a0342%29%20or%20a%20liberal%20%28n%5Cu00a0%3D%5Cu00a0324%29%20transfusion%20strategy%20with%201-year%20prospective%20collection%20of%20resource%20utilization%20and%20quality%20of%20life%20using%20the%20EQ5D3L%20questionnaire.%20The%20economic%20evaluation%20was%20based%20on%20648%20patients%20from%20the%20per-protocol%20population.%20The%20outcomes%20were%2030-day%20and%201-year%20cost-effectiveness%2C%20with%20major%20adverse%20cardiovascular%20events%20%28MACEs%29%20averted%20as%20the%20effectiveness%20outcome.%20and%20a%201-year%20cost%5Cu2013utility%20ratio.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%2030-day%20incremental%20cost%5Cu2013effectiveness%20ratio%20was%20%5Cu20ac33%20065%20saved%20per%20additional%20MACE%20averted%20with%20the%20restrictive%20vs.%20liberal%20strategy%2C%20with%20an%2084%25%20probability%20for%20the%20restrictive%20strategy%20to%20be%20cost-saving%20and%20MACE-reducing%20%28i.e.%20dominant%29.%20At%201%20year%2C%20the%20point%20estimate%20of%20the%20cost%5Cu2013utility%20ratio%20was%20%5Cu20ac191%20500%20saved%20per%20quality-adjusted%20life%20year%20gained%3B%20however%2C%20the%20cumulated%20MACE%20was%20outside%20the%20pre-specified%20non-inferiority%20margin%2C%20resulting%20in%20a%20decremental%20cost%5Cu2013effectiveness%20ratio%20with%20a%20point%20estimate%20of%20%5Cu20ac72%20000%20saved%20per%20additional%20MACE%20with%20the%20restrictive%20strategy.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20AMI%20and%20anaemia%2C%20the%20restrictive%20transfusion%20strategy%20was%20dominant%20%28cost-saving%20and%20outcome-improving%29%20at%2030%20days.%20At%201%20year%2C%20the%20restrictive%20strategy%20remained%20cost-saving%2C%20but%20clinical%20non-inferiority%20on%20MACE%20was%20no%20longer%20maintained.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.gov%20Identifier%3A%20NCT02648113.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20One%20sentence%20summary%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20use%20of%20a%20restrictive%20transfusion%20strategy%20in%20patients%20with%20acute%20myocardial%20infarction%20is%20associated%20with%20lower%20healthcare%20costs%2C%20but%20more%20evidence%20is%20needed%20to%20ascertain%20its%20long-term%20clinical%20impact.%22%2C%22date%22%3A%222023-02-28%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjqcco%5C%2Fqcac029%22%2C%22ISSN%22%3A%222058-5225%2C%202058-1742%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjqcco%5C%2Farticle%5C%2F9%5C%2F2%5C%2F194%5C%2F6591568%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A16Z%22%7D%7D%2C%7B%22key%22%3A%227WCKCK5A%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Miller%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMiller%20M%2C%20Bhatt%20DL%2C%20Steg%20PG%2C%20Brinton%20EA%2C%20Jacobson%20TA%2C%20Jiao%20L%2C%20Tardif%20J-C%2C%20Ballantyne%20CM%2C%20Budoff%20M%2C%20Mason%20RP.%202023.%20Potential%20effects%20of%20icosapent%20ethyl%20on%20cardiovascular%20outcomes%20in%20cigarette%20smokers%3A%20REDUCE-IT%20smoking.%20European%20Heart%20Journal%20-%20Cardiovascular%20Pharmacotherapy%209%3A129%26%23x2013%3B137.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Potential%20effects%20of%20icosapent%20ethyl%20on%20cardiovascular%20outcomes%20in%20cigarette%20smokers%3A%20REDUCE-IT%20smoking%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliot%20A%22%2C%22lastName%22%3A%22Brinton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%20A%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lixia%22%2C%22lastName%22%3A%22Jiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Budoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20Preston%22%2C%22lastName%22%3A%22Mason%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Cigarette%20smoking%20is%20among%20the%20most%20well-established%20risk%20factors%20for%20adverse%20cardiovascular%20outcomes.%20We%20sought%20to%20determine%20whether%20icosapent%20ethyl%20%28IPE%29%2C%20a%20highly%20purified%20form%20of%20eicosapentaenoic%20acid%20with%20antiatherothrombotic%20properties%2C%20may%20reduce%20the%20excessive%20risk%20of%20cardiovascular%20disease%20%28CVD%29%20attributable%20to%20smoking.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Reduction%20of%20Cardiovascular%20Events%20with%20Icosapent%20Ethyl%20Trial%20%28REDUCE-IT%29%20was%20a%20multinational%2C%20double-blind%20trial%20that%20randomized%208179%20statin-treated%20patients%20with%20elevated%20triglycerides%20and%20CV%20risk%20to%20IPE%20or%20placebo%2C%20with%20a%20median%20follow-up%20period%20of%204.9%20years.%20Icosapent%20ethyl%20reduced%20the%20primary%20composite%20endpoint%20%5BCV%20death%2C%20non-fatal%20myocardial%20infarction%20%28MI%29%2C%20non-fatal%20stroke%2C%20coronary%20revascularization%2C%20or%20hospitalization%20for%20unstable%20angina%5D%20by%2025%25%20%28P%5Cu00a0%26lt%3B%5Cu00a00.0001%29.%20In%20the%20current%20analyses%2C%20the%20effect%20of%20IPE%20was%20evaluated%20in%20REDUCE-IT%20using%20post%20hoc%20analyses%20based%20on%20smoking%20history.%20Groups%20were%20classified%20as%20current%20smokers%20%28n%5Cu00a0%3D%5Cu00a01241%29%2C%20former%20smokers%20%28n%5Cu00a0%3D%5Cu00a03672%29%2C%20and%20never%20smokers%20%28n%5Cu00a0%3D%5Cu00a03264%29.%20Compared%20with%20placebo%2C%20IPE%20use%20in%20combined%20current%20and%20former%20smokers%20%28n%5Cu00a0%3D%5Cu00a04913%29%20was%20associated%20with%20significant%20reductions%20in%20time%20to%20the%20primary%20composite%20endpoint%20%7Bhazard%20ratio%3A%200.77%20%5B95%25%20confidence%20interval%20%28CI%29%3A%200.68%5Cu20130.87%5D%3B%20P%5Cu00a0%26lt%3B%5Cu00a00.0001%7D%20and%20in%20total%20events%20%5Brate%20ratio%3A%200.71%20%2895%25%20CI%3A%200.61%5Cu20130.82%29%3B%20P%5Cu00a0%26lt%3B%5Cu00a00.0001%5D.%20These%20benefits%20remained%20significant%20when%20subdivided%20into%20current%20and%20former%20smokers%20%28P%5Cu00a0%3D%5Cu00a00.04%2C%20P%5Cu00a0%3D%5Cu00a00.005%29%2C%20with%20reductions%20in%20the%20key%20secondary%20composite%20endpoint%20%28P%5Cu00a0%26lt%3B%5Cu00a00.0001%29%20and%20in%20the%20individual%20components%20of%20CV%20death%20or%20non-fatal%20MI%20%28P%5Cu00a0%3D%5Cu00a00.04%2C%20P%5Cu00a0%3D%5Cu00a00.01%29%20and%20fatal%20or%20non-fatal%20MI%20%28P%5Cu00a0%3D%5Cu00a00.009%2C%20P%5Cu00a0%3D%5Cu00a00.01%29%2C%20respectively.%20Benefits%20were%20consistent%20and%20significant%20in%20non-smokers%20as%20well.%20Overall%2C%20there%20were%20similar%20estimated%20rates%20of%20first%20occurrences%20of%20primary%20CVD%20endpoints%20in%20current%20smokers%20%2823.8%25%29%20and%20former%20smokers%20%2823.0%25%29%20assigned%20to%20IPE%20compared%20with%20never%20smokers%20on%20placebo%20%2825.7%25%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20REDUCE-IT%2C%20IPE%20treatment%20was%20associated%20with%20a%20reduced%20risk%20of%20CV%20events%20in%20current%20and%20former%20smokers%20to%20levels%20observed%20in%20never%20smokers.%20While%20smoking%20cessation%20should%20always%20be%20recommended%2C%20these%20data%20raise%20the%20possibility%20that%20IPE%20treatment%20may%20attenuate%20CV%20hazards%20attributable%20to%20smoking.%22%2C%22date%22%3A%222023-02-02%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjcvp%5C%2Fpvac045%22%2C%22ISSN%22%3A%222055-6837%2C%202055-6845%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjcvp%5C%2Farticle%5C%2F9%5C%2F2%5C%2F129%5C%2F6661415%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22YVH5CRHI%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baugh%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBaugh%20CW%2C%20Freund%20Y%2C%20Steg%20PG%2C%20Body%20R%2C%20Maron%20DJ%2C%20Yiadom%20MYAB.%202023.%20Strategies%20to%20mitigate%20emergency%20department%20crowding%20and%20its%20impact%20on%20cardiovascular%20patients.%20European%20Heart%20Journal%3A%20Acute%20Cardiovascular%20Care%2012%3A633%26%23x2013%3B643.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Strategies%20to%20mitigate%20emergency%20department%20crowding%20and%20its%20impact%20on%20cardiovascular%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20W%22%2C%22lastName%22%3A%22Baugh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yonathan%22%2C%22lastName%22%3A%22Freund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Body%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J%22%2C%22lastName%22%3A%22Maron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maame%20Yaa%20A%20B%22%2C%22lastName%22%3A%22Yiadom%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Emergency%20department%20%28ED%29%20crowding%20is%20a%20worsening%20global%20problem%20caused%20by%20hospital%20capacity%20and%20other%20health%20system%20challenges.%20While%20patients%20across%20a%20broad%20spectrum%20of%20illnesses%20may%20be%20affected%20by%20crowding%20in%20the%20ED%2C%20patients%20with%20cardiovascular%20emergencies%5Cu2014such%20as%20acute%20coronary%20syndrome%2C%20malignant%20arrhythmias%2C%20pulmonary%20embolism%2C%20acute%20aortic%20syndrome%2C%20and%20cardiac%20tamponade%5Cu2014are%20particularly%20vulnerable.%20Because%20of%20crowding%2C%20patients%20with%20dangerous%20and%20time-sensitive%20conditions%20may%20either%20avoid%20the%20ED%20due%20to%20anticipation%20of%20extended%20waits%2C%20leave%20before%20their%20treatment%20is%20completed%2C%20or%20experience%20delays%20in%20receiving%20care.%20In%20this%20educational%20paper%2C%20we%20present%20the%20underlying%20causes%20of%20crowding%20and%20its%20impact%20on%20common%20cardiovascular%20emergencies%20using%20the%20input%5Cu2013throughput%5Cu2013output%20process%20framework%20for%20patient%20flow.%20In%20addition%2C%20we%20review%20current%20solutions%20and%20potential%20innovations%20to%20mitigate%20the%20negative%20effect%20of%20ED%20crowding%20on%20patient%20outcomes.%22%2C%22date%22%3A%222023-09-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjacc%5C%2Fzuad049%22%2C%22ISSN%22%3A%222048-8726%2C%202048-8734%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjacc%5C%2Farticle%5C%2F12%5C%2F9%5C%2F633%5C%2F7159323%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22F4W9668H%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parker%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EParker%20WAE%2C%20Angiolillo%20DJ%2C%20Rollini%20F%2C%20Franchi%20F%2C%20Bonaca%20MP%2C%20Bhatt%20DL%2C%20Steg%20PhG%2C%20Orme%20RC%2C%20Thomas%20MR%2C%20Judge%20HM%2C%20Sabatine%20MS%2C%20Storey%20RF.%202023.%20Influence%20of%20body%20weight%20and%20body%20mass%20index%20on%20the%20chronic%20pharmacokinetic%20and%20pharmacodynamic%20responses%20to%20clinically%20available%20doses%20of%20ticagrelor%20in%20patients%20with%20chronic%20coronary%20syndromes.%20Vascular%20Pharmacology%20149%3A107145.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20body%20weight%20and%20body%20mass%20index%20on%20the%20chronic%20pharmacokinetic%20and%20pharmacodynamic%20responses%20to%20clinically%20available%20doses%20of%20ticagrelor%20in%20patients%20with%20chronic%20coronary%20syndromes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20A.E.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%20J.%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabiana%22%2C%22lastName%22%3A%22Rollini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Franchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Bonaca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20C.%22%2C%22lastName%22%3A%22Orme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20R.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heather%20M.%22%2C%22lastName%22%3A%22Judge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S.%22%2C%22lastName%22%3A%22Sabatine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.vph.2023.107145%22%2C%22ISSN%22%3A%2215371891%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1537189123000058%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A18%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22ECU59DJU%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abtan%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbtan%20J%2C%20Bhatt%20DL%2C%20Elbez%20Y%2C%20Ducrocq%20G%2C%20Goto%20S%2C%20Smith%20SC%2C%20Ohman%20EM%2C%20Eagle%20KA%2C%20Fox%20K%2C%20Harrington%20RA%2C%20Leiter%20LA%2C%20Mehta%20SR%2C%20Simon%20T%2C%20Petrov%20I%2C%20Sinnaeve%20PR%2C%20Pais%20P%2C%20Lev%20E%2C%20Bueno%20H%2C%20Wilson%20P%2C%20Steg%20PG.%202023.%20External%20applicability%20of%20the%20Effect%20of%20ticagrelor%20on%20Health%20Outcomes%20in%20diabEtes%20Mellitus%20patients%20Intervention%20Study%20%28THEMIS%29%20trial%3A%20An%20analysis%20of%20patients%20with%20diabetes%20and%20coronary%20artery%20disease%20in%20the%20REduction%20of%20Atherothrombosis%20for%20Continued%20Health%20%28REACH%29%20registry.%20International%20Journal%20of%20Cardiology%20370%3A51%26%23x2013%3B57.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22External%20applicability%20of%20the%20Effect%20of%20ticagrelor%20on%20Health%20Outcomes%20in%20diabEtes%20Mellitus%20patients%20Intervention%20Study%20%28THEMIS%29%20trial%3A%20An%20analysis%20of%20patients%20with%20diabetes%20and%20coronary%20artery%20disease%20in%20the%20REduction%20of%20Atherothrombosis%20for%20Continued%20Health%20%28REACH%29%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinya%22%2C%22lastName%22%3A%22Goto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sidney%20C.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Magnus%22%2C%22lastName%22%3A%22Ohman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20A.%22%2C%22lastName%22%3A%22Eagle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%20A.%22%2C%22lastName%22%3A%22Leiter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivo%22%2C%22lastName%22%3A%22Petrov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20R.%22%2C%22lastName%22%3A%22Sinnaeve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prem%22%2C%22lastName%22%3A%22Pais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eli%22%2C%22lastName%22%3A%22Lev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9ctor%22%2C%22lastName%22%3A%22Bueno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2201%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijcard.2022.10.132%22%2C%22ISSN%22%3A%2201675273%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0167527322016436%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A17%3A08Z%22%7D%7D%2C%7B%22key%22%3A%224CDK7QH2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Popovic%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPopovic%20B%2C%20Ducrocq%20G%2C%20Elbez%20Y%2C%20Bode%20C%2C%20Mehta%20ShamirR%2C%20Pollack%20CV%2C%20Sabate%20M%2C%20Rao%20SV%2C%20Parkhomenko%20A%2C%20Feldman%20LJ%2C%20Sayah%20N%2C%20Sabatine%20MS%2C%20Steg%20PG.%202023.%20Clinical%20Significance%20of%20Culprit%20Vessel%20Occlusion%20in%20Patients%20With%20Non%26%23x2013%3BST-Elevation%20Myocardial%20Infarction%20Who%20Underwent%20Percutaneous%20Coronary%20Intervention.%20The%20American%20Journal%20of%20Cardiology%20188%3A95%26%23x2013%3B101.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Significance%20of%20Culprit%20Vessel%20Occlusion%20in%20Patients%20With%20Non%5Cu2013ST-Elevation%20Myocardial%20Infarction%20Who%20Underwent%20Percutaneous%20Coronary%20Intervention%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batric%22%2C%22lastName%22%3A%22Popovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Bode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir.%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20V.%22%2C%22lastName%22%3A%22Pollack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Sabate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunil%20V.%22%2C%22lastName%22%3A%22Rao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20J.%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neila%22%2C%22lastName%22%3A%22Sayah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S.%22%2C%22lastName%22%3A%22Sabatine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.amjcard.2022.11.013%22%2C%22ISSN%22%3A%2200029149%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0002914922012000%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A16%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22GNREKMJU%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carson%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECarson%20JL%2C%20Brooks%20MM%2C%20Chaitman%20BR%2C%20Alexander%20JH%2C%20Goodman%20SG%2C%20Bertolet%20M%2C%20Abbott%20JD%2C%20Cooper%20HA%2C%20Rao%20SV%2C%20Triulzi%20DJ%2C%20Fergusson%20DA%2C%20Kostis%20WJ%2C%20Noveck%20H%2C%20Simon%20T%2C%20Steg%20PG%2C%20DeFilippis%20AP%2C%20Goldsweig%20AM%2C%20Lopes%20RD%2C%20White%20H%2C%20Alsweiler%20C%2C%20Morton%20E%2C%20H%26%23xE9%3Bbert%20PC%2C%20Carson%20JL%2C%20Ghafghazi%20S%2C%20Cooper%20HA%2C%20Wood%20F%2C%20Menegus%20M%2C%20Uretsky%20B%2C%20Vallurupalli%20S%2C%20Maniatis%20G%2C%20Gruberg%20L%2C%20Roswell%20R%2C%20Rossi%20J%2C%20Abtahian%20F%2C%20Tessalee%20M%2C%20Barsness%20G%2C%20Abbott%20JD%2C%20Aronow%20H%2C%20Ramanathan%20K%2C%20Schmidhofer%20M%2C%20Keating%20F%2C%20Carson%20M%2C%20Kontos%20M%2C%20Qureshi%20M%2C%20Clegg%20S%2C%20Laskey%20W%2C%20Polonsky%20T%2C%20Gupta%20R%2C%20Sheikh%20MA%2C%20Uhl%20L%2C%20Mullen%20P%2C%20Bracey%20A%2C%20Matthai%20W%2C%20Stowell%20C%2C%20Dudzinski%20D%2C%20Marhefka%20G%2C%20Weinstock%20P%2C%20Lawson%20W%2C%20Keller%20N%2C%20Yuriditsky%20E%2C%20Thomas%20M%2C%20Jacobs%20A%2C%20Hochberg%20C%2C%20Siddiqi%20O%2C%20Schulman-Marcus%20J%2C%20Torosoff%20M%2C%20Gitter%20M%2C%20Dai%20X%2C%20Traverse%20J%2C%20McCamant%20E%2C%20Scott%20J%2C%20Swaminathan%20R%2C%20Rao%20S%2C%20Goldsweig%20AM%2C%20DeFilippis%20AP%2C%20Salisbury%20A%2C%20Landers%20D%2C%20Raveendran%20G%2C%20Ebrahimi%20R%2C%20Bach%20R%2C%20Delehanty%20J%2C%20Shah%20RC%2C%20Brener%20S%2C%20Doroshow%20J%2C%20Caixeta%20A%2C%20Precoma%20D%2C%20Dall%26%23x2019%3BOrto%20FTC%2C%20De%20Andrade%20PB%2C%20Dracoulakis%20M%2C%20Maia%20LN%2C%20Ritt%20LEF%2C%20Quadros%20A%2C%20Filho%20DCS%2C%20De%20Martino%20F%2C%20Huynh%20T%2C%20Schnell%20G%2C%20Senaratne%20M%2C%20Tandon%20V%2C%20Tandon%20V%2C%20Neary%20J%2C%20Laflamme%20D%2C%20Dery%20J-P%2C%20Bainey%20K%2C%20Haichin%20R%2C%20Dehghani%20P%2C%20Quraishi%20AUR%2C%20Potter%20BJ%2C%20Carrier%20FM%2C%20Goldfarb%20M%2C%20Fordyce%20C%2C%20Sia%20YT%2C%20Daneault%20B%2C%20Madan%20M%2C%20McPherson%20T%2C%20Ducas%20J%2C%20Minhas%20K%2C%20Brass%20N%2C%20Bagai%20A%2C%20Robinson%20S%2C%20D%26%23x17E%3Bav%26%23xED%3Bk%20V%2C%20Khan%20R%2C%20Michaud%20N%2C%20Steg%20G%2C%20Ducrocq%20G%2C%20Puymirat%20E%2C%20Lemesle%20G%2C%20Ferrari%20E%2C%20Lattuca%20B%2C%20Silvain%20J%2C%20Vanzetto%20G%2C%20Cetran%20L%2C%20Lhermusier%20T%2C%20Cottin%20Y%2C%20Rosamel%20Y%2C%20Angoulvant%20D%2C%20Dillinger%20JG%2C%20Thuaire%20C%2C%20Popovic%20B%2C%20Durand%20E%2C%20Bouleti%20C%2C%20Roubille%20F%2C%20Delorme%20L%2C%20Crozier%20I%2C%20Benatar%20J%2C%20Nandra%20S%2C%20Ternouth%20I%2C%20Fisher%20N%2C%20Brieger%20D%2C%20Hillis%20G.%202023.%20Rationale%20and%20design%20for%20the%20myocardial%20ischemia%20and%20transfusion%20%28MINT%29%20randomized%20clinical%20trial.%20American%20Heart%20Journal%20257%3A120%26%23x2013%3B129.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rationale%20and%20design%20for%20the%20myocardial%20ischemia%20and%20transfusion%20%28MINT%29%20randomized%20clinical%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20L.%22%2C%22lastName%22%3A%22Carson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Mori%22%2C%22lastName%22%3A%22Brooks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%20R.%22%2C%22lastName%22%3A%22Chaitman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20H.%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marnie%22%2C%22lastName%22%3A%22Bertolet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Dawn%22%2C%22lastName%22%3A%22Abbott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Howard%20A.%22%2C%22lastName%22%3A%22Cooper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunil%20V.%22%2C%22lastName%22%3A%22Rao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darrell%20J.%22%2C%22lastName%22%3A%22Triulzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dean%20A.%22%2C%22lastName%22%3A%22Fergusson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20J.%22%2C%22lastName%22%3A%22Kostis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helaine%22%2C%22lastName%22%3A%22Noveck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20P.%22%2C%22lastName%22%3A%22DeFilippis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20M.%22%2C%22lastName%22%3A%22Goldsweig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Alsweiler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erin%22%2C%22lastName%22%3A%22Morton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20C.%22%2C%22lastName%22%3A%22H%5Cu00e9bert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20L.%22%2C%22lastName%22%3A%22Carson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahab%22%2C%22lastName%22%3A%22Ghafghazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Howard%20A.%22%2C%22lastName%22%3A%22Cooper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frances%22%2C%22lastName%22%3A%22Wood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Menegus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%22%2C%22lastName%22%3A%22Uretsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srikanth%22%2C%22lastName%22%3A%22Vallurupalli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Maniatis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Gruberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Roswell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farhad%22%2C%22lastName%22%3A%22Abtahian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meechai%22%2C%22lastName%22%3A%22Tessalee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Barsness%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Dawn%22%2C%22lastName%22%3A%22Abbott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herbert%22%2C%22lastName%22%3A%22Aronow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kodangudi%22%2C%22lastName%22%3A%22Ramanathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Schmidhofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Friederike%22%2C%22lastName%22%3A%22Keating%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Carson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Kontos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mansoor%22%2C%22lastName%22%3A%22Qureshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stacey%22%2C%22lastName%22%3A%22Clegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Warren%22%2C%22lastName%22%3A%22Laskey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamar%22%2C%22lastName%22%3A%22Polonsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mujeeb%20Abdul%22%2C%22lastName%22%3A%22Sheikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lynne%22%2C%22lastName%22%3A%22Uhl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Mullen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Bracey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Matthai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Stowell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Dudzinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregary%22%2C%22lastName%22%3A%22Marhefka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perry%22%2C%22lastName%22%3A%22Weinstock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Lawson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norma%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Yuriditsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Hochberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%22%2C%22lastName%22%3A%22Siddiqi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%22%2C%22lastName%22%3A%22Schulman-Marcus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikhail%22%2C%22lastName%22%3A%22Torosoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Gitter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xuming%22%2C%22lastName%22%3A%22Dai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%22%2C%22lastName%22%3A%22Traverse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22McCamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Swaminathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunil%22%2C%22lastName%22%3A%22Rao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20M.%22%2C%22lastName%22%3A%22Goldsweig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20P.%22%2C%22lastName%22%3A%22DeFilippis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Salisbury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Landers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ganesh%22%2C%22lastName%22%3A%22Raveendran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramin%22%2C%22lastName%22%3A%22Ebrahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Bach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Delehanty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raj%20C.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sorin%22%2C%22lastName%22%3A%22Brener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Doroshow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriano%22%2C%22lastName%22%3A%22Caixeta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalton%22%2C%22lastName%22%3A%22Precoma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederico%20Toledo%20Campo%22%2C%22lastName%22%3A%22Dall%27Orto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20Beraldo%22%2C%22lastName%22%3A%22De%20Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianna%22%2C%22lastName%22%3A%22Dracoulakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00edlia%20Nigro%22%2C%22lastName%22%3A%22Maia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luiz%20Eduardo%20Fontelles%22%2C%22lastName%22%3A%22Ritt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Quadros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%5Cu00e1rio%20Celestino%20Sobral%22%2C%22lastName%22%3A%22Filho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22De%20Martino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thao%22%2C%22lastName%22%3A%22Huynh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Schnell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manohara%22%2C%22lastName%22%3A%22Senaratne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vikas%22%2C%22lastName%22%3A%22Tandon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vikas%22%2C%22lastName%22%3A%22Tandon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Neary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laflamme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Dery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Bainey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Haichin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Payam%22%2C%22lastName%22%3A%22Dehghani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ata%20Ur%20Rehman%22%2C%22lastName%22%3A%22Quraishi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20J.%22%2C%22lastName%22%3A%22Potter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%20Martin%22%2C%22lastName%22%3A%22Carrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Goldfarb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Fordyce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ying%20Tung%22%2C%22lastName%22%3A%22Sia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Daneault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mina%22%2C%22lastName%22%3A%22Madan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%22%2C%22lastName%22%3A%22McPherson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Ducas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kunal%22%2C%22lastName%22%3A%22Minhas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%22%2C%22lastName%22%3A%22Brass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akshay%22%2C%22lastName%22%3A%22Bagai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Robinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladim%5Cu00edr%22%2C%22lastName%22%3A%22D%5Cu017eav%5Cu00edk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Razi%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Michaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emile%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Lattuca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanne%22%2C%22lastName%22%3A%22Silvain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rald%22%2C%22lastName%22%3A%22Vanzetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Cetran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Lhermusier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Rosamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Angoulvant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Guillaume%22%2C%22lastName%22%3A%22Dillinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Thuaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batric%22%2C%22lastName%22%3A%22Popovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Durand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Bouleti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Roubille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Delorme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Crozier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jocelyne%22%2C%22lastName%22%3A%22Benatar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samraj%22%2C%22lastName%22%3A%22Nandra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ternouth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nick%22%2C%22lastName%22%3A%22Fisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brieger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Hillis%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2203%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ahj.2022.11.015%22%2C%22ISSN%22%3A%2200028703%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0002870322002976%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A15%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22B28SR27Y%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Belhassen%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBelhassen%20M%2C%20Hanon%20O%2C%20Steg%20PG%2C%20Mah%26%23xE9%3B%20I%2C%20N%26%23xE9%3Be%20M%2C%20Jacoud%20F%2C%20Dalon%20F%2C%20Cott%26%23xE9%3B%20F-E%2C%20Guitard-Dehoux%20D%2C%20Marant-Micallef%20C%2C%20Van%20Ganse%20E%2C%20Danchin%20N.%202023.%20Apixaban%20versus%20other%20anticoagulants%20in%20patients%20with%20nonvalvular%20fibrillation%3A%20a%20comparison%20of%20all-cause%20and%20event-related%20costs%20in%20real-life%20setting%20in%20France.%20Eur%20J%20Health%20Econ%2024%3A867%26%23x2013%3B875.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Apixaban%20versus%20other%20anticoagulants%20in%20patients%20with%20nonvalvular%20fibrillation%3A%20a%20comparison%20of%20all-cause%20and%20event-related%20costs%20in%20real-life%20setting%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Belhassen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Hanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Mah%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22N%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flore%22%2C%22lastName%22%3A%22Jacoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faustine%22%2C%22lastName%22%3A%22Dalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Emery%22%2C%22lastName%22%3A%22Cott%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Guitard-Dehoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Marant-Micallef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Van%20Ganse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Objectives%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Compare%20costs%20associated%20with%20all-cause%20healthcare%20resource%20use%20%28HCRU%29%2C%20stroke%5C%2Fsystemic%20thromboembolism%20%28STE%29%20and%20major%20bleedings%20%28MB%29%20between%20patients%20with%20non-valvular%20atrial%20fibrillation%20%28NVAF%29%20initiating%20apixaban%20or%20other%20oral%20anticoagulants%20%28OACs%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20performed%20a%20retrospective%20cohort%20study%20using%20the%20French%20healthcare%20claims%20database%2C%20including%20NVAF%20patients%20between%202014%5C%2F01%5C%2F01%20and%202016%5C%2F12%5C%2F31%2C%20followed%20until%202016%5C%2F12%5C%2F31.%20We%20used%204%20sub-cohorts%20of%20OAC-naive%20patients%2C%20respectively%20initiating%20apixaban%2C%20dabigatran%2C%20rivaroxaban%20or%20VKAs.%20We%20matched%20patients%20initiating%20apixaban%20with%20patients%20initiating%20each%20other%20OACs%20using%201%3An%20propensity%20score%20matching.%20All-cause%20HCRU%20and%20event-related%20costs%20by%20OAC%20treatment%20were%20estimated%20and%20compared%20between%20matched%20patients%20using%20generalised-linear%20models%20with%20gamma-distribution%20and%20two-part%20models.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20There%20were%20175%2C766%20patients%20in%20the%20apixaban%5Cu2013VKA%2C%20181%2C809%20in%20the%20apixaban%5Cu2013rivaroxaban%2C%20and%2042%2C490%20in%20the%20apixaban%5Cu2013dabigatran%20matched%20cohorts.%20Patients%20initiating%20apixaban%20had%20significantly%20lower%20HCRU%20costs%20than%20patients%20initiating%20VKA%20%28%5Cu20ac1%2C105%20vs.%20%5Cu20ac1%2C578%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3C%5Cu20090.0001%29%2C%20dabigatran%20%28%5Cu20ac993%20vs.%20%5Cu20ac1%2C140%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3C%5Cu20090.0001%29%20and%20rivaroxaban%20%28%5Cu20ac1%2C013%20vs.%20%5Cu20ac1%2C088%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3C%5Cu20090.0001%29.%20They%20have%20had%20significantly%20lower%20costs%20related%20to%20stroke%5C%2FSTE%20and%20MB%20than%20patients%20initiating%20VKA%20%28respectively%2C%20%5Cu20ac183%20vs.%20%5Cu20ac449%20and%20%5Cu20ac147%20vs.%20%5Cu20ac413%3B%20p%5Cu2009%3C%5Cu20090.0001%29%2C%20rivaroxaban%20%28respectively%2C%20%5Cu20ac145%20vs.%20%5Cu20ac197%20and%20%5Cu20ac129%20vs.%20%5Cu20ac193%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3C%5Cu20090.0001%29%2C%20and%20lower%20costs%20related%20to%20stroke%5C%2FSTE%20than%20patients%20initiating%20dabigatran%20%28%5Cu20ac135%20vs.%20%5Cu20ac192%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3C%5Cu20090.02%29.%20Costs%20related%20to%20MB%20were%20not%20significantly%20different%20in%20patients%20initiating%20apixaban%20and%20those%20initiating%20dabigatran%20%28%5Cu20ac119%20vs.%20%5Cu20ac149%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3D%5Cu20090.07%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20HCRU%20and%20most%20event-related%20costs%20were%20lower%20in%20patients%20initiating%20apixaban%20compared%20to%20other%20OACs.%20Apixaban%20may%20be%20cost-saving%20compared%20to%20VKAs%2C%20and%20significantly%20cheaper%20than%20other%20DOACs%2C%20although%20cost%20differences%20are%20limited.%22%2C%22date%22%3A%2208%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10198-022-01513-2%22%2C%22ISSN%22%3A%221618-7598%2C%201618-7601%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flink.springer.com%5C%2F10.1007%5C%2Fs10198-022-01513-2%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A15%3A14Z%22%7D%7D%5D%7D1.Clapp L, Giembycz M, Heinemann A, Jones RL, Narumiya S, Norel X, Sugimoto Y, Woodward DF, Yao C. 2023. Prostanoid receptors in GtoPdb v.2023.1. GtoPdb CITE 2023.1.Mimouni M, Bulsei J, Darlington M, Estellat C, Rouzet F, Hyafil F, Durand-Zaleski I, the RUBIS Trial Group, Chequer R, Ducrocq G, Alfaiate T, Regaieg H, Abtan J, Leygnac S, Milliner M, Burg S, Azzouna RB, Potier L, Laouénan C, Quintin C, Roussel R, Steg G, Le Guludec D, Sorbets E, Imbert L, Marie P-Y, Hartemann A, Montalescot G. 2023. Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease. EJNMMI Res 13:9.1.Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG, for the ODYSSEY OUTCOMES Investigators. 2023. Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial. JAHA 12:e029216.1.Marquis‐Gravel G, Boivin‐Proulx L, Huang Z, Zelenkofske SL, Lincoff AM, Mehran R, Steg PG, Bode C, Alexander JH, Povsic TJ. 2023. Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention. JAHA 12:e025666.1.Olshansky B, Bhatt DL, Miller M, Steg PhG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Kowey PR, Reiffel JA, Tardif J, Ballantyne CM, Chung MK, the REDUCE‐IT Investigators. 2023. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT. JAHA 12:e026756.1.Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg PG, Stables RH, Mehran R, James SK, Frigoli E, Goldstein P, Li Y, Shahzad A, Schüpke S, Mehdipoor G, Chen S, Redfors B, Crowley A, Zhou Z, Stone GW. 2023. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. Circulation 148:1207–1219.1.Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O’Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracoń R, López-Sendón J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ, Hochman JS, Maron DJ, Reynolds HR, Bangalore S, Mavromichalis S, Chang M, Contreras A, Esquenazi-Karonika S, Gilsenan M, Gwiszcz E, Mathews P, Mohamed S, Naumova A, Roberts A, VanLoo K, Anthopolos R, Xu Y, Troxel AB, Lu Y, Huang Z, Broderick S, Guzmán L, Selvanayagam J, Lopes RD, Goodman SG, Steg G, Juliard J-M, Doerr R, Keltai M, Bhargava B, Thomas B, Sharir T, Nikolsky E, Maggioni AP, Kohsaka S, Escobedo J, White HD, Pracoń R, Bockeria O, López-Sendón J, Held C, Senior R, Banfield A, Shaw LJ, Phillips L, Berman D, Kwong RY, Picard MH, Chaitman BR, Ali Z, Min J, Mancini GBJ, Leipsic J, Guzmán L, Hillis G, Thambar S, Joseph M, Selvanayagam J, Beltrame J, Lang I, Schuchlenz H, Huber K, Goetschalckx K, Hueb W, Caramori PR, De Quadros A, Smanio P, Mesquita C, Lopes RD, Vitola J, Marin-Neto J, Da Silva ER, Tumelero R, Andrade M, Alves AR, Dall’Orto F, Polanczyk C, Figueiredo E, Howarth A, Gosselin G, Cheema A, Bainey K, Phaneuf D, Diaz A, Garg P, Mehta S, Wong G, Lam A, Cha J, Galiwango P, Uxa A, Chow B (Ben), Hameed A, Udell J, Cheema A, Hamid M, Hauguel-Moreau M, Furber A, Goube P, Steg P-G, Barone-Rochette G, Thuaire C, Slama M, Doerr R, Nickenig G, Bekeredjian R, Schulze PC, Merkely B, Fontos G, Vértes A, Varga A, Bhargava B, Kumar A, Nair RG, Grant P, Manjunath C, Moorthy N, Satheesh S, Nath RK, Wander G, Christopher J, Dwivedi S, Oomman A, Mathur A, Gadkari M, Naik S, Punnoose E, Kachru R, Christopher J, Kaul U, Sharir T, Kerner A, Tarantini G, Perna GP, Racca E, Mortara A, Monti L, Briguori C, Leone G, Amati R, Salvatori M, Di Chiara A, Calabro P, Galvani M, Provasoli S, Fukuda K, Kohsaka S, Nakano S, Laucevicius A, Kedev S, Khairuddin A, Escobedo J, Riezebos R, Timmer J, Heald S, Stewart R, Ramos WM, Demkow M, Mazurek T, Drozdz J, Szwed H, Witkowski A, Ferreira N, Pinto F, Ramos R, Popescu B, Pop C, Bockeria L, Bockeria O, Demchenko E, Romanov A, Bershtein L, Jizeeri A, Stankovic G, Apostolovic S, Adjic NC, Zdravkovic M, Beleslin B, Dekleva M, Davidovic G, Chua T, Foo D, Poh KK, Ntsekhe M, Sionis A, Marin F, Miró V, López-Sendón J, Blancas MG, González-Juanatey J, Fernández-Avilés F, Peteiro J, Luena JEC, Held C, Aspberg J, Rossi M, Kuanprasert S, Yamwong S, Johnston N, Donnelly P, Moriarty A, Senior R, Elghamaz A, Gurunathan S, Karogiannis N, Shah BN, Trimlett RHJ, Rubens MB, Nicol ED, Mittal TK, Hampson R, Gamma R, De Belder M, Nageh T, Lindsay S, Mavromatis K, Miller T, Banerjee S, Reynolds H, Nour K, Stone P. 2023. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation 147:8–19.1.Steg PG, Kikoïne J. 2023. Do We Need Ischemia Testing to Monitor Asymptomatic Patients With Chronic Coronary Syndromes? Circulation 147:5–7.1.Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, Siaha FN, Gallet R, Khalife K, Morelle J-F, Motreff P, Lemesle G, Dillinger J-G, Lhermusier T, Silvain J, Roule V, Labèque J-N, Rangé G, Ducrocq G, Cottin Y, Blanchard D, Nelson AC, Djadi-Prat J, Chatellier G, Danchin N, the FLOWER-MI study investigators. 2023. Three-year outcomes with fractional flow reserve- or angiography-guided multivessel percutaneous coronary intervention for myocardial infarction. preprint. Cardiovascular Medicine.1.Vidal-Petiot E, Elbez Y, Mesnier J, Ducrocq G, Ford I, Tendera M, Ferrari R, Tardif J-C, Fox KM, Steg PG. 2023. Optimal or standard control of systolic and diastolic blood pressure across risk factor categories in patients with chronic coronary syndromes. European Journal of Preventive Cardiology 30:935–947.1.Costa F, Montalto C, Branca M, Hong S-J, Watanabe H, Franzone A, Vranckx P, Hahn J-Y, Gwon H-C, Feres F, Jang Y, De Luca G, Kedhi E, Cao D, Steg PG, Bhatt DL, Stone GW, Micari A, Windecker S, Kimura T, Hong M-K, Mehran R, Valgimigli M. 2023. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. European Heart Journal 44:954–968.1.Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, Connolly S, Lonn E, Dagenais GR, Branch KRH, Wang W-J, Bhatt DL, Probstfield J, Ertl G, Störk S, Steg PG, Aboyans V, Durand-Zaleski I, Ryden L, Yusuf S. 2023. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes 9:502–510.1.Durand-Zaleski I, Ducrocq G, Mimouni M, Frenkiel J, Avendano-Solá C, Gonzalez-Juanatey JR, Ferrari E, Lemesle G, Puymirat E, Berard L, Cachanado M, Arnaiz JA, Martínez-Sellés M, Silvain J, Ariza-Solé A, Calvo G, Danchin N, Paco S, Drouet E, Abergel H, Rousseau A, Simon T, Steg PG. 2023. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost–effectiveness and cost–utility analyses. European Heart Journal - Quality of Care and Clinical Outcomes 9:194–202.1.Miller M, Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Ballantyne CM, Budoff M, Mason RP. 2023. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. European Heart Journal - Cardiovascular Pharmacotherapy 9:129–137.1.Baugh CW, Freund Y, Steg PG, Body R, Maron DJ, Yiadom MYAB. 2023. Strategies to mitigate emergency department crowding and its impact on cardiovascular patients. European Heart Journal: Acute Cardiovascular Care 12:633–643.1.Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PhG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF. 2023. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology 149:107145.1.Abtan J, Bhatt DL, Elbez Y, Ducrocq G, Goto S, Smith SC, Ohman EM, Eagle KA, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Petrov I, Sinnaeve PR, Pais P, Lev E, Bueno H, Wilson P, Steg PG. 2023. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. International Journal of Cardiology 370:51–57.1.Popovic B, Ducrocq G, Elbez Y, Bode C, Mehta ShamirR, Pollack CV, Sabate M, Rao SV, Parkhomenko A, Feldman LJ, Sayah N, Sabatine MS, Steg PG. 2023. Clinical Significance of Culprit Vessel Occlusion in Patients With Non–ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. The American Journal of Cardiology 188:95–101.1.Carson JL, Brooks MM, Chaitman BR, Alexander JH, Goodman SG, Bertolet M, Abbott JD, Cooper HA, Rao SV, Triulzi DJ, Fergusson DA, Kostis WJ, Noveck H, Simon T, Steg PG, DeFilippis AP, Goldsweig AM, Lopes RD, White H, Alsweiler C, Morton E, Hébert PC, Carson JL, Ghafghazi S, Cooper HA, Wood F, Menegus M, Uretsky B, Vallurupalli S, Maniatis G, Gruberg L, Roswell R, Rossi J, Abtahian F, Tessalee M, Barsness G, Abbott JD, Aronow H, Ramanathan K, Schmidhofer M, Keating F, Carson M, Kontos M, Qureshi M, Clegg S, Laskey W, Polonsky T, Gupta R, Sheikh MA, Uhl L, Mullen P, Bracey A, Matthai W, Stowell C, Dudzinski D, Marhefka G, Weinstock P, Lawson W, Keller N, Yuriditsky E, Thomas M, Jacobs A, Hochberg C, Siddiqi O, Schulman-Marcus J, Torosoff M, Gitter M, Dai X, Traverse J, McCamant E, Scott J, Swaminathan R, Rao S, Goldsweig AM, DeFilippis AP, Salisbury A, Landers D, Raveendran G, Ebrahimi R, Bach R, Delehanty J, Shah RC, Brener S, Doroshow J, Caixeta A, Precoma D, Dall’Orto FTC, De Andrade PB, Dracoulakis M, Maia LN, Ritt LEF, Quadros A, Filho DCS, De Martino F, Huynh T, Schnell G, Senaratne M, Tandon V, Tandon V, Neary J, Laflamme D, Dery J-P, Bainey K, Haichin R, Dehghani P, Quraishi AUR, Potter BJ, Carrier FM, Goldfarb M, Fordyce C, Sia YT, Daneault B, Madan M, McPherson T, Ducas J, Minhas K, Brass N, Bagai A, Robinson S, Džavík V, Khan R, Michaud N, Steg G, Ducrocq G, Puymirat E, Lemesle G, Ferrari E, Lattuca B, Silvain J, Vanzetto G, Cetran L, Lhermusier T, Cottin Y, Rosamel Y, Angoulvant D, Dillinger JG, Thuaire C, Popovic B, Durand E, Bouleti C, Roubille F, Delorme L, Crozier I, Benatar J, Nandra S, Ternouth I, Fisher N, Brieger D, Hillis G. 2023. Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial. American Heart Journal 257:120–129.1.Belhassen M, Hanon O, Steg PG, Mahé I, Née M, Jacoud F, Dalon F, Cotté F-E, Guitard-Dehoux D, Marant-Micallef C, Van Ganse E, Danchin N. 2023. Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. Eur J Health Econ 24:867–875.2460799 5BTMJQCK 2022 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/2460799 5BTMJQCK 2021 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/2460799 5BTMJQCK 2020 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-b18ed34d0e5e33e54ecb5b4d081c4c13%22%2C%22meta%22%3A%7B%22request_last%22%3A100%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22K6VX3AQX%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Franzone%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFranzone%20A%2C%20McFadden%20EP%2C%20Leonardi%20S%2C%20Piccolo%20R%2C%20Vranckx%20P%2C%20Serruys%20PW%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Heg%20D%2C%20Branca%20M%2C%20J%26%23xFC%3Bni%20P%2C%20Windecker%20S%2C%20Valgimigli%20M.%202020.%20Ticagrelor%20alone%20or%20conventional%20dual%20antiplatelet%20therapy%20in%20patients%20with%20stable%20or%20acute%20coronary%20syndromes.%20EuroIntervention%2016%3A627%26%23x2013%3B633.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ticagrelor%20alone%20or%20conventional%20dual%20antiplatelet%20therapy%20in%20patients%20with%20stable%20or%20acute%20coronary%20syndromes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Franzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%20P.%22%2C%22lastName%22%3A%22McFadden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Leonardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22Piccolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dik%22%2C%22lastName%22%3A%22Heg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mattia%22%2C%22lastName%22%3A%22Branca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2020%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4244%5C%2FEIJ-D-20-00145%22%2C%22ISSN%22%3A%221774-024X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Feurointervention.pcronline.com%5C%2Fdoi%5C%2F10.4244%5C%2FEIJ-D-20-00145%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22CRFLGS73%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tomaniak%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ETomaniak%20M%2C%20Chichareon%20P%2C%20Modolo%20R%2C%20Takahashi%20K%2C%20Chang%20CC%2C%20Kogame%20N%2C%20Spitzer%20E%2C%20Buszman%20PE%2C%20Van%20Geuns%20R-JM%2C%20Valkov%20V%2C%20Steinwender%20C%2C%20Geisler%20T%2C%20Prokopczuk%20J%2C%20Sabat%26%23xE9%3B%20M%2C%20Zmudka%20K%2C%20Rademaker-Havinga%20T%2C%20Tijssen%20JGP%2C%20J%26%23xFC%3Bni%20P%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Onuma%20Y%2C%20Vranckx%20P%2C%20Valgimigli%20M%2C%20Windecker%20S%2C%20Baber%20U%2C%20Anderson%20R%2C%20Dominici%20M%2C%20Serruys%20PW.%202020.%20Ticagrelor%20monotherapy%20beyond%20one%20month%20after%20PCI%20in%20ACS%20or%20stable%20CAD%20in%20elderly%20patients%3A%20a%20pre-specified%20analysis%20of%20the%20GLOBAL%20LEADERS%20trial.%20EuroIntervention%2015%3Ae1605%26%23x2013%3Be1614.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ticagrelor%20monotherapy%20beyond%20one%20month%20after%20PCI%20in%20ACS%20or%20stable%20CAD%20in%20elderly%20patients%3A%20a%20pre-specified%20analysis%20of%20the%20GLOBAL%20LEADERS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Chin%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Spitzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pawel%20E.%22%2C%22lastName%22%3A%22Buszman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert-Jan%20M.%22%2C%22lastName%22%3A%22Van%20Geuns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veselin%22%2C%22lastName%22%3A%22Valkov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemens%22%2C%22lastName%22%3A%22Steinwender%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Geisler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janusz%22%2C%22lastName%22%3A%22Prokopczuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Sabat%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krzysztof%22%2C%22lastName%22%3A%22Zmudka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tessa%22%2C%22lastName%22%3A%22Rademaker-Havinga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20G.P.%22%2C%22lastName%22%3A%22Tijssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcello%22%2C%22lastName%22%3A%22Dominici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4244%5C%2FEIJ-D-19-00699%22%2C%22ISSN%22%3A%221969-6213%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Feurointervention.pcronline.com%5C%2Fdoi%5C%2F10.4244%5C%2FEIJ-D-19-00699%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22XX9LFNZU%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Takahashi%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ETakahashi%20K%2C%20Chichareon%20P%2C%20Modolo%20R%2C%20Kogame%20N%2C%20Chang%20CC%2C%20Tomaniak%20M%2C%20Moschovitis%20A%2C%20Curzen%20N%2C%20Haude%20M%2C%20Jung%20W%2C%20Holmvang%20L%2C%20Garg%20S%2C%20Tijssen%20JGP%2C%20Wykrzykowska%20JJ%2C%20De%20Winter%20RJ%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Stoll%20H-P%2C%20Onuma%20Y%2C%20Valgimigli%20M%2C%20Vranckx%20P%2C%20Windecker%20S%2C%20Serruys%20PW.%202020.%20Impact%20of%20ticagrelor%20monotherapy%20on%20two-year%20clinical%20outcomes%20in%20patients%20with%20long%20stenting%3A%20a%20post%20hoc%20analysis%20of%20the%20GLOBAL%20LEADERS%20trial.%20EuroIntervention%2016%3A634%26%23x2013%3B644.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20ticagrelor%20monotherapy%20on%20two-year%20clinical%20outcomes%20in%20patients%20with%20long%20stenting%3A%20a%20post%20hoc%20analysis%20of%20the%20GLOBAL%20LEADERS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Chin%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aris%22%2C%22lastName%22%3A%22Moschovitis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nick%22%2C%22lastName%22%3A%22Curzen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Haude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Werner%22%2C%22lastName%22%3A%22Jung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lene%22%2C%22lastName%22%3A%22Holmvang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20G.P.%22%2C%22lastName%22%3A%22Tijssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20J.%22%2C%22lastName%22%3A%22Wykrzykowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robbert%20J.%22%2C%22lastName%22%3A%22De%20Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Peter%22%2C%22lastName%22%3A%22Stoll%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2020%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4244%5C%2FEIJ-D-19-00498%22%2C%22ISSN%22%3A%221774-024X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Feurointervention.pcronline.com%5C%2Fdoi%5C%2F10.4244%5C%2FEIJ-D-19-00498%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22XMV2NXCH%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Meseguer%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-13%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMeseguer%20E%2C%20Diallo%20D%2C%20Labreuche%20J%2C%20Charles%20H%2C%20Delbosc%20S%2C%20Mangin%20G%2C%20Monteiro%20Tavares%20L%2C%20Caligiuri%20G%2C%20Nicoletti%20A%2C%20Amarenco%20P.%202020.%20Osteopontin%20Predicts%20Three-Month%20Outcome%20in%20Stroke%20Patients%20Treated%20by%20Reperfusion%20Therapies.%20JCM%209%3A4028.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Osteopontin%20Predicts%20Three-Month%20Outcome%20in%20Stroke%20Patients%20Treated%20by%20Reperfusion%20Therapies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Devy%22%2C%22lastName%22%3A%22Diallo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Charles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Delbosc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%22%2C%22lastName%22%3A%22Mangin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linsay%22%2C%22lastName%22%3A%22Monteiro%20Tavares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppina%22%2C%22lastName%22%3A%22Caligiuri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonino%22%2C%22lastName%22%3A%22Nicoletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Establishing%20a%20prognosis%20at%20hospital%20admission%20after%20stroke%20is%20a%20major%20challenge.%20Inflammatory%20processes%2C%20hemostasis%2C%20vascular%20injury%2C%20and%20tissue%20remodeling%20are%20all%20involved%20in%20the%20early%20response%20to%20stroke.%20This%20study%20analyzes%20whether%2022%20selected%20biomarkers%2C%20sampled%20at%20admission%2C%20predict%20clinical%20outcomes%20in%20153%20stroke%20patients%20treated%20by%20thrombolysis%20and%20mechanical%20endovascular%20treatment%20%28MET%29.%20Biomarkers%20were%20related%20to%20hemostasis%20%28u-plasminogen%20activator%5C%2Furokinase%20%28uPA%5C%2Furokinase%29%2C%20serpin%20E1%5C%2FPAI-1%2C%20serpin%20C1%5C%2Fantithrombin-III%2C%20kallikrein%206%5C%2Fneurosin%2C%20alpha%202-macroglobulin%29%2C%20inflammation%5Bmyloperoxidase%20%28MPO%29%2C%20chemokine%20ligand%202%5C%2Fmonocyte%20chemoattractant%20protein-1%20chemokine%20%28CCL2%5C%2FMCP-1%29%2C%20adiponectin%2C%20resistin%2C%20cell-free%20DNA%20%28cDNA%29%2C%20CD40%20Ligand%20%28CD40L%29%5D%2C%20endothelium%20activation%20%28Vascular%20cell%20adhesion%20protein%201%20%28VCAM-1%29%20intercellular%20adhesion%20molecule%201%20%28ICAM-1%29%2C%20platelet%20endothelial%20cell%20adhesion%20molecule%201%20%28CD31%5C%2FPECAM-1%29%5D%2C%20and%20tissue%20remodeling%20%28total%20cathepsin%20S%2C%20osteopontin%2C%20cystatin%20C%2C%20neuropilin-1%2C%20matrix%20metallopeptidase%202%20%28MMP-2%29%2C%20matrix%20metallopeptidase%203%20%28MMP-3%29%2C%20matrix%20metallopeptidase%209%20%28MMP-9%29%2C%20matrix%20metallopeptidase%2013%20%28MMP-13%29%5D.%20Correlations%20between%20their%20levels%20and%20excellent%20neurological%20improvement%20%28ENI%29%20at%2024%20h%20and%20good%20outcomes%20%28mRS%200%5Cu20132%29%20at%20three%20months%20were%20tested.%20Osteopontin%20and%20favorable%20outcomes%20reached%20the%20significance%20level%20%28p%20%3D%200.008%29%3B%20the%20adjusted%20OR%20per%20SD%20increase%20in%20log-transformed%20osteopontin%20was%200.34%20%2895%25CI%2C%200.18%5Cu20130.62%29.%20The%20relationship%20between%20total%20cathepsin%20S%20and%20MPO%20with%20ENI%2C%20was%20borderline%20of%20significance%20%28p%20%3D%200.064%29%3B%20the%20adjusted%20OR%20per%20SD%20increase%20in%20log-transformed%20of%20total%20cathepsin%20S%20and%20MPO%20was%200.54%20%2895%25CI%2C%200.35%5Cu20130.81%29%20and%200.51%20%2895%25CI%2C%200.32%5Cu20130.80%29%2C%20respectively.%20In%20conclusion%2C%20osteopontin%20levels%20predicted%20three-month%20favorable%20outcomes%2C%20supporting%20the%20use%20of%20this%20biomarker%20as%20a%20complement%20of%20clinical%20and%20radiological%20parameters%20for%20predicting%20stroke%20prognosis.%22%2C%22date%22%3A%222020-12-13%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fjcm9124028%22%2C%22ISSN%22%3A%222077-0383%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2077-0383%5C%2F9%5C%2F12%5C%2F4028%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A45Z%22%7D%7D%2C%7B%22key%22%3A%2232IC2QVU%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Varela%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVarela%20LM%2C%20Meseguer%20E%2C%20Lapergue%20B%2C%20Couret%20D%2C%20Amarenco%20P%2C%20Meilhac%20O.%202020.%20Changes%20in%20High-Density%20Lipoproteins%20Related%20to%20Outcomes%20in%20Patients%20with%20Acute%20Stroke.%20JCM%209%3A2269.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Changes%20in%20High-Density%20Lipoproteins%20Related%20to%20Outcomes%20in%20Patients%20with%20Acute%20Stroke%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lourdes%20M.%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Lapergue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Couret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Meilhac%22%7D%5D%2C%22abstractNote%22%3A%22Modifications%20in%20high-density%20lipoprotein%20%28HDL%29%20particle%20sizes%20and%20HDL-binding%20proteins%20have%20been%20reported%20in%20stroke%20patients.%20We%20evaluated%20whether%20the%20lipoprotein%20profile%2C%20HDL%20composition%20and%20functionality%20were%20altered%20in%20stroke%20patients%20according%20to%20their%20clinical%20outcome%20using%20the%20modified%20Rankin%20Score%20at%203%20months.%20Plasma%20samples%20were%20obtained%20from%20stroke%20patients%20treated%20with%20intravenous%20thrombolysis.%20Levels%20of%20cardiovascular%20and%20inflammatory%20markers%20in%20plasma%20were%20measured%20using%20the%20Human%20CVD%20Panel%201%20%28Milliplex%5Cu00ae%20MAP%29.%20Lipoprotein%20subfractions%20from%20plasma%20were%20quantified%20by%20non-denaturing%20acrylamide%20gel%20electrophoresis%2C%20using%20the%20Lipoprint%5Cu00ae-System%20%28Quantimetrix%5Cu00ae%29%2C%20and%20HDLs%20were%20isolated%20by%20ultracentrifugation.%20Relative%20amounts%20of%20paraoxonase-1%20%28PON1%29%20and%20alpha-1%20anti-trypsin%20%28AAT%29%20in%20the%20isolated%20HDLs%20were%20determined%20by%20Western%20blot.%20HDL%20anti-inflammatory%20function%20was%20evaluated%20in%20human%20blood%5Cu2013brain%20barrier%20endothelial%20cells%20stimulated%20with%20100%20ng%5C%2FmL%20TNF%5Cu03b1%2C%20and%20HDL%20antioxidant%20function%20was%20evaluated%20via%20their%20capacity%20to%20limit%20copper-induced%20low-density%20lipoprotein%20oxidation.%20Stroke%20patients%20with%20unfavorable%20outcomes%20had%20a%20lower%20proportion%20of%20small-sized%20HDLs%20and%20increased%20plasma%20levels%20of%20E-selectin%20%28SELE%29%20and%20the%20intercellular%20adhesion%20molecule%201%20%28ICAM1%29.%20HDLs%20from%20patients%20with%20unfavorable%20outcomes%20had%20lower%20levels%20of%20PON1%20and%20displayed%20a%20blunted%20capacity%20to%20reduce%20the%20expression%20of%20SELE%2C%20interleukin%208%20%28IL8%29%20and%20the%20monocyte%20chemoattractant%20protein-1%20%28MCP1%29%20mRNA%20induced%20by%20TNF%5Cu03b1%20in%20endothelial%20cells.%20These%20HDLs%20also%20had%20a%20reduced%20antioxidant%20capacity%20relative%20to%20HDLs%20from%20healthy%20donors.%20In%20conclusion%2C%20an%20increased%20ratio%20of%20large%5C%2Fsmall%20HDLs%20with%20impaired%20anti-inflammatory%20and%20antioxidant%20capacities%20was%20associated%20with%20unfavorable%20outcomes%20in%20stroke%20patients.%20Alteration%20of%20HDL%20functionality%20was%20mainly%20associated%20with%20a%20low%20amount%20of%20PON1%20and%20high%20amount%20of%20AAT.%22%2C%22date%22%3A%222020-07-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fjcm9072269%22%2C%22ISSN%22%3A%222077-0383%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2077-0383%5C%2F9%5C%2F7%5C%2F2269%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22KX7T5CYW%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Breyer%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBreyer%20RM%2C%20Clapp%20L%2C%20Coleman%20RA%2C%20Giembycz%20M%2C%20Heinemann%20A%2C%20Hills%20R%2C%20Jones%20RL%2C%20Narumiya%20S%2C%20Norel%20X%2C%20Pettipher%20R%2C%20Sugimoto%20Y%2C%20Uddin%20M%2C%20Woodward%20DF%2C%20Yao%20C.%202020.%20Prostanoid%20receptors%20%28version%202020.4%29%20in%20the%20IUPHAR%5C%2FBPS%20Guide%20to%20Pharmacology%20Database.%20GtoPdb%20CITE%202020.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prostanoid%20receptors%20%28version%202020.4%29%20in%20the%20IUPHAR%5C%2FBPS%20Guide%20to%20Pharmacology%20Database%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20M.%22%2C%22lastName%22%3A%22Breyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Clapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Coleman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Giembycz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akos%22%2C%22lastName%22%3A%22Heinemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Hills%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuh%22%2C%22lastName%22%3A%22Narumiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%22%2C%22lastName%22%3A%22Pettipher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukihiko%22%2C%22lastName%22%3A%22Sugimoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohib%22%2C%22lastName%22%3A%22Uddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20F.%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcan%22%2C%22lastName%22%3A%22Yao%22%7D%5D%2C%22abstractNote%22%3A%22Prostanoid%20receptors%20%28nomenclature%20as%20agreed%20by%20the%20NC-IUPHAR%20Subcommittee%20on%20Prostanoid%20Receptors%20%5B661%5D%29%20are%20activated%20by%20the%20endogenous%20ligands%20prostaglandins%20PGD2%2C%20PGE1%2C%20PGE2%20%2C%20PGF2%5Cu03b1%2C%20PGH2%2C%20prostacyclin%20%5BPGI2%5D%20and%20thromboxane%20A2.%20Differences%20and%20similarities%20between%20human%20and%20rodent%20prostanoid%20receptor%20orthologues%2C%20and%20their%20specific%20roles%20in%20pathophysiologic%20conditions%20are%20reviewed%20in%20%5B423%5D.%20%20%20%20Measurement%20of%20the%20potency%20of%20PGI2%20and%20thromboxane%20A2%20is%20hampered%20by%20their%20instability%20in%20physiological%20salt%20solution%3B%20they%20are%20often%20replaced%20by%20cicaprost%20and%20U46619%2C%20respectively%2C%20in%20receptor%20characterization%20studies.%22%2C%22date%22%3A%222020-09-24%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2218%5C%2Fgtopdb%5C%2FF58%5C%2F2020.4%22%2C%22ISSN%22%3A%222633-1020%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.ed.ac.uk%5C%2Fgtopdb-cite%5C%2Farticle%5C%2Fview%5C%2F5055%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22P2M3TYHJ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mesnier%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMesnier%20J%2C%20Cottin%20Y%2C%20Coste%20P%2C%20Ferrari%20E%2C%20Schiele%20F%2C%20Lemesle%20G%2C%20Thuaire%20C%2C%20Angoulvant%20D%2C%20Cayla%20G%2C%20Bouleti%20C%2C%20De%20Saint%20Aurin%20RG%2C%20Goube%20P%2C%20Lhermusier%20T%2C%20Dillinger%20J-G%2C%20Paganelli%20F%2C%20Saib%20A%2C%20Prunier%20F%2C%20Vanzetto%20G%2C%20Dubreuil%20O%2C%20Puymirat%20E%2C%20Boccara%20F%2C%20Eltchaninoff%20H%2C%20Cachanado%20M%2C%20Rousseau%20A%2C%20Drouet%20E%2C%20Steg%20G%2C%20Simon%20T%2C%20Danchin%20N.%202020.%20Hospital%20Admissions%20for%20Acute%20Myocardial%20Infarction%20Before%20and%20After%20Lockdown%20According%20to%20Regional%20Prevalence%20of%20COVID-19%20and%20Patient%20Profile.%20SSRN%20Journal%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2139%5C%2Fssrn.3619808%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2139%5C%2Fssrn.3619808%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hospital%20Admissions%20for%20Acute%20Myocardial%20Infarction%20Before%20and%20After%20Lockdown%20According%20to%20Regional%20Prevalence%20of%20COVID-19%20and%20Patient%20Profile%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jules%22%2C%22lastName%22%3A%22Mesnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emile%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Schiele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Thuaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Angoulvant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cayla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Bouleti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%20Gallet%22%2C%22lastName%22%3A%22De%20Saint%20Aurin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Goube%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Lhermusier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Guillaume%22%2C%22lastName%22%3A%22Dillinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Paganelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anis%22%2C%22lastName%22%3A%22Saib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Prunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerald%22%2C%22lastName%22%3A%22Vanzetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dubreuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Boccara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Eltchaninoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Cachanado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Drouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2139%5C%2Fssrn.3619808%22%2C%22ISSN%22%3A%221556-5068%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ssrn.com%5C%2Fabstract%3D3619808%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22T74S4278%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gao%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-13%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGao%20C%2C%20Tomaniak%20M%2C%20Takahashi%20K%2C%20Kawashima%20H%2C%20Wang%20R%2C%20Hara%20H%2C%20Ono%20M%2C%20Montalescot%20G%2C%20Garg%20S%2C%20Haude%20M%2C%20Slagboom%20T%2C%20Vranckx%20P%2C%20Valgimigli%20M%2C%20Windecker%20S%2C%20Geuns%20R-JV%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Onuma%20Y%2C%20Angiolillo%20D%2C%20Serruys%20PW.%202020.%20Ticagrelor%20Monotherapy%20in%20Patients%20with%20Concomitant%20Diabetes%20Mellitus%20and%20Chronic%20Kidney%20Disease%3A%20A%20post%20hoc%20analysis%20of%20the%20GLOBAL%20LEADERS%20Trial.%20preprint.%20In%20Review.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22report%22%2C%22title%22%3A%22Ticagrelor%20Monotherapy%20in%20Patients%20with%20Concomitant%20Diabetes%20Mellitus%20and%20Chronic%20Kidney%20Disease%3A%20A%20post%20hoc%20analysis%20of%20the%20GLOBAL%20LEADERS%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hideyuki%22%2C%22lastName%22%3A%22Kawashima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rutao%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hironori%22%2C%22lastName%22%3A%22Hara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masafumi%22%2C%22lastName%22%3A%22Ono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Haude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ton%22%2C%22lastName%22%3A%22Slagboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert-Jan%20Van%22%2C%22lastName%22%3A%22Geuns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20both%20diabetes%20mellitus%20%28DM%29%20and%20chronic%20kidney%20disease%20%28CKD%29%20are%20a%20subpopulation%20characterized%20by%20ultrahigh%20ischemic%20and%20bleeding%20risk%20after%20percutaneous%20coronary%20intervention.%20There%20are%20limited%20data%20on%20the%20impact%20of%20ticagrelor%20monotherapy%20among%20these%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20In%20this%5Cn%20%20%20%20%20%20%20%20%20%20%20%20post%20hoc%5Cn%20%20%20%20%20%20%20%20%20%20%20%20analysis%20of%20the%20GLOBAL-LEADERS%20trial%2C%20the%20treatment%20effects%20of%20the%20experimental%20%28one-month%20dual-antiplatelet%20therapy%20%5BDAPT%5D%20followed%20by%2023-month%20ticagrelor%20monotherapy%29%20versus%20the%20reference%20regimen%20%2812-month%20DAPT%20followed%20by%2012-month%20aspirin%20alone%29%20were%20analyzed%20according%20to%20DM%5C%2FCKD%20status.%20The%20primary%20endpoint%20was%20a%20composite%20endpoint%20of%20all-cause%20death%20or%20new%20Q-wave%20myocardial%20infarction%20at%20two-years.%20The%20patient-oriented%20composite%20endpoint%20%28POCE%29%20was%20defined%20as%20the%20composite%20of%20all-cause%20death%2C%20any%20stroke%2C%20site-reported%20MI%20and%20any%20revascularization%2C%20whereas%20net%20adverse%20clinical%20events%20%28NACE%29%20combined%20POCE%20with%20BARC%20type%203%20or%205%20bleeding%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20At%20two%20years%2C%20the%20DM%2B%5C%2FCKD%2B%20patients%20had%20significantly%20higher%20incidences%20of%20the%20primary%20endpoint%20%289.5%25%20versus%203.1%25%2C%20adjusted%20HR%202.16%3B%2095%25CI%20%5B1.66-2.80%5D%2C%20p%3C0.001%29%2C%20BARC%20type%203%20or%205%20bleeding%20events%2C%20stroke%2C%20site-reported%20myocardial%20infraction%2C%20all%20revascularization%2C%20POCE%2C%20and%20NACE%2C%20compared%20with%20the%20DM-%5C%2FCKD-%20patients.%20Among%20the%20DM%2B%5C%2FCKD%2B%20patients%2C%20after%20adjustment%2C%20there%20were%20no%20significant%20differences%20in%20the%20primary%20endpoints%20between%20the%20experimental%20and%20reference%20regimen%3B%20however%2C%20the%20experimental%20regimen%20was%20associated%20with%20lower%20rates%20of%20POCE%20%2820.6%25%20versus%2025.9%25%2C%20HR%200.74%3B%2095%25CI%20%5B0.55-0.99%5D%2C%20p%3D0.043%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%3D0.155%29%20and%20NACE%20%2822.7%25%20versus%2028.3%25%2C%20HR%200.75%3B%2095%25CI%20%5B0.56-0.99%5D%2C%20p%3D0.044%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%3D0.310%29%2C%20which%20was%20mainly%20driven%20by%20a%20lower%20rate%20of%20all%20revascularization%2C%20as%20compared%20with%20the%20reference%20regimen.%20The%20landmark%20analysis%20showed%20that%20while%20the%20experimental%20and%20reference%20regimen%20had%20similar%20rates%20of%20all%20the%20clinical%20endpoints%20during%20the%20first%20year%2C%20the%20experimental%20regimen%20was%20associated%20with%20significantly%20lower%20rates%20of%20POCE%20%285.8%25%20versus%2011.0%25%2C%20HR%200.49%3B%2095%25CI%20%5B0.29-0.82%5D%2C%20p%3D0.007%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%3D0.040%29%20and%20NACE%20%285.8%25%20versus%2011.2%25%2C%20HR%200.48%3B%2095%25CI%20%5B0.29-0.82%5D%2C%20p%3D0.007%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%3D0.013%29%20in%20the%20second%20year.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Among%20patients%20with%20both%20DM%20and%20CKD%2C%20ticagrelor%20monotherapy%20was%20not%20associated%20with%20lower%20rates%20of%20all-cause%20death%20or%20new%20Q-wave%2C%20or%20major%20bleeding%20complications%3B%20however%2C%20it%20was%20associated%20with%20lower%20rates%20of%20POCE%20and%20NACE.%20These%20findings%20should%20be%20interpreted%20as%20hypothesis-generating.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.gov%20%28NCT01813435%29.%22%2C%22reportNumber%22%3A%22%22%2C%22reportType%22%3A%22preprint%22%2C%22institution%22%3A%22In%20Review%22%2C%22date%22%3A%222020-10-13%22%2C%22language%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.researchsquare.com%5C%2Farticle%5C%2Frs-38823%5C%2Fv2%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22FWPHDUEX%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sorbets%20and%20Steg%22%2C%22parsedDate%22%3A%222020-02-26%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESorbets%20E%2C%20Steg%20PG.%202020.%20Direct-acting%20Anticoagulants%20in%20Chronic%20Coronary%20Syndromes.%20Eur%20Cardiol%2015%3Ae10.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Direct-acting%20Anticoagulants%20in%20Chronic%20Coronary%20Syndromes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sorbets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22Direct-acting%20oral%20anticoagulants%20%28DOACs%29%20are%20easier%20to%20use%2C%20safer%20than%20and%20as%20effective%20as%20vitamin%20K%20antagonists%20%28VKA%29%20in%20the%20treatment%20of%20non-valvular%20AF%20%28NVAF%29.%20Because%20of%20their%20favourable%20safety%20profile%20and%20easier%20use%20than%20VKAs%2C%20DOACs%20as%20anti-thrombotic%20therapy%20may%20have%20a%20role%20in%20the%20management%20of%20chronic%20coronary%20syndromes%20%28CCS%29.%20To%20date%2C%20few%20studies%20have%20evaluated%20DOACs%20in%20this%20setting.%20Initial%20studies%20have%20focused%20on%20patients%20receiving%20DOACs%20for%20NVAF%20undergoing%20acute%20or%20elective%20percutaneous%20coronary%20intervention%20who%20additionally%20require%20dual%20antiplatelet%20therapy%20%28DAPT%29.%20Rivaroxaban%2015%20mg%20once%20daily%20plus%20a%20P2Y12%20inhibitor%20compared%20with%20a%20VKA%20regimen%20was%20associated%20with%20a%20reduction%20of%20bleedings%20%28HR%200.59%3B%2095%25%20CI%20%5B0.47%5Cu20130.76%5D%3B%20p%3C0.001%29.%20Rivaroxaban%202.5%20mg%20twice%20daily%20plus%20DAPT%20up%20to%2012%20months%20followed%20by%20rivaroxaban%2015%5Cu00a0mg%20once%20daily%20plus%20P2Y12%20inhibitor%20showed%20similar%20results.%20Dabigatran%20110%20mg%20twice%20daily%20plus%20a%20P2Y12%20inhibitor%20versus%20a%20VKA%20regimen%20was%20associated%20with%20a%20reduction%20of%20bleedings%20%28HR%200.52%3B%2095%25%20CI%20%5B0.42%5Cu20130.63%5D%3B%20p%3C0.001%29%2C%20after%20a%20mean%20follow-up%20of%2014%20months.%20A%20dabigatran%20150%20mg%20regimen%20showed%20similar%20results.%20Apixaban%205%20mg%20twice%20daily%20plus%20a%20P2Y12%20inhibitor%20versus%20a%20VKA%20regimen%20confirmed%20at%206%20months%20the%20safety%20of%20DOACs%20with%20a%20reduction%20of%20bleedings%20%28HR%200.69%3B%2095%25%20CI%20%5B0.58%5Cu20130.81%5D%3B%20p%3C0.001%20for%20non-inferiority%20and%20superiority%29.%20Edoxaban%2060%20mg%20once%20daily%20plus%20a%20P2Y12%20inhibitor%20was%20non-inferior%20to%20a%20VKA%20regimen%20on%20bleeding%20outcomes%20%28major%20bleeding%20or%20non-major%20clinically%20relevant%20non-major%20bleeding%29%20after%20a%2012-month%20follow-up%20%28HR%200.83%3B%2095%25%20CI%20%5B0.65%5Cu20131.05%5D%3B%20p%3D0.001%20for%20non-inferiority%3B%20p%3D0.1154%20for%20superiority%29.%20Meta-analysis%20of%20these%20four%20trials%20confirmed%20the%20safety%20of%20DOACs%20regarding%20bleeding%20outcomes%2C%20but%20showed%20a%20trend%20toward%20stent%20thrombosis%20for%20dual%20antithrombotic%20therapy%20using%20DOACs%20versus%20triple%20antithrombotic%20therapy%20using%20VKAs.%20DOACs%20may%20show%20promise%20in%20the%20management%20of%20high-risk%20patients%20with%20chronic%20coronary%20syndromes.%20In%20these%20patients%2C%20rivaroxaban%202.5%20mg%20twice%20daily%20in%20addition%20to%20aspirin%20was%20shown%20to%20reduce%20the%20composite%20outcome%20of%20cardiovascular%20death%2C%20stroke%20or%20MI%20compared%20to%20aspirin%20alone%20%28HR%200.76%3B%2095%25%20CI%20%5B0.66%5Cu20130.86%5D%3B%20p%3C0.001%29.%20All-cause%20death%2C%20cardiovascular%20death%20and%20stroke%20were%20also%20significantly%20lower.%20This%20benefit%20was%20at%20the%20cost%20of%20an%20increase%20in%20non-fatal%20bleeding.%22%2C%22date%22%3A%222020-2-26%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.15420%5C%2Fecr.2018.24.2%22%2C%22ISSN%22%3A%2217583764%2C%2017583756%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ecrjournal.com%5C%2Farticleindex%5C%2Fecr.2018.24.2%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22TMPP7UBU%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croyal%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECroyal%20M%2C%20Saulnier%20P-J%2C%20Aguesse%20A%2C%20Gand%20E%2C%20Ragot%20S%2C%20Roussel%20R%2C%20Halimi%20J-M%2C%20Ducrocq%20G%2C%20Cariou%20B%2C%20Montaigne%20D%2C%20Wargny%20M%2C%20Krempf%20M%2C%20Hadjadj%20S.%202020.%20Plasma%20Trimethylamine%20N-Oxide%20and%20Risk%20of%20Cardiovascular%20Events%20in%20Patients%20With%20Type%202%20Diabetes.%20The%20Journal%20of%20Clinical%20Endocrinology%20%26amp%3B%20Metabolism%20105%3A2371%26%23x2013%3B2380.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasma%20Trimethylamine%20N-Oxide%20and%20Risk%20of%20Cardiovascular%20Events%20in%20Patients%20With%20Type%202%20Diabetes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Croyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Saulnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Aguesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Gand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Ragot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronan%22%2C%22lastName%22%3A%22Roussel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Halimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Cariou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Montaigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Wargny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Krempf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samy%22%2C%22lastName%22%3A%22Hadjadj%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Objective%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Even%20though%20trimethylamine%20N-oxide%20%28TMAO%29%20has%20been%20demonstrated%20to%20interfere%20with%20atherosclerosis%20and%20diabetes%20pathophysiology%2C%20the%20association%20between%20TMAO%20and%20major%20adverse%20cardiovascular%20events%20%28MACE%29%20has%20not%20been%20specifically%20established%20in%20type%202%20diabetes%20%28T2D%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Research%20Design%20and%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20examined%20the%20association%20of%20plasma%20TMAO%20concentrations%20with%20MACE%20and%20all-cause%20mortality%20in%20a%20single-center%20prospective%20cohort%20of%20consecutively%20recruited%20patients%20with%20T2D.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20study%20population%20consisted%20in%201463%20SURDIENE%20participants%20%2858%25%20men%29%2C%20aged%2065%5Cu2005%5Cu00b1%5Cu200510%20years.%20TMAO%20concentrations%20were%20significantly%20associated%20with%20diabetes%20duration%2C%20renal%20function%2C%20high-density%20lipoprotein%20cholesterol%2C%20soluble%20tumor%20necrosis%20factor%20receptor%201%20%28sTNFR1%29%20concentrations%20%28R2%20%3D%200.27%29%20and%20were%20significantly%20higher%20in%20patients%20on%20metformin%2C%20even%20after%20adjustment%20for%20estimated%20glomerular%20filtration%20rate%20%28eGFR%29%3A%206.7%20%288.5%29%20vs%208.5%20%2813.6%29%20%5Cu00b5mol%5C%2FL%2C%20respectively%20%28PeGFR-adjusted%20%3D%200.0207%29.%20During%20follow-up%20%28median%20duration%20%5Binterquartile%20range%5D%2C%2085%20%5B75%5D%20months%29%2C%20403%20MACE%20and%20538%20deaths%20were%20registered.%20MACE-free%20survival%20and%20all-cause%20mortality%20were%20significantly%20associated%20with%20the%20quartile%20distribution%20of%20TMAO%20concentrations%2C%20patients%20with%20the%20highest%20TMAO%20levels%20displaying%20the%20greatest%20risk%20of%20outcomes%20%28P%5Cu2005%26lt%3B%5Cu20050.0001%29.%20In%20multivariate%20Cox%20models%2C%20compared%20with%20patients%20from%20the%20first%203%20quartiles%2C%20those%20from%20the%20fourth%20quartile%20of%20TMAO%20concentration%20had%20an%20independently%20increased%20risk%20for%20MACE%3A%20adjusted%20hazard%20ratio%20%28adjHR%29%201.32%20%281.02-1.70%29%3B%20P%5Cu2005%3D%5Cu20050.0325.%20Similarly%2C%20TMAO%20was%20significantly%20associated%20with%20mortality%20in%20multivariate%20analysis%3A%20adjHR%201.75%20%281.17-2.09%29%3B%20P%5Cu2005%3D%5Cu20050.0124%2C%20but%20not%20when%20sTNFR1%20and%20angiopoietin%20like%202%20were%20considered%3A%20adjHR%201.16%20%280.95-1.42%29%3B%20P%5Cu2005%3D%5Cu20050.1514.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20revealed%20an%20association%20between%20higher%20TMAO%20concentrations%20and%20increased%20risk%20of%20MACE%20and%20all-cause%20mortality%2C%20thereby%20opening%20some%20avenues%20on%20the%20role%20of%20dysbiosis%20in%20cardiovascular%20risk%2C%20in%20T2D%20patients.%22%2C%22date%22%3A%222020-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1210%5C%2Fclinem%5C%2Fdgaa188%22%2C%22ISSN%22%3A%220021-972X%2C%201945-7197%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fjcem%5C%2Farticle%5C%2F105%5C%2F7%5C%2F2371%5C%2F5821201%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A11Z%22%7D%7D%2C%7B%22key%22%3A%225NADWN5X%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gao%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGao%20C%2C%20Tomaniak%20M%2C%20Takahashi%20K%2C%20Kawashima%20H%2C%20Wang%20R%2C%20Hara%20H%2C%20Ono%20M%2C%20Montalescot%20G%2C%20Garg%20S%2C%20Haude%20M%2C%20Slagboom%20T%2C%20Vranckx%20P%2C%20Valgimigli%20M%2C%20Windecker%20S%2C%20Van%20Geuns%20R-J%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Onuma%20Y%2C%20Angiolillo%20DJ%2C%20Serruys%20PW.%202020.%20Ticagrelor%20monotherapy%20in%20patients%20with%20concomitant%20diabetes%20mellitus%20and%20chronic%20kidney%20disease%3A%20a%20post%20hoc%20analysis%20of%20the%20GLOBAL%20LEADERS%20trial.%20Cardiovasc%20Diabetol%2019%3A179.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ticagrelor%20monotherapy%20in%20patients%20with%20concomitant%20diabetes%20mellitus%20and%20chronic%20kidney%20disease%3A%20a%20post%20hoc%20analysis%20of%20the%20GLOBAL%20LEADERS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hideyuki%22%2C%22lastName%22%3A%22Kawashima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rutao%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hironori%22%2C%22lastName%22%3A%22Hara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masafumi%22%2C%22lastName%22%3A%22Ono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Haude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ton%22%2C%22lastName%22%3A%22Slagboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert-Jan%22%2C%22lastName%22%3A%22Van%20Geuns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%20J.%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20both%20diabetes%20mellitus%20%28DM%29%20and%20chronic%20kidney%20disease%20%28CKD%29%20are%20a%20subpopulation%20characterized%20by%20ultrahigh%20ischemic%20and%20bleeding%20risk%20after%20percutaneous%20coronary%20intervention.%20There%20are%20limited%20data%20on%20the%20impact%20of%20ticagrelor%20monotherapy%20among%20these%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20post%20hoc%20analysis%20of%20the%20GLOBAL-LEADERS%20trial%2C%20the%20treatment%20effects%20of%20the%20experimental%20%28one-month%20dual-antiplatelet%20therapy%20%5BDAPT%5D%20followed%20by%2023-month%20ticagrelor%20monotherapy%29%20versus%20the%20reference%20regimen%20%2812-month%20DAPT%20followed%20by%2012-month%20aspirin%20alone%29%20were%20analyzed%20according%20to%20DM%5C%2FCKD%20status.%20The%20primary%20endpoint%20was%20a%20composite%20endpoint%20of%20all-cause%20death%20or%20new%20Q-wave%20myocardial%20infarction%20at%202-years.%20The%20patient-oriented%20composite%20endpoint%20%28POCE%29%20was%20defined%20as%20the%20composite%20of%20all-cause%20death%2C%20any%20stroke%2C%20site-reported%20MI%20and%20any%20revascularization%2C%20whereas%20net%20adverse%20clinical%20events%20%28NACE%29%20combined%20POCE%20with%20BARC%20type%203%20or%205%20bleeding%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20At%202%20years%2C%20the%20DM%5Cu2009%2B%5Cu2009%5C%2FCKD%5Cu2009%2B%5Cu2009patients%20had%20significantly%20higher%20incidences%20of%20the%20primary%20endpoint%20%289.5%25%20versus%203.1%25%2C%20adjusted%20HR%202.16%3B%2095%25%20CI%20%5B1.66%5Cu20132.80%5D%2C%20p%5Cu2009%3C%5Cu20090.001%29%2C%20BARC%20type%203%20or%205%20bleeding%20events%2C%20stroke%2C%20site-reported%20myocardial%20infraction%2C%20all%20revascularization%2C%20POCE%2C%20and%20NACE%2C%20compared%20with%20the%20DM-%5C%2FCKD-%20patients.%20Among%20the%20DM%5Cu2009%2B%5Cu2009%5C%2FCKD%5Cu2009%2B%5Cu2009patients%2C%20after%20adjustment%2C%20there%20were%20no%20significant%20differences%20in%20the%20primary%20endpoints%20between%20the%20experimental%20and%20reference%20regimen%3B%20however%2C%20the%20experimental%20regimen%20was%20associated%20with%20lower%20rates%20of%20POCE%20%2820.6%25%20versus%2025.9%25%2C%20HR%200.74%3B%2095%25%20CI%20%5B0.55%5Cu20130.99%5D%2C%20p%5Cu2009%3D%5Cu20090.043%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3D%5Cu20090.155%29%20and%20NACE%20%2822.7%25%20versus%2028.3%25%2C%20HR%200.75%3B%2095%25%20CI%20%5B0.56%5Cu20130.99%5D%2C%20p%5Cu2009%3D%5Cu20090.044%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3D%5Cu20090.310%29%2C%20which%20was%20mainly%20driven%20by%20a%20lower%20rate%20of%20all%20revascularization%2C%20as%20compared%20with%20the%20reference%20regimen.%20The%20landmark%20analysis%20showed%20that%20while%20the%20experimental%20and%20reference%20regimen%20had%20similar%20rates%20of%20all%20the%20clinical%20endpoints%20during%20the%20first%20year%2C%20the%20experimental%20regimen%20was%20associated%20with%20significantly%20lower%20rates%20of%20POCE%20%285.8%25%20versus%2011.0%25%2C%20HR%200.49%3B%2095%25%20CI%20%5B0.29%5Cu20130.82%5D%2C%20p%5Cu2009%3D%5Cu20090.007%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3D%5Cu20090.040%29%20and%20NACE%20%285.8%25%20versus%2011.2%25%2C%20HR%200.48%3B%2095%25%20CI%20%5B0.29%5Cu20130.82%5D%2C%20p%5Cu2009%3D%5Cu20090.007%2C%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2009%3D%5Cu20090.013%29%20in%20the%20second%20year.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20patients%20with%20both%20DM%20and%20CKD%2C%20ticagrelor%20monotherapy%20was%20not%20associated%20with%20lower%20rates%20of%20all-cause%20death%20or%20new%20Q-wave%2C%20or%20major%20bleeding%20complications%3B%20however%2C%20it%20was%20associated%20with%20lower%20rates%20of%20POCE%20and%20NACE.%20These%20findings%20should%20be%20interpreted%20as%20hypothesis-generating.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.gov%20%28NCT01813435%29.%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12933-020-01153-x%22%2C%22ISSN%22%3A%221475-2840%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fcardiab.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs12933-020-01153-x%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22Z58E3P8R%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abtan%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbtan%20J%2C%20Ducrocq%20G%2C%20Steg%20G.%202020.%20Chest%20pain%20triage%3A%20do%20genetics%20have%20a%20role%3F%20European%20Heart%20Journal%20Acute%20Cardiovascular%20Care%209%3A729%26%23x2013%3B730.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Chest%20pain%20triage%3A%20do%20genetics%20have%20a%20role%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2048872620952728%22%2C%22ISSN%22%3A%222048-8734%2C%202048-8726%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjacc%5C%2Farticle%5C%2F9%5C%2F7%5C%2F729-730%5C%2F6125612%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22A9MQ4JZG%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Schiele%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESchiele%20F%2C%20Lemesle%20G%2C%20Angoulvant%20D%2C%20Krempf%20M%2C%20Kownator%20S%2C%20Cheggour%20S%2C%20Belle%20L%2C%20Ferri%26%23xE8%3Bres%20J%2C%20Bauters%20C%2C%20Bergerot%20C%2C%20Beygui%20F%2C%20Boccara%20F%2C%20Bonnefoy%20E%2C%20Bruckert%20E%2C%20Cayla%20G%2C%20Collet%20J-P%2C%20Coste%20P%2C%20Descotes-Genon%20V%2C%20Ducrocq%20G%2C%20Elbaz%20M%2C%20Farnier%20M%2C%20Ferrari%20E%2C%20Guedj%20D%2C%20Levai%20L%2C%20Mansourati%20J%2C%20Mansencal%20N%2C%20Meneveau%20N%2C%20Meune%20C%2C%20Morel%20O%2C%20Ohlmann%20P%2C%20Paillard%20F%2C%20Piot%20C%2C%20Puymirat%20E%2C%20Rioufol%20G%2C%20Roubille%20F%2C%20Sabouret%20P%2C%20Teiger%20E.%202020.%20Proposal%20for%20a%20standardized%20discharge%20letter%20after%20hospital%20stay%20for%20acute%20myocardial%20infarction.%20European%20Heart%20Journal%20Acute%20Cardiovascular%20Care%209%3A788%26%23x2013%3B801.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proposal%20for%20a%20standardized%20discharge%20letter%20after%20hospital%20stay%20for%20acute%20myocardial%20infarction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Schiele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Angoulvant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Krempf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Kownator%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saida%22%2C%22lastName%22%3A%22Cheggour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Belle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Ferri%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Bauters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrille%22%2C%22lastName%22%3A%22Bergerot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farzin%22%2C%22lastName%22%3A%22Beygui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Boccara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bonnefoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bruckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cayla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Collet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Descotes-Genon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meyer%22%2C%22lastName%22%3A%22Elbaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Farnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emile%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Guedj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laszlo%22%2C%22lastName%22%3A%22Levai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Mansourati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Mansencal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meneveau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Meune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Ohlmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Paillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Piot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Rioufol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Roubille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sabouret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Teiger%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20admitted%20for%20acute%20myocardial%20infarction%2C%20the%20communication%20and%20transition%20from%20specialists%20to%20primary%20care%20physicians%20is%20often%20delayed%2C%20and%20the%20information%20imparted%20to%20subsequent%20healthcare%20providers%20%28HCPs%29%20may%20be%20sub-optimal.%20A%20French%20group%20of%20cardiologists%2C%20lipidologists%20and%20diabetologists%20decided%20to%20establish%20a%20consensus%20to%20optimize%20the%20discharge%20letter%20after%20hospitalization%20for%20acute%20myocardial%20infarction.%20The%20aim%20is%20to%20improve%20both%20the%20timeframe%20and%20the%20quality%20of%20the%20content%20transmitted%20to%20subsequent%20HCPs%2C%20including%20information%20regarding%20baseline%20assessment%2C%20procedures%20during%20hospitalization%2C%20residual%20risk%2C%20discharge%20treatments%2C%20therapeutic%20targets%20and%20follow-up%20recommendations%20in%20compliance%20with%20European%20Society%20of%20Cardiology%20guidelines.%20A%20consensus%20was%20obtained%20regarding%20a%20template%20discharge%20letter%2C%20to%20be%20released%20within%20two%20days%20after%20patient%5Cu2019s%20discharge%2C%20and%20containing%20the%20description%20of%20the%20patient%5Cu2019s%20history%2C%20risk%20factors%2C%20acute%20management%2C%20risk%20assessment%2C%20discharge%20treatments%20and%20follow-up%20pathway.%20Specifically%20for%20post%20acute%20MI%20patients%2C%20tailored%20details%20are%20necessary%20regarding%20the%20antithrombotic%20regimen%2C%20lipid-lowering%20and%20anti-diabetic%20treatments%2C%20including%20therapeutic%20targets.%20Lastly%2C%20the%20follow-up%20pathway%20needs%20to%20be%20precisely%20mentioned%20in%20the%20discharge%20letter.%20Additional%20information%20such%20as%20technical%20descriptions%2C%20imaging%2C%20and%20quality%20indicators%20may%20be%20provided%20separately.%20A%20template%20for%20a%20standardized%20discharge%20letter%20based%20on%208%20major%20headings%20could%20be%20useful%20for%20implementation%20in%20routine%20practice%20and%20help%20to%20improve%20the%20quality%20and%20timing%20of%20information%20transmission%20between%20HCPs%20after%20acute%20MI.%22%2C%22date%22%3A%222020-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2048872619844444%22%2C%22ISSN%22%3A%222048-8734%2C%202048-8726%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjacc%5C%2Farticle%5C%2F9%5C%2F7%5C%2F788-801%5C%2F6125650%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A58Z%22%7D%7D%2C%7B%22key%22%3A%229KBK5Z6G%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Biscaglia%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBiscaglia%20S%2C%20Campo%20G%2C%20Sorbets%20E%2C%20Ford%20I%2C%20Fox%20KM%2C%20Greenlaw%20N%2C%20Parkhomenko%20A%2C%20Tardif%20J-C%2C%20Tavazzi%20L%2C%20Tendera%20M%2C%20Wetherall%20K%2C%20Ferrari%20R%2C%20Steg%20PhG%2C%20on%20behalf%20of%20the%20CLARIFY%20investigators.%202020.%20Relationship%20between%20physical%20activity%20and%20long-term%20outcomes%20in%20patients%20with%20stable%20coronary%20artery%20disease.%20Eur%20J%20Prev%20Cardiolog%2027%3A426%26%23x2013%3B436.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Relationship%20between%20physical%20activity%20and%20long-term%20outcomes%20in%20patients%20with%20stable%20coronary%20artery%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Biscaglia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gianluca%22%2C%22lastName%22%3A%22Campo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sorbets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Greenlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luigi%22%2C%22lastName%22%3A%22Tavazzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kirsty%22%2C%22lastName%22%3A%22Wetherall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20CLARIFY%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20aims%20of%20this%20study%20were%20to%20ascertain%20the%20relationship%20between%20level%20of%20physical%20activity%20and%20outcomes%20and%20to%20discriminate%20the%20determinants%20of%20physical%20activity%20performance%20or%20avoidance.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CLARIFY%20is%20an%20international%20prospective%20registry%20of%2032%2C370%20consecutive%20outpatients%20with%20stable%20coronary%20artery%20disease%20who%20were%20followed%20for%20up%20to%20five%20years.%20Patients%20were%20grouped%20according%20to%20the%20level%20and%20frequency%20of%20physical%20activity%3A%20i%29%20sedentary%20%28%20n%5Cu2009%3D%5Cu20095223%3B%2016.1%25%29%3B%20ii%29%20only%20light%20physical%20activity%20most%20weeks%20%28light%3B%20n%5Cu2009%3D%5Cu200916%2C634%3B%2051.4%25%29%3B%20iii%29%20vigorous%20physical%20activity%20once%20or%20twice%20per%20week%20%28vigorous%5Cu2009%5Cu2264%5Cu20092%5Cu00d7%3B%20n%5Cu2009%3D%5Cu20095427%3B%2016.8%25%29%3B%20iv%29%20vigorous%20physical%20activity%20three%20or%20more%20times%20per%20week%20%28vigorous%20%3E2%5Cu00d7%3B%20n%5Cu2009%3D%5Cu20095086%3B%2015.7%25%29.%20The%20primary%20outcome%20was%20the%20composite%20of%20cardiovascular%20death%2C%20myocardial%20infarction%20and%20stroke.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20performing%20vigorous%20physical%20activity%20%5Cu22642%5Cu2009%5Cu00d7%5Cu2009had%20the%20lowest%20risk%20of%20the%20primary%20outcome%20%28hazard%20ratio%2C%200.82%3B%2095%25%20confidence%20interval%2C%200.71%5Cu20130.93%3B%20p%5Cu2009%3D%5Cu20090.0031%29%20taking%20the%20light%20group%20as%20reference.%20Engaging%20in%20more%20frequent%20exercise%20did%20not%20result%20in%20further%20outcome%20benefit.%20All-cause%20death%2C%20cardiovascular%20death%2C%20and%20stroke%20occurred%20less%20frequently%20in%20patients%20performing%20vigorous%20physical%20activity%20%5Cu22642%5Cu00d7.%20However%2C%20the%20rate%20of%20myocardial%20infarction%20was%20comparable%20between%20the%20four%20physical%20activity%20groups.%20Female%20sex%2C%20peripheral%20artery%20disease%2C%20diabetes%2C%20previous%20myocardial%20infarction%20or%20stroke%2C%20pulmonary%20disease%20and%20body%20mass%20index%20all%20emerged%20as%20independent%20predictors%20of%20lower%20physical%20activity.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Vigorous%20physical%20activity%20once%20or%20twice%20per%20week%20was%20associated%20with%20superior%20cardiac%20outcomes%20compared%20with%20patients%20performing%20no%20or%20a%20low%20level%20of%20physical%20activity%20in%20outpatients%20with%20stable%20coronary%20artery%20disease.%22%2C%22date%22%3A%2203%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2047487319871217%22%2C%22ISSN%22%3A%222047-4873%2C%202047-4881%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurjpc%5C%2Farticle%5C%2F27%5C%2F4%5C%2F426-436%5C%2F5924867%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22BZVRHKUS%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ong%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EOng%20E%2C%20Meseguer%20E%2C%20Guidoux%20C%2C%20Lavall%26%23xE9%3Be%20PC%2C%20Hobeanu%20C%2C%20Charles%20H%2C%20Labreuche%20J%2C%20Cabrejo%20L%2C%20Martin-Bechet%20A%2C%20Rigual%20R%2C%20Nighoghossian%20N%2C%20Amarenco%20P.%202020.%20Prevalence%20and%20Outcome%20of%20Potential%20Candidates%20for%20Left%20Atrial%20Appendage%20Closure%20After%20Stroke%20With%20Atrial%20Fibrillation%3A%20WATCH-AF%20Registry.%20Stroke%2051%3A2355%26%23x2013%3B2363.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20and%20Outcome%20of%20Potential%20Candidates%20for%20Left%20Atrial%20Appendage%20Closure%20After%20Stroke%20With%20Atrial%20Fibrillation%3A%20WATCH-AF%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Guidoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C.%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Hobeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Charles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Cabrejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Martin-Bechet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricardo%22%2C%22lastName%22%3A%22Rigual%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Nighoghossian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20As%20a%20result%20of%20contraindications%20%28eg%2C%20frailty%2C%20cognitive%20impairment%2C%20comorbidities%29%20or%20patient%20refusal%2C%20many%20patients%20with%20stroke%20and%20atrial%20fibrillation%20cannot%20be%20discharged%20on%20oral%20anticoagulant.%20Among%20them%2C%20the%20proportion%20of%20potential%20candidates%20for%20left%20atrial%20appendage%20closure%20%28LAAC%29%20and%20their%2012-month%20outcome%20is%20not%20well%20known.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20prospective%20WATCH-AF%20registry%20%28Warfarin%20Aspirin%20Ten-A%20Inhibitors%20and%20Cerebral%20Infarction%20and%20Hemorrhage%20and%20Atrial%20Fibrillation%29%20enrolled%20consecutive%20patients%20admitted%20within%2072%20hours%20of%20an%20acute%20stroke%20associated%20with%20atrial%20fibrillation%20in%202%20stroke%20centers.%20Scales%20to%20evaluate%20stroke%20severity%2C%20disability%2C%20functional%20independence%2C%20risk%20of%20fall%2C%20cognition%2C%20ischemic%20and%20hemorrhagic%20risk-stratification%2C%20and%20comorbidities%20were%20systematically%20collected%20at%20admission%2C%20discharge%2C%203%2C%2012%20months%20poststroke.%20The%202%20main%20end%20points%20were%20death%20or%20dependency%20%28modified%20Rankin%20Scale%20score%20%3E3%29%20and%20recurrent%20stroke%20%28brain%20infarction%20and%20brain%20hemorrhage%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20400%20enrolled%20patients%20%28370%20with%20brain%20infarction%2C%2030%20with%20brain%20hemorrhage%29%2C%2031%20died%20before%20discharge%20and%2057%20%2814.3%25%29%20were%20possible%20European%20Heart%20Rhythm%20Association%5C%2FEuropean%20Society%20of%20Cardiology%20and%20American%20Heart%20Association%5C%2FAmerican%20College%20of%20Cardiology%5C%2FHeart%20Rhythm%20Society%20candidates%20for%20LAAC.%20At%2012%20months%2C%20the%20rate%20of%20death%20or%20dependency%20was%2017.9%25%2C%20and%20the%20rate%20of%20stroke%20recurrence%20was%209.8%25%20in%20the%20274%5C%2F400%20%2868.5%25%29%20patients%20discharged%20on%20a%20long-term%20oral%20anticoagulant%20strategy%2C%20as%20compared%20with%2017.5%25%20and%2024.7%25%2C%20respectively%2C%20in%2057%20patients%20candidate%20for%20LAAC.%20As%20compared%20with%20patients%20on%20a%20long-term%20oral%20anticoagulant%20strategy%2C%20there%20was%20a%202-fold%20increase%20in%20the%20risk%20of%20stroke%20recurrence%20in%20the%20group%20with%20an%20indication%20for%20LAAC%20%28adjusted%20hazard%20ratio%2C%202.58%20%5B95%25%20CI%2C%201.40%5Cu20134.76%5D%3B%20P%3D0.002%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Fourteen%20percent%20of%20patients%20with%20stroke%20associated%20with%20atrial%20fibrillation%20were%20potential%20candidates%20for%20LAAC.%20The%2012-month%20stroke%20risk%20of%20these%20candidates%20was%203-fold%20the%20risk%20of%20anticoagulated%20patients.%22%2C%22date%22%3A%2208%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.120.029267%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.120.029267%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22NI87WX6G%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Van%20Ganse%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVan%20Ganse%20E%2C%20Danchin%20N%2C%20Mah%26%23xE9%3B%20I%2C%20Hanon%20O%2C%20Jacoud%20F%2C%20Nolin%20M%2C%20Dalon%20F%2C%20Lefevre%20C%2C%20Cott%26%23xE9%3B%20F-E%2C%20Gollety%20S%2C%20Falissard%20B%2C%20Belhassen%20M%2C%20Steg%20PhG.%202020.%20Comparative%20Safety%20and%20Effectiveness%20of%20Oral%20Anticoagulants%20in%20Nonvalvular%20Atrial%20Fibrillation%3A%20The%20NAXOS%20Study.%20Stroke%2051%3A2066%26%23x2013%3B2075.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20Safety%20and%20Effectiveness%20of%20Oral%20Anticoagulants%20in%20Nonvalvular%20Atrial%20Fibrillation%3A%20The%20NAXOS%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Van%20Ganse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Mah%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Hanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flore%22%2C%22lastName%22%3A%22Jacoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu00ebva%22%2C%22lastName%22%3A%22Nolin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faustine%22%2C%22lastName%22%3A%22Dalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cinira%22%2C%22lastName%22%3A%22Lefevre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Emery%22%2C%22lastName%22%3A%22Cott%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Gollety%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Falissard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Belhassen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20effects%20of%20direct%20oral%20anticoagulants%20in%20nonvalvular%20atrial%20fibrillation%20should%20be%20assessed%20in%20actual%20conditions%20of%20use.%20France%20has%20near-universal%20healthcare%20coverage%20with%20a%20unified%20healthcare%20information%20system%2C%20allowing%20large%20population-based%20analyses.%20NAXOS%20%28Evaluation%20of%20Apixaban%20in%20Stroke%20and%20Systemic%20Embolism%20Prevention%20in%20Patients%20With%20Nonvalvular%20Atrial%20Fibrillation%29%20aimed%20to%20compare%20the%20safety%2C%20effectiveness%2C%20and%20mortality%20of%20apixaban%20with%20vitamin%20K%20antagonists%20%28VKAs%29%2C%20rivaroxaban%2C%20and%20dabigatran%2C%20in%20oral%20anticoagulant-naive%20patients%20with%20nonvalvular%20atrial%20fibrillation.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20was%20an%20observational%20study%20using%20French%20National%20Health%20System%20claims%20data%20and%20including%20all%20adults%20with%20nonvalvular%20atrial%20fibrillation%20who%20initiated%20oral%20anticoagulant%20between%202014%20and%202016.%20Outcomes%20of%20interest%20were%20major%20bleeding%20events%20leading%20to%20hospitalization%20%28safety%29%2C%20stroke%20and%20systemic%20thromboembolic%20events%20%28effectiveness%29%2C%20and%20all-cause%20mortality.%20Four%20approaches%20were%20used%20for%20comparative%20analyses%3A%20matching%20on%20propensity%20score%20%28PS%3B%201%3An%29%3B%20as%20a%20sensitivity%20analysis%2C%20matching%20on%20high-dimensional%20PS%3B%20adjustment%20on%20PS%3B%20and%20adjustment%20on%20known%20confounders.%20For%20each%20outcome%2C%20cumulative%20incidence%20rates%20accounting%20for%20competing%20risks%20of%20death%20were%20estimated.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Overall%2C%20321%20501%20patients%20were%20analyzed%2C%20of%20whom%2035.0%25%2C%2027.2%25%2C%2031.1%25%2C%20and%206.6%25%20initiated%20VKAs%2C%20apixaban%2C%20rivaroxaban%2C%20and%20dabigatran%2C%20respectively.%20Apixaban%20was%20associated%20with%20a%20lower%20PS%5Cu2013matched%20risk%20of%20major%20bleeding%20compared%20with%20VKAs%20%28hazard%20ratio%20%5BHR%5D%2C%200.43%20%5B95%25%20CI%2C%200.40%5Cu20130.46%5D%29%20and%20rivaroxaban%20%28HR%2C%200.67%20%5B95%25%20CI%2C%200.63%5Cu20130.72%5D%29%2C%20but%20not%20dabigatran%20%28HR%2C%200.93%20%5B95%25%20CI%2C%200.81%5Cu20131.08%5D%29.%20Apixaban%20was%20associated%20with%20a%20lower%20risk%20of%20stroke%20and%20systemic%20thromboembolic%20event%20compared%20with%20VKAs%20%28HR%2C%200.60%20%5B95%25%20CI%2C%200.56%5Cu20130.65%5D%29%2C%20but%20not%20rivaroxaban%20%28HR%2C%201.05%20%5B95%25%20CI%2C%200.97%5Cu20131.15%5D%29%20or%20dabigatran%20%28HR%2C%200.93%20%5B95%25%20CI%2C%200.78%5Cu20131.11%5D%29.%20All-cause%20mortality%20was%20lower%20with%20apixaban%20than%20with%20VKAs%2C%20but%20not%20lower%20than%20with%20rivaroxaban%20or%20dabigatran.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Apixaban%20was%20associated%20with%20superior%20safety%2C%20effectiveness%2C%20and%20lower%20mortality%20than%20VKAs%3B%20with%20superior%20safety%20than%20rivaroxaban%20and%20similar%20safety%20to%20dabigatran%3B%20and%20with%20similar%20effectiveness%20when%20compared%20with%20rivaroxaban%20or%20dabigatran.%20These%20observational%20data%20suggest%20potentially%20important%20differences%20in%20outcomes%20between%20direct%20oral%20anticoagulants%2C%20which%20should%20be%20explored%20in%20randomized%20trials.%22%2C%22date%22%3A%2207%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.120.028825%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.120.028825%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22XTN348H2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amarenco%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAmarenco%20P%2C%20Kim%20JS%2C%20Labreuche%20J%2C%20Charles%20H%2C%20Giroud%20M%2C%20Lee%20B-C%2C%20Mahagne%20M-H%2C%20Nighoghossian%20N%2C%20Gabriel%20Steg%20P%2C%20Vicaut%20%26%23xC9%3B%2C%20Bruckert%20E%2C%20Touboul%20P-J%2C%20Leys%20D%2C%20B%26%23xE9%3Bjot%20Y%2C%20Lavall%26%23xE9%3Be%20P%2C%20Pico%20F%2C%20Touz%26%23xE9%3B%20E%2C%20Ducrocq%20G%2C%20Abtan%20J%2C%20Varenne%20O%2C%20Touboul%20P-J%2C%20Kemmel%20A%2C%20Syana%20F%2C%20Ledra%20M%2C%20Nagasara%20T%2C%20Ledjeroud%20M%2C%20Samia%20B%2C%20Hadia%20H%2C%20Hazare%20B%2C%20El%20Jaghouni%20I%2C%20Yelles%20N%2C%20Zemouri%20S%2C%20Ladjeroud%20M%2C%20Kerai%20S%2C%20In%20YJ%2C%20Meseguer%20E%2C%20Lavall%26%23xE9%3Be%20PC%2C%20Hobeanu%20C%2C%20Guidoux%20C%2C%20Cabrejo%20L%2C%20Lapergue%20B%2C%20Sabben%20C%2C%20Gonzalez-Valcarcel%20J%2C%20Rigual%20R%2C%20Sirimarco%20G%2C%20Martin-Bechet%20A%2C%20Viedma%20E%2C%20Avram%20I%2C%20Samson%20Y%2C%20Rosso%20C%2C%20Crozier%20S%2C%20Leder%20S%2C%20L%26%23xE9%3Bger%20A%2C%20Deltour%20S%2C%20Mutlu%20G%2C%20Yger%20M%2C%20Zavanone%20C%2C%20Baronnet%20F%2C%20Pires%20C%2C%20Lapergue%20B%2C%20Wang%20A%2C%20Evrard%20S%2C%20Tchikviladze%20M%2C%20Bourdain%20F%2C%20Lopez%20D%2C%20Pico%20F%2C%20De%20La%20Tour%20LB%2C%20Chadenat%20M-L%2C%20Duong%20DL%2C%20Genty%20S%2C%20Hirel%20C%2C%20Mutlu%20G%2C%20Nifle%20C%2C%20Servan%20J%2C%20Stanciu%20D%2C%20Sudacevschi%20V%2C%20Tir%20M%2C%20Troussi%26%23xE8%3Bre%20A-C%2C%20Yeung%20J%2C%20Zeghoudi%20A-C%2C%20Tidafi-Bayou%20I%2C%20Lachaud%20S%2C%20Cho%20T-H%2C%20Mechtouff%20L%2C%20Ritzenthaller%20T%2C%20Derex%20L%2C%20Albanesi%20C%2C%20Ong%20E%2C%20Benoit%20A%2C%20Berhoune%20N%2C%20Felix%20S%2C%20Esteban-Mader%20M%2C%20Sibon%20I%2C%20Kazadi%20A%2C%20Rouanet%20F%2C%20Renou%20P%2C%20Debruxelles%20S%2C%20Poli%20M%2C%20Sagnier%20S%2C%20Mas%20J-L%2C%20Domigo%20V%2C%20Lamy%20C%2C%20Bodiguel%20E%2C%20Grimaud%20J%2C%20Bohotin%20V%2C%20Obadia%20M%2C%20Sabben%20C%2C%20Morvan%20E%2C%20Rodier%20G%2C%20Vadot%20W%2C%20H%26%23xE9%3Bnon%20H%2C%20Cordonnier%20C%2C%20Dumont%20F%2C%20Bodenant%20M%2C%20Lucas%20C%2C%20Moulin%20S%2C%20Dequatre%20N%2C%20Alamowitch%20S%2C%20Muresan%20J-P%2C%20Drouet%20T%2C%20Gallea%20M%2C%20Dalloz%20M-A%2C%20Delorme%20S%2C%20Yger%20M%2C%20B%26%23xE9%3Bjot%20Y%2C%20Loisel%20P%2C%20Bonnin%20C%2C%20Bernigal%20V%2C%20Osseby%20GV%2C%20Marsac%20MH-B%2C%20Garnier%20P%2C%20Accassat%20S%2C%20Epinat%20M%2C%20Varvat%20J%2C%20Marinescu%20D%2C%20Triquenot-Bagan%20A%2C%20Ozkul-Wermester%20O%2C%20Philippeau%20F%2C%20Olaru%20A%2C%20Vieillart%20A%2C%20Lannuzel%20A%2C%20Demoly%20A%2C%20Wolff%20V%2C%20Diaconu%20M%2C%20Bataillard%20M%2C%20Montoro%20FM%2C%20Faugeras%20F%2C%20Gimenez%20L%2C%20Abdallah-Lebeau%20F%2C%20Timsit%20S%2C%20Viakhireva-Dovganyuk%20I%2C%20Tirel-Badets%20A%2C%20Merrien%20F-M%2C%20Goas%20P%2C%20Rouhart%20F%2C%20Jourdain%20A%2C%20Guillon%20B%2C%20H%26%23xE9%3Brissson%20F%2C%20Sevin-Allouet%20M%2C%20Nasr%20N%2C%20Olivot%20J-M%2C%20Lecluse%20A%2C%20Marc%20G%2C%20Touz%26%23xE9%3B%20E%2C%20De%20La%20Sayette%20V%2C%20Apoil%20M%2C%20Lin%20L%2C%20Cogez%20J%2C%20Guettier%20S%2C%20Godefroy%20O%2C%20Lamy%20C%2C%20Bugnicourt%20J-M%2C%20Taurin%20G%2C%20M%26%23xE9%3Brienne%20M%2C%20Gere%20J%2C%20Chessak%20A-M%2C%20Habet%20T%2C%20Ferrier%20A%2C%20Bourgois%20N%2C%20Minier%20D%2C%20Caillier-Minier%20M%2C%20Cont%26%23xE9%3Bgal-Callier%20F%2C%20Vion%20P%2C%20Vaschalde%20Y%2C%20El%20Amrani%2C%20Emilie%20M%2C%20Zuber%20M%2C%20Bruandet%20M%2C%20Join-Lambert%20C%2C%20Garcia%20P-Y%2C%20Serre%20I%2C%20Faucheux%20J-M%2C%20Radji%20F%2C%20Leca-Radu%20E%2C%20Debroucker%20T%2C%20Cumurcuc%20R%2C%20Cakmak%20S%2C%20Peysson%20S%2C%20Ellie%20E%2C%20Bernady%20P%2C%20Moulin%20T%2C%20Montiel%20P%2C%20Revenco%20E%2C%20Decavel%20P%2C%20Medeiros%20E%2C%20Bouveret%20M%2C%20Louchart%20P%2C%20Vaduva%20C%2C%20Couvreur%20G%2C%20Sartori%20E%2C%20Alnajar-Carpentier%20E%2C%20Levasseur%20M%2C%20Louchart%20P%2C%20Neau%20J-P%2C%20Vandamme%20X%2C%20Meresse%20I%2C%20Stantescu%2C%20Bataillard%20M%2C%20Ozsancak%20C%2C%20Beauvais%20K%2C%20Auzou%20P%2C%20Amevigbe%20J%2C%20Vuillemet%20F%2C%20Dugay-Arentz%20M-H%2C%20Carelli%20G%2C%20Martinez%20M%2C%20Maillet-Vioud%20M%2C%20Escaillas%20J-P%2C%20Chapuis%20S%2C%20Tardy%20J%2C%20Manchon%20E%2C%20Varnet%20O%2C%20Kim%20Y-J%2C%20Chang%20Y%2C%20Song%20T-J%2C%20Han%20J-H%2C%20Noh%20KC%2C%20Lee%20E-J%2C%20Kang%20D-W%2C%20Kwon%20SU%2C%20Kwon%20B%2C%20Park%20S%2C%20Lee%20D%2C%20Kwon%20HS%2C%20Jeong%20D%2C%20Lee%20M%2C%20Kim%20J%2C%20Lee%20H%2C%20Nam%20HJ%2C%20Lee%20SH%2C%20Kim%20BJ%2C%20Cha%20J%2C%20Kim%20D%2C%20Young%20Kim%20R%2C%20Sohn%20SW%2C%20Shim%20D-H%2C%20Lee%20H%2C%20Nah%20H-W%2C%20Sung%20SM%2C%20Lee%20KB%2C%20Lee%20JY%2C%20Yoon%20JE%2C%20Kim%20E-G%2C%20Seo%20JH%2C%20Kim%20Y-W%2C%20Hwang%20Y%2C%20Park%20MS%2C%20Kim%20J-T%2C%20Choi%20K-H%2C%20Nam%20HS%2C%20Heo%20JH%2C%20Kim%20YD%2C%20Hwang%20IG%2C%20Park%20HJ%2C%20Kim%20KS%2C%20Baek%20JH%2C%20Song%20DB%2C%20Yoo%20JS%2C%20Park%20J-M%2C%20Kwon%20O%2C%20Lee%20W-W%2C%20Lee%20J-J%2C%20Kang%20K%2C%20Kim%20BK%2C%20Lim%20J-S%2C%20Oh%20MS%2C%20Yu%20K-H%2C%20Hong%20B%2C%20Jang%20M%2C%20Jang%20S%2C%20Jin%20JE%2C%20Kim%20J%2C%20Jeong%20HS%2C%20Hong%20KS%2C%20Park%20HK%2C%20Cho%20YJ%2C%20Bang%20OY%2C%20Seo%20W-K%2C%20Chung%20J.%202020.%20Benefit%20of%20Targeting%20a%20LDL%20%28Low-Density%20Lipoprotein%29%20Cholesterol%20%26lt%3B70%20mg%5C%2FdL%20During%205%20Years%20After%20Ischemic%20Stroke.%20Stroke%2051%3A1231%26%23x2013%3B1239.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Benefit%20of%20Targeting%20a%20LDL%20%28Low-Density%20Lipoprotein%29%20Cholesterol%20%3C70%20mg%5C%2FdL%20During%205%20Years%20After%20Ischemic%20Stroke%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jong%20S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Charles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Giroud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Byung-Chul%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Mahagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Nighoghossian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gabriel%20Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9ric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bruckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Leys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22B%5Cu00e9jot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Pico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Touz%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Varenne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Kemmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausta%22%2C%22lastName%22%3A%22Syana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manele%22%2C%22lastName%22%3A%22Ledra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tharani%22%2C%22lastName%22%3A%22Nagasara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mervette%22%2C%22lastName%22%3A%22Ledjeroud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bahous%22%2C%22lastName%22%3A%22Samia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hafirassou%22%2C%22lastName%22%3A%22Hadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benyoub%22%2C%22lastName%22%3A%22Hazare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ikrame%22%2C%22lastName%22%3A%22El%20Jaghouni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nessima%22%2C%22lastName%22%3A%22Yelles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofia%22%2C%22lastName%22%3A%22Zemouri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mervette%22%2C%22lastName%22%3A%22Ladjeroud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Kerai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yun%20Jeong%22%2C%22lastName%22%3A%22In%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Hobeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Guidoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Cabrejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Lapergue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Sabben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaime%22%2C%22lastName%22%3A%22Gonzalez-Valcarcel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricardo%22%2C%22lastName%22%3A%22Rigual%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaia%22%2C%22lastName%22%3A%22Sirimarco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Martin-Bechet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Viedma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioan%22%2C%22lastName%22%3A%22Avram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Samson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Rosso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Crozier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Leder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22L%5Cu00e9ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Deltour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gurkan%22%2C%22lastName%22%3A%22Mutlu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Yger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Zavanone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flore%22%2C%22lastName%22%3A%22Baronnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Pires%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Lapergue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Bourdain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Pico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%20Bayon%22%2C%22lastName%22%3A%22De%20La%20Tour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Chadenat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Duc%20Long%22%2C%22lastName%22%3A%22Duong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Genty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Hirel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gurkan%22%2C%22lastName%22%3A%22Mutlu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Servan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Stanciu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Sudacevschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22Tir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-C%5Cu00e9cile%22%2C%22lastName%22%3A%22Troussi%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Yeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-C%5Cu00e9line%22%2C%22lastName%22%3A%22Zeghoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ikram%22%2C%22lastName%22%3A%22Tidafi-Bayou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Lachaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tae-Hee%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Mechtouff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Ritzenthaller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Derex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Albanesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Benoit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Berhoune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Felix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Esteban-Mader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%22%2C%22lastName%22%3A%22Sibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annabelle%22%2C%22lastName%22%3A%22Kazadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Rouanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Renou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Debruxelles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Poli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharmila%22%2C%22lastName%22%3A%22Sagnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Domigo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bodiguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Grimaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentin%22%2C%22lastName%22%3A%22Bohotin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Obadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Sabben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Morvan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Rodier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilfried%22%2C%22lastName%22%3A%22Vadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hilde%22%2C%22lastName%22%3A%22H%5Cu00e9non%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Cordonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Dumont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Bodenant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lucas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Dequatre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Alamowitch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Paul%22%2C%22lastName%22%3A%22Muresan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Drouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%22%2C%22lastName%22%3A%22Gallea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dalloz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Delorme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Yger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22B%5Cu00e9jot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Loisel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Bonnin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Bernigal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%20Victor%22%2C%22lastName%22%3A%22Osseby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Hervieu-B%5Cu00e8gue%22%2C%22lastName%22%3A%22Marsac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Accassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Epinat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Varvat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Do%5Cu00efna%22%2C%22lastName%22%3A%22Marinescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Triquenot-Bagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ozlem%22%2C%22lastName%22%3A%22Ozkul-Wermester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Philippeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%22%2C%22lastName%22%3A%22Olaru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Vieillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annie%22%2C%22lastName%22%3A%22Lannuzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Demoly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Wolff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihaela%22%2C%22lastName%22%3A%22Diaconu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Bataillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%20Macian%22%2C%22lastName%22%3A%22Montoro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Faugeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laeticia%22%2C%22lastName%22%3A%22Gimenez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Abdallah-Lebeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Timsit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%22%2C%22lastName%22%3A%22Viakhireva-Dovganyuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Tirel-Badets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Mathias%22%2C%22lastName%22%3A%22Merrien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Goas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Rouhart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Jourdain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Guillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22H%5Cu00e9rissson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Sevin-Allouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Olivot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alderic%22%2C%22lastName%22%3A%22Lecluse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Marc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Touz%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22De%20La%20Sayette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Apoil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Li%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cogez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Guettier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Godefroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Bugnicourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Taurin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22M%5Cu00e9rienne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Gere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22Chessak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tarik%22%2C%22lastName%22%3A%22Habet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Ferrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Bourgois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Minier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Caillier-Minier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Cont%5Cu00e9gal-Callier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Vion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Vaschalde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammed%22%2C%22lastName%22%3A%22El%20Amrani%2C%20Emilie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Zuber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Bruandet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Join-Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Serre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Faucheux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatia%22%2C%22lastName%22%3A%22Radji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Leca-Radu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Debroucker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodica%22%2C%22lastName%22%3A%22Cumurcuc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serkan%22%2C%22lastName%22%3A%22Cakmak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Peysson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Ellie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Bernady%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Montiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugeniu%22%2C%22lastName%22%3A%22Revenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Decavel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Medeiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Bouveret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Louchart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Vaduva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Couvreur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Alnajar-Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mich%5Cu00e8le%22%2C%22lastName%22%3A%22Levasseur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Louchart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Vandamme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Meresse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Stantescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Bataillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Canan%22%2C%22lastName%22%3A%22Ozsancak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katell%22%2C%22lastName%22%3A%22Beauvais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Auzou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9phine%22%2C%22lastName%22%3A%22Amevigbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Vuillemet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Dugay-Arentz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Carelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikel%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Maillet-Vioud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Escaillas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Chapuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Tardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Varnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jae%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoonkyung%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tae-Jin%22%2C%22lastName%22%3A%22Song%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jung-Hoon%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyung%20Chul%22%2C%22lastName%22%3A%22Noh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eun-Jae%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dong-Wha%22%2C%22lastName%22%3A%22Kang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sun%20Uck%22%2C%22lastName%22%3A%22Kwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boseoung%22%2C%22lastName%22%3A%22Kwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seongho%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dongwhane%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyuk%20Sung%22%2C%22lastName%22%3A%22Kwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daeun%22%2C%22lastName%22%3A%22Jeong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22MinHwan%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joonggoo%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanbin%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyo%20Jung%22%2C%22lastName%22%3A%22Nam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sang%20Hun%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bum%20Joon%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae-kwan%22%2C%22lastName%22%3A%22Cha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22DaeHyun%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rae%22%2C%22lastName%22%3A%22Young%20Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sang%20Wuk%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dong-Hyun%22%2C%22lastName%22%3A%22Shim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyungjin%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyun-Wook%22%2C%22lastName%22%3A%22Nah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sang%20Min%22%2C%22lastName%22%3A%22Sung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyung%20Bok%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeong%20Yoon%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jee%20Eun%22%2C%22lastName%22%3A%22Yoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eung-Gyu%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jung%20Hwa%22%2C%22lastName%22%3A%22Seo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Won%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yangha%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Man%20Seok%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joon-Tae%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kang-Ho%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyo%20Suk%22%2C%22lastName%22%3A%22Nam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ji%20Hoe%22%2C%22lastName%22%3A%22Heo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Young%20Dae%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%20Gun%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyung%20Jong%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyoung%20Sub%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jang%20Hyun%22%2C%22lastName%22%3A%22Baek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dong%20Beom%22%2C%22lastName%22%3A%22Song%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joon%20Sang%22%2C%22lastName%22%3A%22Yoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jong-Moo%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ohyun%22%2C%22lastName%22%3A%22Kwon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Woong-Woo%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jung-Ju%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyusik%22%2C%22lastName%22%3A%22Kang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Byung%20Kun%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae-Sung%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mi%20Sun%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyung-Ho%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bora%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihoon%22%2C%22lastName%22%3A%22Jang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seyoung%22%2C%22lastName%22%3A%22Jang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jung%20Eun%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jei%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hye%20Seon%22%2C%22lastName%22%3A%22Jeong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keun%20Sik%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hong%20Kyun%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong%20Jin%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oh%20Young%22%2C%22lastName%22%3A%22Bang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Woo-Keun%22%2C%22lastName%22%3A%22Seo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jongwon%22%2C%22lastName%22%3A%22Chung%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20TST%20trial%20%28Treat%20Stroke%20to%20Target%29%20evaluated%20the%20benefit%20of%20targeting%20a%20LDL%20%28low-density%20lipoprotein%29%20cholesterol%20of%20%3C70%20mg%5C%2FdL%20to%20reduce%20the%20risk%20of%20cardiovascular%20events%20in%202860%20patients%20with%20ischemic%20stroke%20with%20atherosclerotic%20stenosis%20of%20cerebral%20vasculature%20or%20aortic%20arch%20plaque%20%3E4%20mm%2C%20in%20a%20French%20and%20Korean%20population.%20The%20follow-up%20lasted%20a%20median%20of%205.3%20years%20in%20French%20patients%20%28similar%20to%20the%20median%20follow-up%20time%20in%20the%20SPARCL%20trial%20%5BStroke%20Prevention%20by%20Aggressive%20Reduction%20in%20Cholesterol%20Level%5D%29%20and%202.0%20years%20in%20Korean%20patients.%20Exposure%20duration%20to%20statin%20is%20a%20well-known%20driver%20for%20cardiovascular%20risk%20reduction.%20We%20report%20here%20the%20TST%20results%20in%20the%20French%20cohort.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20One%20thousand%20seventy-three%20French%20patients%20were%20assigned%20to%20%3C70%20mg%5C%2FdL%20%281.8%20mmol%5C%2FL%29%20and%201075%20to%20100%5Cu00b110%20mg%5C%2FdL%20%2890%5Cu2013110%20mg%5C%2FdL%2C%202.3%5Cu20132.8%20mmol%5C%2FL%29.%20To%20achieve%20these%20goals%2C%20investigators%20used%20the%20statin%20and%20dosage%20of%20their%20choice%20and%20added%20ezetimibe%20on%20top%20if%20needed.%20The%20primary%20outcome%20was%20the%20composite%20of%20ischemic%20stroke%2C%20myocardial%20infarction%2C%20new%20symptoms%20requiring%20urgent%20coronary%20or%20carotid%20revascularization%20and%20vascular%20death.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20a%20median%20follow-up%20of%205.3%20years%2C%20the%20achieved%20LDL%20cholesterol%20was%2066%20%281.69%20mmol%5C%2FL%29%20and%2096%20mg%5C%2FdL%20%282.46%20mmol%5C%2FL%29%20on%20average%2C%20respectively.%20The%20primary%20end%20point%20occurred%20in%209.6%25%20and%2012.9%25%20of%20patients%2C%20respectively%20%28HR%2C%200.74%20%5B95%25%20CI%2C%200.57%5Cu20130.94%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.019%29.%20Cerebral%20infarction%20or%20urgent%20carotid%20revascularization%20following%20transient%20ischemic%20attack%20was%20reduced%20by%2027%25%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.046%29.%20Cerebral%20infarction%20or%20intracranial%20hemorrhage%20was%20reduced%20by%2028%25%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.023%29.%20The%20primary%20outcome%20or%20intracranial%20hemorrhage%20was%20reduced%20by%2025%25%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.021%29.%20Intracranial%20hemorrhages%20occurred%20in%2013%20and%2011%20patients%2C%20respectively%20%28HR%2C%201.17%20%5B95%25%20CI%2C%200.53%5Cu20132.62%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.70%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20an%20ischemic%20stroke%20of%20documented%20atherosclerotic%20origin%2C%20targeting%20a%20LDL%20cholesterol%20of%20%3C70%20mg%5C%2FdL%20during%205.3%20years%20avoided%201%20subsequent%20major%20vascular%20event%20in%204%20%28number%20needed%20to%20treat%20of%2030%29%20and%20no%20increase%20in%20intracranial%20hemorrhage.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01252875.%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.119.028718%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.119.028718%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22JFUSBQHE%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kamel%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EKamel%20H%2C%20Pearce%20LA%2C%20Ntaios%20G%2C%20Gladstone%20DJ%2C%20Perera%20K%2C%20Roine%20RO%2C%20Meseguer%20E%2C%20Shoamanesh%20A%2C%20Berkowitz%20SD%2C%20Mundl%20H%2C%20Sharma%20M%2C%20Connolly%20SJ%2C%20Hart%20RG%2C%20Healey%20JS.%202020.%20Atrial%20Cardiopathy%20and%20Nonstenosing%20Large%20Artery%20Plaque%20in%20Patients%20With%20Embolic%20Stroke%20of%20Undetermined%20Source.%20Stroke%2051%3A938%26%23x2013%3B943.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Atrial%20Cardiopathy%20and%20Nonstenosing%20Large%20Artery%20Plaque%20in%20Patients%20With%20Embolic%20Stroke%20of%20Undetermined%20Source%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hooman%22%2C%22lastName%22%3A%22Kamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lesly%20A.%22%2C%22lastName%22%3A%22Pearce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Ntaios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Gladstone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanjana%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Risto%20O.%22%2C%22lastName%22%3A%22Roine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashkan%22%2C%22lastName%22%3A%22Shoamanesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Berkowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardi%22%2C%22lastName%22%3A%22Mundl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mukul%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20G.%22%2C%22lastName%22%3A%22Hart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeff%20S.%22%2C%22lastName%22%3A%22Healey%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Atrial%20cardiopathy%20and%20atherosclerotic%20plaque%20are%20two%20potential%20mechanisms%20underlying%20embolic%20strokes%20of%20undetermined%20source%20%28ESUS%29.%20The%20relationship%20between%20these%20two%20mechanisms%20among%20ESUS%20patients%20remains%20unclear.%20A%20better%20understanding%20of%20their%20association%20may%20inform%20targeted%20secondary%20prevention%20strategies.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20examined%20the%20association%20between%20atrial%20cardiopathy%20and%20atherosclerotic%20plaque%20in%20the%20NAVIGATE%20ESUS%20trial%20%28New%20Approach%20Rivaroxaban%20Inhibition%20of%20Factor%20Xa%20in%20a%20Global%20Trial%20Versus%20ASA%20to%20Prevent%20Embolism%20in%20Embolic%20Stroke%20of%20Undetermined%20Source%29%2C%20which%20enrolled%207213%20patients%20with%20recent%20ESUS%20during%202014%20to%202017.%20For%20this%20analysis%2C%20we%20included%20patients%20with%20data%20on%20left%20atrial%20dimension%2C%20location%20of%20brain%20infarction%2C%20and%20cervical%20large%20artery%20plaque.%20The%20variables%20of%20primary%20interest%20were%20left%20atrial%20diameter%20and%20cervical%20plaque%20ipsilateral%20to%20brain%20infarction.%20Secondary%20markers%20of%20atrial%20cardiopathy%20were%20premature%20atrial%20contractions%20on%20Holter%20monitoring%20and%20newly%20diagnosed%20atrial%20fibrillation.%20For%20descriptive%20purposes%2C%20left%20atrial%20enlargement%20was%20defined%20as%20%5Cu22654.7%20cm.%20Multivariable%20logistic%20regression%20was%20used%20to%20examine%20the%20association%20between%20atrial%20cardiopathy%20markers%20and%20ipsilateral%20plaque%20after%20adjustment%20for%20age%2C%20sex%2C%20body%20mass%20index%2C%20hypertension%2C%20diabetes%20mellitus%2C%20current%20smoking%2C%20and%20hyperlipidemia.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%203983%20eligible%20patients%2C%20235%20%285.9%25%29%20had%20left%20atrial%20enlargement%2C%20939%20%2823.6%25%29%20had%20ipsilateral%20plaque%2C%20and%2094%20%282.4%25%29%20had%20both.%20Shared%20risk%20factors%20for%20left%20atrial%20enlargement%20and%20ipsilateral%20plaque%20were%20male%20sex%2C%20white%20race%2C%20hypertension%2C%20tobacco%20use%2C%20and%20coronary%20artery%20disease.%20Despite%20shared%20risk%20factors%2C%20increasing%20left%20atrial%20dimension%20was%20not%20associated%20with%20ipsilateral%20plaque%20after%20adjustment%20for%20covariates%20%28odds%20ratio%20per%20cm%2C%201.1%20%5B95%25%20CI%2C%201.0%5Cu20131.2%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.08%29.%20We%20found%20no%20consistent%20associations%20between%20secondary%20markers%20of%20atrial%20cardiopathy%20and%20ipsilateral%20plaque.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20a%20large%20population%20of%20patients%20with%20ESUS%2C%20we%20did%20not%20observe%20a%20notable%20association%20between%20atrial%20cardiopathy%20and%20atherosclerotic%20plaque%2C%20and%20few%20patients%20had%20both%20conditions.%20These%20findings%20suggest%20that%20atrial%20cardiopathy%20and%20atherosclerotic%20plaque%20may%20be%20distinct%2C%20nonoverlapping%20risk%20factors%20for%20stroke%20among%20ESUS%20patients.%22%2C%22date%22%3A%2203%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.119.028154%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.119.028154%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22AUIGMEPW%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cheng%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECheng%20B%2C%20Boutitie%20F%2C%20Nickel%20A%2C%20Wouters%20A%2C%20Cho%20T-H%2C%20Ebinger%20M%2C%20Endres%20M%2C%20Fiebach%20JB%2C%20Fiehler%20J%2C%20Galinovic%20I%2C%20Puig%20J%2C%20Thijs%20V%2C%20Lemmens%20R%2C%20Muir%20KW%2C%20Nighoghossian%20N%2C%20Pedraza%20S%2C%20Simonsen%20CZ%2C%20Gerloff%20C%2C%20Thomalla%20G%2C%20on%20behalf%20of%20the%20WAKE-UP%20Investigators%2A%2C%20Golsari%20A%2C%20Alegiani%20A%2C%20Beck%20C%2C%20Choe%20C%2C%20Voget%20D%2C%20Hoppe%20J%2C%20Schr%26%23xF6%3Bder%20J%2C%20Rozanski%20M%2C%20Nave%20AH%2C%20Wollboldt%20C%2C%20Van%20Sloten%20I%2C%20G%26%23xF6%3Bhler%20J%2C%20Herm%20J%2C%20Jungeh%26%23xFC%3Blsing%20J%2C%20L%26%23xFC%3Bckl%20J%2C%20Kr%26%23xF6%3Bber%20JM%2C%20Schurig%20J%2C%20Koehler%20L%2C%20Schlemm%20L%2C%20Knops%20M%2C%20Roennefarth%20M%2C%20Ipsen%20N%2C%20Harmel%20P%2C%20Bathe-Peters%20R%2C%20Fleischmann%20R%2C%20Ganeshan%20R%2C%20Geran%20R%2C%20Hellwig%20S%2C%20Schmidt%20S%2C%20T%26%23xFC%3Bt%26%23xFC%3Bnc%26%23xFC%3B%20S%2C%20Krause%20T%2C%20Gramse%20V%2C%20R%26%23xF6%3Bther%20J%2C%20Michels%20P%2C%20Michalski%20D%2C%20Pelz%20J%2C%20Schulz%20A%2C%20Hobohm%20C%2C%20Weise%20C%2C%20Weise%20G%2C%20Orthgie%26%23xDF%3B%20J%2C%20Pomrehn%20K%2C%20Wegscheider%20M%2C%20Mueller%20AK%2C%20Hennerici%20M%2C%20Griebe%20M%2C%20Alonso%20A%2C%20Filipov%20A%2C%20Marzina%20A%2C%20Anders%20B%2C%20B%26%23xE4%3Bhr%20C%2C%20Hoyer%20C%2C%20Schwarzbach%20C%2C%20Weber%20C%2C%20Hornberger%20E%2C%20Pledl%20H-W%2C%20Klockziem%20M%2C%20Stuermlinger%20M%2C%20Wittayer%20M%2C%20Wolf%20M%2C%20Meyer%20N%2C%20Eisele%20P%2C%20Steinert%20S%2C%20Sauer%20T%2C%20Held%20V%2C%20Ringleb%20P%2C%20Nagel%20S%2C%20Veltkamp%20R%2C%20Schwarting%20S%2C%20Schwarz%20A%2C%20Gumbinger%20C%2C%20Hametner%20C%2C%20Amiri%20H%2C%20Purrucker%20J%2C%20Ciatipis%20M%2C%20Menn%20O%2C%20Mundiyanapurath%20S%2C%20Schieber%20S%2C%20Kessler%20T%2C%20Reiff%20T%2C%20Panitz%20V%2C%20Singer%20O%2C%20Foerch%20C%2C%20Lauer%20A%2C%20M%26%23xE4%3Bnner%20A%2C%20Seiler%20A%2C%20Guerzoglu%20D%2C%20Sch%26%23xE4%3Bfer%20JH%2C%20Filipski%20K%2C%20Lorenz%20M%2C%20Kurka%20N%2C%20Zeiner%20P%2C%20Pfeilschifter%20W%2C%20Dziewas%20R%2C%20Minnerup%20J%2C%20Albiker%20C%2C%20Ritter%20M%2C%20Seidel%20M%2C%20Dittrich%20R%2C%20Kallm%26%23xFC%3Bnzer%20B%2C%20Bobinger%20T%2C%20Madzar%20D%2C%20Stark%20D%2C%20Sembill%20J%2C%20Macha%20K%2C%20Winder%20K%2C%20Breuer%20L%2C%20Koehrmann%20M%2C%20Spruegel%20M%2C%20Gerner%20S%2C%20Kraft%20P%2C%20Mackenrodt%20D%2C%20Kleinschnitz%20C%2C%20Elhfnawy%20A%2C%20Heinen%20F%2C%20Gunreben%20I%2C%20Poli%20S%2C%20Ziemann%20U%2C%20Gaenslen%20A%2C%20Schlak%20D%2C%20Haertig%20F%2C%20Russo%20F%2C%20Richter%20H%2C%20Ebner%20M%2C%20Ribitsch%20M%2C%20Wolf%20M%2C%20Weimar%20C%2C%20Zegarac%20V%2C%20Chen%20H-C%2C%20Althaus%20K%2C%20Neugebauer%20H%2C%20J%26%23xFC%3Bttler%20E%2C%20Meier%20J%2C%20St%26%23xF6%3Bsser%20S%2C%20Puetz%20V%2C%20Bodechtel%20U%2C%20Ostergaard%20L%2C%20M%26%23xF8%3Bller%20A%2C%20Damgaard%20D%2C%20Dupont%20KH%2C%20Poulsen%20M%2C%20Hjort%20N%2C%20De%20Morales%20NR%2C%20Von%20Weitzel%20P%2C%20Harbo%20T%2C%20Marstrand%20J%2C%20Hansen%20A%2C%20Christensen%20H%2C%20Aegidius%20K%2C%20Jeppesen%20L%2C%20Meden%20P%2C%20Rosenbaum%20S%2C%20Iversen%20H%2C%20Hansen%20J%2C%20Michelsen%20L%2C%20Truelsen%20T%2C%20Modrau%20B%2C%20Vestergaard%20K%2C%20Oppel%20L%2C%20Sygehus%20A%2C%20Aalborg%20S%2C%20Swinnen%20B%2C%20Smets%20I%2C%20Demeestere%20J%2C%20Dobbels%20L%2C%20Brouns%20R%2C%20De%20Smedt%20A%2C%20DeKeyser%20J%2C%20Yperzeele%20L%2C%20Van%20Hooff%20R-J%2C%20Peeters%20A%2C%20Dusart%20A%2C%20Etexberria%20A%2C%20Hanseeuw%20B%2C%20London%20F%2C%20Leempoel%20J%2C%20Hohenbichler%20K%2C%20Younan%20N%2C%20Maqueda%20V%2C%20Laloux%20P%2C%20De%20Coene%20B%2C%20De%20Maeseneire%20C%2C%20Turine%20G%2C%20Vandermeeren%20Y%2C%20De%20Klippel%20N%2C%20Willems%20C%2C%20De%20Hollander%20I%2C%20Soors%20P%2C%20Hermans%20S%2C%20Hemelsoet%20D%2C%20Desfontaines%20P%2C%20Vanacker%20P%2C%20Rutgers%20M%2C%20Druart%20C%2C%20Peeters%20D%2C%20Bruneel%20B%2C%20Vancaester%20E%2C%20Vanhee%20F%2C%20Meersman%20G%2C%20Bourgeois%20P%2C%20Vanderdonckt%20P%2C%20Benoit%20A%2C%20Derex%20L%2C%20Mechthouff%20L%2C%20Berhoune%20N%2C%20Ritzenthaler%20T%2C%20Amarenco%20P%2C%20Hobeanu%20C%2C%20Gancedo%20EM%2C%20Calvet%20D%2C%20Ladoux%20A%2C%20Machet%20A%2C%20Lamy%20C%2C%20Mellerio%20C%2C%20Oppenheim%20C%2C%20Rodriguez-Regent%20C%2C%20Bodiguel%20E%2C%20Turc%20G%2C%20Birchenall%20J%2C%20Legrand%20L%2C%20Morin%20L%2C%20Edjali-Goujon%20M%2C%20Naggara%20O%2C%20Raphaelle%20S%2C%20Godon-Hardy%20S%2C%20Domigo%20V%2C%20Guiraud%20V%2C%20Samson%20Y%2C%20Leger%20A%2C%20Rosso%20C%2C%20Baronnet-Chauvet%20F%2C%20Crozier%20S%2C%20Deltour%20S%2C%20Yger%20M%2C%20Sibon%20I%2C%20Renou%20P%2C%20Sagnier%20S%2C%20Zuber%20M%2C%20Tamazyan%20R%2C%20Rodier%20G%2C%20Morel%20N%2C%20Felix%20S%2C%20Vadot%20W%2C%20Wolff%20V%2C%20Aniculaesei%20A%2C%20Yalo%20B%2C%20Bindila%20D%2C%20Quenardelle%20V%2C%20Blanc-Lasserre%20K%2C%20Landrault%20E%2C%20Breynaert%20L%2C%20Cakmak%20S%2C%20Peysson%20S%2C%20Viguier%20A%2C%20Lebely%20C%2C%20Raposo%20N%2C%20Vallet%20A-E%2C%20Vallet%20P%2C%20Brugirard%20S%2C%20Cheripelli%20B%2C%20Kalladka%20D%2C%20Moreton%20F%2C%20Dani%20K%2C%20Tawil%20SE%2C%20Ramachandran%20S%2C%20Huang%20X%2C%20Warburton%20E%2C%20Evans%20N%2C%20Perry%20R%2C%20Patel%20B%2C%20Cloud%20G%2C%20Pereira%20A%2C%20Moynihan%20B%2C%20Lovelock%20C%2C%20Choy%20L%2C%20Khan%20U%2C%20Roffe%20C%2C%20Tyrell%20P%2C%20Smith%20C%2C%20Dixit%20A%2C%20Louw%20S%2C%20Broughton%20D%2C%20Shetty%20A%2C%20Appleton%20J%2C%20Sprigg%20N%2C%20Acosta%20BR%2C%20Van%20Eendenburg%20C%2C%20Leal%20JS%2C%20Mar%20Castellanos%20Rodrigo%20MD%2C%20Izaga%20MT%2C%20Guillamon%20OB%2C%20Arenillas%20J%2C%20Calleja%20A%2C%20Cortijo%20E%2C%20Mulero%20P%2C%20De%20La%20Ossa%20NP%2C%20Garrido%20A%2C%20Martinez%20A%2C%20Esper%26%23xF3%3Bn%20CG%2C%20Guerrero%20C%2C%20Carrera%20D%2C%20Vilas%20D%2C%20Lopez-cancio%20E%2C%20Palomeras%20E%2C%20Lucente%20G%2C%20Gomis%20M%2C%20Isern%20I%2C%20Becerra%20JL%2C%20Vicente%20JH%2C%20S%26%23xE1%3Bnchez%20J%2C%20Dorado%20L%2C%20Grau%20L%2C%20Ispierto%20L%2C%20Prats%20L%2C%20Almendrote%20M%2C%20Hern%26%23xE1%3Bndez%20M%2C%20Jimenez%20M%2C%20S%26%23xE1%3Bnchez%20ML%2C%20Torne%20MM%2C%20Presas%20S%2C%20Ustrell%20X%2C%20Pellis%26%23xE9%3B%20A%2C%20Navalpotro%20I%2C%20Luna%20A%2C%20Schonewille%20W%2C%20Nederkoorn%20P%2C%20Majoie%20C%2C%20Van%20Den%20Berg%20L%2C%20Van%20Den%20Berg%20S%2C%20Zonneveld%20T%2C%20Remmers%20M%2C%20Fazekas%20F%2C%20Pichler%20A%2C%20Fandler%20S%2C%20Gattringer%20T%2C%20Mutzenbach%20J%2C%20Weber%20J%2C%20H%26%23xF6%3Bfner%20E%2C%20Kohlf%26%23xFC%3Brst%20H%2C%20Weinstich%20K%2C%20Kellert%20L%2C%20Bayer-Karpinska%20A%2C%20Opherk%20C%2C%20Wollenweber%20F%2C%20Klein%20M%2C%20Neumann-%20Haefelin%20T%2C%20Pierskalla%20A%2C%20Harloff%20A%2C%20Bardutzky%20J%2C%20Buggle%20F%2C%20Von%20Schrader%20J%2C%20Kollmar%20R%2C%20Schill%20J%2C%20L%26%23xF6%3Bbbe%20A-M%2C%20Moulin%20T%2C%20Bouamra%20B%2C%20Bonnet%20L%2C%20Touz%26%23xE9%3B%20E%2C%20Bonnet%20A-L%2C%20Touze%20E%2C%20Cogez%20J%2C%20Li%20L%2C%20Guettier%20S%2C%20Kar%20A%2C%20Sivagnanaratham%20A%2C%20Geraghty%20O%2C%20Bojaryn%20U%2C%20Nallasivan%20A%2C%20Gonzales%20MB%2C%20Rodr%26%23xED%3Bguez-Y%26%23xE1%3B%26%23xF1%3Bez%20M%2C%20Tembl%20J%2C%20Gorriz%20D%2C%20Oberndorfer%20S%2C%20Prohaska%20E.%202020.%20Quantitative%20Signal%20Intensity%20in%20Fluid-Attenuated%20Inversion%20Recovery%20and%20Treatment%20Effect%20in%20the%20WAKE-UP%20Trial.%20Stroke%2051%3A209%26%23x2013%3B215.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quantitative%20Signal%20Intensity%20in%20Fluid-Attenuated%20Inversion%20Recovery%20and%20Treatment%20Effect%20in%20the%20WAKE-UP%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastian%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Boutitie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alina%22%2C%22lastName%22%3A%22Nickel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anke%22%2C%22lastName%22%3A%22Wouters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tae-Hee%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Ebinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Endres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jochen%20B.%22%2C%22lastName%22%3A%22Fiebach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Fiehler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivana%22%2C%22lastName%22%3A%22Galinovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%22%2C%22lastName%22%3A%22Puig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Thijs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Lemmens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20W.%22%2C%22lastName%22%3A%22Muir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Nighoghossian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salvador%22%2C%22lastName%22%3A%22Pedraza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claus%20Z.%22%2C%22lastName%22%3A%22Simonsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Gerloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00f6tz%22%2C%22lastName%22%3A%22Thomalla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20WAKE-UP%20Investigators%2A%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amir%22%2C%22lastName%22%3A%22Golsari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Alegiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Beck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chi-un%22%2C%22lastName%22%3A%22Choe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dieke%22%2C%22lastName%22%3A%22Voget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Hoppe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julian%22%2C%22lastName%22%3A%22Schr%5Cu00f6der%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Rozanski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20H.%22%2C%22lastName%22%3A%22Nave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Wollboldt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Van%20Sloten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%22%2C%22lastName%22%3A%22G%5Cu00f6hler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliane%22%2C%22lastName%22%3A%22Herm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Jungeh%5Cu00fclsing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janos%22%2C%22lastName%22%3A%22L%5Cu00fcckl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20M.%22%2C%22lastName%22%3A%22Kr%5Cu00f6ber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Schurig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luzie%22%2C%22lastName%22%3A%22Koehler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludwig%22%2C%22lastName%22%3A%22Schlemm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Knops%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Roennefarth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Ipsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Harmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rouven%22%2C%22lastName%22%3A%22Bathe-Peters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Fleischmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramanan%22%2C%22lastName%22%3A%22Ganeshan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohat%22%2C%22lastName%22%3A%22Geran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Hellwig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sein%22%2C%22lastName%22%3A%22Schmidt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serdar%22%2C%22lastName%22%3A%22T%5Cu00fct%5Cu00fcnc%5Cu00fc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Krause%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Verena%22%2C%22lastName%22%3A%22Gramse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joachim%22%2C%22lastName%22%3A%22R%5Cu00f6ther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Michels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominik%22%2C%22lastName%22%3A%22Michalski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johann%22%2C%22lastName%22%3A%22Pelz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Schulz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%22%2C%22lastName%22%3A%22Hobohm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Weise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gesa%22%2C%22lastName%22%3A%22Weise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Orthgie%5Cu00df%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%22%2C%22lastName%22%3A%22Pomrehn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mirko%22%2C%22lastName%22%3A%22Wegscheider%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20K.%22%2C%22lastName%22%3A%22Mueller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Hennerici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Griebe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelika%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Filipov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annika%22%2C%22lastName%22%3A%22Marzina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Anders%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22B%5Cu00e4hr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolin%22%2C%22lastName%22%3A%22Hoyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Schwarzbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Hornberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Werner%22%2C%22lastName%22%3A%22Pledl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matti%22%2C%22lastName%22%3A%22Klockziem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Markus%22%2C%22lastName%22%3A%22Stuermlinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Wittayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Wolf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadja%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Eisele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanne%22%2C%22lastName%22%3A%22Steinert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamara%22%2C%22lastName%22%3A%22Sauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentin%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Ringleb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Nagel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roland%22%2C%22lastName%22%3A%22Veltkamp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00f6nke%22%2C%22lastName%22%3A%22Schwarting%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Schwarz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Gumbinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hametner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hemasse%22%2C%22lastName%22%3A%22Amiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Purrucker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mareva%22%2C%22lastName%22%3A%22Ciatipis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Menn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sibu%22%2C%22lastName%22%3A%22Mundiyanapurath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Schieber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Kessler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tilman%22%2C%22lastName%22%3A%22Reiff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Verena%22%2C%22lastName%22%3A%22Panitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Singer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Foerch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arne%22%2C%22lastName%22%3A%22Lauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anika%22%2C%22lastName%22%3A%22M%5Cu00e4nner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Seiler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damla%22%2C%22lastName%22%3A%22Guerzoglu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20H.%22%2C%22lastName%22%3A%22Sch%5Cu00e4fer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Filipski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Lorenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Kurka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pia%22%2C%22lastName%22%3A%22Zeiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waltraud%22%2C%22lastName%22%3A%22Pfeilschifter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rainer%22%2C%22lastName%22%3A%22Dziewas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Minnerup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Albiker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Ritter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Seidel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Dittrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernd%22%2C%22lastName%22%3A%22Kallm%5Cu00fcnzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Bobinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominik%22%2C%22lastName%22%3A%22Madzar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Stark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jochen%22%2C%22lastName%22%3A%22Sembill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kosmas%22%2C%22lastName%22%3A%22Macha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klemens%22%2C%22lastName%22%3A%22Winder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenz%22%2C%22lastName%22%3A%22Breuer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Koehrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maximilian%22%2C%22lastName%22%3A%22Spruegel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Gerner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Kraft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Mackenrodt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Kleinschnitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Elhfnawy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Heinen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignaz%22%2C%22lastName%22%3A%22Gunreben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sven%22%2C%22lastName%22%3A%22Poli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulf%22%2C%22lastName%22%3A%22Ziemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Gaenslen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dennis%22%2C%22lastName%22%3A%22Schlak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Haertig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Russo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardy%22%2C%22lastName%22%3A%22Richter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Ebner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Ribitsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Wolf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Weimar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vesna%22%2C%22lastName%22%3A%22Zegarac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hsin-Chieh%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Althaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hermann%22%2C%22lastName%22%3A%22Neugebauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22J%5Cu00fcttler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Meier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22St%5Cu00f6sser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volker%22%2C%22lastName%22%3A%22Puetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulf%22%2C%22lastName%22%3A%22Bodechtel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leif%22%2C%22lastName%22%3A%22Ostergaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anette%22%2C%22lastName%22%3A%22M%5Cu00f8ller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorte%22%2C%22lastName%22%3A%22Damgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristina%20Hougaard%22%2C%22lastName%22%3A%22Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marika%22%2C%22lastName%22%3A%22Poulsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niels%22%2C%22lastName%22%3A%22Hjort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noelia%20Ruiz%22%2C%22lastName%22%3A%22De%20Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Von%20Weitzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Harbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22Marstrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanne%22%2C%22lastName%22%3A%22Christensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Aegidius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Jeppesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Meden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sverre%22%2C%22lastName%22%3A%22Rosenbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helle%22%2C%22lastName%22%3A%22Iversen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakob%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lene%22%2C%22lastName%22%3A%22Michelsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Truelsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boris%22%2C%22lastName%22%3A%22Modrau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karsten%22%2C%22lastName%22%3A%22Vestergaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenz%22%2C%22lastName%22%3A%22Oppel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aalborg%22%2C%22lastName%22%3A%22Sygehus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Syd%22%2C%22lastName%22%3A%22Aalborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bart%22%2C%22lastName%22%3A%22Swinnen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ide%22%2C%22lastName%22%3A%22Smets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jelle%22%2C%22lastName%22%3A%22Demeestere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurens%22%2C%22lastName%22%3A%22Dobbels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raf%22%2C%22lastName%22%3A%22Brouns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22De%20Smedt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22DeKeyser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetita%22%2C%22lastName%22%3A%22Yperzeele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robbert-%20Jan%22%2C%22lastName%22%3A%22Van%20Hooff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Peeters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Dusart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Etexberria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Hanseeuw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22London%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Leempoel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Hohenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Younan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vicky%22%2C%22lastName%22%3A%22Maqueda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Laloux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatrijs%22%2C%22lastName%22%3A%22De%20Coene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22De%20Maeseneire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetane%22%2C%22lastName%22%3A%22Turine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Vandermeeren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22De%20Klippel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Willems%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%22%2C%22lastName%22%3A%22De%20Hollander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Soors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvia%22%2C%22lastName%22%3A%22Hermans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitri%22%2C%22lastName%22%3A%22Hemelsoet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Desfontaines%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanacker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Rutgers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Druart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22Peeters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bart%22%2C%22lastName%22%3A%22Bruneel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evelien%22%2C%22lastName%22%3A%22Vancaester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederik%22%2C%22lastName%22%3A%22Vanhee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Meersman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Bourgeois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vanderdonckt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Benoit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Derex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Mechthouff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Berhoune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Ritzenthaler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Hobeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%20Meseguer%22%2C%22lastName%22%3A%22Gancedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Calvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Ladoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Machet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Mellerio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Oppenheim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Rodriguez-Regent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bodiguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Turc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Birchenall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Legrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Edjali-Goujon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Naggara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soulliard%22%2C%22lastName%22%3A%22Raphaelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Godon-Hardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Domigo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Guiraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Samson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Leger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Rosso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flore%22%2C%22lastName%22%3A%22Baronnet-Chauvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Crozier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Deltour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Yger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%22%2C%22lastName%22%3A%22Sibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Renou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharmilla%22%2C%22lastName%22%3A%22Sagnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Zuber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruben%22%2C%22lastName%22%3A%22Tamazyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Rodier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Felix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilfried%22%2C%22lastName%22%3A%22Vadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Wolff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%22%2C%22lastName%22%3A%22Aniculaesei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Yalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Bindila%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Quenardelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Blanc-Lasserre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Landrault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Breynaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serkan%22%2C%22lastName%22%3A%22Cakmak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Peysson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Viguier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Lebely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Raposo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Evelyne%22%2C%22lastName%22%3A%22Vallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Vallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastian%22%2C%22lastName%22%3A%22Brugirard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bharath%22%2C%22lastName%22%3A%22Cheripelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dheeraj%22%2C%22lastName%22%3A%22Kalladka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fiona%22%2C%22lastName%22%3A%22Moreton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krishna%22%2C%22lastName%22%3A%22Dani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salwa%20El%22%2C%22lastName%22%3A%22Tawil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sankaranarayanan%22%2C%22lastName%22%3A%22Ramachandran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xuya%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Warburton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%22%2C%22lastName%22%3A%22Evans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Perry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhavni%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Cloud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%22%2C%22lastName%22%3A%22Moynihan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Lovelock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lillian%22%2C%22lastName%22%3A%22Choy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Roffe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pippa%22%2C%22lastName%22%3A%22Tyrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anand%22%2C%22lastName%22%3A%22Dixit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Louw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Broughton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashit%22%2C%22lastName%22%3A%22Shetty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Appleton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikola%22%2C%22lastName%22%3A%22Sprigg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boris%20Raul%22%2C%22lastName%22%3A%22Acosta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecile%22%2C%22lastName%22%3A%22Van%20Eendenburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joaquin%20Serena%22%2C%22lastName%22%3A%22Leal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Del%22%2C%22lastName%22%3A%22Mar%20Castellanos%20Rodrigo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikel%20Terceno%22%2C%22lastName%22%3A%22Izaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%20Belch%5Cu00ed%22%2C%22lastName%22%3A%22Guillamon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Arenillas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Calleja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Cortijo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Mulero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%20P%5Cu00e9rez%22%2C%22lastName%22%3A%22De%20La%20Ossa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Garrido%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%20Garc%5Cu00eda%22%2C%22lastName%22%3A%22Esper%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Guerrero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Carrera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolores%22%2C%22lastName%22%3A%22Vilas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Lopez-cancio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Palomeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Lucente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meritxell%22%2C%22lastName%22%3A%22Gomis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%22%2C%22lastName%22%3A%22Isern%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20L.%22%2C%22lastName%22%3A%22Becerra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Hervas%22%2C%22lastName%22%3A%22Vicente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Dorado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laia%22%2C%22lastName%22%3A%22Grau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lourdes%22%2C%22lastName%22%3A%22Ispierto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Almendrote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Jimenez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%20Lozano%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%20Mill%5Cu00e1n%22%2C%22lastName%22%3A%22Torne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Presas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ustrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Pellis%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Navalpotro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Luna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wouter%22%2C%22lastName%22%3A%22Schonewille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Nederkoorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Majoie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Van%20Den%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Van%20Den%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Zonneveld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Remmers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz%22%2C%22lastName%22%3A%22Fazekas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Pichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Fandler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Gattringer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Mutzenbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00f6rg%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elmar%22%2C%22lastName%22%3A%22H%5Cu00f6fner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heinz%22%2C%22lastName%22%3A%22Kohlf%5Cu00fcrst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karin%22%2C%22lastName%22%3A%22Weinstich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Kellert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Bayer-Karpinska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Opherk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Wollenweber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Neumann-%20Haefelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Pierskalla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Harloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00fcrgen%22%2C%22lastName%22%3A%22Bardutzky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Buggle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00f6rg%22%2C%22lastName%22%3A%22Von%20Schrader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rainer%22%2C%22lastName%22%3A%22Kollmar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Schill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna-Mareike%22%2C%22lastName%22%3A%22L%5Cu00f6bbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Bouamra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Touz%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Touze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cogez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lin%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Guettier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arindam%22%2C%22lastName%22%3A%22Kar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aravinth%22%2C%22lastName%22%3A%22Sivagnanaratham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Geraghty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Urszula%22%2C%22lastName%22%3A%22Bojaryn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arumugam%22%2C%22lastName%22%3A%22Nallasivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%20Blanco%22%2C%22lastName%22%3A%22Gonzales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez-Y%5Cu00e1%5Cu00f1ez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Tembl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Gorriz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Oberndorfer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Prohaska%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Relative%20signal%20intensity%20of%20acute%20ischemic%20stroke%20lesions%20in%20fluid-attenuated%20inversion%20recovery%20%28fluid-attenuated%20inversion%20recovery%20relative%20signal%20intensity%20%5BFLAIR-rSI%5D%29%20magnetic%20resonance%20imaging%20is%20associated%20with%20time%20elapsed%20since%20stroke%20onset%20with%20higher%20intensities%20signifying%20longer%20time%20intervals.%20In%20the%20randomized%20controlled%20WAKE-UP%20trial%20%28Efficacy%20and%20Safety%20of%20MRI-Based%20Thrombolysis%20in%20Wake-Up%20Stroke%20Trial%29%2C%20intravenous%20alteplase%20was%20effective%20in%20patients%20with%20unknown%20onset%20stroke%20selected%20by%20visual%20assessment%20of%20diffusion%20weighted%20imaging%20fluid-attenuated%20inversion%20recovery%20mismatch%2C%20that%20is%2C%20in%20those%20with%20no%20marked%20fluid-attenuated%20inversion%20recovery%20hyperintensity%20in%20the%20region%20of%20the%20acute%20diffusion%20weighted%20imaging%20lesion.%20In%20this%20post%20hoc%20analysis%2C%20we%20investigated%20whether%20quantitatively%20measured%20FLAIR-rSI%20modifies%20treatment%20effect%20of%20intravenous%20alteplase.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20FLAIR-rSI%20of%20stroke%20lesions%20was%20measured%20relative%20to%20signal%20intensity%20in%20a%20mirrored%20region%20in%20the%20contralesional%20hemisphere.%20The%20relationship%20between%20FLAIR-rSI%20and%20treatment%20effect%20on%20functional%20outcome%20assessed%20by%20the%20modified%20Rankin%20Scale%20%28mRS%29%20after%2090%20days%20was%20analyzed%20by%20binary%20logistic%20regression%20using%20different%20end%20points%2C%20that%20is%2C%20favorable%20outcome%20defined%20as%20mRS%20score%20of%200%20to%201%2C%20independent%20outcome%20defined%20as%20mRS%20score%20of%200%20to%202%2C%20ordinal%20analysis%20of%20mRS%20scores%20%28shift%20analysis%29.%20All%20models%20were%20adjusted%20for%20National%20Institutes%20of%20Health%20Stroke%20Scale%20at%20symptom%20onset%20and%20stroke%20lesion%20volume.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20FLAIR-rSI%20was%20successfully%20quantified%20in%20stroke%20lesions%20in%20433%20patients%20%2886%25%20of%20503%20patients%20included%20in%20WAKE-UP%29.%20Mean%20FLAIR-rSI%20was%201.06%20%28SD%2C%200.09%29.%20Interaction%20of%20FLAIR-rSI%20and%20treatment%20effect%20was%20not%20significant%20for%20mRS%20score%20of%200%20to%201%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.169%29%20and%20shift%20analysis%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.086%29%20but%20reached%20significance%20for%20mRS%20score%20of%200%20to%202%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.004%29.%20We%20observed%20a%20smooth%20continuing%20trend%20of%20decreasing%20treatment%20effects%20in%20relation%20to%20clinical%20end%20points%20with%20increasing%20FLAIR-rSI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20in%20whom%20no%20marked%20parenchymal%20fluid-attenuated%20inversion%20recovery%20hyperintensity%20was%20detected%20by%20visual%20judgement%20in%20the%20WAKE-UP%20trial%2C%20higher%20FLAIR-rSI%20of%20diffusion%20weighted%20imaging%20lesions%20was%20associated%20with%20decreased%20treatment%20effects%20of%20intravenous%20thrombolysis.%20This%20parallels%20the%20known%20association%20of%20treatment%20effect%20and%20elapsing%20time%20of%20stroke%20onset.%22%2C%22date%22%3A%2201%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.119.027390%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.119.027390%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A42Z%22%7D%7D%2C%7B%22key%22%3A%222N78636V%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boccara%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBoccara%20F%2C%20Mary%26%23x2010%3BKrause%20M%2C%20Potard%20V%2C%20Teiger%20E%2C%20Lang%20S%2C%20Hammoudi%20N%2C%20Chauvet%20M%2C%20Ederhy%20S%2C%20Dufour%26%23x2010%3BSoulat%20L%2C%20Ancedy%20Y%2C%20Nhan%20P%2C%20Adavane%20S%2C%20Steg%20PhG%2C%20Funck%26%23x2010%3BBrentano%20C%2C%20Costagliola%20D%2C%20Cohen%20A%2C%20Weber%20S%2C%20Wahbi%20K%2C%20Beaufils%20P%2C%20Henri%20P%2C%20Sideris%20G%2C%20Thomas%20D%2C%20Montalescot%20G%2C%20Beygui%20F%2C%20Meuleman%20C%2C%20Janower%20S%2C%20Raoux%20F%2C%20Dufaitre%20G%2C%20Benyounes%20N%2C%20Michel%20PL%2C%20Petillon%20B%2C%20Hammoudi%20N%2C%20Gueret%20P%2C%20Dubois%26%23x2010%3BRande%20JL%2C%20Teiger%20E%2C%20Lim%20P%2C%20Slama%20M%2C%20Colin%20P%2C%20Saudubray%20C%2C%20Dubourg%20O%2C%20Milleron%20O%2C%20Gallet%20B%2C%20Duclos%20F%2C%20Godard%20S%2C%20Fuchs%20L%2C%20Dormagen%20V%2C%20Lewy%20P%2C%20Cattan%20S%2C%20Nallet%20O%2C%20Grollier%20G%2C%20Shayne%20J%2C%20Wolf%20JE%2C%20Cottin%20Y%2C%20Machecourt%20J%2C%20Bouvaist%20H%2C%20Finet%20G%2C%20De%20Breyne%20B%2C%20Trochu%20JN%2C%20Baudouy%20M%2C%20Ferrari%20E%2C%20Benhamou%20M%2C%20Allal%20J%2C%20Coisne%20D%2C%20Le%20Breton%20H%2C%20Bedossa%20M%2C%20Puel%20J%2C%20Elbaz%20M%2C%20Larifla%20L%2C%20Matheron%20S%2C%20Landman%20R%2C%20Fremont%20G%2C%20Spiridon%20G%2C%20Blanche%20P%2C%20Morini%20JP%2C%20Sicard%20D%2C%20Zeller%20V%2C%20Batisse%20D%2C%20Clevenbergh%20P%2C%20Cessot%20G%2C%20Dohin%20E%2C%20Valantin%20MA%2C%20Khelifa%20S%2C%20Girard%20PM%2C%20Lallemand%20F%2C%20Lefebvre%20B%2C%20Laporte%20JP%2C%20Meynard%20JL%2C%20Bideault%20H%2C%20Picard%20O%2C%20Meyohas%20MC%2C%20Campa%20P%2C%20Tredup%20J%2C%20Fonquernie%20L%2C%20Raguin%20G%2C%20Molina%20JM%2C%20Furco%20A%2C%20Gharakanian%20S%2C%20Vincensini%20JP%2C%20Guiard%26%23x2010%3BSchmid%20JB%2C%20Pialoux%20G%2C%20Cardon%20B%2C%20Lascaux%20AS%2C%20Chaix%20F%2C%20Lesprit%20P%2C%20Fior%20R%2C%20Boue%20F%2C%20Dupont%20C%2C%20Bellier%20C%2C%20Blanc%20A%2C%20Lambert%20T%2C%20Touahri%20T%2C%20Force%20G%2C%20De%20Truchis%20P%2C%20Compagnucci%26%23x2010%3BSeguenot%20MA%2C%20Cahitte%20I%2C%20Roudi%26%23xE8%3Bre%20L%2C%20Techer%20ME%2C%20Thelpin%20P%2C%20Troisvallets%20D%2C%20Lepretre%20A%2C%20Echard%20M%2C%20Le%20Mercier%20Y%2C%20Houlbert%20D%2C%20Dargere%20S%2C%20Bazin%20C%2C%20Verdon%20R%2C%20De%20Goer%20B%2C%20Duong%20M%2C%20Chavanet%20P%2C%20Gozlan%20E%2C%20Leclercq%20P%2C%20Brunel%26%23x2010%3BDal%20Mas%20F%2C%20Durant%20J%2C%20Heudier%20P%2C%20Brunet%26%23x2010%3BFran%26%23xE7%3Bois%20C%2C%20Le%20Moal%20G%2C%20Chapplin%20JM%2C%20Arvieux%20C%2C%20Chaumentin%20G%2C%20Guerin%20B%2C%20Bonnet%20E%2C%20Poinsignon%20Y%2C%20Boulard%20F%2C%20De%20Lacroix%20I%2C%20Goerger%26%23x2010%3BSow%20MT%2C%20Kirstetter%20M%2C%20Volstein%20M%2C%20Laylavoix%20F%2C%20Copin%20X%2C%20Ceppi%20C.%202020.%20HIV%20Infection%20and%20Long%26%23x2010%3BTerm%20Residual%20Cardiovascular%20Risk%20After%20Acute%20Coronary%20Syndrome.%20JAHA%209%3Ae017578.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20Infection%20and%20Long%5Cu2010Term%20Residual%20Cardiovascular%20Risk%20After%20Acute%20Coronary%20Syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Boccara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murielle%22%2C%22lastName%22%3A%22Mary%5Cu2010Krause%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Potard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Teiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadjib%22%2C%22lastName%22%3A%22Hammoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Chauvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Ederhy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurie%22%2C%22lastName%22%3A%22Dufour%5Cu2010Soulat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Ancedy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Nhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saroumadi%22%2C%22lastName%22%3A%22Adavane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Funck%5Cu2010Brentano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Costagliola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariel%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wahbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Beaufils%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Henri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sideris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Beygui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Meuleman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Janower%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Raoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Dufaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Benyounes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20L.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Petillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Hammoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Gueret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Dubois%5Cu2010Rande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Teiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Slama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Saudubray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Dubourg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Milleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Gallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Duclos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Godard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fuchs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Dormagen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lewy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cattan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Nallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Grollier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Shayne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Wolf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Machecourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bouvaist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Finet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22De%20Breyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20N.%22%2C%22lastName%22%3A%22Trochu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Baudouy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Benhamou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Coisne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Le%20Breton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bedossa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Puel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Elbaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Larifla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Matheron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Landman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fremont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Spiridon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Blanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Morini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Sicard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Zeller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Batisse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Clevenbergh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Cessot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Dohin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Valantin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khelifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Lallemand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Laporte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Meynard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bideault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Meyohas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Campa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Tredup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fonquernie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Raguin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Furco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gharakanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Vincensini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20B.%22%2C%22lastName%22%3A%22Guiard%5Cu2010Schmid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Pialoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Cardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%22%2C%22lastName%22%3A%22Lascaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lesprit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Fior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Boue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bellier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Blanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Touahri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Force%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22De%20Truchis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Compagnucci%5Cu2010Seguenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Cahitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Roudi%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Techer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Thelpin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Troisvallets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lepretre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Echard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Le%20Mercier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Houlbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Dargere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bazin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Verdon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22De%20Goer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Duong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Chavanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gozlan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Leclercq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brunel%5Cu2010Dal%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Durant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Heudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Brunet%5Cu2010Fran%5Cu00e7ois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Le%20Moal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Chapplin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Arvieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Chaumentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Guerin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Poinsignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Boulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22De%20Lacroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22Goerger%5Cu2010Sow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kirstetter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Volstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Laylavoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Copin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ceppi%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20It%20is%20unclear%20whether%20HIV%20infection%20affects%20the%20long%5Cu2010term%20prognosis%20after%20an%20acute%20coronary%20syndrome%20%28ACS%29.%20The%20objective%20of%20the%20current%20study%20was%20to%20compare%20rates%20of%20major%20adverse%20cardiac%20and%20cerebrovascular%20events%20after%20a%20first%20ACS%20between%20people%20living%20with%20HIV%20%28PLHIV%29%20and%20HIV%5Cu2010uninfected%20%28HIV%5Cu2212%29%20patients%2C%20and%20to%20identify%20determinants%20of%20cardiovascular%20prognosis.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Consecutive%20PLHIV%20and%20matched%20HIV%5Cu2212%20patients%20with%20a%20first%20episode%20of%20ACS%20were%20enrolled%20in%2023%20coronary%20intensive%20care%20units%20in%20France.%20Patients%20were%20matched%20for%20age%2C%20sex%2C%20and%20ACS%20type.%20The%20primary%20end%20point%20was%20major%20adverse%20cardiac%20and%20cerebrovascular%20events%20%28cardiac%20death%2C%20recurrent%20ACS%2C%20recurrent%20coronary%20revascularization%2C%20and%20stroke%29%20at%2036%5Cu2010month%20follow%5Cu2010up.%20A%20total%20of%20103%20PLHIV%20and%20195%20HIV%5Cu2212%20patients%20%28mean%20age%2C%2049%20years%20%5BSD%2C%209%20years%5D%3B%2094.0%25%20men%29%20were%20included.%20After%20a%20mean%20of%2036.6%20months%20%28SD%2C%206.1%20months%29%20of%20follow%5Cu2010up%2C%20the%20risk%20of%20major%20adverse%20cardiac%20and%20cerebrovascular%20events%20was%20not%20statistically%20significant%20between%20PLHIV%20and%20HIV%5Cu2212%20patients%20%2817.8%25%20and%2015.1%25%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.22%3B%20multivariable%20hazard%20ratio%20%5BHR%5D%2C%201.60%3B%2095%25%20CI%2C%200.67%5Cu20133.82%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.29%5D%29.%20Recurrence%20of%20ACS%20was%20more%20frequent%20among%20PLHIV%20%28multivariable%20HR%2C%206.31%3B%2095%25%20CI%2C%201.32%5Cu201330.21%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.02%5D%29.%20Stratified%20multivariable%20Cox%20models%20showed%20that%20HIV%20infection%20was%20the%20only%20independent%20predictor%20for%20ACS%20recurrence.%20PLHIV%20were%20less%20likely%20to%20stop%20smoking%20%2847%25%20versus%2075%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.01%29%20and%20had%20smaller%20total%20cholesterol%20decreases%20%28%5Cu201322.3%20versus%20%5Cu201335.0%5Cu00a0mg%5C%2FdL%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.04%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Although%20the%20overall%20risk%20of%20major%20adverse%20cardiac%20and%20cerebrovascular%20events%20was%20not%20statistically%20significant%20between%20PLHIV%20and%20HIV%5Cu2212%20individuals%2C%20PLHIV%20had%20a%20higher%20rate%20of%20recurrent%20ACS.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clini%5Cu200bcaltr%5Cu200bials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT00139958.%22%2C%22date%22%3A%2209%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.119.017578%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.119.017578%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22V39VCECT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Furtado%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFurtado%20RHM%2C%20Venkateswaran%20RV%2C%20Nicolau%20JC%2C%20Gurmu%20Y%2C%20Bhatt%20DL%2C%20Storey%20RF%2C%20Steg%20PG%2C%20Magnani%20G%2C%20Goto%20S%2C%20Dellborg%20M%2C%20Kamensky%20G%2C%20Isaza%20D%2C%20Aylward%20P%2C%20Johanson%20P%2C%20Bonaca%20MP.%202020.%20Caffeinated%20Beverage%20Intake%2C%20Dyspnea%20With%20Ticagrelor%2C%20and%20Cardiovascular%20Outcomes%3A%20Insights%20From%20the%20PEGASUS%26%23x2010%3BTIMI%2054%20Trial.%20JAHA%209%3Ae015785.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Caffeinated%20Beverage%20Intake%2C%20Dyspnea%20With%20Ticagrelor%2C%20and%20Cardiovascular%20Outcomes%3A%20Insights%20From%20the%20PEGASUS%5Cu2010TIMI%2054%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Remo%20H.%20M.%22%2C%22lastName%22%3A%22Furtado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramkumar%20V.%22%2C%22lastName%22%3A%22Venkateswaran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20C.%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Gurmu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuglia%22%2C%22lastName%22%3A%22Magnani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinya%22%2C%22lastName%22%3A%22Goto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Dellborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Kamensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Isaza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Aylward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Johanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Bonaca%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20proposed%20cause%20of%20dyspnea%20induced%20by%20ticagrelor%20is%20an%20increase%20in%20adenosine%20blood%20levels.%20Because%20caffeine%20is%20an%20adenosine%20antagonist%2C%20it%20can%20potentially%20improve%20drug%20tolerability%20with%20regard%20to%20dyspnea.%20Furthermore%2C%20association%20between%20caffeine%20and%20cardiovascular%20events%20is%20of%20clinical%20interest.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20prespecified%20analysis%20used%20data%20from%20the%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PEGASUS%20TIMI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2054%20%28Prevention%20of%20Cardiovascular%20Events%20in%20Patients%20With%20Prior%20Heart%20Attack%20Using%20Ticagrelor%20Compared%20to%20Placebo%20on%20a%20Background%20of%20Aspirin%5Cu2013Thrombolysis%20in%20Myocardial%20Infarction%2054%29%20trial%2C%20which%20randomized%2021%5Cu00a0162%20patients%20with%20prior%20myocardial%20infarction%20to%20ticagrelor%2060%5Cu00a0mg%20or%2090%5Cu00a0mg%20or%20matching%20placebo%20%28twice%20daily%29.%20Baseline%20caffeine%20intake%20in%20cups%20per%20week%20was%20prospectively%20collected%20for%209694%20patients.%20Outcomes%20of%20interest%20included%20dyspnea%2C%20major%20adverse%20cardiovascular%20events%20%28ie%2C%20the%20composite%20of%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20stroke%29%2C%20and%20arrhythmias.%20Dyspnea%20analyses%20considered%20the%20pooled%20ticagrelor%20group%2C%20whereas%20cardiovascular%20outcome%20analyses%20included%20patients%20from%20the%203%20randomized%20arms.%20After%20adjustment%2C%20caffeine%20intake%2C%20compared%20with%20no%20intake%2C%20was%20not%20associated%20with%20lower%20rates%20of%20dyspnea%20in%20patients%20taking%20ticagrelor%20%28adjusted%20hazard%20ratio%20%28HR%29%2C%200.91%3B%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%200.76%5Cu20131.10%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.34%29.%20There%20was%20no%20excess%20risk%20with%20caffeine%20for%20major%20adverse%20cardiovascular%20events%20%28adjusted%20HR%2C%200.78%3B%2095%25%20CI%2C%200.63%5Cu20130.98%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.031%29%2C%20sudden%20cardiac%20death%20%28adjusted%20HR%2C%200.98%3B%2095%25%20CI%2C%200.57%5Cu20131.70%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.95%29%2C%20or%20atrial%20fibrillation%20%28adjusted%20odds%20ratio%2C%201.07%3B%2095%25%20CI%2C%200.56%5Cu20132.04%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.84%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20taking%20ticagrelor%20for%20secondary%20prevention%20after%20myocardial%20infarction%2C%20caffeine%20intake%20at%20baseline%20was%20not%20associated%20with%20lower%20rates%20of%20dyspnea%20compared%20with%20no%20intake.%20Otherwise%2C%20caffeine%20appeared%20to%20be%20safe%20in%20this%20population%2C%20with%20no%20apparent%20increase%20in%20atherothrombotic%20events%20or%20clinically%20significant%20arrhythmias.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clini%5Cu200bcaltr%5Cu200bials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2001225562.%22%2C%22date%22%3A%222020-05-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.119.015785%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.119.015785%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22H6JFAYAK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gencer%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGencer%20B%2C%20Li%20XS%2C%20Gurmu%20Y%2C%20Bonaca%20MP%2C%20Morrow%20DA%2C%20Cohen%20M%2C%20Bhatt%20DL%2C%20Steg%20PG%2C%20Storey%20RF%2C%20Johanson%20P%2C%20Wang%20Z%2C%20Hazen%20SL%2C%20Sabatine%20MS.%202020.%20Gut%20Microbiota%26%23x2010%3BDependent%20Trimethylamine%20N%26%23x2010%3Boxide%20and%20Cardiovascular%20Outcomes%20in%20Patients%20With%20Prior%20Myocardial%20Infarction%3A%20A%20Nested%20Case%20Control%20Study%20From%20the%20PEGASUS%26%23x2010%3BTIMI%2054%20Trial.%20JAHA%209%3Ae015331.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Gut%20Microbiota%5Cu2010Dependent%20Trimethylamine%20N%5Cu2010oxide%20and%20Cardiovascular%20Outcomes%20in%20Patients%20With%20Prior%20Myocardial%20Infarction%3A%20A%20Nested%20Case%20Control%20Study%20From%20the%20PEGASUS%5Cu2010TIMI%2054%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baris%22%2C%22lastName%22%3A%22Gencer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xinmin%20S.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Gurmu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Bonaca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Morrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Johanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeneng%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanley%20L.%22%2C%22lastName%22%3A%22Hazen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S.%22%2C%22lastName%22%3A%22Sabatine%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trimethylamine%20N%5Cu2010oxide%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20may%20have%20prothrombotic%20properties.%20We%20examined%20the%20association%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20quartiles%20with%20major%20adverse%20cardiovascular%20events%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MACE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20and%20the%20effect%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20on%20the%20efficacy%20of%20ticagrelor.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PEGASUS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TIMI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2054%20%28Prevention%20of%20Cardiovascular%20Events%20in%20Patients%20With%20Prior%20Heart%20Attack%20Using%20Ticagrelor%20Compared%20to%20Placebo%20on%20a%20Background%20of%20Aspirin%20%5Cu2010%20Thrombolysis%20in%20Myocardial%20Infarction%2054%29%20randomized%20patients%20with%20prior%20myocardial%20infarction%20to%20ticagrelor%20or%20placebo%20%28median%20follow%5Cu2010up%2033%5Cu00a0months%29.%20Baseline%20plasma%20concentrations%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20were%20measured%20in%20a%20nested%20case%5Cu2010control%20study%20of%20597%20cases%20with%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20stroke%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MACE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20and%201206%20controls%20matched%20for%20age%2C%20sex%2C%20and%20estimated%20glomerular%20filtration%20rate%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20eGFR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5D.%20Odds%20ratios%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20were%20used%20for%20the%20association%20between%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20quartiles%20and%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MACE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20adjusting%20for%20baseline%20clinical%20characteristics%20%28age%2C%20sex%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20eGFR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20region%2C%20body%20mass%20index%2C%20hypertension%2C%20hypercholesterolemia%2C%20diabetes%20mellitus%2C%20smoking%2C%20peripheral%20artery%20disease%2C%20index%20event%2C%20aspirin%20dosage%20and%20treatment%20arm%29%2C%20and%20cardiovascular%20biomarkers%20%28hs%5Cu2010TnT%20%5Bhigh%5Cu2010sensitivity%20troponin%20T%5D%2C%20hs%5Cu2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CRP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Bhigh%5Cu2010sensitivity%20C%5Cu2010reactive%20protein%5D%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2010pro%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20BNP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5BN%5Cu2010terminal%5Cu2010pro%5Cu2010B%5Cu2010type%20natriuretic%20peptide%5D%29.%20Higher%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20quartiles%20were%20associated%20with%20risk%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MACE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20for%20quartile%204%20versus%20quartile%201%2C%201.43%2C%2095%25%20CI%2C%201.06%5Cu20131.93%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3D0.015%29.%20The%20association%20was%20driven%20by%20cardiovascular%20death%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202.25%2C%2095%25%20CI%2C%201.28%5Cu20133.96%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3D0.003%29%20and%20stroke%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202.68%2C%2095%25%20CI%2C%201.39%5Cu20135.17%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3C0.001%29.%20After%20adjustment%20for%20clinical%20factors%2C%20the%20association%20persisted%20for%20cardiovascular%20death%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20adj%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%201.89%2C%2095%25%20CI%2C%201.03%5Cu20133.45%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3D0.027%29%20and%20stroke%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20adj%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202.01%2C%2095%25%20CI%2C%201.01%5Cu20134.01%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3D0.022%29%2C%20but%20was%20slightly%20attenuated%20after%20adjustment%20for%20cardiovascular%20biomarkers%20%28cardiovascular%20death%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20adj%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%201.74%2C%2095%25%20CI%2C%200.88%5Cu20133.45%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3D0.079%3B%20and%20stroke%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20adj%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%201.82%2C%2095%25%20CI%2C%200.88%5Cu20133.78%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%3D0.056%29.%20The%20reduction%20in%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MACE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20with%20ticagrelor%20was%20consistent%20across%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20quartiles%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%3D0.92%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20patients%20with%20prior%20myocardial%20infarction%2C%20higher%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20levels%20were%20associated%20with%20cardiovascular%20death%20and%20stroke%20but%20not%20with%20recurrent%20myocardial%20infarction.%20The%20efficacy%20of%20ticagrelor%20was%20consistent%20regardless%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TMAO%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20levels.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clini%5Cu200bcaltr%5Cu200bials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifiers%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PEGASUS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20TIMI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2054%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2001225562.%22%2C%22date%22%3A%222020-05-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.119.015331%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.119.015331%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A17Z%22%7D%7D%2C%7B%22key%22%3A%222A2SDN7M%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Schwartz%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESchwartz%20GG%2C%20Szarek%20M%2C%20Bittner%20VA%2C%20Steg%20PG.%202020.%20Response%20by%20Schwartz%20et%20al%20to%20Letter%20Regarding%20Article%2C%20%26%23x201C%3BPeripheral%20Artery%20Disease%20and%20Venous%20Thromboembolic%20Events%20After%20Acute%20Coronary%20Syndrome%3A%20Role%20of%20Lipoprotein%28a%29%20and%20Modification%20by%20Alirocumab%3A%20Prespecified%20Analysis%20of%20the%20ODYSSEY%20OUTCOMES%20Randomized%20Clinical%20Trial.%26%23x201D%3B%20Circulation%20142.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Response%20by%20Schwartz%20et%20al%20to%20Letter%20Regarding%20Article%2C%20%5Cu201cPeripheral%20Artery%20Disease%20and%20Venous%20Thromboembolic%20Events%20After%20Acute%20Coronary%20Syndrome%3A%20Role%20of%20Lipoprotein%28a%29%20and%20Modification%20by%20Alirocumab%3A%20Prespecified%20Analysis%20of%20the%20ODYSSEY%20OUTCOMES%20Randomized%20Clinical%20Trial%5Cu201d%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-11-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.120.050609%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.120.050609%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A44Z%22%7D%7D%2C%7B%22key%22%3A%222IXVU2AK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amarenco%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAmarenco%20P%2C%20Hobeanu%20C%2C%20Labreuche%20J%2C%20Charles%20H%2C%20Giroud%20M%2C%20Meseguer%20E%2C%20Lavall%26%23xE9%3Be%20PC%2C%20Gabriel%20Steg%20P%2C%20Vicaut%20%26%23xC9%3B%2C%20Bruckert%20E%2C%20Touboul%20P-J.%202020.%20Carotid%20Atherosclerosis%20Evolution%20When%20Targeting%20a%20Low-Density%20Lipoprotein%20Cholesterol%20Concentration%20%26lt%3B70%20mg%5C%2FdL%20After%20an%20Ischemic%20Stroke%20of%20Atherosclerotic%20Origin.%20Circulation%20142%3A748%26%23x2013%3B757.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Carotid%20Atherosclerosis%20Evolution%20When%20Targeting%20a%20Low-Density%20Lipoprotein%20Cholesterol%20Concentration%20%3C70%20mg%5C%2FdL%20After%20an%20Ischemic%20Stroke%20of%20Atherosclerotic%20Origin%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Hobeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Charles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Giroud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C.%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gabriel%20Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9ric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bruckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20TST%20trial%20%28Treat%20Stroke%20to%20Target%29%20showed%20the%20benefit%20of%20targeting%20a%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20concentration%20of%20%3C70%20mg%5C%2FdL%20in%20terms%20of%20reducing%20the%20risk%20of%20major%20cardiovascular%20events%20in%202860%20patients%20with%20ischemic%20stroke%20with%20atherosclerotic%20stenosis%20of%20cerebral%20vasculature.%20The%20impact%20on%20carotid%20atherosclerosis%20evolution%20is%20not%20known.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20TST-PLUS%20%28Treat%20Stroke%20to%20Target%5Cu2013Plaque%20Ultrasound%20Study%29%20included%20201%20patients%20assigned%20to%20an%20LDL-C%20concentration%20of%20%3C70%20mg%5C%2FdL%20and%20212%20patients%20assigned%20to%20a%20target%20of%20100%5Cu00b110%20mg%5C%2FdL.%20To%20achieve%20these%20goals%2C%20investigators%20used%20the%20statin%20and%20dosage%20of%20their%20choice%20and%20added%20ezetimibe%20as%20needed.%20Ultrasonographers%20were%20certified%20and%20carotid%20ultrasound%20examinations%20were%20performed%20using%20M%5Cu2032Ath%20software%20at%20baseline%20and%20at%202%2C%203%2C%20and%205%20years.%20All%20images%20were%20uploaded%20to%20the%20Intelligence%20in%20Medical%20Technologies%20database%20directly%20from%20the%20carotid%20ultrasound%20device.%20The%20central%20core%20laboratory%20performed%20all%20offline%20measurements%20of%20the%20intima%5Cu2013media%20thickness%20of%20both%20common%20carotid%20arteries%20blinded%20from%20the%20randomization%20arm.%20The%20main%20outcomes%20were%20newly%20diagnosed%20atherosclerotic%20plaque%20on%20carotid%20bifurcation%20or%20internal%20carotid%20artery%20using%20the%20Mannheim%20consensus%20definition%20and%20between-group%20comparison%20of%20common%20carotid%20arteries%20intima%5Cu2013media%20thickness%20change.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20a%20median%20follow-up%20of%203.1%20years%2C%20the%20achieved%20LDL-C%20concentrations%20were%2064%20mg%5C%2FdL%20%281.64%20mmol%5C%2FL%29%20in%20the%20lower-target%20group%20and%20106%20mg%5C%2FdL%20%282.72%20mmol%5C%2FL%29%20in%20the%20higher-target%20group.%20Compared%20with%20the%20higher-target%20group%2C%20patients%20in%20the%20lower-target%20group%20had%20a%20similar%20incidence%20of%20newly%20diagnosed%20carotid%20plaque%3A%2046%5C%2F201%20%285-year%20rate%2C%2026.1%25%29%20versus%2045%5C%2F212%20%285-year%20rate%2C%2029.7%25%29.%20The%20change%20in%20common%20carotid%20arteries%20intima%5Cu2013media%20thickness%20was%20%5Cu22122.69%20%5Cu00b5m%20%2895%25%20CI%2C%20%5Cu22126.55%20to%201.18%29%20in%20the%20higher-target%20group%20and%20%5Cu221210.53%20%5Cu00b5m%20%2895%25%20CI%2C%20%5Cu221214.21%20to%20%5Cu22126.85%29%20in%20the%20lower-target%20group%2C%20resulting%20in%20an%20absolute%20between-group%20difference%20of%20%5Cu22127.84%20%5Cu00b5m%20%2895%25%20CI%2C%20%5Cu221213.18%20to%20%5Cu22122.51%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.004%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20ischemic%20stroke%20and%20atherosclerosis%2C%20an%20LDL-C%20target%20of%20%3C70%20mg%5C%2FdL%20%281.8%20mmol%5C%2FL%29%20did%20not%20reduce%20the%20incidence%20of%20new%20carotid%20plaques%20but%20produced%20significantly%20greater%20regression%20of%20carotid%20atherosclerosis%20than%20an%20LDL-C%20target%20of%2090%20to%20110%20mg%5C%2FdL.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01252875.%22%2C%22date%22%3A%222020-08-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.120.046774%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.120.046774%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22V45R2VCC%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Schwartz%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESchwartz%20GG%2C%20Steg%20PG%2C%20Szarek%20M%2C%20Bittner%20VA%2C%20Diaz%20R%2C%20Goodman%20SG%2C%20Kim%20Y-U%2C%20Jukema%20JW%2C%20Pordy%20R%2C%20Roe%20MT%2C%20White%20HD%2C%20Bhatt%20DL%2C%20For%20the%20ODYSSEY%20OUTCOMES%20Committees%20and%20Investigators%2A.%202020.%20Peripheral%20Artery%20Disease%20and%20Venous%20Thromboembolic%20Events%20After%20Acute%20Coronary%20Syndrome%3A%20Role%20of%20Lipoprotein%28a%29%20and%20Modification%20by%20Alirocumab%3A%20Prespecified%20Analysis%20of%20the%20ODYSSEY%20OUTCOMES%20Randomized%20Clinical%20Trial.%20Circulation%20141%3A1608%26%23x2013%3B1617.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Peripheral%20Artery%20Disease%20and%20Venous%20Thromboembolic%20Events%20After%20Acute%20Coronary%20Syndrome%3A%20Role%20of%20Lipoprotein%28a%29%20and%20Modification%20by%20Alirocumab%3A%20Prespecified%20Analysis%20of%20the%20ODYSSEY%20OUTCOMES%20Randomized%20Clinical%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Un%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22For%20the%20ODYSSEY%20OUTCOMES%20Committees%20and%20Investigators%2A%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20acute%20coronary%20syndrome%20are%20at%20risk%20for%20peripheral%20artery%20disease%20%28PAD%29%20events%20and%20venous%20thromboembolism%20%28VTE%29.%20PCSK9%20%28proprotein%20convertase%20subtilisin%5C%2Fkexin%20type%209%29%20inhibitors%20reduce%20lipoprotein%28a%29%20and%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20levels.%20Our%20objective%20was%20to%20ascertain%20whether%20PCSK9%20inhibition%20reduces%20the%20risk%20of%20PAD%20events%20or%20VTE%20after%20acute%20coronary%20syndrome%2C%20and%20if%20such%20effects%20are%20related%20to%20levels%20of%20lipoprotein%28a%29%20or%20LDL-C.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20was%20a%20prespecified%20analysis%20of%20the%20ODYSSEY%20OUTCOMES%20randomized%20clinical%20trial%20%28Evaluation%20of%20Cardiovascular%20Outcomes%20After%20an%20Acute%20Coronary%20Syndrome%29%2C%20which%20was%20conducted%20in%2018%5Cu2009924%20patients%20with%20recent%20acute%20coronary%20syndrome%20on%20intensive%20or%20maximum-tolerated%20statin%20treatment%20who%20were%20randomized%20to%20the%20PCSK9%20inhibitor%20alirocumab%20or%20placebo.%20In%20a%20prespecified%20analysis%2C%20PAD%20events%20%28critical%20limb%20ischemia%2C%20limb%20revascularization%2C%20or%20amputation%20for%20ischemia%29%20and%20VTE%20%28deep%20vein%20thrombosis%20or%20pulmonary%20embolism%29%20were%20assessed.%20LDL-C%20was%20corrected%20%28LDL-C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20corrected%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20for%20cholesterol%20content%20in%20lipoprotein%28a%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20At%20baseline%2C%20median%20lipoprotein%28a%29%20and%20LDL-C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20corrected%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20were%2021%20and%2075%20mg%5C%2FdL%2C%20respectively%3B%20with%20alirocumab%2C%20median%20relative%20reductions%20were%2023.5%25%20and%2070.6%25%2C%20respectively.%20PAD%20events%20and%20VTE%20occurred%20in%20246%20and%2092%20patients%2C%20respectively.%20In%20the%20placebo%20group%2C%20risk%20of%20PAD%20events%20was%20related%20to%20baseline%20quartile%20of%20lipoprotein%28a%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.0021%29%2C%20and%20tended%20to%20associate%20with%20baseline%20quartile%20of%20LDL-C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20corrected%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.06%29%3B%20VTE%20tended%20to%20associate%20with%20baseline%20quartile%20of%20lipoprotein%28a%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.06%29%2C%20but%20not%20LDL-C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20corrected%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.85%29.%20Alirocumab%20reduced%20risk%20of%20PAD%20events%20%28hazard%20ratio%20%5BHR%5D%2C%200.69%20%5B95%25%20CI%2C%200.54%5Cu20130.89%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.004%29%2C%20with%20nonsignificantly%20fewer%20VTE%20events%20%28HR%2C%200.67%20%5B95%25%20CI%2C%200.44%5Cu20131.01%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.06%29.%20Reduction%20in%20PAD%20events%20with%20alirocumab%20was%20associated%20with%20baseline%20quartile%20of%20lipoprotein%28a%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29%2C%20but%20not%20LDL-C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20corrected%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.50%29.%20With%20alirocumab%2C%20the%20change%20from%20baseline%20to%20Month%204%20in%20lipoprotein%28a%29%2C%20but%20not%20LDL-C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20corrected%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20was%20associated%20with%20the%20risk%20of%20VTE%20and%20the%20composite%20of%20VTE%20and%20PAD%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20statin-treated%20patients%20with%20recent%20acute%20coronary%20syndrome%2C%20risk%20of%20PAD%20events%20is%20related%20to%20lipoprotein%28a%29%20level%20and%20is%20reduced%20by%20alirocumab%2C%20particularly%20among%20those%20with%20high%20lipoprotein%28a%29.%20Further%20study%20is%20required%20to%20confirm%20whether%20risk%20of%20VTE%20is%20related%20to%20lipoprotein%28a%29%20level%20and%20its%20reduction%20with%20alirocumab.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01663402.%22%2C%22date%22%3A%222020-05-19%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.120.046524%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.120.046524%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22LJTFXNVQ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bhatt%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBhatt%20DL%2C%20Eikelboom%20JW%2C%20Connolly%20SJ%2C%20Steg%20PG%2C%20Anand%20SS%2C%20Verma%20S%2C%20Branch%20KRH%2C%20Probstfield%20J%2C%20Bosch%20J%2C%20Shestakovska%20O%2C%20Szarek%20M%2C%20Maggioni%20AP%2C%20Widimsk%26%23xFD%3B%20P%2C%20Avezum%20A%2C%20Diaz%20R%2C%20Lewis%20BS%2C%20Berkowitz%20SD%2C%20Fox%20KAA%2C%20Ryden%20L%2C%20Yusuf%20S%2C%20Aboyans%20V%2C%20Alings%20M%2C%20Commerford%20P%2C%20Cook-Bruns%20N%2C%20Dagenais%20G%2C%20Dans%20A%2C%20Ertl%20G%2C%20Felix%20C%2C%20Guzik%20T%2C%20Hart%20R%2C%20Hori%20M%2C%20Kakkar%20A%2C%20Keltai%20K%2C%20Keltai%20M%2C%20Kim%20J%2C%20Lamy%20A%2C%20Lanas%20F%2C%20Liang%20Y%2C%20Liu%20L%2C%20Lonn%20E%2C%20Lopez-Jaramillo%20P%2C%20Metsarinne%20K%2C%20Moayyedi%20P%2C%20O%26%23x2019%3BDonnell%20M%2C%20Parkhomenko%20A%2C%20Piegas%20L%2C%20Pogosova%20N%2C%20Sharma%20M%2C%20Stoerk%20S%2C%20Tonkin%20A%2C%20Torp-Pedersen%20C%2C%20Varigos%20J%2C%20Verhamme%20P%2C%20Vinereanu%20D%2C%20Yusoff%20K%2C%20Zhu%20J.%202020.%20Role%20of%20Combination%20Antiplatelet%20and%20Anticoagulation%20Therapy%20in%20Diabetes%20Mellitus%20and%20Cardiovascular%20Disease%3A%20Insights%20From%20the%20COMPASS%20Trial.%20Circulation%20141%3A1841%26%23x2013%3B1854.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Role%20of%20Combination%20Antiplatelet%20and%20Anticoagulation%20Therapy%20in%20Diabetes%20Mellitus%20and%20Cardiovascular%20Disease%3A%20Insights%20From%20the%20COMPASS%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Eikelboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%20S.%22%2C%22lastName%22%3A%22Anand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subodh%22%2C%22lastName%22%3A%22Verma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelley%20R.H.%22%2C%22lastName%22%3A%22Branch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%22%2C%22lastName%22%3A%22Probstfield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackie%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Shestakovska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aldo%20Pietro%22%2C%22lastName%22%3A%22Maggioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Widimsk%5Cu00fd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Avezum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Basil%20S.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Berkowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A.A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Ryden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Yusuf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Aboyans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Alings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Commerford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Cook-Bruns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Dagenais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ertl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Felix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Guzik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Hart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kakkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Keltai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Keltai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Lanas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Lonn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lopez-Jaramillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Metsarinne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Moayyedi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22O%5Cu2019Donnell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Piegas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Pogosova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Stoerk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Tonkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Torp-Pedersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Varigos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Verhamme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Vinereanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Yusoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Zhu%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20established%20coronary%20artery%20disease%20or%20peripheral%20artery%20disease%20often%20have%20diabetes%20mellitus.%20These%20patients%20are%20at%20high%20risk%20of%20future%20vascular%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20a%20prespecified%20analysis%20of%20the%20COMPASS%20trial%20%28Cardiovascular%20Outcomes%20for%20People%20Using%20Anticoagulation%20Strategies%29%2C%20we%20compared%20the%20effects%20of%20rivaroxaban%20%282.5%20mg%20twice%20daily%29%20plus%20aspirin%20%28100%20mg%20daily%29%20versus%20placebo%20plus%20aspirin%20in%20patients%20with%20diabetes%20mellitus%20versus%20without%20diabetes%20mellitus%20in%20preventing%20major%20vascular%20events.%20The%20primary%20efficacy%20end%20point%20was%20the%20composite%20of%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20stroke.%20Secondary%20end%20points%20included%20all-cause%20mortality%20and%20all%20major%20vascular%20events%20%28cardiovascular%20death%2C%20myocardial%20infarction%2C%20stroke%2C%20or%20major%20adverse%20limb%20events%2C%20including%20amputation%29.%20The%20primary%20safety%20end%20point%20was%20a%20modification%20of%20the%20International%20Society%20on%20Thrombosis%20and%20Haemostasis%20criteria%20for%20major%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20There%20were%2010%5Cu2009341%20patients%20with%20diabetes%20mellitus%20and%2017%5Cu2009054%20without%20diabetes%20mellitus%20in%20the%20overall%20trial.%20A%20consistent%20and%20similar%20relative%20risk%20reduction%20was%20seen%20for%20benefit%20of%20rivaroxaban%20plus%20aspirin%20%28n%3D9152%29%20versus%20placebo%20plus%20aspirin%20%28n%3D9126%29%20in%20patients%20both%20with%20%28n%3D6922%29%20and%20without%20%28n%3D11%5Cu2009356%29%20diabetes%20mellitus%20for%20the%20primary%20efficacy%20end%20point%20%28hazard%20ratio%2C%200.74%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.002%3B%20and%20hazard%20ratio%2C%200.77%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.005%2C%20respectively%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.77%29%20and%20all-cause%20mortality%20%28hazard%20ratio%2C%200.81%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.05%3B%20and%20hazard%20ratio%2C%200.84%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.09%2C%20respectively%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.82%29.%20However%2C%20although%20the%20absolute%20risk%20reductions%20appeared%20numerically%20larger%20in%20patients%20with%20versus%20without%20diabetes%20mellitus%2C%20both%20subgroups%20derived%20similar%20benefit%20%282.3%25%20versus%201.4%25%20for%20the%20primary%20efficacy%20end%20point%20at%203%20years%2C%20Gail-Simon%20qualitative%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%3B%201.9%25%20versus%200.6%25%20for%20all-cause%20mortality%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.02%3B%202.7%25%20versus%201.7%25%20for%20major%20vascular%20events%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29.%20Because%20the%20bleeding%20hazards%20were%20similar%20among%20patients%20with%20and%20without%20diabetes%20mellitus%2C%20the%20prespecified%20net%20benefit%20for%20rivaroxaban%20appeared%20particularly%20favorable%20in%20the%20patients%20with%20diabetes%20mellitus%20%282.7%25%20versus%201.0%25%3B%20Gail-Simon%20qualitative%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.001%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20stable%20atherosclerosis%2C%20the%20combination%20of%20aspirin%20plus%20rivaroxaban%202.5%20mg%20twice%20daily%20provided%20a%20similar%20relative%20degree%20of%20benefit%20on%20coronary%2C%20cerebrovascular%2C%20and%20peripheral%20end%20points%20in%20patients%20with%20and%20without%20diabetes%20mellitus.%20Given%20their%20higher%20baseline%20risk%2C%20the%20absolute%20benefits%20appeared%20larger%20in%20those%20with%20diabetes%20mellitus%2C%20including%20a%203-fold%20greater%20reduction%20in%20all-cause%20mortality.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01776424.%22%2C%22date%22%3A%222020-06-09%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.120.046448%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.120.046448%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22WYZDS3NM%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bainey%20et%20al.%22%2C%22parsedDate%22%3A%222020-04-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBainey%20KR%2C%20Welsh%20RC%2C%20Connolly%20SJ%2C%20Marsden%20T%2C%20Bosch%20J%2C%20Fox%20KAA%2C%20Steg%20PG%2C%20Vinereanu%20D%2C%20Connolly%20DL%2C%20Berkowitz%20SD%2C%20Foody%20JM%2C%20Probstfield%20JL%2C%20Branch%20KR%2C%20Lewis%20BS%2C%20Diaz%20R%2C%20Muehlhofer%20E%2C%20Widimsky%20P%2C%20Yusuf%20S%2C%20Eikelboom%20JW%2C%20Bhatt%20DL%2C%20On%20behalf%20of%20the%20COMPASS%20Investigators.%202020.%20Rivaroxaban%20Plus%20Aspirin%20Versus%20Aspirin%20Alone%20in%20Patients%20With%20Prior%20Percutaneous%20Coronary%20Intervention%20%28COMPASS-PCI%29.%20Circulation%20141%3A1141%26%23x2013%3B1151.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rivaroxaban%20Plus%20Aspirin%20Versus%20Aspirin%20Alone%20in%20Patients%20With%20Prior%20Percutaneous%20Coronary%20Intervention%20%28COMPASS-PCI%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20R.%22%2C%22lastName%22%3A%22Bainey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20C.%22%2C%22lastName%22%3A%22Welsh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamara%22%2C%22lastName%22%3A%22Marsden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackie%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A.A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dragos%22%2C%22lastName%22%3A%22Vinereanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derek%20L.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Berkowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22JoAnne%20M.%22%2C%22lastName%22%3A%22Foody%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20L.%22%2C%22lastName%22%3A%22Probstfield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelley%20R.%22%2C%22lastName%22%3A%22Branch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Basil%20S.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Muehlhofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Widimsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Yusuf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Eikelboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22On%20behalf%20of%20the%20COMPASS%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20COMPASS%20trial%20%28Cardiovascular%20Outcomes%20for%20People%20using%20Anticoagulation%20Strategies%29%20demonstrated%20that%20dual%20pathway%20inhibition%20%28DPI%29%20with%20rivaroxaban%202.5%20mg%20twice%20daily%20plus%20aspirin%20100%20mg%20once%20daily%20versus%20aspirin%20100%20mg%20once%20daily%20reduced%20the%20primary%20major%20adverse%20cardiovascular%20event%20%28MACE%29%20outcome%20of%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20stroke%2C%20as%20well%20as%2C%20mortality%2C%20in%20patients%20with%20chronic%20coronary%20syndromes%20or%20peripheral%20arterial%20disease.%20Whether%20this%20remains%20true%20in%20patients%20with%20a%20history%20of%20percutaneous%20coronary%20intervention%20%28PCI%29%20is%20unknown.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20a%20prespecified%20subgroup%20analysis%20from%20COMPASS%2C%20we%20examined%20the%20outcomes%20of%20patients%20with%20a%20chronic%20coronary%20syndrome%20with%20or%20without%20a%20previous%20PCI%20treated%20with%20DPI%20versus%20aspirin%20alone.%20Among%20patients%20with%20a%20previous%20PCI%2C%20we%20studied%20the%20effects%20of%20treatment%20according%20to%20the%20timing%20of%20the%20previous%20PCI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Of%20the%2027%5Cu2009395%20patients%20in%20COMPASS%2C%2016%5Cu2009560%20patients%20with%20a%20chronic%20coronary%20syndrome%20were%20randomly%20assigned%20to%20DPI%20or%20aspirin%2C%20and%2C%20of%20these%2C%209862%20%2859.6%25%29%20had%20previous%20PCI%20%28mean%20age%2068.2%5Cu00b17.8%2C%20female%2019.4%25%2C%20diabetes%20mellitus%2035.7%25%2C%20previous%20myocardial%20infarction%2074.8%25%2C%20multivessel%20PCI%2038.0%25%29.%20Average%20time%20from%20PCI%20to%20randomization%20was%205.4%20years%20%28SD%2C%204.4%29%20and%20follow-up%20was%201.98%20%28SD%2C%200.72%29%20years.%20Regardless%20of%20previous%20PCI%2C%20DPI%20versus%20aspirin%20produced%20consistent%20reductions%20in%20MACE%20%28PCI%3A%204.0%25%20versus%205.5%25%3B%20hazard%20ratio%20%5BHR%5D%2C%200.74%20%5B95%25%20CI%2C%200.61%5Cu20130.88%5D%3B%20no%20PCI%3A%204.4%25%20versus%205.7%25%3B%20HR%2C%200.76%20%5B95%25%20CI%2C%200.61%5Cu20130.94%5D%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20-interaction%3D0.85%29%20and%20mortality%20%28PCI%3A%202.5%25%20versus%203.5%25%3B%20HR%2C%200.73%20%5B95%25%20CI%2C%200.58%5Cu20130.92%5D%3B%20no%20PCI%3A%204.1%25%20versus%205.0%25%3B%20HR%2C%200.80%20%5B95%25%20CI%2C%200.64%5Cu20131.00%5D%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20-interaction%3D0.59%29%2C%20but%20increased%20major%20bleeding%20%28PCI%3A%203.3%25%20versus%202.0%25%3B%20HR%2C%201.72%20%5B95%25%20CI%2C%201.34%5Cu20132.21%5D%3B%20no%20PCI%3A%202.9%25%20versus%201.8%25%3B%20HR%2C%201.58%20%5B95%25%20CI%2C%201.15%5Cu20132.17%5D%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20-interaction%3D0.68%29.%20In%20those%20with%20previous%20PCI%2C%20DPI%20compared%20with%20aspirin%20produced%20consistent%20%28robust%29%20reductions%20in%20MACE%20irrespective%20of%20time%20since%20previous%20PCI%20%28as%20early%20as%201%20year%20and%20as%20far%20as%2010%20years%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20-interaction%3D0.65%29%2C%20irrespective%20of%20having%20a%20previous%20myocardial%20infarction%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20-interaction%3D0.64%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20DPI%20compared%20with%20aspirin%20produced%20consistent%20reductions%20in%20MACE%20and%20mortality%20but%20with%20increased%20major%20bleeding%20with%20or%20without%20previous%20PCI.%20Among%20those%20with%20previous%20PCI%201%20year%20and%20beyond%2C%20the%20effects%20on%20MACE%20and%20mortality%20were%20consistent%20irrespective%20of%20time%20since%20last%20PCI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01776424.%22%2C%22date%22%3A%222020-04-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.119.044598%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.119.044598%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22V7MBCGEK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bhatt%20et%20al.%22%2C%22parsedDate%22%3A%222020-02-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBhatt%20DL%2C%20Miller%20M%2C%20Brinton%20EA%2C%20Jacobson%20TA%2C%20Steg%20PhG%2C%20Ketchum%20SB%2C%20Doyle%20RT%2C%20Juliano%20RA%2C%20Jiao%20L%2C%20Granowitz%20C%2C%20Tardif%20J-C%2C%20Olshansky%20B%2C%20Chung%20MK%2C%20Gibson%20CM%2C%20Giugliano%20RP%2C%20Budoff%20MJ%2C%20Ballantyne%20CM%2C%20On%20behalf%20of%20the%20REDUCE-IT%20Investigators.%202020.%20REDUCE-IT%20USA%3A%20Results%20From%20the%203146%20Patients%20Randomized%20in%20the%20United%20States.%20Circulation%20141%3A367%26%23x2013%3B375.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22REDUCE-IT%20USA%3A%20Results%20From%20the%203146%20Patients%20Randomized%20in%20the%20United%20States%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliot%20A.%22%2C%22lastName%22%3A%22Brinton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%20A.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20B.%22%2C%22lastName%22%3A%22Ketchum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20T.%22%2C%22lastName%22%3A%22Doyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%20A.%22%2C%22lastName%22%3A%22Juliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lixia%22%2C%22lastName%22%3A%22Jiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%22%2C%22lastName%22%3A%22Granowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Olshansky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mina%20K.%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20P.%22%2C%22lastName%22%3A%22Giugliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Budoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22On%20behalf%20of%20the%20REDUCE-IT%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Some%20trials%20have%20found%20that%20patients%20from%20the%20United%20States%20derive%20less%20benefit%20than%20patients%20enrolled%20outside%20the%20United%20States.%20This%20prespecified%20REDUCE-IT%20%28Reduction%20of%20Cardiovascular%20Events%20with%20Icosapent%20Ethyl%20-%20Intervention%20Trial%29%20subgroup%20analysis%20was%20conducted%20to%20determine%20the%20degree%20of%20benefit%20of%20icosapent%20ethyl%20in%20the%20United%20States.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20REDUCE-IT%20randomized%208179%20statin-treated%20patients%20with%20qualifying%20triglycerides%20%5Cu2265135%20and%20%3C500%20mg%5C%2FdL%20and%20low-density%20lipoprotein%20cholesterol%20%3E40%20and%20%5Cu2264100%20mg%5C%2FdL%20and%20a%20history%20of%20atherosclerosis%20or%20diabetes%20mellitus%20to%20icosapent%20ethyl%204%20g%5C%2Fd%20or%20placebo.%20The%20primary%20composite%20end%20point%20was%20cardiovascular%20death%2C%20nonfatal%20myocardial%20infarction%2C%20nonfatal%20stroke%2C%20coronary%20revascularization%2C%20or%20hospitalization%20for%20unstable%20angina.%20The%20key%20secondary%20composite%20end%20point%20was%20cardiovascular%20death%2C%20nonfatal%20myocardial%20infarction%2C%20or%20nonfatal%20stroke.%20A%20hierarchy%20was%20prespecified%20for%20examination%20of%20individual%20and%20composite%20end%20points.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20total%20of%203146%20US%20patients%20%2838.5%25%20of%20the%20trial%29%20were%20randomized%20and%20followed%20for%20a%20median%20of%204.9%20years%3B%2032.3%25%20were%20women%20and%209.7%25%20were%20Hispanic.%20The%20primary%20composite%20end%20point%20occurred%20in%2024.7%25%20of%20placebo-treated%20patients%20versus%2018.2%25%20of%20icosapent%20ethyl-treated%20patients%20%28hazard%20ratio%20%5BHR%5D%2C%200.69%20%5B95%25%20CI%2C%200.59%5Cu20130.80%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.000001%29%3B%20the%20key%20secondary%20composite%20end%20point%20occurred%20in%2016.6%25%20versus%2012.1%25%20%28HR%2C%200.69%20%5B95%25%20CI%2C%200.57%5Cu20130.83%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.00008%29.%20All%20prespecified%20hierarchical%20end%20points%20were%20meaningfully%20and%20significantly%20reduced%2C%20including%20cardiovascular%20death%20%286.7%25%20to%204.7%25%3B%20HR%2C%200.66%20%5B95%25%20CI%2C%200.49%5Cu20130.90%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.007%29%2C%20myocardial%20infarction%20%288.8%25%20to%206.7%25%3B%20HR%2C%200.72%20%5B95%25%20CI%2C%200.56%5Cu20130.93%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.01%29%2C%20stroke%20%284.1%25%20to%202.6%25%3B%20HR%2C%200.63%20%5B95%25%20CI%2C%200.43%5Cu20130.93%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.02%29%2C%20and%20all-cause%20mortality%20%289.8%25%20to%207.2%25%3B%20HR%2C%200.70%20%5B95%25%20CI%2C%200.55%5Cu20130.90%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.004%29%3B%20for%20all-cause%20mortality%20in%20the%20US%20versus%20non-US%20patients%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.02.%20Safety%20and%20tolerability%20findings%20were%20consistent%20with%20the%20full%20study%20cohort.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Whereas%20the%20non-US%20subgroup%20showed%20significant%20reductions%20in%20the%20primary%20and%20key%20secondary%20end%20points%2C%20the%20US%20subgroup%20demonstrated%20particularly%20robust%20risk%20reductions%20across%20a%20variety%20of%20individual%20and%20composite%20end%20points%2C%20including%20all-cause%20mortality.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01492361.%22%2C%22date%22%3A%222020-02-04%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.119.044440%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.119.044440%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22MCEEL956%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Damask%20et%20al.%22%2C%22parsedDate%22%3A%222020-02-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDamask%20A%2C%20Steg%20PG%2C%20Schwartz%20GG%2C%20Szarek%20M%2C%20Hagstr%26%23xF6%3Bm%20E%2C%20Badimon%20L%2C%20Chapman%20MJ%2C%20Boileau%20C%2C%20Tsimikas%20S%2C%20Ginsberg%20HN%2C%20Banerjee%20P%2C%20Manvelian%20G%2C%20Pordy%20R%2C%20Hess%20S%2C%20Overton%20JD%2C%20Lotta%20LA%2C%20Yancopoulos%20GD%2C%20Abecasis%20GR%2C%20Baras%20A%2C%20Paulding%20C%2C%20On%20behalf%20of%20the%20Regeneron%20Genetics%20Center%20and%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202020.%20Patients%20With%20High%20Genome-Wide%20Polygenic%20Risk%20Scores%20for%20Coronary%20Artery%20Disease%20May%20Receive%20Greater%20Clinical%20Benefit%20From%20Alirocumab%20Treatment%20in%20the%20ODYSSEY%20OUTCOMES%20Trial.%20Circulation%20141%3A624%26%23x2013%3B636.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patients%20With%20High%20Genome-Wide%20Polygenic%20Risk%20Scores%20for%20Coronary%20Artery%20Disease%20May%20Receive%20Greater%20Clinical%20Benefit%20From%20Alirocumab%20Treatment%20in%20the%20ODYSSEY%20OUTCOMES%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Damask%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emil%22%2C%22lastName%22%3A%22Hagstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lina%22%2C%22lastName%22%3A%22Badimon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Chapman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Boileau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sotirios%22%2C%22lastName%22%3A%22Tsimikas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henry%20N.%22%2C%22lastName%22%3A%22Ginsberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Poulabi%22%2C%22lastName%22%3A%22Banerjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garen%22%2C%22lastName%22%3A%22Manvelian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sibylle%22%2C%22lastName%22%3A%22Hess%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20D.%22%2C%22lastName%22%3A%22Overton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%20A.%22%2C%22lastName%22%3A%22Lotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20D.%22%2C%22lastName%22%3A%22Yancopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Goncalo%20R.%22%2C%22lastName%22%3A%22Abecasis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aris%22%2C%22lastName%22%3A%22Baras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Paulding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22On%20behalf%20of%20the%20Regeneron%20Genetics%20Center%20and%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Alirocumab%2C%20an%20antibody%20that%20blocks%20PCSK9%20%28proprotein%20convertase%20subtilisin%5C%2Fkexin%20type%209%29%2C%20was%20associated%20with%20reduced%20major%20adverse%20cardiovascular%20events%20%28MACE%29%20and%20death%20in%20the%20ODYSSEY%20OUTCOMES%20trial%20%28Evaluation%20of%20Cardiovascular%20Outcomes%20After%20an%20Acute%20Coronary%20Syndrome%20During%20Treatment%20With%20Alirocumab%29.%20In%20this%20study%2C%20higher%20baseline%20levels%20of%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20predicted%20greater%20benefit%20from%20alirocumab%20treatment.%20Recent%20studies%20indicate%20high%20polygenic%20risk%20scores%20%28PRS%29%20for%20coronary%20artery%20disease%20%28CAD%29%20identify%20individuals%20at%20higher%20risk%20who%20derive%20increased%20benefit%20from%20statins.%20We%20performed%20post%20hoc%20analyses%20to%20determine%20whether%20high%20PRS%20for%20CAD%20identifies%20higher-risk%20individuals%2C%20independent%20of%20baseline%20LDL-C%20and%20other%20known%20risk%20factors%2C%20who%20might%20derive%20greater%20benefit%20from%20alirocumab%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ODYSSEY%20OUTCOMES%20was%20a%20randomized%2C%20double-blind%2C%20placebo-controlled%20trial%20comparing%20alirocumab%20or%20placebo%20in%2018%5Cu2009924%20patients%20with%20acute%20coronary%20syndrome%20and%20elevated%20atherogenic%20lipoproteins%20despite%20optimized%20statin%20treatment.%20The%20primary%20endpoint%20%28MACE%29%20comprised%20death%20of%20CAD%2C%20nonfatal%20myocardial%20infarction%2C%20ischemic%20stroke%2C%20or%20unstable%20angina%20requiring%20hospitalization.%20A%20genome-wide%20PRS%20for%20CAD%20comprising%206%5Cu2009579%5Cu2009025%20genetic%20variants%20was%20evaluated%20in%2011%5Cu2009953%20patients%20with%20available%20DNA%20samples.%20Analysis%20of%20MACE%20risk%20was%20performed%20in%20placebo-treated%20patients%2C%20whereas%20treatment%20benefit%20analysis%20was%20performed%20in%20all%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20incidence%20of%20MACE%20in%20the%20placebo%20group%20was%20related%20to%20PRS%20for%20CAD%3A%2017.0%25%20for%20high%20PRS%20patients%20%28%3E90th%20percentile%29%20and%2011.4%25%20for%20lower%20PRS%20patients%20%28%5Cu226490th%20percentile%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%3B%20this%20PRS%20relationship%20was%20not%20explained%20by%20baseline%20LDL-C%20or%20other%20established%20risk%20factors.%20Both%20the%20absolute%20and%20relative%20reduction%20of%20MACE%20by%20alirocumab%20compared%20with%20placebo%20was%20greater%20in%20high%20versus%20low%20PRS%20patients.%20There%20was%20an%20absolute%20reduction%20by%20alirocumab%20in%20high%20versus%20low%20PRS%20groups%20of%206.0%25%20and%201.5%25%2C%20respectively%2C%20and%20a%20relative%20risk%20reduction%20by%20alirocumab%20of%2037%25%20in%20the%20high%20PRS%20group%20%28hazard%20ratio%2C%200.63%20%5B95%25%20CI%2C%200.46%5Cu20130.86%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.004%29%20versus%20a%2013%25%20reduction%20in%20the%20low%20PRS%20group%20%28hazard%20ratio%2C%200.87%20%5B95%25%20CI%2C%200.78%5Cu20130.98%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.022%3B%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.04%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20high%20PRS%20for%20CAD%20is%20associated%20with%20elevated%20risk%20for%20recurrent%20MACE%20after%20acute%20coronary%20syndrome%20and%20a%20larger%20absolute%20and%20relative%20risk%20reduction%20with%20alirocumab%20treatment%2C%20providing%20an%20independent%20tool%20for%20risk%20stratification%20and%20precision%20medicine.%22%2C%22date%22%3A%222020-02-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.119.044434%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.119.044434%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22I624V4W7%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hara%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHara%20H%2C%20Van%20Klaveren%20D%2C%20Takahashi%20K%2C%20Kogame%20N%2C%20Chichareon%20P%2C%20Modolo%20R%2C%20Tomaniak%20M%2C%20Ono%20M%2C%20Kawashima%20H%2C%20Wang%20R%2C%20Gao%20C%2C%20Niethammer%20M%2C%20Fontos%20G%2C%20Angioi%20M%2C%20Ribeiro%20VG%2C%20Barbato%20E%2C%20Leandro%20S%2C%20Hamm%20C%2C%20Valgimigli%20M%2C%20Windecker%20S%2C%20J%26%23xFC%3Bni%20P%2C%20Steg%20PG%2C%20Verbeeck%20J%2C%20Tijssen%20JGP%2C%20Sharif%20F%2C%20Onuma%20Y%2C%20Serruys%20PW%2C%20for%20the%20GLOBAL%20LEADERS%20Trial%20Investigators.%202020.%20Comparative%20Methodological%20Assessment%20of%20the%20Randomized%20GLOBAL%20LEADERS%20Trial%20Using%20Total%20Ischemic%20and%20Bleeding%20Events.%20Circ%3A%20Cardiovascular%20Quality%20and%20Outcomes%2013%3Ae006660.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20Methodological%20Assessment%20of%20the%20Randomized%20GLOBAL%20LEADERS%20Trial%20Using%20Total%20Ischemic%20and%20Bleeding%20Events%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hironori%22%2C%22lastName%22%3A%22Hara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Van%20Klaveren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masafumi%22%2C%22lastName%22%3A%22Ono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hideyuki%22%2C%22lastName%22%3A%22Kawashima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rutao%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margit%22%2C%22lastName%22%3A%22Niethammer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geza%22%2C%22lastName%22%3A%22Fontos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Angioi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vasco%20Gama%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Barbato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Leandro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Verbeeck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20G.P.%22%2C%22lastName%22%3A%22Tijssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Sharif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20GLOBAL%20LEADERS%20Trial%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Time-to-first-event%20analysis%20considers%20only%20the%20first%20event%20irrespective%20of%20its%20severity.%20There%20are%20several%20methods%20to%20assess%20trial%20outcomes%20beyond%20time-to-first-event%20analysis%2C%20such%20as%20analyzing%20total%20events%20and%20ranking%20outcomes.%20In%20the%20GLOBAL%20LEADERS%20study%2C%20time-to-first-event%20analysis%20did%20not%20show%20superiority%20of%20ticagrelor%20monotherapy%20following%20one-month%20dual%20antiplatelet%20therapy%20%28DAPT%29%20after%20percutaneous%20coronary%20intervention%20to%20conventional%2012-month%20DAPT%20followed%20by%20aspirin%20monotherapy%20in%20the%20reduction%20of%20the%20primary%20composite%20end%20point%20of%20all-cause%20mortality%20or%20new%20Q-wave%20myocardial%20infarction.%20This%20study%20sought%20to%20explore%20various%20analytical%20approaches%20in%20assessing%20total%20ischemic%20and%20bleeding%20events%20after%20percutaneous%20coronary%20intervention%20in%20the%20GLOBAL%20LEADERS%20study.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Total%20ischemic%20and%20bleeding%20events%20were%20defined%20as%20all-cause%20mortality%2C%20any%20stroke%2C%20any%20myocardial%20infarction%2C%20any%20revascularization%2C%20or%20Bleeding%20Academic%20Research%20Consortium%20grade%202%20or%203%20bleeding.%20We%20used%20various%20analytical%20approaches%20to%20analyze%20the%20benefit%20of%20ticagrelor%20monotherapy%20over%20conventional%20DAPT.%20For%20ischemic%20and%20bleeding%20events%20at%202%20years%20after%20percutaneous%20coronary%20intervention%2C%20ticagrelor%20monotherapy%20demonstrated%20a%206%25%20risk%20reduction%2C%20compared%20with%20conventional%2012-month%20DAPT%20in%20time-to-first-event%20analysis%20%28hazard%20ratio%2C%200.94%20%5B95%25%20CI%2C%200.88%5Cu20131.01%5D%3B%20log-rank%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.10%29.%20In%20win%20ratio%20analysis%2C%20win%20ratio%20was%201.05%20%2895%25%20CI%2C%200.97%5Cu20131.13%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.20%29.%20Negative%20binomial%20regression%20and%20Andersen-Gill%20analyses%20which%20include%20repeated%20events%20showed%20statistically%20significant%20advantage%20for%20ticagrelor%20monotherapy%20%28rate%20ratio%2C%200.92%20%5B95%25%20CI%2C%200.85%5Cu20130.99%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.020%5D%20and%20hazard%20ratio%2C%200.92%20%5B95%25%20CI%2C%200.85%5Cu20130.99%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.028%5D%2C%20respectively%29%2C%20although%20in%20weighted%20composite%20end%20point%20analysis%2C%20the%20hazard%20ratio%20was%200.93%20%2895%25%20CI%2C%200.84%5Cu20131.04%3B%20log-rank%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.22%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Statistical%20analyses%20considering%20repeated%20events%20or%20event%20severity%20showed%20that%20ticagrelor%20monotherapy%20consistently%20reduced%20ischemic%20and%20bleeding%20events%20by%205%25%20to%208%25%2C%20compared%20with%20conventional%201-year%20DAPT.%20Applying%20multiple%20statistical%20methods%20could%20emphasize%20the%20multiple%20facets%20of%20a%20trial%20and%20result%20in%20accurate%20and%20more%20appropriate%20analyses.%20Considering%20the%20recurrence%20of%20ischemic%20and%20bleeding%20events%2C%20ticagrelor%20monotherapy%20appeared%20to%20be%20beneficial%20after%20percutaneous%20coronary%20intervention.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT01813435.%22%2C%22date%22%3A%2208%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCOUTCOMES.120.006660%22%2C%22ISSN%22%3A%221941-7713%2C%201941-7705%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCOUTCOMES.120.006660%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A21Z%22%7D%7D%2C%7B%22key%22%3A%2249SIE75B%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fuchs%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFuchs%20A%2C%20Urena%20M%2C%20Chong-Nguyen%20C%2C%20Kiko%26%23xEF%3Bne%20J%2C%20Brochet%20E%2C%20Abtan%20J%2C%20Fischer%20Q%2C%20Ducrocq%20G%2C%20Vahanian%20A%2C%20Iung%20B%2C%20Himbert%20D.%202020.%20Valve-in-Valve%20and%20Valve-in-Ring%20Transcatheter%20Mitral%20Valve%20Implantation%20in%20Young%20Women%20Contemplating%20Pregnancy.%20Circ%3A%20Cardiovascular%20Interventions%2013%3Ae009579.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Valve-in-Valve%20and%20Valve-in-Ring%20Transcatheter%20Mitral%20Valve%20Implantation%20in%20Young%20Women%20Contemplating%20Pregnancy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Fuchs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Urena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Chong-Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Kiko%5Cu00efne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Brochet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9mie%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quentin%22%2C%22lastName%22%3A%22Fischer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alec%22%2C%22lastName%22%3A%22Vahanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Iung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Himbert%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Transcatheter%20mitral%20valve%20implantation%20%28TMVI%29%20is%20emerging%20as%20an%20alternative%20to%20surgical%20mitral%20valve%20replacement%20in%20selected%20high-risk%20patients.%20Delaying%20definitive%20mechanical%20mitral%20valve%20replacement%20and%20the%20constraints%20of%20anticoagulation%20thanks%20to%20TMVI%20may%20be%20an%20attractive%20option%20in%20young%20women%20contemplating%20pregnancy%20and%20suffering%20from%20failure%20of%20mitral%20bioprosthesis%20or%20annuloplasty.%20The%20aim%20of%20the%20study%20was%20to%20evaluate%20the%20possibility%2C%20safety%2C%20and%20outcomes%20of%20pregnancy%20after%20TMVI%20in%20this%20population.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20From%202013%20to%202019%2C%2012%20young%20women%20contemplating%20pregnancy%20underwent%20transseptal%20valve-in-valve%20or%20valve-in-ring%20TMVI%20using%20the%20Edwards%20SAPIEN%20XT%5C%2F3%20valves%20and%20were%20prospectively%20followed%20up%20at%201%20month%2C%206%20months%2C%201%20year%2C%20and%20yearly%20thereafter.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Mean%20age%20of%20the%20patients%20was%2030%5Cu00b16%20years.%20Bioprosthesis%20degeneration%20was%20observed%20in%207%20cases%20and%20annuloplasty%20failure%20in%205.%20Three%20valve-in-ring%20patients%20required%20the%20implantation%20of%20a%20second%20valve%2C%20which%20led%20to%20an%20overall%20procedural%20success%20rate%20of%2075%25.%20One%20delayed%20left%20ventricular%20outflow%20tract%20obstruction%20required%20elective%20surgical%20mitral%20valve%20replacement.%20At%206%20months%5C%2F1%20year%2C%2083%25%20of%20the%20patients%20were%20in%20New%20York%20Heart%20Association%20classes%20I%5C%2FII.%20Mitral%20regurgitation%20was%20%5Cu22642%2B%20in%20all%20the%20cases%20and%20mean%20gradient%20was%207%5Cu00b12%20mm%5Cu2009Hg.%20Four%20patients%20could%20complete%206%20full-term%20pregnancies.%20One%20symptomatic%20thrombosis%20occurred%20and%20resolved%20under%20aspirin%20and%20anticoagulation%20therapy.%20All%20others%20pregnancies%20were%20uneventful.%20Predelivery%20mean%20gradient%20was%2011%20mm%5Cu2009Hg%2C%20and%20systolic%20pulmonary%20artery%20pressure%20was%2032%20mm%5Cu2009Hg.%20There%20were%204%20vaginal%20deliveries%20and%202%20cesarians.%20Newborns%20were%20alive%20and%20healthy.%20At%20last%20follow-up%2C%20there%20was%20no%20death%2C%20and%203%20patients%20required%20elective%20surgical%20mitral%20valve%20replacement%20at%206-%20to%2054-month%20follow-up.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Our%20study%20suggests%20that%2C%20in%20young%20women%2C%20transseptal%20TMVI%20to%20treat%20failing%20bioprostheses%20may%20result%20in%20good%20short-term%20outcomes%20that%20allow%20uneventful%20pregnancies.%20The%20results%20are%20less%20favorable%20in%20women%20with%20failed%20annuloplasty%20rings.%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.120.009579%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.120.009579%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A11Z%22%7D%7D%2C%7B%22key%22%3A%226QU78349%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hara%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHara%20H%2C%20Takahashi%20K%2C%20Kogame%20N%2C%20Tomaniak%20M%2C%20Kerkmeijer%20LSM%2C%20Ono%20M%2C%20Kawashima%20H%2C%20Wang%20R%2C%20Gao%20C%2C%20Wykrzykowska%20JJ%2C%20De%20Winter%20RJ%2C%20Neumann%20F-J%2C%20Plante%20S%2C%20Lemos%20Neto%20PA%2C%20Garg%20S%2C%20J%26%23xFC%3Bni%20P%2C%20Vranckx%20P%2C%20Windecker%20S%2C%20Valgimigli%20M%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Onuma%20Y%2C%20Serruys%20PW.%202020.%20Impact%20of%20Bleeding%20and%20Myocardial%20Infarction%20on%20Mortality%20in%20All-Comer%20Patients%20Undergoing%20Percutaneous%20Coronary%20Intervention.%20Circ%3A%20Cardiovascular%20Interventions%2013%3Ae009177.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Bleeding%20and%20Myocardial%20Infarction%20on%20Mortality%20in%20All-Comer%20Patients%20Undergoing%20Percutaneous%20Coronary%20Intervention%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hironori%22%2C%22lastName%22%3A%22Hara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20S.M.%22%2C%22lastName%22%3A%22Kerkmeijer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masafumi%22%2C%22lastName%22%3A%22Ono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hideyuki%22%2C%22lastName%22%3A%22Kawashima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rutao%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20J.%22%2C%22lastName%22%3A%22Wykrzykowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robbert%20J.%22%2C%22lastName%22%3A%22De%20Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz-Josef%22%2C%22lastName%22%3A%22Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Plante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20Alves%22%2C%22lastName%22%3A%22Lemos%20Neto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Bleeding%20and%20myocardial%20infarction%20%28MI%29%20after%20percutaneous%20coronary%20intervention%20are%20independent%20risk%20factors%20for%20mortality.%20This%20study%20aimed%20to%20investigate%20the%20association%20of%20all-cause%20mortality%20after%20percutaneous%20coronary%20intervention%20with%20site-reported%20bleeding%20and%20MI%2C%20when%20considered%20as%20individual%2C%20repeated%2C%20or%20combined%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20used%20the%20data%20from%20the%20GLOBAL%20LEADERS%20trial%20%28GLOBAL%20LEADERS%3A%20A%20Clinical%20Study%20Comparing%20Two%20Forms%20of%20Anti-Platelet%20Therapy%20After%20Stent%20Implantation%29%2C%20an%20all-comers%20trial%20of%2015%5Cu2009968%20patients%20undergoing%20percutaneous%20coronary%20intervention.%20Bleeding%20was%20defined%20as%20Bleeding%20Academic%20Research%20Consortium%20%28BARC%29%202%2C%203%2C%20or%205%2C%20whereas%20MI%20included%20periprocedural%20and%20spontaneous%20MIs%20according%20to%20the%20Third%20Universal%20Definition.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20At%202-year%20follow-up%2C%201061%20and%20498%20patients%20%286.64%25%20and%203.12%25%29%20experienced%20bleeding%20and%20MI%2C%20respectively.%20Patients%20with%20a%20bleeding%20event%20had%20a%2010.8%25%20mortality%20%28hazard%20ratio%20%5BHR%5D%2C%205.97%20%5B95%25%20CI%2C%204.76%5Cu20137.49%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20and%20the%20mortality%20of%20patients%20with%20an%20MI%20was%2010.4%25%20%28HR%2C%205.06%20%5B95%25%20CI%2C%203.72%5Cu20136.90%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20whereas%20the%20overall%20mortality%20was%202.99%25.%20Albeit%20reduced%20over%20time%2C%20MI%20and%20even%20minor%20BARC%202%20bleeding%20significantly%20influenced%20mortality%20beyond%201%20year%20after%20adverse%20events%20%28HR%20of%20MI%2C%202.32%20%5B95%25%20CI%2C%201.18%5Cu20134.55%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.014%2C%20and%20HR%20of%20BARC%202%20bleeding%2C%201.79%20%5B95%25%20CI%2C%201.02%5Cu20133.15%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.044%29.%20The%20mortality%20rates%20in%20patients%20with%20repetitive%20bleeding%2C%20repetitive%20MI%2C%20and%20both%20bleeding%20and%20MI%20were%2016.1%25%2C%2019.2%25%2C%20and%2019.0%25%2C%20and%20their%20HRs%20for%202-year%20mortality%20were%208.58%20%2895%25%20CI%2C%205.63%5Cu201313.09%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%205.57%20%2895%25%20CI%2C%202.53%5Cu201312.25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20and%206.60%20%2895%25%20CI%2C%203.44%5Cu201312.65%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20respectively.%20De-escalation%20of%20antiplatelet%20therapy%20at%20the%20time%20of%20BARC%203%20bleeding%20was%20associated%20with%20a%20lower%20subsequent%20bleeding%20or%20MI%20rate%2C%20compared%20with%20continuation%20of%20antiplatelet%20therapy%20%28HR%2C%200.32%20%5B95%25%20CI%2C%200.11%5Cu20130.92%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.034%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20fatal%20impact%20of%20bleeding%20and%20MI%20persisted%20beyond%20one%20year.%20Additional%20bleeding%20or%20MIs%20resulted%20in%20a%20poorer%20prognosis.%20De-escalation%20of%20antiplatelet%20therapy%20at%20the%20time%20of%20BARC%203%20bleeding%20could%20have%20a%20major%20safety%20merit.%20These%20results%20emphasize%20the%20importance%20of%20considering%20the%20net%20clinical%20benefit%20including%20ischemic%20and%20bleeding%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01813435.%22%2C%22date%22%3A%2209%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.120.009177%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.120.009177%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22QDVMMFNK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Duthoit%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDuthoit%20G%2C%20Silvain%20J%2C%20Marijon%20E%2C%20Ducrocq%20G%2C%20Lepillier%20A%2C%20Frere%20C%2C%20Dimby%20S-F%2C%20Popovic%20B%2C%20Lellouche%20N%2C%20Martin-Toutain%20I%2C%20Spaulding%20C%2C%20Brochet%20E%2C%20Attias%20D%2C%20Mansourati%20J%2C%20Lorgis%20L%2C%20Klug%20D%2C%20Zannad%20N%2C%20Hauguel-Moreau%20M%2C%20Braik%20N%2C%20Deltour%20S%2C%20Ceccaldi%20A%2C%20Wang%20H%2C%20Hammoudi%20N%2C%20Brugier%20D%2C%20Vicaut%20E%2C%20Juliard%20J-M%2C%20Montalescot%20G%2C%20for%20the%20ADRIFT%20Investigators.%202020.%20Reduced%20Rivaroxaban%20Dose%20Versus%20Dual%20Antiplatelet%20Therapy%20After%20Left%20Atrial%20Appendage%20Closure%3A%20ADRIFT%20a%20Randomized%20Pilot%20Study.%20Circ%3A%20Cardiovascular%20Interventions%2013%3Ae008481.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reduced%20Rivaroxaban%20Dose%20Versus%20Dual%20Antiplatelet%20Therapy%20After%20Left%20Atrial%20Appendage%20Closure%3A%20ADRIFT%20a%20Randomized%20Pilot%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Duthoit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanne%22%2C%22lastName%22%3A%22Silvain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eloi%22%2C%22lastName%22%3A%22Marijon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Lepillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Frere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solohaja-Faniaha%22%2C%22lastName%22%3A%22Dimby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batric%22%2C%22lastName%22%3A%22Popovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lellouche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Martin-Toutain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Spaulding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Brochet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Attias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Mansourati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Lorgis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Klug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noura%22%2C%22lastName%22%3A%22Zannad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Hauguel-Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%22%2C%22lastName%22%3A%22Braik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Deltour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Ceccaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hui%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadjib%22%2C%22lastName%22%3A%22Hammoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Brugier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Juliard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20ADRIFT%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Percutaneous%20left%20atrial%20appendage%20closure%20%28LAAC%29%20exposes%20to%20the%20risk%20of%20device%20thrombosis%20in%20patients%20with%20atrial%20fibrillation%20who%20frequently%20have%20a%20contraindication%20to%20full%20anticoagulation.%20Thereby%2C%20dual%20antiplatelet%20therapy%20%28DAPT%29%20is%20usually%20preferred.%20No%20randomized%20study%20has%20evaluated%20nonvitamin%20K%20antagonist%20oral%20anticoagulant%20after%20LAAC%2C%20and%20we%20decided%20to%20evaluate%20the%20efficacy%20and%20safety%20of%20reduced%20doses%20of%20rivaroxaban%20after%20LAAC.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ADRIFT%20%28Assessment%20of%20Dual%20Antiplatelet%20Therapy%20Versus%20Rivaroxaban%20in%20Atrial%20Fibrillation%20Patients%20Treated%20With%20Left%20Atrial%20Appendage%20Closure%29%20is%20a%20multicenter%2C%20phase%20IIb%20study%2C%20which%20randomized%20105%20patients%20after%20successful%20LAAC%20to%20either%20rivaroxaban%2010%20mg%20%28R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20n%3D37%29%2C%20rivaroxaban%2015%20mg%20%28R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2015%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20n%3D35%29%2C%20or%20DAPT%20with%20aspirin%2075%20mg%20and%20clopidogrel%2075%20mg%20%28n%3D33%29.%20The%20primary%20end%20point%20was%20thrombin%20generation%20%28prothrombin%20fragments%201%2B2%29%20measured%202%20to%204%20hours%20after%20drug%20intake%2C%2010%20days%20after%20treatment%20initiation.%20Thrombin-antithrombin%20complex%2C%20D-dimers%2C%20rivaroxaban%20concentrations%20were%20also%20measured%20at%2010%20days%20and%203%20months.%20Clinical%20end%20points%20were%20evaluated%20at%203-month%20follow-up.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20primary%20end%20point%20was%20reduced%20with%20R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28179%20pmol%5C%2FL%20%5Binterquartile%20range%20%28IQR%29%2C%20129%5Cu2013273%5D%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%20and%20R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2015%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28163%20pmol%5C%2FL%20%5BIQR%2C%20112%5Cu2013231%5D%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%20as%20compared%20with%20DAPT%20%28322%20pmol%5C%2FL%20%5BIQR%2C%20218%5Cu2013528%5D%29.%20We%20observed%20no%20significant%20reduction%20of%20the%20primary%20end%20point%20between%20R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2015%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20while%20rivaroxaban%20concentrations%20increased%20significantly%20from%20184%20ng%5C%2FmL%20%28IQR%2C%20127%5Cu2013290%29%20with%20R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20to%20274%20ng%5C%2FmL%20%28IQR%2C%20192%5Cu2013377%29%20with%20R%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2015%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001.%20Thrombin-antithrombin%20complex%20and%20D-dimers%20were%20numerically%20lower%20with%20both%20rivaroxaban%20doses%20than%20with%20DAPT.%20These%20findings%20were%20all%20confirmed%20at%203%20months.%20The%20clinical%20end%20points%20were%20not%20different%20between%20groups.%20A%20device%20thrombosis%20was%20noted%20in%202%20patients%20assigned%20to%20DAPT.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Thrombin%20generation%20measured%20after%20LAAC%20was%20lower%20in%20patients%20treated%20by%20reduced%20rivaroxaban%20doses%20than%20DAPT%2C%20supporting%20an%20alternative%20to%20the%20antithrombotic%20regimens%20currently%20used%20after%20LAAC%20and%20deserves%20further%20evaluation%20in%20larger%20studies.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT03273322.%22%2C%22date%22%3A%2207%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.119.008481%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.119.008481%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22DLSP5WKR%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Berry%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBerry%20NC%2C%20Mauri%20L%2C%20Steg%20PG%2C%20Bhatt%20DL%2C%20Hohnloser%20SH%2C%20Nordaby%20M%2C%20Miede%20C%2C%20Kimura%20T%2C%20Lip%20GYH%2C%20Oldgren%20J%2C%20Ten%20Berg%20JM%2C%20Cannon%20CP%2C%20on%20behalf%20of%20the%20REDUAL%20PCI%20Steering%20Committee%20and%20Investigators.%202020.%20Effect%20of%20Lesion%20Complexity%20and%20Clinical%20Risk%20Factors%20on%20the%20Efficacy%20and%20Safety%20of%20Dabigatran%20Dual%20Therapy%20Versus%20Warfarin%20Triple%20Therapy%20in%20Atrial%20Fibrillation%20After%20Percutaneous%20Coronary%20Intervention%3A%20A%20Subgroup%20Analysis%20From%20the%20REDUAL%20PCI%20Trial.%20Circ%3A%20Cardiovascular%20Interventions%2013%3Ae008349.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Lesion%20Complexity%20and%20Clinical%20Risk%20Factors%20on%20the%20Efficacy%20and%20Safety%20of%20Dabigatran%20Dual%20Therapy%20Versus%20Warfarin%20Triple%20Therapy%20in%20Atrial%20Fibrillation%20After%20Percutaneous%20Coronary%20Intervention%3A%20A%20Subgroup%20Analysis%20From%20the%20REDUAL%20PCI%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%20C.%22%2C%22lastName%22%3A%22Berry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Mauri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20H.%22%2C%22lastName%22%3A%22Hohnloser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matias%22%2C%22lastName%22%3A%22Nordaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinna%22%2C%22lastName%22%3A%22Miede%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takeshi%22%2C%22lastName%22%3A%22Kimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20Y.H.%22%2C%22lastName%22%3A%22Lip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonas%22%2C%22lastName%22%3A%22Oldgren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurri%5Cu00ebn%20M.%22%2C%22lastName%22%3A%22Ten%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P.%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20REDUAL%20PCI%20Steering%20Committee%20and%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20REDUAL%20PCI%20trial%20%28Evaluation%20of%20Dual%20Therapy%20With%20Dabigatran%20vs%20Triple%20Therapy%20With%20Warfarin%20in%20Patients%20With%20AF%20That%20Undergo%20a%20PCI%20With%20Stenting%29%20demonstrated%20that%2C%20in%20patients%20with%20atrial%20fibrillation%20following%20percutaneous%20coronary%20intervention%2C%20bleeding%20risk%20was%20lower%20with%20dabigatran%20plus%20clopidogrel%20or%20ticagrelor%20%28dual%20therapy%29%20than%20warfarin%20plus%20clopidogrel%20or%20ticagrelor%20and%20aspirin%20%28triple%20therapy%29.%20Dual%20therapy%20was%20noninferior%20for%20risk%20of%20thromboembolic%20events.%20Whether%20these%20results%20apply%20equally%20to%20patients%20at%20higher%20risk%20of%20ischemic%20events%20due%20to%20lesion%20complexity%20or%20clinical%20risk%20factors%20is%20unclear.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20primary%20end%20point%20was%20time%20to%20first%20major%20or%20clinically%20relevant%20nonmajor%20bleeding%20event.%20The%20composite%20efficacy%20end%20point%20was%20death%2C%20thromboembolic%20event%2C%20or%20unplanned%20revascularization.%20Our%20prespecified%20subgroup%20analysis%20categorized%20patients%20by%20presence%20of%20procedural%20complexity%20and%5C%2For%20clinical%20complexity%20factors%20at%20baseline.%20A%20modified%20dual%20antiplatelet%20therapy%20score%20categorized%20patients%20according%20to%20degree%20of%20clinical%20risk.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Of%202725%20patients%2C%2043.1%25%20had%20clinical%20complexity%20factors%20alone%2C%209.9%25%20procedural%20factors%20alone%2C%2010.0%25%20both%2C%20and%2037.0%25%20neither.%20Risk%20of%20the%20primary%20bleeding%20end%20point%20was%20lower%20in%20both%20dabigatran%20dual%20therapy%20groups%20than%20warfarin%20triple%20therapy%20groups%2C%20regardless%20of%20procedural%20and%5C%2For%20clinical%20lesion%20complexity%20%28interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20values%3A%200.90%20and%200.37%2C%20respectively%29.%20Importantly%2C%20a%20similar%20risk%20of%20the%20efficacy%20end%20point%20was%20observed%20between%20dabigatran%20dual%20and%20warfarin%20triple%20therapy%2C%20regardless%20of%20the%20presence%20of%20clinical%20or%20procedural%20complexity%20factors%20%28interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20values%3A%200.67%20and%200.54%2C%20dabigatran%20110%20and%20150%20mg%20dual%20therapy%2C%20respectively%29.%20Similar%20benefit%20was%20seen%20for%20each%20dose%20of%20dabigatran%20dual%20therapy%20for%20bleeding%20events%20regardless%20of%20dual%20antiplatelet%20therapy%20score%20%28interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20values%3A%200.53%20and%200.54%2C%20respectively%29%2C%20with%20similar%20risk%20of%20thromboembolic%20events%20%28interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20values%3A%200.20%20and%200.08%2C%20respectively%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20atrial%20fibrillation%20undergoing%20percutaneous%20coronary%20intervention%2C%20dabigatran%20110%20and%20150%20mg%20dual%20therapy%20reduced%20bleeding%20risk%20compared%20with%20warfarin%20triple%20therapy%2C%20with%20a%20similar%20risk%20of%20thromboembolic%20outcomes%2C%20irrespective%20of%20procedural%20and%5C%2For%20clinical%20complexity%20and%20modified%20dual%20antiplatelet%20therapy%20score.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fclinicaltrials.gov%5C%2F%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3B%20Unique%20identifier%3A%20NCT02164864.%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.119.008349%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.119.008349%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22KF7ZEWH6%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sorrentino%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESorrentino%20S%2C%20Sartori%20S%2C%20Baber%20U%2C%20Claessen%20BE%2C%20Giustino%20G%2C%20Chandrasekhar%20J%2C%20Chandiramani%20R%2C%20Cohen%20DJ%2C%20Henry%20TD%2C%20Guedeney%20P%2C%20Ariti%20C%2C%20Dangas%20G%2C%20Gibson%20CM%2C%20Krucoff%20MW%2C%20Moliterno%20DJ%2C%20Colombo%20A%2C%20Vogel%20B%2C%20Chieffo%20A%2C%20Kini%20AS%2C%20Witzenbichler%20B%2C%20Weisz%20G%2C%20Steg%20PG%2C%20Pocock%20S%2C%20Urban%20P%2C%20Mehran%20R.%202020.%20Bleeding%20Risk%2C%20Dual%20Antiplatelet%20Therapy%20Cessation%2C%20and%20Adverse%20Events%20After%20Percutaneous%20Coronary%20Intervention%3A%20The%20PARIS%20Registry.%20Circ%3A%20Cardiovascular%20Interventions%2013%3Ae008226.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bleeding%20Risk%2C%20Dual%20Antiplatelet%20Therapy%20Cessation%2C%20and%20Adverse%20Events%20After%20Percutaneous%20Coronary%20Intervention%3A%20The%20PARIS%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabato%22%2C%22lastName%22%3A%22Sorrentino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bimmer%20E.%22%2C%22lastName%22%3A%22Claessen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gennaro%22%2C%22lastName%22%3A%22Giustino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaya%22%2C%22lastName%22%3A%22Chandrasekhar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rishi%22%2C%22lastName%22%3A%22Chandiramani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20D.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Guedeney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cono%22%2C%22lastName%22%3A%22Ariti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%20W.%22%2C%22lastName%22%3A%22Krucoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Moliterno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alaide%22%2C%22lastName%22%3A%22Chieffo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annapoorna%20S.%22%2C%22lastName%22%3A%22Kini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernhard%22%2C%22lastName%22%3A%22Witzenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giora%22%2C%22lastName%22%3A%22Weisz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Urban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Whether%20the%20underlying%20risk%20of%20bleeding%20influences%20the%20associations%20between%20patterns%20of%20dual%20antiplatelet%20therapy%20%28DAPT%29%20cessation%20and%20adverse%20events%20after%20percutaneous%20coronary%20intervention%20is%20unknown.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20enrolled%20in%20the%20prospective%2C%20international%2C%20multicenter%20PARIS%20registry%20%28Patterns%20of%20Non-Adherence%20to%20Anti-Platelet%20Regimens%20in%20Stented%20Patients%29%20were%20categorized%20according%20to%20their%20risk%20of%20bleeding%20using%20the%20PARIS%20bleeding%20risk%20score.%20We%20evaluated%20the%20incidence%2C%20patterns%2C%20and%20association%20between%20modes%20of%20DAPT%20cessation%20and%20outcomes%20across%20bleeding%20risk%20groups.%20Modes%20of%20DAPT%20cessations%20were%20defined%20as%20physician-guided%20DAPT%20discontinuation%2C%20brief%20interruption%20%28%3C14%20days%29%20or%20disruption%20for%20bleeding%2C%20or%20noncompliance.%20The%20primary%20end%20point%20of%20interest%20was%20major%20adverse%20cardiac%20events%2C%20defined%20as%20the%20composite%20of%20cardiac%20death%2C%20myocardial%20infarction%2C%20or%20definite-probable%20stent%20thrombosis.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20From%20a%20total%20of%205018%20patients%2C%20513%20%2810.2%25%29%20were%20classified%20as%20high%2C%202058%20%2841.0%25%29%20as%20intermediate%2C%20and%202447%20%2848.8%25%29%20as%20low%20risk%20for%20bleeding.%20High%20bleeding%20risk%20%28HBR%29%20patients%20were%20older%20and%20had%20greater%20prevalence%20of%20comorbidities.%20Compared%20with%20non-HBR%2C%20HBR%20patients%20had%20higher%20rates%20of%20both%20ischemic%20and%20bleeding%20events.%20The%20cumulative%20incidence%20of%20DAPT%20cessation%20was%20higher%20in%20HBR%20patients%2C%20mostly%20driven%20by%20physician-guided%20discontinuation%20and%20disruption.%20Of%20note%2C%20DAPT%20disruption%20occurred%20in%2017.7%25%2C%2010.4%25%2C%20and%207.8%25%20at%201%20year%20and%2022.0%25%2C%2015.1%25%2C%20and%2012.0%25%20at%202%20years%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%20in%20high%2C%20intermediate%2C%20and%20low%20bleeding%20risk%20groups%2C%20respectively.%20Physician-guided%20DAPT%20discontinuation%20was%20not%20associated%20with%20increased%20risk%20of%20major%20adverse%20cardiac%20events%20in%20both%20HBR%20and%20non-HBR%20patients%2C%20while%20DAPT%20disruption%20was%20associated%20with%20an%20increased%20risk%20of%20major%20adverse%20cardiac%20events%20across%20all%20bleeding%20risk%20groups.%20There%20was%20no%20interaction%20between%20bleeding%20risk%20status%20and%20clinical%20outcomes%20for%20any%20cessation%20mode.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20at%20HBR%20remain%20at%20higher%20risk%20of%20adverse%20events.%20Disruption%20of%20DAPT%20is%20associated%20with%20an%20increased%20risk%20of%20major%20adverse%20cardiac%20events%20irrespective%20of%20the%20underlying%20bleeding%20risk.%20Physician-guided%20discontinuation%20of%20DAPT%20appears%20to%20be%20safe%2C%20irrespective%20of%20HBR.%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.119.008226%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.119.008226%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22TMS6DAZB%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stavres%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EStavres%20J%2C%20Luck%20JC%2C%20Ducrocq%20GP%2C%20Cauffman%20AE%2C%20Pai%20S%2C%20Sinoway%20LI.%202020.%20Central%20and%20peripheral%20modulation%20of%20exercise%20pressor%20reflex%20sensitivity%20after%20nonfatiguing%20work.%20American%20Journal%20of%20Physiology-Regulatory%2C%20Integrative%20and%20Comparative%20Physiology%20319%3AR575%26%23x2013%3BR583.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Central%20and%20peripheral%20modulation%20of%20exercise%20pressor%20reflex%20sensitivity%20after%20nonfatiguing%20work%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jon%22%2C%22lastName%22%3A%22Stavres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Carter%22%2C%22lastName%22%3A%22Luck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%20P.%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%20E.%22%2C%22lastName%22%3A%22Cauffman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Pai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%20I.%22%2C%22lastName%22%3A%22Sinoway%22%7D%5D%2C%22abstractNote%22%3A%22Autonomic%20blood%20pressure%20control%20is%20fundamentally%20altered%20during%20a%20single%20bout%20of%20exercise%2C%20as%20evidenced%20by%20the%20downward%20resetting%20of%20the%20baroreflex%20following%20exercise%20%28postexercise%20hypotension%29.%20However%2C%20it%20is%20unclear%20if%20an%20acute%20bout%20of%20exercise%20is%20also%20associated%20with%20a%20change%20in%20the%20sensitivity%20of%20the%20exercise%20pressor%20response%20to%20a%20controlled%20stimulus%2C%20such%20as%20a%20static%20contraction.%20This%20study%20tested%20the%20hypothesis%20that%20the%20blood%20pressure%20response%20to%20a%20controlled%20static%20contraction%20would%20be%20attenuated%20after%20unilateral%20cycling%20of%20the%20contralateral%20%28opposite%29%20leg%2C%20but%20preserved%20after%20cycling%20of%20the%20ipsilateral%20%28same%29%20leg.%20To%20test%20this%2C%20the%20blood%20pressure%20response%20to%2090%20s%20of%20isometric%20plantar%20flexion%20%5B50%25%20maximal%20voluntary%20contraction%20%28MVC%29%5D%20was%20compared%20before%20and%20after%2020%20min%20of%20contralateral%20and%20ipsilateral%20single-leg%20cycling%20at%2020%25%20peak%20oxygen%20consumption%20and%20rest%20%28control%29%20in%2010%20healthy%20subjects%20%28three%20males%20and%20seven%20females%29.%20The%20mean%20arterial%20pressure%20response%20was%20significantly%20attenuated%20after%20contralateral%20single-leg%20cycling%20%28%2B9.8%5Cu2009%5Cu00b1%5Cu20097.5%25%20%5Cu2206mmHg%20vs.%20%2B6.7%5Cu2009%5Cu00b1%5Cu20096.6%25%20%5Cu2206mmHg%20pre%20and%20postexercise%2C%20respectively%2C%20P%20%3D%200.04%29%20and%20rest%20%28%2B9.0%5Cu2009%5Cu00b1%5Cu20097.5%25%20%5Cu2206mmHg%20vs.%20%2B6.6%5Cu2009%5Cu00b1%5Cu20095.2%25%20%5Cu2206mmHg%20pre%20and%20postexercise%2C%20respectively%2C%20P%20%3D%200.03%29.%20In%20contrast%2C%20the%20pressor%20response%20nonsignificantly%20increased%20following%20ipsilateral%20single-leg%20cycling%20%28%2B5.5%5Cu2009%5Cu00b1%5Cu20095.2%25%20%5Cu2206mmHg%20vs.%20%2B8.9%5Cu2009%5Cu00b1%5Cu20097.2%25%20%5Cu2206mmHg%20pre%20and%20postexercise%2C%20respectively%2C%20P%20%3D%200.08%29.%20The%20heart%20rate%2C%20leg%20blood%20flow%2C%20and%20leg%20conductance%20responses%20to%20plantar%20flexion%20were%20not%20affected%20by%20any%20condition%20%28%20P%20%5Cu2265%200.12%29.%20These%20results%20are%20consistent%20with%20the%20notion%20that%20peripheral%2C%20but%20not%20central%20mechanisms%20promote%20exercise%20pressor%20reflex%20sensitivity%20after%20exercise.%22%2C%22date%22%3A%222020-11-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1152%5C%2Fajpregu.00127.2020%22%2C%22ISSN%22%3A%220363-6119%2C%201522-1490%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.physiology.org%5C%2Fdoi%5C%2F10.1152%5C%2Fajpregu.00127.2020%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22BSZRGRW2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Estrada%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EEstrada%20JA%2C%20Ducrocq%20GP%2C%20Kim%20JS%2C%20Kaufman%20MP.%202020.%20Intrathecal%20injection%20of%20brilliant%20blue%20G%2C%20a%20P2X7%20antagonist%2C%20attenuates%20the%20exercise%20pressor%20reflex%20in%20rats.%20American%20Journal%20of%20Physiology-Regulatory%2C%20Integrative%20and%20Comparative%20Physiology%20319%3AR223%26%23x2013%3BR232.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intrathecal%20injection%20of%20brilliant%20blue%20G%2C%20a%20P2X7%20antagonist%2C%20attenuates%20the%20exercise%20pressor%20reflex%20in%20rats%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20A.%22%2C%22lastName%22%3A%22Estrada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%20P.%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joyce%20S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Kaufman%22%7D%5D%2C%22abstractNote%22%3A%22Purinergic%202X%20%28P2X%29%20receptors%20on%20the%20endings%20of%20group%20III%20and%20IV%20afferents%20play%20a%20role%20in%20evoking%20the%20exercise%20pressor%20reflex.%20Particular%20attention%20has%20been%20paid%20to%20P2X3%20receptors%20because%20their%20blockade%20in%20the%20periphery%20attenuated%20this%20reflex.%20In%20contrast%2C%20nothing%20is%20known%20about%20the%20role%20played%20by%20P2X%20receptors%20in%20the%20spinal%20cord%20in%20evoking%20the%20exercise%20pressor%20reflex%20in%20rats.%20P2X7%20receptors%2C%20in%20particular%2C%20may%20be%20especially%20important%20in%20this%20regard%20because%20they%20are%20found%20in%20abundance%20on%20spinal%20glial%20cells%20and%20may%20communicate%20with%20neurons%20to%20effect%20reflexes%20controlling%20cardiovascular%20function.%20Consequently%2C%20we%20investigated%20the%20role%20played%20by%20spinal%20P2X7%20receptors%20in%20evoking%20the%20exercise%20pressor%20reflex%20in%20decerebrated%20rats.%20We%20found%20that%20intrathecal%20injection%20of%20the%20P2X7%20antagonist%20brilliant%20blue%20G%20%28BBG%29%20attenuated%20the%20exercise%20pressor%20reflex%20%28blood%20pressure%20index%3A%20294%5Cu2009%5Cu00b1%20112%20mmHg%5Cu00b7s%20before%20vs.%207%5Cu2009%5Cu00b1%5Cu200932%20mmHg%5Cu00b7s%20after%3B%20P%20%3C%200.05%29.%20Likewise%2C%20intrathecal%20injection%20of%20minocycline%2C%20which%20inhibits%20microglial%20cell%20output%2C%20attenuated%20the%20reflex.%20In%20contrast%2C%20intrathecal%20injection%20of%20BBG%20did%20not%20attenuate%20the%20pressor%20response%20evoked%20by%20intracarotid%20injection%20of%20sodium%20cyanide%2C%20a%20maneuver%20that%20stimulated%20carotid%20chemoreceptors.%20Moreover%2C%20injections%20of%20BBG%20either%20into%20the%20arterial%20supply%20of%20the%20contracting%20hindlimb%20muscles%20or%20into%20the%20jugular%20vein%20did%20not%20attenuate%20the%20exercise%20pressor%20reflex.%20Our%20findings%20support%20the%20hypothesis%20that%20P2X7%20receptors%20on%20microglial%20cells%20within%20the%20spinal%20cord%20play%20a%20role%20in%20evoking%20the%20exercise%20pressor%20reflex.%22%2C%22date%22%3A%222020-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1152%5C%2Fajpregu.00093.2020%22%2C%22ISSN%22%3A%220363-6119%2C%201522-1490%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.physiology.org%5C%2Fdoi%5C%2F10.1152%5C%2Fajpregu.00093.2020%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22245E4676%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ducrocq%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDucrocq%20GP%2C%20Kim%20JS%2C%20Estrada%20JA%2C%20Kaufman%20MP.%202020.%20ASIC1a%20does%20not%20play%20a%20role%20in%20evoking%20the%20metabolic%20component%20of%20the%20exercise%20pressor%20reflex%20in%20a%20rat%20model%20of%20peripheral%20artery%20disease.%20American%20Journal%20of%20Physiology-Heart%20and%20Circulatory%20Physiology%20319%3AH171%26%23x2013%3BH182.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ASIC1a%20does%20not%20play%20a%20role%20in%20evoking%20the%20metabolic%20component%20of%20the%20exercise%20pressor%20reflex%20in%20a%20rat%20model%20of%20peripheral%20artery%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%20P.%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joyce%20S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20A.%22%2C%22lastName%22%3A%22Estrada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Kaufman%22%7D%5D%2C%22abstractNote%22%3A%22The%20role%20of%20ASIC1a%20in%20evoking%20the%20metabolic%20component%20of%20the%20exercise%20pressor%20reflex%20in%20peripheral%20artery%20disease%20is%20unknown.%20Using%20a%20within-rat%20experimental%20design%2C%20we%20found%20that%20the%20contribution%20of%20ASIC1a%20decreased%20in%20a%20rat%20model%20of%20peripheral%20artery%20disease.%20These%20results%20have%20key%20implications%20to%20help%20finding%20better%20treatments%20and%20improve%20morbidity%2C%20quality%20of%20life%2C%20and%20mortality%20in%20patients%20with%20peripheral%20artery%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%2C%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20The%20role%20of%20the%20ASIC1a%20in%20evoking%20the%20exercise%20pressor%20reflex%20in%20rats%20with%20simulated%20peripheral%20artery%20disease%20is%20unknown.%20This%20prompted%20us%20to%20determine%20whether%20ASIC1a%20plays%20a%20role%20in%20evoking%20the%20exaggerated%20exercise%20pressor%20reflex%20in%20decerebrated%20rats%20with%20simulated%20peripheral%20artery%20disease.%20To%20simulate%20peripheral%20artery%20disease%2C%20we%20ligated%20the%20left%20femoral%20artery%2072%20h%20before%20the%20experiment.%20The%20right%20femoral%20artery%20was%20freely%20perfused%20and%20used%20as%20a%20control.%20To%20test%20our%20hypothesis%2C%20we%20measured%20the%20effect%20of%20injecting%20two%20ASIC1a%20blockers%20into%20the%20arterial%20supply%20of%20the%20triceps%20surae%20muscles%20with%20and%20without%20the%20femoral%20artery%20ligated%20on%20the%20reflex%20pressor%20responses%20to%201%29%20static%20contraction%20of%20the%20triceps%20surae%20muscles%2C%202%29%20calcaneal%20tendon%20stretch%2C%20and%203%29%20intra-arterial%20injection%20of%20diprotonated%20phosphate%20%28pH%206.0%29.%20We%20found%20that%20the%20ASIC1a%20blockers%20psalmotoxin-1%20%28200%20ng%5C%2Fkg%29%20and%20mambalgin-1%20%286.5%20%5Cu03bcg%5C%2Fkg%29%20decreased%20the%20pressor%20responses%20to%20static%20contraction%20as%20well%20as%20the%20peak%20pressor%20responses%20to%20injection%20of%20diprotonated%20phosphate%20when%20these%20responses%20were%20evoked%20from%20the%20freely%20perfused%20hindlimb.%20In%20contrast%2C%20ASIC1a%20blockers%20only%20decreased%20the%20peak%20pressor%20responses%20evoked%20by%20injection%20of%20diprotonated%20phosphate%20in%20the%20hindlimb%20circulation%20with%20simulated%20peripheral%20artery%20disease.%20This%20inhibitory%20effect%20was%20less%20than%20the%20one%20measured%20from%20the%20healthy%20hindlimb.%20Independently%20of%20the%20hindlimb%20of%20interest%2C%20ASIC1a%20blockers%20had%20no%20effect%20on%20the%20pressor%20responses%20to%20tendon%20stretch.%20Our%20results%20do%20not%20support%20the%20hypothesis%20that%20ASIC1a%20play%20a%20role%20in%20evoking%20the%20exercise%20pressor%20reflex%20arising%20from%20a%20hindlimb%20with%20simulated%20peripheral%20artery%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20NEW%20%26%20NOTEWORTHY%20The%20role%20of%20ASIC1a%20in%20evoking%20the%20metabolic%20component%20of%20the%20exercise%20pressor%20reflex%20in%20peripheral%20artery%20disease%20is%20unknown.%20Using%20a%20within-rat%20experimental%20design%2C%20we%20found%20that%20the%20contribution%20of%20ASIC1a%20decreased%20in%20a%20rat%20model%20of%20peripheral%20artery%20disease.%20These%20results%20have%20key%20implications%20to%20help%20finding%20better%20treatments%20and%20improve%20morbidity%2C%20quality%20of%20life%2C%20and%20mortality%20in%20patients%20with%20peripheral%20artery%20disease.%22%2C%22date%22%3A%222020-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1152%5C%2Fajpheart.00257.2020%22%2C%22ISSN%22%3A%220363-6135%2C%201522-1539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.physiology.org%5C%2Fdoi%5C%2F10.1152%5C%2Fajpheart.00257.2020%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22JNY3FB9I%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Li%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELi%20L%2C%20Luengo-Fernandez%20R%2C%20Zuurbier%20SM%2C%20Beddows%20NC%2C%20Lavallee%20P%2C%20Silver%20LE%2C%20Kuker%20W%2C%20Rothwell%20PM.%202020.%20Ten-year%20risks%20of%20recurrent%20stroke%2C%20disability%2C%20dementia%20and%20cost%20in%20relation%20to%20site%20of%20primary%20intracerebral%20haemorrhage%3A%20population-based%20study.%20J%20Neurol%20Neurosurg%20Psychiatry%2091%3A580%26%23x2013%3B585.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ten-year%20risks%20of%20recurrent%20stroke%2C%20disability%2C%20dementia%20and%20cost%20in%20relation%20to%20site%20of%20primary%20intracerebral%20haemorrhage%3A%20population-based%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linxin%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%22%2C%22lastName%22%3A%22Luengo-Fernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanna%20M%22%2C%22lastName%22%3A%22Zuurbier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%20C%22%2C%22lastName%22%3A%22Beddows%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%22%2C%22lastName%22%3A%22Lavallee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%20E%22%2C%22lastName%22%3A%22Silver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilhelm%22%2C%22lastName%22%3A%22Kuker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20Malcolm%22%2C%22lastName%22%3A%22Rothwell%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20primary%20intracerebral%20haemorrhage%20%28ICH%29%20are%20at%20increased%20long-term%20risks%20of%20recurrent%20stroke%20and%20other%20comorbidities.%20However%2C%20available%20estimates%20come%20predominantly%20from%20hospital-based%20studies%20with%20relatively%20short%20follow-up.%20Moreover%2C%20there%20are%20also%20uncertainties%20about%20the%20influence%20of%20ICH%20location%20on%20risks%20of%20recurrent%20stroke%2C%20disability%2C%20dementia%20and%20quality%20of%20life.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20a%20population-based%20study%20%28Oxford%20Vascular%20Study%5C%2F2002%5Cu20132018%29%20of%20patients%20with%20a%20first%20ICH%20with%20follow-up%20to%2010%20years%2C%20we%20determined%20the%20long-term%20risks%20of%20recurrent%20stroke%2C%20disability%2C%20quality%20of%20life%2C%20dementia%20and%20hospital%20care%20costs%20stratified%20by%20haematoma%20location.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Of%20255%20cases%20with%20primary%20ICH%20%28mean%5C%2FSD%20age%2075.5%5C%2F13.1%29%2C%20109%20%2842.7%25%29%20had%20lobar%20ICH%2C%20144%20%2856.5%25%29%20non-lobar%20ICH%20and%202%20%280.8%25%29%20had%20uncertain%20location.%20Annual%20rates%20of%20recurrent%20ICH%20were%20higher%20after%20lobar%20versus%20non-lobar%20ICH%20%28lobar%3D4.0%25%2C%202.7%5Cu20137.2%20vs%201.1%25%2C%200.3%5Cu20132.8%3B%20p%3D0.02%29.%20Moreover%2C%20cumulative%20rate%20of%20dementia%20was%20also%20higher%20for%20lobar%20versus%20non-lobar%20ICH%20%28n%5C%2F%25%20lobar%3D20%5C%2F36.4%25%20vs%2016%5C%2F20.8%25%2C%20p%3D0.047%29%2C%20and%20there%20was%20a%20higher%20proportion%20of%20disability%20at%205%20years%20in%20survivors%20%2815%5C%2F60.0%25%20vs%209%5C%2F31.0%25%2C%20p%3D0.03%29.%20The%2010-year%20quality-adjusted%20life%20years%20%28QALYs%29%20were%20also%20lower%20after%20lobar%20versus%20non-lobar%20ICH%20%282.9%20vs%203.8%20for%20non-lobar%2C%20p%3D0.04%29.%20Overall%2C%20the%20mean%2010-year%20censor-adjusted%20costs%20were%20%5Cu00a319%20292%2C%20with%20over%2080%25%20of%20costs%20due%20to%20inpatient%20hospital%20admission%20costs%2C%20which%20did%20not%20vary%20by%20haematoma%20location%20%28p%3D0.90%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Compared%20with%20non-lobar%20ICH%2C%20the%20substantially%20higher%2010-year%20risks%20of%20recurrent%20stroke%2C%20dementia%20and%20lower%20QALYs%20after%20lobar%20ICH%20highlight%20the%20need%20for%20more%20effective%20prevention%20for%20this%20patient%20group.%22%2C%22date%22%3A%2206%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2019-322663%22%2C%22ISSN%22%3A%220022-3050%2C%201468-330X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjnnp.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fjnnp-2019-322663%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22DQ8FR3G5%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Norel%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ENorel%20X%2C%20Sugimoto%20Y%2C%20Ozen%20G%2C%20Abdelazeem%20H%2C%20Amgoud%20Y%2C%20Bouhadoun%20A%2C%20Bassiouni%20W%2C%20Goepp%20M%2C%20Mani%20S%2C%20Manikpurage%20HD%2C%20Senbel%20A%2C%20Longrois%20D%2C%20Heinemann%20A%2C%20Yao%20C%2C%20Clapp%20LH.%202020.%20International%20Union%20of%20Basic%20and%20Clinical%20Pharmacology.%20CIX.%20Differences%20and%20Similarities%20between%20Human%20and%20Rodent%20Prostaglandin%20E%20%3Csub%3E2%3C%5C%2Fsub%3E%20Receptors%20%28EP1%26%23x2013%3B4%29%20and%20Prostacyclin%20Receptor%20%28IP%29%3A%20Specific%20Roles%20in%20Pathophysiologic%20Conditions.%20Pharmacol%20Rev%2072%3A910%26%23x2013%3B968.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22International%20Union%20of%20Basic%20and%20Clinical%20Pharmacology.%20CIX.%20Differences%20and%20Similarities%20between%20Human%20and%20Rodent%20Prostaglandin%20E%20%3Csub%3E2%3C%5C%2Fsub%3E%20Receptors%20%28EP1%5Cu20134%29%20and%20Prostacyclin%20Receptor%20%28IP%29%3A%20Specific%20Roles%20in%20Pathophysiologic%20Conditions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukihiko%22%2C%22lastName%22%3A%22Sugimoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulsev%22%2C%22lastName%22%3A%22Ozen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heba%22%2C%22lastName%22%3A%22Abdelazeem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasmine%22%2C%22lastName%22%3A%22Amgoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amel%22%2C%22lastName%22%3A%22Bouhadoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wesam%22%2C%22lastName%22%3A%22Bassiouni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Goepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salma%22%2C%22lastName%22%3A%22Mani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hasanga%20D.%22%2C%22lastName%22%3A%22Manikpurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amira%22%2C%22lastName%22%3A%22Senbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Longrois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akos%22%2C%22lastName%22%3A%22Heinemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcan%22%2C%22lastName%22%3A%22Yao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%20H.%22%2C%22lastName%22%3A%22Clapp%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Eliot%20H.%22%2C%22lastName%22%3A%22Ohlstein%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1124%5C%2Fpr.120.019331%22%2C%22ISSN%22%3A%220031-6997%2C%201521-0081%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fpharmrev.aspetjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1124%5C%2Fpr.120.019331%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A29Z%22%7D%7D%2C%7B%22key%22%3A%226UZRED4G%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ducrocq%20and%20Kaufman%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDucrocq%20GP%2C%20Kaufman%20MP.%202020.%20Inorganic%20phosphate%20and%20lactate%20potentiate%20the%20pressor%20response%20to%20acidic%20stimuli%20in%20rats.%20Experimental%20Physiology%20105%3A613%26%23x2013%3B621.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inorganic%20phosphate%20and%20lactate%20potentiate%20the%20pressor%20response%20to%20acidic%20stimuli%20in%20rats%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%20P.%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Kaufman%22%7D%5D%2C%22abstractNote%22%3A%22New%20Findings%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20What%20is%20the%20central%20question%20of%20this%20study%3F%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20What%20is%20the%20contribution%20of%20the%20main%20acidic%20compounds%20accumulated%20during%20contractions%2C%20namely%20H%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20lactic%20acid%20and%20inorganic%20phosphate%2C%20to%20evoke%20the%20metabolic%20component%20of%20the%20exercise%20pressor%20reflex%3F%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20What%20is%20the%20main%20finding%20and%20its%20importance%3F%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20found%20that%20the%20pressor%20response%20to%20acidic%20stimuli%20is%20driven%20by%20the%20concentration%20of%20hydrogen%20ions%20and%20that%20lactate%20and%20inorganic%20phosphate%20act%20as%20potentiating%20agents.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20H%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ions%2C%20lactate%20and%20inorganic%20phosphate%20are%20produced%20by%20contracting%20skeletal%20muscles%20and%20evoke%2C%20in%20part%2C%20the%20metabolic%20component%20of%20the%20exercise%20pressor%20reflex.%20Owing%20to%20their%20disparate%20dissociation%20constants%20%28i.e.%20pK%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20a%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%2C%20the%20contribution%20of%20each%20acid%20to%20the%20muscle%20metaboreflex%20is%20unclear.%20This%20lack%20of%20information%20prompted%20us%20to%20determine%20the%20reflex%20pressor%20responses%20to%20injection%20of%20acidic%20saline%2C%20lactate%20%2824%5Cu00a0m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%5Cu00a0and%20inorganic%20phosphate%5Cu00a0%2886%5Cu00a0m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%5Cu00a0at%20various%20values%20of%20pH%20%28from%202.66%20to%207.5%29%2C%20alone%20or%20in%20combination%2C%20into%20the%20arterial%20supply%20of%20hindlimb%20skeletal%20muscle%20of%20decerebrate%20rats.%20In%20particular%2C%20we%20tested%20the%20hypothesis%20that%20the%20pressor%20response%20to%20an%20injection%20of%20a%20combination%20of%20lactate%20and%20phosphate%20at%20an%20acidic%20pH%20is%20greater%20than%20that%20evoked%20by%20injection%20of%20either%20phosphate%20or%20lactate%20alone%20at%20the%20same%20pH.%20We%20found%20that%20injection%20of%20acidic%20saline%20produced%20a%20pressor%20response%20only%20at%20a%20pH%20of%202.66%20%287%5Cu00a0%5Cu00b1%5Cu00a04%5Cu00a0mmHg%29%2C%20an%20effect%20that%20was%20potentiated%20when%20the%20solution%20contained%20lactate%20%2850%5Cu00a0%5Cu00b1%5Cu00a020%5Cu00a0mmHg%29.%20At%20a%20pH%20of%206.0%2C%20however%2C%20this%20effect%20was%20lost.%20At%20a%20pH%20of%206.0%2C%20only%20the%20injection%20of%20inorganic%20phosphate%20produced%20a%20significant%20pressor%20response%20%2823%5Cu00a0%5Cu00b1%5Cu00a012%5Cu00a0mmHg%29.%20A%20large%20potentiating%20effect%20was%20found%20when%20lactate%20was%20added%20to%20the%20inorganic%20phosphate%20solution%20%2839%5Cu00a0%5Cu00b1%5Cu00a018%5Cu00a0mmHg%29%2C%20an%20effect%20that%20was%20lost%20at%20a%20pH%5Cu00a0%3E7.0.%20Our%20findings%20led%20to%20the%20conclusion%20that%20the%20pressor%20response%20to%20injection%20of%20acidic%20solutions%20was%20driven%20by%20H%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ions%20and%20that%20inorganic%20phosphate%20and%20lactate%20functioned%20as%20sensitizing%20agents.%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1113%5C%2FEP088349%22%2C%22ISSN%22%3A%220958-0670%2C%201469-445X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fphysoc.onlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1113%5C%2FEP088349%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22N7DWT2T5%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lapergue%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELapergue%20B%2C%20Lyoubi%20A%2C%20Meseguer%20E%2C%20Avram%20I%2C%20Denier%20C%2C%20Venditti%20L%2C%20Consoli%20A%2C%20Guedon%20A%2C%20Houdart%20E%2C%20Weisenburger%26%23x2010%3BLile%20D%2C%20Piotin%20M%2C%20Maier%20B%2C%20Obadia%20M%2C%20Broucker%20TDE.%202020.%20Large%20vessel%20stroke%20in%20six%20patients%20following%20SARS%26%23x2010%3BCoV%26%23x2010%3B2%20infection%3A%20a%20retrospective%20case%20study%20series%20of%20acute%20thrombotic%20complications%20on%20stable%20underlying%20atherosclerotic%20disease.%20Euro%20J%20of%20Neurology%2027%3A2308%26%23x2013%3B2311.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Large%20vessel%20stroke%20in%20six%20patients%20following%20SARS%5Cu2010CoV%5Cu20102%20infection%3A%20a%20retrospective%20case%20study%20series%20of%20acute%20thrombotic%20complications%20on%20stable%20underlying%20atherosclerotic%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lapergue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lyoubi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Avram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Denier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Venditti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Consoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Guedon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Houdart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Weisenburger%5Cu2010Lile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Piotin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Maier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Obadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.D.E.%22%2C%22lastName%22%3A%22Broucker%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20purpose%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Ischaemic%20stroke%20has%20been%20described%20in%20association%20with%20COVID%5Cu201019.%20Several%20pathophysiological%20mechanisms%20have%20been%20suggested%2C%20i.e.%20prothrombotic%20state%2C%20cardiac%20injury%20etc.%20It%20was%20sought%20to%20assess%20the%20potential%20association%20between%20ischaemic%20stroke%20associated%20with%20SARS%5Cu2010CoV%5Cu20102%20infection%20and%20underlying%20atherosclerotic%20lesions.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20retrospective%20analysis%20of%20stroke%20related%20to%20large%20vessel%20occlusion%20was%20conducted%20amongst%20patients%20with%20SARS%5Cu2010CoV%5Cu20102%20infection%20and%20underlying%20mild%20atherosclerotic%20disease%2C%20between%2019%20March%20and%2019%20April%202020%20in%20six%20different%20stroke%20centers%20in%20the%20%5Cu00cele%5Cu2010de%20France%20area%2C%20France.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20median%20age%20was%2052%5Cu00a0years%2C%20median%20body%20mass%20index%20was%2029.5%20kg%5C%2Fm%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20All%20patients%20displayed%20previous%20vascular%20risk%20factors%20such%20as%20high%20blood%20pressure%2C%20diabetes%2C%20dyslipidemia%20or%20body%20mass%20index%20%3E%5Cu00a025.%20The%20delay%20between%20the%20first%20respiratory%20symptoms%20of%20COVID%5Cu201019%20and%20stroke%20was%2011.5%5Cu00a0days.%20At%20baseline%2C%20all%20had%20tandem%20occlusions%2C%20i.e.%20intracerebral%20and%20extracerebral%20thrombus%20assessed%20with%20computed%20tomography%20or%20magnetic%20resonance%20imaging.%20Cases%20displayed%20a%20large%20thrombus%20in%20the%20cervical%20carotid%20artery%20with%20underlying%20mild%20non%5Cu2010stenosing%20atheroma%2C%20after%20an%20etiological%20workup%20based%20on%20angio%5Cu2010computed%20tomography%20or%20magnetic%20resonance%20imaging%20and%5C%2For%20cervical%20echography.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Our%20study%20should%20alert%20clinicians%20to%20scrutinize%20any%20new%20onset%20of%20ischaemic%20stroke%20during%20COVID%5Cu201019%20infection%2C%20mainly%20in%20patients%20with%20vascular%20risk%20factors%20or%20underlying%20atherosclerotic%20lesions.%22%2C%22date%22%3A%2211%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.14466%22%2C%22ISSN%22%3A%221351-5101%2C%201468-1331%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fene.14466%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22J6QPIN5V%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ozen%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EOzen%20G%2C%20Benyahia%20C%2C%20Mani%20S%2C%20Boukais%20K%2C%20Silverstein%20AM%2C%20Bayles%20R%2C%20Nelsen%20AC%2C%20Castier%20Y%2C%20Danel%20C%2C%20Mal%20H%2C%20Clapp%20LH%2C%20Longrois%20D%2C%20Norel%20X.%202020.%20Bronchodilation%20induced%20by%20PGE%20%3Csub%3E2%3C%5C%2Fsub%3E%20is%20impaired%20in%20Group%20III%20pulmonary%20hypertension.%20British%20J%20Pharmacology%20177%3A161%26%23x2013%3B174.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bronchodilation%20induced%20by%20PGE%20%3Csub%3E2%3C%5C%2Fsub%3E%20is%20impaired%20in%20Group%20III%20pulmonary%20hypertension%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulsev%22%2C%22lastName%22%3A%22Ozen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chabha%22%2C%22lastName%22%3A%22Benyahia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salma%22%2C%22lastName%22%3A%22Mani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kamel%22%2C%22lastName%22%3A%22Boukais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20M.%22%2C%22lastName%22%3A%22Silverstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Bayles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20C.%22%2C%22lastName%22%3A%22Nelsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Castier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Danel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Mal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%20H.%22%2C%22lastName%22%3A%22Clapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Longrois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20pulmonary%20hypertension%20%28PH%29%20associated%20with%20lung%20disease%20and%5C%2For%20hypoxia%20%28Group%20III%29%2C%20decreased%20pulmonary%20vascular%20tone%20and%20tissue%20hypoxia%20is%20therapeutically%20beneficial.%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20induce%20potent%20relaxation%20of%20human%20bronchi%20from%20non%5Cu2010PH%20%28control%29%20patients%20via%20EP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%204%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20IP%20receptors%2C%20respectively.%20However%2C%20the%20effects%20of%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5C%2FPGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20their%20mimetics%20on%20human%20bronchi%20from%20PH%20patients%20are%20unknown.%20Here%2C%20we%20have%20compared%20relaxant%20effects%20of%20several%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2013mimetics%20approved%20for%20treating%20PH%20Group%20I%20with%20several%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2013mimetics%2C%20in%20bronchial%20preparations%20derived%20from%20PH%20Group%20III%20and%20control%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Experimental%20Approach%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Relaxation%20of%20bronchial%20muscle%20was%20assessed%20in%20samples%20isolated%20from%20control%20and%20PH%20Group%20III%20patients.%20Expression%20of%20prostanoid%20receptors%20was%20analysed%20by%20western%20blot%20and%20real%5Cu2010time%20PCR%2C%20and%20endogenous%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20and%20cAMP%20levels%20were%20determined%20by%20ELISA.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Key%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Maximal%20relaxations%20induced%20by%20different%20EP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%204%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20receptor%20agonists%20%28PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20L%5Cu2010902688%2C%20and%20ONO%5Cu2010AE1%5Cu2010329%29%20were%20decreased%20in%20human%20bronchi%20from%20PH%20patients%2C%20compared%20with%20controls.%20However%2C%20maximal%20relaxations%20produced%20by%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2013mimetics%20%28iloprost%2C%20treprostinil%2C%20and%20beraprost%29%20were%20similar%20for%20both%20groups%20of%20patients.%20Both%20EP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%204%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20IP%20receptor%20protein%20and%20mRNA%20expressions%20were%20significantly%20lower%20in%20human%20bronchi%20from%20PH%20patients.%20cAMP%20levels%20significantly%20correlated%20with%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20but%20not%20with%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20levels.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%20and%20Implications%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2013mimetics%20retained%20maximal%20bronchodilation%20in%20PH%20Group%20III%20patients%2C%20whereas%20bronchodilation%20induced%20by%20EP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%204%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20receptor%20agonists%20was%20decreased.%20Restoration%20of%20EP%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%204%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20receptor%20expression%20in%20airways%20of%20PH%20Group%20III%20patients%20with%20respiratory%20diseases%20could%20bring%20additional%20therapeutic%20benefit.%22%2C%22date%22%3A%2201%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fbph.14854%22%2C%22ISSN%22%3A%220007-1188%2C%201476-5381%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbpspubs.onlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fbph.14854%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22HNAR87CF%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Furtado%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFurtado%20RHM%2C%20Nicolau%20JC%2C%20Magnani%20G%2C%20Im%20K%2C%20Bhatt%20DL%2C%20Storey%20RF%2C%20Steg%20PG%2C%20Spinar%20J%2C%20Budaj%20A%2C%20Kontny%20F%2C%20Corbalan%20R%2C%20Kiss%20RG%2C%20Abola%20MT%2C%20Johanson%20P%2C%20Jensen%20EC%2C%20Braunwald%20E%2C%20Sabatine%20MS%2C%20Bonaca%20MP.%202020.%20Long-term%20ticagrelor%20for%20secondary%20prevention%20in%20patients%20with%20prior%20myocardial%20infarction%20and%20no%20history%20of%20coronary%20stenting%3A%20insights%20from%20PEGASUS-TIMI%2054.%20European%20Heart%20Journal%2041%3A1625%26%23x2013%3B1632.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20ticagrelor%20for%20secondary%20prevention%20in%20patients%20with%20prior%20myocardial%20infarction%20and%20no%20history%20of%20coronary%20stenting%3A%20insights%20from%20PEGASUS-TIMI%2054%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Remo%20H%20M%22%2C%22lastName%22%3A%22Furtado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20C%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulia%22%2C%22lastName%22%3A%22Magnani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyungah%22%2C%22lastName%22%3A%22Im%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jindrich%22%2C%22lastName%22%3A%22Spinar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrzej%22%2C%22lastName%22%3A%22Budaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Kontny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%22%2C%22lastName%22%3A%22Corbalan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20G%22%2C%22lastName%22%3A%22Kiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Teresa%22%2C%22lastName%22%3A%22Abola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Johanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20C%22%2C%22lastName%22%3A%22Jensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Braunwald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S%22%2C%22lastName%22%3A%22Sabatine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P%22%2C%22lastName%22%3A%22Bonaca%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20PEGASUS-TIMI%2054%20demonstrated%20that%20long-term%20dual%20antiplatelet%20therapy%20%28DAPT%29%20with%20aspirin%20and%20ticagrelor%20reduced%20the%20risk%20of%20major%20adverse%20cardiovascular%20events%20%28MACE%29%2C%20with%20an%20acceptable%20increase%20in%20bleeding%2C%20in%20patients%20with%20prior%20myocardial%20infarction%20%28MI%29.%20While%20much%20of%20the%20discussion%20around%20prolonged%20DAPT%20has%20been%20focused%20on%20stented%20patients%2C%20patients%20with%20prior%20MI%20without%20prior%20coronary%20stenting%20comprise%20a%20clinically%20important%20subgroup.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20was%20a%20pre-specified%20analysis%20from%20PEGASUS-TIMI%2054%2C%20which%20randomized%2021%5Cu00a0162%20patients%20with%20prior%20MI%20%281%5Cu20133%5Cu2009years%29%20and%20additional%20high-risk%20features%20to%20ticagrelor%2060%5Cu2009mg%2C%2090%5Cu2009mg%2C%20or%20placebo%20twice%20daily%20in%20addition%20to%20aspirin.%20A%20total%20of%204199%20patients%20had%20no%20history%20of%20coronary%20stenting%20at%20baseline.%20The%20primary%20efficacy%20outcome%20%28MACE%29%20was%20the%20composite%20of%20cardiovascular%20death%2C%20MI%2C%20or%20stroke.%20Patients%20without%20history%20of%20coronary%20stenting%20had%20higher%20baseline%20risk%20of%20MACE%20%5B13.2%25%20vs.%208.0%25%2C%20adjusted%20hazard%20ratio%20%28HR%29%201.41%2C%2095%25%20confidence%20interval%20%28CI%29%201.15%5Cu20131.73%2C%20in%20the%20placebo%20arm%5D.%20The%20relative%20risk%20reduction%20in%20MACE%20with%20ticagrelor%20%28pooled%20doses%29%20was%20similar%20in%20patients%20without%20%28HR%200.82%2C%2095%25%20CI%200.68%5Cu20130.99%29%20and%20with%20prior%20stenting%20%28HR%200.85%2C%2095%25%20CI%200.75%5Cu20130.96%3B%20P%20for%20interaction%20%3D%200.76%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Long-term%20ticagrelor%20reduces%20thrombotic%20events%20in%20patients%20with%20prior%20MI%20regardless%20of%20whether%20they%20had%20prior%20coronary%20stenting.%20These%20data%20highlight%20the%20benefits%20of%20DAPT%20in%20prevention%20of%20spontaneous%20atherothrombotic%20events%20and%20indicate%20that%20long-term%20ticagrelor%20may%20be%20considered%20in%20high-risk%20patients%20with%20prior%20MI%20even%20if%20they%20have%20not%20been%20treated%20with%20stenting.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.gov%20Identifier%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT01225562.%22%2C%22date%22%3A%222020-05-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz821%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F41%5C%2F17%5C%2F1625%5C%2F5663567%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22VMW6F3I8%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sinnaeve%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESinnaeve%20PR%2C%20Schwartz%20GG%2C%20Wojdyla%20DM%2C%20Alings%20M%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Chiang%20C-E%2C%20Correa%20Flores%20RM%2C%20Diaz%20R%2C%20Dorobantu%20M%2C%20Goodman%20SG%2C%20Jukema%20JW%2C%20Kim%20Y-U%2C%20Pordy%20R%2C%20Roe%20MT%2C%20Sy%20RG%2C%20Szarek%20M%2C%20White%20HD%2C%20Zeiher%20AM%2C%20Steg%20PG%2C%20for%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202020.%20Effect%20of%20alirocumab%20on%20cardiovascular%20outcomes%20after%20acute%20coronary%20syndromes%20according%20to%20age%3A%20an%20ODYSSEY%20OUTCOMES%20trial%20analysis.%20European%20Heart%20Journal%2041%3A2248%26%23x2013%3B2258.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20alirocumab%20on%20cardiovascular%20outcomes%20after%20acute%20coronary%20syndromes%20according%20to%20age%3A%20an%20ODYSSEY%20OUTCOMES%20trial%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20R%22%2C%22lastName%22%3A%22Sinnaeve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20M%22%2C%22lastName%22%3A%22Wojdyla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Alings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chern-En%22%2C%22lastName%22%3A%22Chiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20M%22%2C%22lastName%22%3A%22Correa%20Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Dorobantu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Un%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rody%20G%22%2C%22lastName%22%3A%22Sy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Lowering%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20reduces%20cardiovascular%20risk%20irrespective%20of%20age%2C%20but%20the%20evidence%20is%20less%20strong%20for%20older%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20prespecified%20analysis%20from%20ODYSSEY%20OUTCOMES%20compared%20the%20effect%20of%20alirocumab%20vs.%20placebo%20in%2018%5Cu00a0924%20patients%20with%20recent%20acute%20coronary%20syndrome%20%28ACS%29%20according%20to%20age.%20We%20examined%20the%20effect%20of%20assigned%20treatment%20on%20occurrence%20of%20the%20primary%20study%20outcome%2C%20a%20composite%20of%20coronary%20heart%20disease%20death%2C%20myocardial%20infarction%2C%20ischaemic%20stroke%2C%20or%20unstable%20angina%20requiring%20hospitalization%20%5Bmajor%20adverse%20cardiovascular%20event%20%28MACE%29%5D%20and%20all-cause%20death.%20Relative%20risk%20reductions%20were%20consistent%20for%20patients%20%5Cu226565%20vs.%20%26lt%3B65%5Cu2009years%20for%20MACE%20%5Bhazard%20ratio%20%28HR%29%200.78%2C%2095%25%20confidence%20interval%20%28CI%29%200.68%5Cu20130.91%20vs.%200.89%2C%200.80%5Cu20131.00%3B%20P%20%5Cu00a0interaction%5Cu2009%3D%5Cu20090.19%5D%20and%20all-cause%20death%20%5BHR%200.77%2C%200.62%5Cu20130.95%20vs.%200.94%2C%200.77%5Cu20131.15%3B%20P%20%5Cu00a0interaction%5Cu2009%3D%5Cu20090.46%5D%2C%20and%20consistent%20for%20MACE%20when%20dichotomizing%20at%20age%2075%20years%20%28HR%200.85%2C%200.64%5Cu20131.13%20in%20%5Cu226575%20vs.%200.85%2C%200.78%5Cu20130.93%20in%20%26lt%3B75%2C%20P%20%5Cu00a0interaction%5Cu2009%3D%5Cu20090.19%29.%20When%20considering%20age%20as%20a%20continuous%20variable%20in%20regression%20models%2C%20advancing%20age%20increased%20risk%20of%20MACE%2C%20as%20well%20as%20the%20absolute%20reduction%20in%20MACE%20with%20alirocumab%2C%20with%20numbers-needed-to-treat%20for%20MACE%20at%203%5Cu2009years%20of%2043%20%2825%5Cu2013186%29%20at%20age%2045%20years%2C%2026%20%2815%5Cu201397%29%20at%20age%2075%20years%2C%20and%2012%20%286%5Cu201381%29%20for%20those%20at%20age%2085%20years.%20Although%20adverse%20events%20were%20more%20frequent%20in%20older%20patients%2C%20there%20were%20no%20differences%20between%20alirocumab%20and%20placebo.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20recent%20ACS%2C%20alirocumab%20improves%20outcomes%20irrespective%20of%20age.%20Increasing%20absolute%20benefit%20but%20not%20harm%20with%20advancing%20age%20suggests%20that%20LDL-C%20lowering%20is%20an%20important%20preventive%20intervention%20for%20older%20patients%20after%20ACS.%22%2C%22date%22%3A%222020-06-21%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz809%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F41%5C%2F24%5C%2F2248%5C%2F5626150%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22NZ2ZC93H%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sorbets%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESorbets%20E%2C%20Fox%20KM%2C%20Elbez%20Y%2C%20Danchin%20N%2C%20Dorian%20P%2C%20Ferrari%20R%2C%20Ford%20I%2C%20Greenlaw%20N%2C%20Kalra%20PR%2C%20Parma%20Z%2C%20Shalnova%20S%2C%20Tardif%20J-C%2C%20Tendera%20M%2C%20Zamorano%20JL%2C%20Vidal-Petiot%20E%2C%20Steg%20PG%2C%20CLARIFY%20investigators.%202020.%20Long-term%20outcomes%20of%20chronic%20coronary%20syndrome%20worldwide%3A%20insights%20from%20the%20international%20CLARIFY%20registry.%20European%20Heart%20Journal%2041%3A347%26%23x2013%3B356.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20outcomes%20of%20chronic%20coronary%20syndrome%20worldwide%3A%20insights%20from%20the%20international%20CLARIFY%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sorbets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Dorian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Greenlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20R%22%2C%22lastName%22%3A%22Kalra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zofia%22%2C%22lastName%22%3A%22Parma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svetlana%22%2C%22lastName%22%3A%22Shalnova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22Zamorano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Vidal-Petiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CLARIFY%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Over%20the%20last%20decades%2C%20the%20profile%20of%20chronic%20coronary%20syndrome%20has%20changed%20substantially.%20We%20aimed%20to%20determine%20characteristics%20and%20management%20of%20patients%20with%20chronic%20coronary%20syndrome%20in%20the%20contemporary%20era%2C%20as%20well%20as%20outcomes%20and%20their%20determinants.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Data%20from%2032%5Cu00a0703%20patients%20%2845%20countries%29%20with%20chronic%20coronary%20syndrome%20enrolled%20in%20the%20prospective%20observational%20CLARIFY%20registry%20%28November%202009%20to%20June%202010%29%20with%20a%205-year%20follow-up%2C%20were%20analysed.%20The%20primary%20outcome%20%5Bcardiovascular%20death%20or%20non-fatal%20myocardial%20infarction%20%28MI%29%5D%205-year%20rate%20was%208.0%25%20%5B95%25%20confidence%20interval%20%28CI%29%207.7%5Cu20138.3%5D%20overall%20%5Bmale%208.1%25%20%287.8%5Cu20138.5%29%3B%20female%207.6%25%20%287.0%5Cu20138.3%29%5D.%20A%20cox%20proportional%20hazards%20model%20showed%20that%20the%20main%20independent%20predictors%20of%20the%20primary%20outcome%20were%20prior%20hospitalization%20for%20heart%20failure%2C%20current%20smoking%2C%20atrial%20fibrillation%2C%20living%20in%20Central%5C%2FSouth%20America%2C%20prior%20MI%2C%20prior%20stroke%2C%20diabetes%2C%20current%20angina%2C%20and%20peripheral%20artery%20disease.%20There%20was%20an%20interaction%20between%20angina%20and%20prior%20MI%20%28P%5Cu2009%3D%5Cu20090.0016%29%3B%20among%20patients%20with%20prior%20MI%2C%20angina%20was%20associated%20with%20a%20higher%20primary%20event%20rate%20%5B11.8%25%20%2895%25%20CI%2010.9%5Cu201312.9%29%20vs.%208.2%25%20%2895%25%20CI%207.8%5Cu20138.7%29%20in%20patients%20with%20no%20angina%2C%20P%5Cu2009%26lt%3B%5Cu20090.001%5D%2C%20whereas%20among%20patients%20without%20prior%20MI%2C%20event%20rates%20were%20similar%20for%20patients%20with%20%5B6.3%25%20%2895%25%20CI%205.4%5Cu20137.3%29%5D%20or%20without%20angina%20%5B6.4%25%20%2895%25%20CI%205.9%5Cu20137.0%29%5D%2C%20P%5Cu2009%26gt%3B%5Cu20090.99.%20Prescription%20rates%20of%20evidence-based%20secondary%20prevention%20therapies%20were%20high.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20description%20of%20the%20spectrum%20of%20chronic%20coronary%20syndrome%20patients%20shows%20that%2C%20despite%20high%20rates%20of%20prescription%20of%20evidence-based%20therapies%2C%20patients%20with%20both%20angina%20and%20prior%20MI%20are%20an%20easily%20identifiable%20high-risk%20group%20who%20may%20deserve%20intensive%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20registry%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ISRCTN43070564%22%2C%22date%22%3A%222020-01-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz660%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F41%5C%2F3%5C%2F347%5C%2F5556903%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22M5GCIJMV%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baber%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBaber%20U%2C%20Dangas%20G%2C%20Angiolillo%20DJ%2C%20Cohen%20DJ%2C%20Sharma%20SK%2C%20Nicolas%20J%2C%20Briguori%20C%2C%20Cha%20JY%2C%20Collier%20T%2C%20Dudek%20D%2C%20D%26%23x17E%3Bavik%20V%2C%20Escaned%20J%2C%20Gil%20R%2C%20Gurbel%20P%2C%20Hamm%20CW%2C%20Henry%20T%2C%20Huber%20K%2C%20Kastrati%20A%2C%20Kaul%20U%2C%20Kornowski%20R%2C%20Krucoff%20M%2C%20Kunadian%20V%2C%20Marx%20SO%2C%20Mehta%20S%2C%20Moliterno%20D%2C%20Ohman%20EM%2C%20Oldroyd%20K%2C%20Sardella%20G%2C%20Sartori%20S%2C%20Shlofmitz%20R%2C%20Steg%20PG%2C%20Weisz%20G%2C%20Witzenbichler%20B%2C%20Han%20Y-L%2C%20Pocock%20S%2C%20Gibson%20CM%2C%20Mehran%20R.%202020.%20Ticagrelor%20alone%20vs.%20ticagrelor%20plus%20aspirin%20following%20percutaneous%20coronary%20intervention%20in%20patients%20with%20non-ST-segment%20elevation%20acute%20coronary%20syndromes%3A%20TWILIGHT-ACS.%20European%20Heart%20Journal%2041%3A3533%26%23x2013%3B3545.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ticagrelor%20alone%20vs.%20ticagrelor%20plus%20aspirin%20following%20percutaneous%20coronary%20intervention%20in%20patients%20with%20non-ST-segment%20elevation%20acute%20coronary%20syndromes%3A%20TWILIGHT-ACS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%20Joseph%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Joel%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samin%20Kumar%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johny%22%2C%22lastName%22%3A%22Nicolas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Briguori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jin%20Yu%22%2C%22lastName%22%3A%22Cha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Collier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dariusz%22%2C%22lastName%22%3A%22Dudek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22D%5Cu017eavik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Escaned%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Gurbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Huber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Kaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Kornowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%22%2C%22lastName%22%3A%22Krucoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Kunadian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20Owen%22%2C%22lastName%22%3A%22Marx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Moliterno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20Magnus%22%2C%22lastName%22%3A%22Ohman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Oldroyd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gennaro%22%2C%22lastName%22%3A%22Sardella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Shlofmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giora%22%2C%22lastName%22%3A%22Weisz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernhard%22%2C%22lastName%22%3A%22Witzenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ya-Ling%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20aim%20of%20this%20study%20was%20to%20determine%20the%20effect%20of%20ticagrelor%20monotherapy%20on%20clinically%20relevant%20bleeding%20and%20major%20ischaemic%20events%20in%20relation%20to%20clinical%20presentation%20with%20and%20without%20non-ST%20elevation%20acute%20coronary%20syndromes%20%28NSTE-ACS%29%20among%20patients%20undergoing%20percutaneous%20coronary%20intervention%20%28PCI%29%20with%20drug-eluting%20stents%20%28DES%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20conducted%20a%20pre-specified%20subgroup%20analysis%20of%20The%20Ticagrelor%20With%20Aspirin%20or%20Alone%20in%20High%20Risk%20Patients%20After%20Coronary%20Intervention%20%28TWILIGHT%29%20trial%2C%20which%20enrolled%209006%20patients%20with%20high-risk%20features%20undergoing%20PCI%20with%20DES.%20After%203%20months%20of%20dual%20antiplatelet%20therapy%20%28DAPT%29%20with%20ticagrelor%20plus%20aspirin%2C%207119%20adherent%20and%20event-free%20patients%20were%20randomized%20in%20a%20double-blind%20manner%20to%20ticagrelor%20plus%20placebo%20versus%20ticagrelor%20plus%20aspirin%20for%2012%20months.%20The%20primary%20outcome%20was%20Bleeding%20Academic%20Research%20Consortium%20%28BARC%29%20type%202%2C%203%2C%20or%205%20bleeding%20while%20the%20composite%20of%20all-cause%20death%2C%20myocardial%20infarction%20%28MI%29%2C%20or%20stroke%20was%20the%20key%20secondary%20outcome.%20Among%20patients%20with%20NSTE-ACS%20%28n%20%3D%204614%29%2C%20ticagrelor%20monotherapy%20reduced%20BARC%202%2C%203%2C%20or%205%20bleeding%20by%2053%25%20%5B3.6%25%20vs.%207.6%25%3B%20hazard%20ratio%20%28HR%29%200.47%3B%2095%25%20confidence%20interval%20%28CI%29%200.36%5Cu20130.61%3B%20P%20%26lt%3B%200.001%29%20and%20in%20stable%20patients%20%28n%20%3D%202503%29%20by%2024%25%20%284.8%25%20vs.%206.2%25%3B%20HR%200.76%3B%2095%25%20CI%200.54%5Cu20131.06%3B%20P%20%3D%200.11%3B%20nominal%20P%20%5Cu00a0int%20%3D%200.03%29.%20Rates%20of%20all-cause%20death%2C%20MI%2C%20or%20stroke%20among%20those%20with%20%284.3%25%20vs.%204.4%25%3B%20HR%200.97%3B%2095%25%20CI%200.74%5Cu20131.28%3B%20P%20%3D%200.84%29%20and%20without%20%283.1%25%20vs.%203.2%25%3B%20HR%200.96%3B%2095%25%20CI%200.61%5Cu20131.49%3B%20P%20%3D%200.85%29%20NSTE-ACS%20were%20similar%20between%20treatment%20arms%20irrespective%20of%20clinical%20presentation%20%28P%20%5Cu00a0int%20%3D%200.96%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20patients%20with%20or%20without%20NSTE-ACS%20who%20have%20completed%20an%20initial%203-month%20course%20of%20DAPT%20following%20PCI%20with%20DES%2C%20ticagrelor%20monotherapy%20reduced%20clinically%20meaningful%20bleeding%20events%20without%20increasing%20ischaemic%20risk%20as%20compared%20with%20ticagrelor%20plus%20aspirin.%20The%20benefits%20of%20ticagrelor%20monotherapy%20with%20respect%20to%20bleeding%20events%20were%20more%20pronounced%20in%20patients%20with%20NSTE-ACS.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinicaltrials.gov%20identifier%3A%20NCT02270242.%22%2C%22date%22%3A%222020-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehaa670%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F41%5C%2F37%5C%2F3533%5C%2F5934642%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22PXHIEPWT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Szarek%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESzarek%20M%2C%20Bittner%20VA%2C%20Aylward%20P%2C%20Baccara-Dinet%20M%2C%20Bhatt%20DL%2C%20Diaz%20R%2C%20Fras%20Z%2C%20Goodman%20SG%2C%20Halvorsen%20S%2C%20Harrington%20RA%2C%20Jukema%20JW%2C%20Moriarty%20PM%2C%20Pordy%20R%2C%20Ray%20KK%2C%20Sinnaeve%20P%2C%20Tsimikas%20S%2C%20Vogel%20R%2C%20White%20HD%2C%20Zahger%20D%2C%20Zeiher%20AM%2C%20Steg%20PG%2C%20Schwartz%20GG%2C%20for%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202020.%20Lipoprotein%28a%29%20lowering%20by%20alirocumab%20reduces%20the%20total%20burden%20of%20cardiovascular%20events%20independent%20of%20low-density%20lipoprotein%20cholesterol%20lowering%3A%20ODYSSEY%20OUTCOMES%20trial.%20European%20Heart%20Journal%2041%3A4245%26%23x2013%3B4255.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lipoprotein%28a%29%20lowering%20by%20alirocumab%20reduces%20the%20total%20burden%20of%20cardiovascular%20events%20independent%20of%20low-density%20lipoprotein%20cholesterol%20lowering%3A%20ODYSSEY%20OUTCOMES%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Aylward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Baccara-Dinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zlatko%22%2C%22lastName%22%3A%22Fras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sigrun%22%2C%22lastName%22%3A%22Halvorsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20M%22%2C%22lastName%22%3A%22Moriarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kausik%20K%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Sinnaeve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sotirios%22%2C%22lastName%22%3A%22Tsimikas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doron%22%2C%22lastName%22%3A%22Zahger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Lipoprotein%28a%29%20concentration%20is%20associated%20with%20first%20cardiovascular%20events%20in%20clinical%20trials.%20It%20is%20unknown%20if%20this%20relationship%20holds%20for%20total%20%28first%20and%20subsequent%29%20events.%20In%20the%20ODYSSEY%20OUTCOMES%20trial%20in%20patients%20with%20recent%20acute%20coronary%20syndrome%20%28ACS%29%2C%20the%20proprotein%20convertase%20subtilisin%5C%2Fkexin%20type%209%20inhibitor%20alirocumab%20reduced%20lipoprotein%28a%29%2C%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%2C%20and%20cardiovascular%20events%20compared%20with%20placebo.%20This%20post%20hoc%20analysis%20determined%20whether%20baseline%20levels%20and%20alirocumab-induced%20changes%20in%20lipoprotein%28a%29%20and%20LDL-C%20%5Bcorrected%20for%20lipoprotein%28a%29%20cholesterol%5D%20independently%20predicted%20total%20cardiovascular%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Cardiovascular%20events%20included%20cardiovascular%20death%2C%20non-fatal%20myocardial%20infarction%2C%20stroke%2C%20hospitalization%20for%20unstable%20angina%20or%20heart%20failure%2C%20ischaemia-driven%20coronary%20revascularization%2C%20peripheral%20artery%20disease%20events%2C%20and%20venous%20thromboembolism.%20Proportional%20hazards%20models%20estimated%20relationships%20between%20baseline%20lipoprotein%28a%29%20and%20total%20cardiovascular%20events%20in%20the%20placebo%20group%2C%20effects%20of%20alirocumab%20treatment%20on%20total%20cardiovascular%20events%20by%20baseline%20lipoprotein%28a%29%2C%20and%20relationships%20between%20lipoprotein%28a%29%20reduction%20with%20alirocumab%20and%20subsequent%20risk%20of%20total%20cardiovascular%20events.%20Baseline%20lipoprotein%28a%29%20predicted%20total%20cardiovascular%20events%20with%20placebo%2C%20while%20higher%20baseline%20lipoprotein%28a%29%20levels%20were%20associated%20with%20greater%20reduction%20in%20total%20cardiovascular%20events%20with%20alirocumab%20%28hazard%20ratio%20P%20%5Cu00a0trend%20%3D%200.045%29.%20Alirocumab-induced%20reductions%20in%20lipoprotein%28a%29%20%28median%20%5Cu22125.0%20%5B%5Cu221213.6%2C%200%5D%20mg%5C%2FdL%29%20and%20corrected%20LDL-C%20%28median%20%5Cu221251.3%20%5B%5Cu221267.1%2C%20%5Cu221234.0%5D%20mg%5C%2FdL%29%20independently%20predicted%20lower%20risk%20of%20total%20cardiovascular%20events.%20Each%205-mg%5C%2FdL%20reduction%20in%20lipoprotein%28a%29%20predicted%20a%202.5%25%20relative%20reduction%20in%20cardiovascular%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Baseline%20lipoprotein%28a%29%20predicted%20the%20risk%20of%20total%20cardiovascular%20events%20and%20risk%20reduction%20by%20alirocumab.%20Lipoprotein%28a%29%20lowering%20contributed%20independently%20to%20cardiovascular%20event%20reduction%2C%20supporting%20the%20concept%20of%20lipoprotein%28a%29%20as%20a%20treatment%20target%20after%20ACS.%22%2C%22date%22%3A%222020-11-21%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehaa649%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F41%5C%2F44%5C%2F4245%5C%2F5922803%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A23Z%22%7D%7D%2C%7B%22key%22%3A%223UTPF7ZR%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tu%5Cu00f1%5Cu00f3n%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ETu%26%23xF1%3B%26%23xF3%3Bn%20J%2C%20Steg%20PG%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20D%26%23xED%3Baz%20R%2C%20Goodman%20SG%2C%20Jukema%20JW%2C%20Kim%20Y-U%2C%20Li%20QH%2C%20Mueller%20C%2C%20Parkhomenko%20A%2C%20Pordy%20R%2C%20Sritara%20P%2C%20Szarek%20M%2C%20White%20HD%2C%20Zeiher%20AM%2C%20Schwartz%20GG%2C%20for%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202020.%20Effect%20of%20alirocumab%20on%20major%20adverse%20cardiovascular%20events%20according%20to%20renal%20function%20in%20patients%20with%20a%20recent%20acute%20coronary%20syndrome%3A%20prespecified%20analysis%20from%20the%20ODYSSEY%20OUTCOMES%20randomized%20clinical%20trial.%20European%20Heart%20Journal%2041%3A4114%26%23x2013%3B4123.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20alirocumab%20on%20major%20adverse%20cardiovascular%20events%20according%20to%20renal%20function%20in%20patients%20with%20a%20recent%20acute%20coronary%20syndrome%3A%20prespecified%20analysis%20from%20the%20ODYSSEY%20OUTCOMES%20randomized%20clinical%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Tu%5Cu00f1%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22D%5Cu00edaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Un%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qian%20H%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Mueller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piyamitr%22%2C%22lastName%22%3A%22Sritara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Statins%20reduce%20cardiovascular%20risk%20in%20patients%20with%20acute%20coronary%20syndrome%20%28ACS%29%20and%20normal-to-moderately%20impaired%20renal%20function.%20It%20is%20not%20known%20whether%20proprotein%20convertase%20subtilisin-kexin%20type%209%20%28PCSK9%29%20inhibitors%20provide%20similar%20benefit%20across%20a%20range%20of%20renal%20function.%20We%20determined%20whether%20effects%20of%20the%20PCSK9%20inhibitor%20alirocumab%20to%20reduce%20cardiovascular%20events%20and%20death%20after%20ACS%20are%20influenced%20by%20renal%20function.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ODYSSEY%20OUTCOMES%20compared%20alirocumab%20with%20placebo%20in%20patients%20with%20recent%20ACS%20and%20dyslipidaemia%20despite%20intensive%20statin%20treatment.%20Estimated%20glomerular%20filtration%20rate%20%28eGFR%29%20%26lt%3B30%5Cu2009mL%5C%2Fmin%5C%2F1.73%20m2%20was%20exclusionary.%20In%2018%20918%20patients%2C%20baseline%20eGFR%20was%2082.8%5Cu2009%5Cu00b1%5Cu200917.6%5Cu2009mL%5C%2Fmin%5C%2F1.73%20m2%2C%20and%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20was%2092%5Cu2009%5Cu00b1%5Cu200931%5Cu2009mg%5C%2FdL.%20At%2036%5Cu2009months%2C%20alirocumab%20decreased%20LDL-C%20by%2048.5%25%20vs.%20placebo%20but%20did%20not%20affect%20eGFR%20%28P%5Cu2009%3D%5Cu20090.65%29.%20Overall%2C%20alirocumab%20reduced%20risk%20of%20the%20primary%20outcome%20%28coronary%20heart%20disease%20death%2C%20non-fatal%20myocardial%20infarction%2C%20ischaemic%20stroke%2C%20or%20unstable%20angina%20requiring%20hospitalization%29%20with%20fewer%20deaths.%20There%20was%20no%20interaction%20between%20continuous%20eGFR%20and%20treatment%20on%20the%20primary%20outcome%20or%20death%20%28P%5Cu2009%3D%5Cu20090.14%20and%200.59%2C%20respectively%29.%20Alirocumab%20reduced%20primary%20outcomes%20in%20patients%20with%20eGFR%20%5Cu226590%5Cu2009mL%5C%2Fmin%5C%2F1.73%20m2%20%28n%5Cu2009%3D%5Cu20097470%3B%20hazard%20ratio%200.784%2C%2095%25%20confidence%20interval%200.670%5Cu20130.919%3B%20P%5Cu2009%3D%5Cu20090.003%29%20and%2060%20to%20%26lt%3B90%20%28n%5Cu2009%3D%5Cu20099326%3B%200.833%2C%200.731%5Cu20130.949%3B%20P%5Cu2009%3D%5Cu20090.006%29%2C%20but%20not%20in%20those%20with%20eGFR%5Cu2009%26lt%3B%5Cu200960%20%28n%5Cu2009%3D%5Cu20092122%3B%200.974%2C%200.805%5Cu20131.178%3B%20P%5Cu2009%3D%5Cu20090.784%29.%20Adverse%20events%20other%20than%20local%20injection-site%20reactions%20were%20similar%20in%20both%20groups%20across%20all%20categories%20of%20eGFR.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20recent%20ACS%2C%20alirocumab%20was%20associated%20with%20fewer%20cardiovascular%20events%20and%20deaths%20across%20the%20range%20of%20renal%20function%20studied%2C%20with%20larger%20relative%20risk%20reductions%20in%20those%20with%20eGFR%5Cu2009%26gt%3B%5Cu200960%5Cu2009mL%5C%2Fmin%5C%2F1.73%20m2.%22%2C%22date%22%3A%222020-11-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehaa498%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F41%5C%2F42%5C%2F4114%5C%2F5895197%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22ZJBXM7NV%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tomaniak%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ETomaniak%20M%2C%20Chichareon%20P%2C%20Takahashi%20K%2C%20Kogame%20N%2C%20Modolo%20R%2C%20Chang%20CC%2C%20Spitzer%20E%2C%20Neumann%20F-J%2C%20Plante%20S%2C%20Hern%26%23xE1%3Bndez%20Antolin%20R%2C%20Jambrik%20Z%2C%20Gelev%20V%2C%20Brunel%20P%2C%20Konteva%20M%2C%20Beygui%20F%2C%20Morelle%20J-F%2C%20Filipiak%20KJ%2C%20Van%20Geuns%20R-J%2C%20Soliman%20O%2C%20Tijssen%20J%2C%20Rademaker-Havinga%20T%2C%20Storey%20RF%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Windecker%20S%2C%20Onuma%20Y%2C%20Valgimigli%20M%2C%20Serruys%20PW%2C%20for%20the%20GLOBAL%20LEADERS%20Study%20Investigators.%202020.%20Impact%20of%20chronic%20obstructive%20pulmonary%20disease%20and%20dyspnoea%20on%20clinical%20outcomes%20in%20ticagrelor%20treated%20patients%20undergoing%20percutaneous%20coronary%20intervention%20in%20the%20randomized%20GLOBAL%20LEADERS%20trial.%20European%20Heart%20Journal%20-%20Cardiovascular%20Pharmacotherapy%206%3A222%26%23x2013%3B230.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20chronic%20obstructive%20pulmonary%20disease%20and%20dyspnoea%20on%20clinical%20outcomes%20in%20ticagrelor%20treated%20patients%20undergoing%20percutaneous%20coronary%20intervention%20in%20the%20randomized%20GLOBAL%20LEADERS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Chin%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Spitzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz-Josef%22%2C%22lastName%22%3A%22Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Plante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosana%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%20Antolin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoltan%22%2C%22lastName%22%3A%22Jambrik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeri%22%2C%22lastName%22%3A%22Gelev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Brunel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Konteva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farzin%22%2C%22lastName%22%3A%22Beygui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Francois%22%2C%22lastName%22%3A%22Morelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krzysztof%20J%22%2C%22lastName%22%3A%22Filipiak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert-Jan%22%2C%22lastName%22%3A%22Van%20Geuns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Osama%22%2C%22lastName%22%3A%22Soliman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Tijssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tessa%22%2C%22lastName%22%3A%22Rademaker-Havinga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20GLOBAL%20LEADERS%20Study%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20evaluate%20long-term%20safety%20and%20efficacy%20of%20ticagrelor%20monotherapy%20in%20patients%20undergoing%20percutaneous%20coronary%20interventions%20%28PCIs%29%20in%20relation%20to%20chronic%20obstructive%20pulmonary%20disease%20%28COPD%29%20at%20baseline%20and%20the%20occurrence%20of%20dyspnoea%20reported%20as%20adverse%20event%20%28AE%29%20that%20may%20lead%20to%20treatment%20non-adherence.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20is%20a%20non-prespecified%2C%20post%20hoc%20analysis%20of%20the%20randomized%20GLOBAL%20LEADERS%20trial%20%28n%5Cu2009%3D%5Cu200915%5Cu00a0991%29%2C%20comparing%20the%20experimental%20strategy%20of%2023-month%20ticagrelor%20monotherapy%20following%201-month%20dual%20antiplatelet%20therapy%20%28DAPT%29%20after%20PCI%20with%20the%20reference%20strategy%20of%2012-month%20DAPT%20followed%20by%2012-month%20aspirin%20monotherapy.%20Impact%20of%20COPD%20and%20dyspnoea%20AE%20%28as%20a%20time-dependent%20covariate%29%20on%20clinical%20outcomes%20was%20evaluated%20up%20to%202%20years.%20The%20primary%20endpoint%20was%20a%202-year%20all-cause%20mortality%20or%20non-fatal%2C%20centrally%20adjudicated%2C%20new%20Q-wave%20myocardial%20infarction.%20The%20presence%20of%20COPD%20%28n%5Cu2009%3D%5Cu2009832%29%20was%20the%20strongest%20clinical%20predictor%20of%202-year%20all-cause%20mortality%20after%20PCI%20%5Bhazard%20ratio%20%28HR%29%202.84%3B%2095%25%20confidence%20interval%20%28CI%29%202.21%5Cu20133.66%3B%20P%20adjusted%5Cu2009%3D%5Cu20090.001%5D%20in%20this%20cohort%20%28n%5Cu2009%3D%5Cu200915%5Cu00a0991%29.%20No%20differential%20treatment%20effects%20on%202-year%20clinical%20outcomes%20were%20found%20in%20patients%20with%20and%20without%20COPD%20%28primary%20endpoint%3A%20HR%200.88%3B%2095%25%20CI%200.58%5Cu20131.35%3B%20P%5Cu2009%3D%5Cu20090.562%3B%20P%20int%5Cu2009%3D%5Cu20090.952%29.%20Overall%2C%20at%202%20years%20dyspnoea%20was%20reported%20as%20an%20AE%20in%202101%20patients%2C%20more%20frequently%20among%20COPD%20patients%2C%20irrespective%20of%20treatment%20allocation%20%2827.2%25%20in%20experimental%20arm%20vs.%2014.5%25%20in%20reference%20arm%2C%20P%5Cu2009%3D%5Cu20090.001%29.%20Its%20occurrence%20was%20not%20associated%20with%20a%20higher%20rate%20of%20the%20primary%20endpoint%20%28P%20adjusted%5Cu2009%3D%5Cu20090.640%29%20in%20the%20experimental%20vs.%20the%20reference%20arm.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20exploratory%20analysis%2C%20COPD%20negatively%20impacted%20long-term%20prognosis%20after%20PCI.%20Despite%20higher%20incidence%20of%20dyspnoea%20in%20the%20experimental%20arm%2C%20in%20particular%20among%20COPD%20patients%2C%20the%20safety%20of%20the%20experimental%20treatment%20strategy%20appeared%20not%20to%20be%20affected.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20trial%20registration%20unique%20identifier%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT01813435.%22%2C%22date%22%3A%222020-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjcvp%5C%2Fpvz052%22%2C%22ISSN%22%3A%222055-6837%2C%202055-6845%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjcvp%5C%2Farticle%5C%2F6%5C%2F4%5C%2F222%5C%2F5670530%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A15Z%22%7D%7D%5D%7D1.Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Hamm C, Steg PG, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M. 2020. Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention 16:627–633.1.Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang CC, Kogame N, Spitzer E, Buszman PE, Van Geuns R-JM, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen JGP, Jüni P, Hamm C, Steg PG, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys PW. 2020. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention 15:e1605–e1614.1.Takahashi K, Chichareon P, Modolo R, Kogame N, Chang CC, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen JGP, Wykrzykowska JJ, De Winter RJ, Hamm C, Steg PG, Stoll H-P, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys PW. 2020. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention 16:634–644.1.Meseguer E, Diallo D, Labreuche J, Charles H, Delbosc S, Mangin G, Monteiro Tavares L, Caligiuri G, Nicoletti A, Amarenco P. 2020. Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies. JCM 9:4028.1.Varela LM, Meseguer E, Lapergue B, Couret D, Amarenco P, Meilhac O. 2020. Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke. JCM 9:2269.1.Breyer RM, Clapp L, Coleman RA, Giembycz M, Heinemann A, Hills R, Jones RL, Narumiya S, Norel X, Pettipher R, Sugimoto Y, Uddin M, Woodward DF, Yao C. 2020. Prostanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database. GtoPdb CITE 2020.1.Mesnier J, Cottin Y, Coste P, Ferrari E, Schiele F, Lemesle G, Thuaire C, Angoulvant D, Cayla G, Bouleti C, De Saint Aurin RG, Goube P, Lhermusier T, Dillinger J-G, Paganelli F, Saib A, Prunier F, Vanzetto G, Dubreuil O, Puymirat E, Boccara F, Eltchaninoff H, Cachanado M, Rousseau A, Drouet E, Steg G, Simon T, Danchin N. 2020. Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile. SSRN Journal https://doi.org/10.2139/ssrn.3619808.1.Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, Geuns R-JV, Hamm C, Steg PG, Onuma Y, Angiolillo D, Serruys PW. 2020. Ticagrelor Monotherapy in Patients with Concomitant Diabetes Mellitus and Chronic Kidney Disease: A post hoc analysis of the GLOBAL LEADERS Trial. preprint. In Review.1.Sorbets E, Steg PG. 2020. Direct-acting Anticoagulants in Chronic Coronary Syndromes. Eur Cardiol 15:e10.1.Croyal M, Saulnier P-J, Aguesse A, Gand E, Ragot S, Roussel R, Halimi J-M, Ducrocq G, Cariou B, Montaigne D, Wargny M, Krempf M, Hadjadj S. 2020. Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 105:2371–2380.1.Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, Van Geuns R-J, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. 2020. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol 19:179.1.Abtan J, Ducrocq G, Steg G. 2020. Chest pain triage: do genetics have a role? European Heart Journal Acute Cardiovascular Care 9:729–730.1.Schiele F, Lemesle G, Angoulvant D, Krempf M, Kownator S, Cheggour S, Belle L, Ferrières J, Bauters C, Bergerot C, Beygui F, Boccara F, Bonnefoy E, Bruckert E, Cayla G, Collet J-P, Coste P, Descotes-Genon V, Ducrocq G, Elbaz M, Farnier M, Ferrari E, Guedj D, Levai L, Mansourati J, Mansencal N, Meneveau N, Meune C, Morel O, Ohlmann P, Paillard F, Piot C, Puymirat E, Rioufol G, Roubille F, Sabouret P, Teiger E. 2020. Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. European Heart Journal Acute Cardiovascular Care 9:788–801.1.Biscaglia S, Campo G, Sorbets E, Ford I, Fox KM, Greenlaw N, Parkhomenko A, Tardif J-C, Tavazzi L, Tendera M, Wetherall K, Ferrari R, Steg PhG, on behalf of the CLARIFY investigators. 2020. Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. Eur J Prev Cardiolog 27:426–436.1.Ong E, Meseguer E, Guidoux C, Lavallée PC, Hobeanu C, Charles H, Labreuche J, Cabrejo L, Martin-Bechet A, Rigual R, Nighoghossian N, Amarenco P. 2020. Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. Stroke 51:2355–2363.1.Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté F-E, Gollety S, Falissard B, Belhassen M, Steg PhG. 2020. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Stroke 51:2066–2075.1.Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee B-C, Mahagne M-H, Nighoghossian N, Gabriel Steg P, Vicaut É, Bruckert E, Touboul P-J, Leys D, Béjot Y, Lavallée P, Pico F, Touzé E, Ducrocq G, Abtan J, Varenne O, Touboul P-J, Kemmel A, Syana F, Ledra M, Nagasara T, Ledjeroud M, Samia B, Hadia H, Hazare B, El Jaghouni I, Yelles N, Zemouri S, Ladjeroud M, Kerai S, In YJ, Meseguer E, Lavallée PC, Hobeanu C, Guidoux C, Cabrejo L, Lapergue B, Sabben C, Gonzalez-Valcarcel J, Rigual R, Sirimarco G, Martin-Bechet A, Viedma E, Avram I, Samson Y, Rosso C, Crozier S, Leder S, Léger A, Deltour S, Mutlu G, Yger M, Zavanone C, Baronnet F, Pires C, Lapergue B, Wang A, Evrard S, Tchikviladze M, Bourdain F, Lopez D, Pico F, De La Tour LB, Chadenat M-L, Duong DL, Genty S, Hirel C, Mutlu G, Nifle C, Servan J, Stanciu D, Sudacevschi V, Tir M, Troussière A-C, Yeung J, Zeghoudi A-C, Tidafi-Bayou I, Lachaud S, Cho T-H, Mechtouff L, Ritzenthaller T, Derex L, Albanesi C, Ong E, Benoit A, Berhoune N, Felix S, Esteban-Mader M, Sibon I, Kazadi A, Rouanet F, Renou P, Debruxelles S, Poli M, Sagnier S, Mas J-L, Domigo V, Lamy C, Bodiguel E, Grimaud J, Bohotin V, Obadia M, Sabben C, Morvan E, Rodier G, Vadot W, Hénon H, Cordonnier C, Dumont F, Bodenant M, Lucas C, Moulin S, Dequatre N, Alamowitch S, Muresan J-P, Drouet T, Gallea M, Dalloz M-A, Delorme S, Yger M, Béjot Y, Loisel P, Bonnin C, Bernigal V, Osseby GV, Marsac MH-B, Garnier P, Accassat S, Epinat M, Varvat J, Marinescu D, Triquenot-Bagan A, Ozkul-Wermester O, Philippeau F, Olaru A, Vieillart A, Lannuzel A, Demoly A, Wolff V, Diaconu M, Bataillard M, Montoro FM, Faugeras F, Gimenez L, Abdallah-Lebeau F, Timsit S, Viakhireva-Dovganyuk I, Tirel-Badets A, Merrien F-M, Goas P, Rouhart F, Jourdain A, Guillon B, Hérissson F, Sevin-Allouet M, Nasr N, Olivot J-M, Lecluse A, Marc G, Touzé E, De La Sayette V, Apoil M, Lin L, Cogez J, Guettier S, Godefroy O, Lamy C, Bugnicourt J-M, Taurin G, Mérienne M, Gere J, Chessak A-M, Habet T, Ferrier A, Bourgois N, Minier D, Caillier-Minier M, Contégal-Callier F, Vion P, Vaschalde Y, El Amrani, Emilie M, Zuber M, Bruandet M, Join-Lambert C, Garcia P-Y, Serre I, Faucheux J-M, Radji F, Leca-Radu E, Debroucker T, Cumurcuc R, Cakmak S, Peysson S, Ellie E, Bernady P, Moulin T, Montiel P, Revenco E, Decavel P, Medeiros E, Bouveret M, Louchart P, Vaduva C, Couvreur G, Sartori E, Alnajar-Carpentier E, Levasseur M, Louchart P, Neau J-P, Vandamme X, Meresse I, Stantescu, Bataillard M, Ozsancak C, Beauvais K, Auzou P, Amevigbe J, Vuillemet F, Dugay-Arentz M-H, Carelli G, Martinez M, Maillet-Vioud M, Escaillas J-P, Chapuis S, Tardy J, Manchon E, Varnet O, Kim Y-J, Chang Y, Song T-J, Han J-H, Noh KC, Lee E-J, Kang D-W, Kwon SU, Kwon B, Park S, Lee D, Kwon HS, Jeong D, Lee M, Kim J, Lee H, Nam HJ, Lee SH, Kim BJ, Cha J, Kim D, Young Kim R, Sohn SW, Shim D-H, Lee H, Nah H-W, Sung SM, Lee KB, Lee JY, Yoon JE, Kim E-G, Seo JH, Kim Y-W, Hwang Y, Park MS, Kim J-T, Choi K-H, Nam HS, Heo JH, Kim YD, Hwang IG, Park HJ, Kim KS, Baek JH, Song DB, Yoo JS, Park J-M, Kwon O, Lee W-W, Lee J-J, Kang K, Kim BK, Lim J-S, Oh MS, Yu K-H, Hong B, Jang M, Jang S, Jin JE, Kim J, Jeong HS, Hong KS, Park HK, Cho YJ, Bang OY, Seo W-K, Chung J. 2020. Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke. Stroke 51:1231–1239.1.Kamel H, Pearce LA, Ntaios G, Gladstone DJ, Perera K, Roine RO, Meseguer E, Shoamanesh A, Berkowitz SD, Mundl H, Sharma M, Connolly SJ, Hart RG, Healey JS. 2020. Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. Stroke 51:938–943.1.Cheng B, Boutitie F, Nickel A, Wouters A, Cho T-H, Ebinger M, Endres M, Fiebach JB, Fiehler J, Galinovic I, Puig J, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G, on behalf of the WAKE-UP Investigators*, Golsari A, Alegiani A, Beck C, Choe C, Voget D, Hoppe J, Schröder J, Rozanski M, Nave AH, Wollboldt C, Van Sloten I, Göhler J, Herm J, Jungehülsing J, Lückl J, Kröber JM, Schurig J, Koehler L, Schlemm L, Knops M, Roennefarth M, Ipsen N, Harmel P, Bathe-Peters R, Fleischmann R, Ganeshan R, Geran R, Hellwig S, Schmidt S, Tütüncü S, Krause T, Gramse V, Röther J, Michels P, Michalski D, Pelz J, Schulz A, Hobohm C, Weise C, Weise G, Orthgieß J, Pomrehn K, Wegscheider M, Mueller AK, Hennerici M, Griebe M, Alonso A, Filipov A, Marzina A, Anders B, Bähr C, Hoyer C, Schwarzbach C, Weber C, Hornberger E, Pledl H-W, Klockziem M, Stuermlinger M, Wittayer M, Wolf M, Meyer N, Eisele P, Steinert S, Sauer T, Held V, Ringleb P, Nagel S, Veltkamp R, Schwarting S, Schwarz A, Gumbinger C, Hametner C, Amiri H, Purrucker J, Ciatipis M, Menn O, Mundiyanapurath S, Schieber S, Kessler T, Reiff T, Panitz V, Singer O, Foerch C, Lauer A, Männer A, Seiler A, Guerzoglu D, Schäfer JH, Filipski K, Lorenz M, Kurka N, Zeiner P, Pfeilschifter W, Dziewas R, Minnerup J, Albiker C, Ritter M, Seidel M, Dittrich R, Kallmünzer B, Bobinger T, Madzar D, Stark D, Sembill J, Macha K, Winder K, Breuer L, Koehrmann M, Spruegel M, Gerner S, Kraft P, Mackenrodt D, Kleinschnitz C, Elhfnawy A, Heinen F, Gunreben I, Poli S, Ziemann U, Gaenslen A, Schlak D, Haertig F, Russo F, Richter H, Ebner M, Ribitsch M, Wolf M, Weimar C, Zegarac V, Chen H-C, Althaus K, Neugebauer H, Jüttler E, Meier J, Stösser S, Puetz V, Bodechtel U, Ostergaard L, Møller A, Damgaard D, Dupont KH, Poulsen M, Hjort N, De Morales NR, Von Weitzel P, Harbo T, Marstrand J, Hansen A, Christensen H, Aegidius K, Jeppesen L, Meden P, Rosenbaum S, Iversen H, Hansen J, Michelsen L, Truelsen T, Modrau B, Vestergaard K, Oppel L, Sygehus A, Aalborg S, Swinnen B, Smets I, Demeestere J, Dobbels L, Brouns R, De Smedt A, DeKeyser J, Yperzeele L, Van Hooff R-J, Peeters A, Dusart A, Etexberria A, Hanseeuw B, London F, Leempoel J, Hohenbichler K, Younan N, Maqueda V, Laloux P, De Coene B, De Maeseneire C, Turine G, Vandermeeren Y, De Klippel N, Willems C, De Hollander I, Soors P, Hermans S, Hemelsoet D, Desfontaines P, Vanacker P, Rutgers M, Druart C, Peeters D, Bruneel B, Vancaester E, Vanhee F, Meersman G, Bourgeois P, Vanderdonckt P, Benoit A, Derex L, Mechthouff L, Berhoune N, Ritzenthaler T, Amarenco P, Hobeanu C, Gancedo EM, Calvet D, Ladoux A, Machet A, Lamy C, Mellerio C, Oppenheim C, Rodriguez-Regent C, Bodiguel E, Turc G, Birchenall J, Legrand L, Morin L, Edjali-Goujon M, Naggara O, Raphaelle S, Godon-Hardy S, Domigo V, Guiraud V, Samson Y, Leger A, Rosso C, Baronnet-Chauvet F, Crozier S, Deltour S, Yger M, Sibon I, Renou P, Sagnier S, Zuber M, Tamazyan R, Rodier G, Morel N, Felix S, Vadot W, Wolff V, Aniculaesei A, Yalo B, Bindila D, Quenardelle V, Blanc-Lasserre K, Landrault E, Breynaert L, Cakmak S, Peysson S, Viguier A, Lebely C, Raposo N, Vallet A-E, Vallet P, Brugirard S, Cheripelli B, Kalladka D, Moreton F, Dani K, Tawil SE, Ramachandran S, Huang X, Warburton E, Evans N, Perry R, Patel B, Cloud G, Pereira A, Moynihan B, Lovelock C, Choy L, Khan U, Roffe C, Tyrell P, Smith C, Dixit A, Louw S, Broughton D, Shetty A, Appleton J, Sprigg N, Acosta BR, Van Eendenburg C, Leal JS, Mar Castellanos Rodrigo MD, Izaga MT, Guillamon OB, Arenillas J, Calleja A, Cortijo E, Mulero P, De La Ossa NP, Garrido A, Martinez A, Esperón CG, Guerrero C, Carrera D, Vilas D, Lopez-cancio E, Palomeras E, Lucente G, Gomis M, Isern I, Becerra JL, Vicente JH, Sánchez J, Dorado L, Grau L, Ispierto L, Prats L, Almendrote M, Hernández M, Jimenez M, Sánchez ML, Torne MM, Presas S, Ustrell X, Pellisé A, Navalpotro I, Luna A, Schonewille W, Nederkoorn P, Majoie C, Van Den Berg L, Van Den Berg S, Zonneveld T, Remmers M, Fazekas F, Pichler A, Fandler S, Gattringer T, Mutzenbach J, Weber J, Höfner E, Kohlfürst H, Weinstich K, Kellert L, Bayer-Karpinska A, Opherk C, Wollenweber F, Klein M, Neumann- Haefelin T, Pierskalla A, Harloff A, Bardutzky J, Buggle F, Von Schrader J, Kollmar R, Schill J, Löbbe A-M, Moulin T, Bouamra B, Bonnet L, Touzé E, Bonnet A-L, Touze E, Cogez J, Li L, Guettier S, Kar A, Sivagnanaratham A, Geraghty O, Bojaryn U, Nallasivan A, Gonzales MB, Rodríguez-Yáñez M, Tembl J, Gorriz D, Oberndorfer S, Prohaska E. 2020. Quantitative Signal Intensity in Fluid-Attenuated Inversion Recovery and Treatment Effect in the WAKE-UP Trial. Stroke 51:209–215.1.Boccara F, Mary‐Krause M, Potard V, Teiger E, Lang S, Hammoudi N, Chauvet M, Ederhy S, Dufour‐Soulat L, Ancedy Y, Nhan P, Adavane S, Steg PhG, Funck‐Brentano C, Costagliola D, Cohen A, Weber S, Wahbi K, Beaufils P, Henri P, Sideris G, Thomas D, Montalescot G, Beygui F, Meuleman C, Janower S, Raoux F, Dufaitre G, Benyounes N, Michel PL, Petillon B, Hammoudi N, Gueret P, Dubois‐Rande JL, Teiger E, Lim P, Slama M, Colin P, Saudubray C, Dubourg O, Milleron O, Gallet B, Duclos F, Godard S, Fuchs L, Dormagen V, Lewy P, Cattan S, Nallet O, Grollier G, Shayne J, Wolf JE, Cottin Y, Machecourt J, Bouvaist H, Finet G, De Breyne B, Trochu JN, Baudouy M, Ferrari E, Benhamou M, Allal J, Coisne D, Le Breton H, Bedossa M, Puel J, Elbaz M, Larifla L, Matheron S, Landman R, Fremont G, Spiridon G, Blanche P, Morini JP, Sicard D, Zeller V, Batisse D, Clevenbergh P, Cessot G, Dohin E, Valantin MA, Khelifa S, Girard PM, Lallemand F, Lefebvre B, Laporte JP, Meynard JL, Bideault H, Picard O, Meyohas MC, Campa P, Tredup J, Fonquernie L, Raguin G, Molina JM, Furco A, Gharakanian S, Vincensini JP, Guiard‐Schmid JB, Pialoux G, Cardon B, Lascaux AS, Chaix F, Lesprit P, Fior R, Boue F, Dupont C, Bellier C, Blanc A, Lambert T, Touahri T, Force G, De Truchis P, Compagnucci‐Seguenot MA, Cahitte I, Roudière L, Techer ME, Thelpin P, Troisvallets D, Lepretre A, Echard M, Le Mercier Y, Houlbert D, Dargere S, Bazin C, Verdon R, De Goer B, Duong M, Chavanet P, Gozlan E, Leclercq P, Brunel‐Dal Mas F, Durant J, Heudier P, Brunet‐François C, Le Moal G, Chapplin JM, Arvieux C, Chaumentin G, Guerin B, Bonnet E, Poinsignon Y, Boulard F, De Lacroix I, Goerger‐Sow MT, Kirstetter M, Volstein M, Laylavoix F, Copin X, Ceppi C. 2020. HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome. JAHA 9:e017578.1.Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M, Kamensky G, Isaza D, Aylward P, Johanson P, Bonaca MP. 2020. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial. JAHA 9:e015785.1.Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. 2020. Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial. JAHA 9:e015331.1.Schwartz GG, Szarek M, Bittner VA, Steg PG. 2020. Response by Schwartz et al to Letter Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.” Circulation 142.1.Amarenco P, Hobeanu C, Labreuche J, Charles H, Giroud M, Meseguer E, Lavallée PC, Gabriel Steg P, Vicaut É, Bruckert E, Touboul P-J. 2020. Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin. Circulation 142:748–757.1.Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim Y-U, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, For the ODYSSEY OUTCOMES Committees and Investigators*. 2020. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 141:1608–1617.1.Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimský P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S, Aboyans V, Alings M, Commerford P, Cook-Bruns N, Dagenais G, Dans A, Ertl G, Felix C, Guzik T, Hart R, Hori M, Kakkar A, Keltai K, Keltai M, Kim J, Lamy A, Lanas F, Liang Y, Liu L, Lonn E, Lopez-Jaramillo P, Metsarinne K, Moayyedi P, O’Donnell M, Parkhomenko A, Piegas L, Pogosova N, Sharma M, Stoerk S, Tonkin A, Torp-Pedersen C, Varigos J, Verhamme P, Vinereanu D, Yusoff K, Zhu J. 2020. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation 141:1841–1854.1.Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, Steg PG, Vinereanu D, Connolly DL, Berkowitz SD, Foody JM, Probstfield JL, Branch KR, Lewis BS, Diaz R, Muehlhofer E, Widimsky P, Yusuf S, Eikelboom JW, Bhatt DL, On behalf of the COMPASS Investigators. 2020. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation 141:1141–1151.1.Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PhG, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, On behalf of the REDUCE-IT Investigators. 2020. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation 141:367–375.1.Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C, On behalf of the Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators. 2020. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation 141:624–636.1.Hara H, Van Klaveren D, Takahashi K, Kogame N, Chichareon P, Modolo R, Tomaniak M, Ono M, Kawashima H, Wang R, Gao C, Niethammer M, Fontos G, Angioi M, Ribeiro VG, Barbato E, Leandro S, Hamm C, Valgimigli M, Windecker S, Jüni P, Steg PG, Verbeeck J, Tijssen JGP, Sharif F, Onuma Y, Serruys PW, for the GLOBAL LEADERS Trial Investigators. 2020. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circ: Cardiovascular Quality and Outcomes 13:e006660.1.Fuchs A, Urena M, Chong-Nguyen C, Kikoïne J, Brochet E, Abtan J, Fischer Q, Ducrocq G, Vahanian A, Iung B, Himbert D. 2020. Valve-in-Valve and Valve-in-Ring Transcatheter Mitral Valve Implantation in Young Women Contemplating Pregnancy. Circ: Cardiovascular Interventions 13:e009579.1.Hara H, Takahashi K, Kogame N, Tomaniak M, Kerkmeijer LSM, Ono M, Kawashima H, Wang R, Gao C, Wykrzykowska JJ, De Winter RJ, Neumann F-J, Plante S, Lemos Neto PA, Garg S, Jüni P, Vranckx P, Windecker S, Valgimigli M, Hamm C, Steg PG, Onuma Y, Serruys PW. 2020. Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. Circ: Cardiovascular Interventions 13:e009177.1.Duthoit G, Silvain J, Marijon E, Ducrocq G, Lepillier A, Frere C, Dimby S-F, Popovic B, Lellouche N, Martin-Toutain I, Spaulding C, Brochet E, Attias D, Mansourati J, Lorgis L, Klug D, Zannad N, Hauguel-Moreau M, Braik N, Deltour S, Ceccaldi A, Wang H, Hammoudi N, Brugier D, Vicaut E, Juliard J-M, Montalescot G, for the ADRIFT Investigators. 2020. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study. Circ: Cardiovascular Interventions 13:e008481.1.Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP, on behalf of the REDUAL PCI Steering Committee and Investigators. 2020. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ: Cardiovascular Interventions 13:e008349.1.Sorrentino S, Sartori S, Baber U, Claessen BE, Giustino G, Chandrasekhar J, Chandiramani R, Cohen DJ, Henry TD, Guedeney P, Ariti C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Urban P, Mehran R. 2020. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ: Cardiovascular Interventions 13:e008226.1.Stavres J, Luck JC, Ducrocq GP, Cauffman AE, Pai S, Sinoway LI. 2020. Central and peripheral modulation of exercise pressor reflex sensitivity after nonfatiguing work. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 319:R575–R583.1.Estrada JA, Ducrocq GP, Kim JS, Kaufman MP. 2020. Intrathecal injection of brilliant blue G, a P2X7 antagonist, attenuates the exercise pressor reflex in rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 319:R223–R232.1.Ducrocq GP, Kim JS, Estrada JA, Kaufman MP. 2020. ASIC1a does not play a role in evoking the metabolic component of the exercise pressor reflex in a rat model of peripheral artery disease. American Journal of Physiology-Heart and Circulatory Physiology 319:H171–H182.1.Li L, Luengo-Fernandez R, Zuurbier SM, Beddows NC, Lavallee P, Silver LE, Kuker W, Rothwell PM. 2020. Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study. J Neurol Neurosurg Psychiatry 91:580–585.1.Norel X, Sugimoto Y, Ozen G, Abdelazeem H, Amgoud Y, Bouhadoun A, Bassiouni W, Goepp M, Mani S, Manikpurage HD, Senbel A, Longrois D, Heinemann A, Yao C, Clapp LH. 2020. International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E 2 Receptors (EP1–4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions. Pharmacol Rev 72:910–968.1.Ducrocq GP, Kaufman MP. 2020. Inorganic phosphate and lactate potentiate the pressor response to acidic stimuli in rats. Experimental Physiology 105:613–621.1.Lapergue B, Lyoubi A, Meseguer E, Avram I, Denier C, Venditti L, Consoli A, Guedon A, Houdart E, Weisenburger‐Lile D, Piotin M, Maier B, Obadia M, Broucker TDE. 2020. Large vessel stroke in six patients following SARS‐CoV‐2 infection: a retrospective case study series of acute thrombotic complications on stable underlying atherosclerotic disease. Euro J of Neurology 27:2308–2311.1.Ozen G, Benyahia C, Mani S, Boukais K, Silverstein AM, Bayles R, Nelsen AC, Castier Y, Danel C, Mal H, Clapp LH, Longrois D, Norel X. 2020. Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension. British J Pharmacology 177:161–174.1.Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP. 2020. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal 41:1625–1632.1.Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim Y-U, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG, for the ODYSSEY OUTCOMES Investigators. 2020. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal 41:2248–2258.1.Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, Ford I, Greenlaw N, Kalra PR, Parma Z, Shalnova S, Tardif J-C, Tendera M, Zamorano JL, Vidal-Petiot E, Steg PG, CLARIFY investigators. 2020. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal 41:347–356.1.Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, Džavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han Y-L, Pocock S, Gibson CM, Mehran R. 2020. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal 41:3533–3545.1.Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, for the ODYSSEY OUTCOMES Investigators. 2020. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal 41:4245–4255.1.Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim Y-U, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG, for the ODYSSEY OUTCOMES Investigators. 2020. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal 41:4114–4123.1.Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann F-J, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle J-F, Filipiak KJ, Van Geuns R-J, Soliman O, Tijssen J, Rademaker-Havinga T, Storey RF, Hamm C, Steg PG, Windecker S, Onuma Y, Valgimigli M, Serruys PW, for the GLOBAL LEADERS Study Investigators. 2020. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy 6:222–230.2460799 5BTMJQCK 2019 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-21f9f47500a2267f338412e452a6bb91%22%2C%22meta%22%3A%7B%22request_last%22%3A100%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22G5YBB45V%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Serruys%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESerruys%20PW%2C%20Tomaniak%20M%2C%20Chichareon%20P%2C%20Modolo%20R%2C%20Kogame%20N%2C%20Takahashi%20K%2C%20Chang%20CC%2C%20Spitzer%20E%2C%20Walsh%20SJ%2C%20Adlam%20D%2C%20Hildick-Smith%20D%2C%20%26%23xC9%3Bdes%20I%2C%20Van%20De%20Harst%20P%2C%20Krackhardt%20F%2C%20Tijssen%20JGP%2C%20Rademaker-Havinga%20T%2C%20Garg%20S%2C%20Steg%20PG%2C%20Hamm%20C%2C%20J%26%23xFC%3Bni%20P%2C%20Vranckx%20P%2C%20Onuma%20Y%2C%20Verheugt%20FWA.%202019.%20Patient-oriented%20composite%20endpoints%20and%20net%20adverse%20clinical%20events%20with%20ticagrelor%20monotherapy%20following%20percutaneous%20coronary%20intervention%3A%20insights%20from%20the%20randomised%20GLOBAL%20LEADERS%20trial.%20EuroIntervention%2015%3Ae1090%26%23x2013%3Be1098.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patient-oriented%20composite%20endpoints%20and%20net%20adverse%20clinical%20events%20with%20ticagrelor%20monotherapy%20following%20percutaneous%20coronary%20intervention%3A%20insights%20from%20the%20randomised%20GLOBAL%20LEADERS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Chin%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Spitzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20J.%22%2C%22lastName%22%3A%22Walsh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Adlam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Hildick-Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Istv%5Cu00e1n%22%2C%22lastName%22%3A%22%5Cu00c9des%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pim%22%2C%22lastName%22%3A%22Van%20De%20Harst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Krackhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20G.P.%22%2C%22lastName%22%3A%22Tijssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tessa%22%2C%22lastName%22%3A%22Rademaker-Havinga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freek%20W.A.%22%2C%22lastName%22%3A%22Verheugt%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2019%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4244%5C%2FEIJ-D-19-00202%22%2C%22ISSN%22%3A%221969-6213%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Feurointervention.pcronline.com%5C%2Fdoi%5C%2F10.4244%5C%2FEIJ-D-19-00202%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A49Z%22%7D%7D%2C%7B%22key%22%3A%223I7DN9J4%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chichareon%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EChichareon%20P%2C%20Onuma%20Y%2C%20Van%20Klaveren%20D%2C%20Modolo%20R%2C%20Kogame%20N%2C%20Takahashi%20K%2C%20Chang%20CC%2C%20Tomaniak%20M%2C%20Asano%20T%2C%20Katagiri%20Y%2C%20Van%20Geuns%20R-JM%2C%20Bolognese%20L%2C%20Tumscitz%20C%2C%20Vrolix%20M%2C%20Petrov%20I%2C%20Garg%20S%2C%20Naber%20CK%2C%20Sabat%26%23xE9%3B%20M%2C%20Iqbal%20J%2C%20Wykrzykowska%20JJ%2C%20Piek%20JJ%2C%20Spitzer%20E%2C%20J%26%23xFC%3Bni%20P%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Valgimigli%20M%2C%20Vranckx%20P%2C%20Windecker%20S%2C%20Serruys%20PW.%202019.%20Validation%20of%20the%20updated%20logistic%20clinical%20SYNTAX%20score%20for%20all-cause%20mortality%20in%20the%20GLOBAL%20LEADERS%20trial.%20EuroIntervention%2015%3Ae539%26%23x2013%3Be546.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Validation%20of%20the%20updated%20logistic%20clinical%20SYNTAX%20score%20for%20all-cause%20mortality%20in%20the%20GLOBAL%20LEADERS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Van%20Klaveren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Chin%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Taku%22%2C%22lastName%22%3A%22Asano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuki%22%2C%22lastName%22%3A%22Katagiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert-Jan%20M.%22%2C%22lastName%22%3A%22Van%20Geuns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Bolognese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Tumscitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathias%22%2C%22lastName%22%3A%22Vrolix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivo%22%2C%22lastName%22%3A%22Petrov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%20Kurt%22%2C%22lastName%22%3A%22Naber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Sabat%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javaid%22%2C%22lastName%22%3A%22Iqbal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20J.%22%2C%22lastName%22%3A%22Wykrzykowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20J.%22%2C%22lastName%22%3A%22Piek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Spitzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2019%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4244%5C%2FEIJ-D-19-00184%22%2C%22ISSN%22%3A%221969-6213%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Feurointervention.pcronline.com%5C%2Fdoi%5C%2F10.4244%5C%2FEIJ-D-19-00184%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A48Z%22%7D%7D%2C%7B%22key%22%3A%224IYW3LDP%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vidal-Petiot%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVidal-Petiot%20E%2C%20Greenlaw%20N%2C%20Kalra%20PR%2C%20Garcia-Moll%20X%2C%20Tardif%20J-C%2C%20Ford%20I%2C%20Zamorano%20J%2C%20Ferrari%20R%2C%20Tendera%20M%2C%20Fox%20KM%2C%20Steg%20PG%2C%20on%20behalf%20of%20the%20CLARIFY%20investigators%20on%20behalf%20of%20the%20CLARIFY%20investigators.%202019.%20Chronic%20Kidney%20Disease%20Has%20a%20Graded%20Association%20with%20Death%20and%20Cardiovascular%20Outcomes%20in%20Stable%20Coronary%20Artery%20Disease%3A%20An%20Analysis%20of%2021%2C911%20Patients%20from%20the%20CLARIFY%20Registry.%20JCM%209%3A4.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Chronic%20Kidney%20Disease%20Has%20a%20Graded%20Association%20with%20Death%20and%20Cardiovascular%20Outcomes%20in%20Stable%20Coronary%20Artery%20Disease%3A%20An%20Analysis%20of%2021%2C911%20Patients%20from%20the%20CLARIFY%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Vidal-Petiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Greenlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20R.%22%2C%22lastName%22%3A%22Kalra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Garcia-Moll%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Zamorano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20CLARIFY%20investigators%20on%20behalf%20of%20the%20CLARIFY%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22Chronic%20kidney%20disease%20%28CKD%29%20is%20associated%20with%20an%20increased%20cardiovascular%20risk%20in%20a%20broad%20spectrum%20of%20populations.%20However%2C%20the%20risk%20associated%20with%20a%20reduced%20estimated%20glomerular%20filtration%20rate%20%28eGFR%29%20in%20patients%20with%20stable%20coronary%20artery%20disease%20receiving%20standard%20care%20in%20the%20modern%20era%2C%20independently%20of%20baseline%20cardiovascular%20disease%2C%20risk%20factors%2C%20and%20comorbidities%2C%20remains%20unclear.%20We%20analyzed%20data%20from%2021%2C911%20patients%20with%20stable%20coronary%20artery%20disease%2C%20enrolled%20in%2045%20countries%20between%20November%202009%20and%20July%202010%20in%20the%20CLARIFY%20registry.%20Patients%20with%20abnormal%20renal%20function%20were%20older%2C%20with%20more%20comorbidities%2C%20and%20received%20slightly%20lower%5Cu2014although%20overall%20high%5Cu2014rates%20of%20evidence-based%20secondary%20prevention%20therapies%20than%20patients%20with%20normal%20renal%20function.%20The%20event%20rate%20of%20patients%20with%20CKD%20stage%203b%20or%20more%20%28eGFR%20%3C45%20mL%5C%2Fmin%5C%2F1.73%20m2%29%20was%20much%20higher%20than%20that%20associated%20with%20any%20comorbid%20condition.%20In%20a%20multivariable%20adjusted%20Cox%20proportional%20hazards%20model%2C%20lower%20eGFR%20was%20independently%20associated%20with%20a%20graded%20increased%20risk%20of%20cardiovascular%20mortality%2C%20with%20adjusted%20HRs%20%2895%25%20CI%29%20of%200.98%20%280.81%5Cu20131.18%29%2C%201.31%20%281.05%5Cu20131.63%29%2C%201.77%20%281.38%5Cu20132.27%29%2C%20and%203.12%20%282.25%5Cu20134.33%29%20for%20eGFR%2060%5Cu201389%2C%2045%5Cu201359%2C%2030%5Cu201344%2C%20and%20%3C30%20mL%5C%2Fmin%5C%2F1.73%20m2%2C%20compared%20with%20eGFR%20%5Cu226590%20mL%5C%2Fmin%5C%2F1.73%20m2.%20A%20strong%20graded%20independent%20relationship%20exists%20between%20the%20degree%20of%20CKD%20and%20cardiovascular%20mortality%20in%20this%20large%20cohort%20of%20patients%20with%20chronic%20coronary%20artery%20disease%2C%20despite%20high%20rates%20of%20secondary%20prevention%20therapies.%20Among%20clinical%20risk%20factors%20and%20comorbid%20conditions%2C%20CKD%20stage%203b%20or%20more%20is%20associated%20with%20the%20highest%20cardiovascular%20mortality.%22%2C%22date%22%3A%222019-12-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fjcm9010004%22%2C%22ISSN%22%3A%222077-0383%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2077-0383%5C%2F9%5C%2F1%5C%2F4%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22J3W5P6NQ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Breyer%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-13%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBreyer%20RM%2C%20Clapp%20L%2C%20Coleman%20RA%2C%20Giembycz%20M%2C%20Heinemann%20A%2C%20Hills%20R%2C%20Jones%20RL%2C%20Narumiya%20S%2C%20Norel%20X%2C%20Pettipher%20R%2C%20Sugimoto%20Y%2C%20Uddin%20M%2C%20Woodward%20DF%2C%20Yao%20C.%202019.%20Prostanoid%20receptors%20%28version%202019.5%29%20in%20the%20IUPHAR%5C%2FBPS%20Guide%20to%20Pharmacology%20Database.%20GtoPdb%20CITE%202019.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prostanoid%20receptors%20%28version%202019.5%29%20in%20the%20IUPHAR%5C%2FBPS%20Guide%20to%20Pharmacology%20Database%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20M.%22%2C%22lastName%22%3A%22Breyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Clapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Coleman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Giembycz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akos%22%2C%22lastName%22%3A%22Heinemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Hills%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuh%22%2C%22lastName%22%3A%22Narumiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%22%2C%22lastName%22%3A%22Pettipher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukihiko%22%2C%22lastName%22%3A%22Sugimoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohib%22%2C%22lastName%22%3A%22Uddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20F.%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcan%22%2C%22lastName%22%3A%22Yao%22%7D%5D%2C%22abstractNote%22%3A%22Prostanoid%20receptors%20%28nomenclature%20as%20agreed%20by%20the%20NC-IUPHAR%20Subcommittee%20on%20Prostanoid%20Receptors%20%5B659%5D%29%20are%20activated%20by%20the%20endogenous%20ligands%20prostaglandins%20PGD2%2C%20PGE1%2C%20PGE2%20%2C%20PGF2%5Cu03b1%2C%20PGH2%2C%20prostacyclin%20%5BPGI2%5D%20and%20thromboxane%20A2.%20Measurement%20of%20the%20potency%20of%20PGI2%20and%20thromboxane%20A2%20is%20hampered%20by%20their%20instability%20in%20physiological%20salt%20solution%3B%20they%20are%20often%20replaced%20by%20cicaprost%20and%20U46619%2C%20respectively%2C%20in%20receptor%20characterization%20studies.%22%2C%22date%22%3A%222019-11-13%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2218%5C%2Fgtopdb%5C%2FF58%5C%2F2019.5%22%2C%22ISSN%22%3A%222633-1020%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.ed.ac.uk%5C%2Fgtopdb-cite%5C%2Farticle%5C%2Fview%5C%2F4092%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22G7ACQVFT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Breyer%20et%20al.%22%2C%22parsedDate%22%3A%222019-09-16%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBreyer%20RM%2C%20Clapp%20L%2C%20Coleman%20RA%2C%20Giembycz%20M%2C%20Heinemann%20A%2C%20Hills%20R%2C%20Jones%20RL%2C%20Narumiya%20S%2C%20Norel%20X%2C%20Pettipher%20R%2C%20Sugimoto%20Y%2C%20Woodward%20DF%2C%20Yao%20C.%202019.%20Prostanoid%20receptors%20%28version%202019.4%29%20in%20the%20IUPHAR%5C%2FBPS%20Guide%20to%20Pharmacology%20Database.%20GtoPdb%20CITE%202019.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prostanoid%20receptors%20%28version%202019.4%29%20in%20the%20IUPHAR%5C%2FBPS%20Guide%20to%20Pharmacology%20Database%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20M.%22%2C%22lastName%22%3A%22Breyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Clapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Coleman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Giembycz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akos%22%2C%22lastName%22%3A%22Heinemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Hills%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuh%22%2C%22lastName%22%3A%22Narumiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%22%2C%22lastName%22%3A%22Pettipher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukihiko%22%2C%22lastName%22%3A%22Sugimoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20F.%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcan%22%2C%22lastName%22%3A%22Yao%22%7D%5D%2C%22abstractNote%22%3A%22Prostanoid%20receptors%20%28nomenclature%20as%20agreed%20by%20the%20NC-IUPHAR%20Subcommittee%20on%20Prostanoid%20Receptors%20%5B644%5D%29%20are%20activated%20by%20the%20endogenous%20ligands%20prostaglandins%20PGD2%2C%20PGE1%2C%20PGE2%20%2C%20PGF2%5Cu03b1%2C%20PGH2%2C%20prostacyclin%20%5BPGI2%5D%20and%20thromboxane%20A2.%20Measurement%20of%20the%20potency%20of%20PGI2%20and%20thromboxane%20A2%20is%20hampered%20by%20their%20instability%20in%20physiological%20salt%20solution%3B%20they%20are%20often%20replaced%20by%20cicaprost%20and%20U46619%2C%20respectively%2C%20in%20receptor%20characterization%20studies.%22%2C%22date%22%3A%222019-09-16%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2218%5C%2Fgtopdb%5C%2FF58%5C%2F2019.4%22%2C%22ISSN%22%3A%222633-1020%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.ed.ac.uk%5C%2Fgtopdb-cite%5C%2Farticle%5C%2Fview%5C%2F3210%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22NLVCNU5U%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parma%20et%20al.%22%2C%22parsedDate%22%3A%222019-04-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EParma%20Z%2C%20Young%20R%2C%20Roleder%20T%2C%20Marona%20M%2C%20Ford%20I%2C%20Tendera%20M%2C%20Steg%20PG%2C%20St%26%23x119%3Bpi%26%23x144%3Bska%20J.%202019.%20Management%20strategies%20and%205-year%20outcomes%20in%20Polish%20patients%20with%20stable%20coronary%20artery%20disease%20in%20the%20CLARIFY%20registry%20versus%20other%20European%20countries.%20Polish%20Archives%20of%20Internal%20Medicine%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.20452%5C%2Fpamw.14789%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.20452%5C%2Fpamw.14789%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20strategies%20and%205-year%20outcomes%20in%20Polish%20patients%20with%20stable%20coronary%20artery%20disease%20in%20the%20CLARIFY%20registry%20versus%20other%20European%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zofia%22%2C%22lastName%22%3A%22Parma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Roleder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mi%5Cu0142osz%22%2C%22lastName%22%3A%22Marona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micha%5Cu0142%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janina%22%2C%22lastName%22%3A%22St%5Cu0119pi%5Cu0144ska%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-04-05%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.20452%5C%2Fpamw.14789%22%2C%22ISSN%22%3A%221897-9483%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mp.pl%5C%2Fpaim%5C%2Fissue%5C%2Farticle%5C%2F14789%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22LIRX356I%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zelniker%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EZelniker%20TA%2C%20Morrow%20DA%2C%20Mosenzon%20O%2C%20Gurmu%20Y%2C%20Im%20K%2C%20Cahn%20A%2C%20Raz%20I%2C%20Steg%20PG%2C%20Leiter%20LA%2C%20Braunwald%20E%2C%20Bhatt%20DL%2C%20Scirica%20BM.%202019.%20Cardiac%20and%20Inflammatory%20Biomarkers%20Are%20Associated%20with%20Worsening%20Renal%20Outcomes%20in%20Patients%20with%20Type%202%20Diabetes%20Mellitus%3A%20Observations%20from%20SAVOR-TIMI%2053.%20Clinical%20Chemistry%2065%3A781%26%23x2013%3B790.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiac%20and%20Inflammatory%20Biomarkers%20Are%20Associated%20with%20Worsening%20Renal%20Outcomes%20in%20Patients%20with%20Type%202%20Diabetes%20Mellitus%3A%20Observations%20from%20SAVOR-TIMI%2053%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20A%22%2C%22lastName%22%3A%22Zelniker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A%22%2C%22lastName%22%3A%22Morrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ofri%22%2C%22lastName%22%3A%22Mosenzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Gurmu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyungah%22%2C%22lastName%22%3A%22Im%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Avivit%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Itamar%22%2C%22lastName%22%3A%22Raz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%20A%22%2C%22lastName%22%3A%22Leiter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Braunwald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20M%22%2C%22lastName%22%3A%22Scirica%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20BACKGROUND%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Cardiac%20and%20renal%20diseases%20commonly%20occur%20with%20bidirectional%20interactions.%20We%20hypothesized%20that%20cardiac%20and%20inflammatory%20biomarkers%20may%20assist%20in%20identification%20of%20patients%20with%20type%202%20diabetes%20mellitus%20%28T2DM%29%20at%20high%20risk%20of%20worsening%20renal%20function.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20exploratory%20analysis%20from%20SAVOR-TIMI%2053%2C%20concentrations%20of%20high-sensitivity%20cardiac%20troponin%20T%20%28hs-TnT%29%2C%20N-terminal%20pro%5Cu2013B-type%20natriuretic%20peptide%20%28NT-proBNP%29%2C%20and%20high-sensitivity%20C-reactive%20protein%20%28hs-CRP%29%20were%20measured%20in%20baseline%20serum%20samples%20of%2012310%20patients.%20The%20primary%20end%20point%20for%20this%20analysis%20was%20a%20%5Cu226540%25%20decrease%20in%20estimated%20glomerular%20filtration%20rate%20%28eGFR%29%20at%20end%20of%20treatment%20%28EOT%29%20at%20a%20median%20of%202.1%20years.%20The%20relationships%20between%20biomarkers%20and%20the%20end%20point%20were%20modeled%20using%20adjusted%20logistic%20and%20Cox%20regression.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20multivariable%20adjustment%20including%20baseline%20renal%20function%2C%20each%20biomarker%20was%20independently%20associated%20with%20an%20increased%20risk%20of%20%5Cu226540%25%20decrease%20in%20eGFR%20at%20EOT%20%5BQuartile%20%28Q%29%20Q4%20vs%20Q1%3A%20hs-TnT%20adjusted%20odds%20ratio%20%28OR%29%2C%205.63%20%283.49%5Cu20139.10%29%3B%20NT-proBNP%20adjusted%20OR%2C%203.53%20%282.29%5Cu20135.45%29%3B%20hs-CRP%20adjusted%20OR%2C%201.84%20%2895%25%20CI%2C%201.27%5Cu20132.68%29%3B%20all%20P%20values%20%5Cu22640.001%5D.%20Furthermore%2C%20each%20biomarker%20was%20independently%20associated%20with%20higher%20risk%20of%20worsening%20of%20urinary%20albumin-to-creatinine%20ratio%20%28UACR%29%20category%20%28all%20P%20values%20%5Cu22640.002%29.%20Sensitivity%20analyses%20in%20patients%20without%20heart%20failure%20and%20eGFR%20%26gt%3B60%20mL%5C%2Fmin%20provided%20similar%20results.%20In%20an%20adjusted%20multimarker%20model%2C%20hs-TnT%20and%20NT-proBNP%20remained%20significantly%20associated%20with%20both%20renal%20outcomes%20%28all%20P%20values%20%26lt%3B0.01%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSIONS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20hs-TnT%2C%20NT-proBNP%2C%20and%20hs-CRP%20were%20each%20associated%20with%20worsening%20of%20renal%20function%20%5Breduction%20in%20eGFR%20%28%5Cu226540%25%29%20and%20deterioration%20in%20UACR%20class%5D%20in%20high-risk%20patients%20with%20T2DM.%20Patients%20with%20high%20cardiac%20or%20inflammatory%20biomarkers%20should%20be%20treated%20not%20only%20for%20their%20risk%20of%20cardiovascular%20outcomes%20but%20also%20followed%20for%20renal%20deterioration.%22%2C%22date%22%3A%222019-06-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1373%5C%2Fclinchem.2018.298489%22%2C%22ISSN%22%3A%220009-9147%2C%201530-8561%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fclinchem%5C%2Farticle%5C%2F65%5C%2F6%5C%2F781%5C%2F5608058%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22V5ULLM4T%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amarenco%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAmarenco%20P%2C%20Kim%20JS%2C%20Labreuche%20J%2C%20Giroud%20M%2C%20Lee%20B-C%2C%20Mahagne%20M-H%2C%20Nighoghossian%20N%2C%20Simon%20T%2C%20Steg%20PG%2C%20Touboul%20P-J%2C%20Vicaut%20E%2C%20Yelles%20N%2C%20Bruckert%20E.%202019.%20Treat%20stroke%20to%20target%20trial%20design%3A%20First%20trial%20comparing%20two%20LDL%20targets%20in%20patients%20with%20atherothrombotic%20strokes.%20European%20Stroke%20Journal%204%3A271%26%23x2013%3B280.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treat%20stroke%20to%20target%20trial%20design%3A%20First%20trial%20comparing%20two%20LDL%20targets%20in%20patients%20with%20atherothrombotic%20strokes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jong%20S%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Giroud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Byung-Chul%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Mahagne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Nighoghossian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nessima%22%2C%22lastName%22%3A%22Yelles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bruckert%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2396987319838100%22%2C%22ISSN%22%3A%222396-9873%2C%202396-9881%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.sagepub.com%5C%2Fdoi%5C%2F10.1177%5C%2F2396987319838100%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22RENAJMTI%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hoshino%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHoshino%20T%2C%20Sissani%20L%2C%20Labreuche%20J%2C%20Bousser%20M-G%2C%20Chamorro%20A%2C%20Fisher%20M%2C%20Ford%20I%2C%20Fox%20KM%2C%20Hennerici%20MG%2C%20Mattle%20HP%2C%20Rothwell%20PM%2C%20Gabriel%20Steg%20P%2C%20Vicaut%20E%2C%20Amarenco%20P.%202019.%20Non-cardioembolic%20stroke%5C%2Ftransient%20ischaemic%20attack%20in%20Asians%20and%20non-Asians%3A%20A%20post-hoc%20analysis%20of%20the%20PERFORM%20study.%20European%20Stroke%20Journal%204%3A65%26%23x2013%3B74.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Non-cardioembolic%20stroke%5C%2Ftransient%20ischaemic%20attack%20in%20Asians%20and%20non-Asians%3A%20A%20post-hoc%20analysis%20of%20the%20PERFORM%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takao%22%2C%22lastName%22%3A%22Hoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Germaine%22%2C%22lastName%22%3A%22Bousser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%22%2C%22lastName%22%3A%22Chamorro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Fisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20G%22%2C%22lastName%22%3A%22Hennerici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heinrich%20P%22%2C%22lastName%22%3A%22Mattle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M%22%2C%22lastName%22%3A%22Rothwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gabriel%20Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20aimed%20to%20compare%20the%20characteristics%20and%20vascular%20outcomes%20between%20Asian%20and%20non-Asian%20patients%20with%20non-cardioembolic%20stroke%5C%2Ftransient%20ischaemic%20attack%20receiving%20antiplatelet%20monotherapy%20and%20to%20identify%20population-specific%20predictors%20for%20recurrent%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20and%20methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20conducted%20a%20post-hoc%20analysis%20of%20data%20from%20the%20PERFORM%20study%2C%20in%20which%2019%2C100%20patients%20%28mean%20age%2C%2067.2%20years%3B%20male%2C%2063%25%3B%202178%20Asian%20and%2016%2C922%20non-Asian%20patients%29%20with%20non-cardioembolic%20ischaemic%20stroke%5C%2Ftransient%20ischaemic%20attack%20were%20randomised%20to%20aspirin%20or%20terutroban%20and%20followed%20for%20two%20years.%20The%20primary%20outcome%20was%20a%20composite%20of%20major%20adverse%20cardiovascular%20events%20%28non-fatal%20myocardial%20infarction%2C%20non-fatal%20stroke%20and%20cardiovascular%20death%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20There%20was%20no%20difference%20in%20major%20adverse%20cardiovascular%20events%20risk%20between%20Asian%20and%20non-Asian%20populations%20%2811.1%25%20vs.%2010.5%25%3B%20p%5Cu2009%3D%5Cu20090.39%29.%20However%2C%20Asian%20patients%20were%20at%20significantly%20higher%20risk%20of%20intracranial%20haemorrhage%20%282.4%25%20vs.%201.3%25%3B%20hazard%20ratio%20%28HR%29%201.87%3B%2095%25%20confidence%20interval%20%28CI%29%201.34%5Cu20132.60%3B%20p%5Cu2009%3C%5Cu20090.001%29%20and%20major%20bleeding%20%285.4%25%20vs.%204.1%25%3B%20HR%201.30%3B%2095%25%20CI%201.04%5Cu20131.61%3B%20p%5Cu2009%3D%5Cu20090.02%29.%20Stroke%20risk%20was%20significantly%20higher%20in%20Asian%20than%20in%20non-Asian%20populations%20among%20patients%20with%20lacunar%20stroke%20%287.4%25%20vs.%204.5%25%3B%20p%5Cu2009%3D%5Cu20090.02%29.%20In%20multivariable%20analysis%2C%20diastolic%20blood%20pressure%20%28HR%20per%205%20mm%20Hg%201.08%3B%2095%25%20CI%201.01%5Cu20131.16%3B%20p%5Cu2009%3D%5Cu20090.03%29%20and%20diabetes%20%28HR%201.36%3B%2095%25%20CI%201.22%5Cu20131.52%3B%20p%5Cu2009%3C%5Cu20090.001%29%20were%20independent%20predictors%20of%20major%20adverse%20cardiovascular%20events%20for%20Asian%20and%20non-Asian%20patients%2C%20respectively.%20Conclusion%3A%20Compared%20with%20non-Asian%20patients%2C%20Asian%20patients%20had%20significantly%20higher%20risk%20of%20haemorrhagic%20events%20when%20given%20antiplatelet%20monotherapy%20for%20secondary%20prevention%20after%20non-cardioembolic%20stroke%5C%2Ftransient%20ischaemic%20attack.%20Lacunar%20stroke%20and%20elevated%20diastolic%20blood%20pressure%20were%20more%20associated%20with%20recurrence%20risk%20in%20Asian%20patients.%22%2C%22date%22%3A%2203%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2396987318797245%22%2C%22ISSN%22%3A%222396-9873%2C%202396-9881%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.sagepub.com%5C%2Fdoi%5C%2F10.1177%5C%2F2396987318797245%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A02Z%22%7D%7D%2C%7B%22key%22%3A%228YW754WY%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tan%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ETan%20NS%2C%20Sarak%20B%2C%20Fox%20KA%2C%20Brieger%20D%2C%20Steg%20PhG%2C%20Gale%20CP%2C%20Bhatt%20DL%2C%20Spencer%20FA%2C%20Grondin%20FR%2C%20Goodman%20SG%2C%20Yan%20AT%2C%20on%20behalf%20of%20the%20Canadian%20GRACE%5C%2FGRACE-2%20and%20CANRACE%20Investigators.%202019.%20Pulse%20pressure%20in%20acute%20coronary%20syndromes%3A%20Comparative%20prognostic%20significance%20with%20systolic%20blood%20pressure.%20European%20Heart%20Journal%3A%20Acute%20Cardiovascular%20Care%208%3A309%26%23x2013%3B317.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pulse%20pressure%20in%20acute%20coronary%20syndromes%3A%20Comparative%20prognostic%20significance%20with%20systolic%20blood%20pressure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nigel%20S%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%22%2C%22lastName%22%3A%22Sarak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20Aa%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brieger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%20P%22%2C%22lastName%22%3A%22Gale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%20A%22%2C%22lastName%22%3A%22Spencer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%20R%22%2C%22lastName%22%3A%22Grondin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20T%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20Canadian%20GRACE%5C%2FGRACE-2%20and%20CANRACE%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Pulse%20pressure%20is%20a%20readily%20available%20vital%20sign%20that%20has%20been%20shown%20to%20independently%20predict%20outcomes%20in%20several%20cardiovascular%20disease%20states.%20We%20investigated%20the%20prognostic%20significance%20of%20pulse%20pressure%20%28PP%29%20and%20systolic%20blood%20pressure%20%28SBP%29%20among%20patients%20with%20acute%20coronary%20syndromes%20%28ACS%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20total%20of%2014%2C514%20patients%20with%20ACS%20in%20the%20prospective%2C%20multicentre%20Global%20Registry%20of%20Acute%20Coronary%20Events%20%28GRACE%29%2C%20expanded%20GRACE%20%28GRACE-2%29%20and%20Canadian%20Registry%20of%20Acute%20Coronary%20Events%20%28CANRACE%29%20were%20stratified%20by%20initial%20PP%20on%20presentation.%20Patient%20characteristics%20and%20in-hospital%20outcomes%20were%20compared%20by%20PP%20quartiles%20and%20the%20independent%20prognostic%20significance%20of%20PP%20for%20in-hospital%20mortality%20was%20quantified.%20We%20compared%20the%20discriminative%20ability%20%28c-statistic%29%20of%20models%20incorporating%20either%20PP%20or%20SBP.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20higher%20PPs%20were%20older%2C%20more%20frequently%20female%20and%20had%20higher%20prevalence%20rates%20of%20conventional%20cardiovascular%20risk%20factors%20%28all%20p%5Cu2009%3C%5Cu20090.01%29.%20Lower%20PP%20was%20associated%20with%20ST-segment%20elevation%20myocardial%20infarction%20presentation%2C%20higher%20GRACE%20risk%20scores%20and%20higher%20rates%20of%20adverse%20in-hospital%20outcomes%20%28%20p%5Cu2009%3C%5Cu20090.001%29.%20PP%20was%20strongly%20correlated%20with%20SBP%20%28Pearson%5Cu2019s%20correlation%20coefficient%5Cu2009%3D%5Cu20090.79%2C%20p%5Cu2009%3C%5Cu20090.001%29.%20After%20adjustment%20for%20other%20GRACE%20risk%20model%20predictors%2C%20lower%20PP%20was%20independently%20associated%20with%20in-hospital%20mortality%20%28first%20vs.%20fourth%20quartile%20%5Breference%5D%3A%20adjusted%20odds%20ratio%202.57%2C%2095%25%20confidence%20interval%201.80%5Cu20133.67%29.%20The%20c-statistic%20was%20slightly%20higher%20for%20the%20multivariable%20model%20incorporating%20SBP%20as%20compared%20to%20the%20model%20with%20PP%20%280.868%20vs.%200.864%2C%20respectively%2C%20p%5Cu2009%3D%5Cu20090.028%29%20for%20in-hospital%20mortality.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Higher%20presenting%20PP%20is%20associated%20with%20increased%20age%20and%20more%20prevalent%20cardiovascular%20risk%20factors%2C%20whereas%20patients%20with%20lower%20PP%20present%20with%20worse%20clinical%20characteristics%20and%20in-hospital%20outcomes.%20Lower%20PP%20is%20an%20independent%20adverse%20prognosticator%20in%20ACS.%20However%2C%20PP%20did%20not%20improve%20the%20discriminatory%20performance%20of%20the%20GRACE%20risk%20score%20compared%20with%20SBP.%22%2C%22date%22%3A%2206%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2048872617700871%22%2C%22ISSN%22%3A%222048-8726%2C%202048-8734%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjacc%5C%2Farticle%5C%2F8%5C%2F4%5C%2F309-317%5C%2F5943978%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22BV72WKVK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kemlin%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EKemlin%20C%2C%20Moulton%20E%2C%20Lamy%20J-C%2C%20Houot%20M%2C%20Valabregue%20R%2C%20Leder%20S%2C%20Obadia%20MA%2C%20Meseguer%20E%2C%20Yger%20M%2C%20Brochard%20V%2C%20Corvol%20J-C%2C%20Samson%20Y%2C%20Rosso%20C.%202019.%20Elucidating%20the%20Structural%20and%20Functional%20Correlates%20of%20Upper-Limb%20Poststroke%20Motor%20Impairment.%20Stroke%2050%3A3647%26%23x2013%3B3649.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Elucidating%20the%20Structural%20and%20Functional%20Correlates%20of%20Upper-Limb%20Poststroke%20Motor%20Impairment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Kemlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Moulton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Charles%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Houot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Valabregue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Leder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%20A.%22%2C%22lastName%22%3A%22Obadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Yger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Brochard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Corvol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Samson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Rosso%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Many%20studies%20have%20attempted%20to%20bring%20to%20light%20the%20neural%20correlates%20of%20poststroke%20motor%20impairment%2C%20but%20few%20have%20used%20multimodal%20approach%20to%20explain%20it.%20The%20aim%20of%20this%20study%20was%20to%20elucidate%20neural%20structural%20and%20functional%20correlates%20of%20upper%20limb%20motor%20impairment%20by%20combining%20electrophysiological%2C%20anatomic%2C%20and%20functional%20neuroimaging%20data.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Forty%20ischemic%20stroke%20patients%20%28median%20%5Bmin%5Cu2013max%5D%20age%3A%2063%20%5B33%5Cu201382%5D%20years%2C%20time%20poststroke%3A%203.5%20%5B1.1%5Cu201358%5D%20months%29%20with%20unilateral%20upper%20limb%20weakness%20were%20included.%20The%20upper%20limb%20motor%20impairment%20was%20defined%20by%20a%20motor%20composite%20score.%20Simple%20linear%20analysis%20followed%20by%20multiple%20linear%20regression%20analysis%20were%20performed%20to%20identify%20which%20variables%20%28corticospinal%20excitability%2C%20laterality%20indices%20within%20the%20primary%20motor%20cortex%20or%20corticospinal%20%5BCST%5D%2C%20and%20corpus%20callosum%20tracts%20integrity%29%20were%20the%20best%20explaining%20factors%20of%20upper%20limb%20motor%20impairment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20There%20was%20a%20significant%20correlation%20between%20the%20resting%20motor%20threshold%20ratio%20and%20CST%20damage%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20r%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D%20%5Cu22120.50%20%5B95%25%20CI%2C%20%5Cu22120.70%20to%20%5Cu22120.22%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%20as%20well%20as%20the%20motor-evoked%20potentials%20amplitude%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20r%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D%20%5Cu22120.73%20%5B95%25%20CI%2C%20%5Cu22120.85%20to%20%5Cu22120.54%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%20Only%20the%20resting%20motor%20threshold%20ratio%20was%20retained%20by%20the%20multiple%20regression%20model%20and%20explained%20half%20of%20the%20variance%20%2849%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%20of%20the%20upper%20limb%20motor%20impairment%20after%20stroke.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20implementation%20of%20quantitative%20neurophysiological%20measurements%20such%20as%20the%20resting%20motor%20threshold%20as%20a%20surrogate%20marker%20of%20impairment%20could%20be%20considered%20in%20neurorehabilitation%20trials.%22%2C%22date%22%3A%2212%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.119.027126%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.119.027126%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22ZS67LCBJ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ntaios%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ENtaios%20G%2C%20Pearce%20LA%2C%20Meseguer%20E%2C%20Endres%20M%2C%20Amarenco%20P%2C%20Ozturk%20S%2C%20Lang%20W%2C%20Bornstein%20NM%2C%20Molina%20CA%2C%20Pagola%20J%2C%20Mundl%20H%2C%20Berkowitz%20SD%2C%20Liu%20YY%2C%20Sen%20S%2C%20Connolly%20SJ%2C%20Hart%20RG%2C%20on%20behalf%20of%20the%20NAVIGATE%20ESUS%20Investigators.%202019.%20Aortic%20Arch%20Atherosclerosis%20in%20Patients%20With%20Embolic%20Stroke%20of%20Undetermined%20Source%3A%20An%20Exploratory%20Analysis%20of%20the%20NAVIGATE%20ESUS%20Trial.%20Stroke%2050%3A3184%26%23x2013%3B3190.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Aortic%20Arch%20Atherosclerosis%20in%20Patients%20With%20Embolic%20Stroke%20of%20Undetermined%20Source%3A%20An%20Exploratory%20Analysis%20of%20the%20NAVIGATE%20ESUS%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Ntaios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lesly%20A.%22%2C%22lastName%22%3A%22Pearce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Endres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serefnur%22%2C%22lastName%22%3A%22Ozturk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilfried%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natan%20M.%22%2C%22lastName%22%3A%22Bornstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%20A.%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pagola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardi%22%2C%22lastName%22%3A%22Mundl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Berkowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%20Yun%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Souvik%22%2C%22lastName%22%3A%22Sen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20G.%22%2C%22lastName%22%3A%22Hart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20NAVIGATE%20ESUS%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aortic%20arch%20atherosclerosis%20%28AAA%29%20is%20a%20possible%20source%20of%20embolism%20in%20patients%20with%20embolic%20stroke%20of%20undetermined%20source.%20Previous%20studies%20reported%20high%20rates%20of%20embolic%20events%20in%20patients%20with%20AAA%2C%20especially%20those%20with%20high-risk%20AAA.%20This%20exploratory%20analysis%20of%20NAVIGATE%20ESUS%20%28New%20Approach%20Rivaroxaban%20Inhibition%20of%20Factor%20Xa%20in%20a%20Global%20Trial%20Versus%20ASA%20to%20Prevent%20Embolism%20in%20Embolic%20Stroke%20of%20Undetermined%20Source%29%20focused%20on%20patients%20with%20AAA%20and%20assessed%20their%20characteristics%2C%20stroke%20recurrence%20rates%2C%20and%20response%20to%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20detection%20of%20AAA%20and%20the%20assessment%20of%20its%20features%20were%20based%20on%20transesophageal%20echocardiography%20that%20was%20done%20in%2019%25%20of%20participants.%20AAA%20plaques%20were%20considered%20to%20have%20complex%20features%20when%20reported%20as%20complex%20or%20ulcerated%20or%20were%20%5Cu22654%20mm%20in%20thickness%20or%20had%20a%20mobile%20thrombus%20present.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%201382%20participants%20who%20had%20transesophageal%20echocardiography%2C%20397%20%2829%25%29%20had%20AAA%20and%20112%20%288%25%29%20had%20complex%20AAA.%20Mean%20%28SD%29%20age%20%2863%20%5B10%5D%20versus%2067%20%5B9%5D%20versus%2069%20%5B9%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20prevalence%20of%20diabetes%20mellitus%20%2819%25%20versus%2026%25%2C%20versus%2032%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.002%29%2C%20and%20aortic%20valvulopathy%20%2810%20versus%2020%20versus%2020%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%20increased%20across%20no%20versus%20noncomplex%20versus%20complex%20AAA%2C%20respectively.%20In%20multivariable%20analyses%2C%20increasing%20age%2C%20diabetes%20mellitus%2C%20aortic%20valvulopathy%2C%20statin%20use%20before%20randomization%2C%20chronic%20infarcts%20on%20imaging%2C%20and%20region%20were%20independently%20associated%20with%20any%20AAA%20versus%20no%20AAA%20and%20also%20with%20complex%20AAA%20versus%20no%20AAA.%20Multiterritorial%20qualifying%20infarcts%20rather%20than%20single-territory%20infarcts%20were%20observed%20in%2021%25%20with%20complex%20AAA%20versus%2017%25%20noncomplex%20versus%2013%25%20no%20AAA%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.07%29.%20Annualized%20rates%20of%20ischemic%20stroke%20recurrence%20were%207.2%25%20versus%204.2%25%20versus%205.6%25%20for%20complex%20versus%20noncomplex%20versus%20no%20AAA%2C%20respectively.%20While%20prevalence%20of%20complex%20AAA%20increased%20with%20increasing%20risk%20score%2C%20after%20adjusting%20for%20risk%20score%2C%20we%20did%20not%20observe%20increased%20risk%20of%20recurrent%20stroke%20for%20patients%20with%20complex%20AAA%20%28hazard%20ratio%2C%201.1%3B%2095%25%20CI%2C%200.53%5Cu20132.4%29%2C%20although%20the%20number%20of%20outcomes%20was%20limited.%20In%20patients%20with%20complex%20AAA%2C%204%20strokes%20occurred%20among%20rivaroxaban-assigned%20patients%20and%204%20strokes%20among%20aspirin-assigned%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Complex%20AAA%20is%20prevalent%20in%20embolic%20stroke%20of%20undetermined%20source%20patients%20and%20is%20associated%20with%20atherosclerotic%20burden.%20Whether%20complex%20AAA%20independently%20increases%20recurrent%20stroke%20risk%20and%20whether%20a%20non-vitamin-K%20oral%20anticoagulant%20as%20compared%20with%20aspirin%20may%20be%20effective%20for%20reducing%20recurrent%20stroke%20requires%20additional%20study.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT02313909.%22%2C%22date%22%3A%2211%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.119.025813%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.119.025813%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22RRURWJM2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ntaios%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ENtaios%20G%2C%20Swaminathan%20B%2C%20Berkowitz%20SD%2C%20Gagliardi%20RJ%2C%20Lang%20W%2C%20Siegler%20JE%2C%20Lavados%20P%2C%20Mundl%20H%2C%20Bornstein%20N%2C%20Meseguer%20E%2C%20Amarenco%20P%2C%20Cucchiara%20B%2C%20Camps-Renom%20P%2C%20Makaritsis%20K%2C%20Korompoki%20E%2C%20Papavasileiou%20V%2C%20Marti-Fabregas%20J%2C%20Milionis%20H%2C%20Vemmos%20K%2C%20Connolly%20SJ%2C%20Hart%20RG%2C%20on%20behalf%20of%20the%20NAVIGATE%20ESUS%20Investigators.%202019.%20Efficacy%20and%20Safety%20of%20Rivaroxaban%20Versus%20Aspirin%20in%20Embolic%20Stroke%20of%20Undetermined%20Source%20and%20Carotid%20Atherosclerosis.%20Stroke%2050%3A2477%26%23x2013%3B2485.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20Safety%20of%20Rivaroxaban%20Versus%20Aspirin%20in%20Embolic%20Stroke%20of%20Undetermined%20Source%20and%20Carotid%20Atherosclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Ntaios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Balakumar%22%2C%22lastName%22%3A%22Swaminathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Berkowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rubens%20Jos%5Cu00e9%22%2C%22lastName%22%3A%22Gagliardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilfried%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20E.%22%2C%22lastName%22%3A%22Siegler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Lavados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardi%22%2C%22lastName%22%3A%22Mundl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natan%22%2C%22lastName%22%3A%22Bornstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Cucchiara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pol%22%2C%22lastName%22%3A%22Camps-Renom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%22%2C%22lastName%22%3A%22Makaritsis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleni%22%2C%22lastName%22%3A%22Korompoki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vasileios%22%2C%22lastName%22%3A%22Papavasileiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan%22%2C%22lastName%22%3A%22Marti-Fabregas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haralampos%22%2C%22lastName%22%3A%22Milionis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%22%2C%22lastName%22%3A%22Vemmos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20G.%22%2C%22lastName%22%3A%22Hart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20NAVIGATE%20ESUS%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20sources%20of%20emboli%20in%20patients%20with%20embolic%20stroke%20of%20undetermined%20source%20%28ESUS%29%20are%20multiple%20and%20may%20not%20respond%20uniformly%20to%20anticoagulation.%20In%20this%20exploratory%20subgroup%20analysis%20of%20patients%20with%20carotid%20atherosclerosis%20in%20the%20NAVIGATE%20%28New%20Approach%20Rivaroxaban%20Inhibition%20of%20Factor%20Xa%20in%20a%20Global%20Trial%20Versus%20ASA%20to%20Prevent%20Embolism%29-ESUS%20trial%2C%20we%20assessed%20whether%20the%20treatment%20effect%20in%20this%20subgroup%20is%20consistent%20with%20the%20overall%20trial%20population%20and%20investigated%20the%20association%20of%20carotid%20atherosclerosis%20with%20recurrent%20ischemic%20stroke.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Carotid%20atherosclerosis%20was%20analyzed%20either%20as%20the%20presence%20of%20mild%20%28ie%2C%2020%25%5Cu201349%25%29%20atherosclerotic%20stenosis%20or%2C%20separately%2C%20as%20the%20presence%20of%20carotid%20plaque.%20Primary%20efficacy%20outcome%20was%20ischemic%20stroke%20recurrence.%20Safety%20outcomes%20were%20major%20bleeding%20and%20symptomatic%20intracerebral%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Carotid%20plaque%20was%20present%20in%2040%25%20of%20participants%20and%20mild%20carotid%20stenosis%20in%2011%25.%20There%20was%20no%20significant%20difference%20in%20ischemic%20stroke%20recurrence%20between%20rivaroxaban-%20and%20aspirin-treated%20patients%20among%20490%20patients%20with%20carotid%20stenosis%20%285.0%20versus%205.9%5C%2F100%20patient-years%2C%20respectively%2C%20hazard%20ratio%20%5BHR%5D%2C%200.85%3B%2095%25%20CI%2C%200.39%5Cu20131.87%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20for%20interaction%20of%20treatment%20effect%20with%20patients%20without%20carotid%20stenosis%200.78%29%20and%20among%202905%20patients%20with%20carotid%20plaques%20%285.9%20versus%204.9%5C%2F100%20patient-years%2C%20respectively%2C%20HR%2C%201.20%3B%2095%25%20CI%2C%200.86%5Cu20131.68%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20for%20interaction%20of%20treatment%20effect%20with%20patients%20without%20carotid%20stenosis%200.2%29.%20Among%20patients%20with%20carotid%20plaque%2C%20major%20bleeding%20was%20more%20frequent%20in%20rivaroxaban-treated%20patients%20compared%20with%20aspirin-treated%20%282.0%20versus%200.5%5C%2F100%20patient-years%2C%20HR%2C%203.75%3B%2095%25%20CI%2C%201.63%5Cu20138.65%29.%20Patients%20with%20carotid%20stenosis%20had%20similar%20rate%20of%20ischemic%20stroke%20recurrence%20compared%20with%20those%20without%20%285.4%20versus%204.9%5C%2F100%20patient-years%2C%20respectively%2C%20HR%2C%201.11%3B%2095%25%20CI%2C%200.73%5Cu20131.69%29%2C%20but%20there%20was%20a%20strong%20trend%20of%20higher%20rate%20of%20ischemic%20stroke%20recurrence%20in%20patients%20with%20carotid%20plaque%20compared%20with%20those%20without%20%285.4%20versus%204.3%5C%2F100%20patient-years%2C%20respectively%2C%20HR%2C%201.23%3B%2095%25%20CI%2C%200.99%5Cu20131.54%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20ESUS%20patients%20with%20carotid%20atherosclerosis%2C%20we%20found%20no%20difference%20in%20efficacy%20between%20rivaroxaban%20and%20aspirin%20for%20prevention%20of%20recurrent%20stroke%2C%20but%20aspirin%20was%20safer%2C%20consistent%20with%20the%20overall%20trial%20results.%20Carotid%20plaque%20was%20much%20more%20often%20present%20ipsilateral%20to%20the%20qualifying%20ischemic%20stroke%20than%20contralateral%2C%20supporting%20an%20important%20etiological%20role%20of%20nonstenotic%20carotid%20disease%20in%20ESUS.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT02313909.%22%2C%22date%22%3A%2209%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.119.025168%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.119.025168%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A38Z%22%7D%7D%2C%7B%22key%22%3A%2234R2KFDC%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abboud%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbboud%20H%2C%20Monteiro%20Tavares%20L%2C%20Labreuche%20J%2C%20Arauz%20A%2C%20Bryer%20A%2C%20Lavados%20PM%2C%20Massaro%20A%2C%20Munoz%20Collazos%20M%2C%20Steg%20PG%2C%20Yamout%20BI%2C%20Vicaut%20E%2C%20Amarenco%20P%2C%20for%20the%20OPTIC%20Registry%20Investigators.%202019.%20Impact%20of%20Low%20Ankle-Brachial%20Index%20on%20the%20Risk%20of%20Recurrent%20Vascular%20Events%3A%20Insights%20From%20the%20OPTIC%20Registry.%20Stroke%2050%3A853%26%23x2013%3B858.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Low%20Ankle-Brachial%20Index%20on%20the%20Risk%20of%20Recurrent%20Vascular%20Events%3A%20Insights%20From%20the%20OPTIC%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Halim%22%2C%22lastName%22%3A%22Abboud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linsay%22%2C%22lastName%22%3A%22Monteiro%20Tavares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Arauz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%22%2C%22lastName%22%3A%22Bryer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20M.%22%2C%22lastName%22%3A%22Lavados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayrton%22%2C%22lastName%22%3A%22Massaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Munoz%20Collazos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bassem%20I.%22%2C%22lastName%22%3A%22Yamout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20OPTIC%20Registry%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Low%20ankle-brachial%20index%20%28ABI%29%20identifies%20a%20stroke%20subgroup%20with%20high%20risk%20of%20recurrent%20stroke%2C%20cardiovascular%20events%2C%20and%20death.%20However%2C%20limited%20data%20exist%20on%20the%20relationship%20between%20low%20ABI%20and%20stroke%20in%20low%20and%20middle-income%20countries.%20Therefore%2C%20we%20evaluated%20the%20prevalence%20of%20ABI%20%5Cu22640.90%20%28which%20is%20diagnostic%20of%20peripheral%20artery%20disease%29%20in%20nonembolic%20stroke%20patients%20or%20transient%20ischemic%20attack%20and%20assessed%20the%20correlation%20of%20low%20ABI%20with%20stroke%20risk%2C%20factors%2C%20and%20recurrent%20vascular%20events%20and%20death.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20%5Cu226545%20years%20with%20acute%20transient%20ischemic%20attack%20or%20minor%20ischemic%20strokes%20were%20recruited%20consecutively%20from%20over%2017%20low-income%20and%20middle-income%20countries%20%28Latin%20America%20%5B1543%20patients%5D%2C%20Middle%20East%20%5B1041%20patients%5D%2C%20North%20Africa%20%5B834%20patients%5D%2C%20and%20South%20Africa%20%5B217%20patients%5D%29.%20The%20ABI%20measurement%20was%20performed%20at%20a%20single%20visit.%20Stroke%20recurrence%20and%20risk%20of%20new%20vascular%20events%20were%20assessed%20after%2024%20months%20of%20follow-up.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%203487%20enrolled%20patients%2C%20abnormal%20ABI%20%28%3C0.9%29%20was%20present%20in%2022.3%20%25.%20Patients%20with%20an%20ABI%20of%20%5Cu22640.9%20were%20more%20likely%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.05%29%20to%20be%20male%2C%20older%2C%20and%20have%20a%20history%20of%20peripheral%20artery%20disease%2C%20hypertension%2C%20and%20diabetes%20mellitus.%20During%202-year%20follow-up%2C%20the%20rate%20of%20major%20cardiovascular%20event%20was%20higher%20in%20patients%20with%20ABI%20%3C0.9%20than%20those%20with%20ABI%20%5Cu22650.9%20%28Kaplan-Meier%20estimates%2C%2022.5%25%3B%2095%25%20CI%2C%2019.6%5Cu201325.8%20versus%2013.7%25%3B%2021.4%5Cu201315.1%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20and%20when%20ABI%20was%20categorized%20into%204%20groups%20%28%5Cu22640.6%3B%2095%25%20CI%2C%200.6%5Cu20130.9%3B%200.9%5Cu20131%3B%201%5Cu20131.4%29%2C%20the%20rate%20of%20major%20cardiovascular%20event%20was%20higher%20in%20those%20with%20ABI%20%5Cu22640.6%20than%20the%20other%20groups%20%28Kaplan-Meier%20estimates%2C%2032.6%25%3B%2095%25%20CI%2C%2021.0%5Cu201348.3%20for%20ABI%5Cu22640.6%20versus%2021.7%25%3B%2095%25%20CI%2C%2018.8%5Cu201325.0%20for%20ABI%200.6%5Cu20130.9%20versus%2014.3%25%3B%2095%25%20CI%2C%2012.4%5Cu201316.6%20for%20ABI%200.9%5Cu20131%20versus%2013.3%25%3B%2095%25%20CI%2C%2011.6%5Cu201315.2%20for%20ABI%201%5Cu20131.4%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20patients%20with%20nonembolic%20ischemic%20stroke%20or%20transient%20ischemic%20attack%2C%20those%20with%20low%20ABI%20had%20a%20higher%20rate%20of%20vascular%20events%20and%20death%20in%20this%20population.%20Screening%20for%20ABI%20in%20stroke%20patients%20may%20help%20identify%20patients%20at%20high%20risk%20of%20future%20events.%22%2C%22date%22%3A%2204%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.118.022180%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.118.022180%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22PDL3C6QV%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Desnos%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDesnos%20C%2C%20Iung%20B%2C%20Himbert%20D%2C%20Ducrocq%20G%2C%20Urena%20M%2C%20Cormier%20B%2C%20Brochet%20E%2C%20Ou%20P%2C%20Vahanian%20A%2C%20Bouleti%20C.%202019.%20Temporal%20Trends%20on%20Percutaneous%20Mitral%20Commissurotomy%3A%2030%20Years%20of%20Experience.%20JAHA%208%3Ae012031.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Temporal%20Trends%20on%20Percutaneous%20Mitral%20Commissurotomy%3A%2030%20Years%20of%20Experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrielle%22%2C%22lastName%22%3A%22Desnos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Iung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Himbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Urena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Cormier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Brochet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phalla%22%2C%22lastName%22%3A%22Ou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alec%22%2C%22lastName%22%3A%22Vahanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Bouleti%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Percutaneous%20mitral%20commissurotomy%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20was%20the%20first%20available%20transcatheter%20technique%20for%20treatment%20of%20mitral%20valve%20diseases.%20Experience%20has%20led%20to%20extending%20the%20indications%20to%20patients%20with%20less%20favorable%20characteristics.%20We%20aimed%20to%20analyze%20%281%29%20the%20temporal%20trends%20in%20characteristic%20and%20outcomes%20of%20patients%20undergoing%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20in%20a%20single%20center%20over%2030%5Cu00a0years%20and%20%282%29%20the%20predictive%20factors%20of%20poor%20immediate%20results%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20From%201987%20to%202016%2C%201%20full%20year%20for%20each%20decade%20was%20analyzed%3A%201987%2C%201996%2C%202006%2C%20and%202016.%20Poor%20immediate%20results%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20were%20defined%20as%20a%20mitral%20valve%20area%20%3C1.5%5Cu00a0cm%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20or%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20MR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28mitral%20regurgitation%29%20grade%20%3E2.%20Mitral%20anatomy%20was%20assessed%20using%20the%20Cormier%20classification%20and%20the%20fluoroscopic%20extent%20of%20calcification.%20Six%20hundred%20three%20patients%20were%20included%3A%20111%2C%20202%2C%20205%2C%20and%2085%2C%20respectively.%20Mean%20age%20increased%20%3E10%5Cu00a0years%20over%20time%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29.%20Mitral%20anatomy%20was%20less%20favorable%20over%20the%20years%3A%20the%20presence%20of%20calcification%20increased%20from%2025%25%20of%20patients%20at%20the%20beginning%20of%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20to%20%3E40%25%20during%20the%20past%20decade%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%20with%20a%203%5Cu2010fold%20increase%20in%20severe%20mitral%20calcification.%20Consistently%2C%20the%20proportion%20of%20good%20immediate%20results%20decreased%20over%20time%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.05%29%20but%20remained%20at%2076%25%20in%202016.%20Multivariate%20analysis%20showed%203%20predictive%20factors%20of%20poor%20immediate%20results%3A%20smaller%20baseline%20mitral%20valve%20area%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%2C%20pre%5Cu2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%20MR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20grade%202%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.01%29%2C%20and%20the%20presence%20or%20amount%20of%20calcification%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20clinic%27s%20patients%20became%20significantly%20older%20with%20more%20frequent%20and%20severe%20calcification%20in%20the%20past%20decade.%20Predictive%20factors%20of%20poor%20immediate%20results%20were%20related%20to%20valve%20anatomy%2C%20including%20calcification.%20Despite%20challenges%20raised%20by%20severe%20calcification%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20PMC%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20was%20still%20successful%20in%20%3E3%20out%20of%204%20patients%20in%20recent%20years.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%2C%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20See%20Editorial%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Palacios%22%2C%22date%22%3A%222019-07-02%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.119.012031%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.119.012031%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22XTFLN5GT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Himbert%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHimbert%20D%2C%20Urena%20M%2C%20Ducrocq%20G.%202019.%20Is%20Transcatheter%20Aortic%20Valve%20Replacement%20Becoming%20the%20Standard%20of%20Care%20in%20Octogenarians%3F%20JAHA%208%3Ae011833.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Is%20Transcatheter%20Aortic%20Valve%20Replacement%20Becoming%20the%20Standard%20of%20Care%20in%20Octogenarians%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Himbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Urena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%5D%2C%22abstractNote%22%3A%22See%20Article%20by%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Sheng%20et%20al%22%2C%22date%22%3A%222019-01-22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.118.011833%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.118.011833%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22VW3U3LRC%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jukema%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EJukema%20JW%2C%20Zijlstra%20LE%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Diaz%20R%2C%20Drexel%20H%2C%20Goodman%20SG%2C%20Kim%20Y-U%2C%20Pordy%20R%2C%20Reiner%20%26%23x17D%3B%2C%20Roe%20MT%2C%20Tse%20H-F%2C%20Montenegro%20Valdovinos%20PC%2C%20White%20HD%2C%20Zeiher%20AM%2C%20Szarek%20M%2C%20Schwartz%20GG%2C%20Steg%20PG%2C%20For%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202019.%20Effect%20of%20Alirocumab%20on%20Stroke%20in%20ODYSSEY%20OUTCOMES.%20Circulation%20140%3A2054%26%23x2013%3B2062.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Alirocumab%20on%20Stroke%20in%20ODYSSEY%20OUTCOMES%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurien%20E.%22%2C%22lastName%22%3A%22Zijlstra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heinz%22%2C%22lastName%22%3A%22Drexel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Un%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu017deljko%22%2C%22lastName%22%3A%22Reiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hung-Fat%22%2C%22lastName%22%3A%22Tse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20Carlos%22%2C%22lastName%22%3A%22Montenegro%20Valdovinos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M.%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22For%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Lowering%20of%20atherogenic%20lipoproteins%2C%20including%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%2C%20reduces%20the%20risk%20of%20ischemic%20stroke.%20However%2C%20concerns%20have%20been%20raised%20about%20very%20low%20LDL-C%20levels%20and%20a%20potential%20increased%20risk%20of%20hemorrhagic%20stroke.%20ODYSSEY%20OUTCOMES%20compared%20the%20PCSK9%20inhibitor%20alirocumab%20with%20placebo%20in%2018%20924%20patients%20with%20recent%20acute%20coronary%20syndrome%20and%20elevated%20atherogenic%20lipoproteins%2C%20despite%20intensive%20statin%20therapy%2C%20targeting%20LDL-C%20levels%20of%2025%20to%2050%20mg%5C%2FdL%20and%20avoiding%20sustained%20LDL-C%20%3C15%20mg%5C%2FdL.%20This%20prespecified%20analysis%20was%20designed%20to%20assess%20the%20effect%20of%20alirocumab%20on%20ischemic%20and%20hemorrhagic%20stroke.%20We%20hypothesized%20that%20for%20patients%20treated%20with%20alirocumab%20there%20would%20be%20a%20reduction%20in%20risk%20of%20ischemic%20stroke%20without%20increasing%20hemorrhagic%20stroke%2C%20irrespective%20of%20baseline%20LDL-C%20and%20of%20history%20of%20cerebrovascular%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20were%20randomized%20to%20alirocumab%20or%20placebo%201%20to%2012%20months%20after%20acute%20coronary%20syndrome.%20The%20risk%20of%20nonfatal%20or%20fatal%20ischemic%20or%20hemorrhagic%20stroke%20was%20evaluated%2C%20stratified%20by%20baseline%20LDL-C%20concentration%20and%20history%20of%20cerebrovascular%20disease.%20A%20potential%20association%20of%20very%20low%20achieved%20LDL-C%20with%20alirocumab%20treatment%20at%20month%204%20and%20subsequent%20hemorrhagic%20stroke%20was%20assessed.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Median%20follow-up%20was%202.8%20years.%20In%20total%2C%20263%20ischemic%20and%2033%20hemorrhagic%20strokes%20occurred.%20Alirocumab%20reduced%20the%20risk%20of%20any%20stroke%20%28HR%2C%200.72%20%5B95%25%20CI%2C%200.57%5Cu22120.91%5D%29%20and%20ischemic%20stroke%20%28HR%2C%200.73%20%5B95%25%20CI%2C%200.57%5Cu22120.93%5D%29%20without%20increasing%20hemorrhagic%20stroke%20%28HR%2C%200.83%20%5B95%25%20CI%2C%200.42%5Cu22121.65%5D%29.%20In%20total%2C%207164%20%2837.9%25%29%2C%206128%20%2832.4%25%29%2C%20and%205629%20%2829.7%25%29%20patients%20had%20a%20baseline%20LDL-C%20of%20%3C80%2C%2080%20to%20100%2C%20and%20%3E100%20mg%5C%2FdL%2C%20respectively.%20The%20treatment%20effect%20on%20stroke%20appeared%20numerically%20greater%20for%20patients%20with%20higher%20baseline%20LDL-C%2C%20but%20there%20was%20no%20formal%20evidence%20of%20heterogeneity%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.31%29.%20The%20effect%20of%20alirocumab%20on%20stroke%20was%20similar%20among%20944%20patients%20%285.0%25%29%20with%20a%20history%20of%20previous%20cerebrovascular%20disease%20and%20among%20those%20without%20a%20history%20of%20cerebrovascular%20disease%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.37%29.%20There%20was%20no%20apparent%20adverse%20relation%20between%20lower%20achieved%20LDL-C%20and%20incidence%20of%20hemorrhagic%20stroke%20in%20the%20alirocumab%20group.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20recent%20acute%20coronary%20syndrome%20and%20dyslipidemia%20despite%20intensive%20statin%20therapy%2C%20alirocumab%20decreased%20the%20risk%20of%20stroke%2C%20irrespective%20of%20baseline%20LDL-C%20and%20history%20of%20cerebrovascular%20disease%2C%20over%20a%20median%20follow-up%20of%202.8%20years.%20Furthermore%2C%20risk%20of%20hemorrhagic%20stroke%20did%20not%20depend%20on%20achieved%20LDL-C%20levels%20within%20the%20alirocumab%20group.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01663402.%22%2C%22date%22%3A%222019-12-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.119.043826%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.119.043826%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22SZPYQY58%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roe%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ERoe%20MT%2C%20Li%20QH%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Diaz%20R%2C%20Goodman%20SG%2C%20Harrington%20RA%2C%20Jukema%20JW%2C%20Lopez-Jaramillo%20P%2C%20Lopes%20RD%2C%20Louie%20MJ%2C%20Moriarty%20PM%2C%20Szarek%20M%2C%20Vogel%20R%2C%20White%20HD%2C%20Zeiher%20AM%2C%20Baccara-Dinet%20MT%2C%20Steg%20PhG%2C%20Schwartz%20GG%2C%20For%20the%20ODYSSEY%20OUTCOMES%20Investigators.%202019.%20Risk%20Categorization%20Using%20New%20American%20College%20of%20Cardiology%5C%2FAmerican%20Heart%20Association%20Guidelines%20for%20Cholesterol%20Management%20and%20Its%20Relation%20to%20Alirocumab%20Treatment%20Following%20Acute%20Coronary%20Syndromes.%20Circulation%20140%3A1578%26%23x2013%3B1589.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk%20Categorization%20Using%20New%20American%20College%20of%20Cardiology%5C%2FAmerican%20Heart%20Association%20Guidelines%20for%20Cholesterol%20Management%20and%20Its%20Relation%20to%20Alirocumab%20Treatment%20Following%20Acute%20Coronary%20Syndromes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qian%20H.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricio%22%2C%22lastName%22%3A%22Lopez-Jaramillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Louie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20M.%22%2C%22lastName%22%3A%22Moriarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M.%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20T.%22%2C%22lastName%22%3A%22Baccara-Dinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22For%20the%20ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%202018%20US%20cholesterol%20management%20guidelines%20recommend%20additional%20lipid-lowering%20therapies%20for%20secondary%20prevention%20in%20patients%20with%20low-density%20lipoprotein%20cholesterol%20%5Cu226570%20mg%5C%2FdL%20or%20non%5Cu2212high-density%20lipoprotein%20cholesterol%20%5Cu2265100%20mg%5C%2FdL%20despite%20maximum%20tolerated%20statin%20therapy.%20Such%20patients%20are%20considered%20at%20very%20high%20risk%20%28VHR%29%20based%20on%20a%20history%20of%20%3E1%20major%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%20event%20or%20a%20single%20ASCVD%20event%20and%20multiple%20high-risk%20conditions.%20We%20investigated%20the%20association%20of%20US%20guideline-defined%20risk%20categories%20with%20the%20occurrence%20of%20ischemic%20events%20after%20acute%20coronary%20syndrome%20and%20reduction%20of%20those%20events%20by%20alirocumab%2C%20a%20PCSK9%20%28proprotein%20convertase%20subtilisin%5C%2Fkexin%20type%209%29%20inhibitor.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20ODYSSEY%20OUTCOMES%20trial%20%28Evaluation%20of%20Cardiovascular%20Outcomes%20After%20an%20Acute%20Coronary%20Syndrome%20During%20Treatment%20With%20Alirocumab%29%2C%20patients%20with%20recent%20acute%20coronary%20syndrome%20and%20residual%20dyslipidemia%20despite%20optimal%20statin%20therapy%20were%20randomly%20assigned%20to%20alirocumab%20or%20placebo.%20The%20primary%20trial%20outcome%20%28major%20adverse%20cardiovascular%20events%2C%20ie%2C%20coronary%20heart%20disease%20death%2C%20nonfatal%20myocardial%20infarction%2C%20ischemic%20stroke%2C%20or%20hospitalization%20for%20unstable%20angina%29%20was%20examined%20according%20to%20American%20College%20of%20Cardiology%5C%2FAmerican%20Heart%20Association%20risk%20category.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Of%2018%5Cu2009924%20participants%20followed%20for%20a%20median%20of%202.8%20years%2C%2011%5Cu2009935%20%2863.1%25%29%20were%20classified%20as%20VHR%3A%204450%20%2837.3%25%29%20had%20multiple%20prior%20ASCVD%20events%20and%207485%20%2862.7%25%29%20had%201%20major%20ASCVD%20event%20and%20multiple%20high-risk%20conditions.%20Major%20adverse%20cardiovascular%20events%20occurred%20in%2014.4%25%20of%20placebo-treated%20patients%20at%20VHR%20versus%205.6%25%20of%20those%20not%20at%20VHR.%20In%20the%20VHR%20category%2C%20major%20adverse%20cardiovascular%20events%20occurred%20in%2020.4%25%20with%20multiple%20prior%20ASCVD%20events%20versus%2010.7%25%20with%201%20ASCVD%20event%20and%20multiple%20high-risk%20conditions.%20Alirocumab%20was%20associated%20with%20consistent%20relative%20risk%20reductions%20in%20both%20risk%20categories%20%28hazard%20ratio%3D0.84%20for%20VHR%3B%20hazard%20ratio%3D0.86%20for%20not%20VHR%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.820%29%20and%20by%20stratification%20within%20the%20VHR%20group%20%28hazard%20ratio%3D0.86%20for%20multiple%20prior%20ASCVD%20events%3B%20hazard%20ratio%3D0.82%20for%201%20major%20ASCVD%20event%20and%20multiple%20high-risk%20conditions%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.672%29.%20The%20absolute%20risk%20reduction%20for%20major%20adverse%20cardiovascular%20events%20with%20alirocumab%20was%20numerically%20greater%20%28but%20not%20statistically%20different%29%20in%20the%20VHR%20group%20versus%20those%20not%20at%20VHR%20%282.1%25%20versus%200.8%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.095%29%20and%20among%20patients%20at%20VHR%20with%20multiple%20prior%20ASCVD%20events%20versus%20a%20single%20prior%20ASCVD%20event%20%282.4%25%20versus%201.8%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.661%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20US%20guideline%20criteria%20identify%20patients%20with%20recent%20acute%20coronary%20syndrome%20and%20dyslipidemia%20who%20are%20at%20VHR%20for%20recurrent%20ischemic%20events%20and%20who%20may%20derive%20a%20larger%20absolute%20benefit%20from%20treatment%20with%20alirocumab.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01663402.%22%2C%22date%22%3A%222019-11-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.119.042551%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.119.042551%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22QLQEATMK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bergmark%20et%20al.%22%2C%22parsedDate%22%3A%222019-09-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBergmark%20BA%2C%20Bhatt%20DL%2C%20McGuire%20DK%2C%20Cahn%20A%2C%20Mosenzon%20O%2C%20Steg%20PhG%2C%20Im%20K%2C%20Kanevsky%20E%2C%20Gurmu%20Y%2C%20Raz%20I%2C%20Braunwald%20E%2C%20Scirica%20BM%2C%20On%20behalf%20of%20the%20SAVOR-TIMI%2053%20Steering%20Committee%20and%20Investigators.%202019.%20Metformin%20Use%20and%20Clinical%20Outcomes%20Among%20Patients%20With%20Diabetes%20Mellitus%20With%20or%20Without%20Heart%20Failure%20or%20Kidney%20Dysfunction%3A%20Observations%20From%20the%20SAVOR-TIMI%2053%20Trial.%20Circulation%20140%3A1004%26%23x2013%3B1014.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metformin%20Use%20and%20Clinical%20Outcomes%20Among%20Patients%20With%20Diabetes%20Mellitus%20With%20or%20Without%20Heart%20Failure%20or%20Kidney%20Dysfunction%3A%20Observations%20From%20the%20SAVOR-TIMI%2053%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20A.%22%2C%22lastName%22%3A%22Bergmark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20K.%22%2C%22lastName%22%3A%22McGuire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Avivit%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ofri%22%2C%22lastName%22%3A%22Mosenzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22KyungAh%22%2C%22lastName%22%3A%22Im%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estella%22%2C%22lastName%22%3A%22Kanevsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Gurmu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Itamar%22%2C%22lastName%22%3A%22Raz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Braunwald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20M.%22%2C%22lastName%22%3A%22Scirica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22On%20behalf%20of%20the%20SAVOR-TIMI%2053%20Steering%20Committee%20and%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Metformin%20is%20first-line%20therapy%20for%20type%202%20diabetes%20mellitus%2C%20although%20its%20effects%20on%20the%20cardiovascular%20system%20are%20unproved.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20post%20hoc%20analysis%2C%20patients%20in%20SAVOR-TIMI%2053%20%28Saxagliptin%20and%20Cardiovascular%20Outcomes%20in%20Patients%20With%20Type%202%20Diabetes%20Mellitus%29%20with%20baseline%20biomarker%20samples%20%28n%3D12%5Cu2009156%29%20were%20classified%20as%20ever%20versus%20never%20taking%20metformin%20during%20the%20trial%20period.%20Associations%20between%20metformin%20exposure%20and%20outcomes%20were%20estimated%20with%20inverse%20probability%20of%20treatment%20weighting%20Cox%20modeling%20for%20the%20composite%20end%20point%20of%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20ischemic%20stroke%2C%20as%20well%20as%20cardiovascular%20death%20and%20all-cause%20mortality%2C%20with%20biomarkers%20included%20as%20covariates.%20Additional%20sensitivity%20analyses%20included%20propensity%20score%20matching%20and%20Cox%20multivariable%20models.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Of%20the%2012%5Cu2009156%20patients%20with%20baseline%20biomarker%20samples%2C%208971%20%2874%25%29%20had%20metformin%20exposure%2C%201611%20%2813%25%29%20had%20prior%20heart%20failure%2C%20and%201332%20%2811%25%29%20had%20at%20least%20moderate%20chronic%20kidney%20disease%20%28estimated%20glomerular%20filtration%20rate%20%5Cu226445%20mL%5Cu00b7min%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu22121%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu00b71.73%20m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu22122%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29.%20Metformin%20use%20was%20associated%20with%20no%20difference%20in%20risk%20for%20the%20composite%20end%20point%20%28hazard%20ratio%20for%20inverse%20probability%20of%20treatment%20weighting%2C%200.92%20%5B95%25%20CI%2C%200.76%5Cu20131.11%5D%29%20but%20lower%20risk%20of%20all-cause%20mortality%20%28hazard%20ratio%20for%20inverse%20probability%20of%20treatment%20weighting%2C%200.75%20%5B95%25%20CI%2C%200.59%5Cu20130.95%5D%29.%20There%20was%20no%20significant%20relationship%20between%20metformin%20use%20and%20these%20end%20points%20in%20patients%20with%20prior%20heart%20failure%20or%20moderate%20to%20severe%20chronic%20kidney%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20a%20cohort%20of%2012%5Cu2009156%20patients%20with%20type%202%20diabetes%20mellitus%20and%20high%20cardiovascular%20risk%2C%20metformin%20use%20was%20associated%20with%20lower%20rates%20of%20all-cause%20mortality%2C%20including%20after%20adjustment%20for%20clinical%20variables%20and%20biomarkers%2C%20but%20not%20lower%20rates%20of%20the%20composite%20end%20point%20of%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20ischemic%20stroke.%20This%20association%20was%20most%20apparent%20in%20patients%20without%20prior%20heart%20failure%20or%20moderate%20to%20severe%20chronic%20kidney%20disease.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01107886.%22%2C%22date%22%3A%222019-09-17%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.119.040144%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.119.040144%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22IGGE2X5E%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Steg%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESteg%20PG%2C%20Szarek%20M%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Br%26%23xE9%3Bgeault%20M-F%2C%20Dalby%20AJ%2C%20Diaz%20R%2C%20Edelberg%20JM%2C%20Goodman%20SG%2C%20Hanotin%20C%2C%20Harrington%20RA%2C%20Jukema%20JW%2C%20Lecorps%20G%2C%20Mahaffey%20KW%2C%20Moryusef%20A%2C%20Ostadal%20P%2C%20Parkhomenko%20A%2C%20Pordy%20R%2C%20Roe%20MT%2C%20Tricoci%20P%2C%20Vogel%20R%2C%20White%20HD%2C%20Zeiher%20AM%2C%20Schwartz%20GG%2C%20For%20the%20ODYSSEY%20OUTCOMES%20Committees%20and%20Investigators%26%23x2020%3B.%202019.%20Effect%20of%20Alirocumab%20on%20Mortality%20After%20Acute%20Coronary%20Syndromes%3A%20An%20Analysis%20of%20the%20ODYSSEY%20OUTCOMES%20Randomized%20Clinical%20Trial.%20Circulation%20140%3A103%26%23x2013%3B112.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Alirocumab%20on%20Mortality%20After%20Acute%20Coronary%20Syndromes%3A%20An%20Analysis%20of%20the%20ODYSSEY%20OUTCOMES%20Randomized%20Clinical%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-France%22%2C%22lastName%22%3A%22Br%5Cu00e9geault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20J.%22%2C%22lastName%22%3A%22Dalby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%20M.%22%2C%22lastName%22%3A%22Edelberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Hanotin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Lecorps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W.%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e8le%22%2C%22lastName%22%3A%22Moryusef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Ostadal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierluigi%22%2C%22lastName%22%3A%22Tricoci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M.%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22For%20the%20ODYSSEY%20OUTCOMES%20Committees%20and%20Investigators%5Cu2020%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Previous%20trials%20of%20PCSK9%20%28proprotein%20convertase%20subtilisin-kexin%20type%209%29%20inhibitors%20demonstrated%20reductions%20in%20major%20adverse%20cardiovascular%20events%2C%20but%20not%20death.%20We%20assessed%20the%20effects%20of%20alirocumab%20on%20death%20after%20index%20acute%20coronary%20syndrome.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ODYSSEY%20OUTCOMES%20%28Evaluation%20of%20Cardiovascular%20Outcomes%20After%20an%20Acute%20Coronary%20Syndrome%20During%20Treatment%20With%20Alirocumab%29%20was%20a%20double-blind%2C%20randomized%20comparison%20of%20alirocumab%20or%20placebo%20in%2018%20924%20patients%20who%20had%20an%20ACS%201%20to%2012%20months%20previously%20and%20elevated%20atherogenic%20lipoproteins%20despite%20intensive%20statin%20therapy.%20Alirocumab%20dose%20was%20blindly%20titrated%20to%20target%20achieved%20low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20between%2025%20and%2050%20mg%5C%2FdL.%20We%20examined%20the%20effects%20of%20treatment%20on%20all-cause%20death%20and%20its%20components%2C%20cardiovascular%20and%20noncardiovascular%20death%2C%20with%20log-rank%20testing.%20Joint%20semiparametric%20models%20tested%20associations%20between%20nonfatal%20cardiovascular%20events%20and%20cardiovascular%20or%20noncardiovascular%20death.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Median%20follow-up%20was%202.8%20years.%20Death%20occurred%20in%20334%20%283.5%25%29%20and%20392%20%284.1%25%29%20patients%2C%20respectively%2C%20in%20the%20alirocumab%20and%20placebo%20groups%20%28hazard%20ratio%20%5BHR%5D%2C%200.85%3B%2095%25%20CI%2C%200.73%20to%200.98%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%2C%20nominal%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20value%29.%20This%20resulted%20from%20nonsignificantly%20fewer%20cardiovascular%20%28240%20%5B2.5%25%5D%20vs%20271%20%5B2.9%25%5D%3B%20HR%2C%200.88%3B%2095%25%20CI%2C%200.74%20to%201.05%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.15%29%20and%20noncardiovascular%20%2894%20%5B1.0%25%5D%20vs%20121%20%5B1.3%25%5D%3B%20HR%2C%200.77%3B%2095%25%20CI%2C%200.59%20to%201.01%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.06%29%20deaths%20with%20alirocumab.%20In%20a%20prespecified%20analysis%20of%208242%20patients%20eligible%20for%20%5Cu22653%20years%20follow-up%2C%20alirocumab%20reduced%20death%20%28HR%2C%200.78%3B%2095%25%20CI%2C%200.65%20to%200.94%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.01%29.%20Patients%20with%20nonfatal%20cardiovascular%20events%20were%20at%20increased%20risk%20for%20cardiovascular%20and%20noncardiovascular%20deaths%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%20for%20the%20associations%29.%20Alirocumab%20reduced%20total%20nonfatal%20cardiovascular%20events%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%20and%20thereby%20may%20have%20attenuated%20the%20number%20of%20cardiovascular%20and%20noncardiovascular%20deaths.%20A%20post%20hoc%20analysis%20found%20that%2C%20compared%20to%20patients%20with%20lower%20LDL-C%2C%20patients%20with%20baseline%20LDL-C%20%5Cu2265100%20mg%5C%2FdL%20%282.59%20mmol%5C%2FL%29%20had%20a%20greater%20absolute%20risk%20of%20death%20and%20a%20larger%20mortality%20benefit%20from%20alirocumab%20%28HR%2C%200.71%3B%2095%25%20CI%2C%200.56%20to%200.90%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.007%29.%20In%20the%20alirocumab%20group%2C%20all-cause%20death%20declined%20with%20achieved%20LDL-C%20at%204%20months%20of%20treatment%2C%20to%20a%20level%20of%20approximately%2030%20mg%5C%2FdL%20%28adjusted%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.017%20for%20linear%20trend%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Alirocumab%20added%20to%20intensive%20statin%20therapy%20has%20the%20potential%20to%20reduce%20death%20after%20acute%20coronary%20syndrome%2C%20particularly%20if%20treatment%20is%20maintained%20for%20%5Cu22653%20years%2C%20if%20baseline%20LDL-C%20is%20%5Cu2265100%20mg%5C%2FdL%2C%20or%20if%20achieved%20LDL-C%20is%20low.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01663402.%22%2C%22date%22%3A%222019-07-09%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.118.038840%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.118.038840%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22Q7F9272I%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Szarek%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESzarek%20M%2C%20Steg%20PhG%2C%20DiCenso%20D%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Budaj%20A%2C%20Diaz%20R%2C%20Goodman%20SG%2C%20Gotcheva%20N%2C%20Jukema%20JW%2C%20Pordy%20R%2C%20Roe%20MT%2C%20Sourdille%20T%2C%20White%20HD%2C%20Xavier%20D%2C%20Zeiher%20AM%2C%20Schwartz%20GG%2C%20for%20the%20ODYSSEY%20OUTCOMES%20Committees%20and%20Investigators%2A.%202019.%20Alirocumab%20Reduces%20Total%20Hospitalizations%20and%20Increases%20Days%20Alive%20and%20Out%20of%20Hospital%20in%20the%20ODYSSEY%20OUTCOMES%20Trial.%20Circ%3A%20Cardiovascular%20Quality%20and%20Outcomes%2012%3Ae005858.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Alirocumab%20Reduces%20Total%20Hospitalizations%20and%20Increases%20Days%20Alive%20and%20Out%20of%20Hospital%20in%20the%20ODYSSEY%20OUTCOMES%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dina%22%2C%22lastName%22%3A%22DiCenso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A.%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrzej%22%2C%22lastName%22%3A%22Budaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22Gotcheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timoth%5Cu00e9e%22%2C%22lastName%22%3A%22Sourdille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Xavier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M.%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20ODYSSEY%20OUTCOMES%20Committees%20and%20Investigators%2A%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20ODYSSEY%20OUTCOMES%20%28Evaluation%20of%20Cardiovascular%20Outcomes%20After%20an%20Acute%20Coronary%20Syndrome%20During%20Treatment%20With%20Alirocumab%29%2C%20alirocumab%20was%20compared%20with%20placebo%2C%20added%20to%20high-intensity%20or%20maximum%20tolerated%20statin%20treatment%20after%20acute%20coronary%20syndrome%20in%2018%5Cu2009924%20patients.%20Alirocumab%20reduced%20first%20occurrence%20of%20the%20primary%20composite%20end%20point%5Cu2014coronary%20heart%20disease%20death%2C%20nonfatal%20myocardial%20infarction%2C%20fatal%20or%20nonfatal%20ischemic%20stroke%2C%20or%20hospitalization%20for%20unstable%20angina%5Cu2014as%20well%20as%20total%20nonfatal%20cardiovascular%20events%20and%20all-cause%20deaths.%20The%20present%20analysis%20determined%20whether%20alirocumab%20reduced%20total%20%28first%20and%20subsequent%29%20hospitalizations%20and%20death%20and%20increased%20days%20alive%20and%20out%20of%20hospital%20%28DAOH%29%20and%20percent%20DAOH%20in%20ODYSSEY%20OUTCOMES.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20prespecified%20analyses%2C%20hazard%20functions%20for%20total%20hospitalizations%20and%20death%20were%20jointly%20estimated%20by%20a%20semiparametric%20model%2C%20while%20in%20post%20hoc%20analyses%2C%20DAOH%20and%20percent%20DAOH%20were%20compared%20between%20treatment%20groups%20with%20Poisson%20regression%20and%20one-inflated%20beta%20regression%2C%20respectively.%20With%2016%5Cu2009629%20total%20hospitalizations%20and%20726%20deaths%2C%20331%20fewer%20hospitalizations%2C%20and%2058%20fewer%20deaths%20were%20observed%20with%20alirocumab%20compared%20with%20placebo%2C%20translating%20to%2015.6%20total%20hospitalizations%20or%20deaths%20avoided%20with%20alirocumab%20per%201000%20patient-years%20of%20assigned%20treatment.%20Alirocumab%20reduced%20total%20hospitalizations%20%28hazard%20ratio%2C%200.96%20%5B95%25%20CI%2C%200.92%5Cu20131.00%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.04%29%20and%20increased%20DAOH%20relative%20to%20placebo%20%28rate%20ratio%2C%201.003%20%5B95%25%20CI%2C%201.000%5Cu20131.007%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.05%29%2C%20primarily%20through%20a%20reduction%20in%20days%20dead%20%28rate%20ratio%2C%200.847%20%5B95%25%20CI%2C%200.728%5Cu20130.986%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29.%20Patients%20randomized%20to%20alirocumab%20were%20also%20more%20likely%20to%20survive%20to%20the%20end%20of%20the%20study%20without%20hospitalization%20%28odds%20ratio%2C%201.06%20%5B95%25%20CI%2C%201.00%5Cu20131.13%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Alirocumab%20reduced%20total%20hospitalizations%20with%20corresponding%20small%20increases%20in%20DAOH%20and%20percent%20DAOH.%20These%20outcomes%20provide%20alternative%20patient-centered%20metrics%20to%20capture%20the%20totality%20of%20alirocumab%20clinical%20efficacy%20after%20acute%20coronary%20syndrome.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01663402.%22%2C%22date%22%3A%2211%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCOUTCOMES.119.005858%22%2C%22ISSN%22%3A%221941-7713%2C%201941-7705%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCOUTCOMES.119.005858%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22D4BY9IEM%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baber%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBaber%20U%2C%20Leisman%20DE%2C%20Cohen%20DJ%2C%20Gibson%20CM%2C%20Henry%20TD%2C%20Dangas%20G%2C%20Moliterno%20D%2C%20Kini%20A%2C%20Krucoff%20M%2C%20Colombo%20A%2C%20Chieffo%20A%2C%20Sartori%20S%2C%20Witzenbichler%20B%2C%20Steg%20PG%2C%20Pocock%20SJ%2C%20Mehran%20R.%202019.%20Tailoring%20Antiplatelet%20Therapy%20Intensity%20to%20Ischemic%20and%20Bleeding%20Risk%3A%20A%20Cost%20Consequence%20Simulation%20From%20PARIS.%20Circ%3A%20Cardiovascular%20Quality%20and%20Outcomes%2012%3Ae004945.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tailoring%20Antiplatelet%20Therapy%20Intensity%20to%20Ischemic%20and%20Bleeding%20Risk%3A%20A%20Cost%20Consequence%20Simulation%20From%20PARIS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20E.%22%2C%22lastName%22%3A%22Leisman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20D.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Moliterno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annapoorna%22%2C%22lastName%22%3A%22Kini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%22%2C%22lastName%22%3A%22Krucoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alaide%22%2C%22lastName%22%3A%22Chieffo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernhard%22%2C%22lastName%22%3A%22Witzenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Balancing%20ischemic%20and%20bleeding%20risk%20is%20an%20evolving%20framework.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Our%20objectives%20were%20to%20simulate%20changes%20in%20risks%20for%20adverse%20events%20and%20event-driven%20costs%20with%20use%20of%20ticagrelor%20or%20prasugrel%20versus%20clopidogrel%20according%20to%20varying%20levels%20of%20ischemic%20and%20bleeding%20risk.%20Using%20the%20validated%20PARIS%20risk%20functions%2C%20we%20estimated%201-year%20ischemic%20%28myocardial%20infarction%20or%20stent%20thrombosis%29%20and%20bleeding%20%28Bleeding%20Academic%20Research%20Consortium%20types%203%20or%205%29%20event%20rates%20among%20PARIS%20study%20participants%20who%20underwent%20percutaneous%20coronary%20intervention%20with%20drug-eluting%20stent%20implantation%20for%20an%20acute%20coronary%20syndrome%20and%20were%20discharged%20with%20aspirin%20and%20clopidogrel%20%28n%3D1497%29.%20Simulated%20changes%20in%20adverse%20events%20with%20ticagrelor%20or%20prasugrel%20were%20calculated%20by%20applying%20treatment%20effects%20from%20randomized%20trials%20for%20a%201-year%20time%20horizon.%20Event%20costs%20were%20estimated%20using%20National%20Inpatient%20Sample%20data.%20Net%20costs%20were%20calculated%20between%20antiplatelet%20therapy%20groups%20according%20to%20level%20of%20ischemic%20and%20bleeding%20risk.%20After%20weighting%20events%20for%20quality-of-life%20impact%2C%20we%20calculated%20event%20rates%20and%20costs%20for%20risk-tailored%20treatment%20versus%20clopidogrel%20under%20multiple%20drug%20pricing%20assumptions.%20One-year%20rates%20%28per%201000%20person-years%29%20for%20ischemic%20events%20were%2012.6%2C%2024.1%2C%20and%2066.1%2C%20respectively%2C%20among%20those%20at%20low%20%28n%3D630%29%2C%20intermediate%20%28n%3D536%29%2C%20and%20high%20%28n%3D331%29%20ischemic%20risk.%20Analogous%20bleeding%20rates%20were%2011.0%2C%2023.9%2C%20and%2066.2%2C%20respectively%2C%20among%20low%20%28n%3D728%29%2C%20intermediate%20%28n%3D634%29%2C%20and%20high%20%28n%3D135%29%20bleeding%20risk%20patients.%20Mean%20per%20event%20costs%20were%20%2422%5Cu2009174%20%28ischemic%29%20and%20%2412%5Cu2009203%20%28bleeding%29.%20When%20risks%20for%20ischemia%20matched%20or%20exceeded%20bleeding%2C%20simulated%20utility-weighted%20event%20rates%20favored%20ticagrelor%5C%2Fprasugrel%2C%20whereas%20clopidogrel%20reduced%20utility-weighted%20events%20when%20bleeding%20exceeded%20ischemic%20risk.%20One-year%20costs%20were%20sensitive%20to%20drug%20pricing%20assumptions%2C%20and%20risk-tailored%20treatment%20with%20either%20agent%20progressed%20from%20cost%20incurring%20to%20cost%20saving%20with%20increasing%20generic%20market%20share.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Tailoring%20antiplatelet%20therapy%20intensity%20to%20patient%20risk%20may%20improve%20health%20utility%20and%20could%20produce%20cost%20savings%20in%20the%20first%20year%20after%20percutaneous%20coronary%20intervention.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT00998127.%22%2C%22date%22%3A%2201%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCOUTCOMES.118.004945%22%2C%22ISSN%22%3A%221941-7713%2C%201941-7705%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCOUTCOMES.118.004945%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22K4YZM858%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baber%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBaber%20U%2C%20Stefanini%20GG%2C%20Giustino%20G%2C%20Stone%20GW%2C%20Leon%20MB%2C%20Sartori%20S%2C%20Aquino%20M%2C%20Steg%20PG%2C%20Windecker%20S%2C%20Wijns%20W%2C%20Serruys%20PW%2C%20Valgimigli%20M%2C%20Morice%20M%2C%20Camenzind%20E%2C%20Weisz%20G%2C%20Smits%20PC%2C%20Kandzari%20DE%2C%20Von%20Birgelen%20C%2C%20Dangas%20GD%2C%20Galatius%20S%2C%20Jeger%20RV%2C%20Kimura%20T%2C%20Mikhail%20GW%2C%20Itchhaporia%20D%2C%20Mehta%20L%2C%20Ortega%20R%2C%20Kim%20H-S%2C%20Kastrati%20A%2C%20Chieffo%20A%2C%20Mehran%20R.%202019.%20Impact%20of%20Diabetes%20Mellitus%20in%20Women%20Undergoing%20Percutaneous%20Coronary%20Intervention%20With%20Drug-Eluting%20Stents%3A%20From%20the%20Women%20in%20Innovation%20and%20Drug-Eluting%20Stents%20Collaborative%20Patient-Level%20Pooled%20Analysis.%20Circ%3A%20Cardiovascular%20Interventions%2012%3Ae007734.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Diabetes%20Mellitus%20in%20Women%20Undergoing%20Percutaneous%20Coronary%20Intervention%20With%20Drug-Eluting%20Stents%3A%20From%20the%20Women%20in%20Innovation%20and%20Drug-Eluting%20Stents%20Collaborative%20Patient-Level%20Pooled%20Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%20G.%22%2C%22lastName%22%3A%22Stefanini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gennaro%22%2C%22lastName%22%3A%22Giustino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20B.%22%2C%22lastName%22%3A%22Leon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Aquino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Wijns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%5Cu2013Claude%22%2C%22lastName%22%3A%22Morice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edoardo%22%2C%22lastName%22%3A%22Camenzind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giora%22%2C%22lastName%22%3A%22Weisz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pieter%20C.%22%2C%22lastName%22%3A%22Smits%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20E.%22%2C%22lastName%22%3A%22Kandzari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemens%22%2C%22lastName%22%3A%22Von%20Birgelen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20D.%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soren%22%2C%22lastName%22%3A%22Galatius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raban%20V.%22%2C%22lastName%22%3A%22Jeger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takeshi%22%2C%22lastName%22%3A%22Kimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghada%20W.%22%2C%22lastName%22%3A%22Mikhail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dipti%22%2C%22lastName%22%3A%22Itchhaporia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laxmi%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Ortega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyo-Soo%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alaide%22%2C%22lastName%22%3A%22Chieffo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Data%20examining%20the%20impact%20of%20diabetes%20mellitus%20%28DM%29%20on%20ischemic%20risk%20after%20percutaneous%20coronary%20intervention%20in%20women%20are%20limited%20as%20most%20clinical%20trial%20participants%20are%20male.%20We%20evaluated%20%281%29%20the%20impact%20of%20DM%20on%20ischemic%20outcomes%20in%20women%20undergoing%20drug-eluting%20stent%20%28DES%29%20implantation%20and%20%282%29%20whether%20the%20outcomes%20of%20new-%20versus%20early-generation%20DES%20vary%20by%20DM%20status.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20pooled%20patient-level%20data%20of%2010%20448%20women%20undergoing%20percutaneous%20coronary%20intervention%20with%20DES%20from%2026%20randomized%20trials.%20Baseline%20characteristics%20and%203-year%20clinical%20outcomes%20were%20stratified%20according%20to%20DM%20status%20%28noninsulin-dependent%20and%20insulin-dependent%29%20and%20DES%20generation.%20The%20primary%20end%20point%20was%20the%20composite%20of%20all-cause%20death%20or%20myocardial%20infarction.%20Secondary%20end%20points%20were%20definite%20or%20probable%20stent%20thrombosis%20and%20target%20lesion%20revascularization.%20Compared%20with%20women%20without%20DM%20%28n%3D7154%2C%2068.5%25%29%2C%20adjusted%20risks%20%28adjusted%20hazard%20ratios%20%5B95%25%20CI%5D%29%20for%20death%20or%20myocardial%20infarction%20among%20women%20with%20noninsulin-dependent%20DM%20%28n%3D2241%2C%2021.4%25%29%20and%20insulin-dependent%20DM%20%28n%3D1053%2C%2010.1%25%29%20were%201.30%20%281.11%5Cu20131.53%29%20and%201.71%20%281.41%5Cu20132.07%29%2C%20respectively%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20trend%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%20Similar%20trends%20were%20observed%20for%20def%5C%2Fprob%20stent%20thrombosis%20and%20target%20lesion%20revascularization.%20Compared%20with%20early-generation%20DES%2C%20use%20of%20newer-generation%20DES%20was%20associated%20with%20significant%20reductions%20in%20death%20or%20myocardial%20infarction%20in%20the%20absence%20of%20DM%20whereas%20differences%20were%20nonsignificant%20in%20the%20presence%20of%20DM%2C%20with%20similar%20findings%20for%20def%5C%2Fprob%20stent%20thrombosis%20and%20target%20lesion%20revascularization.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20presence%20of%20DM%20is%20associated%20with%20substantial%2C%20graded%2C%20and%20durable%20risks%20for%20ischemic%20events%20among%20women%20undergoing%20percutaneous%20coronary%20intervention%20with%20DES.%20The%20safety%20and%20efficacy%20profile%20of%20newer-generation%20DES%20is%20preserved%20among%20women%20without%20DM%2C%20while%20benefits%20are%20nonsignificant%20among%20women%20with%20DM.%22%2C%22date%22%3A%2207%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.118.007734%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.118.007734%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22CAZ9TGZK%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Palmerini%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPalmerini%20T%2C%20Bruno%20AG%2C%20Gilard%20M%2C%20Morice%20M-C%2C%20Valgimigli%20M%2C%20Montalescot%20G%2C%20Collet%20J-P%2C%20Della%20Riva%20D%2C%20Bacchi-Reggiani%20ML%2C%20Steg%20PG%2C%20Diallo%20A%2C%20Vicaut%20E%2C%20Helft%20G%2C%20Nakamura%20M%2C%20G%26%23xE9%3Bn%26%23xE9%3Breux%20P%2C%20Vahl%20TP%2C%20Stone%20GW.%202019.%20Risk-Benefit%20Profile%20of%20Longer-Than-1-Year%20Dual-Antiplatelet%20Therapy%20Duration%20After%20Drug-Eluting%20Stent%20Implantation%20in%20Relation%20to%20Clinical%20Presentation%3A%20A%20Pairwise%20Meta-Analysis%20of%206%20Trials%20and%2021%20457%20Patients.%20Circ%3A%20Cardiovascular%20Interventions%2012%3Ae007541.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk-Benefit%20Profile%20of%20Longer-Than-1-Year%20Dual-Antiplatelet%20Therapy%20Duration%20After%20Drug-Eluting%20Stent%20Implantation%20in%20Relation%20to%20Clinical%20Presentation%3A%20A%20Pairwise%20Meta-Analysis%20of%206%20Trials%20and%2021%20457%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tullio%22%2C%22lastName%22%3A%22Palmerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%20G.%22%2C%22lastName%22%3A%22Bruno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Gilard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Claude%22%2C%22lastName%22%3A%22Morice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Collet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%22%2C%22lastName%22%3A%22Della%20Riva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Letizia%22%2C%22lastName%22%3A%22Bacchi-Reggiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdourahmane%22%2C%22lastName%22%3A%22Diallo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Helft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masato%22%2C%22lastName%22%3A%22Nakamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22G%5Cu00e9n%5Cu00e9reux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Torsten%20P.%22%2C%22lastName%22%3A%22Vahl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20sought%20to%20determine%20whether%20the%20risks%20and%20benefits%20of%20prolonging%20dual-antiplatelet%20therapy%20%28DAPT%29%20beyond%201%20year%20after%20drug-eluting%20stent%20implantation%20depend%20on%20clinical%20presentation%20in%20a%20meta-analysis%20of%20randomized%20controlled%20trials.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Randomized%20controlled%20trials%20comparing%20%5Cu22641-%20versus%20%3E1-year%20DAPT%20after%20drug-eluting%20stent%20placement%20were%20searched%20through%20MEDLINE%2C%20EMBASE%2C%20Cochrane%20databases%2C%20and%20proceedings%20of%20international%20meetings.%20The%20primary%20efficacy%20end%20point%20was%20myocardial%20infarction%2C%20whereas%20the%20primary%20safety%20end%20point%20was%20major%20bleeding.%20Net%20clinical%20benefit%20was%20defined%20as%20the%20composite%20of%20myocardial%20infarction%20or%20major%20bleeding.%20Outcomes%20were%20analyzed%20according%20to%20patient%20presentation%20with%20stable%20ischemic%20heart%20disease%20versus%20acute%20coronary%20syndromes.%20The%20meta-analysis%20included%206%20trials%20with%20a%20total%20of%2021%5Cu2009457%20patients%2C%20including%2014%5Cu2009132%20with%20stable%20ischemic%20heart%20disease%20and%207325%20with%20acute%20coronary%20syndrome.%20After%20a%20median%20follow-up%20of%2019.5%20months%2C%20%5Cu22641-year%20DAPT%20was%20associated%20with%20higher%20rates%20of%20myocardial%20infarction%20compared%20with%20%3E1-year%20DAPT%20%28hazard%20ratio%20%5BHR%5D%2C%201.63%3B%2095%25%20CI%2C%201.37%5Cu20131.95%29%2C%20with%20no%20interaction%20apparent%20between%20treatment%20effect%20and%20clinical%20presentation.%20Shorter%20DAPT%20was%20associated%20with%20reduced%20rates%20of%20major%20bleeding%20compared%20with%20longer%20DAPT%20%28HR%2C%200.64%3B%2095%25%20CI%2C%200.42%5Cu20130.99%29%20with%20no%20significant%20interaction%20between%20treatment%20effect%20and%20clinical%20presentation.%20However%2C%20a%20net%20clinical%20benefit%20of%20%3E1-year%20DAPT%20was%20present%20in%20patients%20with%20acute%20coronary%20syndrome%20%28HR%20of%20shorter%20versus%20longer%20DAPT%2C%201.59%3B%2095%25%20CI%2C%201.24%5Cu20132.02%29%20but%20not%20in%20those%20with%20stable%20ischemic%20heart%20disease%20%28HR%2C%201.15%3B%2095%25%20CI%2C%200.89%5Cu20131.51%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.04%29.%20Shorter%20DAPT%20was%20also%20associated%20with%20lower%20rates%20of%20noncardiac%20mortality%20compared%20with%20longer%20DAPT%20%28HR%2C%200.71%3B%2095%25%20CI%2C%200.52%5Cu20130.96%29%2C%20with%20no%20significant%20interaction%20between%20treatment%20effect%20and%20clinical%20presentation%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.12%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Compared%20with%20%5Cu22641-year%20DAPT%2C%20%3E1-year%20DAPT%20reduces%20the%20risk%20of%20myocardial%20infarction%20but%20increases%20the%20risk%20of%20major%20bleeding%20and%20noncardiac%20mortality.%20A%20net%20clinical%20benefit%20of%20extended%20DAPT%20was%20apparent%20for%20patients%20with%20acute%20coronary%20syndrome%20but%20not%20for%20those%20with%20stable%20ischemic%20heart%20disease.%22%2C%22date%22%3A%2203%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.118.007541%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.118.007541%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22WGS964U3%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abtan%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbtan%20J%2C%20Ducrocq%20G%2C%20Steg%20PG%2C%20Stone%20GW%2C%20Mahaffey%20KW%2C%20Gibson%20CM%2C%20Hamm%20CW%2C%20Price%20MJ%2C%20Prats%20J%2C%20Deliargyris%20EN%2C%20White%20HD%2C%20Harrington%20RA%2C%20Bhatt%20DL%2C%20on%20behalf%20of%20the%20CHAMPION%20PHOENIX%20Investigators.%202019.%20Periprocedural%20Outcomes%20According%20to%20Timing%20of%20Clopidogrel%20Loading%20Dose%20in%20Patients%20Who%20Did%20Not%20Receive%20P2Y%20%3Csub%3E12%3C%5C%2Fsub%3E%20Inhibitor%20Pretreatment%3A%20Analysis%20From%20the%20CHAMPION%20PHOENIX%20Trial.%20Circ%3A%20Cardiovascular%20Interventions%2012%3Ae007445.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Periprocedural%20Outcomes%20According%20to%20Timing%20of%20Clopidogrel%20Loading%20Dose%20in%20Patients%20Who%20Did%20Not%20Receive%20P2Y%20%3Csub%3E12%3C%5C%2Fsub%3E%20Inhibitor%20Pretreatment%3A%20Analysis%20From%20the%20CHAMPION%20PHOENIX%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W.%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W.%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Efthymios%20N.%22%2C%22lastName%22%3A%22Deliargyris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20CHAMPION%20PHOENIX%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20undergoing%20percutaneous%20coronary%20intervention%20%28PCI%29%2C%20who%20did%20not%20receive%20P2Y%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2012%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20inhibitor%20pretreatment%2C%20the%20optimal%20timing%20of%20P2Y%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2012%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20inhibitor%20loading%20dose%20remains%20debated.%20We%20sought%20to%20examine%20whether%20the%20choice%20of%20administration%20of%20the%20clopidogrel%20loading%20dose%20before%20or%20after%20the%20start%20of%20PCI%20had%20an%20impact%20on%20periprocedural%20complications%2C%20including%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20CHAMPION%20PHOENIX%20%28A%20Clinical%20Trial%20Comparing%20Cangrelor%20to%20Clopidogrel%20Standard%20Therapy%20in%20Subjects%20Who%20Require%20Percutaneous%20Coronary%20Intervention%29%20double-blind%20randomized%20trial%20compared%20cangrelor%20with%20clopidogrel%20loading%20dose%20at%20the%20time%20of%20PCI.%20Pretreatment%20with%20clopidogrel%20before%20randomization%20was%20not%20permitted%20per%20protocol.%20In%20the%20clopidogrel-only%20group%20%28n%3D5438%29%2C%20a%20loading%20dose%20was%20given%20before%20%28early%20load%20%5BEL%5D%29%20or%20after%20the%20start%20of%20PCI%20%28late%20load%20%5BLL%5D%29%20according%20to%20physician%20choice.%20Overall%2C%203442%20%2863.3%25%29%20patients%20had%20EL%20and%201997%20LL%20%2836.7%25%29.%20Median%20times%20were%205%20minutes%20before%20and%2020%20minutes%20after%20the%20start%20of%20PCI%2C%20respectively.%20EL%20was%20more%20frequently%20used%20among%20patients%20with%20ST-segment%5Cu2013elevation%20myocardial%20infarction%20%2884.4%25%29%20and%20non%5Cu2013ST-segment%5Cu2013elevation%20acute%20coronary%20syndromes%20%2871.5%25%29%20than%20in%20stable%20patients%20%2853.7%25%29.%20At%2048%20hours%2C%20rates%20of%20the%20primary%20outcome%20of%20death%2C%20myocardial%20infarction%2C%20ischemia-driven%20revascularization%2C%20or%20stent%20thrombosis%20were%20similar%20%286.0%25%20versus%205.4%25%29%20for%20EL%20versus%20LL%2C%20respectively%20%28odds%20ratio%20%5BOR%5D%2C%201.11%20%5B95%25%20CI%2C%200.87%5Cu20131.41%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.41%29%2C%20and%20remained%20so%20after%20adjustment%20for%20potential%20confounders%2C%20including%20clinical%20presentation%20%28OR%20%5B95%25%20CI%5D%2C%201.39%20%5B0.90%5Cu20132.15%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.14%29.%20Compared%20with%20clopidogrel%2C%20cangrelor%20consistently%20reduced%20the%20primary%20outcome%20in%20both%20EL%20%284.8%25%20versus%206.0%25%3B%20OR%20%5B95%25%20CI%5D%2C%200.80%20%5B0.64%5Cu20130.98%5D%29%20and%20LL%20%284.3%25%20versus%205.4%25%3B%20OR%20%5B95%25%20CI%5D%2C%200.79%20%5B0.59%5Cu20131.06%5D%3B%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.99%29.%20Global%20Use%20of%20Strategies%20to%20Open%20Occluded%20Coronary%20Arteries%20severe%5C%2Fmoderate%20bleeding%20rates%20were%20similar%20between%20treatment%20arms%20for%20both%20EL%20%28OR%20%5B95%25%20CI%5D%2C%201.24%20%5B0.58%5Cu20132.66%5D%29%20and%20LL%20%28OR%20%5B95%25%20CI%5D%2C%202.53%20%5B0.98%5Cu20136.54%5D%3B%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.25%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20a%20nonrandomized%20comparison%20of%20patients%20with%20clopidogrel%20loading%20before%20or%20after%20the%20start%20of%20PCI%2C%20the%20rates%20of%20periprocedural%20PCI%20complications%2C%20including%20bleeding%2C%20were%20similar%2C%20as%20were%20the%20benefits%20of%20cangrelor%2C%20regardless%20of%20the%20timing.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01156571.%22%2C%22date%22%3A%2203%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.118.007445%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.118.007445%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A02Z%22%7D%7D%2C%7B%22key%22%3A%224GF5E2RP%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Olivier%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EOlivier%20CB%2C%20Bhatt%20DL%2C%20Leonardi%20S%2C%20Stone%20GW%2C%20Gibson%20CM%2C%20Steg%20PhG%2C%20Hamm%20CW%2C%20Wilson%20MD%2C%20Mangum%20S%2C%20Price%20MJ%2C%20Prats%20J%2C%20White%20HD%2C%20Lopes%20RD%2C%20Harrington%20RA%2C%20Mahaffey%20KW%2C%20on%20Behalf%20of%20the%20CHAMPION%20PHOENIX%20Investigators%2A.%202019.%20Central%20Adjudication%20Identified%20Additional%20and%20Prognostically%20Important%20Myocardial%20Infarctions%20in%20Patients%20Undergoing%20Percutaneous%20Coronary%20Intervention%3A%20Results%20From%20CHAMPION%20PHOENIX.%20Circ%3A%20Cardiovascular%20Interventions%2012%3Ae007342.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Central%20Adjudication%20Identified%20Additional%20and%20Prognostically%20Important%20Myocardial%20Infarctions%20in%20Patients%20Undergoing%20Percutaneous%20Coronary%20Intervention%3A%20Results%20From%20CHAMPION%20PHOENIX%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%20B.%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Leonardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W.%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20D.%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stacey%22%2C%22lastName%22%3A%22Mangum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W.%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20Behalf%20of%20the%20CHAMPION%20PHOENIX%20Investigators%2A%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20CHAMPION%20PHOENIX%20trial%2C%20cangrelor%20reduced%20the%20primary%20composite%20end%20point%20of%20death%2C%20myocardial%20infarction%20%28MI%29%2C%20ischemia-driven%20revascularization%2C%20or%20stent%20thrombosis%20at%2048%20hours.%20This%20study%20aimed%20to%20explore%20the%20impact%20of%20event%20adjudication%20and%20the%20prognostic%20importance%20of%20MI%20reported%20by%20a%20clinical%20events%20committee%20%28CEC%29%20or%20site%20investigators%20%28SIs%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Data%20from%20the%20CHAMPION%20PHOENIX%20trial%20of%20patients%20undergoing%20elective%20or%20nonelective%20percutaneous%20coronary%20intervention%20were%20analyzed.%20A%20CEC%20systematically%20identified%20and%20adjudicated%20MI%20using%20predefined%20criteria%2C%20a%20computer%20algorithm%20to%20identify%20suspected%20events%2C%20and%20semilogarithmic%20plots%20to%20review%20biomarker%20changes.%20Thirty-day%20death%20was%20modeled%20using%20baseline%20characteristics.%20Of%2010%5Cu2009942%20patients%2C%20462%20%284.2%25%29%20patients%20had%20at%20least%201%20MI%20by%2048%20hours%20identified%20by%20the%20CEC%20%28207%20%5B3.8%25%5D%20cangrelor%3B%20255%20%5B4.7%25%5D%20clopidogrel%3B%20odds%20ratio%20%5BOR%5D%200.80%3B%2095%25%20CI%2C%200.67%5Cu20130.97%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.022%29%2C%20and%20143%20patients%20had%20at%20least%201%20MI%20by%2048%20hours%20reported%20by%20the%20SI%20%2860%20%5B1.1%25%5D%20cangrelor%3B%2083%20%5B1.5%25%5D%20clopidogrel%3B%20OR%2C%200.72%3B%2095%25%20CI%2C%200.52%5Cu20131.01%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.053%29.%20Of%20the%20462%20MIs%20identified%20by%20the%20CEC%2C%2092%20%2820%25%29%20were%20reported%20by%20SI%2C%20and%20370%20%2880%25%29%20were%20not.%20Of%20the%20143%20MI%20reported%20by%20the%20SI%2C%2051%20%2836%25%29%20were%20not%20confirmed%20by%20CEC.%20All%20categories%20were%20associated%20with%20an%20increased%20adjusted%20risk%20for%2030-day%20death%20%28CEC%3A%20OR%2C%205.35%3B%2095%25%20CI%2C%202.56%5Cu201311.2%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%3B%20SI%3A%209.08%20%5B4.01%5Cu201320.5%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%3B%20CEC%20and%20SI%3A%2010.9%20%5B3.23%5Cu201336.6%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%3B%20CEC%20but%20not%20SI%3A%204.69%20%5B1.94%5Cu201311.3%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%3B%20SI%20but%20not%20CEC%3A%2015.4%20%5B5.26%5Cu201344.9%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20undergoing%20percutaneous%20coronary%20intervention%2C%20CEC%20procedures%20identified%203%20times%20as%20many%20MIs%20as%20the%20SI%20reported.%20Compared%20with%20clopidogrel%2C%20cangrelor%20significantly%20reduced%20MIs%20identified%20by%20the%20CEC%20with%20a%20qualitatively%20similar%20relative%20risk%20reduction%20in%20MIs%20reported%20by%20the%20SI.%20MIs%20identified%20by%20CEC%20or%20reported%20by%20SI%20were%20independently%20associated%20with%20worse%2030-day%20death.%20Central%20adjudication%20identified%20additional%2C%20prognostically%20important%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01156571.%22%2C%22date%22%3A%2207%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.118.007342%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.118.007342%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22PX8Q9A8F%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Faggioni%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFaggioni%20M%2C%20Baber%20U%2C%20Sartori%20S%2C%20Chandrasekhar%20J%2C%20Cohen%20DJ%2C%20Henry%20TD%2C%20Claessen%20BE%2C%20Dangas%20GD%2C%20Gibson%20CM%2C%20Krucoff%20MW%2C%20Vogel%20B%2C%20Moliterno%20DJ%2C%20Sorrentino%20S%2C%20Colombo%20A%2C%20Chieffo%20A%2C%20Kini%20A%2C%20Farhan%20S%2C%20Ariti%20C%2C%20Witzenbichler%20B%2C%20Weisz%20G%2C%20Steg%20PG%2C%20Pocock%20S%2C%20Mehran%20R.%202019.%20Influence%20of%20Baseline%20Anemia%20on%20Dual%20Antiplatelet%20Therapy%20Cessation%20and%20Risk%20of%20Adverse%20Events%20After%20Percutaneous%20Coronary%20Intervention%3A%20Insights%20From%20the%20PARIS%20Registry.%20Circ%3A%20Cardiovascular%20Interventions%2012%3Ae007133.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20Baseline%20Anemia%20on%20Dual%20Antiplatelet%20Therapy%20Cessation%20and%20Risk%20of%20Adverse%20Events%20After%20Percutaneous%20Coronary%20Intervention%3A%20Insights%20From%20the%20PARIS%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michela%22%2C%22lastName%22%3A%22Faggioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaya%22%2C%22lastName%22%3A%22Chandrasekhar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20D.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bimmer%20E.%22%2C%22lastName%22%3A%22Claessen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20D.%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%20W.%22%2C%22lastName%22%3A%22Krucoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Moliterno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabato%22%2C%22lastName%22%3A%22Sorrentino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alaide%22%2C%22lastName%22%3A%22Chieffo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annapoorna%22%2C%22lastName%22%3A%22Kini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serdar%22%2C%22lastName%22%3A%22Farhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cono%22%2C%22lastName%22%3A%22Ariti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Witzenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giora%22%2C%22lastName%22%3A%22Weisz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Anemia%20is%20a%20well-recognized%20risk%20factor%20for%20both%20bleeding%20and%20ischemic%20events%20after%20percutaneous%20coronary%20intervention%20%28PCI%29.%20We%20sought%20to%20determine%20the%20impact%20of%20baseline%20anemia%20on%20dual%20antiplatelet%20therapy%20%28DAPT%29%20cessation%20patterns%20%5Cu22642%20years%20after%20PCI%20and%20the%20subsequent%20risk%20of%20clinical%20adverse%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20PARIS%20%28Patterns%20of%20Non-Adherence%20to%20Dual%20Anti-Platelet%20Regimen%20in%20Stented%20Patients%29%20was%20a%20prospective%20multicenter%20observational%20registry%20of%20PCI-treated%20patients%20%28n%3D5018%29.%20Anemia%20was%20defined%20as%20baseline%20Hb%20%28hemoglobin%29%20%3C12%20g%5C%2FdL%20for%20men%20and%20%3C11%20g%5C%2FdL%20for%20women.%20DAPT%20cessation%20modes%20included%20physician-recommended%20discontinuation%2C%20temporary%20interruption%20%28%5Cu226414%20days%29%2C%20and%20disruption%20due%20to%20bleeding%20or%20noncompliance.%20The%20primary%20end%20point%20was%202-year%20major%20adverse%20cardiovascular%20events%20%28MACE%29%2C%20a%20composite%20of%20cardiac%20death%2C%20myocardial%20infarction%2C%20or%20target%20vessel%20revascularization.%20We%20identified%20824%20%2818%25%29%20anemic%20and%204194%20%2882%25%29%20nonanemic%20patients.%20Anemic%20patients%20were%20older%20and%20had%20a%20higher%20rate%20of%20diabetes%20mellitus%2C%20hypertension%2C%20and%20prior%20PCI.%20DAPT%20interruption%20and%20disruption%20were%20significantly%20more%20common%20in%20anemic%20patients%20throughout%202%20years%20after%20PCI%2C%20whereas%20physician-recommended%20discontinuation%20occurred%20more%20often%20in%20anemic%20patients%20during%20the%20first%20year%20after%20PCI%20and%20in%20nonanemic%20patients%20during%20the%20second%20year.%20The%202-year%20adjusted%20risks%20of%20MACE%20and%20Bleeding%20Academic%20Research%20Consortium%203%20or%205%20bleeding%20events%20were%20significantly%20higher%20in%20anemic%20patients.%20Compared%20with%20uninterrupted%20DAPT%2C%20disruption%2C%20but%20not%20interruption%20and%20physician-recommended%20discontinuation%2C%20was%20associated%20with%20a%20higher%20risk%20of%20myocardial%20infarction%20in%20nonanemic%20patients%20and%20a%20higher%20risk%20of%20both%20myocardial%20infarction%20and%20MACE%20in%20anemic%20patients.%20There%20was%20no%20significant%20interaction%20between%20anemia%20and%20risk%20of%20clinical%20outcomes%20associated%20with%20each%20DAPT%20cessation%20mode.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Baseline%20anemia%20was%20associated%20with%20a%20significantly%20higher%20adjusted%20risk%20of%20MACE%20and%20major%20bleeding.%20Physicians%20more%20frequently%20recommend%20DAPT%20discontinuation%20to%20anemic%20patients%20during%20the%20first%20year%2C%20and%20to%20nonanemic%20patients%20during%20the%20second%20year%20after%20PCI.%20DAPT%20disruption%20was%20associated%20with%20a%20higher%20risk%20of%20MACE%20outcomes.%22%2C%22date%22%3A%2204%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.118.007133%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.118.007133%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22B5BCFLJM%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guidoux%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGuidoux%20C%2C%20Meseguer%20E%2C%20Ong%20E%2C%20Lavall%26%23xE9%3Be%20PC%2C%20Hobeanu%20C%2C%20Monteiro-Tavares%20L%2C%20Charles%20H%2C%20Cabrejo%20L%2C%20Martin-Bechet%20A%2C%20Rigual%20R%2C%20Nighoghossian%20N%2C%20Amarenco%20P.%202019.%20Twelve-month%20outcome%20in%20patients%20with%20stroke%20and%20atrial%20fibrillation%20not%20suitable%20to%20oral%20anticoagulant%20strategy%3A%20the%20WATCH-AF%20registry.%20Open%20Heart%206%3Ae001187.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Twelve-month%20outcome%20in%20patients%20with%20stroke%20and%20atrial%20fibrillation%20not%20suitable%20to%20oral%20anticoagulant%20strategy%3A%20the%20WATCH-AF%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Guidoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Hobeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linsay%22%2C%22lastName%22%3A%22Monteiro-Tavares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Charles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Cabrejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Martin-Bechet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricardo%22%2C%22lastName%22%3A%22Rigual%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Nighoghossian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Long-term%20oral%20anticoagulant%20%28LTOAC%29%20reduces%20ischaemic%20stroke%20recurrences.%20Because%20of%20bleeding%20history%2C%20frailty%2C%20cognitive%20impairment%2C%20comorbidities%20or%20patient%20refusal%2C%20many%20cannot%20be%20discharged%20from%20stroke%20unit%20on%20LTOAC.%20Proportion%20and%20outcome%20of%20these%20patients%20is%20not%20well%20known.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20Warfarin%20Aspirin%20Ten-a%20inhibitor%20Cerebral%20infarction%20and%20Haemorrhage%20and%20atrial%20fibrillation%20%28AF%29%20prospective%20registry%20enrolled%20consecutive%20patients%20with%20an%20acute%20stroke%20associated%20with%20AF.%20Scales%20to%20evaluate%20stroke%20severity%2C%20disability%2C%20functional%20independence%2C%20cognition%2C%20risk%20of%20fall%2C%20ischaemic%20and%20haemorrhagic%20risk%20stratification%20were%20systematically%20collected%20at%20admission%2C%20discharge%2C%203%20and%2012%20months%20poststroke.%20The%20two%20main%2012-month%20endpoints%20were%20death%20or%20dependency%20%28modified%20Rankin%20Scale%20%3E3%29%20and%20recurrent%20stroke.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20400%20patients%20%28370%20brain%20infarctions%2C%2030%20brain%20haemorrhages%29%2C%20274%20were%20discharged%20on%20LTOAC%2C%2031%20died%20before%20discharge%20and%2095%20%2824%25%29%20were%20not%20discharge%20on%20anticoagulant%20%28frailty%2C%20bedridden%20or%20demented%2C%20EHRA%5C%2FESC%20contraindication%20to%20anticoagulant%29.%20Death%20or%20dependency%20and%20recurrent%20stroke%20occurred%20in%2019.8%25%20and%209.9%25%2C%20respectively%2C%20in%20patient%20on%20anticoagulant%2C%20and%2033.5%25%20and%2027.2%25%20in%20those%20not%20on%20anticoagulant%20%28both%20p%3C0.001%29.%20Patient%20not%20anticoagulated%20at%20discharge%20had%20a%201.6-fold%20increase%20in%20the%20risk%20of%20death%20or%20dependency%20at%2012%20months%20%28HR%201.65%3B%2095%25%5Cu2009CI%201.05%20to%202.61%3B%20p%3D0.032%29%20and%20a%202.5-fold%20increase%20in%20the%20risk%20of%20stroke%20%28HR%202.46%3B%2095%25%5Cu2009CI%201.36%20to%204.44%3B%20p%3D0.003%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20One-fourth%20of%20patients%20with%20stroke%20associated%20with%20AF%20are%20not%20discharged%20on%20anticoagulation%20and%20have%20a%20dramatic%20increase%20in%20the%20risk%20of%20death%20or%20dependency%20at%2012%20months%20as%20well%20as%20recurrent%20stroke.%20Alternative%20treatments%20should%20be%20trialled%20in%20these%20patients.%22%2C%22date%22%3A%2212%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fopenhrt-2019-001187%22%2C%22ISSN%22%3A%222053-3624%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fopenheart.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fopenhrt-2019-001187%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A41Z%22%7D%7D%2C%7B%22key%22%3A%2264JJFPDD%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darmon%20and%20Ducrocq%22%2C%22parsedDate%22%3A%222019-05-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDarmon%20A%2C%20Ducrocq%20G.%202019.%20Ischaemic%20and%20bleeding%20risk%20assessment%20after%20myocardial%20infarction%3A%20combination%20is%20the%20key.%20Heart%20heartjnl-2019-315050.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ischaemic%20and%20bleeding%20risk%20assessment%20after%20myocardial%20infarction%3A%20combination%20is%20the%20key%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Darmon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-05-04%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fheartjnl-2019-315050%22%2C%22ISSN%22%3A%221355-6037%2C%201468-201X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fheart.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fheartjnl-2019-315050%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22PFNHPPN4%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gandhi%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGandhi%20S%2C%20Goodman%20SG%2C%20Greenlaw%20N%2C%20Ford%20I%2C%20McSkimming%20P%2C%20Ferrari%20R%2C%20Jang%20Y%2C%20Alcocer-Gamba%20MA%2C%20Fox%20K%2C%20Tardif%20J-C%2C%20Tendera%20M%2C%20Dorian%20P%2C%20Steg%20G%2C%20Udell%20JA.%202019.%20Living%20alone%20and%20cardiovascular%20disease%20outcomes.%20Heart%20105%3A1087%26%23x2013%3B1095.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Living%20alone%20and%20cardiovascular%20disease%20outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sumeet%22%2C%22lastName%22%3A%22Gandhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Greenlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%22%2C%22lastName%22%3A%22McSkimming%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yangsoo%22%2C%22lastName%22%3A%22Jang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Antonio%22%2C%22lastName%22%3A%22Alcocer-Gamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Dorian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%20Allan%22%2C%22lastName%22%3A%22Udell%22%7D%5D%2C%22abstractNote%22%3A%22Objective%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20evaluate%20cardiovascular%20%28CV%29%20outcomes%20in%20outpatients%20with%20coronary%20artery%20disease%20%28CAD%29%20living%20alone%20compared%20with%20those%20living%20with%20others.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20prospeCtive%20observational%20LongitudinAl%20RegIstry%20oF%20patients%20with%20stable%20coronarY%20artery%20disease%20%28CLARIFY%29%20included%20outpatients%20with%20stable%20CAD.%20CLARIFY%20enrolled%20participants%20in%2045%20countries%20from%20November%202009%20to%20July%202010%2C%20with%205%20years%20of%20follow-up.%20Living%20arrangement%20was%20documented%20at%20baseline.%20The%20primary%20outcome%20was%20a%20composite%20of%20major%20adverse%20cardiovascular%20events%20%28MACEs%29%20defined%20as%20CV%20death%2C%20myocardial%20infarction%20%28MI%29%20and%20stroke.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%2032%5Cu2009367%20patients%2C%203648%20patients%20were%20living%20alone%20%2811.3%25%29.%20After%20multivariate%20adjustment%2C%20there%20were%20no%20residual%20differences%20in%20MACE%20among%20patients%20living%20alone%20compared%20with%20those%20living%20with%20others%20%28HR%201.04%2C%2095%25%5Cu2009CI%200.92%20to%201.18%2C%20p%3D0.52%29%3B%20however%2C%20there%20was%20significant%20heterogeneity%20in%20the%20exposure%20effect%20by%20sex%20%28P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.01%29.%20Specifically%2C%20men%20living%20alone%20were%20at%20higher%20risk%20for%20MACE%20%28HR%201.17%2C%2095%25%5Cu2009CI%201.002%20to%201.36%2C%20p%3D0.047%29%20as%20opposed%20to%20women%20living%20alone%20%28HR%200.82%2C%2095%25%5Cu2009CI%200.65%20to%201.04%2C%20p%3D0.1%29%2C%20predominantly%20driven%20by%20a%20heterogeneous%20effect%20by%20sex%20on%20MI%20%28P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.006%29.%20There%20was%20no%20effect%20modification%20for%20MACE%20by%20age%20group%20%28P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.3%29%2C%20although%20potential%20varying%20effects%20by%20age%20for%20MI%20%28P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.046%29%20and%20stroke%20%28P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.05%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Living%20alone%20was%20not%20associated%20with%20an%20independent%20increase%20in%20MACE%2C%20although%20significant%20sex-based%20differences%20were%20apparent.%20Men%20living%20alone%20may%20have%20a%20worse%20prognosis%20from%20CV%20disease%20than%20women%3B%20further%20analyses%20are%20needed%20to%20elucidate%20the%20mechanisms%20underlying%20this%20difference.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%20number%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ISRCTN43070564%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%22%2C%22date%22%3A%2207%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fheartjnl-2018-313844%22%2C%22ISSN%22%3A%221355-6037%2C%201468-201X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fheart.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fheartjnl-2018-313844%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22DWRXPXR4%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Leonardi%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELeonardi%20S%2C%20Franzone%20A%2C%20Piccolo%20R%2C%20McFadden%20E%2C%20Vranckx%20P%2C%20Serruys%20P%2C%20Benit%20E%2C%20Liebetrau%20C%2C%20Janssens%20L%2C%20Ferrario%20M%2C%20Zurakowski%20A%2C%20Van%20Geuns%20R-J%2C%20Dominici%20M%2C%20Huber%20K%2C%20Slagboom%20T%2C%20Buszman%20P%2C%20Bolognese%20L%2C%20Tumscitz%20C%2C%20Bryniarski%20K%2C%20Aminian%20A%2C%20Vrolix%20M%2C%20Petrov%20I%2C%20Garg%20S%2C%20Naber%20C%2C%20Prokopczuk%20J%2C%20Hamm%20C%2C%20Steg%20G%2C%20Heg%20D%2C%20Juni%20P%2C%20Windecker%20S%2C%20Valgimigli%20M.%202019.%20Rationale%20and%20design%20of%20a%20prospective%20substudy%20of%20clinical%20endpoint%20adjudication%20processes%20within%20an%20investigator-reported%20randomised%20controlled%20trial%20in%20patients%20with%20coronary%20artery%20disease%3A%20the%20GLOBAL%20LEADERS%20Adjudication%20Sub-StudY%20%28GLASSY%29.%20BMJ%20Open%209%3Ae026053.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rationale%20and%20design%20of%20a%20prospective%20substudy%20of%20clinical%20endpoint%20adjudication%20processes%20within%20an%20investigator-reported%20randomised%20controlled%20trial%20in%20patients%20with%20coronary%20artery%20disease%3A%20the%20GLOBAL%20LEADERS%20Adjudication%20Sub-StudY%20%28GLASSY%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Leonardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Franzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22Piccolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22McFadden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Benit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Liebetrau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Janssens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurizio%22%2C%22lastName%22%3A%22Ferrario%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleksander%22%2C%22lastName%22%3A%22Zurakowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert-Jan%22%2C%22lastName%22%3A%22Van%20Geuns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcello%22%2C%22lastName%22%3A%22Dominici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Huber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ton%22%2C%22lastName%22%3A%22Slagboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pawe%5Cu0142%22%2C%22lastName%22%3A%22Buszman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Bolognese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Tumscitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krzysztof%22%2C%22lastName%22%3A%22Bryniarski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adel%22%2C%22lastName%22%3A%22Aminian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathias%22%2C%22lastName%22%3A%22Vrolix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivo%22%2C%22lastName%22%3A%22Petrov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scot%22%2C%22lastName%22%3A%22Garg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Naber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janusz%22%2C%22lastName%22%3A%22Prokopczuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dik%22%2C%22lastName%22%3A%22Heg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Juni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20GLOBAL%20LEADERS%20is%20an%20open-label%2C%20pragmatic%20and%20superiority%20randomised%20controlled%20trial%20designed%20to%20challenge%20the%20current%20treatment%20paradigm%20of%20dual%20antiplatelet%20therapy%20%28DAPT%29%20for%2012%20months%20followed%20by%20aspirin%20monotherapy%20among%20patients%20undergoing%20percutaneous%20coronary%20intervention.%20By%20design%2C%20all%20study%20endpoints%20are%20investigator%20reported%20%28IR%29%20and%20not%20subject%20to%20formal%20adjudication%20by%20an%20independent%20Clinical%20Event%20Committee%20%28CEC%29%2C%20which%20may%20introduce%20detection%2C%20reporting%20or%20ascertainment%20bias.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20analysis%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20designed%20the%20GLOBAL%20LEADERS%20Adjudication%20Sub-StudY%20%28GLASSY%29%20to%20prospectively%20implement%2C%20in%20a%20large%20sample%20of%20patients%20enrolled%20within%20the%20GLOBAL%20LEADERS%20trial%20%287585%20of%2015%20991%2C%2047.5%25%29%2C%20an%20independent%20adjudication%20process%20of%20reported%20and%20unreported%20potential%20endpoints%2C%20using%20standardised%20CEC%20procedures%2C%20in%20order%20to%20assess%20whether%2023-month%20ticagrelor%20monotherapy%20%2890%5Cu2009mg%20twice%20daily%29%20after%201-month%20DAPT%20is%20non-inferior%20to%20a%20standard%20regimen%20of%20DAPT%20for%2012%20months%20followed%20by%20aspirin%20monotherapy%20for%20the%20primary%20efficacy%20endpoint%20of%20death%2C%20non-fatal%20myocardial%20infarction%2C%20non-fatal%20stroke%20or%20urgent%20target%20vessel%20revascularisation%20and%20superior%20for%20the%20primary%20safety%20endpoint%20of%20type%203%20or%205%20bleeding%20according%20to%20the%20Bleeding%20Academic%20Research%20Consortium%20criteria.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20study%20will%20comprehensively%20assess%20the%20comparative%20safety%20and%20efficacy%20of%20the%20two%20tested%20antithrombotic%20strategies%20on%20CEC-adjudicated%20ischaemic%20and%20bleeding%20endpoints%20and%20will%20provide%20insights%20into%20the%20role%20of%20a%20standardised%20CEC%20adjudication%20process%20on%20the%20interpretation%20of%20study%20findings%20by%20quantifying%20the%20level%20of%20concordance%20between%20IR-reported%20and%20CEC-adjudicated%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Ethics%20and%20dissemination%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20GLASSY%20has%20been%20approved%20by%20local%20ethics%20committee%20of%20all%20study%20sites%20and%5C%2For%20by%20the%20central%20ethics%20committee%20for%20the%20country%20depending%20on%20country-specific%20regulations.%20In%20all%20cases%2C%20they%20deemed%20that%20it%20was%20not%20necessary%20to%20obtain%20further%20informed%20consent%20from%20individual%20subjects.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%20number%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT01813435%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%22%2C%22date%22%3A%2203%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2018-026053%22%2C%22ISSN%22%3A%222044-6055%2C%202044-6055%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbmjopen.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fbmjopen-2018-026053%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22PYMEJ2QS%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alexander%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAlexander%20SPH%2C%20Christopoulos%20A%2C%20Davenport%20AP%2C%20Kelly%20E%2C%20Mathie%20A%2C%20Peters%20JA%2C%20Veale%20EL%2C%20Armstrong%20JF%2C%20Faccenda%20E%2C%20Harding%20SD%2C%20Pawson%20AJ%2C%20Sharman%20JL%2C%20Southan%20C%2C%20Davies%20JA%2C%20CGTP%20Collaborators.%202019.%20THE%20CONCISE%20GUIDE%20TO%20PHARMACOLOGY%202019%5C%2F20%3A%20G%20protein%26%23x2010%3Bcoupled%20receptors.%20British%20J%20Pharmacology%20176.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22THE%20CONCISE%20GUIDE%20TO%20PHARMACOLOGY%202019%5C%2F20%3A%20G%20protein%5Cu2010coupled%20receptors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20P%20H%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Christopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20P%22%2C%22lastName%22%3A%22Davenport%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eamonn%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alistair%22%2C%22lastName%22%3A%22Mathie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20A%22%2C%22lastName%22%3A%22Peters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%20L%22%2C%22lastName%22%3A%22Veale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%20F%22%2C%22lastName%22%3A%22Armstrong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Faccenda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20D%22%2C%22lastName%22%3A%22Harding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20J%22%2C%22lastName%22%3A%22Pawson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20L%22%2C%22lastName%22%3A%22Sharman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Southan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamie%20A%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CGTP%20Collaborators%22%7D%5D%2C%22abstractNote%22%3A%22The%20Concise%20Guide%20to%20PHARMACOLOGY%202019%5C%2F20%20is%20the%20fourth%20in%20this%20series%20of%20biennial%20publications.%20The%20Concise%20Guide%20provides%20concise%20overviews%20of%20the%20key%20properties%20of%20nearly%201800%20human%20drug%20targets%20with%20an%20emphasis%20on%20selective%20pharmacology%20%28where%20available%29%2C%20plus%20links%20to%20the%20open%20access%20knowledgebase%20source%20of%20drug%20targets%20and%20their%20ligands%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20www.guidetopharmacology.org%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%2C%20which%20provides%20more%20detailed%20views%20of%20target%20and%20ligand%20properties.%20Although%20the%20Concise%20Guide%20represents%20approximately%20400%20pages%2C%20the%20material%20presented%20is%20substantially%20reduced%20compared%20to%20information%20and%20links%20presented%20on%20the%20website.%20It%20provides%20a%20permanent%2C%20citable%2C%20point%5Cu2010in%5Cu2010time%20record%20that%20will%20survive%20database%20updates.%20The%20full%20contents%20of%20this%20section%20can%20be%20found%20at%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fbph.14748%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20G%20protein%5Cu2010coupled%20receptors%20are%20one%20of%20the%20six%20major%20pharmacological%20targets%20into%20which%20the%20Guide%20is%20divided%2C%20with%20the%20others%20being%3A%20ion%20channels%2C%20nuclear%20hormone%20receptors%2C%20catalytic%20receptors%2C%20enzymes%20and%20transporters.%20These%20are%20presented%20with%20nomenclature%20guidance%20and%20summary%20information%20on%20the%20best%20available%20pharmacological%20tools%2C%20alongside%20key%20references%20and%20suggestions%20for%20further%20reading.%20The%20landscape%20format%20of%20the%20Concise%20Guide%20is%20designed%20to%20facilitate%20comparison%20of%20related%20targets%20from%20material%20contemporary%20to%20mid%5Cu20102019%2C%20and%20supersedes%20data%20presented%20in%20the%202017%5C%2F18%2C%202015%5C%2F16%20and%202013%5C%2F14%20Concise%20Guides%20and%20previous%20Guides%20to%20Receptors%20and%20Channels.%20It%20is%20produced%20in%20close%20conjunction%20with%20the%20International%20Union%20of%20Basic%20and%20Clinical%20Pharmacology%20Committee%20on%20Receptor%20Nomenclature%20and%20Drug%20Classification%20%28NC%5Cu2010IUPHAR%29%2C%20therefore%2C%20providing%20official%20IUPHAR%20classification%20and%20nomenclature%20for%20human%20drug%20targets%2C%20where%20appropriate.%22%2C%22date%22%3A%2212%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fbph.14748%22%2C%22ISSN%22%3A%220007-1188%2C%201476-5381%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbpspubs.onlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fbph.14748%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22Z2KQDDS4%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bhatt%20and%20Steg%22%2C%22parsedDate%22%3A%222019-11-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBhatt%20DL%2C%20Steg%20PG.%202019.%20THEMIS%20and%20THEMIS-PCI.%20European%20Heart%20Journal%2040%3A3378%26%23x2013%3B3381.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22THEMIS%20and%20THEMIS-PCI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-11-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz707%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F41%5C%2F3378%5C%2F5572656%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22WYRGI28J%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Serruys%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESerruys%20PW%2C%20Takahashi%20K%2C%20Chichareon%20P%2C%20Kogame%20N%2C%20Tomaniak%20M%2C%20Modolo%20R%2C%20Chang%20CC%2C%20Komiyama%20H%2C%20Soliman%20O%2C%20Wykrzykowska%20JJ%2C%20De%20Winter%20RJ%2C%20Ferrario%20M%2C%20Dominici%20M%2C%20Buszman%20P%2C%20Bolognese%20L%2C%20Tumscitz%20C%2C%20Benit%20E%2C%20Stoll%20H-P%2C%20Hamm%20C%2C%20Steg%20PG%2C%20Onuma%20Y%2C%20J%26%23xFC%3Bni%20P%2C%20Windecker%20S%2C%20Vranckx%20P%2C%20Colombo%20A%2C%20Valgimigli%20M.%202019.%20Impact%20of%20long-term%20ticagrelor%20monotherapy%20following%201-month%20dual%20antiplatelet%20therapy%20in%20patients%20who%20underwent%20complex%20percutaneous%20coronary%20intervention%3A%20insights%20from%20the%20Global%20Leaders%20trial.%20European%20Heart%20Journal%2040%3A2595%26%23x2013%3B2604.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20long-term%20ticagrelor%20monotherapy%20following%201-month%20dual%20antiplatelet%20therapy%20in%20patients%20who%20underwent%20complex%20percutaneous%20coronary%20intervention%3A%20insights%20from%20the%20Global%20Leaders%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuniaki%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ply%22%2C%22lastName%22%3A%22Chichareon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihiro%22%2C%22lastName%22%3A%22Kogame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%22%2C%22lastName%22%3A%22Tomaniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Chin%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hidenori%22%2C%22lastName%22%3A%22Komiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Osama%22%2C%22lastName%22%3A%22Soliman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20J%22%2C%22lastName%22%3A%22Wykrzykowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robbert%20J%22%2C%22lastName%22%3A%22De%20Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurizio%22%2C%22lastName%22%3A%22Ferrario%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcello%22%2C%22lastName%22%3A%22Dominici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pawe%5Cu0142%22%2C%22lastName%22%3A%22Buszman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Bolognese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Tumscitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Benit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Peter%22%2C%22lastName%22%3A%22Stoll%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Onuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20evaluate%20the%20impact%20of%20an%20experimental%20strategy%20%5B23-month%20ticagrelor%20monotherapy%20following%201-month%20dual%20antiplatelet%20therapy%20%28DAPT%29%5D%20vs.%20a%20reference%20regimen%20%2812-month%20aspirin%20monotherapy%20following%2012-month%20DAPT%29%20after%20complex%20percutaneous%20coronary%20intervention%20%28PCI%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20present%20post%20hoc%20analysis%20of%20the%20Global%20Leaders%20trial%2C%20the%20primary%20endpoint%20%5Bcomposite%20of%20all-cause%20death%20or%20new%20Q-wave%20myocardial%20infarction%20%28MI%29%5D%20at%202%20years%20was%20assessed%20in%20patients%20with%20complex%20PCI%2C%20which%20includes%20at%20least%20one%20of%20the%20following%20characteristics%3A%20multivessel%20PCI%2C%20%5Cu22653%20stents%20implanted%2C%20%5Cu22653%20lesions%20treated%2C%20bifurcation%20PCI%20with%20%5Cu22652%20stents%2C%20or%20total%20stent%20length%20%26gt%3B60%20mm.%20In%20addition%2C%20patient-oriented%20composite%20endpoint%20%28POCE%29%20%28composite%20of%20all-cause%20death%2C%20any%20stroke%2C%20any%20MI%2C%20or%20any%20revascularization%29%20and%20net%20adverse%20clinical%20events%20%28NACE%29%20%5Bcomposite%20of%20POCE%20or%20Bleeding%20Academic%20Research%20Consortium%20%28BARC%29%20Type%203%20or%205%20bleeding%5D%20were%20explored.%20Among%2015%5Cu00a0450%20patients%20included%20in%20this%20analysis%2C%204570%20who%20underwent%20complex%20PCI%20had%20a%20higher%20risk%20of%20ischaemic%20and%20bleeding%20events.%20In%20patients%20with%20complex%20PCI%2C%20the%20experimental%20strategy%20significantly%20reduced%20risks%20of%20the%20primary%20endpoint%20%5Bhazard%20ratio%20%28HR%29%3A%200.64%2C%2095%25%20confidence%20interval%20%28CI%29%3A%200.48%5Cu20130.85%5D%20and%20POCE%20%28HR%3A%200.80%2C%2095%25%20CI%3A%200.69%5Cu20130.93%29%2C%20but%20not%20in%20those%20with%20non-complex%20PCI%20%28P%20%5Cu00a0interaction%20%3D%200.015%20and%200.017%2C%20respectively%29.%20The%20risk%20of%20BARC%20Type%203%20or%205%20bleeding%20was%20comparable%20%28HR%3A%200.97%2C%2095%25%20CI%3A%200.67%5Cu20131.40%29%2C%20resulting%20in%20a%20significant%20risk%20reduction%20in%20NACE%20%28HR%3A%200.80%2C%2095%25%20CI%3A%200.69%5Cu20130.92%3B%20P%20%5Cu00a0interaction%20%3D%200.011%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Ticagrelor%20monotherapy%20following%201-month%20DAPT%20could%20provide%20a%20net%20clinical%20benefit%20for%20patients%20with%20complex%20PCI.%20However%2C%20in%20view%20of%20the%20overall%20neutral%20results%20of%20the%20trial%2C%20these%20findings%20of%20a%20post%20hoc%20analysis%20should%20be%20considered%20as%20hypothesis%20generating.%22%2C%22date%22%3A%222019-08-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz453%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F31%5C%2F2595%5C%2F5545469%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22NHSCE8CT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22White%20et%20al.%22%2C%22parsedDate%22%3A%222019-09-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EWhite%20HD%2C%20Steg%20PG%2C%20Szarek%20M%2C%20Bhatt%20DL%2C%20Bittner%20VA%2C%20Diaz%20R%2C%20Edelberg%20JM%2C%20Erglis%20A%2C%20Goodman%20SG%2C%20Hanotin%20C%2C%20Harrington%20RA%2C%20Jukema%20JW%2C%20Lopes%20RD%2C%20Mahaffey%20KW%2C%20Moryusef%20A%2C%20Pordy%20R%2C%20Roe%20MT%2C%20Sritara%20P%2C%20Tricoci%20P%2C%20Zeiher%20AM%2C%20Schwartz%20GG%2C%20ODYSSEY%20OUTCOMES%20Investigators.%202019.%20Effects%20of%20alirocumab%20on%20types%20of%20myocardial%20infarction%3A%20insights%20from%20the%20ODYSSEY%20OUTCOMES%20trial.%20European%20Heart%20Journal%2040%3A2801%26%23x2013%3B2809.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20alirocumab%20on%20types%20of%20myocardial%20infarction%3A%20insights%20from%20the%20ODYSSEY%20OUTCOMES%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Szarek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%20A%22%2C%22lastName%22%3A%22Bittner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%20M%22%2C%22lastName%22%3A%22Edelberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrejs%22%2C%22lastName%22%3A%22Erglis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Hanotin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20Wouter%22%2C%22lastName%22%3A%22Jukema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20D%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angele%22%2C%22lastName%22%3A%22Moryusef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Pordy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T%22%2C%22lastName%22%3A%22Roe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piyamitr%22%2C%22lastName%22%3A%22Sritara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierluigi%22%2C%22lastName%22%3A%22Tricoci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20M%22%2C%22lastName%22%3A%22Zeiher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20G%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ODYSSEY%20OUTCOMES%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20third%20Universal%20Definition%20of%20Myocardial%20Infarction%20%28MI%29%20Task%20Force%20classified%20MIs%20into%20five%20types%3A%20Type%201%2C%20spontaneous%3B%20Type%202%2C%20related%20to%20oxygen%20supply%5C%2Fdemand%20imbalance%3B%20Type%203%2C%20fatal%20without%20ascertainment%20of%20cardiac%20biomarkers%3B%20Type%204%2C%20related%20to%20percutaneous%20coronary%20intervention%3B%20and%20Type%205%2C%20related%20to%20coronary%20artery%20bypass%20surgery.%20Low-density%20lipoprotein%20cholesterol%20%28LDL-C%29%20reduction%20with%20statins%20and%20proprotein%20convertase%20subtilisin%5Cu2013kexin%20Type%209%20%28PCSK9%29%20inhibitors%20reduces%20risk%20of%20MI%2C%20but%20less%20is%20known%20about%20effects%20on%20types%20of%20MI.%20ODYSSEY%20OUTCOMES%20compared%20the%20PCSK9%20inhibitor%20alirocumab%20with%20placebo%20in%2018%5Cu00a0924%20patients%20with%20recent%20acute%20coronary%20syndrome%20%28ACS%29%20and%20elevated%20LDL-C%20%28%5Cu22651.8%5Cu2009mmol%5C%2FL%29%20despite%20intensive%20statin%20therapy.%20In%20a%20pre-specified%20analysis%2C%20we%20assessed%20the%20effects%20of%20alirocumab%20on%20types%20of%20MI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Median%20follow-up%20was%202.8%5Cu2009years.%20Myocardial%20infarction%20types%20were%20prospectively%20adjudicated%20and%20classified.%20Of%201860%20total%20MIs%2C%201223%20%2865.8%25%29%20were%20adjudicated%20as%20Type%201%2C%20386%20%2820.8%25%29%20as%20Type%202%2C%20and%20244%20%2813.1%25%29%20as%20Type%204.%20Few%20events%20were%20Type%203%20%28n%5Cu2009%3D%5Cu20092%29%20or%20Type%205%20%28n%5Cu2009%3D%5Cu20095%29.%20Alirocumab%20reduced%20first%20MIs%20%5Bhazard%20ratio%20%28HR%29%200.85%2C%2095%25%20confidence%20interval%20%28CI%29%200.77%5Cu20130.95%3B%20P%5Cu2009%3D%5Cu20090.003%5D%2C%20with%20reductions%20in%20both%20Type%201%20%28HR%200.87%2C%2095%25%20CI%200.77%5Cu20130.99%3B%20P%5Cu2009%3D%5Cu20090.032%29%20and%20Type%202%20%280.77%2C%200.61%5Cu20130.97%3B%20P%5Cu2009%3D%5Cu20090.025%29%2C%20but%20not%20Type%204%20MI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cu2003%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20ACS%2C%20alirocumab%20added%20to%20intensive%20statin%20therapy%20favourably%20impacted%20on%20Type%201%20and%202%20MIs.%20The%20data%20indicate%20for%20the%20first%20time%20that%20a%20lipid-lowering%20therapy%20can%20attenuate%20the%20risk%20of%20Type%202%20MI.%20Low-density%20lipoprotein%20cholesterol%20reduction%20below%20levels%20achievable%20with%20statins%20is%20an%20effective%20preventive%20strategy%20for%20both%20MI%20types.%22%2C%22date%22%3A%222019-09-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz299%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F33%5C%2F2801%5C%2F5497814%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A58Z%22%7D%7D%2C%7B%22key%22%3A%22TPFTVG8M%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Oldgren%20et%20al.%22%2C%22parsedDate%22%3A%222019-05-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EOldgren%20J%2C%20Steg%20PG%2C%20Hohnloser%20SH%2C%20Lip%20GYH%2C%20Kimura%20T%2C%20Nordaby%20M%2C%20Brueckmann%20M%2C%20Kleine%20E%2C%20Ten%20Berg%20JM%2C%20Bhatt%20DL%2C%20Cannon%20CP.%202019.%20Dabigatran%20dual%20therapy%20with%20ticagrelor%20or%20clopidogrel%20after%20percutaneous%20coronary%20intervention%20in%20atrial%20fibrillation%20patients%20with%20or%20without%20acute%20coronary%20syndrome%3A%20a%20subgroup%20analysis%20from%20the%20RE-DUAL%20PCI%20trial.%20European%20Heart%20Journal%2040%3A1553%26%23x2013%3B1562.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dabigatran%20dual%20therapy%20with%20ticagrelor%20or%20clopidogrel%20after%20percutaneous%20coronary%20intervention%20in%20atrial%20fibrillation%20patients%20with%20or%20without%20acute%20coronary%20syndrome%3A%20a%20subgroup%20analysis%20from%20the%20RE-DUAL%20PCI%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonas%22%2C%22lastName%22%3A%22Oldgren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20H%22%2C%22lastName%22%3A%22Hohnloser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20Y%20H%22%2C%22lastName%22%3A%22Lip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takeshi%22%2C%22lastName%22%3A%22Kimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matias%22%2C%22lastName%22%3A%22Nordaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22Brueckmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Kleine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurrien%20M%22%2C%22lastName%22%3A%22Ten%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P%22%2C%22lastName%22%3A%22Cannon%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20percutaneous%20coronary%20intervention%20%28PCI%29%20in%20patients%20with%20atrial%20fibrillation%2C%20safety%20and%20efficacy%20with%20dabigatran%20dual%20therapy%20were%20evaluated%20in%20pre-specified%20subgroups%20of%20patients%20undergoing%20PCI%20due%20to%20acute%20coronary%20syndrome%20%28ACS%29%20or%20elective%20PCI%2C%20and%20those%20receiving%20ticagrelor%20or%20clopidogrel%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20RE-DUAL%20PCI%20trial%2C%202725%20patients%20were%20randomized%20to%20dabigatran%20110%5Cu2009mg%20or%20150%5Cu2009mg%20with%20P2Y12%20inhibitor%2C%20or%20warfarin%20with%20P2Y12%20inhibitor%20and%20aspirin.%20Mean%20follow-up%20was%2014%5Cu2009months%2C%2050.5%25%20had%20ACS%2C%20and%2012%25%20received%20ticagrelor.%20The%20risk%20of%20the%20primary%20endpoint%2C%20major%20or%20clinically%20relevant%20non-major%20bleeding%20event%2C%20was%20reduced%20with%20both%20dabigatran%20dual%20therapies%20vs.%20warfarin%20triple%20therapy%20in%20patients%20with%20ACS%20%5Bhazard%20ratio%20%2895%25%20confidence%20interval%29%2C%200.47%20%280.35%5Cu20130.63%29%20for%20110%5Cu2009mg%20and%200.67%20%280.50%5Cu20130.90%29%20for%20150%5Cu2009mg%5D%3B%20elective%20PCI%20%5B0.57%20%280.43%5Cu20130.76%29%20for%20110%5Cu2009mg%20and%200.76%20%280.56%5Cu20131.03%29%20for%20150%5Cu2009mg%5D%3B%20receiving%20ticagrelor%20%5B0.46%20%280.28%5Cu20130.76%29%20for%20110%5Cu2009mg%20and%200.59%20%280.34%5Cu20131.04%29%20for%20150%5Cu2009mg%5D%3B%20or%20clopidogrel%20%5B0.51%20%280.41%5Cu20130.64%29%20for%20110%5Cu2009mg%20and%200.73%20%280.58%5Cu20130.91%29%20for%20150%5Cu2009mg%5D%2C%20all%20interaction%20P-values%20%26gt%3B0.10.%20Overall%2C%20dabigatran%20dual%20therapy%20was%20comparable%20to%20warfarin%20triple%20therapy%20for%20the%20composite%20endpoint%20of%20death%2C%20myocardial%20infarction%2C%20stroke%2C%20systemic%20embolism%2C%20or%20unplanned%20revascularization%2C%20with%20minor%20variations%20across%20the%20subgroups%2C%20all%20interaction%20P-values%20%26gt%3B0.10.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20benefits%20of%20both%20dabigatran%20110%5Cu2009mg%20and%20150%5Cu2009mg%20dual%20therapy%20compared%20with%20warfarin%20triple%20therapy%20in%20reducing%20bleeding%20risks%20were%20consistent%20across%20subgroups%20of%20patients%20with%20or%20without%20ACS%2C%20and%20patients%20treated%20with%20ticagrelor%20or%20clopidogrel.%22%2C%22date%22%3A%222019-05-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz059%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F19%5C%2F1553%5C%2F5359476%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22P5XUZQ6Q%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abtan%20and%20Steg%22%2C%22parsedDate%22%3A%222019-04-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbtan%20J%2C%20Steg%20PG.%202019.%20Pre-treatment%20with%20a%20P2Y12%20antagonist%20before%20PCI%20in%20STEMI%3A%20why%20should%20we%20wait%3F%20European%20Heart%20Journal%2040%3A1211%26%23x2013%3B1213.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pre-treatment%20with%20a%20P2Y12%20antagonist%20before%20PCI%20in%20STEMI%3A%20why%20should%20we%20wait%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Abtan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-04-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehz058%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F15%5C%2F1211%5C%2F5372328%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22PVHHJ4N2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sorbets%20et%20al.%22%2C%22parsedDate%22%3A%222019-05-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESorbets%20E%2C%20Steg%20PG%2C%20Young%20R%2C%20Danchin%20N%2C%20Greenlaw%20N%2C%20Ford%20I%2C%20Tendera%20M%2C%20Ferrari%20R%2C%20Merkely%20B%2C%20Parkhomenko%20A%2C%20Reid%20C%2C%20Tardif%20J-C%2C%20Fox%20KM%2C%20for%20the%20CLARIFY%20investigators.%202019.%20%26%23x3B2%3B-blockers%2C%20calcium%20antagonists%2C%20and%20mortality%20in%20stable%20coronary%20artery%20disease%3A%20an%20international%20cohort%20study.%20European%20Heart%20Journal%2040%3A1399%26%23x2013%3B1407.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5Cu03b2-blockers%2C%20calcium%20antagonists%2C%20and%20mortality%20in%20stable%20coronary%20artery%20disease%3A%20an%20international%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sorbets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Greenlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bela%22%2C%22lastName%22%3A%22Merkely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Reid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20CLARIFY%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20effect%20of%20first-line%20antianginal%20agents%2C%20%5Cu03b2-blockers%2C%20and%20calcium%20antagonists%20on%20clinical%20outcomes%20in%20stable%20coronary%20artery%20disease%20%28CAD%29%20remains%20uncertain.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20analysed%20the%20use%20of%20%5Cu03b2-blockers%20or%20calcium%20antagonists%20%28baseline%20and%20annually%29%20and%20outcomes%20in%2022%5Cu00a0006%20stable%20CAD%20patients%20%28enrolled%202009%5Cu20132010%29%20followed%20annually%20to%205%5Cu2009years%2C%20in%20the%20CLARIFY%20registry%20%2845%20countries%29.%20Primary%20outcome%20was%20all-cause%20death.%20Secondary%20outcomes%20were%20cardiovascular%20death%20and%20the%20composite%20of%20cardiovascular%20death%5C%2Fnon-fatal%20myocardial%20infarction%20%28MI%29.%20After%20multivariable%20adjustment%2C%20baseline%20%5Cu03b2-blocker%20use%20was%20not%20associated%20with%20lower%20all-cause%20death%20%5B1345%20%287.8%25%29%20in%20users%20vs.%20407%20%288.4%25%29%20in%20non-users%3B%20hazard%20ratio%20%28HR%29%200.94%2C%2095%25%20confidence%20interval%20%28CI%29%200.84%5Cu20131.06%3B%20P%5Cu2009%3D%5Cu20090.30%5D%3B%20cardiovascular%20death%20%5B861%20%285.0%25%29%20vs.%20262%20%285.4%25%29%3B%20HR%200.91%2C%2095%25%20CI%200.79%5Cu20131.05%3B%20P%5Cu2009%3D%5Cu20090.20%5D%3B%20or%20cardiovascular%20death%5C%2Fnon-fatal%20MI%20%5B1272%20%287.4%25%29%20vs.%20340%20%287.0%25%29%3B%20HR%201.03%2C%2095%25%20CI%200.91%5Cu20131.16%3B%20P%5Cu2009%3D%5Cu20090.66%5D.%20Sensitivity%20analyses%20according%20to%20%5Cu03b2-blocker%20use%20over%20time%20and%20to%20prescribed%20dose%20produced%20similar%20results.%20Among%20prior%20MI%20patients%2C%20for%20those%20enrolled%20in%20the%20year%20following%20MI%2C%20baseline%20%5Cu03b2-blocker%20use%20was%20associated%20with%20lower%20all-cause%20death%20%5B205%20%287.0%25%29%20vs.%2059%20%2810.3%25%29%3B%20HR%200.68%2C%2095%25%20CI%200.50%5Cu20130.91%3B%20P%5Cu2009%3D%5Cu20090.01%5D%3B%20cardiovascular%20death%20%5B132%20%284.5%25%29%20vs.%2049%20%288.5%25%29%3B%20HR%200.52%2C%2095%25%20CI%200.37%5Cu20130.73%3B%20P%5Cu2009%3D%5Cu20090.0001%5D%3B%20and%20cardiovascular%20death%5C%2Fnon-fatal%20MI%20%5B212%20%287.2%25%29%20vs.%2059%20%2810.3%25%29%3B%20HR%200.69%2C%2095%25%20CI%200.52%5Cu20130.93%3B%20P%5Cu2009%3D%5Cu20090.01%5D.%20Calcium%20antagonists%20were%20not%20associated%20with%20any%20difference%20in%20mortality.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20contemporary%20cohort%20of%20stable%20CAD%2C%20%5Cu03b2-blocker%20use%20was%20associated%20with%20lower%205-year%20mortality%20only%20in%20patients%20enrolled%20in%20the%20year%20following%20MI.%20Use%20of%20calcium%20antagonists%20was%20not%20associated%20with%20superior%20mortality%2C%20regardless%20of%20history%20of%20MI.%22%2C%22date%22%3A%222019-05-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehy811%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F18%5C%2F1399%5C%2F5263772%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22GDHS63XI%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thygesen%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EThygesen%20K%2C%20Alpert%20JS%2C%20Jaffe%20AS%2C%20Chaitman%20BR%2C%20Bax%20JJ%2C%20Morrow%20DA%2C%20White%20HD%2C%20ESC%20Scientific%20Document%20Group%2C%20Thygesen%20K%2C%20Alpert%20JS%2C%20Jaffe%20AS%2C%20Chaitman%20BR%2C%20Bax%20JJ%2C%20Morrow%20DA%2C%20White%20HD%2C%20Mickley%20H%2C%20Crea%20F%2C%20Van%20De%20Werf%20F%2C%20Bucciarelli-Ducci%20C%2C%20Katus%20HA%2C%20Pinto%20FJ%2C%20Antman%20EM%2C%20Hamm%20CW%2C%20De%20Caterina%20R%2C%20Januzzi%20JL%2C%20Apple%20FS%2C%20Alonso%20Garcia%20MA%2C%20Underwood%20SR%2C%20Canty%20JM%2C%20Lyon%20AR%2C%20Devereaux%20PJ%2C%20Zamorano%20JL%2C%20Lindahl%20B%2C%20Weintraub%20WS%2C%20Newby%20LK%2C%20Virmani%20R%2C%20Vranckx%20P%2C%20Cutlip%20D%2C%20Gibbons%20RJ%2C%20Smith%20SC%2C%20Atar%20D%2C%20Luepker%20RV%2C%20Robertson%20RM%2C%20Bonow%20RO%2C%20Steg%20PG%2C%20O%26%23x2019%3BGara%20PT%2C%20Fox%20KAA%2C%20Hasdai%20D%2C%20Aboyans%20V%2C%20Achenbach%20S%2C%20Agewall%20S%2C%20Alexander%20T%2C%20Avezum%20A%2C%20Barbato%20E%2C%20Bassand%20J-P%2C%20Bates%20E%2C%20Bittl%20JA%2C%20Breithardt%20G%2C%20Bueno%20H%2C%20Bugiardini%20R%2C%20Cohen%20MG%2C%20Dangas%20G%2C%20De%20Lemos%20JA%2C%20Delgado%20V%2C%20Filippatos%20G%2C%20Fry%20E%2C%20Granger%20CB%2C%20Halvorsen%20S%2C%20Hlatky%20MA%2C%20Ibanez%20B%2C%20James%20S%2C%20Kastrati%20A%2C%20Leclercq%20C%2C%20Mahaffey%20KW%2C%20Mehta%20L%2C%20M%26%23xFC%3Bller%20C%2C%20Patrono%20C%2C%20Piepoli%20MF%2C%20Pi%26%23xF1%3Beiro%20D%2C%20Roffi%20M%2C%20Rubboli%20A%2C%20Sharma%20S%2C%20Simpson%20IA%2C%20Tendera%20M%2C%20Valgimigli%20M%2C%20Van%20Der%20Wal%20AC%2C%20Windecker%20S%2C%20Chettibi%20M%2C%20Hayrapetyan%20H%2C%20Roithinger%20FX%2C%20Aliyev%20F%2C%20Sujayeva%20V%2C%20Claeys%20MJ%2C%20Smaji%26%23x107%3B%20E%2C%20Kala%20P%2C%20Iversen%20KK%2C%20El%20Hefny%20E%2C%20Marandi%20T%2C%20Porela%20P%2C%20Antov%20S%2C%20Gilard%20M%2C%20Blankenberg%20S%2C%20Davlouros%20P%2C%20Gudnason%20T%2C%20Alcalai%20R%2C%20Colivicchi%20F%2C%20Elezi%20S%2C%20Baitova%20G%2C%20Zakke%20I%2C%20Gustiene%20O%2C%20Beissel%20J%2C%20Dingli%20P%2C%20Grosu%20A%2C%20Damman%20P%2C%20Julieb%26%23xF8%3B%20V%2C%20Legutko%20J%2C%20Morais%20J%2C%20Tatu-Chitoiu%20G%2C%20Yakovlev%20A%2C%20Zavatta%20M%2C%20Nedeljkovic%20M%2C%20Radsel%20P%2C%20Sionis%20A%2C%20Jemberg%20T%2C%20M%26%23xFC%3Bller%20C%2C%20Abid%20L%2C%20Abaci%20A%2C%20Parkhomenko%20A%2C%20Corbett%20S.%202019.%20Fourth%20universal%20definition%20of%20myocardial%20infarction%20%282018%29.%20European%20Heart%20Journal%2040%3A237%26%23x2013%3B269.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fourth%20universal%20definition%20of%20myocardial%20infarction%20%282018%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristian%22%2C%22lastName%22%3A%22Thygesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S%22%2C%22lastName%22%3A%22Alpert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allan%20S%22%2C%22lastName%22%3A%22Jaffe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%20R%22%2C%22lastName%22%3A%22Chaitman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeroen%20J%22%2C%22lastName%22%3A%22Bax%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A%22%2C%22lastName%22%3A%22Morrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ESC%20Scientific%20Document%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristian%22%2C%22lastName%22%3A%22Thygesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S%22%2C%22lastName%22%3A%22Alpert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allan%20S%22%2C%22lastName%22%3A%22Jaffe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%20R%22%2C%22lastName%22%3A%22Chaitman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeroen%20J%22%2C%22lastName%22%3A%22Bax%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A%22%2C%22lastName%22%3A%22Morrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%22%2C%22lastName%22%3A%22Mickley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Filippo%22%2C%22lastName%22%3A%22Crea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frans%22%2C%22lastName%22%3A%22Van%20De%20Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Bucciarelli-Ducci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%20A%22%2C%22lastName%22%3A%22Katus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%20J%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elliott%20M%22%2C%22lastName%22%3A%22Antman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22De%20Caterina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20L%22%2C%22lastName%22%3A%22Januzzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fred%20S%22%2C%22lastName%22%3A%22Apple%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Angeles%22%2C%22lastName%22%3A%22Alonso%20Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20Richard%22%2C%22lastName%22%3A%22Underwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20M%22%2C%22lastName%22%3A%22Canty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20R%22%2C%22lastName%22%3A%22Lyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20J%22%2C%22lastName%22%3A%22Devereaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Luis%22%2C%22lastName%22%3A%22Zamorano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertil%22%2C%22lastName%22%3A%22Lindahl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20S%22%2C%22lastName%22%3A%22Weintraub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Kristin%22%2C%22lastName%22%3A%22Newby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renu%22%2C%22lastName%22%3A%22Virmani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don%22%2C%22lastName%22%3A%22Cutlip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%20J%22%2C%22lastName%22%3A%22Gibbons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sidney%20C%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Atar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Russell%20V%22%2C%22lastName%22%3A%22Luepker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rose%20Marie%22%2C%22lastName%22%3A%22Robertson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20O%22%2C%22lastName%22%3A%22Bonow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20T%22%2C%22lastName%22%3A%22O%5Cu2019Gara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A%20A%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Hasdai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Aboyans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Achenbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Agewall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Avezum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Barbato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Bassand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Bates%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20A%22%2C%22lastName%22%3A%22Bittl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00fcenter%22%2C%22lastName%22%3A%22Breithardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9ctor%22%2C%22lastName%22%3A%22Bueno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22Bugiardini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mauricio%20G%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20A%22%2C%22lastName%22%3A%22De%20Lemos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerasimos%22%2C%22lastName%22%3A%22Filippatos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%22%2C%22lastName%22%3A%22Fry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20B%22%2C%22lastName%22%3A%22Granger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sigrun%22%2C%22lastName%22%3A%22Halvorsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20A%22%2C%22lastName%22%3A%22Hlatky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Borja%22%2C%22lastName%22%3A%22Ibanez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22James%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Leclercq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laxmi%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22M%5Cu00fcller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Patrono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%20Francesco%22%2C%22lastName%22%3A%22Piepoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Pi%5Cu00f1eiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Roffi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Rubboli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samin%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iain%20A%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Tendera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allard%20C%22%2C%22lastName%22%3A%22Van%20Der%20Wal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Chettibi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hamlet%22%2C%22lastName%22%3A%22Hayrapetyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz%20Xaver%22%2C%22lastName%22%3A%22Roithinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farid%22%2C%22lastName%22%3A%22Aliyev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volha%22%2C%22lastName%22%3A%22Sujayeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20J%22%2C%22lastName%22%3A%22Claeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elnur%22%2C%22lastName%22%3A%22Smaji%5Cu0107%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Kala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kasper%20Karmak%22%2C%22lastName%22%3A%22Iversen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ehab%22%2C%22lastName%22%3A%22El%20Hefny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toomas%22%2C%22lastName%22%3A%22Marandi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pekka%22%2C%22lastName%22%3A%22Porela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Slobodan%22%2C%22lastName%22%3A%22Antov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Gilard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Blankenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Periklis%22%2C%22lastName%22%3A%22Davlouros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thorarinn%22%2C%22lastName%22%3A%22Gudnason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronny%22%2C%22lastName%22%3A%22Alcalai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Furio%22%2C%22lastName%22%3A%22Colivicchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shpend%22%2C%22lastName%22%3A%22Elezi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulmira%22%2C%22lastName%22%3A%22Baitova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilja%22%2C%22lastName%22%3A%22Zakke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivija%22%2C%22lastName%22%3A%22Gustiene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Beissel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Dingli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurel%22%2C%22lastName%22%3A%22Grosu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Damman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vibeke%22%2C%22lastName%22%3A%22Julieb%5Cu00f8%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacek%22%2C%22lastName%22%3A%22Legutko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00e4o%22%2C%22lastName%22%3A%22Morais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Tatu-Chitoiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexey%22%2C%22lastName%22%3A%22Yakovlev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Zavatta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milan%22%2C%22lastName%22%3A%22Nedeljkovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Radsel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Sionis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Jemberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22M%5Cu00fcller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Abid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Abaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandr%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Corbett%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-01-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehy462%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F3%5C%2F237%5C%2F5079081%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A51Z%22%7D%7D%2C%7B%22key%22%3A%227E79AB3V%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valgimigli%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EValgimigli%20M%2C%20Garcia-Garcia%20HM%2C%20Vrijens%20B%2C%20Vranckx%20P%2C%20McFadden%20EP%2C%20Costa%20F%2C%20Pieper%20K%2C%20Vock%20DM%2C%20Zhang%20M%2C%20Van%20Es%20G-A%2C%20Tricoci%20P%2C%20Baber%20U%2C%20Steg%20G%2C%20Montalescot%20G%2C%20Angiolillo%20DJ%2C%20Serruys%20PW%2C%20Farb%20A%2C%20Windecker%20S%2C%20Kastrati%20A%2C%20Colombo%20A%2C%20Feres%20F%2C%20J%26%23xFC%3Bni%20P%2C%20Stone%20GW%2C%20Bhatt%20DL%2C%20Mehran%20R%2C%20Tijssen%20JGP.%202019.%20Standardized%20classification%20and%20framework%20for%20reporting%2C%20interpreting%2C%20and%20analysing%20medication%20non-adherence%20in%20cardiovascular%20clinical%20trials%3A%20a%20consensus%20report%20from%20the%20Non-adherence%20Academic%20Research%20Consortium%20%28NARC%29.%20European%20Heart%20Journal%2040%3A2070%26%23x2013%3B2085.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Standardized%20classification%20and%20framework%20for%20reporting%2C%20interpreting%2C%20and%20analysing%20medication%20non-adherence%20in%20cardiovascular%20clinical%20trials%3A%20a%20consensus%20report%20from%20the%20Non-adherence%20Academic%20Research%20Consortium%20%28NARC%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Valgimigli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hector%20M%22%2C%22lastName%22%3A%22Garcia-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Vrijens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Vranckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%20P%22%2C%22lastName%22%3A%22McFadden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Pieper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20M%22%2C%22lastName%22%3A%22Vock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Min%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerrit-Anne%22%2C%22lastName%22%3A%22Van%20Es%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierluigi%22%2C%22lastName%22%3A%22Tricoci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%20J%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Farb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Windecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%22%2C%22lastName%22%3A%22Feres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22J%5Cu00fcni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20G%20P%22%2C%22lastName%22%3A%22Tijssen%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Non-adherence%20has%20been%20well%20recognized%20for%20years%20to%20be%20a%20common%20issue%20that%20significantly%20impacts%20clinical%20outcomes%20and%20health%20care%20costs.%20Medication%20adherence%20is%20remarkably%20low%20even%20in%20the%20controlled%20environment%20of%20clinical%20trials%20where%20it%20has%20potentially%20complex%20major%20implications.%20Collection%20of%20non-adherence%20data%20diverge%20markedly%20among%20cardiovascular%20randomized%20trials%20and%2C%20even%20where%20collected%2C%20is%20rarely%20incorporated%20in%20the%20statistical%20analysis%20to%20test%20the%20consistency%20of%20the%20primary%20endpoint%28s%29.%20The%20imprecision%20introduced%20by%20the%20inconsistent%20assessment%20of%20non-adherence%20in%20clinical%20trials%20might%20confound%20the%20estimate%20of%20the%20calculated%20efficacy%20of%20the%20study%20drug.%20Hence%2C%20clinical%20trials%20may%20not%20accurately%20answer%20the%20scientific%20question%20posed%20by%20regulators%2C%20who%20seek%20an%20accurate%20estimate%20of%20the%20true%20efficacy%20and%20safety%20of%20treatment%2C%20or%20the%20question%20posed%20by%20payers%2C%20who%20want%20a%20reliable%20estimate%20of%20the%20effectiveness%20of%20treatment%20in%20the%20marketplace%20after%20approval.%20The%20Non-adherence%20Academic%20Research%20Consortium%20is%20a%20collaboration%20among%20leading%20academic%20research%20organizations%2C%20representatives%20from%20the%20U.S.%20Food%20and%20Drug%20Administration%20and%20physician-scientists%20from%20the%20USA%20and%20Europe.%20One%20in-person%20meeting%20was%20held%20in%20Madrid%2C%20Spain%2C%20culminating%20in%20a%20document%20describing%20consensus%20recommendations%20for%20reporting%2C%20collecting%2C%20and%20analysing%20adherence%20endpoints%20across%20clinical%20trials.%20The%20adoption%20of%20these%20recommendations%20will%20afford%20robustness%20and%20consistency%20in%20the%20comparative%20safety%20and%20effectiveness%20evaluation%20of%20investigational%20drugs%20from%20early%20development%20to%20post-marketing%20approval%20studies.%20These%20principles%20may%20be%20useful%20for%20regulatory%20assessment%2C%20as%20well%20as%20for%20monitoring%20local%20and%20regional%20outcomes%20to%20guide%20quality%20improvement%20initiatives.%22%2C%22date%22%3A%222019-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehy377%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F25%5C%2F2070%5C%2F5050879%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22KZTQHDHE%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fox%20et%20al.%22%2C%22parsedDate%22%3A%222019-05-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFox%20KAA%2C%20Eikelboom%20JW%2C%20Anand%20SS%2C%20Bhatt%20DL%2C%20Bosch%20J%2C%20Connolly%20SJ%2C%20Harrington%20RA%2C%20Steg%20PG%2C%20Yusuf%20S.%202019.%20Anti-thrombotic%20options%20for%20secondary%20prevention%20in%20patients%20with%20chronic%20atherosclerotic%20vascular%20disease%3A%20what%20does%20COMPASS%20add%3F%20European%20Heart%20Journal%2040%3A1466%26%23x2013%3B1471.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-thrombotic%20options%20for%20secondary%20prevention%20in%20patients%20with%20chronic%20atherosclerotic%20vascular%20disease%3A%20what%20does%20COMPASS%20add%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20A%20A%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20W%22%2C%22lastName%22%3A%22Eikelboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20S%22%2C%22lastName%22%3A%22Anand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%20J%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%20A%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20G%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Yusuf%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-05-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehy347%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F40%5C%2F18%5C%2F1466%5C%2F5045239%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22LA64E6CJ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dellborg%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDellborg%20M%2C%20Bonaca%20MP%2C%20Storey%20RF%2C%20Steg%20PG%2C%20Im%20KA%2C%20Cohen%20M%2C%20Bhatt%20DL%2C%20Oude%20Ophuis%20T%2C%20Budaj%20A%2C%20Hamm%20C%2C%20Spinar%20J%2C%20Kiss%20RG%2C%20Lopez-Sendon%20J%2C%20Kamensky%20G%2C%20Van%20De%20Werf%20F%2C%20Ardissino%20D%2C%20Kontny%20F%2C%20Montalescot%20G%2C%20Johanson%20P%2C%20Bengtsson%20O%2C%20Himmelmann%20A%2C%20Braunwald%20E%2C%20Sabatine%20MS.%202019.%20Efficacy%20and%20safety%20with%20ticagrelor%20in%20patients%20with%20prior%20myocardial%20infarction%20in%20the%20approved%20European%20label%3A%20insights%20from%20PEGASUS-TIMI%2054.%20European%20Heart%20Journal%20-%20Cardiovascular%20Pharmacotherapy%205%3A200%26%23x2013%3B206.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20safety%20with%20ticagrelor%20in%20patients%20with%20prior%20myocardial%20infarction%20in%20the%20approved%20European%20label%3A%20insights%20from%20PEGASUS-TIMI%2054%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Dellborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P%22%2C%22lastName%22%3A%22Bonaca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyung%20A%22%2C%22lastName%22%3A%22Im%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ton%22%2C%22lastName%22%3A%22Oude%20Ophuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrezej%22%2C%22lastName%22%3A%22Budaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jindrich%22%2C%22lastName%22%3A%22Spinar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20G%22%2C%22lastName%22%3A%22Kiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Lopez-Sendon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Kamensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frans%22%2C%22lastName%22%3A%22Van%20De%20Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%22%2C%22lastName%22%3A%22Ardissino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Kontny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Johanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olof%22%2C%22lastName%22%3A%22Bengtsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22Himmelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Braunwald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S%22%2C%22lastName%22%3A%22Sabatine%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Aims%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20PEGASUS-TIMI%2054%2C%20ticagrelor%20significantly%20reduced%20the%20risk%20of%20the%20composite%20of%20major%20adverse%20cardiovascular%20%28CV%29%20events%20by%2015%5Cu201316%25%20in%20stable%20patients%20with%20a%20prior%20myocardial%20infarction%20%28MI%29%201%5Cu20133%5Cu2009years%20earlier.%20We%20report%20the%20efficacy%20and%20safety%20in%20the%20subpopulation%20recommended%20for%20treatment%20in%20the%20European%20%28EU%29%20label%2C%20i.e.%20treatment%20with%2060%5Cu2009mg%20b.i.d.%20initiated%20up%20to%202%5Cu2009years%20from%20the%20MI%2C%20or%20within%201%20year%20after%20stopping%20previous%20adenosine%20diphosphate%20receptor%20inhibitor%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Of%20the%2021%5Cu00a0162%20patients%20enrolled%20in%20PEGASUS-TIMI%2054%2C%2010%5Cu00a0779%20patients%20were%20included%20in%20the%20primary%20analysis%20for%20this%20study%2C%20randomized%20to%20ticagrelor%2060%5Cu2009mg%20%28n%5Cu2009%3D%5Cu20095388%29%20or%20matching%20placebo%20%28n%5Cu2009%3D%5Cu20095391%29.%20The%20cumulative%20proportions%20of%20patients%20with%20events%20at%2036%5Cu2009months%20were%20calculated%20by%20the%20Kaplan%5Cu2013Meier%20%28KM%29%20method.%20The%20composite%20of%20CV%20death%2C%20MI%2C%20or%20stroke%20occurred%20less%20frequently%20in%20the%20ticagrelor%20group%20%287.9%25%20KM%20rate%20vs.%209.6%25%29%2C%20hazard%20ratio%20%28HR%29%200.80%20%5B95%25%20confidence%20interval%20%28CI%29%200.70%5Cu20130.91%3B%20P%5Cu2009%3D%5Cu20090.001%5D.%20Ticagrelor%20also%20reduced%20the%20risk%20of%20all-cause%20mortality%2C%20HR%200.80%20%280.67%5Cu20130.96%3B%20P%5Cu2009%3D%5Cu20090.018%29.%20Thrombolysis%20in%20myocardial%20infarction%20major%20bleeding%20was%20more%20frequent%20in%20the%20ticagrelor%20group%202.5%25%20vs.%201.1%25%3B%20HR%202.36%20%281.65%5Cu20133.39%3B%20P%5Cu2009%3C%5Cu20090.001%29.%20The%20corresponding%20HR%20for%20fatal%20or%20intracranial%20bleeding%20was%201.17%20%280.68%5Cu20132.01%3B%20P%5Cu2009%3D%5Cu20090.58%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20PEGASUS-TIMI%2054%2C%20treatment%20with%20ticagrelor%2060%5Cu2009mg%20as%20recommended%20in%20the%20EU%20label%2C%20was%20associated%20with%20a%20relative%20risk%20reduction%20of%2020%25%20in%20CV%20death%2C%20MI%2C%20or%20stroke.%20Thrombolysis%20in%20myocardial%20infarction%20major%20bleeding%20was%20increased%2C%20but%20fatal%20or%20intracranial%20bleeding%20was%20similar%20to%20placebo.%20There%20appears%20to%20be%20a%20favourable%20benefit-risk%20ratio%20for%20long-term%20ticagrelor%2060%5Cu2009mg%20in%20this%20population.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20trial%20registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%20NCT01225562%22%2C%22date%22%3A%222019-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjcvp%5C%2Fpvz020%22%2C%22ISSN%22%3A%222055-6837%2C%202055-6845%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjcvp%5C%2Farticle%5C%2F5%5C%2F4%5C%2F200%5C%2F5520942%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22K2VJ659M%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stone%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EStone%20GW%2C%20Kappetein%20AP%2C%20Sabik%20JF%2C%20Pocock%20SJ%2C%20Morice%20M-C%2C%20Puskas%20J%2C%20Kandzari%20DE%2C%20Karmpaliotis%20D%2C%20Brown%20WM%2C%20Lembo%20NJ%2C%20Banning%20A%2C%20Merkely%20B%2C%20Horkay%20F%2C%20Boonstra%20PW%2C%20Van%20Boven%20AJ%2C%20Ungi%20I%2C%20Bog%26%23xE1%3Bts%20G%2C%20Mansour%20S%2C%20Noiseux%20N%2C%20Sabat%26%23xE9%3B%20M%2C%20Pomar%20J%2C%20Hickey%20M%2C%20Gershlick%20A%2C%20Buszman%20PE%2C%20Bochenek%20A%2C%20Schampaert%20E%2C%20Pag%26%23xE9%3B%20P%2C%20Modolo%20R%2C%20Gregson%20J%2C%20Simonton%20CA%2C%20Mehran%20R%2C%20Kosmidou%20I%2C%20G%26%23xE9%3Bn%26%23xE9%3Breux%20P%2C%20Crowley%20A%2C%20Dressler%20O%2C%20Serruys%20PW.%202019.%20Five-Year%20Outcomes%20after%20PCI%20or%20CABG%20for%20Left%20Main%20Coronary%20Disease.%20N%20Engl%20J%20Med%20381%3A1820%26%23x2013%3B1830.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Five-Year%20Outcomes%20after%20PCI%20or%20CABG%20for%20Left%20Main%20Coronary%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20Pieter%22%2C%22lastName%22%3A%22Kappetein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20F.%22%2C%22lastName%22%3A%22Sabik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Claude%22%2C%22lastName%22%3A%22Morice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Puskas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20E.%22%2C%22lastName%22%3A%22Kandzari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitri%22%2C%22lastName%22%3A%22Karmpaliotis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20Morris%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20J.%22%2C%22lastName%22%3A%22Lembo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%22%2C%22lastName%22%3A%22Banning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9la%22%2C%22lastName%22%3A%22Merkely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferenc%22%2C%22lastName%22%3A%22Horkay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piet%20W.%22%2C%22lastName%22%3A%22Boonstra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ad%20J.%22%2C%22lastName%22%3A%22Van%20Boven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imre%22%2C%22lastName%22%3A%22Ungi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabor%22%2C%22lastName%22%3A%22Bog%5Cu00e1ts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samer%22%2C%22lastName%22%3A%22Mansour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Noiseux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Sabat%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Pomar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Hickey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Gershlick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pawel%20E.%22%2C%22lastName%22%3A%22Buszman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrzej%22%2C%22lastName%22%3A%22Bochenek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erick%22%2C%22lastName%22%3A%22Schampaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Pag%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Modolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Gregson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20A.%22%2C%22lastName%22%3A%22Simonton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioanna%22%2C%22lastName%22%3A%22Kosmidou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22G%5Cu00e9n%5Cu00e9reux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aaron%22%2C%22lastName%22%3A%22Crowley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ovidiu%22%2C%22lastName%22%3A%22Dressler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-11-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1909406%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1909406%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22JIZ78WXD%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mehran%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMehran%20R%2C%20Baber%20U%2C%20Sharma%20SK%2C%20Cohen%20DJ%2C%20Angiolillo%20DJ%2C%20Briguori%20C%2C%20Cha%20JY%2C%20Collier%20T%2C%20Dangas%20G%2C%20Dudek%20D%2C%20D%26%23x17E%3Bav%26%23xED%3Bk%20V%2C%20Escaned%20J%2C%20Gil%20R%2C%20Gurbel%20P%2C%20Hamm%20CW%2C%20Henry%20T%2C%20Huber%20K%2C%20Kastrati%20A%2C%20Kaul%20U%2C%20Kornowski%20R%2C%20Krucoff%20M%2C%20Kunadian%20V%2C%20Marx%20SO%2C%20Mehta%20SR%2C%20Moliterno%20D%2C%20Ohman%20EM%2C%20Oldroyd%20K%2C%20Sardella%20G%2C%20Sartori%20S%2C%20Shlofmitz%20R%2C%20Steg%20PG%2C%20Weisz%20G%2C%20Witzenbichler%20B%2C%20Han%20Y%2C%20Pocock%20S%2C%20Gibson%20CM.%202019.%20Ticagrelor%20with%20or%20without%20Aspirin%20in%20High-Risk%20Patients%20after%20PCI.%20N%20Engl%20J%20Med%20381%3A2032%26%23x2013%3B2042.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ticagrelor%20with%20or%20without%20Aspirin%20in%20High-Risk%20Patients%20after%20PCI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samin%20K.%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%20J.%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Briguori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jin%20Y.%22%2C%22lastName%22%3A%22Cha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Collier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dariusz%22%2C%22lastName%22%3A%22Dudek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladim%5Cu00edr%22%2C%22lastName%22%3A%22D%5Cu017eav%5Cu00edk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Escaned%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Gurbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W.%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Huber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Kaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Kornowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%22%2C%22lastName%22%3A%22Krucoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Kunadian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20O.%22%2C%22lastName%22%3A%22Marx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Moliterno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Magnus%22%2C%22lastName%22%3A%22Ohman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Oldroyd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gennaro%22%2C%22lastName%22%3A%22Sardella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Shlofmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giora%22%2C%22lastName%22%3A%22Weisz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernhard%22%2C%22lastName%22%3A%22Witzenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ya-ling%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-11-21%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1908419%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1908419%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A43Z%22%7D%7D%2C%7B%22key%22%3A%228DW69ZQU%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Steg%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESteg%20PG%2C%20Bhatt%20DL%2C%20Simon%20T%2C%20Fox%20K%2C%20Mehta%20SR%2C%20Harrington%20RA%2C%20Held%20C%2C%20Andersson%20M%2C%20Himmelmann%20A%2C%20Ridderstr%26%23xE5%3Ble%20W%2C%20Leonsson-Zachrisson%20M%2C%20Liu%20Y%2C%20Opolski%20G%2C%20Zateyshchikov%20D%2C%20Ge%20J%2C%20Nicolau%20JC%2C%20Corbal%26%23xE1%3Bn%20R%2C%20Cornel%20JH%2C%20Widimsk%26%23xFD%3B%20P%2C%20Leiter%20LA.%202019.%20Ticagrelor%20in%20Patients%20with%20Stable%20Coronary%20Disease%20and%20Diabetes.%20N%20Engl%20J%20Med%20381%3A1309%26%23x2013%3B1320.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ticagrelor%20in%20Patients%20with%20Stable%20Coronary%20Disease%20and%20Diabetes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marielle%22%2C%22lastName%22%3A%22Andersson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22Himmelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilhelm%22%2C%22lastName%22%3A%22Ridderstr%5Cu00e5le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Leonsson-Zachrisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuyin%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grzegorz%22%2C%22lastName%22%3A%22Opolski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dmitry%22%2C%22lastName%22%3A%22Zateyshchikov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junbo%22%2C%22lastName%22%3A%22Ge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20C.%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ram%5Cu00f3n%22%2C%22lastName%22%3A%22Corbal%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20H.%22%2C%22lastName%22%3A%22Cornel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Widimsk%5Cu00fd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%20A.%22%2C%22lastName%22%3A%22Leiter%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-10-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1908077%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1908077%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22ASJDZLJ4%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mehta%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMehta%20SR%2C%20Wood%20DA%2C%20Storey%20RF%2C%20Mehran%20R%2C%20Bainey%20KR%2C%20Nguyen%20H%2C%20Meeks%20B%2C%20Di%20Pasquale%20G%2C%20L%26%23xF3%3Bpez-Send%26%23xF3%3Bn%20J%2C%20Faxon%20DP%2C%20Mauri%20L%2C%20Rao%20SV%2C%20Feldman%20L%2C%20Steg%20PG%2C%20Avezum%20%26%23xC1%3B%2C%20Sheth%20T%2C%20Pinilla-Echeverri%20N%2C%20Moreno%20R%2C%20Campo%20G%2C%20Wrigley%20B%2C%20Kedev%20S%2C%20Sutton%20A%2C%20Oliver%20R%2C%20Rod%26%23xE9%3Bs-Cabau%20J%2C%20Stankovi%26%23x107%3B%20G%2C%20Welsh%20R%2C%20Lavi%20S%2C%20Cantor%20WJ%2C%20Wang%20J%2C%20Nakamya%20J%2C%20Bangdiwala%20SI%2C%20Cairns%20JA.%202019.%20Complete%20Revascularization%20with%20Multivessel%20PCI%20for%20Myocardial%20Infarction.%20N%20Engl%20J%20Med%20381%3A1411%26%23x2013%3B1421.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Complete%20Revascularization%20with%20Multivessel%20PCI%20for%20Myocardial%20Infarction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Wood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20R.%22%2C%22lastName%22%3A%22Bainey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brandi%22%2C%22lastName%22%3A%22Meeks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Di%20Pasquale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20P.%22%2C%22lastName%22%3A%22Faxon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Mauri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunil%20V.%22%2C%22lastName%22%3A%22Rao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1lvaro%22%2C%22lastName%22%3A%22Avezum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tej%22%2C%22lastName%22%3A%22Sheth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Pinilla-Echeverri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raul%22%2C%22lastName%22%3A%22Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gianluca%22%2C%22lastName%22%3A%22Campo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Wrigley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sasko%22%2C%22lastName%22%3A%22Kedev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Sutton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Oliver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%22%2C%22lastName%22%3A%22Rod%5Cu00e9s-Cabau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Goran%22%2C%22lastName%22%3A%22Stankovi%5Cu0107%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Welsh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahar%22%2C%22lastName%22%3A%22Lavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Warren%20J.%22%2C%22lastName%22%3A%22Cantor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jia%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliet%22%2C%22lastName%22%3A%22Nakamya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shrikant%20I.%22%2C%22lastName%22%3A%22Bangdiwala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20A.%22%2C%22lastName%22%3A%22Cairns%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-10-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1907775%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1907775%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22HD38SYAV%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bhatt%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBhatt%20DL%2C%20Steg%20PG%2C%20Miller%20M%2C%20Brinton%20EA%2C%20Jacobson%20TA%2C%20Ketchum%20SB%2C%20Doyle%20RT%2C%20Juliano%20RA%2C%20Jiao%20L%2C%20Granowitz%20C%2C%20Tardif%20J-C%2C%20Ballantyne%20CM.%202019.%20Cardiovascular%20Risk%20Reduction%20with%20Icosapent%20Ethyl%20for%20Hypertriglyceridemia.%20N%20Engl%20J%20Med%20380%3A11%26%23x2013%3B22.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiovascular%20Risk%20Reduction%20with%20Icosapent%20Ethyl%20for%20Hypertriglyceridemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliot%20A.%22%2C%22lastName%22%3A%22Brinton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%20A.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20B.%22%2C%22lastName%22%3A%22Ketchum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20T.%22%2C%22lastName%22%3A%22Doyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%20A.%22%2C%22lastName%22%3A%22Juliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lixia%22%2C%22lastName%22%3A%22Jiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%22%2C%22lastName%22%3A%22Granowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-01-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1812792%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1812792%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22TRUHCPQH%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22parsedDate%22%3A%222019-09-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3E%202019.%20Open%20versus%20Endovascular%20Repair%20of%20Abdominal%20Aortic%20Aneurysm.%20N%20Engl%20J%20Med%20381%3Ae24.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Open%20versus%20Endovascular%20Repair%20of%20Abdominal%20Aortic%20Aneurysm%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-09-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMc1908829%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMc1908829%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A28Z%22%7D%7D%5D%7D1.Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Spitzer E, Walsh SJ, Adlam D, Hildick-Smith D, Édes I, Van De Harst P, Krackhardt F, Tijssen JGP, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt FWA. 2019. Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention 15:e1090–e1098.1.Chichareon P, Onuma Y, Van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Asano T, Katagiri Y, Van Geuns R-JM, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek JJ, Spitzer E, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Serruys PW. 2019. Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention 15:e539–e546.1.Vidal-Petiot E, Greenlaw N, Kalra PR, Garcia-Moll X, Tardif J-C, Ford I, Zamorano J, Ferrari R, Tendera M, Fox KM, Steg PG, on behalf of the CLARIFY investigators on behalf of the CLARIFY investigators. 2019. Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. JCM 9:4.1.Breyer RM, Clapp L, Coleman RA, Giembycz M, Heinemann A, Hills R, Jones RL, Narumiya S, Norel X, Pettipher R, Sugimoto Y, Uddin M, Woodward DF, Yao C. 2019. Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. GtoPdb CITE 2019.1.Breyer RM, Clapp L, Coleman RA, Giembycz M, Heinemann A, Hills R, Jones RL, Narumiya S, Norel X, Pettipher R, Sugimoto Y, Woodward DF, Yao C. 2019. Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. GtoPdb CITE 2019.1.Parma Z, Young R, Roleder T, Marona M, Ford I, Tendera M, Steg PG, Stępińska J. 2019. Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease in the CLARIFY registry versus other European countries. Polish Archives of Internal Medicine https://doi.org/10.20452/pamw.14789.1.Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM. 2019. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clinical Chemistry 65:781–790.1.Amarenco P, Kim JS, Labreuche J, Giroud M, Lee B-C, Mahagne M-H, Nighoghossian N, Simon T, Steg PG, Touboul P-J, Vicaut E, Yelles N, Bruckert E. 2019. Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes. European Stroke Journal 4:271–280.1.Hoshino T, Sissani L, Labreuche J, Bousser M-G, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Gabriel Steg P, Vicaut E, Amarenco P. 2019. Non-cardioembolic stroke/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study. European Stroke Journal 4:65–74.1.Tan NS, Sarak B, Fox KA, Brieger D, Steg PhG, Gale CP, Bhatt DL, Spencer FA, Grondin FR, Goodman SG, Yan AT, on behalf of the Canadian GRACE/GRACE-2 and CANRACE Investigators. 2019. Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. European Heart Journal: Acute Cardiovascular Care 8:309–317.1.Kemlin C, Moulton E, Lamy J-C, Houot M, Valabregue R, Leder S, Obadia MA, Meseguer E, Yger M, Brochard V, Corvol J-C, Samson Y, Rosso C. 2019. Elucidating the Structural and Functional Correlates of Upper-Limb Poststroke Motor Impairment. Stroke 50:3647–3649.1.Ntaios G, Pearce LA, Meseguer E, Endres M, Amarenco P, Ozturk S, Lang W, Bornstein NM, Molina CA, Pagola J, Mundl H, Berkowitz SD, Liu YY, Sen S, Connolly SJ, Hart RG, on behalf of the NAVIGATE ESUS Investigators. 2019. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke 50:3184–3190.1.Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG, on behalf of the NAVIGATE ESUS Investigators. 2019. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke 50:2477–2485.1.Abboud H, Monteiro Tavares L, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P, for the OPTIC Registry Investigators. 2019. Impact of Low Ankle-Brachial Index on the Risk of Recurrent Vascular Events: Insights From the OPTIC Registry. Stroke 50:853–858.1.Desnos C, Iung B, Himbert D, Ducrocq G, Urena M, Cormier B, Brochet E, Ou P, Vahanian A, Bouleti C. 2019. Temporal Trends on Percutaneous Mitral Commissurotomy: 30 Years of Experience. JAHA 8:e012031.1.Himbert D, Urena M, Ducrocq G. 2019. Is Transcatheter Aortic Valve Replacement Becoming the Standard of Care in Octogenarians? JAHA 8:e011833.1.Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim Y-U, Pordy R, Reiner Ž, Roe MT, Tse H-F, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG, For the ODYSSEY OUTCOMES Investigators. 2019. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation 140:2054–2062.1.Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PhG, Schwartz GG, For the ODYSSEY OUTCOMES Investigators. 2019. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation 140:1578–1589.1.Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PhG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM, On behalf of the SAVOR-TIMI 53 Steering Committee and Investigators. 2019. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation 140:1004–1014.1.Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG, For the ODYSSEY OUTCOMES Committees and Investigators†. 2019. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 140:103–112.1.Szarek M, Steg PhG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG, for the ODYSSEY OUTCOMES Committees and Investigators*. 2019. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circ: Cardiovascular Quality and Outcomes 12:e005858.1.Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. 2019. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS. Circ: Cardiovascular Quality and Outcomes 12:e004945.1.Baber U, Stefanini GG, Giustino G, Stone GW, Leon MB, Sartori S, Aquino M, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Von Birgelen C, Dangas GD, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim H-S, Kastrati A, Chieffo A, Mehran R. 2019. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ: Cardiovascular Interventions 12:e007734.1.Palmerini T, Bruno AG, Gilard M, Morice M-C, Valgimigli M, Montalescot G, Collet J-P, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW. 2019. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation: A Pairwise Meta-Analysis of 6 Trials and 21 457 Patients. Circ: Cardiovascular Interventions 12:e007541.1.Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL, on behalf of the CHAMPION PHOENIX Investigators. 2019. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y 12 Inhibitor Pretreatment: Analysis From the CHAMPION PHOENIX Trial. Circ: Cardiovascular Interventions 12:e007445.1.Olivier CB, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PhG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW, on Behalf of the CHAMPION PHOENIX Investigators*. 2019. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX. Circ: Cardiovascular Interventions 12:e007342.1.Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2019. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry. Circ: Cardiovascular Interventions 12:e007133.1.Guidoux C, Meseguer E, Ong E, Lavallée PC, Hobeanu C, Monteiro-Tavares L, Charles H, Cabrejo L, Martin-Bechet A, Rigual R, Nighoghossian N, Amarenco P. 2019. Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry. Open Heart 6:e001187.1.Darmon A, Ducrocq G. 2019. Ischaemic and bleeding risk assessment after myocardial infarction: combination is the key. Heart heartjnl-2019-315050.1.Gandhi S, Goodman SG, Greenlaw N, Ford I, McSkimming P, Ferrari R, Jang Y, Alcocer-Gamba MA, Fox K, Tardif J-C, Tendera M, Dorian P, Steg G, Udell JA. 2019. Living alone and cardiovascular disease outcomes. Heart 105:1087–1095.1.Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Van Geuns R-J, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, Valgimigli M. 2019. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open 9:e026053.1.Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA, CGTP Collaborators. 2019. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors. British J Pharmacology 176.1.Bhatt DL, Steg PG. 2019. THEMIS and THEMIS-PCI. European Heart Journal 40:3378–3381.1.Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, De Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll H-P, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M. 2019. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal 40:2595–2604.1.White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG, ODYSSEY OUTCOMES Investigators. 2019. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal 40:2801–2809.1.Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. 2019. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal 40:1553–1562.1.Abtan J, Steg PG. 2019. Pre-treatment with a P2Y12 antagonist before PCI in STEMI: why should we wait? European Heart Journal 40:1211–1213.1.Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, Tendera M, Ferrari R, Merkely B, Parkhomenko A, Reid C, Tardif J-C, Fox KM, for the CLARIFY investigators. 2019. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal 40:1399–1407.1.Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, ESC Scientific Document Group, Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van De Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O’Gara PT, Fox KAA, Hasdai D, Aboyans V, Achenbach S, Agewall S, Alexander T, Avezum A, Barbato E, Bassand J-P, Bates E, Bittl JA, Breithardt G, Bueno H, Bugiardini R, Cohen MG, Dangas G, De Lemos JA, Delgado V, Filippatos G, Fry E, Granger CB, Halvorsen S, Hlatky MA, Ibanez B, James S, Kastrati A, Leclercq C, Mahaffey KW, Mehta L, Müller C, Patrono C, Piepoli MF, Piñeiro D, Roffi M, Rubboli A, Sharma S, Simpson IA, Tendera M, Valgimigli M, Van Der Wal AC, Windecker S, Chettibi M, Hayrapetyan H, Roithinger FX, Aliyev F, Sujayeva V, Claeys MJ, Smajić E, Kala P, Iversen KK, El Hefny E, Marandi T, Porela P, Antov S, Gilard M, Blankenberg S, Davlouros P, Gudnason T, Alcalai R, Colivicchi F, Elezi S, Baitova G, Zakke I, Gustiene O, Beissel J, Dingli P, Grosu A, Damman P, Juliebø V, Legutko J, Morais J, Tatu-Chitoiu G, Yakovlev A, Zavatta M, Nedeljkovic M, Radsel P, Sionis A, Jemberg T, Müller C, Abid L, Abaci A, Parkhomenko A, Corbett S. 2019. Fourth universal definition of myocardial infarction (2018). European Heart Journal 40:237–269.1.Valgimigli M, Garcia-Garcia HM, Vrijens B, Vranckx P, McFadden EP, Costa F, Pieper K, Vock DM, Zhang M, Van Es G-A, Tricoci P, Baber U, Steg G, Montalescot G, Angiolillo DJ, Serruys PW, Farb A, Windecker S, Kastrati A, Colombo A, Feres F, Jüni P, Stone GW, Bhatt DL, Mehran R, Tijssen JGP. 2019. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). European Heart Journal 40:2070–2085.1.Fox KAA, Eikelboom JW, Anand SS, Bhatt DL, Bosch J, Connolly SJ, Harrington RA, Steg PG, Yusuf S. 2019. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? European Heart Journal 40:1466–1471.1.Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van De Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. 2019. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy 5:200–206.1.Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice M-C, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, Van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Pagé P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Généreux P, Crowley A, Dressler O, Serruys PW. 2019. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med 381:1820–1830.1.Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han Y, Pocock S, Gibson CM. 2019. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 381:2032–2042.1.Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA. 2019. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med 381:1309–1320.1.Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-Sendón J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg PG, Avezum Á, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley B, Kedev S, Sutton A, Oliver R, Rodés-Cabau J, Stanković G, Welsh R, Lavi S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA. 2019. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med 381:1411–1421.1.Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM. 2019. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380:11–22.1.2019. Open versus Endovascular Repair of Abdominal Aortic Aneurysm. N Engl J Med 381:e24.2460799 5BTMJQCK 2018 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/2460799 5BTMJQCK 2017 items 1 infection-and-immunity 0 default asc year 729 https://lvts.fr/wp-content/plugins/zotpress/%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-94cf461a65fa7df0ae736f45231134e6%22%2C%22meta%22%3A%7B%22request_last%22%3A100%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EKTYA48T%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Assayag%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAssayag%20M%2C%20Abbas%20R%2C%20Chanson%20N%2C%20Perozziello%20A%2C%20Ducrocq%20G%2C%20Alexandra%20J-F%2C%20Dossier%20A%2C%20Papo%20T%2C%20Sacre%20K.%202017.%20Diagnosis%20of%20systemic%20inflammatory%20diseases%20among%20patients%20admitted%20for%20acute%20pericarditis%20with%20pericardial%20effusion%3A%20Journal%20of%20Cardiovascular%20Medicine%2018%3A875%26%23x2013%3B880.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnosis%20of%20systemic%20inflammatory%20diseases%20among%20patients%20admitted%20for%20acute%20pericarditis%20with%20pericardial%20effusion%3A%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maureen%22%2C%22lastName%22%3A%22Assayag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Chanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Perozziello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Alexandra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Dossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Papo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karim%22%2C%22lastName%22%3A%22Sacre%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2211%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2459%5C%2FJCM.0000000000000576%22%2C%22ISSN%22%3A%221558-2027%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F01244665-201711000-00005%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22VCTWZGRJ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Adjedj%20et%20al.%22%2C%22parsedDate%22%3A%222017-05-16%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAdjedj%20J%2C%20Ducrocq%20G%2C%20Bouleti%20C%2C%20Reinhart%20L%2C%20Fabbro%20E%2C%20Elbez%20Y%2C%20Fischer%20Q%2C%20Tesniere%20A%2C%20Feldman%20L%2C%20Varenne%20O.%202017.%20Medical%20Student%20Evaluation%20With%20a%20Serious%20Game%20Compared%20to%20Multiple%20Choice%20Questions%20Assessment.%20JMIR%20Serious%20Games%205%3Ae11.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Medical%20Student%20Evaluation%20With%20a%20Serious%20Game%20Compared%20to%20Multiple%20Choice%20Questions%20Assessment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Adjedj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Bouleti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Reinhart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleonora%22%2C%22lastName%22%3A%22Fabbro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quentin%22%2C%22lastName%22%3A%22Fischer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Tesniere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Varenne%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-05-16%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2196%5C%2Fgames.7033%22%2C%22ISSN%22%3A%222291-9279%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fgames.jmir.org%5C%2F2017%5C%2F2%5C%2Fe11%5C%2F%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22ICKN437F%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parma%20et%20al.%22%2C%22parsedDate%22%3A%222017-01-20%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EParma%20Z%2C%20Steg%20PG%2C%20Greenlaw%20N%2C%20Ferrari%20R%2C%20Ford%20I%2C%20Fox%20K%2C%20Tardif%20J-C%2C%20Morais%20J%2C%20Gamba%20MA%2C%20K%26%23xE4%3B%26%23xE4%3Bb%20S%2C%20Tendera%20For%20The%20Clarify%20Investigators%20M.%202017.%20Differences%20in%20outcomes%20in%20patients%20with%20stable%20coronary%20artery%20disease%20managed%20by%20cardiologists%20versus%20non-cardiologists%3A%20the%20international%20prospective%20CLARIFY%20registry.%20Polish%20Archives%20of%20Internal%20Medicine%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.20452%5C%2Fpamw.3902%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.20452%5C%2Fpamw.3902%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Differences%20in%20outcomes%20in%20patients%20with%20stable%20coronary%20artery%20disease%20managed%20by%20cardiologists%20versus%20non-cardiologists%3A%20the%20international%20prospective%20CLARIFY%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zofia%22%2C%22lastName%22%3A%22Parma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Greenlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Tardif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joao%22%2C%22lastName%22%3A%22Morais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20%20Alcocer%22%2C%22lastName%22%3A%22Gamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22K%5Cu00e4%5Cu00e4b%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micha%5Cu0142%22%2C%22lastName%22%3A%22Tendera%20For%20The%20Clarify%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-01-20%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.20452%5C%2Fpamw.3902%22%2C%22ISSN%22%3A%221897-9483%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fpamw.pl%5C%2Fen%5C%2Fnode%5C%2F3902%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22T99B8PTM%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lindholm%20et%20al.%22%2C%22parsedDate%22%3A%222017-02-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELindholm%20D%2C%20James%20SK%2C%20Bertilsson%20M%2C%20Becker%20RC%2C%20Cannon%20CP%2C%20Giannitsis%20E%2C%20Harrington%20RA%2C%20Himmelmann%20A%2C%20Kontny%20F%2C%20Siegbahn%20A%2C%20Steg%20PG%2C%20Storey%20RF%2C%20Velders%20MA%2C%20Weaver%20WD%2C%20Wallentin%20L.%202017.%20Biomarkers%20and%20Coronary%20Lesions%20Predict%20Outcomes%20after%20Revascularization%20in%20Non%26%23x2013%3BST-Elevation%20Acute%20Coronary%20Syndrome.%20Clinical%20Chemistry%2063%3A573%26%23x2013%3B584.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Biomarkers%20and%20Coronary%20Lesions%20Predict%20Outcomes%20after%20Revascularization%20in%20Non%5Cu2013ST-Elevation%20Acute%20Coronary%20Syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Lindholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20K%22%2C%22lastName%22%3A%22James%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Bertilsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20C%22%2C%22lastName%22%3A%22Becker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evangelos%22%2C%22lastName%22%3A%22Giannitsis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22Himmelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Kontny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agneta%22%2C%22lastName%22%3A%22Siegbahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthijs%20A%22%2C%22lastName%22%3A%22Velders%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%20Douglas%22%2C%22lastName%22%3A%22Weaver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Wallentin%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20BACKGROUND%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Risk%20stratification%20in%20non%5Cu2013ST-elevation%20acute%20coronary%20syndrome%20%28NSTE-ACS%29%20is%20currently%20mainly%20based%20on%20clinical%20characteristics.%20With%20routine%20invasive%20management%2C%20angiography%20findings%20and%20biomarkers%20are%20available%20and%20may%20improve%20prognostication.%20We%20aimed%20to%20assess%20if%20adding%20biomarkers%20%5Bhigh-sensitivity%20cardiac%20troponin%20T%20%28cTnT-hs%29%2C%20N-terminal%20probrain-type%20natriuretic%20peptide%20%28NT-proBNP%29%2C%20growth%20differentiation%20factor%2015%20%28GDF-15%29%5D%20and%20extent%20of%20coronary%20artery%20disease%20%28CAD%29%20might%20improve%20prognostication%20in%20revascularized%20patients%20with%20NSTE-ACS.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20PLATO%20%28Platelet%20Inhibition%20and%20Patient%20Outcomes%29%20trial%2C%205174%20NSTE-ACS%20patients%20underwent%20initial%20angiography%20and%20revascularization%20and%20had%20cTnT-hs%2C%20NT-proBNP%2C%20and%20GDF-15%20measured.%20Cox%20models%20were%20developed%20adding%20extent%20of%20CAD%20and%20biomarker%20levels%20to%20established%20clinical%20risk%20variables%20for%20the%20composite%20of%20cardiovascular%20death%20%28CVD%29%5C%2Fspontaneous%20myocardial%20infarction%20%28MI%29%2C%20and%20CVD%20alone.%20Models%20were%20compared%20using%20c-statistic%20and%20net%20reclassification%20improvement%20%28NRI%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20For%20the%20composite%20end%20point%20and%20CVD%2C%20prognostication%20improved%20when%20adding%20extent%20of%20CAD%2C%20NT-proBNP%2C%20and%20GDF-15%20to%20clinical%20variables%20%28c-statistic%200.685%20and%200.805%2C%20respectively%2C%20for%20full%20model%20vs%200.649%20and%200.760%20for%20clinical%20model%29.%20cTnT-hs%20did%20not%20contribute%20to%20prognostication.%20In%20the%20full%20model%20%28clinical%20variables%2C%20extent%20of%20CAD%2C%20all%20biomarkers%29%2C%20hazard%20ratios%20%2895%25%20CI%29%20per%20standard%20deviation%20increase%20were%20for%20cTnT-hs%200.93%280.81%5Cu20131.05%29%2C%20NT-proBNP%201.32%281.13%5Cu20131.53%29%2C%20GDF-15%201.20%281.07%5Cu20131.36%29%20for%20the%20composite%20end%20point%2C%20driven%20by%20prediction%20of%20CVD%20by%20NT-proBNP%20and%20GDF-15.%20For%20spontaneous%20MI%2C%20there%20was%20an%20association%20with%20NT-proBNP%20or%20GDF-15%2C%20but%20not%20with%20cTnT-hs.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSIONS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20revascularized%20patients%20with%20NSTE-ACS%2C%20the%20extent%20of%20CAD%20and%20concentrations%20of%20NT-proBNP%20and%20GDF-15%20independently%20improve%20prognostication%20of%20CVD%5C%2Fspontaneous%20MI%20and%20CVD%20alone.%20This%20information%20may%20be%20useful%20for%20selection%20of%20patients%20who%20might%20benefit%20from%20more%20intense%20and%5C%2For%20prolonged%20antithrombotic%20treatment.%20ClinicalTrials.gov%20Identifier%3A%20NCT00391872%22%2C%22date%22%3A%222017-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1373%5C%2Fclinchem.2016.261271%22%2C%22ISSN%22%3A%220009-9147%2C%201530-8561%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fclinchem%5C%2Farticle%5C%2F63%5C%2F2%5C%2F573%5C%2F5612869%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A17Z%22%7D%7D%2C%7B%22key%22%3A%225CNFD2FP%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hagstr%5Cu00f6m%20et%20al.%22%2C%22parsedDate%22%3A%222017-01-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHagstr%26%23xF6%3Bm%20E%2C%20Held%20C%2C%20Stewart%20RAH%2C%20Aylward%20PE%2C%20Budaj%20A%2C%20Cannon%20CP%2C%20Koenig%20W%2C%20Krug-Gourley%20S%2C%20Mohler%20ER%2C%20Steg%20PG%2C%20Tarka%20E%2C%20%26%23xD6%3Bstlund%20O%2C%20White%20HD%2C%20Siegbahn%20A%2C%20Wallentin%20L.%202017.%20Growth%20Differentiation%20Factor%2015%20Predicts%20All-Cause%20Morbidity%20and%20Mortality%20in%20Stable%20Coronary%20Heart%20Disease.%20Clinical%20Chemistry%2063%3A325%26%23x2013%3B333.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20Differentiation%20Factor%2015%20Predicts%20All-Cause%20Morbidity%20and%20Mortality%20in%20Stable%20Coronary%20Heart%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emil%22%2C%22lastName%22%3A%22Hagstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20A%20H%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20E%22%2C%22lastName%22%3A%22Aylward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrzej%22%2C%22lastName%22%3A%22Budaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfgang%22%2C%22lastName%22%3A%22Koenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sue%22%2C%22lastName%22%3A%22Krug-Gourley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emile%20R%22%2C%22lastName%22%3A%22Mohler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Tarka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ollie%22%2C%22lastName%22%3A%22%5Cu00d6stlund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agneta%22%2C%22lastName%22%3A%22Siegbahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Wallentin%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20BACKGROUND%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Higher%20growth%20differentiation%20factor%2015%20%28GDF-15%29%20concentrations%20are%20associated%20with%20cardiovascular%20%28CV%29%20and%20non-CV%20morbidity%20and%20mortality.%20However%2C%20information%20on%20associations%20between%20GDF-15%20and%20the%20risk%20of%20specific%20CV%20and%20non-CV%20events%20in%20stable%20coronary%20heart%20disease%20%28CHD%29%20patients%20is%20limited.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%2014%20577%20patients%20with%20stable%20CHD%20participating%20in%20the%20Stabilization%20of%20Atherosclerotic%20Plaque%20by%20Initiation%20of%20Darapladib%20Therapy%20Trial%20%28STABILITY%29%2C%20GDF-15%20and%20other%20prognostic%20biomarkers%20%28N-terminal%20pro%5Cu2013B-type%20natriuretic%20peptide%2C%20high-sensitivity%20troponin%20T%2C%20cystatin%20C%2C%20and%20high-sensitivity%20C-reactive%20protein%29%20were%20measured.%20In%20adjusted%20Cox%20regression%20models%2C%20the%20associations%20between%20GDF-15%20and%20the%20composite%20CV%20end%20point%20%5BCV%20death%2C%20myocardial%20infarction%20%28MI%29%2C%20and%20stroke%5D%2C%20as%20well%20as%20other%20CV%20and%20non-CV%20events%2C%20were%20assessed.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20median%20concentration%20%28interquartile%20range%29%20of%20GDF-15%20at%20baseline%20was%201253%20%28915%5Cu20131827%29%20ng%5C%2FL.%20The%20hazard%20ratio%20for%20the%20composite%20end%20point%20for%20the%20highest%20compared%20to%20the%20lowest%20quartile%20of%20GDF-15%20was%201.8%20%2895%25%20CI%2C%201.5%5Cu20132.2%29%3B%20for%20CV%20death%2C%202.63%20%281.9%5Cu20133.6%29%3B%20for%20sudden%20death%2C%203.06%20%281.9%5Cu20134.8%29%3B%20for%20heart%20failure%20%28HF%29%20death%2C%204.3%20%281.3%5Cu201314%29%3B%20for%20cancer%20death%2C%202.5%20%281.3%5Cu20134.7%29%3B%20for%20hospitalization%20for%20HF%2C%205.8%20%283.2%5Cu201310%29%3B%20for%20MI%201.4%20%2895%25%20CI%2C%201.1%5Cu20131.9%29%3B%20and%20for%20stroke%2C%201.8%20%2895%25%20CI%2C%201.1%5Cu20132.8%29.%20After%20adjustment%20for%20other%20prognostic%20biomarkers%2C%20GDF-15%20remained%20significantly%20associated%20with%20all%20outcomes%20except%20for%20MI.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSIONS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20stable%20CHD%2C%20GDF-15%20was%20independently%20associated%20with%20CV%2C%20non-CV%2C%20and%20cancer%20mortality%2C%20as%20well%20as%20with%20MI%20and%20stroke.%20When%20also%20adjusting%20for%20other%20prognostic%20biomarkers%2C%20the%20associations%20to%20all%20fatal%20and%20nonfatal%20events%20were%20maintained%20except%20for%20MI.%20Information%20on%20GDF-15%2C%20therefore%2C%20might%20be%20helpful%20when%20assessing%20the%20risk%20of%20adverse%20outcomes%20in%20patients%20with%20stable%20CHD.%20ClinicalTrials.gov%20Identifier%3A%20NCT00799903%22%2C%22date%22%3A%222017-01-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1373%5C%2Fclinchem.2016.260570%22%2C%22ISSN%22%3A%220009-9147%2C%201530-8561%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fclinchem%5C%2Farticle%5C%2F63%5C%2F1%5C%2F325%5C%2F5612795%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22ZTX3SDJB%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ducrocq%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDucrocq%20GP%2C%20Hureau%20TJ%2C%20Meste%20O%2C%20Blain%20GM.%202017.%20Increased%20Fatigue%20Response%20to%20Augmented%20Deceptive%20Feedback%20during%20Cycling%20Time%20Trial.%20Medicine%20%26amp%3B%20Science%20in%20Sports%20%26amp%3B%20Exercise%2049%3A1541%26%23x2013%3B1551.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20Fatigue%20Response%20to%20Augmented%20Deceptive%20Feedback%20during%20Cycling%20Time%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%20P.%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20J.%22%2C%22lastName%22%3A%22Hureau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Meste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%20M.%22%2C%22lastName%22%3A%22Blain%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1249%5C%2FMSS.0000000000001272%22%2C%22ISSN%22%3A%220195-9131%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F00005768-201708000-00005%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22HX32S2XZ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hilkens%20et%20al.%22%2C%22parsedDate%22%3A%222017-08-29%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHilkens%20NA%2C%20Algra%20A%2C%20Diener%20H-C%2C%20Reitsma%20JB%2C%20Bath%20PM%2C%20Csiba%20L%2C%20Hacke%20W%2C%20Kappelle%20LJ%2C%20Koudstaal%20PJ%2C%20Leys%20D%2C%20Mas%20J-L%2C%20Sacco%20RL%2C%20Amarenco%20P%2C%20Sissani%20L%2C%20Greving%20JP%2C%20For%20the%20Cerebrovascular%20Antiplatelet%20Trialists%26%23x2019%3B%20Collaborative%20Group%2C%20Cerebrovascular%20Antiplatelet%20Trialists%26%23x2019%3B%20Collaborative%20Group%2C%20Gent%20M%2C%20Beaumont%20D%2C%20Blanchard%20J%2C%20Bousser%20M%2C%20Coffman%20J%2C%20Easton%20JD%2C%20Hampton%20J%2C%20Harker%20L%2C%20Janzon%20L%2C%20Kusmierek%20J%2C%20Panak%20E%2C%20Roberts%20R%2C%20Shannon%20S%2C%20Sicurella%20J%2C%20Tognoni%20G%2C%20Topol%20E%2C%20Verstraete%20M%2C%20Warlow%20C%2C%20Blard%20J%2C%20Capildeo%20R%2C%20Diener%20H%2C%20Ersmark%20B%2C%20Escartin%20A%2C%20Ferro%20J%2C%20Galvin%20R%2C%20Hogenhuis%20L%2C%20Laterre%20C%2C%20Provincial%20L%2C%20Rinne%20U%2C%20Bovim%20G%2C%20Lowenthal%20A%2C%20Diener%20H%2C%20Bogousslavsky%20J%2C%20Brass%20L%2C%20Cimminiello%20C%2C%20Csiba%20L%2C%20Kaste%20M%2C%20Leys%20D%2C%20Matias-Guiu%20J%2C%20Rupprecht%20H%2C%20Berger%20P%2C%20Bhatt%20D%2C%20Black%20H%2C%20Boden%20W%2C%20Cacoub%20P%2C%20Cohen%20E%2C%20Creager%20M%2C%20Easton%20J%2C%20Flather%20M%2C%20Fox%20K%2C%20Hacke%20W%2C%20Haffner%20S%2C%20Hamm%20C%2C%20Hankey%20G%2C%20Johnston%20S%2C%20Mak%20K%2C%20Mas%20J%2C%20Montalescot%20G%2C%20Pearson%20T%2C%20Steg%20P%2C%20Steinhubl%20S%2C%20Topol%20E%2C%20Weber%20M%2C%20Aichner%20F%2C%20Algra%20A%2C%20Bogousslavsky%20J%2C%20Chamorro%20A%2C%20Chen%20C%2C%20De%20Schryver%20E%2C%20Ferro%20J%2C%20Van%20Gijn%20J%2C%20Hankey%20G%2C%20Hertzberger%20L%2C%20Koudstaal%20P%2C%20Leys%20D%2C%20Ricci%20S%2C%20Ringelstein%20E%2C%20Vanhooren%20G%2C%20Venables%20G%2C%20Albers%20G%2C%20Bath%20P%2C%20Bornstein%20N%2C%20Chan%20B%2C%20Chen%20S-T%2C%20Cunha%20L%2C%20Dahl%26%23xF6%3Bf%20B%2C%20DeKeyser%20J%2C%20Diener%20H%2C%20Donnan%20G%2C%20Estol%20C%2C%20Gorelick%20P%2C%20Kaste%20M%2C%20Lu%20C%2C%20Pais%20P%2C%20Roberts%20R%2C%20Sacco%20R%2C%20Skvortsova%20V%2C%20Teal%20P%2C%20Toni%20D%2C%20Weber%20M%2C%20Yoon%20B%2C%20Yusuf%20S%2C%20Amarenco%20P%2C%20Bousser%20M-G%2C%20Chamorro%20A%2C%20Fisher%20M%2C%20Ford%20I%2C%20Fox%20K%2C%20Hennerici%20M%2C%20Mattle%20H%2C%20Rothwell%20P%2C%20Sissani%20L%2C%20Labreuche%20J%2C%20Steg%20G%2C%20Vicaut%20E.%202017.%20Predicting%20major%20bleeding%20in%20patients%20with%20noncardioembolic%20stroke%20on%20antiplatelets%3A%20S%20%3Csub%3E2%3C%5C%2Fsub%3E%20TOP-BLEED.%20Neurology%2089%3A936%26%23x2013%3B943.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Predicting%20major%20bleeding%20in%20patients%20with%20noncardioembolic%20stroke%20on%20antiplatelets%3A%20S%20%3Csub%3E2%3C%5C%2Fsub%3E%20TOP-BLEED%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%20A.%22%2C%22lastName%22%3A%22Hilkens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ale%22%2C%22lastName%22%3A%22Algra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Christoph%22%2C%22lastName%22%3A%22Diener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%20B.%22%2C%22lastName%22%3A%22Reitsma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20M.%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laszlo%22%2C%22lastName%22%3A%22Csiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Werner%22%2C%22lastName%22%3A%22Hacke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20Jaap%22%2C%22lastName%22%3A%22Kappelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20J.%22%2C%22lastName%22%3A%22Koudstaal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Leys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20L.%22%2C%22lastName%22%3A%22Sacco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacoba%20P.%22%2C%22lastName%22%3A%22Greving%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22For%20the%20Cerebrovascular%20Antiplatelet%20Trialists%27%20Collaborative%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Cerebrovascular%20Antiplatelet%20Trialists%27%20Collaborative%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Gent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Beaumont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mg%22%2C%22lastName%22%3A%22Bousser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Coffman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20D%22%2C%22lastName%22%3A%22Easton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jr%22%2C%22lastName%22%3A%22Hampton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22La%22%2C%22lastName%22%3A%22Harker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Janzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jje%22%2C%22lastName%22%3A%22Kusmierek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Panak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rs%22%2C%22lastName%22%3A%22Roberts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Shannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Sicurella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Tognoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ej%22%2C%22lastName%22%3A%22Topol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Verstraete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Warlow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jm%22%2C%22lastName%22%3A%22Blard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Capildeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hc%22%2C%22lastName%22%3A%22Diener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Ersmark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Escartin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Ferro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Galvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lah%22%2C%22lastName%22%3A%22Hogenhuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Laterre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Provincial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uk%22%2C%22lastName%22%3A%22Rinne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Bovim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Lowenthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hc%22%2C%22lastName%22%3A%22Diener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bogousslavsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Brass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Cimminiello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Csiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kaste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Leys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Matias-Guiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hj%22%2C%22lastName%22%3A%22Rupprecht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pb%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dl%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hr%22%2C%22lastName%22%3A%22Black%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22We%22%2C%22lastName%22%3A%22Boden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Cacoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ea%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%22%2C%22lastName%22%3A%22Creager%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jd%22%2C%22lastName%22%3A%22Easton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Md%22%2C%22lastName%22%3A%22Flather%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaa%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22Hacke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sm%22%2C%22lastName%22%3A%22Haffner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cw%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gj%22%2C%22lastName%22%3A%22Hankey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sc%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kh%22%2C%22lastName%22%3A%22Mak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jl%22%2C%22lastName%22%3A%22Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ta%22%2C%22lastName%22%3A%22Pearson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pg%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sr%22%2C%22lastName%22%3A%22Steinhubl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ej%22%2C%22lastName%22%3A%22Topol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Aichner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Algra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Bogousslavsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Chamorro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cplh%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellm%22%2C%22lastName%22%3A%22De%20Schryver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jm%22%2C%22lastName%22%3A%22Ferro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Van%20Gijn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gj%22%2C%22lastName%22%3A%22Hankey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Li%22%2C%22lastName%22%3A%22Hertzberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pj%22%2C%22lastName%22%3A%22Koudstaal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Leys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Ricci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eb%22%2C%22lastName%22%3A%22Ringelstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Vanhooren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gs%22%2C%22lastName%22%3A%22Venables%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Albers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Bornstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S-T%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Cunha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Dahl%5Cu00f6f%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22DeKeyser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hc%22%2C%22lastName%22%3A%22Diener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Donnan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Estol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Gorelick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kaste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Pais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Roberts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%22%2C%22lastName%22%3A%22Sacco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Skvortsova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Teal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Toni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bw%22%2C%22lastName%22%3A%22Yoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Yusuf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M-G%22%2C%22lastName%22%3A%22Bousser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Chamorro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Fisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Km%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mg%22%2C%22lastName%22%3A%22Hennerici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hp%22%2C%22lastName%22%3A%22Mattle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Rothwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Vicaut%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-08-29%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000004289%22%2C%22ISSN%22%3A%220028-3878%2C%201526-632X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.neurology.org%5C%2Fdoi%5C%2F10.1212%5C%2FWNL.0000000000004289%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22M9MTZZ22%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22for%20the%20iDIAPASON%20study%20group%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3Efor%20the%20iDIAPASON%20study%20group%2C%20Bougl%26%23xE9%3B%20A%2C%20Foucrier%20A%2C%20Dupont%20H%2C%20Montravers%20P%2C%20Ouattara%20A%2C%20Kalfon%20P%2C%20Squara%20P%2C%20Simon%20T%2C%20Amour%20J.%202017.%20Impact%20of%20the%20duration%20of%20antibiotics%20on%20clinical%20events%20in%20patients%20with%20Pseudomonas%20aeruginosa%20ventilator-associated%20pneumonia%3A%20study%20protocol%20for%20a%20randomized%20controlled%20study.%20Trials%2018%3A37.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20duration%20of%20antibiotics%20on%20clinical%20events%20in%20patients%20with%20Pseudomonas%20aeruginosa%20ventilator-associated%20pneumonia%3A%20study%20protocol%20for%20a%20randomized%20controlled%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20iDIAPASON%20study%20group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Bougl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Foucrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Montravers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Ouattara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Kalfon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Squara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Amour%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-017-1780-3%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Ftrialsjournal.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs13063-017-1780-3%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A24%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22AKIQLATC%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Feldman%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFeldman%20L%2C%20Steg%20PG%2C%20Amsallem%20M%2C%20Puymirat%20E%2C%20Sorbets%20E%2C%20Elbaz%20M%2C%20Ritz%20B%2C%20Hueber%20A%2C%20Cattan%20S%2C%20Piot%20C%2C%20Ferri%26%23xE8%3Bres%20J%2C%20Simon%20T%2C%20Danchin%20N%2C%20on%20behalf%20of%20the%20FAST-MI%20investigators.%202017.%20Editor%26%23x2019%3Bs%20Choice-Medically%20managed%20patients%20with%20non%26%23x2013%3BST-elevation%20acute%20myocardial%20infarction%20have%20heterogeneous%20outcomes%2C%20based%20on%20performance%20of%20angiography%20and%20extent%20of%20coronary%20artery%20disease.%20European%20Heart%20Journal%3A%20Acute%20Cardiovascular%20Care%206%3A262%26%23x2013%3B271.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Editor%5Cu2019s%20Choice-Medically%20managed%20patients%20with%20non%5Cu2013ST-elevation%20acute%20myocardial%20infarction%20have%20heterogeneous%20outcomes%2C%20based%20on%20performance%20of%20angiography%20and%20extent%20of%20coronary%20artery%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20G%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Amsallem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sorbets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meyer%22%2C%22lastName%22%3A%22Elbaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Ritz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Hueber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Cattan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Piot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Ferri%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20FAST-MI%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2048872615626354%22%2C%22ISSN%22%3A%222048-8726%2C%202048-8734%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjacc%5C%2Farticle%5C%2F6%5C%2F3%5C%2F262-271%5C%2F5921612%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22YZANEAB3%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puymirat%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPuymirat%20E%2C%20Caudron%20J%2C%20Steg%20PG%2C%20Lemesle%20G%2C%20Cottin%20Y%2C%20Coste%20P%2C%20Schiele%20F%2C%20De%20Labriolle%20A%2C%20Bataille%20V%2C%20Ferri%26%23xE8%3Bres%20J%2C%20Simon%20T%2C%20Danchin%20N%2C%20for%20the%20FAST-MI%20investigators.%202017.%20Prognostic%20impact%20of%20non-compliance%20with%20guidelines-recommended%20times%20to%20reperfusion%20therapy%20in%20ST-elevation%20myocardial%20infarction.%20The%20FAST-MI%202010%20registry.%20European%20Heart%20Journal%3A%20Acute%20Cardiovascular%20Care%206%3A26%26%23x2013%3B33.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20impact%20of%20non-compliance%20with%20guidelines-recommended%20times%20to%20reperfusion%20therapy%20in%20ST-elevation%20myocardial%20infarction.%20The%20FAST-MI%202010%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Caudron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20G%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Schiele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22De%20Labriolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Bataille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Ferri%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20FAST-MI%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F2048872615610893%22%2C%22ISSN%22%3A%222048-8726%2C%202048-8734%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjacc%5C%2Farticle%5C%2F6%5C%2F1%5C%2F26-33%5C%2F5921605%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A54Z%22%7D%7D%2C%7B%22key%22%3A%229C4PDCM6%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hoshino%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHoshino%20T%2C%20Uchiyama%20S%2C%20Wong%20LKS%2C%20Sissani%20L%2C%20Albers%20GW%2C%20Bornstein%20NM%2C%20Caplan%20LR%2C%20Donnan%20GA%2C%20Ferro%20JM%2C%20Hennerici%20MG%2C%20Labreuche%20J%2C%20Lavall%26%23xE9%3Be%20PC%2C%20Molina%20C%2C%20Rothwell%20PM%2C%20Steg%20PG%2C%20Touboul%20P-J%2C%20Vicaut%20%26%23xC9%3B%2C%20Amarenco%20P.%202017.%20Differences%20in%20Characteristics%20and%20Outcomes%20Between%20Asian%20and%20Non-Asian%20Patients%20in%20the%20TIAregistry.org.%20Stroke%2048%3A1779%26%23x2013%3B1787.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Differences%20in%20Characteristics%20and%20Outcomes%20Between%20Asian%20and%20Non-Asian%20Patients%20in%20the%20TIAregistry.org%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takao%22%2C%22lastName%22%3A%22Hoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinichiro%22%2C%22lastName%22%3A%22Uchiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%20K.S.%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20W.%22%2C%22lastName%22%3A%22Albers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natan%20M.%22%2C%22lastName%22%3A%22Bornstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20R.%22%2C%22lastName%22%3A%22Caplan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%20A.%22%2C%22lastName%22%3A%22Donnan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20M.%22%2C%22lastName%22%3A%22Ferro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20G.%22%2C%22lastName%22%3A%22Hennerici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C.%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Rothwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9ric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20study%20provides%20the%20contemporary%20causes%20and%20prognosis%20of%20transient%20ischemic%20attack%20%28TIA%29%20and%20minor%20stroke%20in%20Asians%20and%20the%20direct%20comparisons%20with%20non-Asians.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20TIAregistry.org%20enrolled%204789%20patients%20%281149%20Asians%20and%203640%20non-Asians%29%20with%20a%20TIA%20or%20minor%20ischemic%20stroke%20within%207%20days%20of%20onset.%20Every%20participating%20facility%20had%20systems%20dedicated%20to%20urgent%20intervention%20of%20TIA%5C%2Fstroke%20patients%20by%20specialists.%20The%20primary%20outcome%20was%20a%20composite%20of%20cardiovascular%20death%2C%20nonfatal%20stroke%2C%20and%20nonfatal%20acute%20coronary%20syndrome.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Approximately%2080%25%20of%20patients%20were%20evaluated%20within%2024%20hours%20of%20symptom%20onset.%20At%201%20year%2C%20there%20were%20no%20differences%20in%20the%20rates%20of%20composite%20cardiovascular%20events%20%286.8%25%20versus%206.0%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.38%29%20and%20stroke%20%286.0%25%20versus%204.8%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.11%29%20between%20Asians%20and%20non-Asians.%20Asians%20had%20a%20lower%20risk%20of%20cerebrovascular%20disease%20%28stroke%20or%20TIA%29%20than%20non-Asians%20%28adjusted%20hazard%20ratio%2C%200.79%3B%2095%25%20confidence%20interval%2C%200.63%5Cu20130.98%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29%3B%20the%20difference%20was%20primarily%20driven%20by%20a%20lower%20rate%20of%20TIA%20in%20Asians%20%284.2%25%20versus%208.3%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%20Moderately%20severe%20bleeding%20was%20more%20frequent%20in%20Asians%20%280.8%25%20versus%200.3%25%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.02%29.%20In%20multivariable%20analysis%2C%20multiple%20acute%20infarcts%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.005%29%20and%20alcohol%20consumption%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.02%29%20were%20independent%20predictors%20of%20stroke%20recurrence%20in%20Asians%2C%20whereas%20intracranial%20stenosis%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20ABCD%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20score%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20atrial%20fibrillation%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.008%29%2C%20extracranial%20stenosis%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29%2C%20and%20previous%20stroke%20or%20TIA%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29%20were%20independent%20predictors%20in%20non-Asians.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20short-term%20stroke%20risk%20after%20a%20TIA%20or%20minor%20stroke%20was%20lower%20than%20expected%20when%20urgent%20evidence-based%20care%20was%20delivered%2C%20irrespective%20of%20race%5C%2Fethnicity%20or%20region.%20However%2C%20the%20predictors%20of%20stroke%20were%20different%20for%20Asians%20and%20non-Asians.%22%2C%22date%22%3A%2207%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.117.016874%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.117.016874%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22PI8ZEPSR%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hobeanu%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHobeanu%20C%2C%20Lavall%26%23xE9%3Be%20PC%2C%20Rothwell%20PM%2C%20Sissani%20L%2C%20Albers%20GW%2C%20Bornstein%20NM%2C%20Caplan%20LR%2C%20Donnan%20GA%2C%20Ferro%20JM%2C%20Hennerici%20MG%2C%20Labreuche%20J%2C%20Molina%20C%2C%20Steg%20PG%2C%20Touboul%20P-J%2C%20Uchiyama%20S%2C%20Vicaut%20%26%23xC9%3B%2C%20Wong%20LKS%2C%20Amarenco%20P.%202017.%20Symptomatic%20Patients%20Remain%20at%20Substantial%20Risk%20of%20Arterial%20Disease%20Complications%20Before%20and%20After%20Endarterectomy%20or%20Stenting.%20Stroke%2048%3A1005%26%23x2013%3B1010.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Symptomatic%20Patients%20Remain%20at%20Substantial%20Risk%20of%20Arterial%20Disease%20Complications%20Before%20and%20After%20Endarterectomy%20or%20Stenting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Hobeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C.%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Rothwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20W.%22%2C%22lastName%22%3A%22Albers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natan%20M.%22%2C%22lastName%22%3A%22Bornstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20R.%22%2C%22lastName%22%3A%22Caplan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%20A.%22%2C%22lastName%22%3A%22Donnan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20M.%22%2C%22lastName%22%3A%22Ferro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20G.%22%2C%22lastName%22%3A%22Hennerici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinichiro%22%2C%22lastName%22%3A%22Uchiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9ric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%20K.S.%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20carotid%20endarterectomy%20%28CEA%29%20or%20carotid%20artery%20stenting%20%28CAS%29%20in%20patients%20with%20transient%20ischemic%20attack%20or%20minor%20ischemic%20stroke%2C%20recurrent%20stroke%20risk%20falls%20to%20a%20low%20rate%20on%20modern%20medical%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20used%20data%20from%204583%20patients%20with%20recent%20transient%20ischemic%20attack%20or%20minor%20stroke%20enrolled%20in%20the%20TIAregistry.org%20to%20perform%20a%20nested%20case%5Cu2013control%20analysis%20to%20evaluate%20pre-%20and%20post-CEA%5C%2FCAS%20risk.%20Cases%20were%20defined%20as%20patients%20with%20a%20CEA%5C%2FCAS%20during%20the%201-year%20follow-up%20period.%20For%20each%20case%2C%202%20controls%20with%20a%20follow-up%20time%20greater%20than%20the%20time%20from%20qualifying%20event%20to%20CEA%5C%2FCAS%20were%20randomly%20selected%2C%20matched%20by%20age%20and%20sex.%20Primary%20outcome%20was%20defined%20as%20major%20vascular%20events%20%28MVE%2C%20including%20stroke%2C%20cardiovascular%20death%2C%20and%20myocardial%20infarction%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20median%20delay%20from%20symptom%20onset%20of%20qualifying%20event%20to%20CEA%5C%2FCAS%20was%2011%20days%20%28interquartile%20range%2C%206%5Cu201323%29.%20Overall%2C%20patients%20with%20CEA%5C%2FCAS%20had%20a%20higher%201-year%20risk%20of%20MVE%20than%20other%20patients%20%2814.8%25%20versus%205.8%25%3B%20adjusted%20hazard%20ratio%2C%202.40%3B%2095%25%20confidence%20interval%2C%201.61%5Cu20133.60%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%20During%20the%20matched%20preprocedural%20period%2C%20MVE%20occurred%20in%2014%20%287.5%25%29%20cases%20and%20in%2013%20%283.5%25%29%20controls%2C%20with%20an%20adjusted%20odds%20ratio%20%3D2.46%20%2895%25%20confidence%20interval%2C%201.07%5Cu20135.64%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29.%20In%20the%20postprocedural%20period%2C%20the%20risk%20of%20MVE%20was%20also%20higher%20in%20cases%20than%20in%20controls%20%28adjusted%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.03%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20with%20CEA%5C%2FCAS%20had%20a%20higher%2012-month%20risk%20of%20MVE%2C%20as%20well%20as%20during%20pre-%20and%20postprocedural%20periods.%20These%20results%20suggest%20that%20patients%20in%20whom%20CEA%5C%2FCAS%20is%20anticipated%20are%20likely%20to%20be%20an%20informative%20population%20for%20inclusion%20in%20studies%20testing%20new%20antithrombotic%20strategies%20started%20soon%20after%20symptom%20onset.%22%2C%22date%22%3A%2204%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.116.015171%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.116.015171%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A34Z%22%7D%7D%2C%7B%22key%22%3A%222GSFG2FZ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lavall%5Cu00e9e%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELavall%26%23xE9%3Be%20PC%2C%20Sissani%20L%2C%20Labreuche%20J%2C%20Meseguer%20E%2C%20Cabrejo%20L%2C%20Guidoux%20C%2C%20Klein%20IF%2C%20Touboul%20P-J%2C%20Amarenco%20P.%202017.%20Clinical%20Significance%20of%20Isolated%20Atypical%20Transient%20Symptoms%20in%20a%20Cohort%20With%20Transient%20Ischemic%20Attack.%20Stroke%2048%3A1495%26%23x2013%3B1500.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Significance%20of%20Isolated%20Atypical%20Transient%20Symptoms%20in%20a%20Cohort%20With%20Transient%20Ischemic%20Attack%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%20C.%22%2C%22lastName%22%3A%22Lavall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Meseguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Cabrejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Guidoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%20F.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Touboul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Contrary%20to%20typical%20transient%20symptoms%20%28TS%29%2C%20atypical%20TS%2C%20such%20as%20partial%20sensory%20deficit%2C%20dysarthria%2C%20vertigo%5C%2Funsteadiness%2C%20unusual%20cortical%20visual%20deficit%2C%20and%20diplopia%2C%20are%20not%20usually%20classified%20as%20symptoms%20of%20transient%20ischemic%20attack%20when%20they%20occur%20in%20isolation%2C%20and%20their%20clinical%20relevance%20is%20frequently%20denied.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Consecutive%20patients%20with%20recent%20TS%20admitted%20in%20our%20transient%20ischemic%20attack%20clinic%20%282003%5Cu20132008%29%20had%20systematic%20brain%2C%20arterial%2C%20and%20cardiac%20investigations.%20We%20compared%20the%20prevalence%20of%20recent%20infarction%20on%20brain%20imaging%2C%20major%20investigational%20findings%20%28symptomatic%20intracranial%20or%20extracranial%20atherosclerotic%20stenosis%20%5Cu226550%25%2C%20cervical%20arterial%20dissection%2C%20and%20major%20source%20of%20cardiac%20embolism%29%2C%20and%201-year%20risk%20of%20major%20vascular%20events%20in%20patients%20with%20isolated%20typical%20or%20atypical%20TS%20and%20nonisolated%20TS%2C%20after%20exclusion%20of%20the%20main%20differential%20diagnoses.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%201850%20patients%20with%20possible%20or%20definite%20ischemic%20diagnoses%2C%20798%20%2843.1%25%29%20had%20isolated%20TS%3A%20621%20%2833.6%25%29%20typical%20and%20177%20%289.6%25%29%20atypical.%20Acute%20infarction%20on%20brain%20imaging%20was%20similar%20in%20patients%20with%20isolated%20atypical%20and%20typical%20TS%20but%20less%20frequent%20than%20in%20patients%20with%20nonisolated%20TS%2C%20observed%20in%2010.0%25%2C%2011.5%25%2C%20and%2015.3%25%2C%20respectively%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29.%20Major%20investigational%20findings%20were%20found%20in%2018.1%25%2C%2026.4%25%2C%20and%2026.3%25%2C%20respectively%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.06%29.%20One-year%20risk%20of%20a%20major%20vascular%20events%20was%20not%20significantly%20different%20in%20the%203%20groups.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Transient%20ischemic%20attack%20diagnosis%20should%20be%20considered%20and%20investigated%20in%20patients%20with%20isolated%20atypical%20TS.%22%2C%22date%22%3A%2206%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.117.016743%22%2C%22ISSN%22%3A%220039-2499%2C%201524-4628%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FSTROKEAHA.117.016743%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22L93MDKQ9%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bossard%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBossard%20M%2C%20Granger%20CB%2C%20Tanguay%20J%2C%20Montalescot%20G%2C%20Faxon%20DP%2C%20Jolly%20SS%2C%20Widimsky%20P%2C%20Niemela%20K%2C%20Steg%20PG%2C%20Natarajan%20MK%2C%20Gao%20P%2C%20Fox%20KAA%2C%20Yusuf%20S%2C%20Mehta%20SR.%202017.%20Double%26%23x2010%3BDose%20Versus%20Standard%26%23x2010%3BDose%20Clopidogrel%20According%20to%20Smoking%20Status%20Among%20Patients%20With%20Acute%20Coronary%20Syndromes%20Undergoing%20Percutaneous%20Coronary%20Intervention.%20JAHA%206%3Ae006577.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Double%5Cu2010Dose%20Versus%20Standard%5Cu2010Dose%20Clopidogrel%20According%20to%20Smoking%20Status%20Among%20Patients%20With%20Acute%20Coronary%20Syndromes%20Undergoing%20Percutaneous%20Coronary%20Intervention%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Bossard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20B.%22%2C%22lastName%22%3A%22Granger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010Francois%22%2C%22lastName%22%3A%22Tanguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20P.%22%2C%22lastName%22%3A%22Faxon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjit%20S.%22%2C%22lastName%22%3A%22Jolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Widimsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kari%22%2C%22lastName%22%3A%22Niemela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madhu%20K.%22%2C%22lastName%22%3A%22Natarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A.%20A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Yusuf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Prior%20Studies%20have%20suggested%20better%20outcomes%20in%20smokers%20compared%20with%20nonsmokers%20receiving%20clopidogrel%20%28%5Cu201csmoker%27s%20paradox%5Cu201d%29.%20The%20impact%20of%20a%20more%20intensive%20clopidogrel%20regimen%20on%20ischemic%20and%20bleeding%20risks%20in%20smokers%20with%20acute%20coronary%20syndromes%20requiring%20percutaneous%20coronary%20interventions%20remains%20unclear.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20analyzed%2017%5Cu00a0263%20acute%20coronary%20syndrome%20patients%20undergoing%20percutaneous%20coronary%20intervention%20from%20the%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CURRENT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20OASIS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%207%20%28Clopidogrel%20and%20Aspirin%20Optimal%20Dose%20Usage%20to%20Reduce%20Recurrent%20Events%5Cu2014Seventh%20Organization%20to%20Assess%20Strategies%20in%20Ischemic%20Symptoms%29%20trial%2C%20which%20compared%20double%5Cu2010dose%20%28600%5Cu00a0mg%20day%201%3B150%5Cu00a0mg%20days%202%5Cu20137%3B%20then%2075%5Cu00a0mg%20daily%29%20versus%20standard%5Cu2010dose%20%28300%5Cu00a0mg%20day%201%3B%20then%2075%5Cu00a0mg%20daily%29%20clopidogrel%20in%20acute%20coronary%20syndrome%20patients.%20The%20primary%20outcome%20was%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20or%20stroke%20at%2030%5Cu00a0days.%20Interactions%20between%20treatment%20allocation%20and%20smoking%20status%20%28current%20smokers%20versus%20nonsmokers%29%20were%20evaluated.%20Overall%2C%206394%20patients%20%2837.0%25%29%20were%20current%20smokers.%20For%20the%20comparison%20of%20double%5Cu2010%20versus%20standard%5Cu2010dose%20clopidogrel%2C%20there%20were%20significant%20interactions%20in%20smokers%20and%20nonsmokers%20for%20the%20primary%20outcome%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.031%29%20and%20major%20bleeding%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.002%29.%20Double%5Cu2010%20versus%20standard%5Cu2010dose%20clopidogrel%20reduced%20the%20primary%20outcome%20among%20smokers%20by%2034%25%20%28hazard%20ratio%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5D%200.66%2C%2095%25%20confidence%20interval%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5D%2C%200.50%5Cu20130.87%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.003%29%2C%20whereas%20in%20nonsmokers%2C%20there%20was%20no%20apparent%20benefit%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%200.96%2C%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%200.80%5Cu20131.14%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.61%29.%20For%20major%20bleeding%2C%20there%20was%20no%20difference%20between%20the%20groups%20in%20smokers%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%200.77%2C%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%200.48%5Cu20131.24%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.28%29%2C%20whereas%20in%20nonsmokers%2C%20the%20double%5Cu2010dose%20clopidogrel%20regimen%20increased%20bleeding%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%201.89%2C%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.37%5Cu20132.60%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29.%20Double%5Cu2010dose%20clopidogrel%20reduced%20the%20incidence%20of%20definite%20stent%20thrombosis%20in%20smokers%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%200.41%2C%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%200.24%5Cu20130.71%29%20and%20nonsmokers%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%200.63%2C%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%200.42%5Cu20130.93%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20for%20interaction%3D0.19%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20smokers%2C%20a%20double%5Cu2010dose%20clopidogrel%20regimen%20reduced%20major%20cardiovascular%20events%20and%20stent%20thrombosis%20after%20percutaneous%20coronary%20intervention%2C%20with%20no%20increase%20in%20major%20bleeding.%20This%20suggests%20that%20clopidogrel%20dosing%20in%20patients%20with%20acute%20coronary%20syndromes%20should%20be%20personalized%2C%20taking%20into%20consideration%20both%20ischemic%20and%20bleeding%20risk.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2000335452.%22%2C%22date%22%3A%2211%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.117.006577%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.117.006577%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22I5LYEKN2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stewart%20et%20al.%22%2C%22parsedDate%22%3A%222017-08-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EStewart%20RAH%2C%20Hagstr%26%23xF6%3Bm%20E%2C%20Held%20C%2C%20Wang%20TKM%2C%20Armstrong%20PW%2C%20Aylward%20PE%2C%20Cannon%20CP%2C%20Koenig%20W%2C%20L%26%23xF3%3Bpez%26%23x2010%3BSend%26%23xF3%3Bn%20JL%2C%20Mohler%20ER%2C%20Hadziosmanovic%20N%2C%20Krug%26%23x2010%3BGourley%20S%2C%20Ramos%20Corrales%20MA%2C%20Siddique%20S%2C%20Steg%20PG%2C%20White%20HD%2C%20Wallentin%20L%2C%20on%20behalf%20of%20the%20STABILITY%20Investigators.%202017.%20Self%26%23x2010%3BReported%20Health%20and%20Outcomes%20in%20Patients%20With%20Stable%20Coronary%20Heart%20Disease.%20JAHA%206%3Ae006096.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Self%5Cu2010Reported%20Health%20and%20Outcomes%20in%20Patients%20With%20Stable%20Coronary%20Heart%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20A.%20H.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emil%22%2C%22lastName%22%3A%22Hagstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%20Kai%20Ming%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20W.%22%2C%22lastName%22%3A%22Armstrong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20E.%22%2C%22lastName%22%3A%22Aylward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P.%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfgang%22%2C%22lastName%22%3A%22Koenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22L%5Cu00f3pez%5Cu2010Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emile%20R.%22%2C%22lastName%22%3A%22Mohler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nermin%22%2C%22lastName%22%3A%22Hadziosmanovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Krug%5Cu2010Gourley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Antonio%22%2C%22lastName%22%3A%22Ramos%20Corrales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saulat%22%2C%22lastName%22%3A%22Siddique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Wallentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20STABILITY%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20major%20determinants%20and%20prognostic%20importance%20of%20self%5Cu2010reported%20health%20in%20patients%20with%20stable%20coronary%20heart%20disease%20are%20uncertain.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20STABILITY%20%28Stabilization%20of%20Atherosclerotic%20Plaque%20by%20Initiation%20of%20Darapladib%20Therapy%29%20trial%20randomized%2015%5Cu00a0828%20patients%20with%20stable%20coronary%20heart%20disease%20to%20treatment%20with%20darapladib%20or%20placebo.%20At%20baseline%2C%2098%25%20of%20participants%20completed%20a%20questionnaire%20that%20included%20the%20question%2C%20%5Cu201cOverall%2C%20how%20do%20you%20feel%20your%20general%20health%20is%20now%3F%5Cu201d%20Possible%20responses%20were%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20excellent%2C%20very%20good%2C%20good%2C%20average%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20and%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20poor%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Adjudicated%20major%20adverse%20cardiac%20events%2C%20which%20included%20cardiovascular%20death%2C%20myocardial%20infarction%2C%20and%20stroke%2C%20were%20evaluated%20by%20Cox%20regression%20during%203.7%5Cu00a0years%20of%20follow%5Cu2010up%20for%20participants%20who%20reported%20excellent%20or%20very%20good%20health%20%28n%3D2304%29%2C%20good%20health%20%28n%3D6863%29%2C%20and%20average%20or%20poor%20health%20%28n%3D6361%29%2C%20before%20and%20after%20adjusting%20for%2038%20covariates.%20Self%5Cu2010reported%20health%20was%20most%20strongly%20associated%20with%20geographic%20region%2C%20depressive%20symptoms%2C%20and%20low%20physical%20activity%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%20for%20all%29.%20Poor%5C%2Faverage%20compared%20with%20very%20good%5C%2Fexcellent%20self%5Cu2010reported%20health%20was%20independently%20associated%20with%20major%20adverse%20cardiac%20events%20%28hazard%20ratio%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5D%3A%202.30%20%5B95%25%20confidence%20interval%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%2C%201.92%5Cu20132.76%5D%3B%20adjusted%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%201.83%20%5B95%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.51%5Cu20132.22%5D%29%2C%20cardiovascular%20mortality%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%204.36%20%5B95%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%203.09%5Cu20136.16%5D%3B%20adjusted%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%202.15%20%5B95%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.45%5Cu20133.19%5D%29%2C%20and%20myocardial%20infarction%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%201.87%20%5B95%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.46%5Cu20132.39%5D%3B%20adjusted%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%201.68%20%5B95%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.25%5Cu20132.27%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0002%20for%20all%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Self%5Cu2010reported%20health%20is%20strongly%20associated%20with%20geographical%20region%2C%20mood%2C%20and%20physical%20activity.%20In%20a%20global%20coronary%20heart%20disease%20population%2C%20self%5Cu2010reported%20health%20was%20independently%20associated%20with%20major%20cardiovascular%20events%20and%20mortality%20beyond%20what%20is%20measurable%20by%20established%20risk%20indicators.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fwww.ClinicalTrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2000799903.%22%2C%22date%22%3A%222017-08-02%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.117.006096%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.117.006096%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22WQRWHRDN%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lindholm%20et%20al.%22%2C%22parsedDate%22%3A%222017-04-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELindholm%20D%2C%20Hagstr%26%23xF6%3Bm%20E%2C%20James%20SK%2C%20Becker%20RC%2C%20Cannon%20CP%2C%20Himmelmann%20A%2C%20Katus%20HA%2C%20Maurer%20G%2C%20L%26%23xF3%3Bpez%26%23x2010%3BSend%26%23xF3%3Bn%20JL%2C%20Steg%20PG%2C%20Storey%20RF%2C%20Siegbahn%20A%2C%20Wallentin%20L.%202017.%20Growth%20Differentiation%20Factor%2015%20at%201%20Month%20After%20an%20Acute%20Coronary%20Syndrome%20Is%20Associated%20With%20Increased%20Risk%20of%20Major%20Bleeding.%20JAHA%206%3Ae005580.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20Differentiation%20Factor%2015%20at%201%20Month%20After%20an%20Acute%20Coronary%20Syndrome%20Is%20Associated%20With%20Increased%20Risk%20of%20Major%20Bleeding%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Lindholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emil%22%2C%22lastName%22%3A%22Hagstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20K.%22%2C%22lastName%22%3A%22James%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20C.%22%2C%22lastName%22%3A%22Becker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P.%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22Himmelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%20A.%22%2C%22lastName%22%3A%22Katus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerald%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22L%5Cu00f3pez%5Cu2010Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agneta%22%2C%22lastName%22%3A%22Siegbahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Wallentin%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Growth%20differentiation%20factor%5Cu201015%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%29%20is%20related%20to%20major%20bleeding%20when%20measured%20at%20initial%20presentation%20in%20patients%20with%20acute%20coronary%20syndromes%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ACSs%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20treated%20with%20dual%20antiplatelet%20therapy.%20It%20is%20unknown%20whether%20follow%5Cu2010up%20measurements%20provide%20additional%20information.%20The%20objective%20of%20this%20study%20was%20to%20investigate%20whether%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20measured%201%5Cu00a0month%20after%20an%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ACS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20provides%20additional%20information%20beyond%20the%20baseline%20levels%20with%20regard%20to%20the%20risk%20of%20major%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20was%20measured%20at%20baseline%20and%20at%201%5Cu00a0month%20after%20an%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ACS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20in%204049%20patients%20included%20in%20the%20PLATelet%20inhibition%20and%20patient%20Outcomes%20%28PLATO%29%20trial.%20The%20association%20between%201%5Cu2010month%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20level%20and%20non%5Cu2013coronary%20artery%20bypass%20grafting%20surgery%5Cu2010related%20major%20bleeding%20was%20assessed%20by%20a%20multivariable%20Cox%20model%2C%20adjusting%20for%20baseline%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%2C%20age%2C%20anemia%2C%20impaired%20renal%20function%2C%20history%20of%20gastrointestinal%20bleeding%2C%20and%20sex.%20Elevated%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20%28%3E1800%5Cu00a0ng%5C%2FL%29%20at%201%5Cu00a0month%20was%20associated%20with%20an%20increased%20risk%20of%20non%5Cu2010coronary%20artery%20bypass%20grafting%5Cu2010related%20major%20bleeding%20%283.9%25%20versus%201.2%25%3B%20hazard%20ratio%2C%203.38%3B%2095%25%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.89%5Cu20136.06%29%2C%20independent%20of%20baseline%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015.%20Patients%20who%20had%20elevated%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20levels%20at%20baseline%20and%20subsequent%20nonelevated%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20at%201%5Cu00a0month%20had%20a%20similar%20risk%20as%20patients%20who%20had%20nonelevated%20levels%20at%20both%20measurements.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20at%201%5Cu00a0month%20after%20an%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ACS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20is%20related%20to%20the%20risk%20of%20bleeding%20during%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20DAPT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20provides%20additional%20information%20on%20the%20bleeding%20risk%20beyond%20baseline%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20levels.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20GDF%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu201015%20levels%20may%20therefore%20be%20useful%20as%20part%20of%20decision%20support%20concerning%20long%5Cu2010term%20antithrombotic%20treatment%20in%20patients%20post%5Cu2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20ACS%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2000391872.%22%2C%22date%22%3A%222017-04-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.117.005580%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.117.005580%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22LDDW6HT7%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Held%20et%20al.%22%2C%22parsedDate%22%3A%222017-10-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHeld%20C%2C%20White%20HD%2C%20Stewart%20RAH%2C%20Budaj%20A%2C%20Cannon%20CP%2C%20Hochman%20JS%2C%20Koenig%20W%2C%20Siegbahn%20A%2C%20Steg%20PG%2C%20Soffer%20J%2C%20Weaver%20WD%2C%20%26%23xD6%3Bstlund%20O%2C%20Wallentin%20L%2C%20on%20behalf%20of%20the%20STABILITY%20Investigators.%202017.%20Inflammatory%20Biomarkers%20Interleukin%26%23x2010%3B6%20and%20C%26%23x2010%3BReactive%20Protein%20and%20Outcomes%20in%20Stable%20Coronary%20Heart%20Disease%3A%20Experiences%20From%20the%20STABILITY%20%28Stabilization%20of%20Atherosclerotic%20Plaque%20by%20Initiation%20of%20Darapladib%20Therapy%29%20Trial.%20JAHA%206%3Ae005077.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inflammatory%20Biomarkers%20Interleukin%5Cu20106%20and%20C%5Cu2010Reactive%20Protein%20and%20Outcomes%20in%20Stable%20Coronary%20Heart%20Disease%3A%20Experiences%20From%20the%20STABILITY%20%28Stabilization%20of%20Atherosclerotic%20Plaque%20by%20Initiation%20of%20Darapladib%20Therapy%29%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20A.%20H.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrzej%22%2C%22lastName%22%3A%22Budaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P.%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20S.%22%2C%22lastName%22%3A%22Hochman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfgang%22%2C%22lastName%22%3A%22Koenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agneta%22%2C%22lastName%22%3A%22Siegbahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Soffer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20Douglas%22%2C%22lastName%22%3A%22Weaver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ollie%22%2C%22lastName%22%3A%22%5Cu00d6stlund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Wallentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20STABILITY%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Evaluation%20of%20cardiovascular%20prognosis%20in%20patients%20with%20stable%20coronary%20heart%20disease%20is%20based%20on%20clinical%20characteristics%20and%20biomarkers%20indicating%20dysglycemia%2C%20dyslipidemia%2C%20renal%20dysfunction%2C%20and%20possibly%20cardiac%20dysfunction.%20Inflammation%20plays%20a%20key%20role%20in%20atherosclerosis%2C%20but%20the%20association%20between%20inflammatory%20biomarkers%20and%20clinical%20outcomes%20is%20less%20studied%20in%20this%20population.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Overall%2C%2015%5Cu00a0828%20patients%20with%20coronary%20heart%20disease%20in%20the%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20STABILITY%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%28Stabilization%20of%20Atherosclerotic%20Plaque%20by%20Initiation%20of%20Darapladib%20Therapy%29%20trial%20were%20randomized%20to%20treatment%20with%20darapladib%20or%20placebo%20and%20observed%20for%20a%20median%20of%203.7%5Cu00a0years.%20In%2014%5Cu00a0611%20patients%2C%20levels%20of%20interleukin%5Cu20106%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20IL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu20106%29%20and%20high%5Cu2010sensitivity%20C%5Cu2010reactive%20protein%20were%20measured%20in%20plasma%20samples%3A%20median%20levels%20were%202.1%20%28interquartile%20range%2C%201.4%5Cu20133.2%29%20ng%5C%2FL%20and%201.3%20%28interquartile%20range%2C%200.6%5Cu20133.1%29%20mg%5C%2FL%2C%20respectively.%20Associations%20between%20continuous%20levels%20or%20quartile%20groups%20and%20adjudicated%20outcomes%20were%20evaluated%20by%20spline%20graphs%20and%20Cox%20regression%20adjusted%20for%20clinical%20factors%20and%20cardiovascular%20biomarkers.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20IL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu20106%20was%20associated%20with%20increased%20risk%20of%20major%20adverse%20cardiovascular%20events%20%28quartile%204%20versus%20quartile%201%20hazard%20ratio%20%5B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5D%2C%201.60%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.30%5Cu20131.97%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%3B%20cardiovascular%20death%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%202.15%3B%2095%25%20CI%2C%201.53%5Cu20133.04%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%3B%20myocardial%20infarction%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%201.53%3B%2095%25%20CI%2C%201.14%5Cu20132.04%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.05%29%3B%20all%5Cu2010cause%20mortality%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%202.11%3B%2095%25%20CI%2C%201.62%5Cu20132.76%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.0001%29%3B%20and%20risk%20of%20hospitalization%20for%20heart%20failure%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%202.28%3B%2095%25%20CI%2C%201.34%5Cu20133.89%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29.%20Cancer%20death%20was%20doubled%20in%20the%20highest%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20IL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu20106%20quartile%20group%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20HR%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%202.34%3B%2095%25%20CI%2C%201.20%5Cu20134.53%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.05%29.%20High%5Cu2010sensitivity%20C%5Cu2010reactive%20protein%20was%20associated%20with%20both%20cardiovascular%20and%20non%5Cu2010cardiovascular%20events%20in%20the%20unadjusted%20model%2C%20but%20these%20did%20not%20remain%20after%20multivariable%20adjustments.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20IL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu20106%2C%20an%20upstream%20inflammatory%20marker%2C%20was%20independently%20associated%20with%20the%20risk%20of%20major%20adverse%20cardiovascular%20events%2C%20cardiovascular%20and%20all%5Cu2010cause%20mortality%2C%20myocardial%20infarction%2C%20heart%20failure%2C%20and%20cancer%20mortality%20in%20patients%20with%20stable%20coronary%20heart%20disease.%20IL%5Cu20106%20might%20reflect%20a%20pathophysiological%20process%20involved%20in%20the%20development%20of%20these%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2000799903.%22%2C%22date%22%3A%222017-10-11%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.116.005077%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FJAHA.116.005077%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A23%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22WCR5NYHL%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puymirat%20et%20al.%22%2C%22parsedDate%22%3A%222017-11-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPuymirat%20E%2C%20Simon%20T%2C%20Cayla%20G%2C%20Cottin%20Y%2C%20Elbaz%20M%2C%20Coste%20P%2C%20Lemesle%20G%2C%20Motreff%20P%2C%20Popovic%20B%2C%20Khalife%20K%2C%20Lab%26%23xE8%3Bque%20J-N%2C%20Perret%20T%2C%20Le%20Ray%20C%2C%20Orion%20L%2C%20Jouve%20B%2C%20Blanchard%20D%2C%20Peycher%20P%2C%20Silvain%20J%2C%20Steg%20PG%2C%20Goldstein%20P%2C%20Gu%26%23xE9%3Bret%20P%2C%20Belle%20L%2C%20Aissaoui%20N%2C%20Ferri%26%23xE8%3Bres%20J%2C%20Schiele%20F%2C%20Danchin%20N.%202017.%20Acute%20Myocardial%20Infarction%3A%20Changes%20in%20Patient%20Characteristics%2C%20Management%2C%20and%206-Month%20Outcomes%20Over%20a%20Period%20of%2020%20Years%20in%20the%20FAST-MI%20Program%20%28French%20Registry%20of%20Acute%20ST-Elevation%20or%20Non-ST-Elevation%20Myocardial%20Infarction%29%201995%20to%202015.%20Circulation%20136%3A1908%26%23x2013%3B1919.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acute%20Myocardial%20Infarction%3A%20Changes%20in%20Patient%20Characteristics%2C%20Management%2C%20and%206-Month%20Outcomes%20Over%20a%20Period%20of%2020%20Years%20in%20the%20FAST-MI%20Program%20%28French%20Registry%20of%20Acute%20ST-Elevation%20or%20Non-ST-Elevation%20Myocardial%20Infarction%29%201995%20to%202015%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Puymirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Cayla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meyer%22%2C%22lastName%22%3A%22Elbaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Lemesle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Motreff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batric%22%2C%22lastName%22%3A%22Popovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khalife%22%2C%22lastName%22%3A%22Khalife%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Noel%22%2C%22lastName%22%3A%22Lab%5Cu00e8que%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Perret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Le%20Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Orion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Jouve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Peycher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanne%22%2C%22lastName%22%3A%22Silvain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Goldstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Gu%5Cu00e9ret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Belle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Aissaoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Ferri%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Schiele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ST-segment%5Cu2013elevation%20myocardial%20infarction%20%28STEMI%29%20and%20non%5Cu2013ST-segment%5Cu2013elevation%20myocardial%20infarction%20%28NSTEMI%29%20management%20has%20evolved%20considerably%20over%20the%20past%202%20decades.%20Little%20information%20on%20mortality%20trends%20in%20the%20most%20recent%20years%20is%20available.%20We%20assessed%20trends%20in%20characteristics%2C%20treatments%2C%20and%20outcomes%20for%20acute%20myocardial%20infarction%20in%20France%20between%201995%20and%202015.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20used%20data%20from%205%20one-month%20registries%2C%20conducted%205%20years%20apart%2C%20from%201995%20to%202015%2C%20including%2014%5Cu2009423%20patients%20with%20acute%20myocardial%20infarction%20%2859%25%20STEMI%29%20admitted%20to%20cardiac%20intensive%20care%20units%20in%20metropolitan%20France.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20From%201995%20to%202015%2C%20mean%20age%20decreased%20from%2066%5Cu00b114%20to%2063%5Cu00b114%20years%20in%20patients%20with%20STEMI%3B%20it%20remained%20stable%20%2868%5Cu00b114%20years%29%20in%20patients%20with%20NSTEMI%2C%20whereas%20diabetes%20mellitus%2C%20obesity%2C%20and%20hypertension%20increased.%20At%20the%20acute%20stage%2C%20intended%20primary%20percutaneous%20coronary%20intervention%20increased%20from%2012%25%20%281995%29%20to%2076%25%20%282015%29%20in%20patients%20with%20STEMI.%20In%20patients%20with%20NSTEMI%2C%20percutaneous%20coronary%20intervention%20%5Cu226472%20hours%20from%20admission%20increased%20from%209%25%20%281995%29%20to%2060%25%20%282015%29.%20Six-month%20mortality%20consistently%20decreased%20in%20patients%20with%20STEMI%20from%2017.2%25%20in%201995%20to%206.9%25%20in%202010%20and%205.3%25%20in%202015%3B%20it%20decreased%20from%2017.2%25%20to%206.9%25%20in%202010%20and%206.3%25%20in%202015%20in%20patients%20with%20NSTEMI.%20Mortality%20still%20decreased%20after%202010%20in%20patients%20with%20STEMI%20without%20reperfusion%20therapy%2C%20whereas%20no%20further%20mortality%20gain%20was%20found%20in%20patients%20with%20STEMI%20with%20reperfusion%20therapy%20or%20in%20patients%20with%20NSTEMI%2C%20whether%20or%20not%20they%20were%20treated%20with%20percutaneous%20coronary%20intervention.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Over%20the%20past%2020%20years%2C%206-month%20mortality%20after%20acute%20myocardial%20infarction%20has%20decreased%20considerably%20for%20patients%20with%20STEMI%20and%20NSTEMI.%20Mortality%20figures%20continued%20to%20decline%20in%20patients%20with%20STEMI%20until%202015%2C%20whereas%20mortality%20in%20patients%20with%20NSTEMI%20appears%20stable%20since%202010.%22%2C%22date%22%3A%222017-11-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.117.030798%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.117.030798%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A25Z%22%7D%7D%2C%7B%22key%22%3A%2294G7N7N6%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Deharo%20et%20al.%22%2C%22parsedDate%22%3A%222017-11-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDeharo%20P%2C%20Ducrocq%20G%2C%20Bode%20C%2C%20Cohen%20M%2C%20Cuisset%20T%2C%20Mehta%20SR%2C%20Pollack%20C%2C%20Wiviott%20SD%2C%20Elbez%20Y%2C%20Sabatine%20MS%2C%20Steg%20PG.%202017.%20Timing%20of%20Angiography%20and%20Outcomes%20in%20High-Risk%20Patients%20With%20Non%26%23x2013%3BST-Segment%26%23x2013%3BElevation%20Myocardial%20Infarction%20Managed%20Invasively%3A%20Insights%20From%20the%20TAO%20Trial%20%28Treatment%20of%20Acute%20Coronary%20Syndrome%20With%20Otamixaban%29.%20Circulation%20136%3A1895%26%23x2013%3B1907.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Timing%20of%20Angiography%20and%20Outcomes%20in%20High-Risk%20Patients%20With%20Non%5Cu2013ST-Segment%5Cu2013Elevation%20Myocardial%20Infarction%20Managed%20Invasively%3A%20Insights%20From%20the%20TAO%20Trial%20%28Treatment%20of%20Acute%20Coronary%20Syndrome%20With%20Otamixaban%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Deharo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Bode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Cuisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Pollack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20D.%22%2C%22lastName%22%3A%22Wiviott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S.%22%2C%22lastName%22%3A%22Sabatine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20non%5Cu2013ST-segment%5Cu2013elevation%20myocardial%20infarction%20%28NSTEMI%29%20and%20GRACE%20%28Global%20Registry%20of%20Acute%20Coronary%20Events%29%20score%20%3E140%2C%20coronary%20angiography%20%28CAG%29%20is%20recommended%20by%20European%20and%20American%20guidelines%20within%2024%20hours.%20We%20sought%20to%20study%20the%20association%20of%20very%20early%20%28ie%2C%20%5Cu226412%20hours%29%2C%20early%20%2812%5Cu201324%20hours%29%2C%20and%20delayed%20%28%3E24%20hours%29%20CAG%20in%20patients%20with%20NSTEMI%20with%20GRACE%20score%20%3E140%20with%20ischemic%20outcomes.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20TAO%20trial%20%28Treatment%20of%20Acute%20Coronary%20Syndrome%20With%20Otamixaban%29%20randomized%20patients%20with%20NSTEMI%20and%20CAG%20scheduled%20within%2072%20hours%20to%20heparin%20plus%20eptifibatide%20versus%20otamixaban.%20In%20this%20post%20hoc%20analysis%2C%20patients%20with%20a%20GRACE%20score%20%3E140%20were%20categorized%20into%203%20groups%20according%20to%20timing%20of%20CAG%20from%20admission%20%28%3C12%2C%20%5Cu226512%5Cu2013%3C24%2C%20and%20%5Cu226524%20hours%29.%20The%20primary%20ischemic%20outcome%20was%20the%20composite%20of%20all-cause%20death%20and%20myocardial%20infarction%20within%20180%20days%20of%20randomization.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CAG%20was%20performed%20in%204071%20patients%20%28%3C12%20hours%2C%20n%3D1648%20%5B40.5%25%5D%3B%2012%5Cu201324%20hours%2C%20n%3D1420%20%5B34.9%25%5D%3B%20%5Cu226524%20hours%2C%20n%3D1003%20%5B24.6%25%5D%29.%20With%20CAG%20%5Cu226524%20hours%20as%20a%20reference%2C%20CAG%20from%2012%20to%2024%20hours%20was%20not%20associated%20with%20a%20lower%20risk%20of%20primary%20ischemic%20outcome%20at%20180%20days%20%28odds%20ratio%2C%200.96%3B%2095%25%20confidence%20interval%2C%200.75%5Cu20131.23%29%2C%20whereas%20CAG%20%3C12%20hours%20was%20associated%20with%20a%20lower%20risk%20of%20death%20and%20myocardial%20infarction%20%28odds%20ratio%2C%200.71%3B%2095%25%20confidence%20interval%2C%200.55%5Cu20130.91%29.%20Performing%20CAG%20%3C12%20hours%20was%20also%20associated%20with%20a%20lower%20risk%20of%20death%20and%20myocardial%20infarction%20%28odds%20ratio%2C%200.76%3B%2095%25%20confidence%20interval%2C%200.61%5Cu20130.94%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.01%29%20compared%20with%20CAG%20performed%20at%2012%20to%2024%20hours.%20No%20difference%20was%20observed%20in%20bleeding%20complications.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20high-risk%20NSTEMI%2C%20undergoing%20CAG%20within%20the%20initial%2012%20hours%20after%20admission%20%28as%20opposed%20to%20later%2C%20either%2012%5Cu201324%20or%20%5Cu226524%20hours%29%20was%20associated%20with%20lower%20risk%20of%20ischemic%20outcomes%20at%20180%20days.%22%2C%22date%22%3A%222017-11-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.117.029779%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.117.029779%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22AF74HJ6X%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Adriaenssens%20et%20al.%22%2C%22parsedDate%22%3A%222017-09-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAdriaenssens%20T%2C%20Joner%20M%2C%20Godschalk%20TC%2C%20Malik%20N%2C%20Alfonso%20F%2C%20Xhepa%20E%2C%20De%20Cock%20D%2C%20Komukai%20K%2C%20Tada%20T%2C%20Cuesta%20J%2C%20Sirbu%20V%2C%20Feldman%20LJ%2C%20Neumann%20F-J%2C%20Goodall%20AH%2C%20Heestermans%20T%2C%20Buysschaert%20I%2C%20Hlinomaz%20O%2C%20Belmans%20A%2C%20Desmet%20W%2C%20Ten%20Berg%20JM%2C%20Gershlick%20AH%2C%20Massberg%20S%2C%20Kastrati%20A%2C%20Guagliumi%20G%2C%20Byrne%20RA.%202017.%20Optical%20Coherence%20Tomography%20Findings%20in%20Patients%20With%20Coronary%20Stent%20Thrombosis%3A%20A%20Report%20of%20the%20PRESTIGE%20Consortium%20%28Prevention%20of%20Late%20Stent%20Thrombosis%20by%20an%20Interdisciplinary%20Global%20European%20Effort%29.%20Circulation%20136%3A1007%26%23x2013%3B1021.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optical%20Coherence%20Tomography%20Findings%20in%20Patients%20With%20Coronary%20Stent%20Thrombosis%3A%20A%20Report%20of%20the%20PRESTIGE%20Consortium%20%28Prevention%20of%20Late%20Stent%20Thrombosis%20by%20an%20Interdisciplinary%20Global%20European%20Effort%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Adriaenssens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Joner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thea%20C.%22%2C%22lastName%22%3A%22Godschalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikesh%22%2C%22lastName%22%3A%22Malik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Alfonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erion%22%2C%22lastName%22%3A%22Xhepa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dries%22%2C%22lastName%22%3A%22De%20Cock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenichi%22%2C%22lastName%22%3A%22Komukai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomohisa%22%2C%22lastName%22%3A%22Tada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Cuesta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vasile%22%2C%22lastName%22%3A%22Sirbu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20J.%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz-Josef%22%2C%22lastName%22%3A%22Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alison%20H.%22%2C%22lastName%22%3A%22Goodall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ton%22%2C%22lastName%22%3A%22Heestermans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Buysschaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ota%22%2C%22lastName%22%3A%22Hlinomaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ann%22%2C%22lastName%22%3A%22Belmans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walter%22%2C%22lastName%22%3A%22Desmet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurrien%20M.%22%2C%22lastName%22%3A%22Ten%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20H.%22%2C%22lastName%22%3A%22Gershlick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steffen%22%2C%22lastName%22%3A%22Massberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adnan%22%2C%22lastName%22%3A%22Kastrati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Guagliumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Byrne%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Stent%20thrombosis%20%28ST%29%20is%20a%20serious%20complication%20following%20coronary%20stenting.%20Intravascular%20optical%20coherence%20tomography%20%28OCT%29%20may%20provide%20insights%20into%20mechanistic%20processes%20leading%20to%20ST.%20We%20performed%20a%20prospective%2C%20multicenter%20study%20to%20evaluate%20OCT%20findings%20in%20patients%20with%20ST.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Consecutive%20patients%20presenting%20with%20ST%20were%20prospectively%20enrolled%20in%20a%20registry%20by%20using%20a%20centralized%20telephone%20registration%20system.%20After%20angiographic%20confirmation%20of%20ST%2C%20OCT%20imaging%20of%20the%20culprit%20vessel%20was%20performed%20with%20frequency%20domain%20OCT.%20Clinical%20data%20were%20collected%20according%20to%20a%20standardized%20protocol.%20OCT%20acquisitions%20were%20analyzed%20at%20a%20core%20laboratory.%20Dominant%20and%20contributing%20findings%20were%20adjudicated%20by%20an%20imaging%20adjudication%20committee.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Two%20hundred%20thirty-one%20patients%20presenting%20with%20ST%20underwent%20OCT%20imaging%3B%2014%20%286.1%25%29%20had%20image%20quality%20precluding%20further%20analysis.%20Of%20the%20remaining%20patients%2C%2062%20%2828.6%25%29%20and%20155%20%2871.4%25%29%20presented%20with%20early%20and%20late%5C%2Fvery%20late%20ST%2C%20respectively.%20The%20underlying%20stent%20type%20was%20a%20new-generation%20drug-eluting%20stent%20in%2050.3%25.%20Mean%20reference%20vessel%20diameter%20was%202.9%5Cu00b10.6%20mm%20and%20mean%20reference%20vessel%20area%20was%206.8%5Cu00b12.6%20mm%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Stent%20underexpansion%20%28stent%20expansion%20index%20%3C0.8%29%20was%20observed%20in%2044.4%25%20of%20patients.%20The%20predicted%20average%20probability%20%2895%25%20confidence%20interval%29%20that%20any%20frame%20had%20uncovered%20%28or%20thrombus-covered%29%20struts%20was%2099.3%25%20%2896.1%5Cu201399.9%29%2C%2096.6%25%20%2892.4%5Cu201398.5%29%2C%2034.3%25%20%2815.0%5Cu201360.7%29%2C%20and%209.6%25%20%286.2%5Cu201314.5%29%20and%20malapposed%20struts%20was%2021.8%25%20%288.4%5Cu201345.6%29%2C%208.5%25%20%284.6%5Cu201315.3%29%2C%206.7%25%20%282.5%5Cu201316.3%29%2C%20and%202.0%25%20%281.2%5Cu20133.3%29%20for%20acute%2C%20subacute%2C%20late%2C%20and%20very%20late%20ST%2C%20respectively.%20The%20most%20common%20dominant%20finding%20adjudicated%20for%20acute%20ST%20was%20uncovered%20struts%20%2866.7%25%20of%20cases%29%3B%20for%20subacute%20ST%2C%20the%20most%20common%20dominant%20finding%20was%20uncovered%20struts%20%2861.7%25%29%20and%20underexpansion%20%2825.5%25%29%3B%20for%20late%20ST%2C%20the%20most%20common%20dominant%20finding%20was%20uncovered%20struts%20%2833.3%25%29%20and%20severe%20restenosis%20%2819.1%25%29%3B%20and%20for%20very%20late%20ST%2C%20the%20most%20common%20dominant%20finding%20was%20neoatherosclerosis%20%2831.3%25%29%20and%20uncovered%20struts%20%2820.2%25%29.%20In%20patients%20presenting%20very%20late%20ST%2C%20uncovered%20stent%20struts%20were%20a%20common%20dominant%20finding%20in%20drug-eluting%20stents%2C%20and%20neoatherosclerosis%20was%20a%20common%20dominant%20finding%20in%20bare%20metal%20stents.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20patients%20with%20ST%2C%20uncovered%20and%20malapposed%20struts%20were%20frequently%20observed%20with%20the%20incidence%20of%20both%20decreasing%20with%20longer%20time%20intervals%20between%20stent%20implantation%20and%20presentation.%20The%20most%20frequent%20dominant%20observation%20varied%20according%20to%20time%20intervals%20from%20index%20stenting%3A%20uncovered%20struts%20and%20underexpansion%20in%20acute%5C%2Fsubacute%20ST%20and%20neoatherosclerosis%20and%20uncovered%20struts%20in%20late%5C%2Fvery%20late%20ST.%22%2C%22date%22%3A%222017-09-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.117.026788%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.117.026788%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22P62ZLIY2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Simon%20and%20Danchin%22%2C%22parsedDate%22%3A%222017-01-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESimon%20T%2C%20Danchin%20N.%202017.%20Clinical%20Impact%20of%20Pharmacogenomics%20of%20Clopidogrel%20in%20Stroke.%20Circulation%20135%3A34%26%23x2013%3B37.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Impact%20of%20Pharmacogenomics%20of%20Clopidogrel%20in%20Stroke%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Danchin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-01-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.116.025198%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCULATIONAHA.116.025198%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A22%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22J4AZXFB6%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cavender%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECavender%20MA%2C%20Bhatt%20DL%2C%20Stone%20GW%2C%20Steg%20PhG%2C%20Gibson%20CM%2C%20Hamm%20CW%2C%20Price%20MJ%2C%20Prats%20J%2C%20Elkin%20S%2C%20Deliargyris%20EN%2C%20Mahaffey%20KW%2C%20White%20HD%2C%20Harrington%20RA.%202017.%20Cangrelor%20in%20Older%20Patients%20Undergoing%20Percutaneous%20Coronary%20Intervention%3A%20Findings%20From%20CHAMPION%20PHOENIX.%20Circ%3A%20Cardiovascular%20Interventions%2010%3Ae005257.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cangrelor%20in%20Older%20Patients%20Undergoing%20Percutaneous%20Coronary%20Intervention%3A%20Findings%20From%20CHAMPION%20PHOENIX%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20A.%22%2C%22lastName%22%3A%22Cavender%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W.%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Elkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Efthymios%20N.%22%2C%22lastName%22%3A%22Deliargyris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W.%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Older%20patients%20treated%20with%20percutaneous%20coronary%20intervention%20are%20at%20increased%20risk%20of%20periprocedural%20events.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CHAMPION%20%28cangrelor%20versus%20standard%20therapy%20to%20achieve%20optimal%20management%20of%20platelet%20inhibition%29%20PHOENIX%20randomized%2011%5Cu2009145%20patients%20to%20cangrelor%20or%20clopidogrel.%20We%20sought%20to%20determine%20the%20outcomes%20in%20the%20prespecified%20subgroup%20of%20patients%20%5Cu226575%20years%20old%20%28n%3D2010%3B%2018%25%29.%20Cangrelor%20resulted%20in%20directionally%20consistent%20effects%20on%20the%20primary%20end%20point%20%28death%2C%20myocardial%20infarction%2C%20ischemia-driven%20revascularization%2C%20or%20stent%20thrombosis%29%20in%20patients%20%5Cu226575%20years%20old%20%28odds%20ratio%20%5BOR%5D%2C%200.71%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.50%5Cu20131.02%29%20and%20in%20those%20%3C75%20years%20old%20%28OR%2C%200.81%3B%2095%25%20CI%2C%200.67%5Cu20130.98%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Binteraction%5D%3D0.55%29.%20Age%20%5Cu226575%20years%20was%20an%20independent%20predictor%20of%20GUSTO%20%28Global%20Use%20of%20Strategies%20to%20Open%20Occluded%20Coronary%20Arteries%29%20moderate%5C%2Fsevere%20bleeding%20%281.0%25%20versus%200.3%25%3B%20adjusted%20OR%2C%202.94%3B%2095%25%20CI%2C%201.28%5Cu20136.77%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.01%29%20when%20compared%20with%20patients%20%3C75%20years%20old.%20There%20was%20no%20significant%20difference%20in%20GUSTO%20moderate%5C%2Fsevere%20bleeding%20with%20cangrelor%20versus%20clopidogrel%20%281.1%25%20versus%201.0%25%3B%20OR%2C%201.07%3B%2095%25%20CI%200.45%5Cu20132.53%29%20in%20patients%20%5Cu226575%20years%20old%20or%20in%20those%20%3C75%20years%20old%20%280.4%25%20versus%200.2%25%3B%20OR%2C%202.24%3B%2095%25%20CI%2C%201.02%5Cu20134.93%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Binteraction%5D%3D0.21%29.%20For%20the%20net%20composite%20end%20point%20of%20death%2C%20myocardial%20infarction%2C%20ischemia-driven%20revascularization%2C%20or%20stent%20thrombosis%20plus%20GUSTO%20moderate%5C%2Fsevere%20bleeding%2C%20the%20OR%20for%20cangrelor%20in%20those%20%5Cu226575%20years%20old%20was%200.75%20%286.4%25%20versus%208.3%25%3B%2095%25%20CI%2C%200.54%5Cu20131.05%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.09%29.%20The%20effects%20were%20similar%20in%20those%20%3C75%20years%20old%20%284.9%25%20versus%205.8%25%3B%20OR%2C%200.85%3B%2095%25%20CI%2C%200.70%5Cu20131.02%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.08%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Binteraction%5D%3D0.53%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Patients%20%5Cu226575%20years%20old%20have%20an%20overall%20%5Cu22483-fold%20increased%20odds%20of%20moderate%5C%2Fsevere%20bleeding.%20Cangrelor%2C%20when%20compared%20with%20clopidogrel%2C%20provides%20similar%20efficacy%20and%20in%20patients%20%5Cu226575%20years%20old%20as%20in%20those%20%3C75%20years%20old%20but%20does%20not%20increase%20the%20risk%20of%20major%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT01156571.%22%2C%22date%22%3A%2208%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.117.005257%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.117.005257%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22RDVUJEHN%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shah%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EShah%20B%2C%20Baber%20U%2C%20Pocock%20SJ%2C%20Krucoff%20MW%2C%20Ariti%20C%2C%20Gibson%20CM%2C%20Steg%20PG%2C%20Weisz%20G%2C%20Witzenbichler%20B%2C%20Henry%20TD%2C%20Kini%20AS%2C%20Stuckey%20T%2C%20Cohen%20DJ%2C%20Iakovou%20I%2C%20Dangas%20G%2C%20Aquino%20MB%2C%20Sartori%20S%2C%20Chieffo%20A%2C%20Moliterno%20DJ%2C%20Colombo%20A%2C%20Mehran%20R.%202017.%20White%20Blood%20Cell%20Count%20and%20Major%20Adverse%20Cardiovascular%20Events%20After%20Percutaneous%20Coronary%20Intervention%20in%20the%20Contemporary%20Era%3A%20Insights%20From%20the%20PARIS%20Study%20%28Patterns%20of%20Non-Adherence%20to%20Anti-Platelet%20Regimens%20in%20Stented%20Patients%20Registry%29.%20Circ%3A%20Cardiovascular%20Interventions%2010%3Ae004981.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22White%20Blood%20Cell%20Count%20and%20Major%20Adverse%20Cardiovascular%20Events%20After%20Percutaneous%20Coronary%20Intervention%20in%20the%20Contemporary%20Era%3A%20Insights%20From%20the%20PARIS%20Study%20%28Patterns%20of%20Non-Adherence%20to%20Anti-Platelet%20Regimens%20in%20Stented%20Patients%20Registry%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Binita%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Usman%22%2C%22lastName%22%3A%22Baber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%20W.%22%2C%22lastName%22%3A%22Krucoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cono%22%2C%22lastName%22%3A%22Ariti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giora%22%2C%22lastName%22%3A%22Weisz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernhard%22%2C%22lastName%22%3A%22Witzenbichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20D.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annapoorna%20S.%22%2C%22lastName%22%3A%22Kini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Stuckey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioannis%22%2C%22lastName%22%3A%22Iakovou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Dangas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%20B.%22%2C%22lastName%22%3A%22Aquino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Sartori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alaide%22%2C%22lastName%22%3A%22Chieffo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Moliterno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%22%2C%22lastName%22%3A%22Mehran%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Elevated%20white%20blood%20cell%20%28WBC%29%20count%20is%20associated%20with%20increased%20major%20adverse%20cardiovascular%20events%20%28MACE%29%20in%20the%20setting%20of%20acute%20coronary%20syndrome.%20The%20aim%20of%20this%20study%20was%20to%20evaluate%20whether%20similar%20associations%20persist%20in%20an%20all-comers%20population%20of%20patients%20undergoing%20percutaneous%20coronary%20intervention%20in%20the%20contemporary%20era.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20multicenter%2C%20prospective%2C%20observational%20PARIS%20study%20%28Patterns%20of%20Non-Adherence%20to%20Anti-Platelet%20Regimens%20in%20Stented%20Patients%20Registry%29%2C%204222%20patients%20who%20underwent%20percutaneous%20coronary%20intervention%20in%20the%20United%20States%20and%20Europe%20between%20July%201%2C%202009%2C%20and%20December%202%2C%202010%2C%20were%20evaluated.%20The%20associations%20between%20baseline%20WBC%20and%20MACE%20%28composite%20of%20cardiac%20death%2C%20stent%20thrombosis%2C%20spontaneous%20myocardial%20infarction%2C%20or%20target%20lesion%20revascularization%29%20at%2024-month%20follow-up%20were%20analyzed%20using%20multivariable%20Cox%20regression.%20Patients%20with%20higher%20WBC%20were%20more%20often%20younger%2C%20smokers%2C%20and%20with%20less%20comorbid%20risk%20factors%20compared%20with%20those%20with%20lower%20WBC.%20After%20adjustment%20for%20baseline%20and%20procedural%20characteristics%2C%20WBC%20remained%20independently%20associated%20with%20MACE%20%28hazard%20ratio%20%5BHR%5D%20per%2010%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%203%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20cells%5C%2F%5Cu03bcL%20increase%2C%201.05%20%5B95%25%20confidence%20intervals%20%28CI%29%2C%201.02%5Cu20131.09%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.001%29%2C%20cardiac%20death%20%28HR%2C%201.10%20%5B95%25%20CI%2C%201.05%5Cu20131.17%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C0.001%29%2C%20and%20clinically%20indicated%20target%20revascularization%20%28HR%2C%201.04%20%5B95%25%20CI%2C%201.00%5Cu20131.09%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.03%29%20but%20not%20stent%20thrombosis%20%28HR%2C%201.07%20%5B95%25%20CI%2C%200.99%5Cu20131.16%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.10%29%20or%20spontaneous%20myocardial%20infarction%20%28HR%2C%201.03%20%5B95%25%20CI%2C%200.97%5Cu20131.09%5D%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.29%29.%20The%20association%20between%20WBC%20and%20MACE%20was%20consistent%20in%20acute%20coronary%20syndrome%20and%20non%5Cu2013acute%20coronary%20syndrome%20presentations%20%28interaction%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.15%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Increased%20WBC%20is%20an%20independent%20predictor%20of%20MACE%20after%20percutaneous%20coronary%20intervention%20in%20a%20contemporary%20all-comers%20cohort.%20Further%20studies%20to%20delineate%20the%20underlying%20pathophysiologic%20role%20of%20elevated%20WBC%20across%20a%20spectrum%20of%20coronary%20artery%20disease%20presentations%20are%20warranted.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Clinical%20Trial%20Registration%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20URL%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fwww.clinicaltrials.gov%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20Unique%20identifier%3A%20NCT00998127.%22%2C%22date%22%3A%2209%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.117.004981%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.117.004981%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A52Z%22%7D%7D%2C%7B%22key%22%3A%226LL3LTP6%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sawlani%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESawlani%20NN%2C%20Harrington%20RA%2C%20Stone%20GW%2C%20Steg%20PhG%2C%20Gibson%20CM%2C%20Hamm%20CW%2C%20Price%20MJ%2C%20Prats%20J%2C%20Deliargyris%20EN%2C%20Mahaffey%20KW%2C%20White%20HD%2C%20Bhatt%20DL.%202017.%20Impact%20of%20Cerebrovascular%20Events%20Older%20Than%20One%20Year%20on%20Ischemic%20and%20Bleeding%20Outcomes%20With%20Cangrelor%20in%20Percutaneous%20Coronary%20Intervention.%20Circ%3A%20Cardiovascular%20Interventions%2010%3Ae004380.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Cerebrovascular%20Events%20Older%20Than%20One%20Year%20on%20Ischemic%20and%20Bleeding%20Outcomes%20With%20Cangrelor%20in%20Percutaneous%20Coronary%20Intervention%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neal%20N.%22%2C%22lastName%22%3A%22Sawlani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20A.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W.%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Efthymios%20N.%22%2C%22lastName%22%3A%22Deliargyris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W.%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Cangrelor%20is%20a%20potent%20intravenous%20adenosine%20diphosphate%5Cu2013receptor%20antagonist%20that%20in%20the%20CHAMPION%20trials%20reduced%20the%2048-hour%20and%2030-day%20rates%20of%20ischemic%20events%20during%20percutaneous%20coronary%20intervention%20without%20an%20increase%20in%20severe%20bleeding.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20Results%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20CHAMPION%20PCI%20%28A%20Clinical%20Trial%20to%20Demonstrate%20the%20Efficacy%20of%20Cangrelor%29%2C%20CHAMPION%20PLATFORM%20%28Cangrelor%20Versus%20Standard%20Therapy%20to%20Achieve%20Optimal%20Management%20of%20Platelet%20Inhibition%29%2C%20and%20CHAMPION%20PHOENIX%20%28A%20Clinical%20Trial%20Comparing%20Cangrelor%20to%20Clopidogrel%20Standard%20Therapy%20in%20Subjects%20Who%20Require%20Percutaneous%20Coronary%20Intervention%29%20were%203%20randomized%2C%20double-blind%2C%20double-dummy%20trials%20in%20which%20cangrelor%20was%20compared%20with%20clopidogrel%20during%20percutaneous%20coronary%20intervention.%20The%20effect%20of%20cangrelor%20on%20ischemic%20events%20and%20bleeding%20was%20analyzed%20in%20the%20subgroup%20of%20patients%20with%20a%20history%20of%20cerebrovascular%20events%20at%20least%201%20year%20prior%20to%20randomization%3B%20the%20Breslow%5Cu2013Day%20test%20was%20used%20to%20test%20for%20interaction%20of%20treatment%20effect%20in%20subgroups%20with%20and%20without%20such%20a%20history.%20The%20primary%20efficacy%20end%20point%20was%20a%20composite%20of%20death%2C%20myocardial%20infarction%2C%20ischemia-driven%20revascularization%2C%20or%20stent%20thrombosis%20at%2048%20hours.%20Among%2024%5Cu2009910%20randomized%20patients%2C%201270%20patients%20%285.1%25%29%20had%20a%20cerebrovascular%20event%20%3E1%20year%20old%2C%20including%20650%20assigned%20to%20cangrelor%20and%20620%20assigned%20to%20clopidogrel.%20Consistent%20with%20the%20overall%20trial%20results%2C%20the%20rate%20of%20the%20primary%20efficacy%20end%20point%20was%204.3%25%20in%20the%20cangrelor%20group%20versus%205.3%25%20in%20the%20clopidogrel%20group%20%28odds%20ratio%200.80%3B%2095%25%20confidence%20interval%200.48%5Cu20131.34%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.40%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20for%20interaction%20%3D0.97%29%2C%20and%20the%20rate%20of%20GUSTO%20%28Global%20Use%20of%20Strategies%20to%20Open%20Occluded%20Coronary%20Arteries%29%20severe%20bleeding%20was%200.3%25%20in%20both%20groups%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D0.97%3B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20for%20interaction%20%3D0.81%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu2014%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20patients%20in%20the%20CHAMPION%20trials%20with%20a%20prior%20cerebrovascular%20event%20at%20least%201%20year%20before%20the%20percutaneous%20coronary%20intervention%2C%20the%20efficacy%20and%20bleeding%20profile%20of%20cangrelor%20compared%20with%20clopidogrel%20was%20similar%20to%20that%20in%20the%20overall%20trial.%22%2C%22date%22%3A%2201%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.116.004380%22%2C%22ISSN%22%3A%221941-7640%2C%201941-7632%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ahajournals.org%5C%2Fdoi%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.116.004380%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22FA7YN5GT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parker%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EParker%20WA%2C%20Bhatt%20DL%2C%20Prats%20J%2C%20Day%20JRS%2C%20Steg%20PG%2C%20Stone%20GW%2C%20Hamm%20CW%2C%20Mahaffey%20KW%2C%20Price%20MJ%2C%20Michael%20Gibson%20C%2C%20White%20HD%2C%20Storey%20RF%2C%20the%20CHAMPION%20PHOENIX%20Investigators.%202017.%20Characteristics%20of%20dyspnoea%20and%20associated%20clinical%20outcomes%20in%20the%20CHAMPION%20PHOENIX%20study.%20Thromb%20Haemost%20117%3A1093%26%23x2013%3B1100.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characteristics%20of%20dyspnoea%20and%20associated%20clinical%20outcomes%20in%20the%20CHAMPION%20PHOENIX%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20A.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20R.%20S.%22%2C%22lastName%22%3A%22Day%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregg%20W.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W.%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20W.%22%2C%22lastName%22%3A%22Mahaffey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Michael%20Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20CHAMPION%20PHOENIX%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Summary%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Dyspnoea%20may%20be%20induced%20by%20some%20reversibly-binding%20P2Y12%20inhibitors%2C%20including%20cangrelor%20and%20ticagrelor.%20Dyspnoea%20was%20not%20associated%20with%20any%20compromise%20to%20the%20efficacy%20of%20ticagrelor%20in%20the%20PLATO%20study.%20The%20CHAMPION%20PHOENIX%20study%20%28NCT01156571%29%20compared%20initial%20treatment%20with%20cangrelor%20versus%20initial%20treatment%20with%20clopidogrel%20in%20patients%20undergoing%20PCI.%20We%20investigated%20the%20incidence%2C%20characteristics%2C%20and%20associated%20clinical%20outcomes%20in%20patients%20with%20dyspnoea%20in%20CHAMPION%20PHOENIX.%20Adverse%20events%20%28AEs%29%20of%20dyspnoea%20to%2048%20hours%20were%20recorded%20in%20patients%20randomised%20to%20cangrelor%20or%20clopidogrel%20in%20CHAMPION%20PHOENIX.%20The%20composite%20primary%20endpoint%20of%20death%2C%20myocardial%20infarction%2C%20ischaemia-driven%20revascularisation%2C%20or%20stent%20thrombosis%20as%20well%20its%20individual%20components%20were%20assessed%20in%20patients%20who%20did%20or%20did%20not%20report%20dyspnoea.%20A%20total%20of%2068%20%281.2%20%25%29%20cangrelor-treated%20patients%20and%2018%20%280.3%20%25%29%20clopidogrel-treated%20patients%20reported%20dyspnoea%20%28p%3C0.001%29.%20Most%20dyspnoea%20events%20in%20cangrelor-treated%20patients%20were%20considered%20mild%20%2871%20%25%29%20or%20moderate%20%2828%20%25%29%20and%20only%20one%20event%20was%20considered%20severe%20and%20led%20to%20discontinuation%20of%20cangrelor.%20The%20dyspnoea%20events%20in%20the%20clopidogrel-treated%20patients%20were%20mild%20%2878%20%25%29%20or%20moderate%20%2822%20%25%29.%20Characteristics%20of%20dyspnoea%20were%20consistent%20with%20those%20seen%20in%20the%20CHAMPION%20programme%20as%20a%20whole.%20In%20the%20modified%20intention-to-treat%20population%2C%20rates%20of%20the%20composite%20primary%20outcome%20and%20its%20individual%20components%20were%20not%20affected%20by%20the%20presence%20of%20dyspnoea%20in%20cangrelor-treated%20patients.%20Cangrelor-related%20dyspnoea%20is%20transient%2C%20usually%20mild%20or%20moderate%2C%20and%20unlikely%20to%20lead%20to%20discontinuation%20of%20therapy.%20The%20occurrence%20of%20dyspnoea%20does%20not%20seem%20to%20be%20associated%20with%20any%20reduction%20in%20the%20efficacy%20of%20cangrelor%20compared%20with%20clopidogrel%20as%20initial%20therapy%20in%20PCI%20patients.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Supplementary%20Material%20to%20this%20article%20is%20available%20online%20at%20www.thrombosis-online.com.%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1160%5C%2FTH16-12-0958%22%2C%22ISSN%22%3A%220340-6245%2C%202567-689X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.thieme-connect.de%5C%2FDOI%5C%2FDOI%3F10.1160%5C%2FTH16-12-0958%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22WCSP79E4%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thomas%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EThomas%20MR%2C%20Angiolillo%20DJ%2C%20Bonaca%20MP%2C%20Ajjan%20RA%2C%20Judge%20HM%2C%20Rollini%20F%2C%20Franchi%20F%2C%20Ahsan%20AJ%2C%20Bhatt%20DL%2C%20Kuder%20JF%2C%20Steg%20PG%2C%20Cohen%20M%2C%20Muthusamy%20R%2C%20Sabatine%20MS%2C%20Storey%20RF.%202017.%20Consistent%20platelet%20inhibition%20with%20ticagrelor%2060%20mg%20twice-daily%20following%20myocardial%20infarction%20regardless%20of%20diabetes%20status.%20Thromb%20Haemost%20117%3A940%26%23x2013%3B947.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Consistent%20platelet%20inhibition%20with%20ticagrelor%2060%20mg%20twice-daily%20following%20myocardial%20infarction%20regardless%20of%20diabetes%20status%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20R.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominick%20J.%22%2C%22lastName%22%3A%22Angiolillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20P.%22%2C%22lastName%22%3A%22Bonaca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramzi%20A.%22%2C%22lastName%22%3A%22Ajjan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heather%20M.%22%2C%22lastName%22%3A%22Judge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabiana%22%2C%22lastName%22%3A%22Rollini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Franchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arif%20J.%22%2C%22lastName%22%3A%22Ahsan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%20F.%22%2C%22lastName%22%3A%22Kuder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rangasamy%22%2C%22lastName%22%3A%22Muthusamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20S.%22%2C%22lastName%22%3A%22Sabatine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20F.%22%2C%22lastName%22%3A%22Storey%22%7D%5D%2C%22abstractNote%22%3A%22Summary%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Diabetes%20increases%20cardiovascular%20risk%20and%20reduces%20pharmacodynamic%20response%20to%20some%20oral%20antiplatelet%20drugs.%20This%20study%20aimed%20to%20determine%20whether%20ticagrelor%2060%20mg%20twice%20daily%20%28bid%29%20provided%20potent%20and%20consistent%20platelet%20inhibition%20in%20patients%20with%20vs%20without%20diabetes%20in%20the%20PEGASUS-TIMI%2054%20platelet%20function%20substudy.%20Out%20of%20180%20patients%20studied%2C%2058%20patients%20were%20randomised%20to%20and%20had%20received%20at%20least%20four%20weeks%20of%20ticagrelor%2060%20mg%20bid%2C%20with%2020%20%2834%20%25%29%20having%20diabetes%2C%2058%20patients%20received%20ticagrelor%2090%20mg%20bid%2C%20with%2012%20%2821%20%25%29%20having%20diabetes%2C%20and%2064%20patients%20received%20placebo%2C%20with%2018%20%2828%20%25%29%20having%20diabetes.%20Blood%20was%20sampled%20pre-%20and%202%20hours%20post-maintenance%20dose.%20In%20patients%20treated%20with%20ticagrelor%2060%20mg%20bid%2C%20on-treatment%20platelet%20reactivity%20to%20ADP%2C%20as%20determined%20by%20light%20transmission%20aggregometry%20%28LTA%29%2C%20VerifyNow%20and%20VASP%2C%20was%20similar%20in%20patients%20with%20vs%20without%20diabetes%20%28LTA%20post-dose%2C%20ADP%2020%20%3FM%3A%2029%20%5Cu00b1%2014%20vs%2034%20%5Cu00b1%2010%20%25%2C%20respectively%3B%20p%20%3D%200.19%29.%20A%20consistent%20inhibitory%20effect%20of%20ticagrelor%2060%20mg%20bid%20was%20observed%20pre-%20and%20post-dose%20regardless%20of%20diabetes%20status%2C%20even%20in%20insulin-treated%20patients.%20Patients%20with%20diabetes%20did%20not%20have%20an%20increased%20incidence%20of%20high%20platelet%20reactivity%20in%20either%20ticagrelor%20group.%20Platelet%20reactivity%20was%20similar%20in%20patients%20with%20diabetes%20treated%20with%20ticagrelor%2060%20mg%20vs%2090%20mg%20bid.%20Pharmacokinetics%20of%20ticagrelor%20were%20not%20affected%20by%20diabetes%20status.%20In%20conclusion%2C%20ticagrelor%2060%20mg%20bid%20is%20equally%20effective%20at%20reducing%20platelet%20reactivity%20in%20patients%20with%20and%20without%20diabetes%2C%20yielding%20a%20consistently%20high%20level%20of%20platelet%20inhibition%20regardless%20of%20diabetes%20status.%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1160%5C%2FTH16-09-0703%22%2C%22ISSN%22%3A%220340-6245%2C%202567-689X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.thieme-connect.de%5C%2FDOI%5C%2FDOI%3F10.1160%5C%2FTH16-09-0703%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A47Z%22%7D%7D%2C%7B%22key%22%3A%227HILKVPT%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abboud%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbboud%20H%2C%20Sissani%20L%2C%20Labreuche%20J%2C%20Arauz%20A%2C%20Bousser%20M-G%2C%20Bryer%20A%2C%20Chamorro%20A%2C%20Fisher%20M%2C%20Ford%20I%2C%20Fox%20KM%2C%20Hennerici%20MG%2C%20Lavados%20PM%2C%20Massaro%20A%2C%20Mattle%20HP%2C%20Munoz%20Collazos%20M%2C%20Rothwell%20PM%2C%20Steg%20PG%2C%20Vicaut%20E%2C%20Yamouth%20B%2C%20Amarenco%20P%2C%20on%20behalf%20of%20the%20OPTIC%20Registry%20and%20PERFORM%20Trial%20Investigators.%202017.%20Specificities%20of%20Ischemic%20Stroke%20Risk%20Factors%20in%20Arab-Speaking%20Countries.%20Cerebrovasc%20Dis%2043%3A169%26%23x2013%3B177.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Specificities%20of%20Ischemic%20Stroke%20Risk%20Factors%20in%20Arab-Speaking%20Countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Halim%22%2C%22lastName%22%3A%22Abboud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Sissani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Labreuche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Arauz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Germaine%22%2C%22lastName%22%3A%22Bousser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Bryer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%22%2C%22lastName%22%3A%22Chamorro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Fisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20G.%22%2C%22lastName%22%3A%22Hennerici%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20M.%22%2C%22lastName%22%3A%22Lavados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayrton%22%2C%22lastName%22%3A%22Massaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heinrich%20P.%22%2C%22lastName%22%3A%22Mattle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Munoz%20Collazos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Rothwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Vicaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bassem%22%2C%22lastName%22%3A%22Yamouth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Amarenco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20OPTIC%20Registry%20and%20PERFORM%20Trial%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22%3Cb%3E%3Ci%3EBackground%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Stroke%20is%20largely%20preventable%2C%20and%20therefore%2C%20a%20better%20understanding%20of%20risk%20factors%20is%20an%20essential%20step%20in%20reducing%20the%20population%20stroke%20rate%20and%20resulting%20disease%20burden%20in%20Arab%20countries.%20%3Cb%3E%3Ci%3ESummary%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20We%20performed%202%20separate%20analyses%20in%202%20similar%20populations%20of%20patients%20with%20noncardioembolic%20ischemic%20stroke.%20This%20first%20involved%203%2C635%20patients%20in%20the%20Outcomes%20in%20Patients%20with%20TIA%20and%20Cerebrovascular%20disease%20%28OPTIC%29%20registry%20%28followed%20for%202%20years%29%2C%20with%20baseline%20collection%20of%20the%20usual%20risk%20factors%20and%205%20socioeconomic%20variables%20%28unemployment%20status%2C%20residence%20in%20rural%20area%2C%20living%20in%20fully%20serviced%20accommodation%2C%20no%20health-insurance%20coverage%2C%20and%20low%20educational%20level%29.%20The%20second%20involved%20patients%20in%20the%20PERFORM%20trial%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%2019%2C100%20followed%20up%20for%202%20years%29%2C%20with%20baseline%20collection%20of%20the%20usual%20risk%20factors%20and%201%20socioeconomic%20variable%20%28low%20educational%20level%29.%20The%20primary%20outcome%20was%20a%20composite%20of%20nonfatal%20stroke%2C%20nonfatal%20myocardial%20infarction%2C%20or%20cardiovascular%20death.%20Stroke%20risk%20factors%20were%20more%20prevalent%20in%20patients%20in%20Arab%20countries.%20The%20incidence%20of%20major%20cardiovascular%20events%20%28MACE%3B%20age-%20and%20gender-adjusted%29%20was%20higher%20in%20Arab%20countries%20%28OPTIC%2C%2018.5%20vs.%2013.3%25%3B%20PERFORM%2C%2018.4%20vs.%209.7%25%3B%20both%20%3Ci%3Ep%20%3C%5C%2Fi%3E%5Cu2264%200.0001%29.%20These%20results%20remained%20significant%20after%20adjustment%20on%20risk%20factors%20and%20were%20attenuated%20in%20OPTIC%20after%20further%20adjustment%20on%20socioeconomic%20variables%20%28hazard%20ratio%201.24%3B%2095%25%20CI%200.98-1.55%3B%20%3Ci%3Ep%20%3C%5C%2Fi%3E%3D%200.07%29.%20%3Cb%3E%3Ci%3EKey%20Messages%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Patients%20with%20ischemic%20stroke%20living%20in%20Arab%20countries%20had%20a%20lower%20mean%20socioeconomic%20status%2C%20a%20much%20higher%20prevalence%20of%20diabetes%20mellitus%2C%20and%20a%20higher%20rate%20of%20MACE%20compared%20with%20patients%20from%20non-Arab%20countries.%20This%20finding%20is%20partly%20explained%20by%20a%20higher%20prevalence%20of%20risk%20factors%20and%20also%20by%20a%20high%20prevalence%20of%20poverty%20and%20low%20educational%20level.%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1159%5C%2F000454776%22%2C%22ISSN%22%3A%221015-9770%2C%201421-9786%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.karger.com%5C%2FArticle%5C%2FFullText%5C%2F454776%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A46Z%22%7D%7D%2C%7B%22key%22%3A%226F7U7VZR%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Huber%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHuber%20K%2C%20Ducrocq%20G%2C%20Hamm%20CW%2C%20Van%20%26%23x2019%3BT%20Hof%20A%2C%20Lapostolle%20F%2C%20Coste%20P%2C%20Gordini%20G%2C%20Steinmetz%20J%2C%20Verheugt%20FWA%2C%20Adgey%20J%2C%20Nibbe%20L%2C%20Kani%26%23x109%3B%20V%2C%20Clemmensen%20P%2C%20Zeymer%20U%2C%20Bernstein%20D%2C%20Prats%20J%2C%20Deliargyris%20EN%2C%20Gabriel%20Steg%20P.%202017.%20Early%20clinical%20outcomes%20as%20a%20function%20of%20use%20of%20newer%20oral%20P2Y%20%3Csub%3E12%3C%5C%2Fsub%3E%20inhibitors%20versus%20clopidogrel%20in%20the%20EUROMAX%20trial.%20Open%20Heart%204%3Ae000677.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20clinical%20outcomes%20as%20a%20function%20of%20use%20of%20newer%20oral%20P2Y%20%3Csub%3E12%3C%5C%2Fsub%3E%20inhibitors%20versus%20clopidogrel%20in%20the%20EUROMAX%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Huber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20W%22%2C%22lastName%22%3A%22Hamm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnoud%22%2C%22lastName%22%3A%22Van%20%5Cu2019T%20Hof%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Lapostolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Gordini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22Steinmetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freek%20W%20A%22%2C%22lastName%22%3A%22Verheugt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Adgey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lutz%22%2C%22lastName%22%3A%22Nibbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vojko%22%2C%22lastName%22%3A%22Kani%5Cu0109%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Clemmensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uwe%22%2C%22lastName%22%3A%22Zeymer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Debra%22%2C%22lastName%22%3A%22Bernstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Efthymios%20N%22%2C%22lastName%22%3A%22Deliargyris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%22%2C%22lastName%22%3A%22Gabriel%20Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2211%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fopenhrt-2017-000677%22%2C%22ISSN%22%3A%222053-3624%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fopenheart.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fopenhrt-2017-000677%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22Y9WXA4AW%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Potier%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPotier%20L%2C%20Roussel%20R%2C%20Elbez%20Y%2C%20Marre%20M%2C%20Zeymer%20U%2C%20Reid%20CM%2C%20Ohman%20M%2C%20Eagle%20KA%2C%20Bhatt%20DL%2C%20Steg%20PG.%202017.%20Angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers%20in%20high%20vascular%20risk.%20Heart%20103%3A1339%26%23x2013%3B1346.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers%20in%20high%20vascular%20risk%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Potier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronan%22%2C%22lastName%22%3A%22Roussel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yedid%22%2C%22lastName%22%3A%22Elbez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Marre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uwe%22%2C%22lastName%22%3A%22Zeymer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20M%22%2C%22lastName%22%3A%22Reid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magnus%22%2C%22lastName%22%3A%22Ohman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20A%22%2C%22lastName%22%3A%22Eagle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fheartjnl-2016-310705%22%2C%22ISSN%22%3A%221355-6037%2C%201468-201X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fheart.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fheartjnl-2016-310705%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22R3799GH7%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Koutsoukis%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EKoutsoukis%20A%2C%20Halna%20Du%20Fretay%20X%2C%20Dupouy%20P%2C%20Ou%20P%2C%20Laissy%20J-P%2C%20Juliard%20J-M%2C%20Hyafil%20F%2C%20Aubry%20P%2C%20on%20behalf%20of%20the%20ANOCOR%20Investigators.%202017.%20Interobserver%20variability%20in%20the%20classification%20of%20congenital%20coronary%20abnormalities%3A%20A%20substudy%20of%20the%20anomalous%20connections%20of%20the%20coronary%20arteries%20registry.%20Congenital%20Heart%20Disease%2012%3A726%26%23x2013%3B732.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Interobserver%20variability%20in%20the%20classification%20of%20congenital%20coronary%20abnormalities%3A%20A%20substudy%20of%20the%20anomalous%20connections%20of%20the%20coronary%20arteries%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanasios%22%2C%22lastName%22%3A%22Koutsoukis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Halna%20Du%20Fretay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Dupouy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phalla%22%2C%22lastName%22%3A%22Ou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Laissy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Juliard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Hyafil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20ANOCOR%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fchd.12504%22%2C%22ISSN%22%3A%221747079X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fdoi.wiley.com%5C%2F10.1111%5C%2Fchd.12504%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22XNKE59GZ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ozen%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EOzen%20G%2C%20Gomez%20I%2C%20Daci%20A%2C%20Deschildre%20C%2C%20Boubaya%20L%2C%20Teskin%20O%2C%20Uyde%26%23x15F%3B%26%23x2010%3BDo%26%23x11F%3Ban%20BS%2C%20Jakobsson%20P%2C%20Longrois%20D%2C%20Topal%20G%2C%20Norel%20X.%202017.%20%3Cb%3EI%3C%5C%2Fb%3E%20nhibition%20of%20microsomal%20PGE%20synthase%26%23x2010%3B1%20reduces%20human%20vascular%20tone%20by%20increasing%20PGI%20%3Csub%3E2%3C%5C%2Fsub%3E%26%23x202F%3B%3A%20a%20safer%20alternative%20to%20COX%26%23x2010%3B2%20inhibition.%20British%20J%20Pharmacology%20174%3A4087%26%23x2013%3B4098.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%3Cb%3EI%3C%5C%2Fb%3E%20nhibition%20of%20microsomal%20PGE%20synthase%5Cu20101%20reduces%20human%20vascular%20tone%20by%20increasing%20PGI%20%3Csub%3E2%3C%5C%2Fsub%3E%20%3A%20a%20safer%20alternative%20to%20COX%5Cu20102%20inhibition%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulsev%22%2C%22lastName%22%3A%22Ozen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%22%2C%22lastName%22%3A%22Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armond%22%2C%22lastName%22%3A%22Daci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Deschildre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lilia%22%2C%22lastName%22%3A%22Boubaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Onder%22%2C%22lastName%22%3A%22Teskin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%20Sonmez%22%2C%22lastName%22%3A%22Uyde%5Cu015f%5Cu2010Do%5Cu011fan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%5Cu2010Johan%22%2C%22lastName%22%3A%22Jakobsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Longrois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gokce%22%2C%22lastName%22%3A%22Topal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Norel%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20side%20effects%20of%20cyclooxygenase%5Cu20102%20%28COX%5Cu20102%29%20inhibitors%20on%20the%20cardiovascular%20system%20could%20be%20associated%20with%20reduced%20prostaglandin%20%28PG%29I%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20synthesis.%20Microsomal%20PGE%20synthase%5Cu20101%20%28mPGES%5Cu20101%29%20catalyses%20the%20formation%20of%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20from%20COX%5Cu2010derived%20PGH%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20This%20enzyme%20is%20induced%20under%20inflammatory%20conditions%20and%20constitutes%20an%20attractive%20target%20for%20novel%20anti%5Cu2010inflammatory%20drugs.%20However%2C%20it%20is%20not%20known%20whether%20mPGES%5Cu20101%20inhibitors%20could%20be%20devoid%20of%20cardiovascular%20side%20effects.%20The%20aim%20of%20this%20study%20was%20to%20compare%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20in%20vitro%2C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20the%20effects%20of%20mPGES%5Cu20101%20and%20COX%5Cu20102%20inhibitors%20on%20vascular%20tone%20in%20human%20blood%20vessels.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Experimental%20Approach%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20vascular%20tone%20and%20prostanoid%20release%20from%20internal%20mammary%20artery%20%28IMA%29%20and%20saphenous%20vein%20%28SV%29%20incubated%20for%2030%5Cu00a0min%20with%20inhibitors%20of%20mPGES%5Cu20101%20or%20COX%5Cu20102%20were%20investigated%20under%20normal%20and%20inflammatory%20conditions.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Key%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20inflammatory%20conditions%2C%20mPGES%5Cu20101%20and%20COX%5Cu20102%20proteins%20were%20more%20expressed%2C%20and%20increased%20levels%20of%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20were%20released.%20COX%5Cu20102%20and%20NOS%20inhibitors%20increased%20noradrenaline%20induced%20vascular%20contractions%20in%20IMA%20under%20inflammatory%20conditions%20while%20no%20effect%20was%20observed%20in%20SV.%20Interestingly%2C%20the%20mPGES%5Cu20101%20inhibitor%20significantly%20reduced%20%2830%5Cu201340%25%29%20noradrenaline%5Cu2010induced%20contractions%20in%20both%20vessels.%20This%20effect%20was%20reversed%20by%20an%20IP%20%28PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20receptor%29%20antagonist%20but%20not%20modified%20by%20NOS%20inhibition.%20Moreover%2C%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20release%20was%20increased%20with%20the%20mPGES%5Cu20101%20inhibitor%20and%20decreased%20with%20the%20COX%5Cu20102%20inhibitor%2C%20while%20both%20inhibitors%20reduced%20PGE%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20release.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%20and%20Implications%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20contrast%20to%20COX%5Cu20102%20inhibition%2C%20inhibition%20of%20mPGES%5Cu20101%20reduced%20vasoconstriction%20by%20increasing%20PGI%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%202%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20synthesis.%20Targeting%20mPGES%5Cu20101%20could%20provide%20a%20lower%20risk%20of%20cardiovascular%20side%20effects%2C%20compared%20with%20those%20of%20the%20COX%5Cu20102%20inhibitors.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Linked%20Articles%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20article%20is%20part%20of%20a%20themed%20section%20on%20Targeting%20Inflammation%20to%20Reduce%20Cardiovascular%20Disease%20Risk.%20To%20view%20the%20other%20articles%20in%20this%20section%20visit%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fbph.v174.22%5C%2Fissuetoc%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20and%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20http%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fbcp.v82.4%5C%2Fissuetoc%22%2C%22date%22%3A%2211%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fbph.13939%22%2C%22ISSN%22%3A%220007-1188%2C%201476-5381%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbpspubs.onlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fbph.13939%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A21%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22FA6XDBQ5%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22McCarthy%20et%20al.%22%2C%22parsedDate%22%3A%222017-12-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMcCarthy%20CP%2C%20Steg%20G%2C%20Bhatt%20DL.%202017.%20The%20management%20of%20antiplatelet%20therapy%20in%20acute%20coronary%20syndrome%20patients%20with%20thrombocytopenia%3A%20a%20clinical%20conundrum.%20European%20Heart%20Journal%2038%3A3488%26%23x2013%3B3492.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20management%20of%20antiplatelet%20therapy%20in%20acute%20coronary%20syndrome%20patients%20with%20thrombocytopenia%3A%20a%20clinical%20conundrum%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cian%20P%22%2C%22lastName%22%3A%22McCarthy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-12-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehx531%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F38%5C%2F47%5C%2F3488%5C%2F4107906%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22NICETWQ5%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Silva%20and%20Steg%22%2C%22parsedDate%22%3A%222017-11-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EDe%20Silva%20R%2C%20Steg%20PG.%202017.%20Identifying%20patients%20with%20acute%20total%20coronary%20occlusion%20in%20NSTEACS%3A%20finding%20the%20high-risk%20needle%20in%20the%20haystack.%20European%20Heart%20Journal%2038%3A3090%26%23x2013%3B3093.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identifying%20patients%20with%20acute%20total%20coronary%20occlusion%20in%20NSTEACS%3A%20finding%20the%20high-risk%20needle%20in%20the%20haystack%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ranil%22%2C%22lastName%22%3A%22De%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-11-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehx520%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F38%5C%2F41%5C%2F3090%5C%2F4098140%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22D4TUH35S%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Katus%20et%20al.%22%2C%22parsedDate%22%3A%222017-11-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EKatus%20H%2C%20Ziegler%20A%2C%20Ekinci%20O%2C%20Giannitsis%20E%2C%20Stough%20WG%2C%20Achenbach%20S%2C%20Blankenberg%20S%2C%20Brueckmann%20M%2C%20Collinson%20P%2C%20Comaniciu%20D%2C%20Crea%20F%2C%20Dinh%20W%2C%20Ducrocq%20G%2C%20Flachskampf%20FA%2C%20Fox%20KAA%2C%20Friedrich%20MG%2C%20Hebert%20KA%2C%20Himmelmann%20A%2C%20Hlatky%20M%2C%20Lautsch%20D%2C%20Lindahl%20B%2C%20Lindholm%20D%2C%20Mills%20NL%2C%20Minotti%20G%2C%20M%26%23xF6%3Bckel%20M%2C%20Omland%20T%2C%20Semjonow%20V.%202017.%20Early%20diagnosis%20of%20acute%20coronary%20syndrome.%20European%20Heart%20Journal%2038%3A3049%26%23x2013%3B3055.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20diagnosis%20of%20acute%20coronary%20syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Katus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Ziegler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Okan%22%2C%22lastName%22%3A%22Ekinci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evangelos%22%2C%22lastName%22%3A%22Giannitsis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wendy%20Gattis%22%2C%22lastName%22%3A%22Stough%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Achenbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Blankenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22Brueckmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Collinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorin%22%2C%22lastName%22%3A%22Comaniciu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Filippo%22%2C%22lastName%22%3A%22Crea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilfried%22%2C%22lastName%22%3A%22Dinh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9gory%22%2C%22lastName%22%3A%22Ducrocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20A.%22%2C%22lastName%22%3A%22Flachskampf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A.%20A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20G.%22%2C%22lastName%22%3A%22Friedrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathy%20A.%22%2C%22lastName%22%3A%22Hebert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22Himmelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Hlatky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominik%22%2C%22lastName%22%3A%22Lautsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertil%22%2C%22lastName%22%3A%22Lindahl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Lindholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20L.%22%2C%22lastName%22%3A%22Mills%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgio%22%2C%22lastName%22%3A%22Minotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22M%5Cu00f6ckel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Torbj%5Cu00f8rn%22%2C%22lastName%22%3A%22Omland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Semjonow%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-11-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehx492%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F38%5C%2F41%5C%2F3049%5C%2F4318805%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22IUNXYK7Y%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vidal-Petiot%20et%20al.%22%2C%22parsedDate%22%3A%222017-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVidal-Petiot%20E%2C%20Stebbins%20A%2C%20Chiswell%20K%2C%20Ardissino%20D%2C%20Aylward%20PE%2C%20Cannon%20CP%2C%20Ramos%20Corrales%20MA%2C%20Held%20C%2C%20L%26%23xF3%3Bpez-Send%26%23xF3%3Bn%20JL%2C%20Stewart%20RAH%2C%20Wallentin%20L%2C%20White%20HD%2C%20Steg%20PG%2C%20on%20behalf%20of%20the%20STABILITY%20Investigators.%202017.%20Visit-to-visit%20variability%20of%20blood%20pressure%20and%20cardiovascular%20outcomes%20in%20patients%20with%20stable%20coronary%20heart%20disease.%20Insights%20from%20the%20STABILITY%20trial.%20European%20Heart%20Journal%2038%3A2813%26%23x2013%3B2822.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Visit-to-visit%20variability%20of%20blood%20pressure%20and%20cardiovascular%20outcomes%20in%20patients%20with%20stable%20coronary%20heart%20disease.%20Insights%20from%20the%20STABILITY%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Vidal-Petiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Stebbins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Chiswell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%22%2C%22lastName%22%3A%22Ardissino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20E.%22%2C%22lastName%22%3A%22Aylward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P.%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20A.%22%2C%22lastName%22%3A%22Ramos%20Corrales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claes%22%2C%22lastName%22%3A%22Held%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Send%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20A.%20H.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Wallentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harvey%20D.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20STABILITY%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehx250%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F38%5C%2F37%5C%2F2813%5C%2F3852229%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22BLXJ5CU2%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Steg%20and%20Simon%22%2C%22parsedDate%22%3A%222017-04-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ESteg%20PG%2C%20Simon%20T.%202017.%20Duration%20of%20antiplatelet%20therapy%20after%20DES%20implantation%3A%20can%20we%20trust%20non-inferiority%20open-label%20trials%3F%20European%20Heart%20Journal%2038%3A1044%26%23x2013%3B1047.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Duration%20of%20antiplatelet%20therapy%20after%20DES%20implantation%3A%20can%20we%20trust%20non-inferiority%20open-label%20trials%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-04-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehx110%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F38%5C%2F14%5C%2F1044%5C%2F3074210%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22WZBMUZHL%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Van%20Den%20Berg%20et%20al.%22%2C%22parsedDate%22%3A%222017-11-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVan%20Den%20Berg%20MJ%2C%20Bhatt%20DL%2C%20Kappelle%20LJ%2C%20De%20Borst%20GJ%2C%20Cramer%20MJ%2C%20Van%20Der%20Graaf%20Y%2C%20Steg%20PG%2C%20Visseren%20FLJ%2C%20on%20behalf%20of%20the%20SMART%20study%20group%2C%20REACH%20Registry%20investigators.%202017.%20Identification%20of%20vascular%20patients%20at%20very%20high%20risk%20for%20recurrent%20cardiovascular%20events%3A%20validation%20of%20the%20current%20ACC%5C%2FAHA%20very%20high%20risk%20criteria.%20European%20Heart%20Journal%2038%3A3211%26%23x2013%3B3218.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identification%20of%20vascular%20patients%20at%20very%20high%20risk%20for%20recurrent%20cardiovascular%20events%3A%20validation%20of%20the%20current%20ACC%5C%2FAHA%20very%20high%20risk%20criteria%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Johanneke%22%2C%22lastName%22%3A%22Van%20Den%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%20Jaap%22%2C%22lastName%22%3A%22Kappelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gert%20J%22%2C%22lastName%22%3A%22De%20Borst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maarten%20J%22%2C%22lastName%22%3A%22Cramer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yolanda%22%2C%22lastName%22%3A%22Van%20Der%20Graaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ph%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20L%20J%22%2C%22lastName%22%3A%22Visseren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20SMART%20study%20group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22REACH%20Registry%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-11-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Feurheartj%5C%2Fehx102%22%2C%22ISSN%22%3A%220195-668X%2C%201522-9645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Feurheartj%5C%2Farticle%5C%2F38%5C%2F43%5C%2F3211%5C%2F3092058%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22MRSLTYDJ%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Abell%20et%20al.%22%2C%22parsedDate%22%3A%222017-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EAbell%20JE%2C%20Laing%20SM%2C%20Barker%20TC%2C%20Norry%20EC%2C%20Starzyk%20K%2C%20Goodman%20SG%2C%20Dellborg%20M%2C%20Steg%20PG%2C%20Giugliano%20RP.%202017.%20Adjunctive%20use%20of%20anticoagulants%20at%20the%20time%20of%20percutaneous%20coronary%20intervention%20in%20patients%20with%20an%20acute%20coronary%20syndrome%20treated%20with%20fondaparinux%3A%20a%20multinational%20retrospective%20review.%20European%20Heart%20Journal%20-%20Cardiovascular%20Pharmacotherapy%203%3A214%26%23x2013%3B220.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Adjunctive%20use%20of%20anticoagulants%20at%20the%20time%20of%20percutaneous%20coronary%20intervention%20in%20patients%20with%20an%20acute%20coronary%20syndrome%20treated%20with%20fondaparinux%3A%20a%20multinational%20retrospective%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jill%20E.%22%2C%22lastName%22%3A%22Abell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shiona%20M.%22%2C%22lastName%22%3A%22Laing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tara%20C.%22%2C%22lastName%22%3A%22Barker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elliott%20C.%22%2C%22lastName%22%3A%22Norry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Starzyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Dellborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20P.%22%2C%22lastName%22%3A%22Giugliano%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjcvp%5C%2Fpvx007%22%2C%22ISSN%22%3A%222055-6837%2C%202055-6845%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjcvp%5C%2Farticle%5C%2F3%5C%2F4%5C%2F214%5C%2F3738816%5C%2FAdjunctive-use-of-anticoagulants-at-the-time-of%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A20%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22862XQSQL%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eikelboom%20et%20al.%22%2C%22parsedDate%22%3A%222017-10-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EEikelboom%20JW%2C%20Connolly%20SJ%2C%20Bosch%20J%2C%20Dagenais%20GR%2C%20Hart%20RG%2C%20Shestakovska%20O%2C%20Diaz%20R%2C%20Alings%20M%2C%20Lonn%20EM%2C%20Anand%20SS%2C%20Widimsky%20P%2C%20Hori%20M%2C%20Avezum%20A%2C%20Piegas%20LS%2C%20Branch%20KRH%2C%20Probstfield%20J%2C%20Bhatt%20DL%2C%20Zhu%20J%2C%20Liang%20Y%2C%20Maggioni%20AP%2C%20Lopez-Jaramillo%20P%2C%20O%26%23x2019%3BDonnell%20M%2C%20Kakkar%20AK%2C%20Fox%20KAA%2C%20Parkhomenko%20AN%2C%20Ertl%20G%2C%20St%26%23xF6%3Brk%20S%2C%20Keltai%20M%2C%20Ryden%20L%2C%20Pogosova%20N%2C%20Dans%20AL%2C%20Lanas%20F%2C%20Commerford%20PJ%2C%20Torp-Pedersen%20C%2C%20Guzik%20TJ%2C%20Verhamme%20PB%2C%20Vinereanu%20D%2C%20Kim%20J-H%2C%20Tonkin%20AM%2C%20Lewis%20BS%2C%20Felix%20C%2C%20Yusoff%20K%2C%20Steg%20PG%2C%20Metsarinne%20KP%2C%20Cook%20Bruns%20N%2C%20Misselwitz%20F%2C%20Chen%20E%2C%20Leong%20D%2C%20Yusuf%20S.%202017.%20Rivaroxaban%20with%20or%20without%20Aspirin%20in%20Stable%20Cardiovascular%20Disease.%20N%20Engl%20J%20Med%20377%3A1319%26%23x2013%3B1330.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rivaroxaban%20with%20or%20without%20Aspirin%20in%20Stable%20Cardiovascular%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Eikelboom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Connolly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackie%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%20R.%22%2C%22lastName%22%3A%22Dagenais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20G.%22%2C%22lastName%22%3A%22Hart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Shestakovska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Alings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20M.%22%2C%22lastName%22%3A%22Lonn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%20S.%22%2C%22lastName%22%3A%22Anand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Widimsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masatsugu%22%2C%22lastName%22%3A%22Hori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Avezum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leopoldo%20S.%22%2C%22lastName%22%3A%22Piegas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelley%20R.H.%22%2C%22lastName%22%3A%22Branch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%22%2C%22lastName%22%3A%22Probstfield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%22%2C%22lastName%22%3A%22Zhu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aldo%20P.%22%2C%22lastName%22%3A%22Maggioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricio%22%2C%22lastName%22%3A%22Lopez-Jaramillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22O%5Cu2019Donnell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%20K.%22%2C%22lastName%22%3A%22Kakkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A.A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20N.%22%2C%22lastName%22%3A%22Parkhomenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Ertl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22St%5Cu00f6rk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matyas%22%2C%22lastName%22%3A%22Keltai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Ryden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nana%22%2C%22lastName%22%3A%22Pogosova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%20L.%22%2C%22lastName%22%3A%22Dans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Lanas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20J.%22%2C%22lastName%22%3A%22Commerford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Torp-Pedersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomek%20J.%22%2C%22lastName%22%3A%22Guzik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20B.%22%2C%22lastName%22%3A%22Verhamme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dragos%22%2C%22lastName%22%3A%22Vinereanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae-Hyung%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20M.%22%2C%22lastName%22%3A%22Tonkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Basil%20S.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camilo%22%2C%22lastName%22%3A%22Felix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khalid%22%2C%22lastName%22%3A%22Yusoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaj%20P.%22%2C%22lastName%22%3A%22Metsarinne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Cook%20Bruns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Misselwitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edmond%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darryl%22%2C%22lastName%22%3A%22Leong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Yusuf%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-10-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1709118%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1709118%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22GXSTZQ22%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cannon%20et%20al.%22%2C%22parsedDate%22%3A%222017-10-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECannon%20CP%2C%20Bhatt%20DL%2C%20Oldgren%20J%2C%20Lip%20GYH%2C%20Ellis%20SG%2C%20Kimura%20T%2C%20Maeng%20M%2C%20Merkely%20B%2C%20Zeymer%20U%2C%20Gropper%20S%2C%20Nordaby%20M%2C%20Kleine%20E%2C%20Harper%20R%2C%20Manassie%20J%2C%20Januzzi%20JL%2C%20Ten%20Berg%20JM%2C%20Steg%20PG%2C%20Hohnloser%20SH.%202017.%20Dual%20Antithrombotic%20Therapy%20with%20Dabigatran%20after%20PCI%20in%20Atrial%20Fibrillation.%20N%20Engl%20J%20Med%20377%3A1513%26%23x2013%3B1524.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dual%20Antithrombotic%20Therapy%20with%20Dabigatran%20after%20PCI%20in%20Atrial%20Fibrillation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P.%22%2C%22lastName%22%3A%22Cannon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L.%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonas%22%2C%22lastName%22%3A%22Oldgren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20Y.H.%22%2C%22lastName%22%3A%22Lip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20G.%22%2C%22lastName%22%3A%22Ellis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takeshi%22%2C%22lastName%22%3A%22Kimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Maeng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bela%22%2C%22lastName%22%3A%22Merkely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uwe%22%2C%22lastName%22%3A%22Zeymer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Savion%22%2C%22lastName%22%3A%22Gropper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matias%22%2C%22lastName%22%3A%22Nordaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Kleine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%22%2C%22lastName%22%3A%22Harper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jenny%22%2C%22lastName%22%3A%22Manassie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20L.%22%2C%22lastName%22%3A%22Januzzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurrien%20M.%22%2C%22lastName%22%3A%22Ten%20Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20H.%22%2C%22lastName%22%3A%22Hohnloser%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-10-19%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1708454%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1708454%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22ZQU2C822%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mas%20et%20al.%22%2C%22parsedDate%22%3A%222017-09-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EMas%20J-L%2C%20Derumeaux%20G%2C%20Guillon%20B%2C%20Massardier%20E%2C%20Hosseini%20H%2C%20Mechtouff%20L%2C%20Arquizan%20C%2C%20B%26%23xE9%3Bjot%20Y%2C%20Vuillier%20F%2C%20Detante%20O%2C%20Guidoux%20C%2C%20Canaple%20S%2C%20Vaduva%20C%2C%20Dequatre-Ponchelle%20N%2C%20Sibon%20I%2C%20Garnier%20P%2C%20Ferrier%20A%2C%20Timsit%20S%2C%20Robinet-Borgomano%20E%2C%20Sablot%20D%2C%20Lacour%20J-C%2C%20Zuber%20M%2C%20Favrole%20P%2C%20Pinel%20J-F%2C%20Apoil%20M%2C%20Reiner%20P%2C%20Lefebvre%20C%2C%20Gu%26%23xE9%3Brin%20P%2C%20Piot%20C%2C%20Rossi%20R%2C%20Dubois-Rand%26%23xE9%3B%20J-L%2C%20Eicher%20J-C%2C%20Meneveau%20N%2C%20Lusson%20J-R%2C%20Bertrand%20B%2C%20Schleich%20J-M%2C%20Godart%20F%2C%20Thambo%20J-B%2C%20Leborgne%20L%2C%20Michel%20P%2C%20Pierard%20L%2C%20Turc%20G%2C%20Barthelet%20M%2C%20Charles-Nelson%20A%2C%20Weimar%20C%2C%20Moulin%20T%2C%20Juliard%20J-M%2C%20Chatellier%20G.%202017.%20Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke.%20N%20Engl%20J%20Med%20377%3A1011%26%23x2013%3B1021.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevi%5Cu00e8ve%22%2C%22lastName%22%3A%22Derumeaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Guillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evelyne%22%2C%22lastName%22%3A%22Massardier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Hosseini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Mechtouff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Arquizan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22B%5Cu00e9jot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Vuillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Detante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Guidoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Canaple%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Vaduva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Dequatre-Ponchelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%22%2C%22lastName%22%3A%22Sibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Ferrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Timsit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Robinet-Borgomano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Sablot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Lacour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Zuber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Favrole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Pinel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Apoil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Reiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Gu%5Cu00e9rin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Piot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roland%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Luc%22%2C%22lastName%22%3A%22Dubois-Rand%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Eicher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meneveau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Ren%5Cu00e9%22%2C%22lastName%22%3A%22Lusson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Schleich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Godart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Benoit%22%2C%22lastName%22%3A%22Thambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Leborgne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrik%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Pierard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Turc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Barthelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22Charles-Nelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Weimar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Juliard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Chatellier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-09-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1705915%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1705915%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22TTW26BRH%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lincoff%20et%20al.%22%2C%22parsedDate%22%3A%222017-05-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELincoff%20AM%2C%20Nicholls%20SJ%2C%20Riesmeyer%20JS%2C%20Barter%20PJ%2C%20Brewer%20HB%2C%20Fox%20KAA%2C%20Gibson%20CM%2C%20Granger%20C%2C%20Menon%20V%2C%20Montalescot%20G%2C%20Rader%20D%2C%20Tall%20AR%2C%20McErlean%20E%2C%20Wolski%20K%2C%20Ruotolo%20G%2C%20Vangerow%20B%2C%20Weerakkody%20G%2C%20Goodman%20SG%2C%20Conde%20D%2C%20McGuire%20DK%2C%20Nicolau%20JC%2C%20Leiva-Pons%20JL%2C%20Pesant%20Y%2C%20Li%20W%2C%20Kandath%20D%2C%20Kouz%20S%2C%20Tahirkheli%20N%2C%20Mason%20D%2C%20Nissen%20SE.%202017.%20Evacetrapib%20and%20Cardiovascular%20Outcomes%20in%20High-Risk%20Vascular%20Disease.%20N%20Engl%20J%20Med%20376%3A1933%26%23x2013%3B1942.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evacetrapib%20and%20Cardiovascular%20Outcomes%20in%20High-Risk%20Vascular%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20Michael%22%2C%22lastName%22%3A%22Lincoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20J.%22%2C%22lastName%22%3A%22Nicholls%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20S.%22%2C%22lastName%22%3A%22Riesmeyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20J.%22%2C%22lastName%22%3A%22Barter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Bryan%22%2C%22lastName%22%3A%22Brewer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20A.A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Michael%22%2C%22lastName%22%3A%22Gibson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Granger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Venu%22%2C%22lastName%22%3A%22Menon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Montalescot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Rader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%20R.%22%2C%22lastName%22%3A%22Tall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22McErlean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathy%22%2C%22lastName%22%3A%22Wolski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giacomo%22%2C%22lastName%22%3A%22Ruotolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Burkhard%22%2C%22lastName%22%3A%22Vangerow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Govinda%22%2C%22lastName%22%3A%22Weerakkody%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaun%20G.%22%2C%22lastName%22%3A%22Goodman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%22%2C%22lastName%22%3A%22Conde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20K.%22%2C%22lastName%22%3A%22McGuire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20C.%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20L.%22%2C%22lastName%22%3A%22Leiva-Pons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Pesant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Weimin%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Kandath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Kouz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naeem%22%2C%22lastName%22%3A%22Tahirkheli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denise%22%2C%22lastName%22%3A%22Mason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20E.%22%2C%22lastName%22%3A%22Nissen%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-05-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1609581%22%2C%22ISSN%22%3A%220028-4793%2C%201533-4406%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJMoa1609581%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22XBPT867N%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rouzier%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ERouzier%20R%2C%20Uzan%20C%2C%20Rousseau%20A%2C%20Guillot%20E%2C%20Zilberman%20S%2C%20Meyer%20C%2C%20Estevez%20P%2C%20Dupre%20P-F%2C%20Kere%20D%2C%20Doridot%20V%2C%20D%26%23x2019%3Bhalluin%20G%2C%20Fritel%20X%2C%20Pouget%20N%2C%20Jankowski%20C%2C%20Mazouni%20C%2C%20Simon%20T%2C%20Coutant%20C.%202017.%20Multicenter%20prospective%20evaluation%20of%20the%20reliability%20of%20the%20combined%20use%20of%20two%20models%20to%20predict%20non-sentinel%20lymph%20node%20status%20in%20breast%20cancer%20patients%20with%20metastatic%20sentinel%20lymph%20nodes%3A%20the%20MSKCC%20nomogram%20and%20the%20Tenon%20score.%20Results%20of%20the%20NOTEGS%20study.%20Br%20J%20Cancer%20116%3A1135%26%23x2013%3B1140.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multicenter%20prospective%20evaluation%20of%20the%20reliability%20of%20the%20combined%20use%20of%20two%20models%20to%20predict%20non-sentinel%20lymph%20node%20status%20in%20breast%20cancer%20patients%20with%20metastatic%20sentinel%20lymph%20nodes%3A%20the%20MSKCC%20nomogram%20and%20the%20Tenon%20score.%20Results%20of%20the%20NOTEGS%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roman%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Uzan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e9nie%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Zilberman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Estevez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Francois%22%2C%22lastName%22%3A%22Dupre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Kere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Doridot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gauthier%22%2C%22lastName%22%3A%22D%27halluin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Fritel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Pouget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Jankowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chafika%22%2C%22lastName%22%3A%22Mazouni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tabassome%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Coutant%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%224%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fbjc.2017.47%22%2C%22ISSN%22%3A%220007-0920%2C%201532-1827%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fbjc201747%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A10Z%22%7D%7D%2C%7B%22key%22%3A%229S25TUAE%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22the%20Papillophar%20Study%20Group%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3Ethe%20Papillophar%20Study%20Group%2C%20Lefevre%20M%2C%20Rousseau%20A%2C%20Rayon%20T%2C%20Dalstein%20V%2C%20Clavel%20C%2C%20Beby-Defaux%20A%2C%20Pretet%20J-L%2C%20Soussan%20P%2C%20Polette%20M%2C%20Lacau%20Saint%20Guily%20J%2C%20Birembaut%20P.%202017.%20Epithelial%20to%20mesenchymal%20transition%20and%20HPV%20infection%20in%20squamous%20cell%20oropharyngeal%20carcinomas%3A%20the%20papillophar%20study.%20Br%20J%20Cancer%20116%3A362%26%23x2013%3B369.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epithelial%20to%20mesenchymal%20transition%20and%20HPV%20infection%20in%20squamous%20cell%20oropharyngeal%20carcinomas%3A%20the%20papillophar%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20Papillophar%20Study%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Lefevre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Rayon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Dalstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Clavel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Beby-Defaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Luc%22%2C%22lastName%22%3A%22Pretet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Soussan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Polette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Lacau%20Saint%20Guily%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Birembaut%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%221%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fbjc.2016.434%22%2C%22ISSN%22%3A%220007-0920%2C%201532-1827%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fbjc2016434%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A19%3A09Z%22%7D%7D%2C%7B%22key%22%3A%226FFZKNCE%22%2C%22library%22%3A%7B%22id%22%3A2460799%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vidal-Petiot%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%20%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVidal-Petiot%20E%2C%20Bhatt%20DL%2C%20Fox%20KM%2C%20Steg%20PG.%202017.%20Blood%20pressure%20and%20cardiovascular%20outcomes%3A%20a%20closer%20look%20%26%23x2013%3B%20Authors%26%23x2019%3B%20reply.%20The%20Lancet%20389%3A1296%26%23x2013%3B1297.%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20pressure%20and%20cardiovascular%20outcomes%3A%20a%20closer%20look%20%5Cu2013%20Authors%27%20reply%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Vidal-Petiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20L%22%2C%22lastName%22%3A%22Bhatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%20M%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%20Gabriel%22%2C%22lastName%22%3A%22Steg%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS0140-6736%2817%2930835-8%22%2C%22ISSN%22%3A%2201406736%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0140673617308358%22%2C%22collections%22%3A%5B%225BTMJQCK%22%5D%2C%22dateModified%22%3A%222024-03-06T22%3A18%3A47Z%22%7D%7D%5D%7D1.Assayag M, Abbas R, Chanson N, Perozziello A, Ducrocq G, Alexandra J-F, Dossier A, Papo T, Sacre K. 2017. Diagnosis of systemic inflammatory diseases among patients admitted for acute pericarditis with pericardial effusion: Journal of Cardiovascular Medicine 18:875–880.1.Adjedj J, Ducrocq G, Bouleti C, Reinhart L, Fabbro E, Elbez Y, Fischer Q, Tesniere A, Feldman L, Varenne O. 2017. Medical Student Evaluation With a Serious Game Compared to Multiple Choice Questions Assessment. JMIR Serious Games 5:e11.1.Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif J-C, Morais J, Gamba MA, Kääb S, Tendera For The Clarify Investigators M. 2017. Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus non-cardiologists: the international prospective CLARIFY registry. Polish Archives of Internal Medicine https://doi.org/10.20452/pamw.3902.1.Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L. 2017. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non–ST-Elevation Acute Coronary Syndrome. Clinical Chemistry 63:573–584.1.Hagström E, Held C, Stewart RAH, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L. 2017. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry 63:325–333.1.Ducrocq GP, Hureau TJ, Meste O, Blain GM. 2017. Increased Fatigue Response to Augmented Deceptive Feedback during Cycling Time Trial. Medicine & Science in Sports & Exercise 49:1541–1551.1.Hilkens NA, Algra A, Diener H-C, Reitsma JB, Bath PM, Csiba L, Hacke W, Kappelle LJ, Koudstaal PJ, Leys D, Mas J-L, Sacco RL, Amarenco P, Sissani L, Greving JP, For the Cerebrovascular Antiplatelet Trialists’ Collaborative Group, Cerebrovascular Antiplatelet Trialists’ Collaborative Group, Gent M, Beaumont D, Blanchard J, Bousser M, Coffman J, Easton JD, Hampton J, Harker L, Janzon L, Kusmierek J, Panak E, Roberts R, Shannon S, Sicurella J, Tognoni G, Topol E, Verstraete M, Warlow C, Blard J, Capildeo R, Diener H, Ersmark B, Escartin A, Ferro J, Galvin R, Hogenhuis L, Laterre C, Provincial L, Rinne U, Bovim G, Lowenthal A, Diener H, Bogousslavsky J, Brass L, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H, Berger P, Bhatt D, Black H, Boden W, Cacoub P, Cohen E, Creager M, Easton J, Flather M, Fox K, Hacke W, Haffner S, Hamm C, Hankey G, Johnston S, Mak K, Mas J, Montalescot G, Pearson T, Steg P, Steinhubl S, Topol E, Weber M, Aichner F, Algra A, Bogousslavsky J, Chamorro A, Chen C, De Schryver E, Ferro J, Van Gijn J, Hankey G, Hertzberger L, Koudstaal P, Leys D, Ricci S, Ringelstein E, Vanhooren G, Venables G, Albers G, Bath P, Bornstein N, Chan B, Chen S-T, Cunha L, Dahlöf B, DeKeyser J, Diener H, Donnan G, Estol C, Gorelick P, Kaste M, Lu C, Pais P, Roberts R, Sacco R, Skvortsova V, Teal P, Toni D, Weber M, Yoon B, Yusuf S, Amarenco P, Bousser M-G, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M, Mattle H, Rothwell P, Sissani L, Labreuche J, Steg G, Vicaut E. 2017. Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S 2 TOP-BLEED. Neurology 89:936–943.1.for the iDIAPASON study group, Bouglé A, Foucrier A, Dupont H, Montravers P, Ouattara A, Kalfon P, Squara P, Simon T, Amour J. 2017. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study. Trials 18:37.1.Feldman L, Steg PG, Amsallem M, Puymirat E, Sorbets E, Elbaz M, Ritz B, Hueber A, Cattan S, Piot C, Ferrières J, Simon T, Danchin N, on behalf of the FAST-MI investigators. 2017. Editor’s Choice-Medically managed patients with non–ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. European Heart Journal: Acute Cardiovascular Care 6:262–271.1.Puymirat E, Caudron J, Steg PG, Lemesle G, Cottin Y, Coste P, Schiele F, De Labriolle A, Bataille V, Ferrières J, Simon T, Danchin N, for the FAST-MI investigators. 2017. Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. European Heart Journal: Acute Cardiovascular Care 6:26–33.1.Hoshino T, Uchiyama S, Wong LKS, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Lavallée PC, Molina C, Rothwell PM, Steg PG, Touboul P-J, Vicaut É, Amarenco P. 2017. Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org. Stroke 48:1779–1787.1.Hobeanu C, Lavallée PC, Rothwell PM, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Molina C, Steg PG, Touboul P-J, Uchiyama S, Vicaut É, Wong LKS, Amarenco P. 2017. Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. Stroke 48:1005–1010.1.Lavallée PC, Sissani L, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, Klein IF, Touboul P-J, Amarenco P. 2017. Clinical Significance of Isolated Atypical Transient Symptoms in a Cohort With Transient Ischemic Attack. Stroke 48:1495–1500.1.Bossard M, Granger CB, Tanguay J, Montalescot G, Faxon DP, Jolly SS, Widimsky P, Niemela K, Steg PG, Natarajan MK, Gao P, Fox KAA, Yusuf S, Mehta SR. 2017. Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JAHA 6:e006577.1.Stewart RAH, Hagström E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, López‐Sendón JL, Mohler ER, Hadziosmanovic N, Krug‐Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin L, on behalf of the STABILITY Investigators. 2017. Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. JAHA 6:e006096.1.Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López‐Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. 2017. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. JAHA 6:e005580.1.Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L, on behalf of the STABILITY Investigators. 2017. Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. JAHA 6:e005077.1.Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, Lemesle G, Motreff P, Popovic B, Khalife K, Labèque J-N, Perret T, Le Ray C, Orion L, Jouve B, Blanchard D, Peycher P, Silvain J, Steg PG, Goldstein P, Guéret P, Belle L, Aissaoui N, Ferrières J, Schiele F, Danchin N. 2017. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation 136:1908–1919.1.Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack C, Wiviott SD, Elbez Y, Sabatine MS, Steg PG. 2017. Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation 136:1895–1907.1.Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, De Cock D, Komukai K, Tada T, Cuesta J, Sirbu V, Feldman LJ, Neumann F-J, Goodall AH, Heestermans T, Buysschaert I, Hlinomaz O, Belmans A, Desmet W, Ten Berg JM, Gershlick AH, Massberg S, Kastrati A, Guagliumi G, Byrne RA. 2017. Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 136:1007–1021.1.Simon T, Danchin N. 2017. Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke. Circulation 135:34–37.1.Cavender MA, Bhatt DL, Stone GW, Steg PhG, Gibson CM, Hamm CW, Price MJ, Prats J, Elkin S, Deliargyris EN, Mahaffey KW, White HD, Harrington RA. 2017. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Circ: Cardiovascular Interventions 10:e005257.1.Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R. 2017. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ: Cardiovascular Interventions 10:e004981.1.Sawlani NN, Harrington RA, Stone GW, Steg PhG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2017. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ: Cardiovascular Interventions 10:e004380.1.Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Michael Gibson C, White HD, Storey RF, the CHAMPION PHOENIX Investigators. 2017. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost 117:1093–1100.1.Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. 2017. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost 117:940–947.1.Abboud H, Sissani L, Labreuche J, Arauz A, Bousser M-G, Bryer A, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Lavados PM, Massaro A, Mattle HP, Munoz Collazos M, Rothwell PM, Steg PG, Vicaut E, Yamouth B, Amarenco P, on behalf of the OPTIC Registry and PERFORM Trial Investigators. 2017. Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries. Cerebrovasc Dis 43:169–177.1.Huber K, Ducrocq G, Hamm CW, Van ’T Hof A, Lapostolle F, Coste P, Gordini G, Steinmetz J, Verheugt FWA, Adgey J, Nibbe L, Kaniĉ V, Clemmensen P, Zeymer U, Bernstein D, Prats J, Deliargyris EN, Gabriel Steg P. 2017. Early clinical outcomes as a function of use of newer oral P2Y 12 inhibitors versus clopidogrel in the EUROMAX trial. Open Heart 4:e000677.1.Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG. 2017. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103:1339–1346.1.Koutsoukis A, Halna Du Fretay X, Dupouy P, Ou P, Laissy J-P, Juliard J-M, Hyafil F, Aubry P, on behalf of the ANOCOR Investigators. 2017. Interobserver variability in the classification of congenital coronary abnormalities: A substudy of the anomalous connections of the coronary arteries registry. Congenital Heart Disease 12:726–732.1.Ozen G, Gomez I, Daci A, Deschildre C, Boubaya L, Teskin O, Uydeş‐Doğan BS, Jakobsson P, Longrois D, Topal G, Norel X. 2017. I nhibition of microsomal PGE synthase‐1 reduces human vascular tone by increasing PGI 2 : a safer alternative to COX‐2 inhibition. British J Pharmacology 174:4087–4098.1.McCarthy CP, Steg G, Bhatt DL. 2017. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. European Heart Journal 38:3488–3492.1.De Silva R, Steg PG. 2017. Identifying patients with acute total coronary occlusion in NSTEACS: finding the high-risk needle in the haystack. European Heart Journal 38:3090–3093.1.Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S, Blankenberg S, Brueckmann M, Collinson P, Comaniciu D, Crea F, Dinh W, Ducrocq G, Flachskampf FA, Fox KAA, Friedrich MG, Hebert KA, Himmelmann A, Hlatky M, Lautsch D, Lindahl B, Lindholm D, Mills NL, Minotti G, Möckel M, Omland T, Semjonow V. 2017. Early diagnosis of acute coronary syndrome. European Heart Journal 38:3049–3055.1.Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PG, on behalf of the STABILITY Investigators. 2017. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. European Heart Journal 38:2813–2822.1.Steg PG, Simon T. 2017. Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials? European Heart Journal 38:1044–1047.1.Van Den Berg MJ, Bhatt DL, Kappelle LJ, De Borst GJ, Cramer MJ, Van Der Graaf Y, Steg PG, Visseren FLJ, on behalf of the SMART study group, REACH Registry investigators. 2017. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. European Heart Journal 38:3211–3218.1.Abell JE, Laing SM, Barker TC, Norry EC, Starzyk K, Goodman SG, Dellborg M, Steg PG, Giugliano RP. 2017. Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. European Heart Journal - Cardiovascular Pharmacotherapy 3:214–220.1.Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S. 2017. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 377:1319–1330.1.Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH. 2017. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 377:1513–1524.1.Mas J-L, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour J-C, Zuber M, Favrole P, Pinel J-F, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé J-L, Eicher J-C, Meneveau N, Lusson J-R, Bertrand B, Schleich J-M, Godart F, Thambo J-B, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard J-M, Chatellier G. 2017. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med 377:1011–1021.1.Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. 2017. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med 376:1933–1942.1.Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre P-F, Kere D, Doridot V, D’halluin G, Fritel X, Pouget N, Jankowski C, Mazouni C, Simon T, Coutant C. 2017. Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study. Br J Cancer 116:1135–1140.1.the Papillophar Study Group, Lefevre M, Rousseau A, Rayon T, Dalstein V, Clavel C, Beby-Defaux A, Pretet J-L, Soussan P, Polette M, Lacau Saint Guily J, Birembaut P. 2017. Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. Br J Cancer 116:362–369.1.Vidal-Petiot E, Bhatt DL, Fox KM, Steg PG. 2017. Blood pressure and cardiovascular outcomes: a closer look – Authors’ reply. The Lancet 389:1296–1297.